Drug ID	NP Name	PubChem CID	Synonymous	Molecule Type	InChI	InChIKey	Canonical SMILES	Formula	CAS Number	CHEBI	HERB ID	SymMap ID	TCMSP ID	TTD ID	DrugBank ID	ETMC ID	GDSC
DR0019	Pemafibrate	CID: 11526038	Pemafibrate; 848259-27-8; UNII-17VGG92R23; (R)-2-(3-((benzo[d]oxazol-2-yl(3-(4-methoxyphenoxy)propyl)amino)methyl)phenoxy)butanoic acid; CHEMBL247951; (R)-K-13675; 17VGG92R23; K-13675, (R)-; 848259-27-8 (free acid); CAS#848259-27-8; (2~{R})-2-[3-[[1,3-benzoxazol-2-yl-[3-(4-methoxyphenoxy)propyl]amino]methyl]phenoxy]butanoic acid; (2R)-2-[3-[[1,3-benzoxazol-2-yl-[3-(4-methoxyphenoxy)propyl]amino]methyl]phenoxy]butanoic acid; Pemafibrate [INN]; Parmodia (TN); P7F; Pemafibrate (JAN); (R)-K 13675; SCHEMBL2766188; DTXSID00233891; BCP20864; EX-A1919; BDBM50214899; CS-6084; DB15212; SB19229; HY-17618; D10711; Q27251943; K-877; (R)-K 13675; CS-2768; K-877; K877; K 877; (R)-K 13675; (R)-K13675; (R)K-13675; (R)-2-[3-[N-(benzoxazol-2-yl)-N-(3-(4-methoxyphenoxy)propyl)aminomethyl]phenoxy]butyric acid	Small molecule	1S/C28H30N2O6/c1-3-25(27(31)32)35-23-9-6-8-20(18-23)19-30(28-29-24-10-4-5-11-26(24)36-28)16-7-17-34-22-14-12-21(33-2)13-15-22/h4-6,8-15,18,25H,3,7,16-17,19H2,1-2H3,(H,31,32)/t25-/m1/s1	ZHKNLJLMDFQVHJ-RUZDIDTESA-N	CCC(C(=O)O)OC1=CC=CC(=C1)CN(CCCOC2=CC=C(C=C2)OC)C3=NC4=CC=CC=C4O3	C28H30N2O6	CAS 848259-27-8	.	.	.	.	D04QIE	.	.	.
DR0043	Ofloxacin	CID: 4583	ofloxacin; 82419-36-1; Floxin; Ofloxacine; Tarivid; Ocuflox; OFLX; Ofloxacino; Ofloxacinum; Exocin; Hoe-280; DL-8280; Floxin otic; HOE 280; 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-3,7-dihydro-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; Oxaldin; Dextrofloxacin; 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; DL-ofloxacin; CHEBI:7731; Oflocet; Visiren; CHEMBL4; MFCD00226105; MLS000028749; Ofloxacina; Ofloxacin Otic; Ofloxacin, 98%; Ofloxacina [DCIT]; Ofloxacine [French]; Ofloxacinum [Latin]; Exocine; Flobacin; SMR000058192; Zanocin; Floxil; Ofloxacino [Spanish]; DSSTox_CID_21085; DSSTox_RID_79623; DSSTox_GSID_41085; 8-Fluoro-3-methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid; OFX; C18H20FN3O4; FLOXIN IN DEXTROSE 5%; DL 8280; MFCD00865049; PT 01; ORF 18489; (-)-(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1;(-)-(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1; 9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid; Floxin (TN); CCRIS 5233; (+/-)-Floxin; SR-01000076050; FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER; BRN 3657947; Monoflocet; ofloxacin;; Ofloxacin-d3; HSDB 8030; J01MA01; Ofloxacin,(S); NCGC00016948-01; Ofloxacin (Floxin); CAS-82419-36-1; Exocin (eye drops); Ofloxacin [USAN:USP:INN:BAN:JAN]; (+-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; WP-0405; Spectrum_001186; (R)-Ofloxacin-[d3]; Opera_ID_1114; Prestwick0_000237; Prestwick1_000237; Prestwick2_000237; Prestwick3_000237; Spectrum2_001464; Spectrum3_001499; Spectrum4_000324; Spectrum5_001063; ACMC-20m40v; Epitope ID:116889; O 8757; Lopac0_000904; Oprea1_242882; SCHEMBL24373; BSPBio_000313; BSPBio_003117; KBioGR_000667; KBioSS_001666; fluoro-methyl-(4-methylpiperazin-1-yl)-oxo-[?]carboxylic acid; MLS001074203; MLS006011774; DivK1c_000721; SPECTRUM1502044; SPBio_001387; SPBio_002234; (S)-Ofloxacin;Levaquin;Quixin; Ofloxacin (JP17/USP/INN); BPBio1_000345; DTXSID3041085; SCHEMBL14163982; GTPL10918; HMS502E03; KBio1_000721; KBio2_001666; KBio2_004234; KBio2_006802; KBio3_002617; NINDS_000721; HMS1568P15; HMS1921H12; HMS2090F07; HMS2092B10; HMS2095P15; HMS2235C05; HMS3259G07; HMS3262F10; HMS3369B01; HMS3393K06; HMS3604B17; HMS3712P15; Pharmakon1600-01502044; 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylicacid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (3R)-; AMY22220; BCP14346; BCP22048; EBD13209; HY-B0125; RKL10083; Ofloxacin, fluoroquinolone antibiotic; Tox21_110703; Tox21_500904; BBL005605; BDBM50045004; CCG-39210; NSC727071; NSC758178; s1463; STK256723; AKOS001033517; AKOS016042783; Ofloxacine; DL-8280; HOE-280; Tox21_110703_1; AC-7616; BCP9000851; CS-1891; DB01165; KS-5011; LP00904; NC00466; NSC 727071; NSC 758178; NSC-727071; NSC-758178; SDCCGSBI-0050879.P004; VA11432; IDI1_000721; NCGC00015772-02; NCGC00015772-03; NCGC00015772-04; NCGC00015772-05; NCGC00015772-06; NCGC00015772-07; NCGC00015772-08; NCGC00015772-09; NCGC00015772-10; NCGC00015772-12; NCGC00015772-13; NCGC00015772-22; NCGC00094219-01; NCGC00094219-02; NCGC00094219-03; NCGC00094219-04; NCGC00094219-05; NCGC00094219-06; NCGC00178284-01; NCGC00178284-02; NCGC00261589-01; Ofloxacin 100 microg/mL in Acetonitrile; (+-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)(1,4)benzoxazin-6-carbonsaeure; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid; 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 2,3-dihydro-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (+-)-; 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (+-)-; 83380-47-6; 9-Fluoro-3,7-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic Acid; AK163167; AK163316; H778; ST073364; SY007392; SBI-0050879.P003; AB0013254; DB-056608; AB00513820; EU-0100904; FT-0627808; FT-0630905; FT-0670773; FT-0673216; O0403; Ofloxacin, VETRANAL(TM), analytical standard; VU0243192-7; 86O854; A10666; C07321; D00453; J10376; O-2800; W-3058; AB00052263-12; AB00052263-13; AB00052263_14; AB00052263_15; Ofloxacin, Antibiotic for Culture Media Use Only; Q411447; SR-01000076050-1; SR-01000076050-4; SR-01000076050-7; BRD-A24228527-001-05-9; BRD-A24228527-001-19-0; Z56761309; F0020-0095; F0472-0226; 138199-71-0 (0.5H2O); 7-Chloro-4-hydroxy-8-methylquinoline-3-carboxylicethylester; Ofloxacin, European Pharmacopoeia (EP) Reference Standard; Ofloxacin, United States Pharmacopeia (USP) Reference Standard; (+/-)-9-Fluoro-2,2,3-de)-1,4-benzoxazine-6-carboxylic acid; 8-Methyl-2,3-dihydrofuro[3,2-e]imidazo-[1,2-c]pyrimidine-9-carboxylicacid; Ofloxacin, Pharmaceutical Secondary Standard; Certified Reference Material; ()-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoazine-6-carboxylic acid; (+/-)-9-Fluoro-2, 3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid; (3R)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; 7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.0^{5,13}]trideca-5(13),6,8,11-tetraene-11-carboxylic acid; 7-Fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5,7,9(13),11-tetraene-11-carboxylic acid; 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-; 9-Fluoro-10-(4-methylpiperazino)-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de]-1,4-benzooxazine-6-carboxylic acid; 9-Fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido [1,2,3-de]-1,4-Benzoxazin-6-carboxylic Acid; 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid; 9-fluoro-3-methyl-10-(4-methylpiperazino)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid	Small molecule	1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)	GSDSWSVVBLHKDQ-UHFFFAOYSA-N	CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O	C18H20FN3O4	CAS 82419-36-1	CHEBI:7731	.	.	.	D03NHW	.	.	.
DR0067	3-methyladenine	CID: 135398661	3-methyladenine; 5142-23-4; 3-Methyl-3H-purin-6-amine; 6-Amino-3-methylpurine; 3-MA; 3-Methyl-3H-adenine; 3H-Purin-6-amine, 3-methyl-; NSC 66389; n3-methyladenine; ADENINE, 3-METHYL-; MFCD00010531; CHEBI:38635; UNII-DR88TV7SNU; DR88TV7SNU; 3-METHYL-3H-PURIN-6-YLAMINE; 3-Methyladenine autophagy inhibitor; 3-Methyladenine, 90+%; 3-MA nucleobase; 3-Methyladenine (3-MA); 3MA; 60192-57-6; N(3)-methyladenine; 3-methylpurin-6-amine; EINECS 225-908-6; BRN 0146087; 3-methyl-7H-purin-6-imine; 3mea; 3-methyl-Adenine; 3-Methyladenine?; NSC66389; 1p7m; 4ai5; Autophagy Inhibitor, 3-MA; NCIOpen2_000270; SCHEMBL48369; 5-26-17-00151 (Beilstein Handbook Reference); MLS006010995; SCHEMBL254058; CHEMBL292268; 3-methyl-3-hydropurin-6-imine; CHEMBL4303725; SCHEMBL15764619; 3-Methyl-3H-purin-6-amine #; AOB2548; DTXSID80199406; EX-A130; 3-methyl-3-hydropurine-6-ylamine; Bio1_000422; Bio1_000911; Bio1_001400; HMS3656P04; ZINC403086; 3-Methyl-7H-purine-6(3H)-imine; ACN-C001131; AMY11868; BCP02452; 3-Methyladenine, autophagy inhibitor; ABP000334; ANW-54285; BDBM50488841; NSC-66389; QC-518; s2767; SBB086626; AKOS003382321; AKOS006228458; ZINC100003619; ACN-001131; CCG-206388; CS-5207; DB04104; MCULE-5086156902; NSC 66389 (3-MA); VZ27096; NCGC00345447-02; AC-28818; AK-94088; AS-19224; HY-19312; SMR002530641; SY026559; AB0007938; DB-051961; A7582; FT-0635560; FT-0671432; M2518; ST50298916; SW220216-1; X5709; 3-methyl-3H-purin-6-amine (ACD/Name 4.0); C00913; Q-9331; 3-methyl-3H-purin-6-ylamine (ACD/Name 4.0); J-640198; J-800199; W-202935; BRD-K81647657-001-01-9; Q27094948	Small molecule	1S/C6H7N5/c1-11-3-10-5(7)4-6(11)9-2-8-4/h2-3,7H,1H3,(H,8,9)	ZPBYVFQJHWLTFB-UHFFFAOYSA-N	CN1C=NC(=N)C2=C1N=CN2	C6H7N5	CAS 5142-23-4	CHEBI:38635	.	.	.	.	.	.	.
DR0141	Oxaliplatin	CID: 9887053	Eloxatin (TN); Medac (TN); Oxaliplatin (TN); Oxaliplatin (JAN/USAN/INN)	Small molecule	1S/C6H12N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-8H,1-4H2;(H,3,4)(H,5,6);/q-2;;+2/t5-,6-;;/m1../s1	DRMCATBEKSVAPL-BNTLRKBRSA-N	C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]	C8H14N2O4Pt	CAS 61825-94-3	CHEBI:31941	.	.	.	D0Y3ME	.	.	Oxaliplatin
DR0161	Methylprednisolone	CID: 6741	methylprednisolone; 83-43-2; Medrol; Medrone; Metilprednisolone; Urbason; 6alpha-Methylprednisolone; Metilbetasone; Medrate; Dopomedrol; Promacortine; Besonia; Medesone; Mesopren; Metastab; Metrisone; Moderin; Noretona; Solomet; Urbasone; Wyacort; Methylprednisolon; Methyleneprednisolone; 6-alpha-Methylprednisolone; Metilprednisolone [DCIT]; delta(1)-6alpha-Methylhydrocortisone; 1-Dehydro-6alpha-methylhydrocortisone; Metilprednisolona; Methylprednisolonum; NSC-19987; Methylprednisolonum [INN-Latin]; Metilprednisolona [INN-Spanish]; Suprametil; Medrol dosepak; Medrol adt pak; 6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione; UNII-X4W7ZR7023; CHEBI:6888; (6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one; 11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione; (6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione; Prednisolone, methyl-; Methylprednisolone, 6-alpha; 11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione; 6alpha-Methylprednisolone base; U 7532; MLS000028541; (6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one; Sieropresol; Esametone; Firmacort; Medixon; Metrocort; Metysolon; Nirypan; Reactenol; Lemod; Artisone-wyeth; X4W7ZR7023; MEPRDL; Predni N Tablinen; Medlone 21; SMR000058330; Summicort;; 6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione; DSSTox_CID_3300; Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6a,11b)-; Prednol- L; DSSTox_RID_76965; DSSTox_GSID_23300; Depo-Medrol (acetate); CAS-83-43-2; Prednisolone, 6alpha-methyl-; HSDB 3127; MLS002638721; EINECS 201-476-4; Prednisolone, 6.alpha.-methyl-; BRN 2340300; delta(sup 1)-6-alpha-Methylhydrocortisone; .DELTA.1-6.alpha.-Methylhydrocortisone; NCGC00016330-01; Prestwick_622; Medrol (TN); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6alpha,11beta)-; 6?-Methylprednisolone; Methylprednisolone [USP:INN:BAN:JAN]; Opera_ID_1576; Prestwick0_000279; Prestwick1_000279; Prestwick2_000279; Prestwick3_000279; 6alpha-methyl prednisolone; 11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione; Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl-; CHEMBL650; EC 201-476-4; 6.alpha.-Methylprednisolone; SCHEMBL5084; BSPBio_000158; 4-08-00-03498 (Beilstein Handbook Reference); MLS001148159; MLS002207191; SPBio_002377; BPBio1_000174; GTPL7088; DTXSID7023300; HMS1568H20; HMS2090B13; HMS2095H20; HMS2230D16; HMS3259J04; HMS3712H20; 6alpha-Methylprednisolone, >=98%; HY-B0260; NSC19987; ZINC3875560; Tox21_110376; Tox21_302018; BDBM50103616; LMST02030178; Methylprednisolone (JP17/USP/INN); MFCD00010591; s1733; AKOS015969744; Pregna-1,4-diene-3,20-dione, 6-alpha-methyl-11-beta-17,21-trihydroxy-; Tox21_110376_1; ACN-037579; CCG-220279; DB00959; J3.872E; KS-1273; NC00691; NCGC00022735-03; NCGC00022735-06; NCGC00255269-01; H972; NCI60_001657; M1665; 2639-EP2277861A1; 2639-EP2286811A1; 2639-EP2292595A1; 2639-EP2295409A1; 2639-EP2298778A1; 2639-EP2305660A1; 2639-EP2308562A2; 2639-EP2314590A1; 2639-EP2371811A2; D00407; 010M591; 124684-EP2295426A1; 124684-EP2295427A1; Q417222; SR-01000003089; Q-201395; SR-01000003089-2; BRD-K35240538-001-03-1; BRD-K35240538-001-11-4; BRD-K35240538-001-26-2; 6-alpha-Methylprednisolone 100 microg/mL in Acetonitrile; 6alpha-Methylprednisolone, VETRANAL(TM), analytical standard; 11?,17?,21-Trihydroxy-6?-methyl-1,4-pregnadiene-3,20-dione; 11beta,17,21-trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione; Methylprednisolone, British Pharmacopoeia (BP) Reference Standard; Methylprednisolone, European Pharmacopoeia (EP) Reference Standard; Pregna-1,20-dione, 11.beta.,17,21-trihydroxy-6.alpha.-methyl-; Pregna-1,20-dione, 6.alpha.-methyl-11.beta.-17,21-trihydroxy-; (6?,11?)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione; (6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione; 11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione; Methylprednisolone, United States Pharmacopeia (USP) Reference Standard; Methylprednisolone for system suitability A, EuropePharmacopoeia (EP) Reference Standard; Methylprednisolone for system suitability, European Pharmacopoeia (EP) Reference Standard; Methylprednisolone, Pharmaceutical Secondary Standard; Certified Reference Material; Pregna-1,20-dione, 11,17,21-trihydroxy-6-methyl-, (6.alpha.,11.beta.)-; Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6I+/-,11I(2))-; Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)	Small molecule	1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1	VHRSUDSXCMQTMA-PJHHCJLFSA-N	CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O	C22H30O5	CAS 83-43-2	CHEBI:6888	.	.	.	D08PIQ	.	.	.
DR0167	GC-SF	.	.	Protein	.	.	.	.	.	.	.	.	.	.	.	.	.
DR0176	Neostigmine	CID: 4456	NEOSTIGMINE; Eustigmin; Eustigmine; Prostigmine; Vagostigmine; Prostigmin; 59-99-4; Juvastigmin; m-Trimethylammoniumphenyldimethylcarbamate; Neostigmine [BAN]; 3-Trimethylammoniumphenyl N,N-dimethylcarbamate; 3-[(dimethylcarbamoyl)oxy]-N,N,N-trimethylanilinium; Vagostigmin; Neostigmine (BAN); UNII-3982TWQ96G; (m-Hydroxyphenyl)trimethylammonium dimethylcarbamate; Prostigmin (TN); Neostigmin; CHEBI:7514; CHEMBL278020; Intrastigmina; Neostigminum; Benzenaminium, 3-(((dimethylamino)carbonyl)oxy)-N,N,N-trimethyl-; 3982TWQ96G; [3-(dimethylcarbamoyloxy)phenyl]-trimethyl-azanium bromide; 3-{[(dimethylamino)carbonyl]oxy}-N,N,N-trimethylanilinium; Benzenaminium, 3-[[(dimethylamino)carbonyl]oxy]-N,N,N-trimethyl-; 3-((dimethylcarbamoyl)oxy)-N,N,N-trimethylbenzenaminium; [3-(dimethylcarbamoyloxy)phenyl]-trimethyl-azanium; sulfonatooxymethane; CCRIS 3079; HSDB 3921; NCGC00163240-01; CAS-114-80-7; BRN 3615946; (m-Hydroxyphenyl)trimethylammonium dimethylcarbamate (ester); Ammonium, (m-hydroxyphenyl)trimethyl-, dimethylcarbamate (ester); [3-(dimethylcarbamoyloxy)phenyl]-trimethylazanium; Spectrum_001061; Prestwick0_000468; Prestwick1_000468; Prestwick2_000468; Prestwick3_000468; Spectrum2_001278; Spectrum4_000072; Spectrum5_001234; Lopac-N-2001; bmse000762; Lopac0_000816; SCHEMBL34419; BSPBio_000576; KBioGR_000623; KBioSS_001541; [3-(dimethylcarbamoyloxy)phenyl]-trimethyl-azanium; DivK1c_000165; DivK1c_000198; SPBio_001276; SPBio_002515; BPBio1_000634; GTPL8993; ZINC1792; DTXSID1023360; ALWKGYPQUAPLQC-UHFFFAOYSA-; KBio1_000165; KBio1_000198; KBio2_001541; KBio2_004109; KBio2_006677; NINDS_000165; NINDS_000198; HMS2089A22; BDBM50022775; STL058953; AKOS005711366; CCG-204900; DB01400; MCULE-3501840981; IDI1_000165; IDI1_000198; MLS-0002855; NCGC00015730-01; NCGC00015730-02; NCGC00015730-03; NCGC00015730-04; NCGC00015730-05; NCGC00015730-06; NCGC00015730-07; NCGC00015730-08; NCGC00015730-09; NCGC00015730-24; NCGC00021658-03; SBI-0050793.P004; AB00053807; C07258; D08261; AB00053807-25; AB00053807-26; AB00053807_27; AB00053807_28; AB00053807_29; Q410546; BRD-K18922609-004-04-1; BRD-K18922609-004-14-0; Benzenaminium, 3-(((dimethylamino)carbonyl)oxy)-N,N,N-trimethyl- (9CI)	Small molecule	1S/C12H19N2O2/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5/h6-9H,1-5H3/q+1	ALWKGYPQUAPLQC-UHFFFAOYSA-N	CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C	C12H19N2O2+	CAS 59-99-4	CHEBI:7514	.	.	.	D08USJ	.	.	.
DR0221	2-deoxy-D-glucose	CID: 108223	154-17-6; Deoxyglucose; 2-Desoxy-D-glucose; 2-DG; 2-Deoxy-D-arabinohexose; 2-Deoxy-D-mannose; D-2-Deoxyglucose; (3R,4S,5R)-3,4,5,6-tetrahydroxyhexanal; arabino-Hexose, 2-deoxy-; UNII-9G2MP84A8W; D-Arabino-hexose, 2-deoxy-; HSDB 5484; D-Glucose, 2-deoxy-; 9G2MP84A8W; 2 Deoxyglucose; 2 Deoxy D glucose; 2 Desoxy D glucose; D-arabino-2-desoxyhexose; 2-Desoxy-D-glucose [French]; CCRIS 9094; MFCD00151328; d-2-glucodesose; EINECS 205-823-0; D-2dGlc; BRN 1723331; deoxy-d-glucose, 2-; 2-DEOXYLGLUCOSE; SCHEMBL7670; 4-01-00-04282 (Beilstein Handbook Reference); CHEMBL2074932; DTXSID1037648; ALBB-022735; AMY10934; ZINC2512351; ANW-21488; CD0012; AKOS015919409; AKOS015924825; DB08831; LS30109; 2-Deoxy-D-glucose, BioXtra, >=98%; AS-12502; AB0012037; DB-024740; D0051; 54D176; D-arabino-Hexose, 2-deoxy- (6CI,8CI,9CI); S-1013; 2-Deoxy-D-glucose, >=98% (GC), crystalline; 2-Deoxy-D-glucose, >=99% (GC), crystalline; Q3266534; 5CFA0332-FB70-485D-A064-6C4C39E7CBA1; 2-Deoxy-D-glucose, United States Pharmacopeia (USP) Reference Standard	Small molecule	1S/C6H12O5/c7-2-1-4(9)6(11)5(10)3-8/h2,4-6,8-11H,1,3H2/t4-,5-,6+/m1/s1		C(C=O)C(C(C(CO)O)O)O	C6H12O5	CAS 154-17-6	.	.	.	.	D0H3KI	.	.	.
DR0234	Empagliflozin	CID: 11949646	Empagliflozin; 864070-44-0; JARDIANCE; BI 10773; Empagliflozin (BI 10773); BI-10773; BI10773; UNII-HDC1R2M35U; HDC1R2M35U; 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene; (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; CHEBI:82720; (1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol; (1S)-1,5-anhydro-1-C-{4-chloro-3-((4-{((3S)-oxolan-3-yl)oxy}phenyl)methyl)phenyl}-D-glucitol; Empagliflozin [USAN:INN]; MFCD22566222; Jardiance (TN); (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol; Tube106; (S)-Empagliflozin D4; BI-10773;Empagliflozin; Empagliflozin (BI10773); C23H27ClO7; SCHEMBL899986; GTPL4754; CHEMBL2107830; Empagliflozin (JAN/USAN/INN); AMY1858; EX-A414; BDBM150162; BBL104150; CE0108; s8022; STL557964; US8980829, EMPAGLIFLOZIN; ZINC36520252; AKOS024464680; CCG-269242; CS-0940; DB09038; DS-9824; PB23119; VA10802; AC-27643; HY-15409; SW219120-1; X5927; C22194; D10459; Q-4526; Q5373824; Empagliflozin  (BI-10773;BI 10773;BI10773); (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-[4-chloro-3-({4-[(3S)-oxolan-3-yloxy]phenyl}methyl)phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol; (2S,3R,4R,5S,6R)-2-[4-CHLORO-3-[[4-[(3S)-OXOLAN-3-YL]OXYPHENYL]METHYL]PHENYL]-6-(HYDROXYMETHYL)OXANE-3,4,5-TRIOL; (2S,3R,4R,5S,6R)-2-[4-Chloro-3-[[4-[(3S)-tetrahydrofuran-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol; D-Glucitol, 1,5-anhydro-1-C-(4-chloro-3-((4-(((3S)-tetrahydro-3-furanyl)oxy)phenyl)methyl)phenyl)-, (1S)-	Small molecule	1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1	OBWASQILIWPZMG-QZMOQZSNSA-N	C1COCC1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl	C23H27ClO7	CAS 864070-44-0	CHEBI:82720	.	.	.	D06ALD	.	.	.
DR0241	Calphostin c	CID: 2533	calphostin C; 121263-19-2; UCN-1028c; CHEMBL261214; MFCD00133155; UCN 1028C; 1-[3,10-dihydroxy-12-(2-{[(4-hydroxyphenoxy)carbonyl]oxy}propyl)-2,6,7,11-tetramethoxy-4,9-dioxo-4,9-dihydroperylen-1-yl]propan-2-yl benzoate; ACMC-20d0wl; Calphostin C, Cladosporium cladosporioides; CBiol_001843; KBioGR_000240; KBioSS_000240; SCHEMBL3469324; SCHEMBL13827621; KBio2_000240; KBio2_002808; KBio2_005376; KBio3_000479; KBio3_000480; DTXSID40923744; Bio1_000129; Bio1_000618; Bio1_001107; Bio2_000240; Bio2_000720; HMS1361L22; BDBM50500850; AKOS024456712; PKF 115584; IDI1_033990; Carbonic acid,(1R)-2-[12-[(2R)-2-(benzoyloxy)propyl]-3,10-dihydro-4,9-dihydroxy-2,6,7,11-tetramethoxy-3,10-dioxo-1-perylenyl]-1-methylethyl4-hydroxyphenyl ester, stereoisomer; Calphostin C from Cladosporium cladosporioides; M04057; J-004473; Calphostin C, Cladosporium cladosporioides - CAS 121263-19-2; Calphostin C from Cladosporium cladosporioides, >=90% (HPLC), powder; (1R)-2-[12-[(2R)-2-(Benzoyloxy)propyl]-3,10-dihydro-4,9-dihydroxy-2,6,7,11-tetramethoxy-3,10-dioxo-1-perylenyl]-1-methylethylcarbonic acid 4-hydroxyphenyl ester; [2-[4,9-dihydroxy-12-[2-(4-hydroxyphenoxy)carbonyloxypropyl]-2,6,7,11-tetramethoxy-3,10-dioxo-perylen-1-yl]-1-methyl-ethyl] benzoate; 1-(4,9-Dihydroxy-12-(2-(((4-hydroxyphenoxy)carbonyl)oxy)propyl)-2,6,7,11-tetramethoxy-3,10-dioxo-3,10-dihydroperylen-1-yl)propan-2-yl benzoate; 1-(4,9-dihydroxy-12-(2-((4-hydroxyphenoxy)carbonyloxy)propyl)-2,6,7,11-tetramethoxy-3,10-dioxo-3,10-dihydroperylen-1-yl)propan-2-yl benzoate; 924657-57-8; Benzoic acid 2-{4,9-dihydroxy-12-[2-(4-hydroxy-phenoxycarbonyloxy)-propyl]-2,6,7,11-tetramethoxy-3,10-dioxo-3,10-dihydro-perylen-1-yl}-1-methyl-ethyl ester; Carbonic acid [2-[[12-[2-(benzoyloxy)propyl]-3,10-dihydro-4,9-dihydroxy-2,6,7,11-tetramethoxy-3,10-dioxoperylen]-1-yl]-1-methylethyl]4-hydroxyphenyl ester; Carbonic acid,(1R)-2-[12-[(2R)-2-(benzoyloxy)propyl]-3,10-dihydro-4,9-dihydroxy-2,6,7,11-tetramethoxy-3,10-dioxo-1-perylenyl]-1-methylethyl4-hydroxyphenyl ester,stereoisomer; COC1=CC(O)=C(C(C(OC)=C(CC(C)OC(=O)OC=2C=CC(O)=CC=2)C2=3)=O)C2=C1C1=C(OC)C=C(O)C(C(C=2OC)=O)=C1C=3C=2CC(C)OC(=O)C1=CC=CC=C1	Small molecule	1S/C44H38O14/c1-20(56-43(50)22-10-8-7-9-11-22)16-25-31-32-26(17-21(2)57-44(51)58-24-14-12-23(45)13-15-24)42(55-6)40(49)34-28(47)19-30(53-4)36(38(32)34)35-29(52-3)18-27(46)33(37(31)35)39(48)41(25)54-5/h7-15,18-21,45,48-49H,16-17H2,1-6H3	LSUTUUOITDQYNO-UHFFFAOYSA-N	CC(CC1=C2C3=C(C(=C(C4=C3C(=C5C2=C(C(=O)C=C5OC)C(=C1OC)O)C(=CC4=O)OC)O)OC)CC(C)OC(=O)OC6=CC=C(C=C6)O)OC(=O)C7=CC=CC=C7	C44H38O14	CAS 121263-19-2	.	.	.	.	D0S6XD	.	.	.
DR0258	Flutamide	CID: 3397	Apimid; ApoFlutamide; Cebatrol; Chimax; Cytamid; Drogenil; Eulexin; Eulexine; Fluken; Flulem; Flumid; FlutaGRY; Flutacell; Flutamida; Flutamidum; Flutamin; Flutandrona; Flutaplex; Flutexin; Fugerel; METHOXYCHLOR; NFBA; Niftholide; Niftolid; Niftolide; NovoFlutamide; Odyne; Oncosal; Prostacur; Prostandril; Prostica; Prostogenat; Testotard; Alphapharm Brand of Flutamide; Apo Flutamide; Apogepha Brand of Flutamide; Apotex Brand of Flutamide; Azupharma Brand of Flutamide; Cell pharm Brand of Flutamide; Chephasaar Brand of Flutamide; Chiron Brand of Flutamide; Ciclum Brand of Flutamide; Esparma Brand of Flutamide; Essex Brand of Flutamide; Fluta GRY; Fluta cell; Gry Brand of Flutamide; Hexal Brand of Flutamide; InibsaBrand of Flutamide; Ipsen Brand of Flutamide; Juta Brand of Flutamide; Kendrick Brand of Flutamide; Lemery Brand of Flutamide; Novo Flutamide; Novopharm Brand of Flutamide; PMS Flutamide; Pharmascience Brand of Flutamide; Prasfarma Brand of Flutamide; Q Pharm Brand of Flutamide; Schering Brand of Flutamide; Schering Plough Brand of Flutamide; TAD Brand of Flutamide; Tedec Meiji Brand of Flutamide; F 9397; F0663; Fluta 1A Pharma; Flutamide USP25; SCH13521; Sch 13521; Apo-Flutamide; Cebatrol, veterinary; Eulexin (TN); Fluta-GRY; Fluta-cell; Flutamida [INN-Spanish]; Flutamide(pubertal study); Flutamidum [INN-Latin]; NK-601; Novo-Flutamide; PMS-Flutamide; PUBERTAL FLUTAMIDE STUDY (PUBERTAL STUDIES OF VINCLOZOLIN; Q-Pharm Brand of Flutamide; Sch-13521; Schering-Plough Brand of Flutamide; Flutamide [USAN:BAN:INN]; Ham's F-12 medium; Eulexin, Flutamin, Drogenil,Flutamide; Flutamide (JAN/USP/INN); Alpha,alpha,alpha-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide; M-propionotoluidide,alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro; M-Propionotoluidide, alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro-(8CI); 1A Brand of Flutamide; 2-Methyl-N-(4-nitro-3-[trifluoromethyl]phenyl)propanamide; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propionamide; 4'-Nitro-3'-(trifluoromethyl)isobutyranilide; 4'-Nitro-3'-trifluoromethylisobutyramilide; 4'-Nitro-3'-trifluoromethylisobutyranilide; 4-Nitro-3-(trifluoromethyl)isobutyranilide; Flutamide (AR inhibitor)	Small molecule	1S/C11H11F3N2O3/c1-6(2)10(17)15-7-3-4-9(16(18)19)8(5-7)11(12,13)14/h3-6H,1-2H3,(H,15,17)	MKXKFYHWDHIYRV-UHFFFAOYSA-N	CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F	C11H11F3N2O3	CAS 13311-84-7	CHEBI:5132	.	.	.	D0Y0SW	.	.	.
DR0261	Zoledronic	CID: 68740	Zoledronic acid; Zoledronate; 118072-93-8; Zometa; Reclast; Aclasta; (1-Hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl)diphosphonic acid; CGP 42446; (1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid; ZOL; CGP-42446; [1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid); Orazol; UNII-70HZ18PH24; (1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid; Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis-; C5H10N2O7P2; Reclast (TN); Zometa (TN); CHEMBL924; CHEBI:46557; [1-hydroxy-2-(1H-imidazol-1-yl)-1-phosphonoethyl]phosphonic acid; 70HZ18PH24; CGP-42446A; NCGC00159521-02; (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid; Zoledronic acid [USAN:INN:BAN]; Phosphonic acid, (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bis-; Zomera; 1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyldiphosphonic acid; Bisphosphonate 3; Zometa (Novartis); Aclasta and Reclast; AK-156; Zoledronic acid (INN); Zoledronic Acid Anhydrous; [1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene]bisphosphonic acid; zoledronic-acid; BPH 91; ZOL 446; PubChem14894; Anhydrous Zoledronic Acid; Zoledronic Acid, Anhydrous; DSSTox_CID_22668; DSSTox_RID_80065; Zoledronic acid, Zoledronate; BIDD:PXR0134; DSSTox_GSID_42668; SCHEMBL19054; BIDD:GT0292; Zoledronic Acid (Zoledronate); GTPL3177; JMC515594 Compound 55; PHO012; DTXSID0042668; BDBM12578; HMS2089O09; BCP22750; EBD33252; ZINC3803652; Tox21_111739; [1-HYDROXY-2-(1H-IMIDAZOL-1-YL)-ETHYLIDENE]BISPHOSPHONIC ACID; ANW-57498; MFCD00867791; NSC721517; s1314; STL452893; AKOS005145739; AB07564; AC-1092; CS-1829; DB00399; HS-0091; MCULE-1604726355; NSC 721517; NSC-721517; NCGC00159521-03; NCGC00159521-04; NCGC00159521-05; NCGC00159521-09; NCGC00159521-18; AK-81486; HY-13777; AB0013187; CAS-118072-93-8; FT-0601384; Y1607; D08689; S00092; Z-1463; 42181-EP2270008A1; 42181-EP2292617A1; 42181-EP2295426A1; 42181-EP2295427A1; 42181-EP2308855A1; 42181-EP2311808A1; 42181-EP2311829A1; AB01273947-01; AB01273947-02; AB01273947-03; AB01273947_04; 072Z938; Q218507; SR-05000001436; Q-201946; SR-05000001436-1; [1-hydroxy-(1H-imidazol-1-yl)-phosphonoethyl] phos; 1-Hydroxy-2-(1-imidazolyl)ethane-1,1-diphosphonic Acid; Z1691545083; Phosphonic acid, P,P'-[1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis-	Small molecule	1S/C5H10N2O7P2/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14)	XRASPMIURGNCCH-UHFFFAOYSA-N	C1=CN(C=N1)CC(O)(P(=O)(O)O)P(=O)(O)O	C5H10N2O7P2	CAS 118072-93-8	CHEBI:46557	.	.	.	D0VM2L	.	.	.
DR0268	Imiquimod	CID: 57469	IMIQUIMOD; 99011-02-6; Aldara; Zyclara; 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine; 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine; Beselna; R 837; 4-Amino-1-isobutyl-1H-imidazo[4,5-c]quinoline; R-837; 4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline; 1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine; S-26308; C14H16N4; 9050-31-1; UNII-P1QW714R7M; MFCD00866946; 1H-Imidazo[4,5-c]quinolin-4-amine, 1-(2-methylpropyl)-; CHEMBL1282; 1-isobutylimidazo[4,5-c]quinolin-4-amine; P1QW714R7M; 1-(2-Methylpropyl)-1H-imidazole[4,5-c]quinoline-4-amine; CHEBI:36704; S26308; 1H-Imidazo(4,5-c)quinolin-4-amine, 1-(2-methylpropyl)-; NCGC00070736-02; Zartra; Imiquimod acetate; DSSTox_CID_21047; DSSTox_RID_79617; DSSTox_GSID_41047; Aldara (TN); CAS-99011-02-6; S 26308; SR-01000611320; Imiquimodum; Imiquimod [USAN:INN:BAN]; Vyloma; MTD-39; HSDB 8129; zlchem 9; TMX 101; TMX-101; Aldara; ; ; Beselna; Imiquimod,(S); 6T0; Imiquimod - Aldara; Zyclara (TN); DZ-2636; PubChem21071; ACMC-209stx; (non-labelled)Imiquimod-d9; Imiquimod (JAN/USP/INN); SCHEMBL26136; MLS000083577; BIDD:GT0859; GTPL5003; DTXSID7041047; AOB6939; ZLA0010; HMS2090M14; HMS2232G07; HMS3373B13; HMS3715N19; HMS3747A13; Pharmakon1600-01502351; BCP05151; EBD27815; HY-B0180; Tox21_110985; AC-529; ANW-41635; BBL010772; BDBM50240849; NSC369100; NSC759651; s1211; STK583860; ZINC19632912; Imiquimod - CAS 99011-02-6; Imiquimod, >=98% (HPLC), solid; AKOS005507352; Tox21_110985_1; 1H-Imidazo[4, 1-(2-methylpropyl)-; CCG-208015; CS-2058; DB00724; KS-5218; MCULE-9421195760; NSC 369100; NSC 741062; NSC 759651; NSC-369100; NSC-759651; Imiquimod 100 microg/mL in Acetonitrile; NCGC00070736-03; NCGC00070736-04; AK209015; SMR000048307; SY017571; FT-0602727; I0747; D02500; J10325; Z-4416; 1-isobutyl-1H-imidazo [4,5-c]quinolin-4-amine; 1-isobutyl-1H-imidazo[4,5-c]quinoline-4-amine; AB00399298-05; AB00399298-06; AB00399298-07; AB00399298_08; AB00399298_09; 011I026; 1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-ylamine; A845945; Q423417; 1-(2-methylpropyl)-4-imidazo[4,5-c]quinolinamine; SR-01000611320-2; SR-01000611320-3; BRD-K26657438-001-01-2; BRD-K26657438-001-13-7; 1-(2-methylpropyl)-1Himidazo[4,5-c]quinolin-4-amine; 1-(2-methylpropyl)-1H-imidazo[4,5-c]-quinolin-4-amine; 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine;; Imiquimod, United States Pharmacopeia (USP) Reference Standard; 4-Amino- 1-isobutyl-1H-imidazo[4,5-c]quinoline; 1-(2-Methylpropyl)-1H-imidazo[4,5-C]quinolin-4-amine	Small molecule	1S/C14H16N4/c1-9(2)7-18-8-16-12-13(18)10-5-3-4-6-11(10)17-14(12)15/h3-6,8-9H,7H2,1-2H3,(H2,15,17)	DOUYETYNHWVLEO-UHFFFAOYSA-N	CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N	C14H16N4	CAS 99011-02-6	CHEBI:36704	.	.	.	D06CTE	.	.	.
DR0344	Imipenem	CID: 104838	imipenem; 64221-86-9; Imipemide; N-Formimidoylthienamycin; Tienamycin; Imipenem anhydrous; Imipenemum; N-formimidoyl thienamycin; imipen; MK 0787; CHEBI:471744; 74431-23-5; Imipenem, N-Formimidoyl thienamycin; UNII-Q20IM7HE75; Imipenem (INN); Primaxin; (5R,6S)-6-((R)-1-Hydroxyethyl)-3-(2-(iminomethylamino)ethylthio)-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carbonsaeure; (5R,6S)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; MK-0787; CHEMBL148; Q20IM7HE75; (5R,6S)-3-((2-(Formimidoylamino)ethyl)thio)-6-((R)-1-hydroxyethyl)-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid; Imipenem [INN]; (5R,6S)-3-(2-Formimidoylamino-ethylsulfanyl)-6-((R)-1-hydroxy-ethyl)-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid; Imipenen; DSSTox_CID_3143; DSSTox_RID_76888; DSSTox_GSID_23143; 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,6-[(1R)-1-hydroxyethyl]-3-[[2-[(iminomethyl)amino]ethyl]thio]-7-oxo-,(5R,6S)-; 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-[(1R)-1-hydroxyethyl]-3-[[2-[(iminomethyl)amino]ethyl]thio]-7-oxo-, (5R,6S)-; Imipenemum [Latin]; CAS-64221-86-9; SR-05000000294; NCGC00016928-01; (5R,6S)-6-[(1R)-1-hydroxyethyl]-3-(2-methanimidamidoethylsulfanyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; 1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-((1R)-1-hydroxyethyl)-3-((2-((iminomethyl)amino)ethyl)thio)-7-oxo-, (5R,6S)-; Prestwick_844; EINECS 264-734-5; MK-787; MK0787; Prestwick0_000519; Prestwick1_000519; Prestwick2_000519; Prestwick3_000519; Epitope ID:120384; BSPBio_000477; cc-394; BIDD:GT0686; SPBio_002398; BPBio1_000525; SCHEMBL1649260; SCHEMBL8781920; DTXSID2023143; GTPL10821; Primaxin (imipenem + cilastatin); HMS1569H19; HMS2090A15; HMS2096H19; HMS3260H20; HMS3713H19; Pharmakon1600-01506001; BCP13012; ZINC4097225; Tox21_110689; Tox21_500279; BDBM50049708; BDBM50213266; NSC717864; NSC759901; AKOS016010844; Tox21_110689_1; CCG-220519; CCG-221583; DB01598; LP00279; NSC-717864; NSC-759901; SDCCGSBI-0633697.P001; NCGC00167958-01; NCGC00167958-02; NCGC00167958-03; NCGC00167958-05; NCGC00167958-09; NCGC00260964-01; (5R,6S)-6-[(1R)-1-hydroxyethyl]-3-({2-[(iminomethyl)amino]ethyl}thio)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; AS-75130; C06665; D04515; X-2302; AB01563339_01; Recarbrio (imipenem + cilastatin + relebactam).; 847I667; Q425152; SR-05000000294-2; SR-05000000294-5; (5R,6S)-3-((2-formimidamidoethyl)thio)-6-((R)-1-hydroxyethyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (5R,6S)-3-({2-[(E)-(aminomethylidene)amino]ethyl}sulfanyl)-6-[(1R)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (5R,6S)-3-(2-formimidamidoethylthio)-6-((R)-1-hydroxyethyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (5R,6S)-6-[(1R)-1-hydroxyethyl]-3-[(2-methanimidamidoethyl)sulfanyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; [5R-[5.alpha.,6.alpha.(R*)]]-6-(1-Hydroxyethyl)-3-[[2- [(iminomethyl)amino]ethyl]thio]-7-oxo-1-azabicyclo[3.2.0]hept-2- ene-2-carboxylic acid monohydrate; 1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-3-((2-((iminomethyl)amino)ethyl)thio)-7-oxo-, (5R-(5-alpha,6-alpha(R*)))-; 103730-39-8; 3-[(2-Aminoethyl)thio]-6-[(1R)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid (4-nitrophenyl)methylester monohydrochloride compd. with 1-methyl-2-pyrrolidinone (1:1)	Small molecule	1S/C12H17N3O4S/c1-6(16)9-7-4-8(20-3-2-14-5-13)10(12(18)19)15(7)11(9)17/h5-7,9,16H,2-4H2,1H3,(H2,13,14)(H,18,19)/t6-,7-,9-/m1/s1	ZSKVGTPCRGIANV-ZXFLCMHBSA-N	CC(C1C2CC(=C(N2C1=O)C(=O)O)SCCN=CN)O	C12H17N3O4S	CAS 64221-86-9	CHEBI:471744	.	.	.	D0H3TD	.	.	.
DR0366	Belinostat	CID: 6918638	Belinostat; 414864-00-9; PXD101; Belinostat (PXD101); 866323-14-0; Beleodaq; PXD-101; (E)-N-hydroxy-3-(3-(N-phenylsulfamoyl)phenyl)acrylamide; NSC726630; N-HYDROXY-3-(3-PHENYLSULFAMOYLPHENYL)ACRYLAMIDE; PXD 101; UNII-F4H96P17NZ; PX-105684; N-HYDROXY-3-[3-[(PHENYLAMINO)SULFONYL]PHENYL]-2-PROPENAMIDE; 2-Propenamide, N-hydroxy-3-[3-[(phenylamino)sulfonyl]phenyl]-, (2E)-; F4H96P17NZ; (2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide; CHEBI:61076; PX 105684; (2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]acrylamide; (E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide.; E-Belinostat; Belinostat [USAN:INN]; N-hydroxy-3-(3-(phenylsulfamoyl)phenyl)prop-2-enamide; PX105684; 2-Propenamide, N-hydroxy-3-(3-((phenylamino)sulfonyl)phenyl)-, (2E)-; Belinostat Ph3; Beleodaq (TN); PubChem22405; Belinostat - PXD101; Belinostat (USAN/INN); Belinostat  (PXD101); N-Hydroxy-3-(3-phenylsulphamoylphenyl)acrylamide; cc-489; MLS006011091; CHEMBL408513; GTPL7496; BDBM25150; CHEBI:94531; AMY1792; DTXSID60194378; EX-A180; QCR-181; (E)-3-[3-(phenylsulfamoyl)phenyl]prop-2-enehydroxamic acid; BCPP000351; AOB87787; BCP01741; ZINC3818726; Belinostat,PXD101, PX105684; Belinostat/PXD101,PX105684/; ABP000140; MFCD08064035; NSC758774; s1085; AKOS025401741; BCP9000386; CCG-208758; DB05015; LS41098; NSC-726630; NSC-758774; SB16466; NCGC00263155-02; NCGC00263155-05; AC-25046; AS-17068; SMR004702879; AB0007889; SW219445-1; EC-000.2286; A25012; D08870; W-5363; J-523584; Q4882925; BRD-K17743125-001-01-9; N-Hydroxy-3-[(phenylamino)sulfonyl]-trans-cinnamamide; (E)-N-Hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide; 5OG	Small molecule	1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+	NCNRHFGMJRPRSK-MDZDMXLPSA-N	C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO	C15H14N2O4S	CAS 866323-14-0	CHEBI:61076	.	.	.	D0XT6W	.	.	.
DR0371	Dacarbazine	CID: 135398738	Biocarbazin; Biocarbazine; DTIC; DTICDome; DTIE; Dacarbazino; Dacarbazinum; Dacatic; Decarbazine; Deticene; Dimethyltriazenoimidazolecarboxamide; ICDMT; ICDT; Biocarbazine R; DTIC Dome; Dimethyl Imidazole Carboxamide; Dimethyl Triazeno Imidazole Carboxamide; Imidazole carboxamide; HE1150000; Carboxamide (TN); Carboxamide, Dimethyl Imidazole; DIC (TN); DTIC (TN); DTIC-Dome; Dacarbazino [INN-Spanish]; Dacarbazinum [INN-Latin]; Imidazole (TN); Imidazole Carboxamide, Dimethyl; NPFAPI-05; DTIC-Dome (TN); Di-me-triazenoimidazolecarboxamide; Di-methyl-triazenoimidazolecarboxamide; Dtic-Dome (TN); DTIC, DTIC-Dome, Dacarbazine; Dacarbazine (JAN/USP/INN); Dacarbazine [USAN:INN:BAN:JAN]; (5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; (Dimethyltriazeno)imidazolecarboxamide; 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide; 4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide; 4-(3,3-Dimethyltriazeno)imidazole-5-carboxamide; 4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide; 4-(Dimethyltriazeno)imidazole-5-c arboxamide; 4-(Dimethyltriazeno)imidazole-5-carboxamide; 4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide; 4-[(1E)-3,3-Dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide; 4-[3,3-dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide; 5(or 4)-(dimethyltriazeno)imidazol e-4(or 5)-carboxamide; 5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide; 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; 5-(3,3-Dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide; 5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide; 5-(3,3-Dimethyltri azeno)imidazole-4-carboxamide; 5-(3,3-Dimethyltriazeno)-imidazole-4-carbamide; 5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide; 5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide; 5-(Dimethyltriazeno)-4-imidazolecarboxamide; 5-(Dimethyltriazeno)imidazole-4-carboxamide; 5-(Dimethyltriazeno)imidazole-4-carboximide; 5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; 5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide	Small molecule	1S/C6H10N6O/c1-12(2)11-10-6-4(5(7)13)8-3-9-6/h3H,1-2H3,(H2,7,13)(H,8,9)/b11-10+	FDKXTQMXEQVLRF-ZHACJKMWSA-N	CN(C)N=NC1=C(NC=N1)C(=O)N	C6H10N6O	CAS 4342-03-4	CHEBI:4305	.	.	.	D0Y7ZU	.	.	.
DR0374	Benznidazole	CID: 31593	BENZNIDAZOLE; 22994-85-0; Radanil; Benznidazol; Benzonidazole; Benznidazolum; Ro 07-1051; 1H-Imidazole-1-acetamide, 2-nitro-N-(phenylmethyl)-; N-Benzyl-2-nitroimidazole-1-acetamide; N-Benzyl-2-nitroimidazol-1-yl-acetamide; N-benzyl-2-(2-nitro-1H-imidazol-1-yl)acetamide; 2-Nitro-N-(phenylmethyl)-1H-imidazole-1-acetamide; UNII-YC42NRJ1ZD; N-Benzyl-2-nitro-1H-imidazole-1-acetamide; N-benzyl-2-(2-nitroimidazol-1-yl)acetamide; Imidazole-1-acetamide, N-benzyl-2-nitro-; YC42NRJ1ZD; CHEMBL110; MMV688773; NSC299972; NSC-299972; Ro-7-1051; NCGC00166238-01; Ro 07-1051;Ro 71051; DSSTox_CID_26570; DSSTox_RID_81729; DSSTox_GSID_46570; Rochagan; Benznidazol [INN-Spanish]; Benznidazolum [INN-Latin]; Ro 71051; SMR000857153; NSC 299972; CAS-22994-85-0; CCRIS 2200; N-benzyl-2-nitro-1-imidazoleacetamide; BRN 0551486; Ragonil; Acetamide, N-benzyl-2-(nitroimidazol-1-yl)-; benznidazole (TN); Rochagan (TN); Radanil (TN); Benznidazole (USAN/INN); Benznidazole [USAN:INN]; SCHEMBL45081; MLS001332409; MLS001332410; MLS001360496; DTXSID9046570; SCHEMBL22493029; ZINC56949; CHEBI:133833; HMS2233G13; HMS3369C11; HY-B1548; Tox21_112364; BDBM50089916; MFCD00243089; s3741; AKOS015916722; AKOS024283499; Tox21_112364_1; CCG-267054; DB11989; MCULE-5592629788; 2-(2-nitroimidazolyl)-N-benzylacetamide; NCGC00166238-02; AK323200; AS-68694; QC-10765; ST069365; CS-0013411; FT-0662547; RO-07-1051; Benznidazol (Ro 07-1051; Ro 71051); D02489; N-Benzyl-2-(2-nitro-imidazol-1-yl)-acetamide; N-benzyl-2-(2-nitro-1Himidazol-1-yl)acetamide; N-benzyl-2-(2-nitro-1H-imidazol-5-yl)acetamide; N-Benzyl-2-nitro-1H-imidazole-1-acetamide, 97%; Q425300; SR-01000841264; 2-(2-nitroimidazol-1-yl)-N-(phenylmethyl)acetamide; J-014932; SR-01000841264-3; BRD-K56156805-001-05-4; 1H-Imidazole-1-acetamide, 2-nitro-N-(phenylmethyl)- (9CI); N-Benzyl-2-(2-nitro-imidazol-1-yl)-acetamide (Benznidazole); Pyridinium,1-dodecyl-2-[(hydroxyimino)methyl]-,iodide(1:1)	Small molecule	1S/C12H12N4O3/c17-11(14-8-10-4-2-1-3-5-10)9-15-7-6-13-12(15)16(18)19/h1-7H,8-9H2,(H,14,17)	CULUWZNBISUWAS-UHFFFAOYSA-N	C1=CC=C(C=C1)CNC(=O)CN2C=CN=C2[N+](=O)[O-]	C12H12N4O3	CAS 22994-85-0	CHEBI:133833	.	.	.	D04XGT	.	.	.
DR0445	Clarithromycin	CID: 84029	clarithromycin; 81103-11-9; Biaxin; 6-O-Methylerythromycin; Klaricid; 6-O-Methylerythromycin a; Clarithromycine; Clathromycin; Abbott-56268; Erythromycin, 6-O-methyl-; A-56268; Macladin; Clarith; Klacid; Kofron; Veclam; Clarithromycinum; Naxy; TE-031; Biaxin XL; UNII-H1250JIK0A; Clarithromycin identity; C38H69NO13; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-14-ethyl-12,13-dihydroxy-4-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-7-methoxy-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione; Prevpac; CHEBI:3732; H1250JIK0A; Claritromicina; Abbotic; Astromen; Bicrolid; Clacine; Clambiotic; Claribid; Claricide; Claridar; Claripen; Fromilid; Heliclar; Klaciped; Mabicrol; Clacee; Clacid; Clarem; Crixan; Cyllid; Klabax; Klarid; Klarin; Maclar; Zeclar; Helas; Mavid; Adel; Biaxin filmtab; Klax; Biaxin HP; Biaxin xl filmtab; Klaricid Pediatric; CLA; Clarithromycin extended release; DRG-0099; Klaricid H.P.; CTY; SMR000466382; Clarithromycine [INN-French]; Clarithromycinum [INN-Latin]; Claritromicina [INN-Spanish]; SR-05000001992; 116836-41-0; Clarithromycin (Biaxin, Klacid); clarithromycina; Cyllind; CCRIS 8833; Klaricid XL; HSDB 8055; (14R)-14-Hydroxyclarithromycin; TE031; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-7-methoxy; Clarithromycin,(S); Biaxin (TN); Clarithromycin, 97%; Spectrum_000089; CPD000466382; Clarithromycin [USAN:USP:INN:BAN:JAN]; SpecPlus_000559; 6-O-methyl erythromycin; O(6)-methylerythromycin; CLA;; Spectrum2_001668; Spectrum3_001667; Spectrum4_000629; Spectrum5_001729; 6-0-methylerythromycin A; CHEMBL1741; SCHEMBL38125; BSPBio_003453; KBioGR_001218; KBioSS_000509; MLS000759516; MLS001201751; MLS001424066; BIDD:GT0200; DivK1c_006655; SPECTRUM1504231; SPBio_001855; Lactoferrin B & Clarithromycin; Lactoferrin H & Clarithromycin; DTXSID3022829; Clarithromycin & Interleukin-12; CLM & IL-12; GTPL10903; KBio1_001599; KBio2_000509; KBio2_003077; KBio2_005645; KBio3_002673; ANX-015; SDP-015; Clarithromycin (JP17/USP/INN); Clarithromycin, >=95% (HPLC); Clarithromycin, >=98% (HPLC); HMS1922H09; HMS2051G18; HMS2090O11; HMS2094M05; HMS2231A08; HMS3715J17; Pharmakon1600-01504231; EBD13493; BDBM50404044; CCG-39086; LMPK04000014; MFCD00865140; NSC758704; s2555; ZINC85534098; AKOS015894242; CS-2576; DB01211; MCULE-7168853332; NC00140; NSC 758704; NSC-758704; NCGC00178054-01; NCGC00178054-06; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione; H781; HY-17508; SBI-0206716.P001; Clarithromycin 100 microg/mL in Acetonitrile; C06912; D00276; J10130; AB00053394-10; AB00053394-12; AB00053394-13; AB00053394_14; AB00053394_15; 103C119; Q118551; Q-200870; SR-05000001992-1; SR-05000001992-2; BRD-K49668410-001-07-1; BRD-K49668410-001-18-8; Clarithromycin, European Pharmacopoeia (EP) Reference Standard; Clarithromycin, United States Pharmacopeia (USP) Reference Standard; Clarithromycin Identity, United States Pharmacopeia (USP) Reference Standard; Clarithromycin, Ready Made Solution, 50 mg/mL in DMSO, 0.2 mum filtered; Clarithromycin for peak identification, European Pharmacopoeia (EP) Reference Standard; Clarithromycin, Pharmaceutical Secondary Standard; Certified Reference Material; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-14-ethyl-12,13-dihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-7-methoxy-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione (non-preferred name); (3R,4S,5S,6R,7R,9R,11S, 12R,13S,14S)-6-{[(2S,3R,4S,6R)- 4-dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy}-14-ethyl-12,13-dihydroxy- 4-{[(2R,4S,5S,6S)-5-hydroxy-4-methoxy-4,6- dimethyloxan-2-yl]oxy}-7-methoxy-3,5,7,9,11,13-hexamethyl-1- oxacyclotetradecane-2,10-dione	Small molecule	1S/C38H69NO13/c1-15-26-38(10,45)31(42)21(4)28(40)19(2)17-37(9,47-14)33(52-35-29(41)25(39(11)12)16-20(3)48-35)22(5)30(23(6)34(44)50-26)51-27-18-36(8,46-13)32(43)24(7)49-27/h19-27,29-33,35,41-43,45H,15-18H2,1-14H3/t19-,20-,21+,22+,23-,24+,25+,26-,27+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1	AGOYDEPGAOXOCK-KCBOHYOISA-N	CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)OC)C)C)O)(C)O	C38H69NO13	CAS 81103-11-9	CHEBI:3732	.	.	.	D0Z1ZM	.	.	.
DR0456	Scopolamine	CID: 3000322	scopolamine; Hyoscine; (-)-Hyoscine; 51-34-3; Scopine (-)-tropate; l-Scopolamine; Scopine tropate; 6,7-Epoxytropine tropate; Transderm-Scop; (-)-Scopolamine; Hyosol; Atrochin; Atroquin; Isopto Hyoscine; Epoxytropine tropate; Scopolamine hydrobromide; 6-beta,7-beta-Epoxy-3-alpha-tropanyl S-(-)-tropate; UNII-DL48G20X8X; Beldavrin; Scopamin; CHEMBL3084722; alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester; Skopolamin; Hyosceine; Scop; DL48G20X8X; Tropic acid, ester with scopine; CHEBI:16794; LSM-4015; Isoscopil; Tranaxine; (1S,3S,5R,6R,7S)-6,7-epoxytropan-3-yl (2S)-3-hydroxy-2-phenylpropanoate; Hysco; Hyoscine bromide; Scopace; Transderm scop; Scopolamine HCl; Boro-Scopol; Scopolaminium bromide; 1alphaH,5alphaH-Tropan-3alpha-ol, 6beta,7beta-epoxy-, (-)-tropate (ester); Scopolammonium bromide; l-Hyoscine hydrobromide; (1R,2R,4S,5S,7s)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl (S)-3-hydroxy-2-phenylpropanoate; SEE; (-)-Scopolamine bromide; l-Scopolamine-hydrobromide; SCOPOLAMINE BROMIDE; (-)-Hyoscine hydrobromide; Scopoderm; (+)-Scopolamine; levo-duboisine; (+)-Hyoscine; (1R,2R,4S,5S,7S)-9-methyl-3-oxa-9-azatricyclo[3.3.1.0(2,4)]non-7-yl (2S)-3-hydroxy-2-phenylpropanoate; [(1R,2R,4S,5S)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate; Hyoscyine hydrobromide; Atroscine Hydrobromide; Hydroscine hydrobromide; hydrobromicum, Scopolaminum; Tropane alkaloid; HSDB 4074; EINECS 200-090-3; NSC61806; S-(-)-Tropate; Prestwick3_000877; EC 200-090-3; 6beta,7beta-Epoxy-3alpha-tropanyl S-(-)-tropate; SCHEMBL16226; BSPBio_000953; GTPL330; 6beta,7beta-Epoxy-1alpha,5alpha-tropan-3alpha-ol; BPBio1_001049; CHEMBL569713; CHEMBL1906925; DTXSID6023573; SCHEMBL22393238; CHEBI:93572; HMS2090N13; HMS3886L22; HY-N0296; AC-968; BDBM50263508; CS0019; s9326; ZINC13118910; AKOS025402477; Tropic acid, 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(sup 2,4))non-7-yl ester; ZINC100037020; ZINC101147375; CCG-267504; CS-6609; DB00747; 3-Oxa-9-azatricyclo(3.3.1.0(sup 2,4))nonan-7-ol, 9-methyl-, tropate (ester); 3-Oxa-9-azatricyclo(3.3.1.O(sup 2,4))nonan-7-ol, 9-methyl-, tropate (ester); SMP1_000270; NCGC00024357-04; NCGC00024357-05; (1R,2R,4S,5S,7S)-9-methyl-3-oxa-9-azatricyclo[3.3.1.0~2,4~]non-7-yl (2S)-3-hydroxy-2-phenylpropanoate; AB00429689; AB00429689-30; AB00429689-31; AB00429689_32; Q337188; (methyl[?]yl) (2S)-3-hydroxy-2-phenyl-propanoate; BRD-K89923877-003-02-4; Q27165268; (1R,2R,4S,5S,7S)-9-methyl-3-oxa-9-azatricyclo[3.3.1.0^{2,4}]nonan-7-yl (2S)-3-hydroxy-2-phenylpropanoate; (1R,2R,4S,5S,7S)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]non-7-yl (2R)-3-hydroxy-2-phenylpropanoate; (1R,2R,4S,5S,7s)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl (2S)-3-hydroxy-2-phenylpropanoate; [7(S)-(1.alpha.,2.beta.,4.beta.,5.alpha.,7.beta.)]-.alpha.-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo-[3.3.1.0^2,4]non-7-yl ester; Benzeneacetic acid, alpha-(hydroxymethyl)-, (1alpha,2beta,4beta,5alpha,7beta)-9-methyl-3-oxa-9-azatricyclo(3.3.1.02,4)non-7-yl ester, (alphaS)-; Benzeneacetic acid, alpha-(hydroxymethyl)-, 9-methyl-3-oxa-9-azatricyclo(3.3.1.02,4)non-7-yl ester, (7(S)-(1alpha,2beta,4beta,5alpha,7beta))-	Small molecule	1S/C17H21NO4/c1-18-13-7-11(8-14(18)16-15(13)22-16)21-17(20)12(9-19)10-5-3-2-4-6-10/h2-6,11-16,19H,7-9H2,1H3/t11?,12-,13-,14+,15-,16+/m1/s1	STECJAGHUSJQJN-USLFZFAMSA-N	CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4	C17H21NO4	CAS 114-49-8	CHEBI:16794	.	.	.	D0B7YT	.	.	.
DR0459	Albiflorin	CID: 24868421	Albiflorin; 39011-90-0; Alibiflorin; Q63399047; 7-Oxatricyclo[4.3.0.03,9]nonan-8-one,9-[(benzoyloxy)methyl]-1-(b-D-glucopyranosyloxy)-4-hydroxy-6-methyl-,(1R,3R,4R,6S)-; CHEBI:132793; HY-N0037; MFCD29477681; ZINC38143679; AKOS032948342; CS-3643; NCGC00169374-01; NCGC00169374-02; AS-75074; C17457; BRD-K76724902-001-01-6; [(1R,3R,4R,6S,9S)-1-(beta-D-glucopyranosyloxy)-4-hydroxy-6-methyl-8-oxo-7-oxatricyclo[4.3.0.0(3,9)]nonan-9-yl]methyl benzoate; [(1R,3R,4R,6S,9S)-4-hydroxy-6-methyl-8-oxo-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-7-oxatricyclo[4.3.0.03,9]nonan-9-yl]methyl benzoate; [(1R,3R,4R,6S,9S)-4-HYDROXY-6-METHYL-8-OXO-1-{[(2S,3R,4S,5S,6R)-3,4,5-TRIHYDROXY-6-(HYDROXYMETHYL)OXAN-2-YL]OXY}-7-OXATRICYCLO[4.3.0.0(3),?]NONAN-9-YL]METHYL BENZOATE	Small molecule	1S/C23H28O11/c1-21-8-13(25)12-7-23(21,33-19-17(28)16(27)15(26)14(9-24)32-19)22(12,20(30)34-21)10-31-18(29)11-5-3-2-4-6-11/h2-6,12-17,19,24-28H,7-10H2,1H3/t12-,13+,14+,15+,16-,17+,19-,21-,22-,23-/m0/s1	QQUHMASGPODSIW-ICECTASOSA-N	CC12CC(C3CC1(C3(C(=O)O2)COC(=O)C4=CC=CC=C4)OC5C(C(C(C(O5)CO)O)O)O)O	C23H28O11	CAS 39011-90-0	CHEBI:132793	.	.	.	.	.	.	.
DR0490	Etoposide	CID: 36462	etoposide; 33419-42-0; VePesid; Toposar; trans-Etoposide; Lastet; (-)-Etoposide; Zuyeyidal; Etoposido; Etoposidum; Etoposidum [INN-Latin]; VP-16; Etoposide (VP16); VP 16-213; VP 16 (pharmaceutical); Vepesid J; Etoposido [INN-Spanish]; Etopophos (phosphate salt); VP 16; VP-16-213; VP 16213; UNII-6PLQ3CP4P3; NK 171; NSC-141540; NSC 141540; CCRIS 2392; HSDB 6517; EINECS 251-509-1; Epipodophyllotoxin VP-162	Small molecule	1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/t11-,15+,20-,21-,22+,24-,25-,26-,27-,29+/m1/s1	VJJPUSNTGOMMGY-MRVIYFEKSA-N	CC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O	C29H32O13	CAS 33419-42-0	.	.	.	.	D06GMG	.	.	Etoposide
DR0615	Benfotiamine	CID: 3032771	benfotiamine; Benphothiamine; Benzoylthiamine monophosphate; 22457-89-2; S-Benzoylthiamine monophosphate; S-Benzoylthiamine O-monophosphate; Benzoylthiamine O-monophosphate; Benfotamine; Benfotiamina; Benfotiaminum; 22457-89-2 (free acid); N-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-N-(4-hydroxy-2-mercapto-1-methyl-1-butenyl)formamide S-benzoate O-phosphate; S-Benzoylthiamine-O-monophosphate; C19H23N4O6PS; (3Z)-4-{N-[(4-amino-2-methylpyrimidin-5-yl)methyl]carbonylamino}-3-(phenylcarb onylthio)pent-3-enyl dihydrogen phosphate; (Z)-S-(2-(N-((4-amino-2-methylpyrimidin-5-yl)methyl)formamido)-5-(phosphonooxy)pent-2-en-3-yl) benzothioate; s-[2-{[(4-amino-2-methylpyrimidin-5-yl)methyl](formyl)amino}-5-(phosphonooxy)pent-2-en-3-yl] benzenecarbothioate; SR-01000872627; CHEBI:41039; MFCD00057343; Prestwick_68; Biotamin (TN); PubChem17412; Prestwick2_000654; Prestwick3_000654; Benfotiamine (JAN/INN); BSPBio_000687; SCHEMBL188070; BPBio1_000757; CHEMBL4303665; SCHEMBL19184708; HMS1570C09; HMS2097C09; HMS3714C09; ZINC2015559; STL453586; AKOS015920320; AC-8280; CCG-220654; DB11748; NCGC00179477-01; H493; ST056187; AB0013076; 57B892; A15020; D01255; SR-01000872627-1; SR-01000872627-2; 137-74-6; S-[(2Z)-2-{[(4-amino-2-methylpyrimidin-5-yl)methyl](formyl)amino}-5-(phosphonooxy)pent-2-en-3-yl] benzenecarbothioate; S-{(1Z)-2-[[(4-Amino-2-methyl-5-pyrimidinyl)methyl](formyl)amino]-1-[2-(phosphonooxy)ethyl]-1-propenyl} benzenecarbothioate, AldrichCPR	Small molecule	1S/C19H23N4O6PS/c1-13(23(12-24)11-16-10-21-14(2)22-18(16)20)17(8-9-29-30(26,27)28)31-19(25)15-6-4-3-5-7-15/h3-7,10,12H,8-9,11H2,1-2H3,(H2,20,21,22)(H2,26,27,28)/b17-13-	BTNNPSLJPBRMLZ-LGMDPLHJSA-N	CC1=NC=C(C(=N1)N)CN(C=O)C(=C(CCOP(=O)(O)O)SC(=O)C2=CC=CC=C2)C	C19H23N4O6PS	CAS 22457-89-2	CHEBI:41039	.	.	.	.	.	.	.
DR0618	Carfilzomib	CID: 11556711	Kyprolis; Carfilzomib (PR-171); PR-171; UNII-72X6E3J5AR; 72X6E3J5AR; CHEMBL451887; CHEBI:65347; NCGC00249613-01; DSSTox_RID_82886; DSSTox_CID_28616; DSSTox_GSID_48690; (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide; N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-L-phenylalaninamide; 868540-17-4	Small molecule	1S/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1	BLMPQMFVWMYDKT-NZTKNTHTSA-N	CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3)NC(=O)CN4CCOCC4	C40H57N5O7	CAS 868540-17-4	CHEBI:65347	.	.	.	D00UVA	.	.	.
DR0619	Paricalcitol	CID: 5281104	Paricalcitol; 131918-61-1; Zemplar; 19-Nor-1alpha,25-dihydroxyvitamin D2; Compound 49510; UNII-6702D36OG5; Compound-49510; CHEBI:7931; 6702D36OG5; (1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (1R,3R,7E)-17beta-[(2R,3E,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-9,10-secoestra-5,7-diene-1,3-diol; NCGC00182706-01; Paracalcin; 19-Nor-1,25-(OH)2D2; Zemplar (TN); 19-Nor-1-alpha,25-dihydroxyvitamin D2; HSDB 7360; Paricalcitol [USAN:USP:INN]; ABT-358; (7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1alpha,3beta,25-triol; Paricalcitol solution; PubChem18825; (1alpha.3beta,7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol; SCHEMBL3655; DSSTox_CID_28566; DSSTox_RID_82838; DSSTox_GSID_48640; BIDD:GT0330; Paricalcitol (JAN/USP/INN); GTPL2791; CHEMBL1200622; DTXSID4048640; AMY2878; BDBM233195; (1R,3R)-5-{2-[(1R,3aS,4E,7aR)-1-[(2R,3E,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}cyclohexane-1,3-diol; ACT07192; EX-A4434; 19-Nor-1,25-dihydroxyvitamin D2; Tox21_112987; LMST04030163; s6681; ZINC13911941; AKOS005145562; AC-1198; BCP9001050; CS-0705; DB00910; 19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol, (1alpha,3beta,7E,22E)-; HY-50919; CAS-131918-61-1; C08127; D00930; W-5365; 918P611; Q155746; (1R,3R,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-octahydro-1-[(1R,2E,4S)-5-hydroxy-1,4,5-trimethyl-2-hexen-1-yl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediol; 1,3-Cyclohexanediol, 5-[(2E)-2-[(1R,3aS,7aR)-octahydro-1-[(1R,2E,4S)-5-hydroxy-1,4,5-trimethyl-2-hexen-1-yl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-, (1R,3R,5Z)-	Small molecule	1S/C27H44O3/c1-18(8-9-19(2)26(3,4)30)24-12-13-25-21(7-6-14-27(24,25)5)11-10-20-15-22(28)17-23(29)16-20/h8-11,18-19,22-25,28-30H,6-7,12-17H2,1-5H3/b9-8+,21-11+/t18-,19+,22-,23-,24-,25+,27-/m1/s1	BPKAHTKRCLCHEA-UBFJEZKGSA-N	CC(C=CC(C)C(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3)O)O)C	C27H44O3	CAS 131918-61-1	CHEBI:7931	.	.	.	D0N1TP	.	.	.
DR0641	Minocycline	CID: 54675783	minocycline; 10118-90-8; Minocyclin; Minociclina; Minocyn; Dynacin; Minocin; Minomycin; CL 59806; MINO; 7-Dimethylamino-6-demethyl-6-deoxytetracycline; UNII-FYY3R43WGO; CHEBI:50694; FYY3R43WGO; (4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE; Tri-minocycline; Minocyclinum; 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)-; Minocyclinum [INN-Latin]; NCGC00183044-01; Borymycin; Minociclina [INN-Spanish]; MIY; minociclinum; Minocline; Minoz; 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide; (4S,4aS,5aR,12aR)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide; HSDB 3130; NSC-141993; Minocin (Hydrochloride); Vectrin (Hydrochloride); Minocycline (USAN/INN); BRN 3077644; Lactoferrin B & Minocycline; Lactoferrin H & Minocycline; Minocycline [USAN:INN:BAN]; SR-05000001675; (minocycline); (4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2- CARBOXAMIDE; (4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide; NSC141993; Spectrum_000967; Prestwick0_000315; Prestwick1_000315; Prestwick2_000315; Spectrum2_001047; Spectrum3_000508; Spectrum4_000062; Spectrum5_001293; SCHEMBL4042; CHEMBL1434; DSSTox_CID_25033; DSSTox_RID_80650; DSSTox_GSID_45033; SCHEMBL24315; BSPBio_002035; KBioGR_000583; KBioSS_001447; 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S-(4alpha,4aalpha,5aalpha,12aalpha))-; cc-666; ls-007; CHEMBL69484; DivK1c_000450; SPBio_000974; SPBio_002529; DTXSID1045033; SCHEMBL16681149; BCBcMAP01_000027; GTPL10831; KBio1_000450; KBio2_001447; KBio2_004015; KBio2_006583; KBio3_001535; NINDS_000450; HMS2090D03; KUC106429N; KSC-12-231B; ZINC4019704; Tox21_113643; BDBM50103599; LMPK07000002; ZINC14879992; AKOS015969674; ZINC100409820; BCP9000928; CL59806; DB01017; IDI1_000450; SMP1_000191; NCGC00178854-01; NCGC00178854-02; NCGC00188954-01; AC-30184; CL-59806; SBI-0051449.P003; CAS-10118-90-8; AM20090714; 1371-EP2269978A2; 1371-EP2269985A2; 1371-EP2269991A2; 1371-EP2272832A1; 1371-EP2284150A2; 1371-EP2284151A2; 1371-EP2284152A2; 1371-EP2284153A2; 1371-EP2284155A2; 1371-EP2284156A2; 1371-EP2284164A2; 1371-EP2287140A2; 1371-EP2287148A2; 1371-EP2287150A2; 1371-EP2289871A1; 1371-EP2292590A2; 1371-EP2292612A2; 1371-EP2295402A2; 1371-EP2295419A2; 1371-EP2295426A1; 1371-EP2295427A1; 1371-EP2298732A1; 1371-EP2301534A1; 1371-EP2301912A2; 1371-EP2301913A1; 1371-EP2301914A1; 1371-EP2301916A2; 1371-EP2305637A2; 1371-EP2308832A1; 1371-EP2308863A1; 1371-EP2311451A1; 1371-EP2311796A1; 1371-EP2311797A1; 1371-EP2311798A1; 1371-EP2311799A1; 1371-EP2316450A1; 18M908; C07225; D05045; AB00053501-03; AB00053501_04; AB00053501_05; Q415336; J-500789; SR-05000001675-3; (2E,4S,4aR,5aS,12aR)-2-(amino-hydroxy-methylidene)-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3 ,12-trione; (4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-	Small molecule	1S/C23H27N3O7/c1-25(2)12-5-6-13(27)15-10(12)7-9-8-11-17(26(3)4)19(29)16(22(24)32)21(31)23(11,33)20(30)14(9)18(15)28/h5-6,9,11,17,27-28,31,33H,7-8H2,1-4H3,(H2,24,32)/t9-,11-,17-,23-/m0/s1	FFTVPQUHLQBXQZ-KVUCHLLUSA-N	CN(C)C1C2CC3CC4=C(C=CC(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C	C23H27N3O7	CAS 10118-90-8	CHEBI:50694	.	.	.	D08LTU	.	.	.
DR0683	Thioridazine	CID: 5452	Aldazine; Mallorol; Malloryl; Meleril; Mellaril; Mellarit; Mellerets; Mellerette; Melleretten; Melleril; Melleryl; Metlaril; Novoridazine; Orsanil; Ridazine; Sonapax; Stalleril; Thioridazin; Thioridazinum; Thioxidazine; Tioridazin; Tioridazina; Thioridazine Hcl; Thioridazine Hcl Intensol; Thioridazine prolongatum; Thoridazine hydrochloride; Dl-Thioridazine; Mellaril (TN); Mellaril-S; Melleril (liquid); Novoridazine (TN); TP-21; Thioridazine, prolongatum; Thioridazinum [INN-Latin]; Thioril (TN); Tioridazina [INN-Spanish]; Mellaril-S (TN); Thioridazine (USP/INN); Thioridazine [USAN:INN:BAN]; Mellaril (*Hydrochloride*); (+-)-Thioridazine; 10-(2-(1-Methyl-2-piperidyl)ethyl)-2-(methylthio)phenothiazine; 10-[2-(1-methyl-2-piperidyl)ethyl]-2-methylsulfanyl-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfanyl)-10H-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylthio)-10H-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfanylphenothiazine; 2-Methylmercapto-10-(2-(N-methyl-2-piperidyl)ethyl)phenothiazine; 3-Methylmercapto-N-(2'-(N-methyl-2-piperidyl)ethyl)phenothiazine	Small molecule	1S/C21H26N2S2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(24-2)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3	KLBQZWRITKRQQV-UHFFFAOYSA-N	CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC	C21H26N2S2	CAS 50-52-2	CHEBI:9566	.	.	.	D0U1OE	.	.	.
DR0684	X-ray irradiation	.	.	Radiotherapy	.	.	.	.	.	.	.	.	.	.	.	.	.
DR0688	Dipyridamole	CID: 3108	dipyridamole; 58-32-2; Dipyridamol; Dipyridamine; Persantin; Dipyudamine; Persantine; Curantyl; Stimolcardio; Cardoxin; Kurantil; Stenocardil; Cardioflux; Dipiridamol; Dipyridan; Peridamol; Anginal; Apricor; Coribon; Corosan; Coroxin; Stenocardiol; Agilease; Chilcolan; Justpertin; Permiltin; Piroan; Cleridium 150; Coronarine; Gulliostin; Prandiol; Natyl; Prandiol 75; Usaf Ge-12; Dypyridamol; 2,2',2'',2'''-((4,8-Di(piperidin-1-yl)pyrimido[5,4-d]pyrimidine-2,6-diyl)bis(azanetriyl))tetraethanol; Dipyridamolum; RA 8; RA-8; Dipyridamole (Persantine); C24H40N8O4; UNII-64ALC7F90C; NSC 515776; NSC-515776; MLS000028420; Cleridium; CHEMBL932; 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido(5,4-d)pyrimidine; Iv Persantine; SMR000058382; 64ALC7F90C; CHEBI:4653; Cardoxil; Pyrimido(5,4-d)pyrimidine, 2,6-bis(bis(2-hydroxyethyl)amino)-4,8-dipiperidino-; MFCD00010555; NSC515776; 2-({6-[bis(2-hydroxyethyl)amino]-4,8-bis(piperidin-1-yl)pyrimido[5,4-d][1,3]diazin-2-yl}(2-hydroxyethyl)amino)ethan-1-ol; 2-[[2-[bis(2-hydroxyethyl)amino]-4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol; Ethanol, 2,2',2'',2'''-[(4,8-di-1-piperidinylpyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]tetrakis-; CAS-58-32-2; NCGC00015385-12; Dypyridamole; Coridil; Protangix; 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine; DSSTox_CID_20668; DSSTox_RID_79531; DSSTox_GSID_40668; 2,2',2'',2'''-((4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidine-2,6-diyl)bis(azanetriyl))tetrakis(ethan-1-ol); 2,2',2'',2'''-{[4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidine-2,6-diyl]dinitrilo}tetraethanol; Ethanol, 2,2',2'',2'''-((4,8-di-1-piperidinylpyrimido(5,4-d)pyrimidine-2,6-diyl)dinitrilo)tetrakis-; Ethanol,2,2',2'',2'''-[(4,8-di-1-piperidinylpyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]tetrakis-; Dipiridamol [INN-Spanish]; Dipyridamolum [INN-Latin]; Permole; Persantine (TN); (3E)-3-[[(1S,4aS,8aS)-Decahydro-5,5,8a-trimethyl-2-methylene-1-naphthalenyl]methylene]dihydro-5-methoxy-2(3H)3-[(1E)-2-[(1S,4aS,8aS)-Decahydro-5,5,8a-trimethyl-2-methylene-1-naphthalenyl]ethenyl]furan; (+)-Coronarin E-furanone; Coronarin D methyl ethe; 2,2',2'',2'''-((4,8-Di(piperidin-1-yl)pyrimido[5,4-d]-pyrimidine-2,6-diyl)bis(azanetriyl))tetraethanol; SR-01000003065; EINECS 200-374-7; BRN 0068373; Dipridacot; Prestwick_145; Dipyridamole [USAN:USP:INN:BAN:JAN]; Spectrum_001004; Tocris-0691; Opera_ID_494; Prestwick0_000142; Prestwick1_000142; Prestwick2_000142; Prestwick3_000142; Spectrum2_000972; Spectrum3_000402; Spectrum4_000522; Spectrum5_000839; Lopac-D-9766; UPCMLD-DP072; D 9766; cid_3108; 2,2',2'',2'''-((4,8-Dipiperidinopyrimido(5,4-d)pyrimidine-2,6-diyl)dinitrilo)tetraethanol; Lopac0_000464; SCHEMBL16119; BSPBio_000244; BSPBio_001554; BSPBio_001924; KBioGR_001123; KBioSS_001484; 4-26-00-03840 (Beilstein Handbook Reference); MLS001076306; MLS001333724; MLS002548866; DivK1c_000696; SPECTRUM1500259; SPBio_001003; SPBio_002183; BPBio1_000270; GTPL4807; DTXSID6040668; Thymidine,6-dihydro-6-methoxy-; UPCMLD-DP072:001; BDBM23620; Dipyridamole (JP17/USP/INN); HMS502C18; IZEKFCXSFNUWAM-UHFFFAOYSA-; KBio1_000696; KBio2_001484; KBio2_004052; KBio2_006620; KBio3_001144; B01AC07; NINDS_000696; BCPP000256; HMS1568M06; HMS1791N16; HMS1920I10; HMS1989N16; HMS2089N15; HMS2091O18; HMS2095M06; HMS2232E19; HMS3259C03; HMS3261M10; HMS3266J17; HMS3371J03; HMS3402N16; HMS3411B03; HMS3655I20; HMS3675B03; HMS3712M06; HMS3742O03; HMS3867F13; Pharmakon1600-01500259; ZINC643046; AMY40468; BCP26947; EBD20789; HY-B0312; Tox21_110133; Tox21_500464; 2,6-Bis(diethanolamine)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine; ANW-49242; BBL027781; CCG-40190; NSC756743; s1895; STL377790; AKOS000509426; Tox21_110133_1; BCP9000613; DB00975; Dipyridamole, >=98% (TLC), powder; HS-0041; LP00464; MCULE-3112669573; MP-0582; NC00448; NSC-619103; NSC-756743; SDCCGSBI-0050449.P005; VA10749; IDI1_000696; SMP2_000208; NCGC00015385-01; NCGC00015385-02; NCGC00015385-03; NCGC00015385-04; NCGC00015385-05; NCGC00015385-06; NCGC00015385-07; NCGC00015385-08; NCGC00015385-09; NCGC00015385-10; NCGC00015385-11; NCGC00015385-13; NCGC00015385-14; NCGC00015385-15; NCGC00015385-16; NCGC00015385-18; NCGC00015385-29; NCGC00023914-02; NCGC00023914-04; NCGC00023914-05; NCGC00023914-06; NCGC00023914-07; NCGC00023914-08; NCGC00023914-09; NCGC00023914-10; NCGC00023914-11; NCGC00261149-01; 2-({6-[bis(2-hydroxyethyl)amino]-4,8-bis(piperidin-1-yl)-[1,3]diazino[5,4-d]pyrimidin-2-yl}(2-hydroxyethyl)amino)ethan-1-ol; 2-[[2-[bis(2-hydroxyethyl)amino]-4,8-bis(1-piperidyl)pyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol; AC-18100; AC-30804; AK-76609; Ethanol, 2,2',2'',2'''-((4,8-dipiperidinopyrimido(5,4-d)pyrimidine-2,6-diyl)dinitrilo)tetra-; H843; NCI60_005689; ST078856; SBI-0050449.P004; 2,8-dipiperidinopyrimido[5,4-d]pyrimidine; AB0013300; AB00051974; B1933; EU-0100464; FT-0603242; SW196456-3; W1467; EN300-70723; BIM-0050449.0001; D00302; J10379; 54290-EP2277865A1; 54290-EP2298773A1; 54290-EP2305653A1; 54290-EP2308562A2; AB00051974-18; AB00051974-19; AB00051974_20; AB00051974_21; A828156; Q419374; SR-01000003065-2; SR-01000003065-4; SR-01000003065-5; SR-01000003065-7; W-105400; BRD-K86301799-001-04-1; BRD-K86301799-001-19-9; BRD-K86301799-001-24-9; Z1259192074; Dipyridamole, British Pharmacopoeia (BP) Reference Standard; Dipyridamole, European Pharmacopoeia (EP) Reference Standard; Dipyridamole, United States Pharmacopeia (USP) Reference Standard; Pyrimido(5, 2,6-bis[bis(2-hydroxyethyl)amino]-4,8-diperidino-; 2,2'',2'''-[4,8-Dipiperidinopyrimido[5,4-d]pyrimidine-2,6-diyl]dinitrilotetraethanol; 2,2',2'',2'''-(4,8-Dipiperidinopyrimido(5,4-d)pyrimidine-2,6-diyl)dinitrilotetraethanol; 2-[[2-(bis(2-hydroxyethyl)amino)-4,8-di(piperidin-1-yl)pyrimido[6,5-e]pyrimidin-; Dipyridamole for peak identification, European Pharmacopoeia (EP) Reference Standard; Ethanol,2',2'',2'''-(4,8-dipiperidinopyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetra-; WLN: T66 BN DN GN INJ CCN HCN E- AT6NTJ B2Q F2Q& J- AT6NTJ B2Q F2Q; 2,2',2'',2'''-(4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidine-2,6-diyl)bis(azanetriyl)tetraethanol; 2,2',2'',2'''-[(4,8-dipiperidin-1-ylpyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]tetraethanol; 2,2',2'',2'''-[(4,8-Dipiperidinylpyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]tetraethanol; 2,2',2'',2'''-[(4,8-Dipiperidinylpyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]tetrakisethanol; 2-({6-[bis(2-hydroxyethyl)amino]-4,8-dipiperidylpyrimidino[5,4-d]pyrimidin-2-y l}(2-hydroxyethyl)amino)ethan-1-ol; 2-[[2-[bis(2-hydroxyethyl)amino]-4,8-bis(1-piperidinyl)-6-pyrimido[5,4-d]pyrimidinyl]-(2-hydroxyethyl)amino]ethanol; 2-[[2-[bis(2-hydroxyethyl)amino]-4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol;; Ethanol, 2,2',2'',2'''-(4,8-dipiperidinopyrimido(5,4-d)pyrimidine-2,6-diyldinitrilo)tetra-; Ethanol, 2,2',2',2'''-((4,8-di-1-iperidinylpyrimido(5,4-d)pyrimidine-2,6-diyl)dinitrilo)tetrakis-; Ethanol,2',2'',2'''-[(4,8-di-1-piperidinylpyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]tetrakis-; Ethanol,2',2'',2'''-[(4,8-dipiperidinopyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]tetra-	Small molecule	1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2	IZEKFCXSFNUWAM-UHFFFAOYSA-N	C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO	C24H40N8O4	CAS 58-32-2	CHEBI:4653	.	.	.	D0F9GE	.	.	.
DR0727	Valproic acid	CID: 3121	VALPROIC ACID; 2-Propylpentanoic acid; 99-66-1; 2-Propylvaleric acid; Dipropylacetic acid; Depakine; Depakene; Ergenyl; Di-n-propylacetic acid; Valproate; Mylproin; Pentanoic acid, 2-propyl-; 4-Heptanecarboxylic acid; n-Dipropylacetic acid; Propylvaleric acid; Myproic Acid; n-DPA; Dipropylacetate; Convulex; Depakin; Di-n-propylessigsaure; Avugane; Baceca; Stavzor; Acido valproico; Kyselina 2-propylvalerova; Acide valproique; 2-n-Propyl-n-valeric acid; Acidum valproicum; Acetic acid, dipropyl-; 2,2-di-n-propylacetic acid; Valproinsaeure; Savicol; Depakine chrono; Depakin chrono; Abbott 44090; Acide valproique [INN-French]; Acido valproico [INN-Spanish]; Acidum valproicum [INN-Latin]; 2-PROPYL-PENTANOIC ACID; Di-n-propylessigsaure [German]; Valeric acid, 2-propyl-; divalproex; Epilim; Kyselina 2-propylvalerova [Czech]; Di-n-propylessigsaeure; VPA;2-Propylpentanoic Acid; UNII-614OI1Z5WI; MFCD00002672; NSC 93819; Delepsine; Sprinkle; Valcote; Valparin; Epilex; PEAC; VPA; Depakene (TN); Vupral; CHEMBL109; (n-C3H7)2CHCOOH; 614OI1Z5WI; CHEBI:39867; NSC-93819; NCGC00091149-01; Deproic; Alti-Valproic; Novo-Valproic; Penta-Valproic; Dom-Valproic; Med Valproic; Nu-Valproic; DSSTox_CID_3733; DSSTox_RID_77171; DSSTox_GSID_23733; Valproic acid USP; PMS-Valproic Acid; 2-Propylpentanoic acid, 99%; Valproic acid (USP); CAS-99-66-1; Depakote (TM); SMR000499581; 362049-65-8; HSDB 3582; 2 PP (base); EINECS 202-777-3; BRN 1750447; Depacane; valproic-acid; Novo-divalproex; Sandoz valproic; Dom-valproate; Gen-divalproex; Apo-valproic; A-44090; AI3-10500; APO-divalproex; DOM-divalproex; Epival er; PHL-valproate; PMS-valproate; PMS-Divalproex; Erganyl; Stavzor; Dom-valproic acid; Apo-valproic syrup; PHL-valproic acid; Epiject I.V.; 2-propyl-Pentanoate; Epical (TM); Epilim (Salt/Mix); Valproic acid [USAN:USP:INN:BAN]; Depacon (Salt/Mix); 345909-03-7; 87745-17-3; Convulex (Salt/Mix); Eurekene (Salt/Mix); G2M-777; Valparin (Salt/Mix); Valproic acid solution; Novo-Valproic - ECC; Spectrum_000521; Divalproex (Salt/Mix); Dom-valproic acid syrup; Ratio-Valproic - ECC; Valdisoval (Salt/Mix); ACMC-209sdq; 2 -propylpentanoic acid; di-n-propyl acetic acid; S(-)-4-En-valproate; Spectrum2_000946; Spectrum3_001733; Spectrum4_000376; DOM-valproic acid E.C.; Heptane-4-carboxylic acid; PHL-valproic acid E.C.; PMS-valproic acid E.C.; Novo-valproic soft gel cap; EC 202-777-3; SCHEMBL2275; S-2-n-Propyl-4-pentenoate; (S)-2-propyl-4-pentanoate; KBioGR_000871; KBioGR_002277; KBioSS_001001; KBioSS_002278; MLS001076682; MLS001335927; MLS001335928; MLS002415770; BIDD:GT0858; DivK1c_000273; SPBio_000912; GTPL7009; DTXSID6023733; WLN: QVY3 & 3; KBio1_000273; KBio2_001001; KBio2_002277; KBio2_003569; KBio2_004845; KBio2_006137; KBio2_007413; KBio3_002626; KBio3_002757; NIJJYAXOARWZEE-UHFFFAOYSA-; Valproic acid [USAN:BAN:INN]; NINDS_000273; HMS2089J06; HMS2231E06; HMS3259C18; HMS3370C21; HMS3715B15; HMS3885G14; ACT05281; ALBB-032973; BCP33204; NSC93819; ZINC3008621; Tox21_111091; Tox21_201963; Tox21_300603; ANW-41052; BDBM50003616; LMFA01020291; s3944; SBB065764; STL445581; AKOS009156895; Tox21_111091_1; Valproic Acid 1.0 mg/ml in Methanol; CCG-221127; CS-1765; DB00313; MCULE-7136317196; NC00584; SDCCGSBI-0050864.P004; NCGC00091149-02; NCGC00091149-03; NCGC00091149-04; NCGC00091149-05; NCGC00091149-06; NCGC00091149-08; NCGC00091149-09; NCGC00162288-07; NCGC00254365-01; NCGC00259512-01; AK128830; AS-11354; HY-10585; SBI-0050864.P003; AB0009719; 791-EP2306789A1; FT-0609289; FT-0675769; P0823; 6400-EP1441224A2; 6400-EP2272537A2; 6400-EP2272827A1; 6400-EP2275420A1; 6400-EP2280008A2; 6400-EP2298764A1; 6400-EP2298765A1; 6400-EP2308867A2; 6400-EP2308870A2; 6400-EP2311494A1; 6400-EP2311840A1; 6400-EP2314585A1; 6400-EP2374790A1; A19450; C07185; D00399; AB00698315-06; 2-(Propyl-3,3,3-d3)pentanoic-5,5,5-d3 Acid; Q240642; Q-200321; Sodium valproate; 2-Propylpentanoic acid sodium salt; SR-01000075242-7; F2191-0115; Z1511532065; Valproic acid, European Pharmacopoeia (EP) Reference Standard; Valproic acid, United States Pharmacopeia (USP) Reference Standard; Valproic acid for system suitability, European Pharmacopoeia (EP) Reference Standard; Valproic acid solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; Valproic acid, Pharmaceutical Secondary Standard; Certified Reference Material	Small molecule	1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)	NIJJYAXOARWZEE-UHFFFAOYSA-N	CCCC(CCC)C(=O)O	C8H16O2	CAS 99-66-1	CHEBI:39867	.	.	.	D0Y3KG	.	.	.
DR0749	Sunitinib	CID: 5329102	Sunitinibum; Sutent; PDGF TK antagonist; SU 11248; SU11248; KS-5022; SU-11248; SU-11248J; SU-12662; Su-011248; Sunitinib (INN); Sunitinib (free base); Sutent (TN); N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; 5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE; Sunitinib (Pan-TK inhibitor)	Small molecule	1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-	WINHZLLDWRZWRT-ATVHPVEESA-N	CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C	C22H27FN4O2	CAS 557795-19-4	CHEBI:38940	.	.	.	D0R0MW	.	.	Sunitinib
DR0767	Vasostatin	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR0775	Amlodipine	CID: 2162	amlodipine; 88150-42-9; Norvasc; AMLODIPINE BASE; Amlodipino; Amlodipinum; Caduet; Istin; Amlodipine Free Base; Amlodipine besilate; Amvaz; Amlodis; CHEBI:2668; 3-ethyl 5-methyl 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; Norvasc (TN); Amlocard; Coroval; Lipinox; 3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; UK-4834011; Amlor; Amlodipinum [Latin]; Amlodipino [Spanish]; 88150-42-9 (free base); Amdepin; Amdipin; Amlodin; Pelmec; MFCD00864687; 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; Amlodipine [INN:BAN]; Racemic Amlodipine; (RS)-3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; C20H25ClN2O5; 3-ethyl 5-methyl 2-{[(2-aminoethyl)oxy]methyl}-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; 3-O-ethyl 5-O-methyl 4-(2-chlorophenyl)-1-deuterio-2-[2-(dideuterioamino)ethoxymethyl]-6-methyl-4H-pyridine-3,5-dicarboxylate; O3-ethyl O5-methyl 2-(2-azanylethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; SR-05000001461; NCGC00165957-04; r-amlodipine; Amlodipine/; Amlodipine D4; HSDB 7079; 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine; 2-[2-aminoethoxymethyl]-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine; 3,5-Pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester; amlodipine (NORVASC); Amlodipine (USP/INN); (R)-Amlodipine-[d4]; 2-[(2-Aminoethoxy)-methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5- pyridinedicarboxylic acid 3-ethyl 5-methyl ester benzene sulfonate; Spectrum2_000486; Spectrum3_001004; Spectrum4_001132; Spectrum5_001550; EC 425-820-1; CHEMBL1491; SCHEMBL26478; BSPBio_002727; KBioGR_001643; MLS001401409; BIDD:GT0810; SPBio_000351; GTPL6981; CHEMBL3211346; CHEMBL3304444; DTXSID7022596; KBio3_001947; Copalia (amlodipine + valsartan); HGP0904; BCPP000403; HMS2052N03; HMS2089H07; HMS2231K08; HMS3370G17; HMS3394N03; HMS3651I04; HMS3713C10; ALBB-027270; BCP02420; HGP-0904; HY-B0317; ABP000734; BBL023710; BDBM50088383; CA0134; s1905; STL356053; CKD-330 COMPONENT AMLODIPINE; AKOS015843475; AC-4535; BCP9000295; CCG-101157; CCG-220414; DB00381; MCULE-8264151664; NC00407; NCGC00165957-01; NCGC00165957-02; NCGC00165957-03; NCGC00165957-05; NCGC00165957-07; 3-Ethyl 5-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3-Ethyl-5-methyl (+-)-2-((2-aminoethoxy)methyl)-4-(2-chlorphenyl)-1,4-dihydro-6-methyl-3,5-pyridindicarboxylat; 3-Ethyl-5-methyl (+-)-2-((2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; AK163198; Amlodipine 100 microg/mL in Acetonitrile; AS-13747; CPD000469198; K577; O3-ethyl O5-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; SMR000469198; SY104813; AB0008128; UK-48,340; FT-0602653; FT-0657130; FT-0662111; FT-0662112; R3932; SW220228-1; 50A429; C06825; D07450; J10237; W-3152; AB01209618-01; AB01274726-01; AB01274726-02; AB01274726_03; AB01274726_04; AB01274726_05; A800681; Q411347; Katerzia&reg (amlodipine oral suspension, 1 mg/mL); SR-05000001461-3; SR-05000001461-4; SR-05000001461-5; BRD-A22032524-074-02-4; BRD-A22032524-074-03-2; BRD-A22032524-074-04-0; 2-(2-aminoethoxy)methyl-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine; 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylic acid O3-ethyl ester O5-methyl ester; 2-[(2-Aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid 3-ethyl 5-methylester; 2-[2-Aminoethoxymethyl]-3-ethoxycarbonyl-4-(2-chlorophenyl)-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine; 3,5-pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester, benzene sulfonate; 3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate benzene sulfonate; 3-Ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorphenyl)-6-methyl-1,4-dihydropyridin-3,5-dicarboxylat; 3-Ethyl 5-methylester, (+/-)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3-Ethyl-5-methyl (.+/-.)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate	Small molecule	1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3	HTIQEAQVCYTUBX-UHFFFAOYSA-N	CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN	C20H25ClN2O5	CAS 88150-42-9	CHEBI:2668	.	.	.	D08JIV	.	.	.
DR0813	hu14.18-IL2 immunicytokine	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR0832	Megestrol acetate	CID: 11683	MEGESTROL ACETATE; 595-33-5; Megace; Megace ES; Magestin; Niagestin; Megestryl acetate; Megeron; Megestat; Ovaban; Ovarid; Maygace; Pallace; BDH 1298; SC 10363; NSC-71423; Volidan; SC10363; UNII-TJ2M0FR8ES; 17alpha-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate; 17alpha-Acetoxy-6-dehydro-6-methylprogesterone; 6-Dehydro-6-methyl-17alpha-acetoxyprogesterone; 6-Methyl-6-dehydro-17alpha-acetoxyprogesterone; 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione 17-acetate; 17-Acetoxy-6-methylpregna-4,6-diene-3,20-dione; 6-Methyl-17alpha-hydroxy-delta(sup 6)-progesterone acetate; TJ2M0FR8ES; [(8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate; 6-Methyl-3,20-dioxopregna-4,6-dien-17-yl acetate; SC-10363; 17-(acetyloxy)-6-methylpregna-4,6-diene-3,20-dione; MLS000028633; Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl-; BDH-1298; SMR000058691; DSSTox_CID_20683; DSSTox_RID_79539; DSSTox_GSID_40683; Megestil; 6-Methyl-17alpha-acetoxypregna-4,6-diene-3,20-dione; Ovaban (Veterinary); 6-Methyl-delta(sup 6)-dehydro-17alpha-acetoxyprogesterone; MegestrolAcetate; 6-Methyl-delta(sup 4,6)-pregnadien-17alpha-ol-3,20-dione acetate; Megestrol-Acetate; 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate; CCRIS 372; Pregna-4,6-diene-3,20-dione, 17-hydroxy-6-methyl-, acetate; Megestrol-17-acetate; EINECS 209-864-5; Megestin; Megestrol acetole [Progestins]; Megestrol acetate [USAN:USP]; Megestrol acetole; BDH1298; 17-alpha-Acetoxy-6-dehydro-6-methylprogesterone; 6-Dehydro-6-methyl-17-alpha-acetoxyprogesterone; 6-Methyl-6-dehydro-17-alpha-acetoxyprogesterone; NCGC00016516-01; (8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,3,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl acetate; CAS-595-33-5; Megace (TN); 17alpha-Acetoxy-6-methylpregna-4,6-diene-3,20-dione; 6-Methyl-17-alpha-acetoxypregna-4,6-diene-3,20-dione; 6-Methyl-17-alpha-hydroxy-delta(sup 6)-progesterone acetate; 6-Methyl-6-dehydro-17.alpha.-acetylprogesterone; 6-Methyl-delta(sup 6)-dehydro-17-alpha-acetoxyprogesterone; 6-Methyl-delta4,6-pregnadien-17alpha-ol-3,20-dione acetate; 17.alpha.-Acetoxy-6-dehydro-6-methylprogesterone; 6-Dehydro-6-methyl-17.alpha.-acetoxyprogesterone; 6-Methyl-6-dehydro-17.alpha.-acetoxyprogesterone; Megestrol acetate (USP); Opera_ID_1511; Prestwick0_000956; Prestwick1_000956; Prestwick2_000956; Prestwick3_000956; 6-Methyl-delta(sup 4,6)-pregnadien-17-alpha-ol-3,20-dione acetate; SCHEMBL745; BSPBio_000952; MLS000759501; MLS001074091; MLS001424055; par-100,2; SPBio_003101; BPBio1_001048; CHEBI:6723; CHEMBL1201139; DTXSID9040683; BCPP000168; HMS1570P14; HMS2051I20; HMS2090N04; HMS2097P14; HMS2235D16; HMS3714P14; Nia; NSC71423; ZINC4097467; Tox21_110469; Tox21_302360; ANW-43468; LMST02030118; MFCD00056470; s1304; AKOS015894927; Tox21_110469_1; BCP9000904; CCG-100899; CS-2065; DB00351; NC00149; 17-Acetoxy-6-methylpregna-4,20-dione; NCGC00024196-03; NCGC00024196-05; NCGC00255456-01; AC-24570; AS-13384; HY-13676; I040; 17.alpha.-Acetoxy-6-methyl-4,20-dione; AB00490013; B1377; 17-Hydroxy-6-methylpregna-4,20-dione acetate; 17.alpha.-Acetoxy-6-methylpregna-4,20-dione; C08151; D00952; 14365-EP2311464A1; 14365-EP2316836A1; AB00383046-13; AB00383046-14; AB00383046-15; AB00383046_16; Pregna-4,20-dione, 17-(acetyloxy)-6-methyl-; 595M335; SR-01000000258; Megestrol-17-acetate 100 microg/mL in Acetonitrile; Pregna-4,20-dione, 17-hydroxy-6-methyl-, acetate; Q-201346; Q6808975; SR-01000000258-4; BRD-K19507340-001-03-1; Megestrol acetate, VETRANAL(TM), analytical standard; 17alpha-Acetoxy-6-methyl-4,6-pregnadiene-3,20-dione; Megestrol acetate, analytical standard, for drug analysis; WLN: L E5 B666 OV KU MUTJ A1 E1 FV1 FOV1 L1; 6-Methyl-17.alpha.-hydroxy-.delta.(sup 6)-progesterone acetate; Megestrol acetate, European Pharmacopoeia (EP) Reference Standard; Megestrol acetate, United States Pharmacopeia (USP) Reference Standard; Megesgtrol Acetate, Pharmaceutical Secondary Standard; Certified Reference Material; Megestrol acetate for peak identification, European Pharmacopoeia (EP) Reference Standard; Megestrol acetate for system suitability, European Pharmacopoeia (EP) Reference Standard	Small molecule	1S/C24H32O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h12-13,18-20H,6-11H2,1-5H3/t18-,19+,20+,22-,23+,24+/m1/s1	RQZAXGRLVPAYTJ-GQFGMJRRSA-N	CC1=CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C	C24H32O4	CAS 595-33-5	CHEBI:6723	.	.	.	.	.	.	.
DR0879	Carboxyamidotriazole	CID: 108144	Carboxyamidotriazole; 99519-84-3; 5-amino-1-(3,5-dichloro-4-(4-chlorobenzoyl)benzyl)-1H-1,2,3-triazole-4-carboxamide; CAI; L651582; L-651582; L-651,582; NSC-609974; 5-amino-1-[[3,5-dichloro-4-(4-chlorobenzoyl)phenyl]methyl]triazole-4-carboxamide; L 651582; UNII-6ST3ZF52WB; NSC609974; MLS003373924; 6ST3ZF52WB; Carboxyamido-triazole; L-651582;CAI; SMR002048715; 1H-1,2,3-Triazole-4-carboxamide, 5-amino-1-((3,5-dichloro-4-(4-chlorobenzoyl)phenyl)methyl)-; 5-Amino-1-((3,5-dichloro-4-(4-chlorobenzoyl)phenyl)methyl)-1H-1,2,3-triazole-4-carboxamide; 4-CAI; NSC 609974; CCRIS 9404; Carboxiamidotriazol; 5-amino-1-(4-(4-chlorobenzoyl)-3,5-dichlorobenzyl)-1,2,3-triazole-4-carboxamide; 5-amino-1-(4-[4-chlorobenzoyl]-3,5-dichlorobenzyl)-1,2,3-triazole-4-carboxamide; 5-amino-1-[4-(4-chlorobenzoyl)-3,5-dichlorobenzyl]-1,2,3-triazole-4-carboxamide; 1H-1,2,3-Triazole-4-carboxamide, 5-amino-1-[[3,5-dichloro-4-(4-chlorobenzoyl)phenyl]methyl]-; 5-AMINO-1-[[3,5-DICHLORO-4-(4-CHLOROBENZOYL)PHENYL]METHYL]-1H-1,2,3-TRIAZOLE-4-CARBOXAMIDE; PubChem13343; NCIStruc1_001699; NCIStruc2_001836; SCHEMBL18866; MLS006010700; CHEMBL95431; cid_108144; MERCK L651582; BDBM97191; DTXSID40244108; RFE-007; ZINC538116; CCG-37684; MFCD00866325; NCGC00014926; NCI609974; AKOS024457417; Carboxyamidotriazole, >=98% (HPLC); AC-6332; DB11960; SB17291; NCGC00014926-02; NCGC00014926-03; NCGC00098026-01; DA-38085; HY-16126; NCI60_004782; B7269; CS-0006152; FT-0740142; X7001; 519A843; SR-01000902267; Q5038072; SR-01000902267-2; 5-amino-1-[3,5-dichloro-4-(4-chlorobenzoyl)benzyl]triazole-4-carboxamide; 5-amino-1(4-[4-chlorobenzoyl]-3,5-dichlorobenzyl)-1,2,3-triazole-4-carboxamide; 5-amino-1-(4-(4-chlorobenzoyl)-3,5-dichlorobenzyl)- 1,2,3-triazole-4-carboxamide; 5-amino-1-(4-(4-chlorobenzoyl)-3,5-dichlorobenzyl)1,2,3-triazole-4-carboxamide; 5-amino-l-(4-(4-chlorobenzoyl)-3,5-dichlorobenzyl)- 1,2,3-triazole-4-carboxamide; 1H-1,3-Triazole-4-carboxamide, 5-amino-1-[[3,5-dichloro-4-(4-chlorobenzoyl)phenyl]methyl]-; 5-amino-1-[[3,5-dichloro-4-(4-chlorobenzoyl)phenyl]methyl]-4,5-dihydrotriazole-4-carboxamide; 5-amino-1-[[3,5-dichloro-4-[(4-chlorophenyl)-oxomethyl]phenyl]methyl]-4-triazolecarboxamide; 5-azanyl-1-[[3,5-bis(chloranyl)-4-(4-chlorophenyl)carbonyl-phenyl]methyl]-1,2,3-triazole-4-carboxamide	Small molecule	1S/C17H12Cl3N5O2/c18-10-3-1-9(2-4-10)15(26)13-11(19)5-8(6-12(13)20)7-25-16(21)14(17(22)27)23-24-25/h1-6H,7,21H2,(H2,22,27)	WNRZHQBJSXRYJK-UHFFFAOYSA-N	C1=CC(=CC=C1C(=O)C2=C(C=C(C=C2Cl)CN3C(=C(N=N3)C(=O)N)N)Cl)Cl	C17H12Cl3N5O2	CAS 99519-84-3	.	.	.	.	D05IIP	.	.	.
DR0904	Bicalutamide	CID: 2375	Casodex; Cosudex; Propanamide; Raffolutil; Astra brand of bicalutamide; AstraZeneca brand of bicalutamide; Zeneca brand of bicalutamide; Calutide (TN); Casodex (TN); Cosudex (TN); KS-1161; Kalumid (TN); Bicalutamide [USAN:INN:BAN]; Bicalutamide (JAN/USP/INN); Casodex, Cosudex, Calutide, Kalumid, Bicalutamide; N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide; (+-)-4'-Cyano-alpha,alpha,alpha-trifluoro-3-((p-fluorophenyl)sulfonyl)-2-methyl-m-lactotoluidide; 4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide	Small molecule	1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)	LKJPYSCBVHEWIU-UHFFFAOYSA-N	CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O	C18H14F4N2O4S	CAS 90357-06-5	CHEBI:3090	.	.	.	D0V9BD	.	.	Bicalutamide
DR0928	Dithiothreitol	CID: 446094	Dithiothreitol; DL-1,4-Dithiothreitol; dl-Dithiothreitol; 3483-12-3; (2S,3S)-1,4-DIMERCAPTOBUTANE-2,3-DIOL; 1,4-Dithiothreitol; D-1,4-Dithiothreitol; D-Dtt; 1,4-Dithiothreithol; Cleland's reagent; (2S,3S)-1,4-disulfanylbutane-2,3-diol; 27565-41-9; DTT; MFCD00004877; D-threo-1,4-Dimercapto-2,3-butanediol; threo-1,4-Dimercapto-2,3-butanediol; CHEBI:42170; (2S,3S)-1,4-bis(sulfanyl)butane-2,3-diol; cis-2,3-Dihydroxy-1,4-butanedithiol; Sputolysin; rac-Dithiothreitol; DL-1,4-Dithiothreitol, 98%, pure; DTV; DL-1,4-Dithiothreitol, 99%, for biochemistry; dithio threitol; DL-1,4-Dithiothreitol, for biochemistry, 1M solution in water; D-Dithiothreitol; WR 34678; (R*,R*)-1,4-Dimercaptobutane-2,3-diol; Reagents, Cleland's; 2,3-Butanediol, 1,4-dimercapto-, (R*,R*)-; (+/-)-Dithiothreitol; DL-Dithiothreitol, 99%; DL-Dithiothreitol, powder; DTT (threitol derivative); DTT, 1,4-Dithiothreitol; D,L-Dithiothreitol (DTT); SCHEMBL10601; CHEMBL1232392; DL-Dithiothreitol, >=99.0%; DTXSID5041017; Dithiothreitol, biochemical grade; ZINC3852211; EINECS 240-263-0; ETHYL4-NITRO-L-PHENYLALANINE; EBD485460; AKOS005259570; AKOS015855399; AT-2091; CCG-207964; DB02184; DL-Dithiothreitol, >=99.0% (RT); Threitol, 1,4-dithio- (7CI,8CI); BRN 2036371; Threitol, 1,4-dithio-, L- (8CI); threo-2,3-Dihydroxy-1,4-butanedithiol; DL-1,4-Dimercapto-2,3-dihydroxybutane; DTT, Dithiothreitol (Cleland's Reagenz); (+/-)-1,4-Dimercapto-2,3-butanediol; 35454-97-8; AS-57473; DL-Dithiothreitol solution, 1 M in H2O; B7294; X4647; 1698-EP2270001A1; 1698-EP2270004A1; 1698-EP2270008A1; 1698-EP2270014A1; 1698-EP2272516A2; 1698-EP2272827A1; 1698-EP2272972A1; 1698-EP2272973A1; 1698-EP2275102A1; 1698-EP2275412A1; 1698-EP2275413A1; 1698-EP2275414A1; 1698-EP2277867A2; 1698-EP2277872A1; 1698-EP2277876A1; 1698-EP2277881A1; 1698-EP2280003A2; 1698-EP2280011A1; 1698-EP2280012A2; 1698-EP2281563A1; 1698-EP2284178A2; 1698-EP2284179A2; 1698-EP2287155A1; 1698-EP2287156A1; 1698-EP2289893A1; 1698-EP2289894A2; 1698-EP2292593A2; 1698-EP2292614A1; 1698-EP2292617A1; 1698-EP2295406A1; 1698-EP2295410A1; 1698-EP2295412A1; 1698-EP2295413A1; 1698-EP2295432A1; 1698-EP2295550A2; 1698-EP2298305A1; 1698-EP2298743A1; 1698-EP2298744A2; 1698-EP2298772A1; 1698-EP2298779A1; 1698-EP2298783A1; 1698-EP2301928A1; 1698-EP2301939A1; 1698-EP2305250A1; 1698-EP2305682A1; 1698-EP2305687A1; 1698-EP2305808A1; 1698-EP2305825A1; 1698-EP2308839A1; 1698-EP2308855A1; 1698-EP2308877A1; 1698-EP2308879A1; 1698-EP2308880A1; 1698-EP2308883A1; 1698-EP2311807A1; 1698-EP2311814A1; 1698-EP2311818A1; 1698-EP2311825A1; 1698-EP2311829A1; 1698-EP2311837A1; 1698-EP2311842A2; 1698-EP2314576A1; 1698-EP2316459A1; 1698-EP2316835A1; DL-Dithiothreitol, BioUltra, >=99.0% (RT); DL-Dithiothreitol, for electrophoresis, >=99%; M02712; M02716; (R-(R*,R*))-1,4-Dimercaptobutane-2,3-diol; A822424; DL-Dithiothreitol, SAJ special grade, >=98.0%; DL-Dithiothreitol, Vetec(TM) reagent grade, 98%; Q414783; (+/-) Dithiothreitol molecular biology grade >99%; 2,3-BUTANEDIOL, 1,4-DIMERCAPTO-, L-threo-; DL-Dithiothreitol, BioXtra, >=99.0% (titration); 2,3-Butanediol, 1,4-dimercapto-, (2R,3R)-rel- (9CI); DL-Dithiothreitol, >=98% (HPLC), >=99.0% (titration); UNII-T8ID5YZU6Y component VHJLVAABSRFDPM-QWWZWVQMSA-N; 2,3-Butanediol, 1,4-dimercapto-, (R-(R*,R*))- (9CI); DL-Dithiothreitol; Cleland inverted exclamation mark s reagent; DL-Dithiothreitol, BioUltra, for molecular biology, >=99.5% (RT); DL-Dithiothreitol solution, BioUltra, for molecular biology, ~1 M in H2O; DL-Dithiothreitol, for molecular biology, >=98% (HPLC), >=99% (titration); Cleland's Reagent DTT racemic '(+/-)-threo-1,4-Dimercapto-2,3-butanediol' C4H10O2S2 154.25  40-43 degrees  125-130 degrees /12mm >110 degrees (230 degrees F)  3483-12-3 '14,3376' 222-468-7 MFCD00004877 EK1610000   Y	Small molecule	1S/C4H10O2S2/c5-3(1-7)4(6)2-8/h3-8H,1-2H2/t3-,4-/m1/s1	VHJLVAABSRFDPM-QWWZWVQMSA-N	C(C(C(CS)O)O)S	C4H10O2S2	CAS 3483-12-3	CHEBI:42170	.	.	.	.	.	.	.
DR0944	Nelfinavir	CID: 64143	nelfinavir; 159989-64-7; Viracept; AG-1343; UNII-HO3OGH5D7I; Nelfinavir free base; C32H45N3O4S; Viracept (TN); HO3OGH5D7I; CHEBI:7496; (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylsulfanylbutyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide; 159989-65-8; 159989-64-7 (free base); 1UN; 2-[2-HYDROXY-3-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-4-PHENYL SULFANYL-BUTYL]-DECAHYDRO-ISOQUINOLINE-3-CARBOXYLIC ACID TERT-BUTYLAMIDE; NLF; Nelfinavir [INN:BAN]; NFV; CHEMBL1205; (3S,4aS,8aS)-N-(tert-Butyl)-2-((2R,3R)-2-hydroxy-3-(3-hydroxy-2-methylbenzamido)-4-(phenylthio)butyl)decahydroisoquinoline-3-carboxamide; (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methyl-benzoyl)amino]-4-phenylsulfanyl-butyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide; (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylphenyl)formamido]-4-(phenylsulfanyl)butyl]-decahydroisoquinoline-3-carboxamide; 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-((2R,3R)-2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-, (3S,4aS,8aS)-; 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, (3S,4aS,8aS)-; Nelfinavir (INN); SMR000596515; NSC722664; NCGC00090782-03; NELFINAVIR MESYLATE AG1343; Met-SDF-1.beta. & Nelfinavir; 1ohr; (3S-(2(2S*,3S*),3alpha,4abeta,8abeta))-N-(1,1-Dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-3-isoquinolinecarboxamide; CHEMBL584; BIDD:PXR0143; SCHEMBL38218; MLS001195634; MLS001304729; N-(1,1-Dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-3-isoquinolinecarboxamide (3S-(2(2S*,3S*),3alpha,4abeta,8abeta))-; BIDD:GT0395; DTXSID5035080; GTPL11090; HMS2232I04; Met-Stromal Cell-derived Factor-1.beta. (Human) & Nelfinavir; ZINC3833846; BDBM50061306; NSC747167; AKOS000280862; AM84529; CS-0677; DB00220; NSC 747167; NSC-747167; MRF-0000208; NCGC00090782-04; NCGC00090782-05; NCGC00090782-17; 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-, (3S-(2-(2S*,3S*),3-alpha,4a-beta,8a-beta))-; AC-20032; AS-75258; HY-15287; 89N647; C07257; D08259; AB00698259-15; A810096; Q423366; (3S, 4aS, 8aS)-2-[(2R, 3R)-2-Hydroxy-3-(3-hydroxy-2-methyl-benzoylamino)-4-phenylthiobutyl]decahydroisoquinoline-3-carboxylic acid t-butylamide; (3S, 4aS, 8aS)-2-[(2R, 3R)-2-hydroxy-3-(3-hydroxy-2-methylbenzoylamino)-4-phenylthiobutyl]decahydroisoquinoline-3-carboxylic acid t-butylamide; (3S,4abeta,8abeta)-N-tert-Butyl-2-[(2R,3R)-2-hydroxy-3-(2-methyl-3-hydroxybenzoylamino)-4-(phenylthio)butyl]decahydroisoquinoline-3alpha-carboxamide; (3S,4aS,8aS)-2-[(2R,3R)-2-Hydroxy-3-(3-hydroxy-2-methyl-benzoylamino)-4-phenylsulfanyl-butyl]-decahydro-isoquinoline-3-carboxylic acid tert-butylamide; compound with methanesulfonic acid; (3S,4aS,8aS)-2-[(2R,3R)-2-hydroxy-3-(3-hydroxy-2-methylbenzoylamino)-4-phenylthiobutyl]decahydroisoquinoline-3-carboxylic acid t-butylamide; (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylsulfanyl)butyl]decahydroisoquinoline-3-carboxamide; (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[[(3-hydroxy-2-methylphenyl)-oxomethyl]amino]-4-(phenylthio)butyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide; (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-{[(3-hydroxy-2-methylphenyl)carbonyl]amino}-4-(phenylsulfanyl)butyl]decahydroisoquinoline-3-carboxamide; (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-3-[(2-methyl-3-oxidanyl-phenyl)carbonylamino]-2-oxidanyl-4-phenylsulfanyl-butyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide; 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2- [(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, (3S,4aS,8aS)-; 3-Isoquinolinecarboxamide,1-dimethyl ethyl)decahydro-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, (3S,4aS,8aS)-; 3-Isoquinolinecarboxamide,1-dimethylethyl)decahydro-2-[2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, [3S-[2(2S*,3S*),3.alpha.,4a.beta.,8a.beta.]]-	Small molecule	1S/C32H45N3O4S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39)/t22-,23+,26-,27-,29+/m0/s1	QAGYKUNXZHXKMR-HKWSIXNMSA-N	CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O	C32H45N3O4S	CAS 159989-64-7	CHEBI:7496	.	.	.	.	.	.	.
DR0951	Anti-PD-1 antibody	.	Anti-programmed cell death-1 (anti-PD-1)	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR0990	Paracetamol	CID: 1983	acetaminophen; Paracetamol; 4-Acetamidophenol; 103-90-2; Tylenol; N-(4-Hydroxyphenyl)acetamide; APAP; Panadol; Acetaminofen; Datril; N-Acetyl-p-aminophenol; p-Hydroxyacetanilide; 4'-Hydroxyacetanilide; p-Acetamidophenol; Algotropyl; Lonarid; Naprinol; p-Acetaminophenol; Acamol; Acenol; Anelix; Multin; Abensanil; Acetagesic; Acetalgin; Clixodyne; Gelocatil; Injectapap; Liquagesic; Pyrinazine; Servigesic; Alvedon; Anaflon; Apamide; Dymadon; Febridol; Febrilix; Febrolin; Finimal; Homoolan; Lestemp; Paracet; Tabalgin; Tralgon; Tussapap; Valadol; Valgesic; Alpiny; Amadil; Anhiba; Calpol; Dirox; Eneril; Fendon; Hedex; Lyteca; Pacemo; Panets; Parmol; Tapar; Tempra; Acetamide, N-(4-hydroxyphenyl)-; Paracetamolo; Doliprane; Dolprone; Momentum; Ortensan; Paldesic; Banesin; Captin; Disprol; Enelfa; Neopap; Salzone; Exdol; p-Acetylaminophenol; Febro-Gesic; NEBS; Biocetamol; Dafalgan; Dolgesic; Elixodyne; Febrectal; Tempanal; Vermidon; Abenol; Apacet; Apadon; Cetadol; Fensum; Janupap; Minoset; Napafen; Neodol; Nobedon; Pacemol; Panodil; Parapan; Pedric; Phendon; Rounox; Suppap; Korum; Pinex; Temlo; 4-(Acetylamino)phenol; Ben-u-ron; Dial-A-Gesic; Anacin-3; Calmanticold; Codoliprane; Demogripal; Dolegrippin; Doloreduct; Dristancito; Duracetamol; Eu-Med; Grippostad; Gynospasmine; Medocodene; Paedialgon; Paracetamolum; Paracetanol; Parakapton; Pediapirin; Phenipirin; Phogoglandin; Predualito; Sanicopyrine; Scentalgyl; Sunetheton; Tachiprina; Termalgine; Treuphadol; Abrolet; Acertol; Acetamol; Acetofen; Afebrin; Afebryl; Aferadol; Algesidal; Algomol; Alpinyl; Analter; Antidol; Apitrelal; Atralidon; Babikan; Bacetamol; Cadafen; Calapol; Causalon; Cefalex; Codabrol; Codalgin; Codapane; Codicet; Codisal; Cofamol; Cosutone; Cuponol; Curadon; Custodial; Darocet; Daygrip; Deminofen; Democyl; Desfebre; Dimindol; Dolefin; Dolofugin; Dolorfug; Dolorstop; Dolotec; Dorocoff; Dularin; Durapan; Ecosetol; Excipain; Fanalgic; Farmadol; Febranine; Febrectol; Febricet; Febrinol; Fepanil; Finiweh; Fluparmol; Geluprane; Ildamol; Inalgex; Infadrops; Kataprin; Labamol; Lekadol; Lemgrip; Lupocet; Magnidol; Malidens; Maxadol; Mexalen; Minafen; Miralgin; Nealgyl; Neodolito; Neotrend; Neuridon; Nodolex; Oralgan; Oxycocet; Pacimol; Panacete; Panadeine; Panadiene; Panaleve; Panamax; Panasorbe; Panofen; Pantalgin; Paracemol; Paracenol; Paracetol; Paracin; Paracod; Paracodol; Parador; Paradrops; Paralen; Paralief; Paralink; Paralyoc; Paramol; Paramolan; Paranox; Parasedol; Parasin; Paraspen; Parcetol; Parogal; Pediatrix; Piramin; Pirinasol; Polmofen; Predimol; Prontina; Puernol; Pulmofen; Pyrigesic; Pyromed; Remedol; Rivalgyl; Rubophen; Rupemol; Sanicet; Schmerzex; Sedalito; Semolacin; Seskamol; Setakop; Setamol; Sifenol; Sinaspril; Sinedol; Stanback; Stopain; Supofen; Tazamol; Termacet; Termalgin; Termofren; Titralgan; Tricoton; Upsanol; Utragin; Veralgina; Viruflu; Vivimed; Zatinol; Abrol; Algina; Anapap; Andox; Arfen; Asetam; Asomal; Aspac; Asplin; Benmyo; Curpol; Dhamol; Dolcor; Dolko; Dresan; Dypap; Febrex; Febrin; Lemsip; Malgis; Noral; Oltyl; Paceco; Pacet; Paedol; Painex; Pamol; Panex; Parake; Paroma; Plicet; Prodol; Reliv; Scanol; Setol; Sinmol; Tiffy; Tylex; Tylol; Tymol; Verpol; Volpan; Zolben; NeoCitran; NilnOcen; Nina; RubieMol; Vips; Supadol mono; Treupel mon; Bickie-mol; Fortalidon P; Gattaphen T; Gripin Bebe; Influbene N; Lonarid Mono; Lyteca Syrup; Panadeine Co; Dymadon Co; Toximer P; Treupel N; Accu-Tap; 4-Acetaminophenol; Helon N; Malex N; Spalt N; Tylex CD; N-Acetyl-4-aminophenol; SK-Apap; Paracetamole; Conacetol; Darvocet; Empracet; Panasorb; Perfalgan; A-Per; Apamid; Ofirmev; Parelan; Prompt; Vicodin; Fevor; Freka-cetamol; Codisal Forte; Croix Blanche; Dolorol Forte; Dymadon Forte; Junior Disprol; Kinder Finimal; Liquigesic Co; Mono Praecimed; Percocet-Demi; Perdolan Mono; Rockamol Plus; Viclor Richet; Actifed Plus; Kratofin simplex; Neo-Fepramol; Paracetamol AL; Paracetamol BC; Paracetamol PB; Acetanilide, 4'-hydroxy-; Claradol Codeine; Geralgine-P; Melabon Infantil; Migraleve Yellow; Paracetamol Saar; Pyregesic-C; Anti-Algos; Para-Suppo; Pasolind N; Supramol-M; No-Febril; Panado-Co; Para-Tabs; Paracetamol Hexal; Paracetamol Raffo; Paracetamol Rosch; Paracetamol Stada; Dol-Stop; Anadin dla dzieci; p-Hydroxyphenolacetamide; Percocet-5; Cod-Acamol Forte; Contra-Schmerz P; Hy-Phen; Medinol Paediatric; Paracetamol Basics; Panado-Co Caplets; Paracetamol von ct; Pe-Tam; Paracetamol Fecofar; Paracetamol Harkley; Paracetamol Heumann; Paracetamol Nycomed; Codral Pain Relief; Paracetamol Hanseler; Paracetamol Winthrop; 4-Hydroxyacetanilide; Phenaphen W/Codeine; Spalt fur die nacht; A.F. Anacin; Capital with Codeine; Paracetamol Genericon; Anexsia; Demilets; Endecon; Intensin; Naldegesic; Propacet; Resfenol; Theraflu; Wygesic; Paracetamol Ratiopharm; Coricidin Sinus; Paracetamol Italfarmaco; Sudafed Sinus; Coricidin D; Paracetamol DC; Quiet World; Paracetamol Antipanin P; St Joseph Aspirin-Free; New Cortal for Children; INFANTS' FEVERALL; St. Joseph Fever Reducer; Midol Teen Formula; Paracetamol Dr. Schmidgall; Acetamide, N-(p-hydroxyphenyl)-; Aspirin-Free Anacin; Children's Tylenol Chewable; NCI-C55801; PCM Paracetamol Lichtenstein; Tylenol Allergy Sinus; p-(Acetylamino)phenol; Rhinex D-Lay Tablets; acetaminophene; Midol Regular Strength; Paracetamol SmithKline Beecham; Scherzatabletten Rezeptur 534; Percogesic with Codeine; 4-Hydroxyanilid kyseliny octove; Bayer Select Head Cold; n-acetyl-4-hydroxyaniline; Bayer Select Allergy-Sinus; Bayer Select Headache Pain; Dristan Cold No Drowsiness; Prestwick_13; St Joseph Aspirin-Free for Children; UNII-362O9ITL9D; 4-acetylaminophenol; Children's Acetaminophen Elixir Drops; MFCD00002328; Children's Acetaminophen Oral Solution; Midol PM Night Time Formula; Triaminic Sore Throat Formula; N-(4-hydroxyphenyl)ethanamide; Bayer Select Sinus Pain Relief; Phenol, p-acetamido-; Sine-Off Sinus Medicine Caplets; CHEBI:46195; Roxicet 5/500; Tocris-1706; N-acetyl-para-aminophenol; 4-(N-Acetylamino)phenol; Acetaminophen (4-hydroxyacetanilide); Bayer Select Menstrual Multi-Symptom; Acetaco; 4-Acetamidophenol, 98%; St. Joseph Cold Tablets for Children; CHEMBL112; N-(4-Hydroxyphenyl)acetamide (Tylenol); N-(4-hydroxyphenyl)-acetamide; 362O9ITL9D; Aminofen; DTXSID2020006; Atasol; Duaneo; Duorol; component of Dialog; component of Dilone; Fever All; NSC-3991; component of Endecon; component of Percocet; NSC-109028; component of Phenaphen; TYL; component of Percogesic; DSSTox_CID_6; NCGC00016361-07; Acetominophen; Actamin; CAS-103-90-2; Pasolind; Redutemp; Robigesic; Valorin; Aceta Elixir; Dafalgan Codeine; Jin Gang; WLN: QR DMV1; DSSTox_RID_75318; DSSTox_GSID_20006; component of Hycomine Compound; Acetavance; Paracetamolo [Italian]; Calonal; Flexsure; Acenol (pharmaceutical); N-(4-Hydroxyphenyl)acetanilide; Drixoral Sinus; Aceta Tablets; Paracetamol [INN:BAN]; Valorin Extra; CCRIS 3; Snaplets-FR; Oraphen-PD; Phenaphen Caplets; Paracetamolum [INN-Latin]; Tylenol (caplet); Tylenol (geltab); Tylenol 8-Hour; SMR000112065; Tavist Allergy/Sinus/Headache; Dapa X-S; Drixoral Cold & Flu; HSDB 3001; SR-01000597517; EINECS 203-157-5; 222 AF; Acetaminophen [USP:JAN]; paracetamol (acetaminophen); NSC 109028; acetominophene; 4-Hydroxyanilid kyseliny octove [Czech]; Children's Acetaminophen Elixir Solution; Claratal; Daphalgan; Resprin; Daga; Apacet Capsules; Atasol Caplets; Atasol Tablets; Tempra Caplets; Tylenol Caplets; Tylenol Elixir; Tylenol Gelcaps; Tylenol Tablets; Actamin Extra; Actamin Super; Aminofen Max; ANEXSIA 10/660; Apacet Elixir; Atasol Drops; Exdol Strong; p-Acetoaminophen; Tempra Drops; Tempra Syrup; Tylenol Drops; alpha-Per; Citramon P; Excedrin Caplets; Dial-alpha-gesic; Apo-Acetaminophen; 4-acetominophenol; Genebs X-Tra; Paracetamol;Tylenol; 4-acetamido phenol; 4-acetamido-phenol; Tempra D.S; APAP, Paracetamol; p-hydroxy-acetanilid; p-hydroxyacetoanilide; Paracetamol (INN); Tylenol (TN); Supac (Salt/Mix); Tylox (Salt/Mix); Acetaminophen (d4); Zydone (Salt/Mix); Atasol Forte Caplets; Atasol Forte Tablets; Atasol Oral Solution; para-acetylaminophenol; Anexsia (Salt/Mix); Endecon (Salt/Mix); Sinubid (Salt/Mix); Talacen (Salt/Mix); Vicodin (Salt/Mix); Wygesic (Salt/Mix); Acetaminophen Uniserts; Datril Extra-Strength; Tylenol Infants Drops; Demilets (Salt/Mix); Empracet (Salt/Mix); Intensin (Salt/Mix); Propacet (Salt/Mix); Suppap-120; Suppap-325; Suppap-650; Panadol Extra Strength; TheraFlu (Salt/Mix); Coricidin (Salt/Mix); Liquiprin (Salt/Mix); Hy-Phen (Salt/Mix); IV-APAP; phenol derivative, 11; PubChem17726; Spectrum_000016; Tempra Chewable Tablets; Naldegesic (Salt/Mix); Actimol Chewable Tablets; Feverall Junior Strength; Darvocet-N (Salt/Mix); Anacin-3 Extra Strength; Liquiprin Infants' Drops; N-acetyl para aminophenol; Prestwick0_000868; Prestwick1_000868; Prestwick2_000868; Prestwick3_000868; Spectrum2_000085; Spectrum3_000283; Spectrum4_000140; Spectrum5_000736; Coricidin D (Salt/Mix); Quiet World (Salt/Mix); Genapap Children's Elixir; Tylenol Children's Elixir; Actifed Plus (Salt/Mix); Epitope ID:117710; Genapap Children's Tablets; Sudafed Sinus (Salt/Mix); EC 203-157-5; Actimol Infants' Suspension; Drixoral Sinus (Salt/Mix); Liquiprin Children's Elixir; N-acetyl-4-hydroxyaniline;; SCHEMBL3480; Acetaminophen (JP17/USP); Coricidin Sinus (Salt/Mix); N-(4-hydroxyfenyl)ethanamid; BSPBio_000915; BSPBio_001786; DDS-06A; KBioGR_000560; KBioSS_000356; 4-13-00-01091 (Beilstein Handbook Reference); Actimol Children's Suspension; Apacet Extra Strength Caplets; Apacet Extra Strength Tablets; Aspirin-Free Excedrin Caplets; Genebs Extra Strength Caplets; MLS001146925; MLS001331684; MLS002154041; BIDD:GT0005; DivK1c_000660; SPECTRUM1500101; Genapap Extra Strength Caplets; Genapap Extra Strength Tablets; SPBio_000010; SPBio_002836; Tapanol Extra Strength Caplets; Tapanol Extra Strength Tablets; Tylenol Extra Strength Caplets; Tylenol Extra Strength Gelcaps; Tylenol Extra Strength Tablets; ACMC-20989w; Actimol Junior Strength Caplets; Apacet Regular Strength Tablets; BPBio1_001007; Excedrin Extra Strength Caplets; Genebs Regular Strength Tablets; GTPL5239; Panadol Junior Strength Caplets; SGCUT00014; Tylenol Junior Strength Caplets; Midol Teen Formula (Salt/Mix); Genapap Regular Strength Tablets; Panadol Maximum Strength Caplets; Panadol Maximum Strength Tablets; SCHEMBL19474893; Tylenol Regular Strength Caplets; Tylenol Regular Strength Tablets; Aspirin-Free Anacin (Salt/Mix); BDBM26197; HMS502A22; KBio1_000660; KBio2_000356; KBio2_002924; KBio2_005492; KBio3_001286; EBD5728; NSC3991; Tylenol Arthritis Extended Relief; Acetaminophen, analytical standard; NINDS_000660; Tylenol Infants' Suspension Drops; BCPP000441; Drixoral Cold & Fl	Small molecule	1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)	RZVAJINKPMORJF-UHFFFAOYSA-N	CC(=O)NC1=CC=C(C=C1)O	C8H9NO2	CAS 103-90-2	CHEBI:46195	.	.	.	D0U5QK	.	.	.
DR1036	Dicyclohexylcarbodiimide	CID: 10868	DICYCLOHEXYLCARBODIIMIDE; 538-75-0; N,N'-Dicyclohexylcarbodiimide; DCCD; 1,3-Dicyclohexylcarbodiimide; Carbodicyclohexylimide; DCCI; n,n-dicyclohexylcarbodiimide; Bis(cyclohexyl)carbodiimide; DCC; Cyclohexanamine, N,N'-methanetetraylbis-; n,n'-methanediylidenedicyclohexanamine; Carbodiimide, dicyclohexyl-; Dicylcohexylcarbodiimide; DCC Crosslinker; N,N'-Methanetetraylbiscyclohexaamine; N,N'-Dicyclohexylcarbodiimide (DCC); NSC 30022; dicyclohexylmethanediimine; N,N'-dicyclohexylmethanediimine; CHEBI:53090; dicyclohexyl carbodiimide; UNII-0T1427205E; Dicyclohexyl-Carbodiimide; MFCD00011659; N,N'-DICYCLOHEXYL-CARBODIIMIDE; n,n-dicychohexylcarbodiimide; n,n'-dicylohexylcarbodiimide; n,n-dichyclohexylcarbodiimide; n,n-dicyclohexyl carbodiimide; n,n'-dicyclohexyl carbodiimide; 0T1427205E; DSSTox_CID_3817; DSSTox_RID_77197; DSSTox_GSID_23817; Cyclohexanamine,N'-methanetetraylbis-; N,N'-Dicyclohexylcarbodiimide, 99%; CAS-538-75-0; Dicyclimide;1,3-dicyclohexylcarbodiimide;N,N-Dicyclohexylcarbodiimide;N,N'-Methanediylidenedicyclohexanamine; 1,3-dicyclohexyl-1,3-diazapropa-1,2-diene; EINECS 208-704-1; n,n'-dicyclohexylcarbodiimid; BRN 0610662; N,N'-dicyclohexylcarbodimide; AI3-08191; CCRIS 9266; HSDB 8049; dicyclohexylcarbodiimid; dicyclohexylcarbodimide; dicylohexylcarbodiimide; Dicylcohexylcarbodimide; dicyciohexylcarbodiimide; Dicyclohexyicarbodiimide; dicyclohexyl carbodimide; dicylohexyl-carbodiimide; PubChem12523; dicyclo-hexylcarbodiimide; dicyclohe-xylcarbodiimide; dicyclohexylcarbo-diimide; dicyclohexylcarbod iimide; dicyclohexylcarbodi-imide; ACMC-1ASTJ; Dicyclohexyl carbo diimide; Dicyclohexyl-carboxydilmide; SCHEMBL303; 1,3dicyclohexylcarbodiimide; Epitope ID:114067; EC 208-704-1; 1,3-dicyclohexylcarbodiimid; 1,3-dicyclohexylcarbodimide; 1.3-dicyclohexylcarbodimide; N,N'dicyclohexylcarbodiimide; 1,3-dicylcohexylcarbodiimide; 1.3-dicyclohexylcarbodiimide; N, N'dicyclohexylcarbodimide; 1,N'-dicyclohexylcarbodimide; n.n'-dicyclohexylcarbodiimide; N,N'-dicylcohexylcarbodiimide; 4-12-00-00072 (Beilstein Handbook Reference); 1, 3-dicyclohexylcarbodiimide; 1,3- dicyclohexylcarbodiimide; 1,3-dicyclo-hexylcarbodiimide; 1,3-dicyclohexyl carbodiimide; 1,3-dicyclohexyl-carbodiimide; 1,3-dicyclohexylcarbo-diimide; N, N'-dicyclohexylcarbodimide; N,N'-Dicyclohexyl carbodimide; n,n' dicyclohexyl carbodiimide; N, N'-dicyclohexylcarbodiimide; N,N'-dicyclo hexylcarbodiimide; N,N'-dicyclo-hexylcarbodiimide; 1,3-di-cyclohexyl carbodiimide; 1,3-dicyclo hexyl carbodiimide; 1,3-dicyclohexyl carbo-diimide; 1,3-dicyclohexyl- carbodiimide; CARBODIIMIDE,DICYCLOHEXYL; CHEMBL162598; N,N,-dichyclohexyl-carbodiimide; DTXSID1023817; N, N'-dicyclohexyl carbodiimide; N,N'- dicyclohexyl carbodiimide; N,N'-dicyclo hexyl carbodiimide; N.N' - dicyclohexylcarbodiimide; BDBM129231; ACT09818; DCC, 99%; Methanediimine, N,N'-dicyclohexyl-; NSC30022; NSC53373; NSC57182; ZINC8585900; DCC, 1.0 M in methylene chloride; Tox21_203000; Tox21_303237; ANW-31872; BBL012208; N,N'-Methanetetraylbiscyclohexanamine; NSC-30022; NSC-53373; NSC-57182; SBB059225; STL089892; AKOS000120067; US8815951, dicyclohexylcarbodiimide; AM83818; CS-W020097; MCULE-5242025177; N,N'-methanediylidene-dicyclohexanamine; US8815951, N/A; DCC, puriss., >=99.0% (GC); NCGC00091497-01; NCGC00091497-02; NCGC00091497-03; NCGC00091497-04; NCGC00257167-01; NCGC00260545-01; AK-43977; BP-13398; DB-002694; N-(N-cyclohexylcarboximidoyl)cyclohexanamine; D0436; D0437; FT-0629452; N-((cyclohexylimino)methylene)cyclohexanamine; ST50825552; N-((cyclohexylimino)methylene) cyclohexanamine; Cyclohexaamine, N,N'-methanetetraylbis- (9CI); 538D750; Q306565; Q-200966; Dicyclohexylcarbodiimide solution, 60 wt. % in xylenes; F0001-1397; N,N'-Dicyclohexylcarbodiimide, 1M solution in dichloromethane, AcroSeal(R)	Small molecule	1S/C13H22N2/c1-3-7-12(8-4-1)14-11-15-13-9-5-2-6-10-13/h12-13H,1-10H2	QOSSAOTZNIDXMA-UHFFFAOYSA-N	C1CCC(CC1)N=C=NC2CCCCC2	C13H22N2	CAS 538-75-0	CHEBI:53090	.	.	.	.	.	.	.
DR1078	Cabazitaxel	CID: 9854073	Jevtana; Taxoid XRP6258; Jevtana (TN)	Small molecule	1S/C45H57NO14/c1-24-28(57-39(51)33(48)32(26-17-13-11-14-18-26)46-40(52)60-41(3,4)5)22-45(53)37(58-38(50)27-19-15-12-16-20-27)35-43(8,36(49)34(55-10)31(24)42(45,6)7)29(54-9)21-30-44(35,23-56-30)59-25(2)47/h11-20,28-30,32-35,37,48,53H,21-23H2,1-10H3,(H,46,52)/t28-,29-,30+,32-,33+,34+,35-,37-,43+,44-,45+/m0/s1	BMQGVNUXMIRLCK-OAGWZNDDSA-N	CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)OC)C)OC	C45H57NO14	CAS 183133-96-2	.	.	.	.	D02HSB	.	.	.
DR1093	Omeprazole	CID: 4594	omeprazole; 73590-58-6; Prilosec; Losec; Antra; Esomeprazole; Omeprazon; Audazol; Omapren; Omepral; Parizac; Zegerid; Mopral; Miol; Belmazol; Ceprandal; Dizprazol; Dudencer; Emeproton; Epirazole; Gastrimut; Gastroloc; Gibancer; Indurgan; Inhibitron; Inhipump; Logastric; Pepticum; Peptilcer; Prazidec; Sanamidol; Secrepina; Ulcometion; Mepral; Miracid; Omeprol; Omezol; Omisec; Omizac; Ompanyt; Ozoken; Prysma; Ramezol; Ulceral; Ulcesep; Ulcozol; Zefxon; Zoltum; Desec; Elgam; Lomac; Ulsen; Ultop; Zimor; Ocid; Omed; Omid; OMEP; Demeprazol; Nopramin; Omeprazol; Omezolan; Paprazol; Pepticus; Prazentol; Prazolit; Procelac; Regulacid; Danlox; Erbolin; Lensor; Morecon; Nilsec; Olexin; Omegast; Omesek; Ortanol; Osiren; Proclor; Result; Ulcsep; Victrix; Zepral; Exter; Gasec; Ulzol; Omebeta 20; Tedec Ulceral; AULCER; Antra MUPS; Omerprazole; Omez; Omepradex; Omeprazolum; Prilosec OTC; Nexium IV; H 168/68; Gastrogard; Nuclosina; 119141-88-7; Esomperazole; MFCD00083192; Prestwick_808; OMZ; C17H19N3O3S; CHEBI:77260; Esomeprazole sodium salt; 5-Methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole; 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole; Aisi'aomeilazuona Esomeprazole Sodium; H-168/68; CHEMBL1503; Nexiam; 6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole; 1H-Benzimidazole, 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-; 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole; 6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; MLS000069373; 73590-58-6 (free form); 5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methanesulfinyl]-1H-1,3-benzodiazole; Omeprazole, 98+%; Omeprazol [INN-Spanish]; Omeprazolum [INN-Latin]; NCGC00016925-06; SMR000058847; Emilok; CAS-73590-58-6; DSSTox_CID_1080; (s)-omeprazole sodium; 2-({[3,5-dimethyl-4-(methyloxy)pyridin-2-yl]methyl}sulfinyl)-5-(methyloxy)-1H-benzimidazole; 5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; DSSTox_RID_75929; DSSTox_GSID_21080; ( -)-Omeprazole; Omeprazone; Omeprazen; Omesec; Omeprazole delayed-release; Omeprazole Pellets; 1H-Benzimidazole,5-methoxy-2-[(R)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-; 5-methoxy-2-((4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl)-1H-benzo[d]imidazole; 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]-1H-benzimidazole; 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]benzimidazole; Prilosec (TN); (+-)-Omeprazole; CCRIS 7099; HSDB 3575; (S)-6-Methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; SR-01000003003; Omperazole; Omeprazole-d6; 161796-78-7; Omeprazole, solid; 5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole; AGI-010; Omeprazole,(S); Omeprazole solution; Omeprazole-[d3]; Omeprazole S-Isomer; 2-(((3,5-Dimethyl-4-methoxy-2-pyridyl)methyl)sulfinyl)-5-methoxy-1H-benzimidazole; DM-3458; Omeprazole [USAN:USP:INN:BAN:JAN]; Omeprazole-13C,D3; Omeprazole (Prilosec); ACMC-20p1du; Maybridge4_002645; Opera_ID_1863; Prestwick0_000493; Prestwick1_000493; Prestwick2_000493; Prestwick3_000493; (.+/-.)-Omeprazole; O0359; UPCMLD-DP075; 5-Methoxy-2[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]-1H-benzimidazole; cid_4594; SCHEMBL1191; BSPBio_000385; MLS001076112; MLS001424148; MLS006010400; MLS006011759; BIDD:GT0189; SPBio_002306; BPBio1_000425; GTPL4279; Omeprazole (JP17/USP/INN); Esomeprazole sodium salt hydrate; DTXSID6021080; SCHEMBL11995456; UPCMLD-DP075:001; CHEBI:91766; HMS1528I05; HMS1569D07; HMS2052G17; HMS2090E16; HMS2090F11; HMS2096D07; HMS2232B21; HMS3269D17; HMS3394G17; HMS3413J07; HMS3651A11; HMS3677J07; HMS3713D07; Pharmakon1600-01505693; (S)-Omeprazole sodium salt hydrate; AMY30573; BCP05852; BCP13592; BCP21299; HY-B0113; 2,3,5-Trimethylpyridine/Omeprazole; Tox21_110686; Tox21_200509; AC-401; BBL028172; BDBM50103597; BDBM50241343; CO0037; DL-462; NSC751450; NSC759192; s1389; STK623746; 119141-88-7 (base); AKOS005066653; AKOS015895343; Tox21_110686_1; AC-4676; CCG-101130; CCG-213517; CS-1868; DB00338; HS-0055; MCULE-3224208952; NC00380; NE55490; NSC 751450; NSC 759192; NSC-751450; NSC-759192; IDI1_032523; NCGC00016925-01; NCGC00016925-02; NCGC00016925-03; NCGC00016925-04; NCGC00016925-05; NCGC00016925-07; NCGC00016925-08; NCGC00016925-10; NCGC00016925-11; NCGC00021522-03; NCGC00021522-04; NCGC00021522-05; NCGC00258063-01; Omeprazole, analytical reference material; AK162396; K253; SY077145; SBI-0206896.P001; AB0014122; FT-0601585; FT-0652860; FT-0653294; FT-0673283; FT-0689771; H 199; SW196942-4; A19447; C07324; D00455; J10125; 668985-31-7 (Mg); 141O887; A837865; Q422210; SR-01000003003-4; SR-01000003003-7; SR-01000003003-8; 5-methoxy-2-((4-methoxy-3,5-dimethylpyridin-2-yl); BRD-A55962179-001-04-9; BRD-A55962179-001-08-0; BRD-A55962179-001-20-5; BRD-A88691025-001-07-4; F0001-2386; Z1672902589; Omeprazole, British Pharmacopoeia (BP) Reference Standard; Omeprazole, European Pharmacopoeia (EP) Reference Standard; Omeprazole, United States Pharmacopeia (USP) Reference Standard; 2-(3-methoxy-2,4-dimethylbenzylsulfinyl)-6-methoxy-1H-benzo[d]imidazole; 5-Methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2- pyridinyl)methyl)sulfinyl)-; Omeprazole, Pharmaceutical Secondary Standard; Certified Reference Material; (+)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-sulfinyl]-1h-benzimidazole; (-)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-sulfinyl]-1h-benzimidazole; (RS)-5-Methoxy-2-(4-methoxy-3,5-dimethyl-2-pyridylmethylsulphinyl)benzimidazole; 5-methoxy 2-[[(4-methoxy-3,5-dimethyl-2-pyrdinyl)-methyl]sulfinyl]-1H-benzimidazole; 5-methoxy 2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1 H-benzimidazole; 5-methoxy 2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole; 5-methoxy-2-(2-(4-methoxy-3,5-dimethylpyridin-2-yl)ethylsulfinyl)-1H-benzo[d]imidazole; 5-Methoxy-2-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfinyl)-1H-benzoimidazole; 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl- 1H-benzimidazole; 5-methoxy-2-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methylsulfinyl]-3H-benzoimidazole; 5-Methoxy-2-[(RS)-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl]-1H-benzimidazole; 5-methoxy-2-[[(3,5-dimethyl-4-methoxy-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole; 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulphinyl]-1H-benzimidazole; 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]-benzimidazole; 5-methoxy-2-[[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulphinyl]1H-benzimidazole; 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methane]sulfinyl}-1H-1,3-benzodiazole; 6-methoxy-2-((4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl)-1H-benzo[d]imidazole; 6-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1H-benzimidazole; 6-methoxy-2-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methylsulfinyl]-1H-benzimidazole; 6-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1h-benzimidazole; 6-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1h-benzimidazole; 6-methoxy-2-[[(4-methoxy-3,5dimethyl-2-pyridinyl)-methyl]sulfinyl]-1h-benzimidazole; 6-methoxy-2-[[(4-methoxy3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1h-benzimidazole; 6-methoxy-2-[[(4methoxy-3,5-dimethyl2-pyridinyl)methyl]sulfinyl]-1h-benzimidazole; Omeprazole for peak identification, European Pharmacopoeia (EP) Reference Standard; Omeprazole solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; (omeprazole)5-Methoxy-2-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfinyl)-1H-benzoimidazole; (RS)-6-methoxy-2-((4-methoxy-3,5-dimethylpyridin-2-yl) methylsulfinyl)-1H-benzo[d]imidazole; 5-Methoxy-2-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfinyl)-1H-benzoimidazole (omeprazole); 5-Methoxy-2-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfinyl)-1H-benzoimidazole(Omeprazole); 6-Methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole sodium salt; 934293-91-1	Small molecule	1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)	SUBDBMMJDZJVOS-UHFFFAOYSA-N	CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC	C17H19N3O3S	CAS 73590-58-6	CHEBI:77260	.	.	.	D01XNB	.	.	.
DR1112	Nitazoxanide	CID: 41684	NITAZOXANIDE; 55981-09-4; Alinia; Nitazoxamide; 2-((5-nitrothiazol-2-yl)carbamoyl)phenyl acetate; Daxon; Nitazoxanidum [INN-Latin]; Nitazoxanida [INN-Spanish]; Benzamide, 2-(acetyloxy)-N-(5-nitro-2-thiazolyl)-; 2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl acetate; 2-(Acetolyloxy)-N-(5-nitro-2-thiazolyl)benzamide; C12H9N3O5S; [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl] acetate; UNII-SOA12P041N; NTZ; NSC697855; 2-Acetyloxy-N-[(5-nitro-2-thiazolyl)]benzamide; Nitazoxanide (Alinia, Annita); SOA12P041N; Nitazoxanida; Nitazoxanide-d4; 2-(Acetyloxy)-N-(5-nitro-2-thiazolyl)benzamide; MFCD00416599; NSC-697855; PH 5776; PH-5776; NCGC00090774-01; Nitazoxanid; Nitazoxanidum; Colufase; Cryptaz; Heliton; DSSTox_CID_13757; DSSTox_RID_79095; DSSTox_GSID_33757; Phavic-1; acetic acid [2-[[(5-nitro-2-thiazolyl)amino]-oxomethyl]phenyl] ester; SMR000466367; NSC 697855; Alinia (TN); AZT + Nitazoxanide; CAS-55981-09-4; 1246819-17-9; EINECS 259-931-8; Nitazoxanide (USAN/INN); (2-((5-Nitro-2-thiazolyl)carbamoyl)phenyl)acetat; BRN 1225475; N-(5-Nitro-2-thiazolyl)salicylamide acetate (ester); Nitrazoxanide; Pacovanton; Dexidex; Kidonax; Nitazox; Paramix; Nitax; Toza; Nitazoxanide [USAN:INN:BAN]; Alinia(TM); N-(5-Nitrothiazol-2-yl)salicylamide acetate ester; o-(N-(5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate; Salicylamide, N-(5-nitro-2-thiazolyl)-, acetate (ester); CPD000466367; NCIMech_000843; CHEMBL1401; Oprea1_263587; SCHEMBL40981; MLS000759492; MLS001424074; MLS006010127; [2-[(5-nitrothiazol-2-yl)carbamoyl]phenyl] acetate; DTXSID5033757; CHEBI:94807; Nitazoxanide, >=98% (HPLC); NTZ;NSC 697855; HMS2051L04; HMS3393L04; HMS3655M11; HMS3715F10; Pharmakon1600-01503843; BCP13918; HY-B0217; ZINC3956788; Tox21_111018; Tox21_201226; BDBM50075050; CCG-35851; CN0040; MMV688991; NSC760057; STK395664; AKOS015915393; Tox21_111018_1; AC-1302; DB00507; KS-1160; MCULE-8701444531; NC00246; NSC-760057; NCGC00090774-02; NCGC00090774-03; NCGC00090774-04; NCGC00090774-05; NCGC00258778-01; AK-26130; NCI60_034935; AB0010620; FT-0601547; N1031; Nitrazoxanide 100 microg/mL in Acetonitrile; S1627; ST51059722; SW197626-2; 2-(5-nitrothiazol-2-ylcarbamoyl)phenyl acetate; D02486; J10428; S-3645; AB00639988-07; AB00639988-09; AB00639988_10; AB00639988_11; 981N094; A830877; Q-201475; Q2943789; NTZ; 2-(Acetyloxy)-N-(5-nitro-2-thiazolyl)benzamide; Salicylamide, N-(5-nitro-2-thiazolyl)- acetate (ester); Z1514087129; 2-[N-(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl acetate; [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl] ethanoate; Nitazoxanide, United States Pharmacopeia (USP) Reference Standard; [2,3,4,5-tetradeuterio-6-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl] acetate; Zox	Small molecule	1S/C12H9N3O5S/c1-7(16)20-9-5-3-2-4-8(9)11(17)14-12-13-6-10(21-12)15(18)19/h2-6H,1H3,(H,13,14,17)	YQNQNVDNTFHQSW-UHFFFAOYSA-N	CC(=O)OC1=CC=CC=C1C(=O)NC2=NC=C(S2)[N+](=O)[O-]	C12H9N3O5S	CAS 55981-09-4	CHEBI:94807	.	.	.	D08EBN	.	.	.
DR1119	Nimesulide	CID: 4495	nimesulide; 51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Aulin; Flogovital; Sulidene; Nimed; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; R-805; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; R 805; Nisulid; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; MFCD00079470; NCGC00015725-02; SMR000058484; CAS-51803-78-2; DSSTox_CID_17250; DSSTox_RID_79316; DSSTox_GSID_37250; Antifloxil; Nimesulida; Nimesulidum; Guaxan; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; NIM; Nimesulide [INN:BAN]; SR-01000000218; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; Aldoron; Nimedex; Orthobid; CCRIS 8225; Nise Gel; Nimesulide,(S); Prestwick_618; Spectrum_001577; Nimesulide (JAN/INN); Opera_ID_1247; Prestwick0_000194; Prestwick1_000194; Prestwick2_000194; Prestwick3_000194; Spectrum2_001541; Spectrum3_001576; Spectrum4_000178; Spectrum5_000964; Lopac-N-1016; N-(4-nitro-2-phenoxy-phenyl)methanesulfonamide; Lopac0_000855; SCHEMBL24882; BSPBio_000147; BSPBio_001103; BSPBio_003112; KBioGR_000443; KBioGR_000695; KBioSS_000443; KBioSS_002057; MLS001148268; DivK1c_000693; SPECTRUM1503231; SPBio_001382; SPBio_002068; N-(4-nitro-2-phenoxyphenyl); BPBio1_000163; GTPL7401; NIM-03; DTXSID3037250; BCBcMAP01_000034; HMS502C15; KBio1_000693; KBio2_000443; KBio2_002057; KBio2_003011; KBio2_004625; KBio2_005579; KBio2_007193; KBio3_000825; KBio3_000826; KBio3_002612; NINDS_000693; Bio2_000382; Bio2_000862; HMS1362G05; HMS1568H09; HMS1792G05; HMS1922K17; HMS1990G05; HMS2089B14; HMS2095H09; HMS2234K19; HMS3262L11; HMS3269G17; HMS3371J19; HMS3403G05; HMS3414P09; HMS3649A04; HMS3655D13; HMS3678P07; HMS3712H09; HMS3884C22; Pharmakon1600-01503231; BCP10076; HY-B0363; ZINC4617749; Tox21_110207; Tox21_301850; Tox21_500855; BDBM50056999; CCG-39319; CN0038; EI-287; NSC758412; s2040; STL018679; AKOS015897356; Tox21_110207_1; AC-4524; DB04743; KS-1277; LP00855; MCULE-4217888990; NSC 758412; NSC-758412; SDCCGSBI-0050831.P004; IDI1_000693; IDI1_002137; NCGC00015725-01; NCGC00015725-03; NCGC00015725-04; NCGC00015725-05; NCGC00015725-06; NCGC00015725-07; NCGC00015725-08; NCGC00015725-09; NCGC00015725-10; NCGC00015725-11; NCGC00015725-12; NCGC00015725-13; NCGC00015725-15; NCGC00015725-16; NCGC00015725-29; NCGC00021842-03; NCGC00021842-04; NCGC00021842-05; NCGC00021842-06; NCGC00021842-07; NCGC00021842-08; NCGC00255661-01; NCGC00261540-01; AK163559; SBI-0050831.P003; DB-052029; AB00052332; EU-0100855; FT-0630650; N0984; ST51015069; SW196785-3; (methylsulfonyl)(4-nitro-2-phenoxyphenyl)amine; D01049; N 1016; Q20994; AB00052332-16; AB00052332_17; AB00052332_18; n-(4-nitro-2-phenoxy-phenyl)-methanesulfonamide; N-[4-nitro-2-(phenoxy)phenyl]methanesulfonamide; 803N782; A828786; SR-01000000218-2; SR-01000000218-6; SR-01000000218-7; W-105866; BRD-K76775527-001-06-2; BRD-K76775527-001-18-7; SR-01000000218-11; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)- (9CI); Nimesulide, European Pharmacopoeia (EP) Reference Standard; Nimesulide, Pharmaceutical Secondary Standard; Certified Reference Material; Nimesulide for peak identification, European Pharmacopoeia (EP) Reference Standard; 1364966-82-4	Small molecule	1S/C13H12N2O5S/c1-21(18,19)14-12-8-7-10(15(16)17)9-13(12)20-11-5-3-2-4-6-11/h2-9,14H,1H3	HYWYRSMBCFDLJT-UHFFFAOYSA-N	CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2	C13H12N2O5S	CAS 51803-78-2	CHEBI:44445	.	.	.	D0C0JT	.	.	.
DR1126	Risedronate	CID: 5245	Risedronic acid; Risedronate; 105462-24-6; Atelvia; Risedronic acid monohydrate; Benet; NE-58095; UNII-KM2Z91756Z; (1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonic acid; Phosphonic acid, [1-hydroxy-2-(3-pyridinyl)ethylidene]bis-; (1-hydroxy-1-phosphono-2-pyridin-3-yl-ethyl)phosphonic acid; Risedronic acid (Actonel); CHEMBL923; CHEBI:8869; Phosphonic acid, (1-hydroxy-2-(3-pyridinyl)ethylidene)bis-; [1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl]phosphonic acid; 1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE BIS-PHOSPHONIC ACID; KM2Z91756Z; RIS; (1-hydroxy-2-pyridin-3-ylethane-1,1-diyl)bis(phosphonic acid); Acido risedronico; Acide risedronique; Acidum risedronicum; Risedronic acid [INN:BAN]; (1-hydroxy-2-(pyridin-3-yl)ethane-1,1-diyl)bis(phosphonic acid); Acide risedronique [INN-French]; Acido risedronico [INN-Spanish]; Acidum risedronicum [INN-Latin]; 115436-72-1; Bisphosphonate 1; C7H11NO7P2.H2O; [1-hydroxy-1-phosphono-2-(3-pyridyl)ethyl]phosphonic acid; Ridron (TN); C7H11NO7P2; MFCD00867080; NE 58019; HSDB 7326; Risedronic acid (INN); 1-Hydroxy-2-(3-pyridyl)-ethan-1,1-bis-phosphonic acid; Risdronate; Risedronate acid; SR-05000001495; M05BA07; (1-Hydroxy-2-(3-pyridyl)ethylidene)diphosphonic acid; PubChem14002; SCHEMBL18378; BIDD:GT0010; GTPL3176; JMC515594 Compound 64; DTXSID2023563; BDBM12576; AMY3524; HMS2090C21; HMS3741A17; BCP13805; HY-B0148; ZINC1531009; 2689AH; s1874; AKOS015892564; AC-1295; CS-1964; DB00884; NCGC00386377-01; AS-13584; I802; AB0013898; FT-0642593; A11675; C08233; D08484; M-1366; AB01275490-01; AB01275490_02; 462R246; A801245; Q408724; SR-05000001495-1; 2-(3-pyridyl)-1-hydroxyethane-1,1-bisphosphonic acid; Z2684418685; (1-Hydroxy-2-(pyridin-3-yl)ethane-1,1-diyl)diphosphonic acid; (1-oxidanyl-1-phosphono-2-pyridin-3-yl-ethyl)phosphonic acid; [1-hydroxy-1-phosphono-2-(3-pyridinyl)ethyl]phosphonic acid; 1-hydroxy-2-(pyridin-3-yl)ethane-1,1-diyldiphosphonic acid	Small molecule	1S/C7H11NO7P2/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15)	IIDJRNMFWXDHID-UHFFFAOYSA-N	C1=CC(=CN=C1)CC(O)(P(=O)(O)O)P(=O)(O)O	C7H11NO7P2	CAS 105462-24-6	CHEBI:8869	.	.	.	D0PA5S	.	.	.
DR1130	PD184352	CID: 6918454	212631-79-3; CI-1040; PD184352; PD 184352; PD-184352; 2-(2-chloro-4-iodophenylamino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide; PD184352 (CI-1040); CI 1040; CI1040; 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide; 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide; PD-18435; UNII-R3K9Y00J04; C.I. 1040; CHEMBL105442; R3K9Y00J04; MFCD02683961; NCGC00189074-01; CI-1040 (PD184352); DSSTox_CID_28871; DSSTox_RID_83140; DSSTox_GSID_48945; C17H14ClF2IN2O2; CAS-212631-79-3; PD 184,352; cc-384; MLS006010176; SCHEMBL570330; PD 184352, Free Base; GTPL5676; QCR-25; DTXSID8048945; CHEBI:91353; SYN1031; HMS3244G05; HMS3244G06; HMS3244H05; HMS3265I07; HMS3265I08; HMS3265J07; HMS3265J08; HMS3654I05; AOB87195; BCP01791; EX-A2202; ZINC1489691; Tox21_113363; ABP000919; BDBM50132260; NSC765695; s1020; 2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide; AKOS022184333; Tox21_113363_1; CCG-269529; CS-0058; DB12429; NSC-765695; SB19417; 2-[(2-CHLORO-4-IODOPHENYL)AMINO]-N-(CYCLOPROPYLMETHOXY)-3,4-DIFLUOROBENZAMIDE; NCGC00189074-03; NCGC00189074-05; AC-25483; AS-19373; HY-50295; SMR004701284; CI-1040,PD184352; PD 184352CI-1040; AB0033705; DB-014962; CI-1040; PD184352; FT-0673543; SW219604-1; X7396; EC-000.2331; PD 184352(CI-1040); PD184352 - CI-1040; A25744; PD184352, >=98% (HPLC); S-7729; CI-1040/CI1040,PD184352; 631C793; US8575391, 341; J-505572; BRD-K05104363-001-01-9; Q27076005; 4-iodophenylamino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide; 2-(2-Chloro4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide; 2-[(2-Chloro-4-iodophenyl)amino]-N-cyclopropylmethoxy)-3,4-difluorobenzamide; Benzamide, 2-((2-chloro-4-iodophenyl)amino)-N-(cyclopropylmethoxy)-3,4-difluoro-; CI-1040; ; ; 2-(2-Chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide	Small molecule	1S/C17H14ClF2IN2O2/c18-12-7-10(21)3-6-14(12)22-16-11(4-5-13(19)15(16)20)17(24)23-25-8-9-1-2-9/h3-7,9,22H,1-2,8H2,(H,23,24)	GFMMXOIFOQCCGU-UHFFFAOYSA-N	C1CC1CONC(=O)C2=C(C(=C(C=C2)F)F)NC3=C(C=C(C=C3)I)Cl	C17H14ClF2IN2O2	CAS 212631-79-3	CHEBI:91353	.	.	.	D0B9BU	.	.	.
DR1137	Meropenem	CID: 441130	meropenem; 96036-03-2; Merrem; Meropenem anhydrous; Meropenemum; Antibiotic SM 7338; MERONEM; SM-7338; MEPM; 119478-56-7; UNII-YOP6PX0BAO; CHEBI:43968; Meropenemum [INN-Latin]; (4R,5S,6S)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; Meropenem (INN); Meropenem [INN]; Meropenem Hydrate; YOP6PX0BAO; Merrem I.V.; ICI-194660; (4R,5S,6S)-3-(((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl)thio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (4r,5s,6s)-3-{[(3s,5s)-5-(Dimethylcarbamoyl)pyrrolidin-3-Yl]sulfanyl}-6-[(1r)-1-Hydroxyethyl]-4-Methyl-7-Oxo-1-Azabicyclo[3.2.0]hept-2-Ene-2-Carboxylic Acid; 96036-03-2 (free); SM 7338; (4R,5S,6S)-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]thio}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; ICI 194,660; NCGC00016962-01; ICI 194660; DSSTox_CID_25526; DSSTox_RID_80930; DSSTox_GSID_45526; Meropen; (1R,5S,6S)-2-[(3S,5S)-5-DIMETHYLAMINOCARBONYLPYRROLIDIN-3-YLTHIO]-6-[(R)-1-HYDROXYETHYL]-1-METHYLCARBAPEN-2-EM-3-CARBOXYLIC ACID; (4R,5S,6S)-3-[[(3S,5S)-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; Meronem (TN); CAS-96036-03-2; MFCD08600005; Merrem I.V. (TN); SR-01000762894; HSDB 8019; Merrem IV; Meropenem,(S); M2279; BRN 6940582; PubChem17275; Meropenem (closed form); Prestwick0_001106; Prestwick1_001106; Prestwick2_001106; Prestwick3_001106; CHEMBL127; Epitope ID:195064; SCHEMBL34442; BSPBio_001212; (1R,5S,6S)-2-[(3S,5S)-5-(dimethylaminocarbonyl)pyrrolidin-3-ylthio]-6-[(R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic acid trihydrate; MLS001401437; BIDD:GT0851; 4-methyl-7-oxo-1-azabicyclo; SPBio_003086; BPBio1_001334; Meropenem with Sodium Carbonate; DTXSID7045526; GTPL10829; HMS1571M14; HMS2051G08; HMS2090C05; HMS2098M14; HMS3715M14; 1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-(((3S,5S)-5-((dimethylamino)carbonyl)-3-pyrrolidinyl)thio)-6-((1R)-1-hydroxyethyl)-4-methyl-7-oxo-, (4R,5S,6S)-; AMY22192; ZINC3808779; 96036-03-2 (anhydr.); Tox21_110715; Tox21_113794; BDBM50129062; AKOS015920140; Tox21_110715_1; CCG-100850; CS-1865; DB00760; KS-5224; NC00100; [3.2.0]hept-2-ene-2-carboxylic acid; NCGC00179259-01; NCGC00179259-06; NCGC00179259-17; NCGC00253670-01; NCGC00262579-02; (6S)-2-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-1beta-methyl-2,3-didehydro-1-carbapenam-3-carboxylic acid; HY-13678; SMR000469184; AB0012458; AB00514051; D08185; J10087; M05727; S-3680; AB00514051-02; AB00698370-05; pyrrolidin-3-ylthio)-6-((R)-1-hydroxyethyl)-; 036M032; Q421670; (4R,5S,6S)-3-((3S,5S)-5-(dimethylcarbamoyl); SR-01000762894-3; SR-01000762894-4; Meropenem trihydrate, Antibiotic for Culture Media Use Only; (1R,5S,6S)-2-[(3S,5S)-5-(dimethylaminocarbonyl)pyrrolidin-3-ylthio]-6-[(R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic acid; (4R,5S,6S)-3-((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (4R,5S,6S)-3-[[(3S,5S)-5-(dimethylaminocarbonyl)-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (4R,6S)-3-((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; 1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-((dimethylamino)carbonyl)-3-pyrrolidinyl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4R-(3(S*,5S*),4-alpha,5-beta,6-beta(R*)))-	Small molecule	1S/C17H25N3O5S/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-9-5-10(18-6-9)15(22)19(3)4/h7-12,18,21H,5-6H2,1-4H3,(H,24,25)/t7-,8-,9+,10+,11-,12-/m1/s1	DMJNNHOOLUXYBV-PQTSNVLCSA-N	CC1C2C(C(=O)N2C(=C1SC3CC(NC3)C(=O)N(C)C)C(=O)O)C(C)O	C17H25N3O5S	CAS 96036-03-2	CHEBI:43968	.	.	.	D0O5FY	.	.	.
DR1182	Chloroquine	CID: 2719	chloroquine; 54-05-7; Aralen; Chlorochin; Chloraquine; Artrichin; Chloroquinium; Chloroquina; Reumachlor; Capquin; Chemochin; Chlorquin; Clorochina; Malaquin; Arthrochin; Bemasulph; Benaquin; Bipiquin; Chingamin; Cidanchin; Cocartrit; Dichinalex; Gontochin; Heliopar; Iroquine; Klorokin; Lapaquin; Mesylith; Pfizerquine; Quinachlor; Quinercyl; Quinilon; Quinoscan; Sanoquin; Silbesan; Solprina; Sopaquin; Tresochin; Amokin; Bemaco; Elestol; Imagon; Malaren; Malarex; Neochin; Roquine; Siragan; Trochin; Nivaquine B; Bemaphate; Resoquine; Nivaquine; Chlorochine; Chloroquinum; Cloroquina; Quingamine; Avloclor; Resochin; Ronaquine; Khingamin; N4-(7-chloroquinolin-4-yl)-N1,N1-diethylpentane-1,4-diamine; Avlochlor; Nivachine; Quinagamin; Quinagamine; Resochen; Resoquina; Reumaquin; Arechin; Delagil; Tanakan; WIN 244; 1,4-Pentanediamine, N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-; RP 3377; W 7618; Chloroin; Miniquine; Rivoquine; Tanakene; Arolen; 7-Chloro-4-((4-(diethylamino)-1-methylbutyl)amino)quinoline; CHEBI:3638; Chloroquine free base; N4-(7-Chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine; Gontochin phosphate; CHEMBL76; SN 6718; 54-05-7 (free base); Ipsen 225; Chlorochinum; N(sup 4)-(7-Chloro-4-quinolinyl)-N(sup 1),N(sup 1)-diethyl-1,4-pentanediamine; MFCD00024009; NSC187208; NSC-187208; SN 7618; Chloroquine (VAN); Clorochina [DCIT]; 7-Chloro-4-[[4-(diethylamino)-1-methylbutyl]amino]quinoline; 4-N-(7-chloroquinolin-4-yl)-1-N,1-N-diethylpentane-1,4-diamine; Quinoline, 7-chloro-4-((4-(diethylamino)-1-methylbutyl)amino)-; 3377 RP; SN-7618; 1,4-Pentanediamine, N(sup 4)-(7-chloro-4-quinolinyl)-N(sup 1),N(sup 1)-diethyl-; ST 21 (pharmaceutical); Chloroquinum [INN-Latin]; Cloroquina [INN-Spanish]; 3377 RP opalate; Chloroquin; Quinoline, 7-chloro-4-[[4-(diethylamino)-1-methylbutyl]amino]-; N(4)-(7-chloro-4-quinolinyl)-N(1),N(1)-diethyl-1,4-pentanediamine; ST 21; (+-)-Chloroquine; NSC14050; CCRIS 3439; HSDB 3029; Chloroquine (USP/INN); EINECS 200-191-2; {4-[(7-chloro(4-quinolyl))amino]pentyl}diethylamine; Malaquin (*Diphosphate*); NSC 187208; BRN 0482809; Cloroquine; Chloroquine [USP:INN:BAN]; Chloroquine, 17; Chloroquine-[d4]; 4,7-Dichloroquine; {4-[(7-chloroquinolin-4-yl)amino]pentyl}diethylamine; Arechin (Salt/Mix); Delagil (Salt/Mix); Tanakan (Salt/Mix); 1246815-14-4; RP-3377; Bemaphate (Salt/Mix); Resoquine (Salt/Mix); Spectrum_000132; Chloroquine + Proveblue; Prestwick0_000548; Prestwick1_000548; Prestwick2_000548; Prestwick3_000548; Spectrum2_000127; Spectrum3_000341; Spectrum4_000279; Spectrum5_000707; (.+/-.)-Chloroquine; 1,4-Pentanediamine, N(4)-(7-chloro-4-quinolinyl)-N(1),N(1)-diethyl-; Epitope ID:131785; MolMap_000009; SCHEMBL8933; Lopac0_000296; BSPBio_000595; BSPBio_002001; KBioGR_000778; KBioSS_000592; DivK1c_000404; CU-01000012392-2; SPBio_000174; SPBio_002516; GNF-Pf-4216; BPBio1_000655; GTPL5535; DTXSID2040446; BDBM22985; KBio1_000404; KBio2_000592; KBio2_003160; KBio2_005728; KBio3_001221; NINDS_000404; HMS2090O03; ALBB-025694; HY-17589A; s6999; SBB072644; AKOS015935106; CCG-204391; CS-W004760; DB00608; KH-0005; MCULE-3610827164; SDCCGSBI-0050284.P005; IDI1_000404; SMP2_000034; NCGC00015256-02; NCGC00015256-03; NCGC00015256-04; NCGC00015256-05; NCGC00015256-06; NCGC00015256-07; NCGC00015256-08; NCGC00015256-09; NCGC00015256-10; NCGC00015256-13; NCGC00015256-17; NCGC00015256-28; NCGC00162120-01; AK116457; NCI60_000894; SY086904; WLN: T66 BNJ EMY1&3N2&2 IG; SBI-0050284.P004; AB00053436; CS-0021871; FT-0623612; ST45028748; C07625; D02366; MLS-0466768.0001; AB00053436-05; AB00053436_06; AB00053436_07; 1, N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-; Q422438; BRD-A91699651-065-01-1; BRD-A91699651-316-06-7; n(sup4)-(7-chloro-4-quinolinyl)-n(sup1),4-pentanediamine; N'-(7-chloroquinolin-4-yl)-N,N-diethylpentane-1,4-diamine; N4-(7-chloro-4-quinolyl)-N1,N1-diethyl-pentane-1,4-diamine; Quinoline, 7-chloro-4-(4-diethylamino-1-methyl-butylamino)-; N(4)-(7-chloroquinolin-4-yl)-N(1),N(1)-diethylpentane-1,4-diamine; 1,4-pentanediamine, N~4~-(7-chloro-4-quinolinyl)-N~1~,N~1~-diethyl-, phosphate (1:2); N(sup4)-(7-chloro-4-quinolinyl)-N(sup1),N(sup1)-diethyl-1,4-pentanediamine; 117399-83-4; Chloroquine; Chloroquine Sulphate; 4-N-(7-chloroquinolin-4-yl)-1-N,1-N-diethylpentane-1,4-diamine	Small molecule	1S/C18H26ClN3/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21)	WHTVZRBIWZFKQO-UHFFFAOYSA-N	CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl	C18H26ClN3	CAS 54-05-7	CHEBI:3638	.	.	.	D09EGZ	.	.	.
DR1194	Octyl disulfamate	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR1229	PP242	CID: 135565635	TORKinib	Small molecule	1S/C16H16N6O/c1-8(2)22-16-13(15(17)18-7-19-16)14(21-22)12-6-9-5-10(23)3-4-11(9)20-12/h3-8,20,23H,1-2H3,(H2,17,18,19)	MFAQYJIYDMLAIM-UHFFFAOYSA-N	CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(N3)C=CC(=C4)O)N	C16H16N6O	CAS 1092351-67-1	.	.	.	.	D0H2CM	.	.	.
DR1235	Monodesbutyl benflumetol	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR1258	Methotrexate	CID: 126941	diazinon; Dimpylate; 333-41-5; Diazinone; Oleodiazinon; Neocidol; Spectracide; Diazitol; Nedcidol; Dassitox; Ciazinon; Ektoband; Nucidol; Flytrol; Exodin; Galesan; Bazuden; Diazol; Diazide; Sarolex; Dazzel; Dacutox; Basudin; Antigal; Dicid; Alfa-tox; Diazajet; Dimpylat; Garden Tox; Neocidol (oil); Bassadinon; Terminator; Kayazol; Dizinon; Disonex; Compass; Meodinon; Kayazinon; Drawizon; Nipsan; Dyzol; Diazinon ag 500; Knox-out; Neodinon; Optimizer; Dimpylatum; Delzinon; Dizictol; Dipofene; Dizinil; Bazudin; Srolex; Basudin 10 G; Geigy 24480; Basudin S; Knox	Small molecule	1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1	FBOZXECLQNJBKD-ZDUSSCGKSA-N	CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O	C20H22N8O5	CAS 59-05-2	.	.	.	.	D0SV8E	.	.	Methotrexate
DR1274	Angiotensin-II converting enzyme inhibitor	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR1277	Diethylcarbamazine	CID: 3052	diethylcarbamazine; 90-89-1; N,N-diethyl-4-methylpiperazine-1-carboxamide; Carbamazine; Diethyl carbamazine; Carbilazine; Ethodryl; Notezine; Bitirazine; Caricide; Cypip; Ditrazine Base; Caracide; Spatonin; 1-Piperazinecarboxamide, N,N-diethyl-4-methyl-; N,N-Diethyl-4-methyl-1-piperazinecarboxamide; N,N-Diethylcarbamazine; UNII-V867Q8X3ZD; RP 3799; 84L; CHEBI:4527; V867Q8X3ZD; Bitirazine; Caracide;Carbamazine; MMV002816; Diaethylcarbamazinum; Dietilcarbamazina; Diethylcarbamazinum; Diethylcarbamazine [INN:BAN]; Diethylcarbamazinum [INN-Latin]; Dietilcarbamazina [INN-Spanish]; NSC1364; N,N-diethyl(4-methylpiperazinyl)carboxamide; Camin (TN); Diethylcarbamazine (INN); EINECS 202-023-3; 1-Diethylcarbamoyl-4-Methylpiperazine; BRN 0143029; AI3-19612; 1-Diethylcarbamyl-4-methylpiperazine; 1-Methyl-4-diethylcarbamoylpiperazine; Banocide (Salt/Mix); Caritrol (Salt/Mix); Nemacide (Salt/Mix); Spectrum_000938; NN-Diethyl-4-methyl-1-piperazinecarboxamide; Prestwick0_000284; Prestwick1_000284; Prestwick2_000284; Prestwick3_000284; Spectrum2_001022; Spectrum3_000390; Spectrum4_000511; Spectrum5_000877; diethyl carbamazine citrate; CHEMBL684; EC 202-023-3; SCHEMBL67289; BSPBio_000188; BSPBio_002179; KBioGR_001081; KBioSS_001418; 4-23-00-00225 (Beilstein Handbook Reference); DivK1c_000548; SPBio_001203; SPBio_002407; BPBio1_000208; ZINC1288; DTXSID1022928; KBio1_000548; KBio2_001418; KBio2_003986; KBio2_006554; KBio3_001399; NINDS_000548; HMS3604F12; 1-Diethylcarbamoyl-4-methylpiperzine; MFCD00023288; SBB008185; AKOS003268016; DB00711; DS-9360; MCULE-7296820622; NE55264; IDI1_000548; NCGC00178778-01; NCGC00178778-02; NCGC00178778-07; AK158485; ST094965; SBI-0051345.P003; DB-080764; R.P. 3799; 1-(N,N-Diethylcarbamoyl)-4-methylpiperazine; AB00053457; FT-0624832; C07968; D07825; N,N-diethyl-4-methyl-piperazine-1-carboxamide; AB00053457_12; Q409267; BRD-K45542189-048-05-6; BRD-K45542189-048-15-5	Small molecule	1S/C10H21N3O/c1-4-12(5-2)10(14)13-8-6-11(3)7-9-13/h4-9H2,1-3H3	RCKMWOKWVGPNJF-UHFFFAOYSA-N	CCN(CC)C(=O)N1CCN(CC1)C	C10H21N3O	CAS 90-89-1	CHEBI:4527	.	.	.	D06RCB	.	.	.
DR1288	Cefotaxime	CID: 5742673	cefotaxime; Cephotaxime; 63527-52-6; Cefotaxime acid; E-cefotaxime; UNII-N2GI8B1GK7; Cefotaximum; Cefotaxima; CHEBI:204928; N2GI8B1GK7; 60846-21-1; (6R,7R)-3-(acetyloxymethyl)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Omnatax; Taxim; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetyloxy)methyl)-7-(((2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-, (6R,7R)-; Cefotaxime [INN:BAN]; Cefotaximum [INN-Latin]; Cefotaxima [INN-Spanish]; Cefotaxima acid; 4kot; (6R,7R)-3-(acetoxymethyl)-7-((E)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-(acetoxymethyl)-7-[[(2Z)-2-(2-aminothiazol-4-yl)-2-methoxyimino-acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6r,7r)-3-(Acetyloxymethyl)-7-[[(2z)-2-(2-Amino-1,3-Thiazol-4-Yl)-2-Methoxyimino-Ethanoyl]amino]-8-Oxo-5-Thia-1-Azabicyclo[4.2.0]oct-2-Ene-2-Carboxylic Acid; (6R,7R)-3-Acetoxymethyl-7-{2-(2-amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[(acetyloxy)methyl]-7-[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-, (6R,7R)-; Cefotaxime (INN); EINECS 264-299-1; Cefotaxim Hikma (TN); RU 24662; Prestwick2_000139; Prestwick3_000139; Claforan (*Sodium salt*); CHEMBL1730; Lopac0_000278; BSPBio_000218; BPBio1_000240; SCHEMBL3731931; DTXSID6022761; HY-A0088A; HMS2090M11; (6R,7R)-3-(acetoxymethyl)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; ZINC3830437; AC-217; BDBM50482777; MFCD00864971; s4720; AKOS015951267; DB00493; SDCCGSBI-0050266.P002; (6R,7R)-3-(Acetoxymethyl)-7-(()-2-(2-amino-4-thiazolyl)-2-methoxyiminoglyoxylamino)-8-oco-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; 3-(Acetyloxymethyl)-7-(((2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyimino-acetyl)amino)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; AS-12690; clo[4.2.0]oct-2-ene-2-carboxylic acid; CS-0013515; C06885; D07647; J90010; 527C526; BRD-K78364995-236-03-5; Q27262497; Di- poundg-chlorotetrakis[2,4-dimethyl-6-(2-quinolinyl-KN)phenyl-KC]di-iridium; (6R)-3-(Acetoxymethyl)-7alpha-[[(2-amino-4-thiazolyl)[(E)-methoxyimino]acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]octa-2-ene-2-carboxylic acid; (6R,7R)-3-(acetyloxymethyl)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyimino-ethanoyl]amino]-8-oxo-5-thia-1-azabicy; (6R,7R)-3-(acetyloxymethyl)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyimino-ethanoyl]amino]-8-oxo-5-thia-1-azabicy clo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(acetyloxy)methyl]-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(acetyloxy)methyl]-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 1056874-43-1; 3-(Acetoxymethyl)-7beta-[(2-amino-4-thiazolyl)(methoxyimino)acetylamino]cepham-3-ene-4-carboxylic acid; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetyloxy)methyl)-7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-, (6R-(6alpha,7beta(Z)))-	Small molecule	1S/C16H17N5O7S2/c1-6(22)28-3-7-4-29-14-10(13(24)21(14)11(7)15(25)26)19-12(23)9(20-27-2)8-5-30-16(17)18-8/h5,10,14H,3-4H2,1-2H3,(H2,17,18)(H,19,23)(H,25,26)/b20-9-/t10-,14-/m1/s1	GPRBEKHLDVQUJE-QSWIMTSFSA-N	CC(=O)OCC1=C(N2C(C(C2=O)NC(=O)C(=NOC)C3=CSC(=N3)N)SC1)C(=O)O	C16H17N5O7S2	CAS 63527-52-6	CHEBI:204928	.	.	.	D0D1HA	.	.	.
DR1293	Clindamycin	CID: 446598	clindamycin; 18323-44-9; Chlolincocin; Dalacine; Dalacin C; Sobelin; Cleocin; UNII-3U02EL437C; 7-Chlorolincomycin; 7-Chloro-7-deoxylincomycin; Clindamycine; Antirobe; Klimicin; ClindaDerm; 3U02EL437C; U 21251; U-21251; U-21,251; Klindan 300; 7(S)-Chloro-7-deoxylincomycin; 7-Deoxy-7(S)-chlorolincomycin; (2S,4R)-N-((1S,2S)-2-chloro-1-((2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)propyl)-1-methyl-4-propylpyrrolidine-2-carboxamide; Clindamycine [French]; Clindamycine [INN-French]; Clindamycinum [INN-Latin]; Clindamicina [INN-Spanish]; 7-CDL; (2S,4R)-N-[(1S,2S)-2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide; methyl 7-chloro-6,7,8-trideoxy-6-{[(4R)-1-methyl-4-propyl-L-prolyl]amino}-1-thio-L-threo-alpha-D-galacto-octopyranoside; Clindamicina; Clindamycinum; L-threo-a-D-galacto-Octopyranoside, methyl7-chloro-6,7,8-trideoxy-6-[[[(2S,4R)-1-methyl-4-propyl-2-pyrrolidinyl]carbonyl]amino]-1-thio-; C18H33ClN2O5S; Clindamycin [USAN:INN:BAN]; SR-05000001477; HSDB 3037; Clindamycin,(S); (2S,4R)-N-[(1S,2S)-2-chloranyl-1-[(2R,3R,4S,5R,6R)-6-methylsulfanyl-3,4,5-tris(oxidanyl)oxan-2-yl]propyl]-1-methyl-4-propyl-pyrrolidine-2-carboxamide; (2S,4R)-N-[(1S,2S)-2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylthio)-2-oxanyl]propyl]-1-methyl-4-propyl-2-pyrrolidinecarboxamide; (2S,4R)-N-[(1S,2S)-2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyl-tetrahydropyran-2-yl]propyl]-1-methyl-4-propyl-pyrrolidine-2-carboxamide; EINECS 242-209-1; CLDM; NSC305832; Clindamycin (USAN/INN); SCHEMBL3154; CHEMBL1753; CLINDA & IL-12; BIDD:GT0418; Clindamycin & Interleukin 12; DTXSID2022836; GTPL10607; HMS2089A05; HMS2089N16; HY-B1455; ZINC4038341; 2327AH; CC0170; AM84752; CCG-268941; CS-11147; L-threo-.alpha.-D-galacto-Octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-[[[(2S,4R)-1-methyl-4-propyl-2-pyrrolidinyl]carbonyl]amino]-1-thio-; L-threo-alpha-D-galacto-Octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-(((1-methyl-4-propyl-2-pyrrolidinyl)carbonyl)amino)-1-thio-, (2S-trans)-; CS-0013163; 58207-19-5; C06914; D00277; AB01275425-01; AB01275425_02; 323C449; A812757; A831786; SR-05000001477-1; L-threo-alpha-D-galacto-Octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-((((2S,4R)-1-methyl-4-propyl-2-pyrrolidinyl)carbonyl)amino)-1-thio-; L-threo-D-galacto-Octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-, trans-alpha-; methyl 7-chloro-6,7,8-trideoxy-6-({[(2S,4R)-1-methyl-4-propyl-2-pyrrolidinyl]carbonyl}amino)-1-thio-L-threo-alpha-D-galacto-octopyranoside	Small molecule	1S/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9-,10+,11-,12+,13-,14+,15+,16+,18+/m0/s1	KDLRVYVGXIQJDK-AWPVFWJPSA-N	CCCC1CC(N(C1)C)C(=O)NC(C2C(C(C(C(O2)SC)O)O)O)C(C)Cl	C18H33ClN2O5S	CAS 18323-44-9	.	.	.	.	D0R0ZL	.	.	.
DR1299	Paromomycin	CID: 165580	paromomycin; Aminosidin; catenulin; AMINOSIDINE; Neomycin E; Hydroxymycin; Zygomycin A1; Crestomycin; Paucimycin; Estomycin; Monomycin A; 7542-37-2; Paromomycine; Paromomycin I; Paramomycin Sulfate; Humatin; Paromomicina; Paromomycinum; Paucimycinum; Antibiotic 503-3; Antibiotic SF 767B; UNII-61JJC8N5ZK; Gabbromycin; Paromomycin (INN); Paromomycin [INN]; R 400; (1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2-amino-2-deoxy-alpha-D-glucopyranoside; 61JJC8N5ZK; Amminosidin; Gabromycin; Humycin; Aminosidine I; Quintomycin C; CHEBI:7934; Antibiotic 2230D; paramomycin sulphate; R-400; Hydroxymycin sulfate; Paramomycin; Monomycin; Paromomycin (TN); Paromomycin sulfate Rx346208; (2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-(((2R,3S,4R,5S)-5-(((1R,2R,3S,5R,6S)-3,5-diamino-2-(((2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-6-hydroxycyclohexyl)oxy)-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-yl)oxy)tetrahydro-2H-pyran-3,4-diol; Aminosidine, sulfate; hATT & Paromomycin; Paromomycin [INN:BAN]; Paromomycine [INN-French]; Paromomycinum [INN-Latin]; Paromomicina [INN-Spanish]; (2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(2R,3S,4R,5S)-5-[(1R,2R,3S,5R,6S)-3,5-diamino-2-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-6-hydroxy-cyclohexoxy]-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-yl]oxy-tetrahydropyran-3,4-diol; EINECS 231-423-0; BRN 0072285; Human .alpha.-1-antitrypsin & Paromomyin; SCHEMBL4072; 4-18-00-07534 (Beilstein Handbook Reference); CHEMBL370143; DTXSID8023424; ZINC60183170; AKOS030489917; DB01421; MCULE-1528618434; NCGC00166210-02; D-Streptamine, O-2-amino-2-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(O-2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl-(1-3)-beta-D-ribofuranosyl-(1-5))-2-deoxy-; O-2-Amino-2-deoxy-.alpha.-D-glucopyranosyl-(1->4)-O-[O-2,6-diamino-2,6-dideoxy-.beta.-L-idopyranosyl-(1->3)-.beta.D-ribofuranosyl(1->5)]-2-deoxy-D-streptamine; C00832; D07467; 10845-EP2301536A1; 10845-EP2301538A1; 10845-EP2311455A1; 10845-EP2316452A1; AB00639998_04; Q415625; PAROMOMYCIN I; AMMINOSIDIN; CATENULIN; CRESTOMYCIN; MONOMYCIN A; NEOMYCIN E; (2R,3S,4R,5R,6S)-5-amino-6-{[(1R,2R,3S,4R,6S)-4,6-diamino-2-{[(2S,3R,4S,5R)-4-{[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy}-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}-3-hydroxycyclohexyl]oxy}-2-(hydroxymethyl)oxane-3,4-diol; Streptamine, O-2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl-(1-3)-O-beta-D-ribofuranosyl-(1-5)-O-(2-amino-2-deoxy-alpha-D-glucopyranosyl-(1-4))-2-deoxy-	Small molecule	1S/C23H45N5O14/c24-2-7-13(32)15(34)10(27)21(37-7)41-19-9(4-30)39-23(17(19)36)42-20-12(31)5(25)1-6(26)18(20)40-22-11(28)16(35)14(33)8(3-29)38-22/h5-23,29-36H,1-4,24-28H2/t5-,6+,7+,8-,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1	UOZODPSAJZTQNH-LSWIJEOBSA-N	C1C(C(C(C(C1N)OC2C(C(C(C(O2)CO)O)O)N)OC3C(C(C(O3)CO)OC4C(C(C(C(O4)CN)O)O)N)O)O)N	C23H45N5O14	CAS 7542-37-2	CHEBI:7934	.	.	.	D04NDM	.	.	.
DR1332	Perospirone	CID: 115368	Perospirone; 150915-41-6; Lullan; UNII-N303OK87DT; N303OK87DT; (3aR,7aS)-2-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-3a,4,5,6,7,7a-hexahydroisoindole-1,3-dione; C23H30N4O2S; 129273-38-7; cis-N-(4-(4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl)butyl)-1,2-cyclohexanedicarboximide; (3aR,7aS)-2-[4-[4-(1,2-benzothiazol-3-yl)-1-piperazinyl]butyl]-3a,4,5,6,7,7a-hexahydroisoindole-1,3-dione; Perospirone [INN]; (3aS,7aR)-2-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-3a,4,5,6,7,7a-hexahydroisoindole-1,3-dione; NCGC00164567-01; Perospirine; Lullan (Japan); SCHEMBL120579; GTPL7556; CHEMBL1472975; DTXSID2048163; CHEBI:94777; HY-B0731A; HMS3715H10; s5185; ZINC13828184; AKOS025311209; CCG-221234; DB08922; VA11509; MRF-0000147; 1H-Isoindole-1,3(2H)-dione,2-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]hexahydro-,(3aR,7aS)-rel-; AS-14845; M813; CS-0019906; 73P387; AB00698486-07; A809087; J-008757; Q6590349; cis-N-[4-[4-(1,2-benzisothiazole-3-yl)-1-piperazinyl]butyl]cyclohexane-1,2-dicarboximide; (3aR,7aS)-2-(4-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)butyl)hexahydro-1H-isoindole-1,3(2H)-dione; 1H-Isoindole-1,3(2H)-dione, 2-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)hexahydro-, (3aR,7aS)-rel-; 1H-Isoindole-1,3(2H)-dione, 2-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)hexahydro-, cis-	Small molecule	1S/C23H30N4O2S/c28-22-17-7-1-2-8-18(17)23(29)27(22)12-6-5-11-25-13-15-26(16-14-25)21-19-9-3-4-10-20(19)30-24-21/h3-4,9-10,17-18H,1-2,5-8,11-16H2/t17-,18+	FBVFZWUMDDXLLG-HDICACEKSA-N	C1CCC2C(C1)C(=O)N(C2=O)CCCCN3CCN(CC3)C4=NSC5=CC=CC=C54	C23H30N4O2S	CAS 150915-41-6	CHEBI:94777	.	.	.	D0F6GV	.	.	.
DR1338	Dibenzoylmethane	CID: 8433	Dibenzoylmethane; 120-46-7; 1,3-Diphenylpropane-1,3-dione; 1,3-DIPHENYL-1,3-PROPANEDIONE; 1,3-Propanedione, 1,3-diphenyl-; 2-Benzoylacetophenone; Phenyl phenacyl ketone; Rhodiastab 83; omega-Benzoylacetophenone; Dibenzoyl-methane; MFCD00003085; UNII-ANS7ME8OKC; 1,3-Diphenyl-propane-1,3-dione; NSC 6266; ANS7ME8OKC; .omega.-Benzoylacetophenone; CHEBI:75417; NSC-6266; Dibenzoylmethane, 98%; Karenzu DK2; dibenzoyl methane; EINECS 204-398-9; BRN 0514910; AI3-19022; CCRIS 8445; Karenzu DK 2; Dibenzoylmethane?DBM); 1, 1,3-diphenyl-; Spectrum2_000038; Spectrum3_001950; ACMC-209a7j; EC 204-398-9; DSSTox_CID_21247; DSSTox_RID_79661; DSSTox_GSID_41247; SCHEMBL39582; BSPBio_003550; MLS002695996; SPECTRUM1505311; SPBio_000135; CHEMBL371523; 1,3-diphenyl-1,3-propandione; 1,3-diphenyl-1,3-propanedion; DTXSID3041247; BDBM22727; KBio3_002841; NSC6266; 1,3-Diphenyl-Propan-1,3-Dion; HMS3091A20; STR01439; ZINC4530702; 1,3-Diphenylpropanedione (Related); Tox21_300686; ANW-17501; CCG-40047; STK372683; AKOS000119639; CS-W010447; MCULE-6320643310; NE10265; 1,3-Diphenyl-1,3-propanedione, 98%; UPCMLD0ENAT5883819:001; NCGC00095298-01; NCGC00095298-02; NCGC00095298-03; NCGC00095298-04; NCGC00254594-01; AC-11379; AK-94186; CAS-120-46-7; M261; SMR001253722; SY014045; DB-041558; AM20020283; D0910; FT-0624640; ST50319429; Dibenzoylmethane 1,3-Diphenyl-1,3-propanedione; Q5272260; W-108476; BRD-K01555864-001-02-8; F0001-0329; Z256709078	Small molecule	1S/C15H12O2/c16-14(12-7-3-1-4-8-12)11-15(17)13-9-5-2-6-10-13/h1-10H,11H2	NZZIMKJIVMHWJC-UHFFFAOYSA-N	C1=CC=C(C=C1)C(=O)CC(=O)C2=CC=CC=C2	C15H12O2	CAS 120-46-7	CHEBI:75417	.	.	.	D02BDL	.	.	.
DR1364	SG611-PDCD5	.	.	Gene therapy	.	.	.	.	.	.	.	.	.	.	.	.	.
DR1391	N, N-dimethyl-D-erythro-sphingosine	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR1442	Growth factor	.	.	Protein	.	.	.	.	.	.	.	.	.	.	.	.	.
DR1480	Parecoxib	CID: 119828	Parecoxib; 198470-84-7; Dynastat; SC-69124; SC 69124; CHEBI:73038; UNII-9TUW81Y3CE; N-((p-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)propionamide; 9TUW81Y3CE; N-[4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)phenyl]sulfonylpropanamide; N-[4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonyl]propanamide; Propanamide, N-[[4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl]sulfonyl]-; Valus-P; Vorth-P; Parocoxib; Propanamide, N-((4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)-; N-{[4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)phenyl]sulfonyl}propanamide; parecoxibum; Parecoxib [USAN:INN:BAN]; Valdecoxib Impurity J; Parecoxib (USAN/INN); SCHEMBL9529; GTPL2895; CHEMBL1206690; DTXSID1044229; HMS3741C09; HMS3885L14; AMY42103; BCP07254; EX-A1993; ZINC5761797; BDBM50506744; CP0130; s4656; AKOS025401810; CCG-268299; CS-1959; DB08439; SC69124; NCGC00181773-03; NCGC00181773-05; NCGC00378576-02; Parecoxib 100 microg/mL in Acetonitrile; AC-25842; AS-72353; HY-17474; FT-0697932; Y1120; Parecoxib, VETRANAL(TM), analytical standard; D03716; Q347941; J-523329; BRD-K13800121-236-01-7; N-[4-(5-Methyl-3-phenyl-oxazol-4-yl)phenyl]sulfonylpropanamde; n-[[4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl]sulfonyl]-propanamide; n-[[4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl]sulfonyl]propanamide; N-{[4-(5-methyl-3-phenylisoxazol-4-yl)phenyl]sulfonyl}propanamide; N-[[4-(5-methyl-3-phenyl-4-isoxazolyl) phenyl] sulfonyl] propanamide; N-?[[4-?(5-?Methyl-?3-?phenyl-?4-?isoxazolyl)?phenyl]?sulfonyl]?propanamide; PXB	Small molecule	1S/C19H18N2O4S/c1-3-17(22)21-26(23,24)16-11-9-14(10-12-16)18-13(2)25-20-19(18)15-7-5-4-6-8-15/h4-12H,3H2,1-2H3,(H,21,22)	TZRHLKRLEZJVIJ-UHFFFAOYSA-N	CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C2=C(ON=C2C3=CC=CC=C3)C	C19H18N2O4S	CAS 198470-84-7	CHEBI:73038	.	.	.	D05UWI	.	.	.
DR1489	Clomiphene citrate	CID: 3033832	Clomifene citrate; CLOMIPHENE CITRATE; 50-41-9; Zuclomiphene citrate; Clomid; Clomiphene A citrate; cis-Clomiphene citrate; Clomiphene citrate salt; Milophene; Serophene; Chloramiphene; Omifin; Clomifene citrate (Serophene); UNII-UY5X264QZV; Clostilbegyt; RMI 16289; Clomivid; Clomphid; Dyneric; Genozym; Ikaclomin; 2-(4-(2-Chloro-1,2-diphenylvinyl)phenoxy)-N,N-diethylethanamine 2-hydroxypropane-1,2,3-tricarboxylate; Zuclomiphene (citrate); MFCD00058322; NSC 35770; 7619-53-6; UY5X264QZV; 50-41-9 (CITRATE); MRL 41; Zuclomid; RMI 16312; (Z)-2-(4-(2-chloro-1,2-diphenylvinyl)phenoxy)-N,N-diethylethan-1-amine 2-hydroxypropane-1,2,3-tricarboxylate; (Z)-Clomiphene citrate; Ethanamine, 2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]-N,N-diethyl-,2-hydroxy-1,2,3-propanetricarboxylate (1:1); MER-41; MRL-41; NSC 151466; NSC-35770; Triethylamine, 2-(p-(2-chloro-1,2-diphenylvinyl)phenoxy)-, citrate (1:1); CAS-50-41-9; Clomiphene citrate, cis-; Triethylamine, 2-(p-(2-chloro-1,2-diphenylvinyl)phenoxy)-, citrate (1:1), (Z)-; MLS001332629; MLS002207099; ARONIS23854; SCHEMBL223472; SPECTRUM1500196; SGCUT00109; CHEMBL1213137; HMS501H04; HY-B1617A; HMS1920O19; HMS2091G06; HMS2232D12; Pharmakon1600-01500196; AMY33425; BCP03057; to_000032; CCG-39553; NSC151466; NSC756698; s2561; SBB080555; AKOS005111131; BCP9000541; DS-6814; NSC-151466; NSC-756698; SB17214; NCGC00017008-01; NCGC00017008-02; NCGC00017008-03; NCGC00094626-01; NCGC00094626-02; NCGC00164385-01; AC-19685; AC-32011; Ethanamine, 2-(4-((1Z)-2-chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1); BCP0726000214; AB0006636; 2-[4-(2-Chloro-1,2-diphenylvinyl)phenoxy; CS-0111663; SW196898-3; C08161; Triethylamine,2-diphenylvinyl)phenoxy]-, citrate; SR-05000001591; SR-05000001591-1; Q27291328; Triethylamine,2-diphenylvinyl)phenoxy]-, citrate (1:1); UNII-1B8447E7YI component PYTMYKVIJXPNBD-OQKDUQJOSA-N; Triethylamine,2-diphenylvinyl)phenoxy]-, citrate (1:1), (Z)-; (2)2-[p-(2-Chloro-1,2-diphenylvinyl)phenoxy]triethylamine citrate (1:1); 2-(4-[2-Chloro-1,2-Diphenylethenyl]Phenoxy)-N,N-Diethylethanamine Citrate salt; (2-(4-[(Z)-2-CHLORO-1,2-DIPHENYLETHENYL]PHENOXY)ETHYL)DIETHYLAMINE, 2-HYDROXYPROPANE-1,2,3-TRICARBOXYLIC ACID; {2-[4-((1Z)-2-chloro-1,2-diphenylvinyl)phenoxy]ethyl}diethylamine, 2-hydroxypr opane-1,2,3-tricarboxylic acid; {2-[4-(2-Chloro-1,2-diphenylvinyl)phenoxy]ethyl}diethylamine 2-hydroxypropane-1,2,3-tricarboxylic acid salt; 2-({4-[(Z)-2-chloro-1,2-diphenylethenyl]phenyl}oxy)-N,N-diethylethanamine 2-hydroxypropane-1,2,3-tricarboxylate (salt); Ethanamine, 2-(4-(2-chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethyl-, (Z)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI); Ethanamine,2-diphenylethenyl)phenoxy]-N,N-diethyl-, (Z)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1); Ethanamine,2-diphenylethenyl)phenoxy]-N,N-diethyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)	Small molecule	1S/C26H28ClNO.C6H8O7/c1-3-28(4-2)19-20-29-24-17-15-22(16-18-24)25(21-11-7-5-8-12-21)26(27)23-13-9-6-10-14-23;7-3(8)1-6(13,5(11)12)2-4(9)10/h5-18H,3-4,19-20H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b26-25-;	PYTMYKVIJXPNBD-OQKDUQJOSA-N	CCN(CC)CCOC1=CC=C(C=C1)C(=C(C2=CC=CC=C2)Cl)C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O	C32H36ClNO8	CAS 7619-53-6	.	.	.	.	D0I5WB	.	.	.
DR1499	Laninamivir	CID: 502272	Laninamivir; 203120-17-6; UNII-B408IW3GL5; R-125489; Laninamivir (CS-8958); B408IW3GL5; (2R,3R,4S)-3-acetamido-4-(diaminomethylideneamino)-2-[(1R,2R)-2,3-dihydroxy-1-methoxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid; 5-(Acetylamino)-2,6-Anhydro-4-Carbamimidamido-3,4,5-Trideoxy-7-O-Methyl-D-Glycero-D-Galacto-Non-2-Enonic Acid; Laninamivir [INN:JAN]; Laninamivir (INN); LANI; R 125489; CHEMBL466246; SCHEMBL12284832; DTXSID60942457; BCPP000190; C13H22N4O7; BCP27633; EX-A4019; ZINC3985629; BDBM50009296; AKOS015850995; AKOS032947260; BCP9000836; DB12791; (2R,3R,4S)-3-acetamido-2-[(1R,2R)-2,3-dihydroxy-1-methoxy-propyl]-4-guanidino-3,4-dihydro-2H-pyran-6-carboxylic acid; HY-14818; CS-0003575; Y0284; C21557; D09410; S-7726; 120L176; A814430; Q6487096; (2R,3R,4S)-3-acetamido-4-[bis(azanyl)methylideneamino]-2-[(1R,2R)-1-methoxy-2,3-bis(oxidanyl)propyl]-3,4-dihydro-2H-pyran-6-carboxylic acid; (4S,5R,6R)-5-acetamido-4-carbamimidamido-6-((1R,2R)-3-hydroxy-2-methoxypropyl)-5,6-dihydro-4H-pyran-2-carboxylic acid; 2,6-Anhydro-4-carbamimidamido-3,4,5-trideoxy-5-[(1-hydroxyethylidene)amino]-7-O-methylnon-2-enonic acid; 5-acetamido-2,6-anhydro-4-carbamimidamido-3,4,5-trideoxy-7-O-methyl-D-glycero-D-galacto-non-2-enonic acid; 5-Acetylamino-4-(diaminomethyl-amino)-6-(2,3-dihydroxy-1-methoxy-propyl)-5,6-dihydro-4H-pyran-2-carboxylic acid	Small molecule	1S/C13H22N4O7/c1-5(19)16-9-6(17-13(14)15)3-8(12(21)22)24-11(9)10(23-2)7(20)4-18/h3,6-7,9-11,18,20H,4H2,1-2H3,(H,16,19)(H,21,22)(H4,14,15,17)/t6-,7+,9+,10+,11+/m0/s1	QNRRHYPPQFELSF-CNYIRLTGSA-N	CC(=O)NC1C(C=C(OC1C(C(CO)O)OC)C(=O)O)N=C(N)N	C13H22N4O7	CAS 203120-17-6	.	.	.	.	.	.	.	.
DR1508	Edaravone	CID: 4021	edaravone; 89-25-8; 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE; 1-Phenyl-3-methyl-5-pyrazolone; Norphenazone; Radicut; MCI-186; Methylphenylpyrazolone; Developer Z; Norantipyrine; Phenylmethylpyrazolone; C.I. Developer 1; Phenyl methyl pyrazolone; 3-Methyl-1-phenyl-1H-pyrazol-5(4H)-one; 5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one; Radicava; 1-Phenyl-3-methyl-5-oxo-2-pyrazoline; 3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-2-phenyl-; 5-methyl-2-phenyl-4H-pyrazol-3-one; 1-Phenyl-3-methylpyrazolone; 1-Phenyl-3-methylpyrazolone-5; 2,4-Dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one; 3-Methyl-1-phenylpyrazol-5-one; 3-Methyl-1-phenyl-2-pyrazoline-5-one; NCI-C03952; 2-Pyrazolin-5-one, 3-methyl-1-phenyl-; 5-Pyrazolone, 3-methyl-1-phenyl-; Edaravone (MCI-186); 1-Fenyl-3-methyl-2-pyrazolin-5-on; MFCD00003138; 3-methyl-1-phenyl-4,5-dihydro-1H-pyrazol-5-one; CHEBI:31530; NSC-2629; NSC-26139; Antipyrine related compound a; MLS000069602; 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE (MCI-186); CI Developer 1; NCGC00164015-01; SMR000059020; DSSTox_CID_1130; DSSTox_RID_75961; DSSTox_GSID_21130; Monopyrazolone; WLN: T5NMV DHJ BR& E1; 1-Phenyl-3-methyl-2-pyrazolin-5-on; CAS-89-25-8; CCRIS 512; Radicut (TN); 3-Methyl-1-phenyl-2-pyrazolin-5-one, 99%; HSDB 4102; 3H-Pyrazol-3-one,4-dihydro-5-methyl-2-phenyl-; SR-01000000135; 1-Fenyl-3-methyl-2-pyrazolin-5-on [Czech]; EINECS 201-891-0; BRN 0609575; AI3-03557; Radicava (TN); (MCI-186); CDS1_000986; PubChem13301; Spectrum_000267; Tocris-0786; MCI-186; Edaravone; Edaravone [USAN:INN]; Maybridge1_005738; Opera_ID_1057; Spectrum2_001574; Spectrum3_000971; Spectrum4_001091; Spectrum5_001217; M0687; EC 201-891-0; SCHEMBL4704; BSPBio_001235; BSPBio_002601; KBioGR_000575; KBioGR_001502; KBioSS_000575; KBioSS_000747; AE-641/00371017; MLS001146878; MLS002415675; MLS006011753; DivK1c_001018; DivK1c_002026; SPECTRUM1503635; SPBio_001508; CHEMBL290916; Edaravone (USAN/JP17/INN); DTXSID9021130; BCBcMAP01_000127; HMS503K17; HMS557M18; KBio1_001018; KBio2_000575; KBio2_000747; KBio2_003143; KBio2_003315; KBio2_005711; KBio2_005883; KBio3_001029; KBio3_001030; KBio3_001821; NSC2629; NINDS_001018; BCPP000246; Bio1_000438; Bio1_000927; Bio1_001416; Bio2_000448; Bio2_000928; HMS1362M17; HMS1792M17; HMS1990M17; HMS2234M19; HMS3266F04; HMS3403M17; HMS3411L05; HMS3654L15; HMS3675L05; HMS3884A11; Pharmakon1600-01503635; ACT07289; BCP26336; HY-B0099; NSC26139; Tox21_112077; Tox21_201747; Tox21_302819; BBL011741; BDBM50200541; CCG-39352; NSC758622; s1326; STK201315; ZINC18203737; 3-methyl-1-phenyl-2-pyrazolin-5one; AKOS000313817; Tox21_112077_1; AC-4745; BCP9000635; CS-1832; DB12243; NE10266; NSC-758622; SB19128; IDI1_001018; IDI1_002203; 1-PEHNYL-3-METHYL-5-PYRAZALONE; NCGC00018218-01; NCGC00018218-02; NCGC00018218-03; NCGC00018218-04; NCGC00018218-05; NCGC00018218-06; NCGC00018218-07; NCGC00018218-08; NCGC00018218-10; NCGC00018218-17; NCGC00022665-02; NCGC00022665-04; NCGC00022665-05; NCGC00022665-06; NCGC00256515-01; NCGC00259296-01; AK128848; ST012744; SBI-0051836.P002; DB-002517; AM20060748; FT-0608243; SW148216-2; 5-methyl-2-phenyl-2,4-dihydro-3-pyrazolone; 5-methyl-2-phenyl-2,4-dihydropyrazol-3-one; 3-Methyl-1-phenyl-2-pyrazoline-5-one, 99%; 4E-901; 5-methyl-2-phenyl-2,4-dihydro-pyrazol-3-one; C13008; D01552; AB00375776_14; AB00375776_15; 2 4-Dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one; 2,4-dihydro-2-phenyl-5-methyl-3H-pyrazol-3-one; Q335099; Q-200386; SR-01000000135-2; SR-01000000135-3; SR-01000000135-5; 5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one #; BRD-K35458079-001-04-2; BRD-K35458079-001-12-5; BRD-K35458079-001-23-2; Z50145861; F0391-0021; 3-Methyl-1-phenyl-2-pyrazoline-5-one, SAJ special grade; 3-Methyl-1-phenyl-2-pyrazoline-5-one, purum, >=98.0% (NT); 5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one (Edaravone); Phenazone impurity A, European Pharmacopoeia (EP) Reference Standard; Antipyrine Related Compound A, United States Pharmacopeia (USP) Reference Standard	Small molecule	1S/C10H10N2O/c1-8-7-10(13)12(11-8)9-5-3-2-4-6-9/h2-6H,7H2,1H3	QELUYTUMUWHWMC-UHFFFAOYSA-N	CC1=NN(C(=O)C1)C2=CC=CC=C2	C10H10N2O	CAS 89-25-8	CHEBI:31530	.	.	.	D06DLI	.	.	.
DR1512	Sclerotherapy	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR1563	Tamoxifen	CID: 2733526	tamoxifen; 10540-29-1; trans-Tamoxifen; Crisafeno; Soltamox; Tamoxifene; Diemon; Tamoxifenum; Tamoxifeno; Tamizam; Istubol; Tamoxen; Citofen; Oncomox; Valodex; Retaxim; Tamoxifene [INN-French]; Tamoxifenum [INN-Latin]; Tamoxifeno [INN-Spanish]; Tamoxifen (Z); Tamoxifen and its salts; Tamoxifen [INN:BAN]; ICI-46474; ICI 47699; TRANS FORM OF TAMOXIFEN; CCRIS 3275; UNII-094ZI81Y45; HSDB 6782; CHEMBL83; EINECS 234-118-0; 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; Citofen; Nourytam; Novaldex; Tamone; Tamoxifeno; Tamoxifenum; Tomaxithen; Gen-Tamoxifen; Istubal (TN); Nolvadex (TN); Nolvadex-D; Novo-Tamoxifen; Pms-Tamoxifen; Tamoplex (TN); Tamoxifen (INN); Tamoxifen (TN); Trans-Tamoxifen; Valodex (TN); TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1)); Trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; (Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene; (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC); (Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE; (Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; 1-p-beta-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene; 1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine; Tamoxifen (Hormonal therapy); [3H]tamoxifen	Small molecule	1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-	NKANXQFJJICGDU-QPLCGJKRSA-N	CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3	C26H29NO	CAS 10540-29-1	CHEBI:41774	.	.	.	D07KSG	.	.	Tamoxifen
DR1567	Terazosin	CID: 5401	terazosin; Terazosine; 63590-64-7; Hytrin; Terazosina; Terazosinum; Flumarc; Fosfomic; Vasomet; Blavin; Terazosine [INN-French]; Terazosinum [INN-Latin]; Terazosina [INN-Spanish]; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)piperazine; CHEMBL611; MLS000069703; Abbott-45975; CHEBI:9445; Terazosin (hydrochloride); [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone; SMR000058309; Terazosin [INN:BAN]; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl)piperazine; 6,7-dimethoxy-2-[4-(oxolane-2-carbonyl)piperazin-1-yl]quinazolin-4-amine; (4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(tetrahydrofuran-2-yl)methanone; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](tetrahydrofuran-2-yl)methanone; 6,7-dimethoxy-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine; Abbott 45975; 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]piperazine; Terazosabb (TN); Terazosin (INN); 141269-45-6; MFCD00467965; 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)4-[(tetrahydro-2-furanyl)carbonyl]piperazine; terazosin a; terazosinhydrochloride; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]piperazine hydrochloride; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)4-[(tetrahydro-2-furanyl)carbonyl]piperazine hydrochloride; Opera_ID_1910; Prestwick0_000751; Prestwick1_000751; Prestwick2_000751; Prestwick3_000751; 141269-44-5; SCHEMBL6528; Lopac0_001138; REGID_for_CID_5401; BSPBio_000762; MLS001201836; MLS006011889; SPBio_002701; BPBio1_000840; GTPL7302; MET029; DTXSID3023639; HMS2090P21; HMS2232N21; HMS3259F04; HMS3369P14; HMS3371E20; HMS3742I09; 109351-34-0; HY-B0371; 4097AH; BBL010743; BDBM50033111; STK567029; AKOS005266642; CCG-205212; DB01162; MCULE-4030111564; NC00689; SDCCGSBI-0051105.P002; VA11839; 6,7-bis(methyloxy)-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine; Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)-; NCGC00016026-04; NCGC00016026-05; NCGC00016026-08; NCGC00016026-11; NCGC00025191-03; AC-11120; H963; LS-14728; FT-0630739; C07127; D08569; 590T647; L000692; Q280786; BRD-A22256192-003-03-7; BRD-A22256192-003-14-4; Z1172269406; 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine; 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)-piperazine; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-{(tetnaphydro-2-furanyl)carbonyl}piperazine; 6,7-dimethoxy-2-[4-(oxolane-2-carbonyl)piperazin-1-yl]-3,4-dihydroquinazolin-4-imine; 6,7-Dimethoxy-2-[4-(tetrahydro-2-furanylcarbonyl)-1-piperazinyl]-4-quinazolinamine #; 6,7-dimethoxy-2-{4-[(oxolan-2-yl)carbonyl]piperazin-1-yl}quinazolin-4-amine; Methanone, [4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl](tetrahydro-2-furanyl)-; 1-(4-amino-6,7-dimethoxyquinazolin-2-yl)-4-[[(2RS)-2,3,4,5-tetrahydrofuran-2-yl]carbonyl]piperazine	Small molecule	1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22)	VCKUSRYTPJJLNI-UHFFFAOYSA-N	COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC	C19H25N5O4	CAS 63590-64-7	CHEBI:9445	.	.	.	D0P9RF	.	.	.
DR1575	Letrozole	CID: 3902	Femara; Femera; Letoval; Letrozol; Novartis Brand of Letrozole; CGS 20267; CGS-20267; FEM-345; Femara (TN); Letrozole [USAN:INN]; CGS 20267, Femara, Piroxicam, Letrozole; Letrozole (JAN/USP/INN); 1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole; 1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole; 4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile; 4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile; 4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile); 4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile; 4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-Benzonitrile Letrozole; 4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile; 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile; 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile; 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile	Small molecule	1S/C17H11N5/c18-9-13-1-5-15(6-2-13)17(22-12-20-11-21-22)16-7-3-14(10-19)4-8-16/h1-8,11-12,17H	HPJKCIUCZWXJDR-UHFFFAOYSA-N	C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3	C17H11N5	CAS 112809-51-5	CHEBI:6413	.	.	.	D0C1WH	.	.	.
DR1590	Leptomycin B	CID: 6917907	Elactocin; Mantuamycin; Antibiotic CI 940; 87081-35-4; Antibiotic CL 1957A; leptomycin; UNII-Y031I2N1EO; CI-940; CHEBI:52646; PD 114720; C33H48O6; antibiotic ATS 1287B; Antibiotic PD 114720; Y031I2N1EO; ATS 1287B; MFCD06795848; (2E,5S,6R,7S,9R,10E,12E,15R,16Z,18E)-17-ethyl-6-hydroxy-3,5,7,9,11,15-hexamethyl-19-[(2S,3S)-3-methyl-6-oxo-3,6-dihydro-2H-pyran-2-yl]-8-oxononadeca-2,10,12,16,18-pentaenoic acid; CI 940; LMB; NSC-364372; (2E,5S,6R,7S,9R,10E,12E,15R,16Z,18E)-17-ethyl-6-hydroxy-3,5,7,9,11,15-hexamethyl-19-((2S,3S)-3-methyl-6-oxo-3,6-dihydro-2H-pyran-2-yl)-8-oxononadeca-2,10,12,16,18-pentaenoic acid; (2E,5S,6R,7S,9R,10E,12E,15R,16Z,18E)-17-ethyl-6-hydroxy-3,5,7,9,11,15-hexamethyl-19-[(2S,3S)-3-methyl-6-oxo-2,3-dihydropyran-2-yl]-8-oxo-nonadeca-2,10,12,16,18-pentaenoic acid; CL 1957A; NSC 364372; CHEMBL486133; SCHEMBL12361304; (2E,5S,6R,7S,9R,10E,12E,15R,16Z,18E)-19-[(2S,3S)-3,6-Dihydro-3-methyl-6-oxo-2H-pyran-2-yl]-17-ethyl-6-hydroxy-3,5,7,9,11,15-hexamethyl-8-oxo-2,10,12,16,18-nonadecapentaenoic acid; CL-1957A; EX-A4641; KOS-1688; 1816AH; 2514AH; BDBM50245464; ZINC17654252; 2,10,12,16,18-Nonadecapentaenoic acid, 19-(3,6-dihydro-3-methyl-6-oxo-2H-pyran-2-yl)-17-ethyl-6-hydroxy-3,5,7,9,11,15-hexamethyl-8-oxo-; HY-16909; Leptomycin B, Streptomyces sp. ATS1287; PD-114720; B6907; CS-0012947; Q6528191; (2E,10E,12E,16E,18E)-17-ethyl-6-hydroxy-3,5,7,9,11,15-hexamethyl-19-(3-methyl-6-oxo-2,3-dihydropyran-2-yl)-8-oxo-nonadeca-2,10,12,16,18-pentaenoic acid; 2,10,12,16,18-Nonadecapentaenoic acid, 19-[(2S,3S)-3,6-dihydro-3-methyl-6-oxo-2H-pyran-2-yl]-17-ethyl-6-hydroxy-3,5,7,9,11,15-hexamethyl-8-oxo-,(2E,5S,6R,7S,9R,10E,12E,15R,16Z,18E)-; 2,10,12,16,18-Nonadecapentanoic acid, 19-(3,6-dihydro-3-methyl-6-oxo-2H-pyran-2-yl)-17-ethyl-6-hydroxy-3,5,7,9,11,15-hexamethyl-8-oxo-; Leptomycin B solution from Streptomyces sp., >=95% (HPLC), Supplied in methanol: water (7:3)	Small molecule	1S/C33H48O6/c1-9-28(14-15-29-24(5)13-16-31(36)39-29)19-22(3)12-10-11-21(2)17-25(6)32(37)27(8)33(38)26(7)18-23(4)20-30(34)35/h10-11,13-17,19-20,22,24-27,29,33,38H,9,12,18H2,1-8H3,(H,34,35)/b11-10+,15-14+,21-17+,23-20+,28-19-/t22-,24+,25-,26+,27-,29+,33-/m1/s1	YACHGFWEQXFSBS-XYERBDPFSA-N	CCC(=CC(C)CC=CC(=CC(C)C(=O)C(C)C(C(C)CC(=CC(=O)O)C)O)C)C=CC1C(C=CC(=O)O1)C	C33H48O6	CAS 87081-35-4	.	.	.	.	.	.	.	.
DR1629	Avibactam	CID: 9835049	Avibactam; NXL104; Avibactam free acid; Avibactam (free acid); 1192500-31-4; NXL 104; UNII-7352665165; CHEMBL1689063; CHEBI:85984; (2S,5R)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide; Avibactam [USAN:INN]; SCHEMBL1666807; GTPL10761; AMY24028; AVI; ZINC9302239; BDBM50339145; CS-0593; DB09060; HY-14879; Q15410251; UNII-06MFO7817I component NDCUAPJVLWFHHB-UHNVWZDZSA-N; trans-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octan-2-carboxamide; (1R,2S,5R)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulfate; [(2S,5R)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate; SULFURIC ACID, MONO[(1R,2S,5R)-2-(AMINOCARBONYL)-7-OXO-1,6-DIAZABICYCLO[3.2.1]OCT-6-YL] ESTER	Small molecule	1S/C7H11N3O6S/c8-6(11)5-2-1-4-3-9(5)7(12)10(4)16-17(13,14)15/h4-5H,1-3H2,(H2,8,11)(H,13,14,15)/t4-,5+/m1/s1	NDCUAPJVLWFHHB-UHNVWZDZSA-N	C1CC(N2CC1N(C2=O)OS(=O)(=O)O)C(=O)N	C7H11N3O6S	CAS 1192500-31-4	CHEBI:85984	.	.	.	.	.	.	.
DR1642	Pinostrobin	CID: 73201	Pinostrobin; 480-37-5; Pinostrombin; Pinocembrin-7-methylether; UNII-SZD9LZS694; SZD9LZS694; CHEMBL254613; (S)-2,3-Dihydro-5-hydroxy-7-methoxy-2-phenyl-4-benzopyrone; CHEBI:80491; (2s)-5-hydroxy-7-methoxyflavanone; 5-Hydroxy-7-methoxy-2-phenyl-2,3-dihydro-4H-chromen-4-one; (2S)-5-hydroxy-7-methoxy-2-phenyl-2,3-dihydrochromen-4-one; pinocembrin-7-methyl ether; dihydrotectochrysin; (-)-pinostrobin; (2S)-pinostrobin; (2S)-5-hydroxy-7-methoxy-2-phenyl-chroman-4-one; SCHEMBL7648566; DTXSID50963979; ZINC391894; Pinostrobin, >=99.0% (TLC); HY-N2127; EINECS 207-548-1; BDBM50338968; (+/-)-5-hydroxy-7-methoxyflavanone; AKOS037515398; CCG-262304; NCGC00163610-01; 5-Hydroxy-7-methoxy-2-phenyl-chroman-4-one; CS-0018678; C16419; 480P375; SR-05000013704; SR-05000013704-1; Q27149542; 5-Hydroxy-7-methoxy-2-phenyl-2,3-dihydro-4H-1-benzopyran-4-one; (2S)-5-hydroxy-7-methoxy-2-phenyl-2,3-dihydro-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 2,3-dihydro-5-hydroxy-7-methoxy-2-phenyl-, (S)-	Small molecule	1S/C16H14O4/c1-19-11-7-12(17)16-13(18)9-14(20-15(16)8-11)10-5-3-2-4-6-10/h2-8,14,17H,9H2,1H3/t14-/m0/s1	ORJDDOBAOGKRJV-AWEZNQCLSA-N	COC1=CC(=C2C(=O)CC(OC2=C1)C3=CC=CC=C3)O	C16H14O4	CAS 480-37-5	CHEBI:80491	.	.	.	.	.	.	.
DR1651	Buthionine sulfoximine	CID: 21157	BUTHIONINE SULFOXIMINE; 5072-26-4; Buthionine sulphoximine; DL-Buthionine-[S,R]-sulfoximine; Butionine sulfoximine; Buthionine sulfoxamine; D,L-Buthionine-(S,R)-sulfoximine; DL-Buthionine-sulfoximine; Buthionine-S,R-sulfoximine; 2-Amino-4-(S-butylsulfonimidoyl)butanoic acid; 2-Amino-4-(butylsulfonimidoyl)butanoic acid; DL-Buthionine-(S,R)-sulfoximine; Butanoic acid, 2-amino-4-(S-butylsulfonimidoyl)-; CHEBI:28714; DL-butathionine-(S,R)-sulfoximine; MFCD00070309; NSC326231; NSC381100; L-Buthionine-(S,R)-sulfoximine; S-butyl-DL-homocysteine (S,R)-sulfoximine; S-Butyl-DL-homocysteine-[S,R]-sulfoximine; 2-amino-4-(S-butylsulfonimidoyl)butyric acid; NSC 326231; BRN 2367136; Buthione sulfoximine; DL-Buthionine (S,R)-sulfoximine, 99%; 71765-30-5; NSC 381100; DL-Buthionine-S,R-sulfoximine; l-buthionine (s,r)-sulfoximine; dl-buthionine (s,r)-sulfoximine; NSC-381100; BSO; Sulfoximine, S-(3-amino-3-carboxypropyl)-S-butyl-; Lopac0_000231; SCHEMBL62033; BSPBio_002464; SPECTRUM1505108; dl-Buthionine(S,R)-sulfoximine; CHEMBL1256575; CHEMBL1627290; DTXSID6044434; CHEBI:176510; HMS3260P03; BCP24029; BCP27775; Tox21_500231; s2433; STL328818; AKOS022106364; CCG-204326; DB12870; LP00231; MCULE-8178742509; SDCCGSBI-0050219.P003; NCGC00015148-03; NCGC00015148-04; NCGC00015148-05; NCGC00015148-06; NCGC00015148-07; NCGC00015148-13; NCGC00093696-01; NCGC00093696-02; NCGC00093696-03; NCGC00260916-01; AS-67962; NCI60_002827; HY-106376; CS-0025687; EU-0100231; FT-0624379; FT-0627738; FT-0663956; ST51012445; DL-Buthionine-sulfoximine, >=99.0% (TLC); 2-Amino-4-(butylsulfonimidoyl)butanoic acid #; B 2640; C04543; SR-01000075713; Q5002519; SR-01000075713-1; 2-amino-4-[butyl(imino)oxo-??-sulfanyl]butanoic acid; BRD-A04020513-001-01-9; D,L-Buthionine-(S,R)-sulfoximine (Butionine sulfoximine)	Small molecule	1S/C8H18N2O3S/c1-2-3-5-14(10,13)6-4-7(9)8(11)12/h7,10H,2-6,9H2,1H3,(H,11,12)	KJQFBVYMGADDTQ-UHFFFAOYSA-N	CCCCS(=N)(=O)CCC(C(=O)O)N	C8H18N2O3S	CAS 5072-26-4	CHEBI:28714	.	.	.	D0Z6VR	.	.	.
DR1669	Cisplatin	CID: 5702198	Abiplatin; Biocisplatinum; Briplatin; Cismaplat; Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Plastin; Platamine; Platidiam; Platinoxan; Randa; Cis-DDP; Cis-Diamminedichloroplatinum; Peyrone's chloride; Peyrone's salt; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Cisplatin (Chemotherapy)	Small molecule	1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2	LXZZYRPGZAFOLE-UHFFFAOYSA-L	N.N.Cl[Pt]Cl	Cl2H6N2Pt	CAS 15663-27-1	CHEBI:27899	.	.	.	D0U5HU	.	.	Cisplatin
DR1725	S-adenosylmethionine	CID: 34755	S-adenosyl-L-methionine; S-adenosylmethionine; Ademetionine; AdoMet; 29908-03-0; SAM-e; SAMe; Donamet; L-S-Adenosylmethionine; Methioninyladenylate; S Amet; adenosylmethionine; Active methionine; L-Methionine, S-adenosyl-; CCRIS 7130; S-adenosyl-L-methioninate; (R)-ademetionine; (S)-ademetionine; UNII-6EZ5466ZUX; UNII-K093C397UL; Methionine, S-adenosyl-; (2S)-2-Amino-4-((((2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)(methyl)sulfonio)butanoate; SAM; 6EZ5466ZUX; CHEBI:67040; UNII-7LP2MPO46S; K093C397UL; Adenosine, 5'-((3-amino-3-carboxypropyl)methylsulfonio)-5'-deoxy-, inner salt, (3S)-; (3S)-5'-((3-Amino-3-carboxylatopropyl)methylsulphonio)-5'-deoxyadenosine; S-adenosyl-L-methioninate (deprotonated carboxy group); 2-S-adenosyl-L-methionine; 7LP2MPO46S; (3S)-5'-[(3-amino-3-carboxylatopropyl)methylsulphonio]-5'-deoxyadenosine; 17176-17-9; Adenosine, 5'-(((3S)-3-amino-3-carboxypropyl)methylsulfonio)-5'-deoxy-, inner salt; S-Adenosyl-L-Methtonine; Ademetionine, (R)-; R,S-adenosylmethionine; S,S-Adenosylmethionine; Adenosine, 5'-((L-3-amino-3-carboxypropyl)methylsulfonio)-5'-deoxy-, hydroxide, inner salt; EINECS 249-946-8; (R,S)-S-Adenosyl-L-methionine; (S,S)-S-Adenosyl-L-methionine; S-adenosylmethione; Adenosine, 5'-[[(3S)-3-amino-3-carboxypropyl)methylsulfonio]-5'-deoxy-, inner salt; S. Amet; [14COOH]AdoMet; 24346-00-7; S-Adenosyl-L-methionine HCl; SCHEMBL1300198; CHEMBL1088977; DTXSID6032019; BDBM28422; MSI-195; HY-B0617; AKOS015963176; S-adenosyl-L-[carboxy-14C]methionine; CCG-268635; DB00118; Adenosine, 5'-((R)-((3S)-3-amino-3-carboxypropyl)methylsulfonio)-5'-deoxy-, inner salt; Adenosine, 5'-((S)-((3S)-3-amino-3-carboxypropyl)methylsulfonio)-5'-deoxy-, inner salt; NCGC00485915-01; S-(5'desoxyadenosin-5'yl)-L-methionine; 91279-78-6; AC-19717; AS-57895; C00019; Methionine, S-adenosyl- (6CI) Active methionine; Q27135598; Q27264758; Q27281766; S-Adenosyl-L-methionine;S-Adenosyl methionine;SAMe;AdoMet; UNII-7LP2MPO46S component MEFKEPWMEQBLKI-FCKMPRQPSA-N; UNII-7LP2MPO46S component MEFKEPWMEQBLKI-TYYLHDHTSA-N; (3S)-5'-[(3-amino-3-carboxylatopropyl)methylsulphonio]-5'-deoxyadenosine inner salt; [(3S)-3-amino-3-carboxylatopropyl](5'-deoxyadenosin-5'-yl)(methyl)sulfonioacetate; (2S)-2-amino-4-({[(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl}(methyl)sulfaniumyl)butanoate; (2S)-2-amino-4-({[(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl}(methyl)sulfanylium)butanoate; (2S)-2-amino-4-[{[(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}(methyl)sulfonio]butanoate (non-preferred name); [(3S)-3-amino-4-hydroxy-4-oxo-butyl]-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl]-methyl-sulfonium; Adenosine, 5'-[(3-amino-3-carboxypropyl)methylsulfonio]-5'-deoxy-, hydroxide, inner salt, (3S)-; Adenosine, 5'-[(L-3-amino-3-carboxypropyl)methylsulfonio]-5'-deoxy-, hydroxide, inner salt (8CI)	Small molecule	1S/C15H22N6O5S/c1-27(3-2-7(16)15(24)25)4-8-10(22)11(23)14(26-8)21-6-20-9-12(17)18-5-19-13(9)21/h5-8,10-11,14,22-23H,2-4,16H2,1H3,(H2-,17,18,19,24,25)/t7-,8+,10+,11+,14+,27?/m0/s1	MEFKEPWMEQBLKI-AIRLBKTGSA-N	C[S+](CCC(C(=O)[O-])N)CC1C(C(C(O1)N2C=NC3=C(N=CN=C32)N)O)O	C15H22N6O5S	CAS 29908-03-0	CHEBI:67040	.	.	.	D0U3YU	.	.	.
DR1750	MK2206	CID: 46930998	1032350-13-2; MK-2206 dihydrochloride; MK-2206 2HCl; MK2206; MK-2206 HCl salt; UNII-Q34I3E28IO; MK 2206; 8-(4-(1-Aminocyclobutyl)phenyl)-9-phenyl-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one dihydrochloride; 8-[4-(1-AMINOCYCLOBUTYL)PHENYL]-9-PHENYL-1,2,4-TRIAZOLO[3,4-F][1,6]NAPHTHYRIDIN-3(2H)-ONE DIHYDROCHLORIDE; Q34I3E28IO; C25H21N5O; MK 2206 2HCl; AHU377 calcium salt; PubChem22473; 1032349-77-1; MK 2206 dihydrochloride; C25H21N5O.HCl; cc-295; C25H21N5O.2HCl; SCHEMBL17100521; EX-A259; SYN1162; AOB87741; ABP000407; MFCD14584463; s1078; AKOS015966903; CCG-264809; MK-2206/MK2206; PB19401; 1,2,4-Triazolo(3,4-f)(1,6)naphthyridin-3(2H)-one, 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-, hydrochloride (1:2); 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one;dihydrochl; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one;dihydrochloride; AC-28437; AK172013; AS-16298; FT-0672430; SW202557-3; X7427; Z1978; W-5580; J-000912; J-519356; Q27286944; (2R,4S)-4-[(3-Carboxy-1-oxopropyl)amino]-4-[(p-phenylphenyl)methyl]-2-methylbutanoic acid ethyl ester; 4-[[(2S,4R)-5-Ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoic acid calcium salt; 4-{[(2S,4R)-1-(4-Biphenylyl)-5-ethoxy-4-methyl-5-oxo-2-pentanyl]amino}-4-oxobutanoic acid; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H,3H-[1,2,4]triazolo[3,4-f]1,6-naphthyridin-3-one hydrochloride	Small molecule	1S/C25H21N5O.2ClH/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31;;/h1-3,5-11,14-15H,4,12-13,26H2,(H,29,31);2*1H	HWUHTJIKQZZBRA-UHFFFAOYSA-N	C1CC(C1)(C2=CC=C(C=C2)C3=C(C=C4C(=N3)C=CN5C4=NNC5=O)C6=CC=CC=C6)N.Cl.Cl	C25H23Cl2N5O	CAS 1032350-13-2	.	.	.	.	.	.	.	.
DR1784	Anti-CD8 (53.6.72) antibody	.	.	Antibody	.	.	.	.	.	.	.	.	.	.	.	.	.
DR1791	Tacrolimus	CID: 445643	tacrolimus; Fujimycin; Prograf; 104987-11-3; Protopic; FK506; Tacrolimus anhydrous; Advagraf; Modigraf; Protopy; Fk-506; LCP-Tacro; Anhydrous Tacrolimus; tacrolimus (fk506); FK 506; FR-900506; 8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN; UNII-Y5L2157C4J; Astagraf XL; FR 900506; (-)-FK 506; Tsukubaenolide; Prograf (TN); FR900506; CHEMBL269732; CHEBI:61049; Y5L2157C4J; K506; NCGC00163470-03; Prograft; Avagraf; Envarsus; Graceptor; Envarsus XR; (3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-Hexadecahydro-5,19-dihydroxy-3-[(1E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propen-1-yl)-15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)tetrone; Tacrolimus (INN); Tacrolimus [USAN]; Tacrolimus, anhydrous; MFCD11045918; Tacrolimus (anhydrous); SR-05000001879; Tacrolimus [USAN:INN]; Hecoria; Talymus; CCRIS 7124; MFCD00869853; HSDB 8195; C44H69NO12; L 679934; FK-506/Tacrolimus; PubChem18875; FK-506 (Tacrolimus); SCHEMBL3088; DSSTox_CID_26354; DSSTox_RID_81557; DSSTox_GSID_46354; BSPBio_001279; CHEMBL66247; L-679934; GTPL6784; DTXSID5046354; CHEBI:93221; HMS503O21; HMS1792O21; HMS1990O21; HMS2093M19; HMS3403O21; Pharmakon1600-01503968; EX-A1677; Tox21_112056; ABP000474; BDBM50030448; BDBM50079777; LMPK04000003; NSC758659; s5003; AKOS005145901; ZINC169289411; AC-1182; AM81227; AT-2441; CCG-270494; CS-1507; DB00864; NSC-758659; IDI1_001040; NCGC00163470-01; NCGC00163470-02; NCGC00163470-04; NCGC00163470-05; NCGC00163470-06; NCGC00163470-07; NCGC00163470-27; (3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone; HY-13756; Fujimycin; ; ; FK-506; ; ; FR-900506; SBI-0052894.P002; AB0012538; CAS-104987-11-3; M2258; C01375; D08556; W-1246; AB01209746-01; AB01209746_03; 581T933; Q411648; Q-201775; SR-05000001879-1; SR-05000001879-2; SR-05000001879-5; BRD-K35452788-001-02-1; BRD-K69608737-001-03-7; BRD-K69608737-001-10-2; [(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethenyl]-14,16-; 15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,; (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-[(E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-17-prop-2-enyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone; (3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethenyl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-prop-2-en-1-yl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone; (E)-(1R,9S,12S,13R,14R,21S,23S,24R,25S,27R)-17-Allyl-1,14-dihydroxy-12-[(E)-2-((3R,4R)-4-hydroxy-3-methoxy-cyclohexyl)-1-methyl-vinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo[22.3.1.0*4,9*]octacos-18-ene-2,3,10,16-tetraone; 15,19-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone, 5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-(2-(4-hydroxy-3-methoxycyclohexyl)-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-, (3S-(3R*(E(1S*,3S*,4S*)),4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*))-; 15,19-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone, 5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-[(1E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyc; 4,5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-heptadecahydro-5,19-dihydroxy-3-; dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-,(3S,4R,5S,8R,12S,14S,15R,16S,18R,19R,26aS)-; lohexyl]-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propen-1-yl)-, (3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-; Tacrolimus solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material	Small molecule	1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3/b25-19+,27-21+/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+/m0/s1	QJJXYPPXXYFBGM-LFZNUXCKSA-N	CC1CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC(=O)C(C=C(C1)C)CC=C)O)C)C(=CC4CCC(C(C4)OC)O)C)O)C)OC)OC	C44H69NO12	CAS 104987-11-3	CHEBI:61049	.	.	.	D06OMK	.	.	.
DR1806	Ivacaftor	CID: 16220172	Ivacaftor; 873054-44-5; VX-770; Kalydeco; Ivacaftor (VX-770); N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide; VX 770; VX770; UNII-1Y740ILL1Z; N-[2,4-Bis(tert-butyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxo-3-quinolinecarboxamide; CHEBI:66901; 1Y740ILL1Z; N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1H-quinoline-3-carboxamide; 3-Quinolinecarboxamide, N-(2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl)-1,4-dihydro-4-oxo-; 3-Quinolinecarboxamide, N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxo-; Kalydeco (TN); Ivacaftor [USAN:INN]; ivacaftorum; Ivacaftor D18; Tube715; Ivacaftor (USAN/INN); VX-770 - Ivacaftor; cc-231; MLS006011119; SCHEMBL351373; GTPL4342; QUI135; VX-770, Ivacaftor, Kalydeco; CHEMBL2010601; DTXSID00236281; EX-A441; QCR-155; BCPP000199; HMS3654E10; HMS3744K05; AOB31714; BCP19794; ABP000259; BDBM50032693; MFCD17171361; s1144; VX-770/VX770; ZINC52509463; AKOS015994762; AKOS032950001; BCP9000799; CCG-268562; CS-0497; DB08820; EX-7211; LE-0002; SB16815; N-(2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide; NCGC00242480-01; NCGC00242480-03; 1413431-05-6; AC-28324; AK170457; HY-13017; SMR004702900; AB0008116; FT-0696681; SW219620-1; X7565; EC-000.2478; A25626; D09916; W-5681; AB01565806_02; Q6095693; CTP-656; CTP-656; CTP-656; d9-ivacaftor;VX-561; Cystic Fibrosis Transmembrane Conductance Regulator Potentiator; N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide; N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide; N-(5-Hydroxy-2,4-bis(2-methyl-2-propanyl)phenyl]-4-oxo-1,4-dihydro-3-quinolinecarboxamide; N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide; 1134822-00-6; Kalydeco; ; ; N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxo-3-quinolinecarboxamide; VX7	Small molecule	1S/C24H28N2O3/c1-23(2,3)16-11-17(24(4,5)6)20(27)12-19(16)26-22(29)15-13-25-18-10-8-7-9-14(18)21(15)28/h7-13,27H,1-6H3,(H,25,28)(H,26,29)	PURKAOJPTOLRMP-UHFFFAOYSA-N	CC(C)(C)C1=CC(=C(C=C1NC(=O)C2=CNC3=CC=CC=C3C2=O)O)C(C)(C)C	C24H28N2O3	CAS 873054-44-5	CHEBI:66901	.	.	.	D0W7WC	.	.	.
DR1849	Hydroxyurea	CID: 3657	hydroxyurea; Hydroxycarbamide; 127-07-1; N-Hydroxyurea; Hydrea; 1-HYDROXYUREA; Oxyurea; Carbamoyl oxime; Biosupressin; Hydroxycarbamine; Urea, hydroxy-; Onco-carbide; Carbamohydroxamic acid; Carbamohydroximic acid; Carbamyl hydroxamate; Hydura; Litalir; Hydurea; N-Carbamoylhydroxylamine; Droxia; Hidrix; Hydroxicarbamidum; Siklos; Hydroxylurea; Hydreia; Litaler; Idrossicarbamide [DCIT]; Hidroxicarbamida; Hydroxyharnstoff; Hydroxycarbamidum; Carbamohydroxyamic acid; N-Hydroxymocovina; Hydroxylamine, N-carbamoyl-; SQ 1089; urea, N-hydroxy-; Hydroxyharnstoff [German]; N-Hydroxymocovina [Czech]; NCI-C04831; Hydroxylamine, N-(aminocarbonyl)-; SK 22591; Hydroxycarbamidum [INN-Latin]; Hidroxicarbamida [INN-Spanish]; HU; CCRIS 958; HYDROXY-UREA; NSC 32065; hydroxy urea; UNII-X6Q56QN5QC; NSC32065; MFCD00007943; AI3-51139; Hydroxyurea (Cytodrox); CHEMBL467; SQ-1089; X6Q56QN5QC; CHEBI:44423; Hydroxyurea, 98%; NSC-32065; Hydroxy Urea-15N; NCGC00015520-03; Hydroxycarbamid; Oncocarbide; Idrossicarbamide; DSSTox_CID_5438; DSSTox_RID_77787; DSSTox_GSID_25438; NHY; Hydroxyurea (D4); N-HYDROXY UREA; Mylocel; carbamide oxide; CAS-127-07-1; SMR000059149; Hydroxyurea (USP); Droxia (TM); Droxia (TN); Hydrea (TM); hydroxyaminomethanamide; HSDB 6887; SR-01000075919; DRG-0253; EINECS 204-821-7; HYDREA (TN); Hydroxyurea [USAN:USP]; BRN 1741548; Hydroxycarbamide (JAN/INN); hydroxyl urea; Xromi; 1-oxidanylurea; S-phase/G-1 interface inhibitor; 15N Hydroxyurea; aminohydroxamic acid; carbamic acid oxime; Carbomohydroxamic acid; Spectrum_000909; Hydroxycarbamide [INN]; WLN: ZVMQ; Hydrea (Bristol Meyers); Spectrum2_000064; Spectrum3_000462; Spectrum4_000012; Spectrum5_000836; Lopac-H-8627; MolMap_000029; H 8627; NCIMech_000139; Hydroxyurea, 98%, powder; ACMC-1C22W; Lopac0_000596; BSPBio_002164; KBioGR_000383; KBioSS_001389; 4-03-00-00170 (Beilstein Handbook Reference); 8029-68-3; hydroxycarbamide (hydroxyurea); MLS001332381; MLS001332382; MLS002153389; DivK1c_000556; N-(Aminocarbonyl)hydroxylamine; SPECTRUM1500344; SPBio_000247; GTPL6822; NC(=O)N[O]; DTXSID6025438; tetratogen: inhibits ribonucleoside diphosphate reductase; HMS501L18; KBio1_000556; KBio2_001389; KBio2_003957; KBio2_006525; KBio3_001384; NINDS_000556; Bio1_000451; Bio1_000940; Bio1_001429; HMS1920F09; HMS2091L17; HMS2234I03; HMS3261H14; HMS3373G18; HMS3655K20; HMS3869C03; NCI C04831; Pharmakon1600-01500344; ACT02611; ALBB-028465; AMY40858; EBD12517; HY-B0313; STR02555; ZINC8034120; Tox21_110168; Tox21_300319; Tox21_500596; ANW-18958; BBL009928; BDBM50017811; CCG-35236; NSC757072; s1896; STL145898; AKOS005716276; AKOS006222547; Tox21_110168_1; ZINC100019199; DB01005; LP00596; MCULE-9465284053; NSC-757072; SDCCGSBI-0050578.P006; IDI1_000556; NCGC00015520-01; NCGC00015520-02; NCGC00015520-04; NCGC00015520-05; NCGC00015520-06; NCGC00015520-07; NCGC00015520-08; NCGC00015520-09; NCGC00015520-10; NCGC00015520-11; NCGC00015520-20; NCGC00093974-01; NCGC00093974-02; NCGC00093974-03; NCGC00093974-04; NCGC00093974-05; NCGC00254007-01; NCGC00261281-01; AC-22674; AK128930; NCI60_002773; SBI-0050578.P004; AB0013265; DB-041849; EU-0100596; FT-0627160; FT-0627175; FT-0670210; SW218071-2; C07044; D00341; Hydroxyurea, Vetec(TM) reagent grade, >=98%; AB00052018-09; AB00052018-10; AB00052018_11; AB00052018_12; 127H071; A805636; Q212272; J-504798; SR-01000075919-1; SR-01000075919-3; SR-01000075919-8; E0723DBA-5AF3-49D1-B5F6-59420AB87AC9; F8880-0905; Z1522566612; Hydroxycarbamide, European Pharmacopoeia (EP) Reference Standard; Hydroxyurea, United States Pharmacopeia (USP) Reference Standard	Small molecule	1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)	VSNHCAURESNICA-UHFFFAOYSA-N	C(=O)(N)NO	CH4N2O2	CAS 127-07-1	CHEBI:44423	.	.	.	D07CWD	.	.	.
DR1850	Ultraviolet A irradiation	.	.	Radiotherapy	.	.	.	.	.	.	.	.	.	.	.	.	.
DR1860	Rosuvastatin	CID: 446157	Rosuvastatin; 287714-41-4; ZD4522; UNII-413KH5ZJ73; CHEMBL1496; CHEBI:38545; 413KH5ZJ73; ZD-4522; (3R,5S,6E)-7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid; (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid; (E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid; 7-[4-(4-fluorophenyl)-6E-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3R,5S-dihydroxy-6-heptenoic acid; Creston (TN); Rosuvastatin (INN); Rosuvastatin [INN:BAN]; C22H28FN3O6S; HSDB 7317; Spectrum5_001695; SCHEMBL2520; BSPBio_003429; SCHEMBL154400; SPECTRUM1505213; GTPL2954; DTXSID8048492; BDBM18372; CHEBI:93454; HMS1922N09; ZINC1535101; CCG-40119; HY-17504A; MFCD18783208; AKOS000280777; AM84890; DB01098; NCGC00178070-01; (3R,5S,6E)-7-{4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid; (3R,5S,E)-7-(4-(4-Fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid; 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-, (3R,5S,6E); AC-30585; AS-12247; SBI-0206727.P001; S5072; A11122; A24862; D08492; 28050-EP2269990A1; 28050-EP2272841A1; 28050-EP2272842A1; 28050-EP2280006A1; 28050-EP2281813A1; 28050-EP2284158A1; 28050-EP2287165A2; 28050-EP2287166A2; 28050-EP2292620A2; 28050-EP2295406A1; 28050-EP2298731A1; 28050-EP2298742A1; 28050-EP2298745A1; 28050-EP2298772A1; 28050-EP2298776A1; 28050-EP2298779A1; 28050-EP2301923A1; 28050-EP2301931A1; 28050-EP2301936A1; 28050-EP2308839A1; 28050-EP2314588A1; Q415159; BRD-K82941592-001-01-3; BRD-K82941592-238-02-9; (3R,5S)-7-[4-(4-fluorophenyl)-2-(methyl-methylsulfonylamino)-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S)-trans-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid; (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6enoic acid; (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid; 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-; 7-[4-(4-Fluorophenyl)-6-(1-methylethyl)-2-(methyl-methylsulfonyl-amino)-pyrimidin-5-yl]-3,5-dihydroxy-hept-6-enoic acid;Rosuvastatin;Rosuvastatin Acid; E-(7-{2-(N-methyl-N-methanesulfonylamino)-4-(4-fluorophenyl)-6-isopropyl-pyrimidin-5-yl}-(3R,5S)-3,5-dihydroxy-hept-6-enoic acid]; E-7-[2-(N-methyl-N-methanesulfonylamino)-4-(4-fluorophenyl)-6-isopropyl-pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid; FBI	Small molecule	1S/C22H28FN3O6S/c1-13(2)20-18(10-9-16(27)11-17(28)12-19(29)30)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)33(4,31)32/h5-10,13,16-17,27-28H,11-12H2,1-4H3,(H,29,30)/b10-9+/t16-,17-/m1/s1	BPRHUIZQVSMCRT-VEUZHWNKSA-N	CC(C)C1=NC(=NC(=C1C=CC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C	C22H28FN3O6S	CAS 287714-41-4	CHEBI:38545	.	.	.	D0JE2E	.	.	.
DR1866	Nitroglycerin	CID: 4510	nitroglycerin; Glyceryl trinitrate; Trinitroglycerin; Nitroglycerine; Nitroglycerol; Nitrostat; 55-63-0; Trinitroglycerol; Glycerol trinitrate; Nitro-dur; Minitran; Nitroderm; Nitroglyn; Nitronet; Nitrospan; Tridil; Transderm-nitro; Transderm Nitro; Epinitril; Lenitral; Natispray; Nitrocine; Nitrolan; Nitrolingual; Perlinganit; Susadrin; Sustonit; Trinitrin; Nitrong; Niong; Nitro-Bid; Nitroderm TTS; Angiolingual; Cordipatch; Corditrine; Klavikordal; Myoglycerin; Nitroglicerina; Nitroletten; Nitroplast; Nitrorectal; Nitroretard; Nitrostabilin; Nysconitrine; Perglottal; Rectogesic; Temponitrin; Trinitrosan; Adesitrin; Angibid; Angorin; Cardamist; Chitamite; Deponit; Glonoin; Glytrin; Millisrol; Niglycon; Nitrodisc; Nitrogard; Nitroglin; Nitrolowe; Nitromel; Nitromex; Nitromint; Percutol; Suscard; Trinalgon; Triniplas; Trinitrol; Vasoglyn; Myocon; Niglin; Nitora; NitroMist; Gilucor nitro; NitroCor; Soup; Blasting oil; Blasting gelatin; Glyceryl nitrate; Nitro-lent; Nitrozell retard; Transiderm-nitro; propane-1,2,3-triyl trinitrate; Coro-Nitro; Nitro-Span; Nitrine-TDC; Spirit of glonoin; Nitrolingual Spray; Glycerin trinitrate; Nitrogliceryna; Nitronal; Transderm-Nitro TTS; Glyceroltrinitraat; Propanetriol Trinitrate; 1,2,3-Propanetriol, trinitrate; 1,2,3-Propanetriyl nitrate; Glycerol, nitric acid triester; Rectiv; Nitroglycerin, spirits of; Spirit of trinitroglycerin; NG; Rcra waste number P081; SK-106N; Solution glyceryl trinitrate; 1,3-dinitrooxypropan-2-yl nitrate; Spirit of glyceryl trinitrate; 1,2,3-propanetrioltrinitrate; NK-843; Glycerol(trinitrate de); 1,2,3-Propanetriol, 1,2,3-trinitrate; NTG; UNII-G59M7S0WS3; Glycerol Nitric Acid Triester; 1,2,3-Propanetriol trinitrate; Gilustenon; Trinitrolong; Sustak; GTN; NitroBid; G59M7S0WS3; Aldonitrin; Cardiodisco; Colenitral; Discotrine; Glycerylnitrat; Lentonitrina; Nitrobukal; Nitrocerin; Nitrocontin; Nitropatch; Nitropercuten; Nitroperlinit; Nitropront; Nitroprontan; Plastranit; Ratiopharm; TNG; Trinipatch; Angiplex; Angonist; Buccard; Cardabid; Cardinit; Dauxona; Diafusor; DTXSID1021407; Glyceryl; Herwicard; Minitram; Mionitrat; Nitradisc; Nitroard; Nitrobaat; Nitroclyn; Nitrocot; Nitrodyl; Nitrolin; Nitropen; Nitroprol; Nitrorex; Nitrovis; Perganit; Polnitrin; Trinitron; Turicard; Vasolator; Vernies; Willong; Anglix; CHEBI:28787; Herzer; Myovin; Nirmin; Nitrek; Sustac; Nitrol Ointment; Trinitrina Erba; Nitradisc Pad; Nitro-Pflaster; Nitrobid Oint; Nitrong Retard; Niong Retard; Nitro Retard; Aquo-Trimitrosan; Nitro Rorer; Nitromack Retard; Nitromint Retard; Nitronal Aqueous; Nitro-Time; Nitrogard-SR; Mi-Trates; Nitradisc TTS; Nitriderm TTS; Nitro-Par; Top-Nitro; Nitrocine 5; Nitrodyl TTS; Nitromint Aerosol; Nitrong-SR; Deponit 5; Deponit-5; Neos nitro OPT; Nit-Ret; Nitroglycerin-ACC; Transderm-N TTS; Nitro Mack Retard; Nitro-M-Bid; Nitro-Mack Retard; Gepan Nitroglicerin; Nitro Dur TTS; Nitroderm TTS-5; GTN-Pohl; Nitroderm TTS Ext; Nitro-Dur 5; Nitrocontin Continus; Deponit TTS 5; Nitro-Gesanit Retard; Cellegesic; Deponit TTS 10; Nitro-Dur 10; Nitrocap; NitroQuick; NitroQuik; NITRO IV; Glycerintrinitrate; Percutol Oint.; Nitrong parenteral; NitrocapT.D.; Glycerine trinitrate; Nitroglycerin (NG); Corangin Nitrokapseln; Trinitroglicerina Fabra; Anogesic; Glonoinum; Gonitro; Minitro; Nitriderm; Nitroject; Vascana; Buccal; Nitrogliceryna [Polish]; Nitroglycerine [French]; Nitrol (pharmaceutical); Tridil sublin; Trinitrine Simple Laleuf; Nitroglicerina [Italian]; Nitroglicerina [Spanish]; Aquo-trinitrosan; Glycerintrinitrate [Czech]; Glyceroltrinitraat [Dutch]; Trinitrin Tablets; NITROLINGUAL PUMPSPRAY; Nitromist (TN); Minitran (TN); HSDB 30; SDM No. 17; Nitroglycerin in Dextrose 5%; Nitro-bid (TN); Nitro-dur (TN); CCRIS 4089; nitroglycerin ointment; Nitric acid triester of gylcerol; Transderm-nitro (TN); Glycerol(trinitrate de) [French]; Glycerol (trinitrate de) [French]; Glycerol (trinitrate de); EINECS 200-240-8; UN0143; UN1204; UN3064; UN3319; Nitroglycerin [USP:JAN]; RCRA waste no. P081; BRN 1802063; 2,3-dinitrooxypropyl nitrate; Nitrofortin; Nitrolande; Nitrosigma; Reminitrol; Solinitrina; Spirits of Nitroglycerin, (1 to 10%); Corangil; Nitrolar; Nitromed; Sutonit; Myocor; trans-nitro; Glonoine oil; Nitro mack; S.N.G.; 2,3-bis(nitrooxy)propyl nitrate; Glycerol-trinitrat; C01DA02; IMX-150; MQX-503; Nitro-PRN; MED-2002; Diluted nitroglycerin; Nitroglycerin tablets; SK-866; SK-878; UN0144; Nitroglycerin Injection; Spirits of nitroglycerin; Nitroglycerine, spirit of; 1,2,3-trinitrooxypropane; CHEMBL730; EC 200-240-8; Nitroglycerin (JP17/USP); 1,2,3-trinitroglycerin-d5; SCHEMBL15421; 4-01-00-02762 (Beilstein Handbook Reference); UN 0143 (Salt/Mix); UN 0144 (Salt/Mix); UN 1204 (Salt/Mix); BIDD:GT0142; Ex168; Nitroglycerin, liquid, not desensitized [Forbidden]; SDM No. 17 (Salt/Mix); SDM No. 27 (Salt/Mix); 1,2,3-Propanetriol trinatrate; 1,2,3-tris-nitryloxy-propane; GTPL7053; Trinitrate 1,2,3-propanetriol; Nitric acid triester of glycerol; HMS2094M15; ZINC8214625; c0061; AKOS030254238; Nitroglycerin, solution in alcohol with > 5% but not > 10% nitroglycerin; DB00727; Nitroglycerin, liquid, not desensitized; FT-0752897; C07455; D00515; 49060-EP2280014A2; 49060-EP2287168A2; 49060-EP2311823A1; 141831-EP2292593A2; Q162867; SR-01000944510; SR-01000944510-1; Nitroglycerin, solution in alcohol, with not >1% nitroglycerin; Nitroglycerin, solution in alcohol, with >1% but not >10% nitroglycerin; Nitroglycerin, solution in alcohol, with >1% but not >5% nitroglycerin; Nitroglycerin mixture with >2% but not >10% nitroglycerin, by mass, desensitized; Nitroglycerin, desensitized with not <40% non-volatile water insoluble phlegmatizer, by mass; 27906-99-6; Nitroglycerin 100 microg/mL in Acetonitrile. Short expiry date due to chemical nature of component(s); Nitroglycerin mixture with >2% but not >10% nitroglycerin, by mass, desensitized [UN3319]  [Flammable solid]; Nitroglycerin, desensitized with not <40% non-volatile water insoluble phlegmatizer, by mass [UN0143]  [Explosive 1.1D, Poison]; Nitroglycerin, solution in alcohol, with >1% but not >10% nitroglycerin [UN0144]  [Explosive 1.1D]; Nitroglycerin, solution in alcohol, with >1% but not >5% nitroglycerin [UN3064]  [Flammable liquid]; Nitroglycerin, solution in alcohol, with not >1% nitroglycerin [UN1204]  [Flammable liquid]; Trinitroglycerin solution, 1 % (w/w) in propylene glycol, ampule of 1 mL, certified reference material; Trinitroglycerin solution, 1 % (w/w) in propylene glycol, ampule of 5 x 0.2 mL, certified reference material; Trinitroglycerin solution, 1000 mug/mL in acetonitrile, ampule of 1 mL, certified reference material	Small molecule	1S/C3H5N3O9/c7-4(8)13-1-3(15-6(11)12)2-14-5(9)10/h3H,1-2H2	SNIOPGDIGTZGOP-UHFFFAOYSA-N	C(C(CO[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-]	C3H5N3O9	CAS 55-63-0	CHEBI:28787	.	.	.	D07YDE	.	.	.
DR1867	Thearubigin	CID: 100945367	Thearubigin	Small molecule	1S/C43H34O22/c44-17-7-23(46)21-11-32(64-42(60)15-3-25(48)36(55)26(49)4-15)39(62-30(21)9-17)14-1-19(35(41(58)59)38(57)29(52)2-14)20(13-34(53)54)40-33(12-22-24(47)8-18(45)10-31(22)63-40)65-43(61)16-5-27(50)37(56)28(51)6-16/h1-10,20,32-33,39-40,44-51,55-56H,11-13H2,(H,52,57)(H,53,54)(H,58,59)/t20?,32-,33-,39-,40-/m1/s1	FNRFUGUISXPIKU-HYMCCRAQSA-N	C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=O)C(=C(C(=C3)C(CC(=O)O)C4C(CC5=C(C=C(C=C5O4)O)O)OC(=O)C6=CC(=C(C(=C6)O)O)O)C(=O)O)O)OC(=O)C7=CC(=C(C(=C7)O)O)O	C43H34O22	.	.	.	.	.	.	.	.	.
DR1885	Mesalazine	CID: 4075	5-Aminosalicylic acid; mesalamine; Mesalazine; 5-Amino-2-hydroxybenzoic acid; 89-57-6; Asacol; Pentasa; Claversal; Canasa; 5-ASA; Salofalk; Rowasa; m-Aminosalicylic acid; Mesasal; Lialda; Benzoic acid, 5-amino-2-hydroxy-; Fisalamine; Lixacol; Apriso; p-Aminosalicylsaeure; Asacolitin; Mesalazina; Mesalazinum; sfRowasa; 5-amino-2-hydroxy-benzoic acid; Asacol HD; 5-Amino Salicylic Acid; SALICYLIC ACID, 5-AMINO-; MFCD00007877; 2-Hydroxy-5-aminobenzoic acid; 3-carboxy-4-hydroxyaniline; UNII-4Q81I59GXC; NSC 38877; MAX-002; MLS001424012; 4Q81I59GXC; CHEBI:6775; NSC-38877; CAS-89-57-6; NCGC00016344-03; Mesalazinum [Latin]; SMR000145728; DSSTox_CID_4506; DSSTox_RID_77435; DSSTox_GSID_24506; 5-Aminosalicylic acid, 99%; Mesalazina [Spanish]; p-Aminosalicylsaeure [German]; Mesavancol; Delzicol; Mesavance; Mezavant; Iialda; Mesalazine MMX; Mezavant XL; Mesalamine (USP); Pentasa (TN); Salofalk Granu-Stix; Apriso (TN); Asacol (TN); Canasa (TN); Lialda (TN); Rowasa (TN); 5-AS; CCRIS 7334; SR-01000763486; Mesalamine [USAN:USP]; EINECS 201-919-1; BRN 2090421; AI3-15564; HSDB 7512; AJG-501; SPD 476; SPD-476; SPD-480; Mesalamine (TN); Delzicol (TN); Sfrowasa (TN); Mesalazine [INN]; mesalamine (USAN); Mesalamine (Lialda); 5-aminosalicylic_acid; MD-0901; 5-Aminosalicyclic acid; 5-amino-salicylic acid; PubChem17623; Mesalamine; ; ; Mesalazine; ACMC-1BKFR; Prestwick0_001069; Prestwick1_001069; Prestwick2_001069; Prestwick3_001069; WLN: ZR DQ CVQ; Z-206; CHEMBL704; Mesalazine (JP17/INN); EC 201-919-1; cid_4075; Oprea1_847633; SCHEMBL31297; 3amino-6-hydroxybenzoic acid; BSPBio_001058; KBioGR_002425; KBioSS_002431; 4-14-00-02058 (Beilstein Handbook Reference); MLS000758287; 5-Aminosalicylic acid, 95%; 5-Aminosalicylic acid, tablet; ARONIS23914; BIDD:GT0811; 3-amino-6-hydroxybenzoic acid; SPBio_002969; BPBio1_001164; GTPL2700; ZINC1688; 5-Amino 2-hydroxy benzoic acid; DTXSID5024506; SCHEMBL18038934; 5-Aminosalicylic acid, >=99%; BDBM60918; KBio2_002425; KBio2_004993; KBio2_007561; KBio3_002904; cMAP_000045; HMS1571E20; HMS2051M21; HMS2090I09; HMS2098E20; HMS3393M21; HMS3649K15; HMS3651M15; HMS3715E20; Pharmakon1600-01505993; BCP05326; NSC38877; Tox21_110384; Tox21_201610; Tox21_303125; 5-?Aminosalicylic Acid (Mesalazine); ANW-39326; BBL013046; NSC759301; s1681; SBB052617; STK301678; AKOS000118959; Tox21_110384_1; AC-2764; BCP9000175; CCG-100829; DB00244; HS-0100; LS11426; MCULE-5752745805; NC00079; NSC-759301; NCGC00016344-01; NCGC00016344-02; NCGC00016344-04; NCGC00016344-05; NCGC00016344-07; NCGC00090934-01; NCGC00090934-02; NCGC00257142-01; NCGC00259159-01; 5-amino-2-hydroxobenzoic acid monohydrate; AK-72925; BP-13074; HY-15027; SY002854; 5-Aminosalicylic acid, analytical standard; ST4109571; A0317; AB00374979; AM20060091; FT-0619950; SW197303-4; 1764-EP2272825A2; 1764-EP2275420A1; C07138; D00377; M-7246; 24215-EP2289518A1; 24215-EP2295053A1; 24215-EP2295409A1; 24215-EP2314574A1; 24215-EP2314590A1; 90701-EP2371811A2; AB00374979-09; AB00374979-10; AB00374979_11; AB00374979_12; Q412479; 5-amino-2-hydroxybenzoic acid,5-Aminosalicylic acid; Q-201355; SR-01000763486-3; SR-01000763486-4; SR-01000763486-9; Z57127471; F1918-0003; Mesalazine, European Pharmacopoeia (EP) Reference Standard; Mesalamine, United States Pharmacopeia (USP) Reference Standard; Mesalamine, Pharmaceutical Secondary Standard; Certified Reference Material; Mesalazine for system suitability, European Pharmacopoeia (EP) Reference Standard; 51481-17-5	Small molecule	1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)	KBOPZPXVLCULAV-UHFFFAOYSA-N	C1=CC(=C(C=C1N)C(=O)O)O	C7H7NO3	CAS 89-57-6	CHEBI:6775	.	.	.	D0C4YC	.	.	.
DR1895	Losartan	CID: 3961	losartan; 114798-26-4; DUP 89; Lortaan; Cozaar; LOSARTAN POTASSIUM; Hyzaar; UNII-JMS50MPO89; CHEBI:6541; MK-954; JMS50MPO89; (2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol; 2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole; DTXSID7023227; DuP 753; MFCD00865831; [2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol; NCGC00095125-01; Losartan [INN:BAN]; DSSTox_CID_3227; DSSTox_RID_76933; DSSTox_GSID_23227; (1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methanol; (1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methanol; [2-butyl-5-chloranyl-3-[[4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol; 1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-((2'-(1H-tetrazol-5-yl)(1,1'- biphenyl)-4-yl)methyl)-; 1H-imidazole-5-methanol, 2-butyl-4-chloro-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-; C22H23ClN6O; (1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methanol; [3H]losartan; Losartan (INN); Losartic (TN); 2-BUTYL-4-CHLORO-1-[[2'-(1H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-1H-IMIDAZOLE-5-METHANOL; [3H]-losartan; CAS-114798-26-4; SR-01000763170; lorastan; 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol; [2-butyl-5-chloro-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol; Losartan-[d3]; PubChem9176; Dup89; Spectrum_001713; SCHEMBL60; Spectrum2_001677; Spectrum3_000998; Spectrum4_001126; Spectrum5_001466; Epitope ID:140137; EC 601-329-8; Oprea1_644635; US9624243, Losartin; BSPBio_002695; GTPL590; KBioGR_001611; KBioSS_002193; (2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1H-imidazol-5-yl)methanol; BIDD:GT0286; SPECTRUM1504268; SPBio_001893; DUP-89; GTPL3941; BDBM82258; HSDB 7043; KBio2_002193; KBio2_004761; KBio2_007329; KBio3_001915; HGP1405; BCPP000183; BDBM318822; EX 89; HMS1922J13; HMS2093E22; HMS3715L11; Pharmakon1600-01504268; BCP27731; HGP-1405; NSC_3961; ZINC3873160; Tox21_111435; CCG-39095; NSC758699; s5067; STL419984; 2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5ylphenyl)benzyl]imidazole-5-methanol; AKOS015917390; AKOS015994740; Tox21_111435_1; AB07507; BCP9000861; DB00678; KS-5004; MCULE-5204931675; NSC 758699; NSC-758699; (2-butyl-4-chloro-1-{[2'-(2H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol; 2-n-butyl-4-chloro-5-hydroxymethyl-1-[[2'-(1H-tetrazol-5-yl)-biphenyl-4-yl]methyl]imidazole; NCGC00095125-02; NCGC00095125-03; NCGC00095125-05; NCGC00095125-08; [2-butyl-4-chloro-1-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-imidazol-5-yl]methanol; 2-Butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl-1H-imidazole-5-methanol; AK326126; HY-17512; I497; SBI-0206766.P001; AB0013723; CAS_114798-26-4; FT-0631074; C07072; D08146; 54244-EP2269989A1; 54244-EP2270011A1; 54244-EP2272841A1; 54244-EP2277879A1; 54244-EP2287165A2; 54244-EP2287166A2; 54244-EP2292620A2; 54244-EP2295053A1; 54244-EP2295406A1; 54244-EP2298772A1; 54244-EP2298776A1; 54244-EP2298779A1; 54244-EP2301923A1; 54244-EP2301931A1; 54244-EP2301936A1; 54244-EP2305219A1; 54244-EP2308562A2; 54244-EP2308839A1; AB01563296_01; 798L264; A803239; L000351; Q410074; Q-201321; SR-01000763170-3; SR-01000763170-4; BRD-K76205745-001-02-5; BRD-K76205745-001-04-1; F2173-0506; [2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-4-imidazolyl]methanol; 2-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)-biphenyl-4-yl)methyl]imidazole; 2-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole; (1-((2'-(2h-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-4-chloro-1h-imidazol-5-yl)methanol; {2-Butyl-5-chloro-3-[2'-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazol-4-yl}-methanol; 1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI); 2-butyl-4-chloro-1-[[2'-(2h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-imidazole-5-methanol; 2-butyl-4-chloro-1-[2'-(2H-tetrazol-5-yl)-1,1'-biphenyl-4-ylmethyl]-1H- imidazole-5-methanol; 2-butyl-4-chloro-5-(hydroxymethyl)-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]imidazole	Small molecule	1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)	PSIFNNKUMBGKDQ-UHFFFAOYSA-N	CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl	C22H23ClN6O	CAS 114798-26-4	CHEBI:6541	.	.	.	D0DD0K	.	.	.
DR1897	Ipriflavone	CID: 3747	ipriflavone; 35212-22-7; Osten; Osteofix; Yambolap; 7-Isopropoxyisoflavone; Iprosten; Ipriflavonum; Ipriflavona; Osteoquine; 7-isopropoxy-3-phenyl-4H-chromen-4-one; 7-Isopropoxy-3-phenyl-4H-1-benzopyran-4-one; Ipriflavone (Osteofix); Ipriflavone [INN:JAN]; 3-phenyl-7-propan-2-yloxychromen-4-one; Osten (TN); Osteochin; TC 80; 7-(1-Methylethoxy)-3-phenyl-4H-1-benzopyran-4-one; UNII-80BJ7WN25Z; FL 113; FL-113; MLS000069470; 3-phenyl-7-(propan-2-yloxy)-4H-chromen-4-one; SMR000059060; 4H-1-Benzopyran-4-one, 7-(1-methylethoxy)-3-phenyl-; 80BJ7WN25Z; CHEBI:31719; MFCD00221719; NCGC00024094-04; Quinogin; DSSTox_CID_20679; DSSTox_RID_79537; DSSTox_GSID_40679; Iprivone; Ostivone; Ipriflavonum [INN-Latin]; Ipriflavona [INN-Spanish]; CAS-35212-22-7; CCRIS 1920; BRN 4754346; Ipriflavon; (Ipriflavone); Ipriflavone, INN; 7-Isoproxyisoflavone; 7-isopropoxy-isoflavone; 7-isopropyloxy-isoflavone; Ipriflavone (JAN/INN); Opera_ID_1176; Ipriflavone (JP17/INN); Cambridge id 6663564; cid_3747; Oprea1_106310; Oprea1_275552; MLS000759494; MLS001146879; MLS001424060; MLS006011644; SCHEMBL111472; 7-isopropoxy-3-phenyl-chromone; CHEMBL165790; ZINC4016; Ipriflavone, analytical standard; DTXSID5040679; BDBM43662; SFBODOKJTYAUCM-UHFFFAOYSA-; FL113; HMS2051J15; HMS2234M05; HMS3371E17; HMS3393J15; HMS3656K19; HMS3715D04; TC-80; TN-39; AMY25650; HY-N0094; Tox21_111532; Tox21_113172; ANW-41668; s2422; STL512460; AKOS003627375; Tox21_111532_1; Tox21_113172_1; AC-8130; CCG-100963; CS-6395; DB13618; MCULE-4241728982; NC00213; NSC 755888; VA11103; 7-(methylethoxy)-3-phenylchromen-4-one; NCGC00018139-01; NCGC00018139-02; NCGC00018139-03; NCGC00018139-04; NCGC00018139-05; NCGC00018139-07; NCGC00018139-08; AK555354; AS-12306; ST083683; 3-phenyl-7-propan-2-yloxy-chromen-4-one; DB-048754; FT-0621442; I0669; SW197593-2; 3-phenyl-7-propan-2-yloxy-1-benzopyran-4-one; D01338; AB00384280-21; 212I227; SR-01000000042; 7-Isopropoxy-3-phenyl-4H-1-benzopyran-4-one 97%; Q1097778; SR-01000000042-2; 7-Isopropoxy-3-phenyl-4H-1-benzopyran-4-one, 97%; F0196-0909	Small molecule	1S/C18H16O3/c1-12(2)21-14-8-9-15-17(10-14)20-11-16(18(15)19)13-6-4-3-5-7-13/h3-12H,1-2H3	SFBODOKJTYAUCM-UHFFFAOYSA-N	CC(C)OC1=CC2=C(C=C1)C(=O)C(=CO2)C3=CC=CC=C3	C18H16O3	CAS 35212-22-7	CHEBI:31719	.	.	.	D0R2OA	.	.	.
DR1920	BS21	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR1922	Proanthocyanidins	CID: 122173182	ZINC584567037; N1697	Small molecule	1S/C30H26O13/c31-14-7-19(35)16-11-25(28(41-23(16)9-14)12-1-3-17(33)20(36)5-12)43-30(13-2-4-18(34)21(37)6-13)29(40)27(39)26-22(38)8-15(32)10-24(26)42-30/h1-10,25,27-29,31-40H,11H2/t25-,27+,28+,29-,30+/m1/s1	HGVVOUNEGQIPMS-JOFXVPDFSA-N	C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)OC4(C(C(C5=C(C=C(C=C5O4)O)O)O)O)C6=CC(=C(C=C6)O)O	C30H26O13	.	.	.	.	.	.	.	.	.
DR1957	Tapentadol	CID: 9838022	Nucynta; Palexia; UNII-H8A007M585; 3-((1R,2R)-3-(Dimethylamino)-1-ethyl-2-methylpropyl)phenol; 3-((2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl)phenol; phenol, 3-[(1r,2r)-3-(dimethylamino)-1-ethyl-2-methylpropyl]-; BN-200; H8A007M585; CG-5503; (R,R)-Tapentadol; Tapentadol [USAN:INN]; 3-[(2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl]phenol; Phenol, 3-((1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl)-; CG5503; BN 200; CG 5503; Tapentadol (USAN/INN); 3-(1-DIMETHYLAMINO-2-METHYL-PENTAN-3-YL)PHENOL; 175591-23-8	Small molecule	1S/C14H23NO/c1-5-14(11(2)10-15(3)4)12-7-6-8-13(16)9-12/h6-9,11,14,16H,5,10H2,1-4H3/t11-,14+/m0/s1	KWTWDQCKEHXFFR-SMDDNHRTSA-N	CCC(C1=CC(=CC=C1)O)C(C)CN(C)C	C14H23NO	CAS 175591-23-8	.	.	.	.	D0K4MH	.	.	.
DR1960	3'-azido-3'-deoxythymidine	CID: 5726	NSC602670; Azidothymidine (AZT); BW-A 509U; Aztec; 3'-Deoxy-3'-azidothymidine; Azitidin; Timazid; Zidovudine, AZT; NSC 602670; NSC-602670; Thymidine, 8CI,; Trizivir (Salt/Mix); ACMC-209hgl; 3-Azido-3-deoxythymidine; 1-[4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione; CHEMBL178240; SCHEMBL13609910; 3'-epi-Azido-3'-deoxythymidine; component of Combivir (Salt/Mix); HMS3369K15; HMS3656A20; BCP03622; STL451000; STL454167; ZINC04164448; AKOS015949577; AKOS037482514; CCG-229922; MCULE-3669241621; NCGC00015044-03; NCGC00015044-04; NCGC00015044-05; NCGC00094963-01; NCGC00094963-02; NCI60_004566; FT-0601543; 1-(3-azido-2,3-dideoxypentofuranosyl)-2-hydroxy-5-methylpyrimidin-4(1H)-one; 1-(3-azido-2,3-dideoxypentofuranosyl)-4-hydroxy-5-methylpyrimidin-2(1H)-one; ZVD	Small molecule	1S/C10H13N5O4/c1-5-3-15(10(18)12-9(5)17)8-2-6(13-14-11)7(4-16)19-8/h3,6-8,16H,2,4H2,1H3,(H,12,17,18)	HBOMLICNUCNMMY-UHFFFAOYSA-N	CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)N=[N+]=[N-]	C10H13N5O4	CAS 30516-87-1	.	.	.	.	.	.	.	.
DR1969	ABT-888	CID: 45480520	Veliparib; 912444-00-9; ABT 888; ABT-888 (Veliparib); Veliparib (ABT-888); ABT888; UNII-01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; CHEBI:62880; 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide; 01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4-; (2r)-2-(7-Carbamoyl-1h-Benzimidazol-2-Yl)-2-Methylpyrrolidinium; Veliparib dihydrochloride	Small molecule	1S/C13H16N4O.2ClH/c1-13(6-3-7-15-13)12-16-9-5-2-4-8(11(14)18)10(9)17-12;;/h2,4-5,15H,3,6-7H2,1H3,(H2,14,18)(H,16,17);2*1H/t13-;;/m1../s1	DSBSVDCHFMEYBX-FFXKMJQXSA-N	CC1(CCCN1)C2=NC3=C(C=CC=C3N2)C(=O)N.Cl.Cl	C13H18Cl2N4O	CAS 912445-05-7	.	.	.	.	D0Q7UD	.	.	ABT-888
DR2073	Sorafenib	CID: 216239	Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)	Small molecule	1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)	MLDQJTXFUGDVEO-UHFFFAOYSA-N	CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F	C21H16ClF3N4O3	CAS 284461-73-0	CHEBI:50924	.	.	.	D0W5HK	.	.	Sorafenib
DR2074	PR-104A	CID: 9848786	PR-104A; 680199-06-8; PR 104A; SN 27858; UNII-397986RF9L; 397986RF9L; 2-((2-Bromoethyl)(2-((2-hydroxyethyl)carbamoyl)-4,6-dinitrophenyl)amino)ethyl methanesulfonate; 2-[N-(2-bromoethyl)-2-(2-hydroxyethylcarbamoyl)-4,6-dinitroanilino]ethyl methanesulfonate; 2-((2-bromoethyl)-2-{[(2-hydroxyethyl)amino]carbonyl}-4,6-dinitroanilino)ethyl methanesulfonate; SCHEMBL366334; CHEMBL4438907; 3,5-Dinitrobenzamide nitrogen mustard; AKOS025147034; J-505203; 2-((2-Bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-N-(2-hydroxyethyl)-3,5-dinitrobenzamide; 2-(N-(2-Bromoethyl)-2-(((2-hydroxyethyl)amino)carbonyl)-4,6-dinitroanilino)ethyl methanesulfonate; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-N-(2-hydroxyethyl)-3,5-dinitro-	Small molecule	1S/C14H19BrN4O9S/c1-29(26,27)28-7-5-17(4-2-15)13-11(14(21)16-3-6-20)8-10(18(22)23)9-12(13)19(24)25/h8-9,20H,2-7H2,1H3,(H,16,21)	AZICEEZSDKZDHX-UHFFFAOYSA-N	CS(=O)(=O)OCCN(CCBr)C1=C(C=C(C=C1[N+](=O)[O-])[N+](=O)[O-])C(=O)NCCO	C14H19BrN4O9S	CAS 680199-06-8	.	.	.	.	.	.	.	.
DR2080	Topotecan	CID: 60700	Hycamptamine; Hycamptin; Hycamtamine; Topotecane; Topotecanum; Topotecan lactone; SKF 104864; SKF-S 104864; TOPOTECAN, HYCAMTIN; Topotecan (BAN); Topotecan [INN:BAN]; Topotecane [INN-French]; Topotecanum [INN-Latin]; Topotecan Monohydrochloride, (S)-Isomer; (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 9-Dimethylaminomethyl-10-hydroxycamptothecin	Small molecule	1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1	UCFGDBYHRUNTLO-QHCPKHFHSA-N	CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O	C23H23N3O5	CAS 123948-87-8	.	.	.	.	D02PMO	.	.	Topotecan
DR2114	Lamotrigine	CID: 3878	lamotrigine; 84057-84-1; 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine; Lamictal; Lamictal Cd; Lamictal XR; Lamotriginum [Latin]; Lamotrigina [Spanish]; Lamotriginum; BW 430C; BW-430C; Lamotrigina; Lamictal ODT; 3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine; 1,2,4-Triazine-3,5-diamine, 6-(2,3-dichlorophenyl)-; 3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine; C9H7Cl2N5; LTG;BW430C; UNII-U3H27498KS; MFCD00865333; CHEMBL741; MLS000069685; CHEBI:6367; U3H27498KS; Lamotrigine, 98%; Lamotrigine-13C3; NCGC00015605-06; Labileno; Lamitor; SMR000058464; DSSTox_CID_3195; DSSTox_RID_76918; DSSTox_GSID_23195; Lamictal (TN); CAS-84057-84-1; BW430C; SR-01000000187; EINECS 281-901-8; HSDB 7526; EUR-1048; Lamotrigine [USAN:USP:INN:BAN]; zine-3,5-diamine; GI 267119X; 1188265-38-4; Lamotrigine-13C-d3; Opera_ID_12; Tocris-1611; hydroxymethyl progesterone; Lopac-L-3791; L 3791; Lopac0_000688; SCHEMBL35439; MLS000759486; MLS001077325; MLS001423991; BIDD:GT0794; Lamotrigine (JAN/USP/INN); Lamotrigine, >=98%, powder; GTPL2622; TRI020; DTXSID2023195; ZINC13156; HMS2051C10; HMS2089M08; HMS2093P21; HMS2230L04; HMS3262I17; HMS3268G17; HMS3371O16; HMS3393C10; HMS3657A17; HMS3715H21; HMS3885M03; Pharmakon1600-01505610; AMY40805; BCP12156; HY-B0495; Lamotrigine 1.0 mg/ml in Methanol; Tox21_110179; Tox21_500688; ANW-44921; BDBM50031299; NSC746307; NSC759171; s3024; STK628377; AKOS005561147; Tox21_110179_1; 6-(2,2,4-triazine-3,5-diyldiamine; CCG-100856; DB00555; KS-1074; LP00688; MCULE-7648410888; NC00106; NE61394; NSC 746307; NSC 759171; NSC-746307; NSC-759171; SDCCGSBI-0050666.P003; SMP2_000303; NCGC00015605-01; NCGC00015605-02; NCGC00015605-03; NCGC00015605-04; NCGC00015605-05; NCGC00015605-07; NCGC00015605-08; NCGC00015605-09; NCGC00015605-10; NCGC00015605-23; NCGC00015605-24; NCGC00022936-02; NCGC00022936-04; NCGC00022936-05; NCGC00261373-01; AC-10298; AC-32483; AK-72807; AT-15488; K499; Lamotrigine 100 microg/mL in Acetonitrile; SBI-0050666.P002; 6-(2,3-Dichloro-phenyl)-[1,2,4]tria; AB0014255; DB-014839; B2249; EU-0100688; FT-0602546; FT-0670713; FT-0670714; L-205; L0241; SW197486-3; 57L841; A11873; D00354; J10032; AB00384359-16; AB00384359_17; AB00384359_18; A840709; Q410346; 3,5-diamino-(2,3-dichlorophenyl)-1,2,4-triazine; Q-201221; SR-01000000187-2; SR-01000000187-4; SR-01000000187-7; BRD-K93460210-071-01-6; SR-01000000187-10; 3,5-diamino-6-(2,3,-dichlorophenyl)-1,2,4-triazine; 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine.; F2173-0540; Z1550648755; 6-(2,3-Dichloro-phenyl)-[1,2,4]triazine-3,5-diamine; 6-[2,3-bis(chloranyl)phenyl]-1,2,4-triazine-3,5-diamine; Lamotrigine, British Pharmacopoeia (BP) Reference Standard; Lamotrigine, European Pharmacopoeia (EP) Reference Standard; 6-(2,3-Dichloro-phenyl)-[1,2,4]triazine-3,5-diamine(lamotrigine); GI 267119X; 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine; Lamotrigine, United States Pharmacopeia (USP) Reference Standard; Lamotrigine, Pharmaceutical Secondary Standard; Certified Reference Material; Lamotrigine for peak identification, European Pharmacopoeia (EP) Reference Standard; Lamotrigine for system suitability, European Pharmacopoeia (EP) Reference Standard; Lamotrigine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material	Small molecule	1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)	PYZRQGJRPPTADH-UHFFFAOYSA-N	C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N	C9H7Cl2N5	CAS 84057-84-1	CHEBI:6367	.	.	.	D03FLC	.	.	.
DR2116	Lonidamine	CID: 39562	lonidamine; 50264-69-2; 1-(2,4-Dichlorobenzyl)-1H-indazole-3-carboxylic acid; Diclondazolic acid; Doridamina; DICA; Lonidamina; Lonidaminum; Lonidamin; AF 1890; 1-[(2,4-dichlorophenyl)methyl]-1H-indazole-3-carboxylic acid; 1-(2,4-Dichlorbenzyl)-indazole-3-carboxylic acid; UNII-U78804BIDR; C15H10Cl2N2O2; 1-(2,4-dichlorobenzyl)indazole-3-carboxylic acid; 1-[(2,4-dichlorophenyl)methyl]indazole-3-carboxylic acid; AF-1890; MLS000028822; U78804BIDR; CHEBI:50138; 1H-Indazole-3-carboxylic acid, 1-[(2,4-dichlorophenyl)methyl]-; AF-1890;Diclondazolic Acid;DICA; MFCD00866285; NCGC00015609-03; SMR000058467; DSSTox_CID_782; DSSTox_RID_75787; DSSTox_GSID_20782; Lonidaminum [INN-Latin]; Lonidamina [INN-Spanish]; Doridamina (TN); Dichlondazolic acid; Lonidamine (INN); CAS-50264-69-2; CCRIS 3516; Lonidamine [INN:BAN]; SR-01000075961; EINECS 256-510-0; BRN 0894483; KN-228; TH-070; Tocris-1646; Lopac-L-4900; L 4900; SCHEMBL7134; Lopac0_000718; cid_39562; ZINC1632; CHEMBL1257030; DTXSID5020782; BDBM59775; 1H-Indazole-3-carboxylic acid, 1-(2,4-dichlorobenzyl)-; HMS2234H24; HMS3262O17; HMS3268K09; HMS3369I01; HMS3412P05; HMS3651F09; HMS3676P05; HMS3874D03; Pharmakon1600-01503225; 1H-Indazole-3-carboxylicacid, 1-[(2,4-dichlorophenyl)methyl]-; ACT02617; BCP06555; HY-B0486; Tox21_110181; Tox21_202306; Tox21_500718; NSC741419; NSC758419; s2610; AKOS012842739; Tox21_110181_1; AC-5626; CCG-204803; DB06266; LP00718; NSC 741419; NSC 758419; NSC-741419; NSC-758419; SDCCGSBI-0050696.P003; NCGC00015609-01; NCGC00015609-02; NCGC00015609-04; NCGC00015609-05; NCGC00015609-06; NCGC00015609-07; NCGC00015609-08; NCGC00015609-09; NCGC00015609-16; NCGC00025244-01; NCGC00025244-02; NCGC00025244-03; NCGC00259855-01; NCGC00261403-01; AS-11653; SBI-0050696.P002; AB0010495; AM20060642; EU-0100718; FT-0650359; SW219810-1; Lonidamine, mitochondrial hexokinase inhibitor; D07257; J90044; S-4929; AB00597141_08; AB00597141_10; 264L692; Q-201318; Q3836670; SR-01000075961-1; SR-01000075961-3; SR-01000075961-6; BRD-K78513633-001-03-3; BRD-K78513633-001-06-6; Z1741977188; 1-[(2,4-dichlorophenyl)methyl]-3-indazolecarboxylic acid; 1H-Indazole-3-carboxylic acid, 1-((2,4-dichlorophenyl)methyl)- (9CI)	Small molecule	1S/C15H10Cl2N2O2/c16-10-6-5-9(12(17)7-10)8-19-13-4-2-1-3-11(13)14(18-19)15(20)21/h1-7H,8H2,(H,20,21)	WDRYRZXSPDWGEB-UHFFFAOYSA-N	C1=CC=C2C(=C1)C(=NN2CC3=C(C=C(C=C3)Cl)Cl)C(=O)O	C15H10Cl2N2O2	CAS 50264-69-2	CHEBI:50138	.	.	.	D09SIR	.	.	.
DR2147	Recombinant tissue plasminogen activator	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR2168	Pioglitazone	CID: 4829	Pioglitazone; 111025-46-8; Actos; 105355-27-9; Pioglitazona; Pioglitazonum; Glustin; Pioglitazonum [INN-Latin]; Pioglitazona [INN-Spanish]; 5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione; Zactos; Duetact; U 72107; AD-4833; Pioglitazone-d4; CHEBI:8228; Pioglitazone (Actos); 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; Actos (TN); 5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione; 5-[4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]BENZYL]-2,4-THIAZOLIDINEDIONE; U-72107; 2,4-thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-; MFCD00865504; 105390-47-4; Pioglitazone [BAN:INN]; Pioglitazone [INN:BAN]; Piozone; Pioglu; 5-({4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione; [( inverted exclamation markA)-5-[[4-[2-(5-ethyl-2-pyridinyl) ethoxy] phenyl] methyl]-2,4-] thiazolidinedione monohydrochlorid; pioglitazone (INN); 1134163-31-7; HSDB 7322; U-72107E; 5-{4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl}-2,4-thiazolidinedione; SR-01000763737; Pioglitazone-[d4]; HS-0047; Spectrum_001623; Spectrum2_001679; Spectrum3_001002; Spectrum4_001130; Spectrum5_001480; Spectrum5_002067; SCHEMBL4121; BSPBio_002723; KBioGR_001619; KBioSS_002103; MLS006011848; SPBio_001897; GTPL2694; DTXSID3037129; KBio2_002103; KBio2_004671; KBio2_007239; KBio3_001943; HMS2089H14; HMS3651D09; HMS3712E16; HMS3884L10; Pharmakon1600-01504401; ACT02635; BCP26474; BBL029068; BDBM50103521; NSC758876; s2590; STL309607; STL373406; (+/-)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione; AKOS015894953; AKOS022109420; AC-1021; CCG-220107; CS-1700; DB01132; MCULE-2346786634; NSC-758876; SB17323; (+/-)-5-[[4-[2-(5-Ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-, (+-)-; NCGC00163128-01; NCGC00163128-02; NCGC00163128-03; NCGC00163128-04; NCGC00163128-05; NCGC00163128-06; NCGC00163128-07; AK-56326; HY-13956; SMR002204015; SY017473; SBI-0206791.P001; AB0004710; DB-027350; FT-0601906; FT-0645030; SW197561-3; C07675; D08378; J10289; K-0703; AB00698454-10; AB00698454_11; AB00698454_12; AB00698454_13; 355P279; A801204; Q417765; J-002506; J-516181; SR-01000763737-5; BRD-A48430263-003-02-4; BRD-A48430263-003-06-5; 5-[4-[2-(5-ethyl-2-pyridyl) ethoxy]benzyl]-2,4-thiazolidinedione; 5-[4-[2-(5-ethyl-2-pyridyl)eth-oxy]benzyl]-2,4-thiazolidinedione; 5-{4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl}-2,4thiazolidinedione; 5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)-thiazolidine-2,4-dione; 5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl-2,4-thiazolidinedione; 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione; 5-[[4-[2-(5-ethyl-2-pyridyl)ethoxy] phenyl]methyl]-2,4-thiazolidinedione; (+/-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]- (9CI); 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-, (+/-)-; 5-[[4-[2-[(5-ethyl-2-pyridyl)]ethoxy]phenyl]methyl]thiazolidine- 2,4-dione; 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-4-hydroxy-1,3-thiazol-2(5H)-one	Small molecule	1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23)	HYAFETHFCAUJAY-UHFFFAOYSA-N	CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3	C19H20N2O3S	CAS 111025-46-8	CHEBI:8228	.	.	.	D03OFF	.	.	.
DR2172	Afatinib	CID: 10184653	Afatinib; 439081-18-2; 850140-72-6; BIBW2992; Tovok; Tomtovok; BIBW 2992; BIBW-2992; Afatinib (BIBW2992); (S,E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide; Afatinib free base; N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-Butenamide; UNII-41UD74L59M; C24H25ClFN5O3; (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydrofuran-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide; CHEMBL1173655; CHEBI:61390; 41UD74L59M; 850140-72-6 (free base); S1011; (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-oxolan-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide; (S,E)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide; (S)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide; (E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide; (S,E)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide.; 2-Butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydro-3-furanyl)oxy)-6-quinazolinyl)-4-(dimethylamino)-, (2E)-; Afatinib [USAN:INN]; afatinibum; MFCD12407405; (E)-4-dimethylamino-but-2-enoic acid-(4-(3-chloro-4-fluoro-phenylamino)-7-((S)-tetrahydrofuran-3-yloxy)-quinazolin-6-yl)-amide; (E)-4-Dimethylamino-but-2-enoic acid-[4-(3-chloro-4-fluoro-phenylamino)-7-((S)-tetrahydrofuran-3-yloxy)-quinazolin-6-yl]-amide; 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-, (2E)-; Afatinib, Free Base; BIBW2992,Afatinib; PubChem22403; Afatinib (USAN/INN); BIBW2992 - Afatinib; Tovok; ; ; BIBW 2992; (2E)-N-(4-(3-chloro-4-fluoroanilino)-7-(((3S)-oxolan-3-yl)oxy)quinoxazolin-6-yl)-4-(dimethylamino)but-2-enamide; cc-109; MLS006010000; GTPL5667; CHEBI:94698; DTXSID20893451; EX-A065; QCR-169; BCPP000338; AOB87785; BCP01779; ZINC3976838; BIBW2992/Tovok,BIBW-2992; 3123AC; ABP000859; BDBM50322823; NSC750691; NSC799327; Afatinib(cis-trans isomerismtautomers); AKOS015850681; AKOS015904219; AKOS025149636; BCP9000407; CCG-264776; DB08916; EX-8656; NSC-750691; NSC-799327; PB28439; NCGC00185000-01; (2e)-n-(4-((3-chloro-4-fluorophenyl)amino)-7-(((3s)-tetrahydro-3-furanyl)oxy)-6-quinazolinyl)-4-(dimethylamino)-2-butenamide; AC-26079; AC-27018; AM808098; DS-14172; SMR004701084; AB0033685; SW219248-1; X7366; A15572; D09724; Q-3651; AB01565886_02; 081B182; SR-01000941576; J-500781; J-502300; Q4688818; SR-01000941576-1; BRD-K66175015-001-01-7; (2E)-N-[4-(3-Chloro-4-fluoroanilino)-7-[[(3S)-oxolane-3-yl]oxy]quinazoline-6-yl]-4-(dimethylamino)-2-buteneamide; (E)-4-dimethylamino-but-2-enoic acid-(4-(3-chloro-4-fluoro-phenylamino)-7-((S)-tetrahydrofuran-3-yloxy)-quinazolin-6yl)-amide; (R,E)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide; (S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3''S'')-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide	Small molecule	1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1	ULXXDDBFHOBEHA-CWDCEQMOSA-N	CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4	C24H25ClFN5O3	CAS 850140-72-6	CHEBI:61390	.	.	.	D05UFG	.	.	.
DR2176	Cyclophosphamide	CID: 2907	ASTA; Ciclofosfamida; Ciclophosphamide; Clafen; Claphene; Cycloblastin; Cyclophosphamid; Cyclophosphamides; Cyclophosphamidum; Cyclophosphan; Cyclophosphane; Cyclophosphanum; Cyclophosphoramide; Cyclostin; Cyklofosfamid; Cytophosphan; Cytophosphane; Cytoxan; Endoxan; Endoxana; Endoxanal; Endoxane; Enduxan; Genoxal; Mitoxan; Neosar; Procytox; Revimmune; Semdoxan; Sendoxan; Senduxan; Zyklophosphamid; Ciclophosphamide [INN]; Cyclophosphamide Sterile; Cyclophosphamide anhydrous; Cyklofosfamid [Czech]; Cytoxan Lyoph; Endoxan R; Lyophilized Cytoxan; Zyklophosphamid [German]; ASTA B518; Asta B 518; B 518; C 0768; CB 4564; SK 20501; B-518; CB-4564; Ciclofosfamida [INN-Spanish]; Cyclophosphamide (INN); Cyclophosphamide (TN); Cyclophosphamide (anhydrous form); Cyclophosphamide (anhydrous); Cyclophosphamidum [INN-Latin]; Cytoxan (TN); Endoxan (TN); Endoxan-Asta; Neosar (TN); Occupation, cyclophosphamide exposure; Procytox (TN); Revimmune (TN); Bis(2-Chloroethyl)phosphami de cyclic propanolamide; Bis(2-Chloroethyl)phosphamide cyclic propanolamide ester; Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester; D,L-Cyclophosphamide; Cyclophosphamide, (+-)-Isomer; N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide; (+-)-Cyclophosphamide; (-)-Cyclophosphamide; (RS)-Cyclophosphamide; 1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine; 1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin; 4-Hydroxy-cyclophosphan-mamophosphatide	Small molecule	1S/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12)	CMSMOCZEIVJLDB-UHFFFAOYSA-N	C1CNP(=O)(OC1)N(CCCl)CCCl	C7H15Cl2N2O2P	CAS 50-18-0	.	.	.	.	D0CT9C	.	.	Cyclophosphamide
DR2202	Candesartan cilexetil	CID: 2540	Candesartan cilexetil; 145040-37-5; Atacand; TCV-116; Amias; Parapres; Kenzen; candesartancilexetil; CANDESARTAN CILEXTIL; TCV 116; C33H34N6O6; CHEMBL1014; CHEBI:3348; 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate; TCY 116; MFCD00871371; 1-(cyclohexyloxycarbonyloxy)ethyl 1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate; 1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate; 1-(((cyclohexyloxy)carbonyl)oxy)ethyl 1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate; 2-Ethoxy-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid 1-cyclohexyloxycarbonyloxy-ethyl ester; 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl 2-ethoxy-1-[[2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-benzimidazole-7-carboxylate; 2-ETHOXY-1-[[2'-(2H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-1H-BENZIMIDAZOLE-7-CARBOXYLIC ACID 1-[[(CYCLOHEXYLOXY)CARBONYL]OXY]ETHYL ESTER; Candesartan cilexetil [USAN]; Racanda; Candesartan hexetil; 1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate; Atacand (TN); candesartan cilexitil; Spectrum_001707; Candesartan (Cilexetil); DSSTox_CID_239; Spectrum2_000485; Spectrum3_000996; Spectrum4_001124; Spectrum5_001462; DSSTox_RID_85567; DSSTox_GSID_20239; SCHEMBL40831; BSPBio_002691; KBioGR_001607; KBioSS_002187; 1H-Benzimidazolium, 7-carboxy-1-(2-((cyclohexylcarbonyl)oxy)ethyl)-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)-, hydroxide, inner salt, (+-)-; Candesartan Cilexetil-[d11]; MLS004774127; Candesartan cilexetil , 97%; SPECTRUM1504261; SPBio_000349; GTPL8352; Candesartan cilexetil (Atacand); DTXSID5020239; KBio2_002187; KBio2_004755; KBio2_007323; KBio3_001911; EBD4212; HMS1922J09; HMS2093E20; HMS3651I08; Pharmakon1600-01504261; Candesartan cilexetil (JP17/USP); BCP22050; Tox21_302202; AC-204; BDBM50318907; CCG-39530; NSC758697; s2037; STL451065; AKOS015894954; AKOS015920180; AB07617; AM90293; BCP9000480; CCG-222334; DB00796; DS-1302; KS-1147; NSC 758697; NSC-758697; VA10473; Candesartan cilexetil, >=98% (HPLC); NCGC00095123-01; NCGC00095123-02; NCGC00095123-03; NCGC00095123-05; NCGC00095123-10; NCGC00095123-16; NCGC00255218-01; (+-)-1-Hydroxyethyl 2-ethoxy-1-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylate, cyclohexyl carbonate (ester); 1-{[(cyclohexyloxy)carbonyl]oxy}ethyl 2-(ethyloxy)-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate; 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, 1-(((cyclohexyloxy)carbonyl)oxy)ethyl ester, (+-)-; AK-75900; HY-17505; SMR003500784; SBI-0206767.P001; AB0012012; C-265; CAS-145040-37-5; FT-0602914; SW220041-1; A-2005; C07709; D00626; J10436; AB01274805-01; AB01274805_02; AB01274805_03; 040C375; H212/91; L006257; SR-05000001976; Camptothecine, Antibiotic for Culture Media Use Only; Q-200786; SR-05000001976-1; BRD-A65671304-001-02-6; BRD-A65671304-001-03-4; Q27075664; Candesartan 1-(((cyclohexyloxy)carbonyl)oxy)ethyl ester; Candesartan cilexetil, European Pharmacopoeia (EP) Reference Standard; Candesartan cilexetil, United States Pharmacopeia (USP) Reference Standard; Candesartan cilexetil for peak identification, European Pharmacopoeia (EP) Reference Standard; Candesartan cilexetil for system suitability, European Pharmacopoeia (EP) Reference Standard; Candesartan Cilexetil, Pharmaceutical Secondary Standard; Certified Reference Material; (+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methylbenzimidazole-7-carboxylate; (+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methylbenzimidazole-7-carboxylate; 1-(Cyclohexyloxycarbonyloxy)ethyl-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazol-7-carboxylate; 1-{[(cyclohexyloxy)carbonyl]oxy}ethyl 2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate; 1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl] methyl]benzimidazole-4-carboxylate; 1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate.; 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester; 2-Ethoxy-1-[2'-(1H-tetrazole-5-yl)-4-biphenylylmethyl]-1H-benzimidazole-7-carboxylic acid 1-(cyclohexyloxycarbonyloxy)ethyl ester; 2-Ethoxy-3-[2''-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid 1-cyclohexyloxycarbonyloxy-ethyl ester; 2-Ethoxy-3-[2''-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid 1-cyclohexyloxycarbonyloxy-ethyl ester; 2-ethoxy-3-[2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-benzoimidazole-4-carboxylic acid 1-cyclohe	Small molecule	1S/C33H34N6O6/c1-3-42-32-34-28-15-9-14-27(31(40)43-21(2)44-33(41)45-24-10-5-4-6-11-24)29(28)39(32)20-22-16-18-23(19-17-22)25-12-7-8-13-26(25)30-35-37-38-36-30/h7-9,12-19,21,24H,3-6,10-11,20H2,1-2H3,(H,35,36,37,38)	GHOSNRCGJFBJIB-UHFFFAOYSA-N	CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)OC(C)OC(=O)OC6CCCCC6	C33H34N6O6	CAS 145040-37-5	CHEBI:3348	.	.	.	.	.	.	.
DR2270	Niclosamide	CID: 4477	niclosamide; 50-65-7; 5-Chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide; Niclocide; Bayluscid; Phenasal; Tredemine; Fenasal; Yomesan; 2',5-Dichloro-4'-nitrosalicylanilide; Dichlosale; Helmiantin; Atenase; Cestocid; Devermin; Devermine; Iomesan; Iomezan; Mansonil; Radeverm; Sagimid; Vermitid; Lintex; Nasemo; Sulqui; Mato; Fedal-Telmin; Bayer 73; Zestocarp; Bayer 2353; BAY 2353; Benzamide, 5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxy-; Chemagro 2353; C13H8Cl2N2O4; 5-Chloro-2'-chloro-4'-nitrosalicylanilide; nicolsamide; HL 2447; WR 46234; Salicylanilide, 2',5-dichloro-4'-nitro-; UNII-8KK8CQ2K8G; ENT 25823; 2-Hydroxy-5-chloro-N-(2-chloro-4-nitrophenyl)benzamide; N-(2-Chloro-4-nitrophenyl)-5-chlorosalicylamide; 2-Chloro-4-nitrophenylamide-6-chlorosalicylic acid; 2',5-Dichlor-4'-nitro-salizylsaeureanilid; 5-Chloro-N-(2'-chloro-4'-nitrophenyl)salicylamide; 8KK8CQ2K8G; SR 73; Radewerm; N-(2'-Chlor-4'-nitrophenyl)-5-chlorsalicylamid; MFCD00057597; Niclosamide Anhydrous; NSC-178296; Niclosamide, 97+%; CAS-50-65-7; NCGC00015735-07; DSSTox_CID_20362; DSSTox_RID_79485; DSSTox_GSID_40362; N-(2'-Chloro-4'-nitrophenyl)-5-chlorosalicylamide; Niclosamida; Niclosamidum; Cestocide; Niclosamidum [INN-Latin]; Niclosamida [INN-Spanish]; Nitrophenyl chlorsalicylamide; Niclosamide [USAN:INN:BAN]; CCRIS 3437; HSDB 1572; SR-01000076024; Niclosamide [BSI:ISO]; EINECS 200-056-8; NSC 178296; BRN 2820605; Yomensan; AI3-25823; 5-Chlorosalicyloyl-(o-chloro-p-nitranilide); B 2353; Niclocide (TN); Prestwick_354; 2',5-Dichlor-4'-nitro-salizylsaeureanilid [German]; Mollutox (Salt/Mix); N-(2'-Chlor-4'-nitrophenyl)-5-chlorsalicylamid [German]; Spectrum_000239; Niclosamide (Niclocide); Clonitralid (Salt/Mix); Clonitralide (Salt/Mix); Prestwick0_000040; Prestwick1_000040; Prestwick2_000040; Prestwick3_000040; Spectrum2_001183; Spectrum3_000667; Spectrum4_000196; Spectrum5_001083; Lopac-N-3510; Niclosamide (USAN/INN); CHEMBL1448; Lopac0_000866; Oprea1_259151; SCHEMBL67182; BSPBio_000139; BSPBio_002333; KBioGR_000771; KBioSS_000719; MLS002154181; DivK1c_000709; SPECTRUM1503265; SPBio_001225; SPBio_002060; BPBio1_000153; CHEBI:7553; GTPL8494; DTXSID7040362; SCHEMBL18563900; WLN: WNR CG DMVR BQ EG; BDBM11242; HMS502D11; KBio1_000709; KBio2_000719; KBio2_003287; KBio2_005855; KBio3_001553; 5-Chloro-N-(2-chloro-4-nitro-phenyl)-2-hydroxy-benzamide; Niclosamide - CAS 50-65-7; NINDS_000709; HMS1568G21; HMS2093A21; HMS2095G21; HMS2231H06; HMS3262N13; HMS3373P08; HMS3712G21; KUC107299N; Pharmakon1600-01503265; BAY-2353; BCP22958; HY-B0497; ZINC3874496; Tox21_110209; Tox21_300749; Tox21_500866; BBL004110; CCG-39641; NSC178296; NSC758440; s3030; Salicylanilide,5-dichloro-4'-nitro-; STK396676; 2,5-dichloro-4-nitrosalicylanilide ?; AKOS003589004; Tox21_110209_1; BCP9000068; DB06803; KS-5210; LP00866; MCULE-9985514311; NSC-758440; SB19414; SDCCGSBI-0050841.P004; 2',5'-Dichloro-4'-nitrosalicylanilide; IDI1_000709; SMP2_000228; 5-chloro-N-(2-chloro-4-nitrophenyl)-; NCGC00015735-01; NCGC00015735-02; NCGC00015735-03; NCGC00015735-04; NCGC00015735-05; NCGC00015735-06; NCGC00015735-08; NCGC00015735-09; NCGC00015735-11; NCGC00015735-12; NCGC00015735-24; NCGC00094190-01; NCGC00094190-02; NCGC00094190-03; NCGC00094190-04; NCGC00254654-01; NCGC00261551-01; AK173020; I012; KSC-18-157-2; SMR000058390; Niclosamide 100 microg/mL in Acetonitrile; SBI-0050841.P003; AB0013423; DB-051812; VU0243604; AB00052340; EU-0100866; FT-0603220; ST50408862; T7903; EN300-92958; D00436; N 3510; AB00052340_08; AB00052340_09; A828227; Q418523; Q-201469; SR-01000076024-1; SR-01000076024-3; SR-01000076024-6; BRD-K35960502-001-06-9; BRD-K35960502-001-11-9; Z57902203; 5-Chloro-N-(2-chloro-4-nitrophenyl) -2-hydroxybenzamide; 5-Chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxy-benzamide; (5-chloro-2-hydroxyphenyl)-N-(2-chloro-4-nitrophenyl)carboxamide; 5-chloranyl-N-(2-chloranyl-4-nitro-phenyl)-2-oxidanyl-benzamide; Niclosamide (anhydrous), European Pharmacopoeia (EP) Reference Standard	Small molecule	1S/C13H8Cl2N2O4/c14-7-1-4-12(18)9(5-7)13(19)16-11-3-2-8(17(20)21)6-10(11)15/h1-6,18H,(H,16,19)	RJMUSRYZPJIFPJ-UHFFFAOYSA-N	C1=CC(=C(C=C1[N+](=O)[O-])Cl)NC(=O)C2=C(C=CC(=C2)Cl)O	C13H8Cl2N2O4	CAS 50-65-7	CHEBI:7553	.	.	.	D0J9ZR	.	.	.
DR2271	Posaconazole	CID: 468595	Posaconazole; 171228-49-2; Noxafil; Sch 56592; SCH56592; SCH-56592; Posaconazole SP; Schering 56592; UNII-6TK1G07BHZ; 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one; 4-(4-(4-(4-(((3R,5R)-5-((1H-1,2,4-TRIAZOL-1-YL)METHYL)-5-(2,4-DIFLUOROPHENYL)TETRAHYDROFURAN-3-YL)METHOXY)PHENYL)PIPERAZIN-1-YL)PHENYL)-1-((2S,3S)-2-HYDROXYPENTAN-3-YL)-1H-1,2,4-TRIAZOL-5(4H)-ONE; 6TK1G07BHZ; CHEMBL1397; CHEBI:64355; 2,5-anhydro-1,3,4-trideoxy-2-(2,4-difluorophenyl)-4-({4-[4-(4-{1-[(2S,3S)-2-hydroxypentan-3-yl]-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl}phenyl)piperazin-1-yl]phenoxy}methyl)-1-(1H-1,2,4-triazol-1-yl)-D-threo-pentitol; pasaconazole; Posaconazole [USAN:INN:BAN]; HSDB 7421; C37H42F2N8O4; 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)tetrahydrofuran-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(1S,2S)-1-ethyl-2-hydroxy-propyl]-1,2,4-triazol-3-one; Noxafil (TN); Posaconazole solution; cc-165; SCHEMBL991747; Posaconazole (JAN/USAN/INN); DTXSID6049066; GTPL11428; AMY30591; BCP01102; ZINC3938482; BDBM50181473; CP0094; MFCD00941162; MMV688774; s1257; AKOS005145917; AC-1350; ACN-040495; CCG-270387; CS-0998; DB01263; KS-1413; PB30668; NCGC00274060-02; HY-17373; M842; Posaconazole in combination with MGCD290; AB0015409; P2477; SW219391-1; D02555; P-7020; Q-4359; AB01274762-01; AB01274762_02; Posaconazole, VETRANAL(TM), analytical standard; 228P492; Q906453; Posaconazole, Antibiotic for Culture Media Use Only; Posaconazole solution, 2.0 mg/mL in methanol, ampule of 1 mL, certified reference material; 1-((1S,2S)-1-Ethyl-2-hydroxypropyl)-4-{4-[4-(4-{[(5S,3R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazolylmethyl)oxolan-3-yl]methoxy}phenyl)piperazinyl]phenyl}-1,2,4-triazolin-5-one; 2,5-anhydro-1,3,4-trideoxy-2-(2,4-difluorophenyl)-4-({4-[4-(4-{1-[(1S,2S)-1-ethyl-2-hydroxypropyl]-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl}phenyl)piperazin-1-yl]phenoxy}methyl)-1-(1H-1,2,4-triazol-1-yl)-D-threo-pentitol; 3H-1,2,4-Triazol-3-one, 4-(4-(4-(4-((5-(2,4-difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furanyl)methoxy)phenyl)-1-piperazinyl)phenyl)-2-(1-ethyl-2-hydroxypropyl)-2,4-dihydro-, (3R-(3alpha(1S*,2S*),5alpha))-; 4-(4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)-tetrahydrofuran-3-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-((2S,3S)-2-hydroxypentan-3-yl)-2H-1,2,4-triazol-3(4H)-one; 4-(4-(4-(4-(((3R,5R)-5-(3,4-difluorophenyl)-5-(1H-1,2,4-triazol-1-yl)tetrahydrofuran-3-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-1-((2S,3S)-2-hydroxypentan-3-yl)-1H-1,2,4-triazol-5(4H)-one; 4-(4-(4-(4-(((5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)-tetrahydrofuran-3-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-((2S,3S)-2-hydroxypentan-3-yl)-2H-1,2,4-triazol-3(4H)-one; 4-(p-(4-(p-(((3R,5R)-5-(2,4-Difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furyl)methoxy)phenyl)-1-piperazinyl)phenyl)-1-((1S,2S)-1-ethyl-2-hydroxypropyl)-delta(sup 2)-1,2,4-triazolin-5-one; 4-[4-(4-{4-[(R)-5-(2,4-difluoro-phenyl)-5-(4,5-dihydro-[1,2,4]triazol-1-ylmethyl)-tetrahydro-furan-3-ylmethoxy]-phenyl}-piperazin-1-yl)-phenyl]-2-((1S,2S)-1-ethyl-2-hydroxy-propyl)-2,4-dihydro-[1,2,4]triazol-3-one; D-threo-Pentitol, 2,5-anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)-4-((4-(4-(4-(1-((1S,2S)-1-etyl-2-hydroxypropyl)-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl)phenyl)-1-piperazinyl)phenoxy)methyl)-1-(1H-1,2,4-triazol-1-yl)-; PCZ	Small molecule	1S/C37H42F2N8O4/c1-3-35(26(2)48)47-36(49)46(25-42-47)31-7-5-29(6-8-31)43-14-16-44(17-15-43)30-9-11-32(12-10-30)50-20-27-19-37(51-21-27,22-45-24-40-23-41-45)33-13-4-28(38)18-34(33)39/h4-13,18,23-27,35,48H,3,14-17,19-22H2,1-2H3/t26-,27+,35-,37-/m0/s1	RAGOYPUPXAKGKH-XAKZXMRKSA-N	CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F	C37H42F2N8O4	CAS 171228-49-2	CHEBI:64355	.	.	.	D07ABV	.	.	.
DR2276	Diazinon	CID: 3017	diazinon; Dimpylate; 333-41-5; Diazinone; Oleodiazinon; Neocidol; Ciazinon; Dassitox; Diazitol; Ektoband; Nedcidol; Spectracide; Antigal; Basudin; Bazuden; Dacutox; Dazzel; Diazide; Diazol; Exodin; Flytrol; Galesan; Nucidol; Sarolex; Dicid; Alfa-tox; Diazajet; Dimpylat; Garden Tox; Neocidol (oil); Bassadinon; Terminator; Compass; Disonex; Dizinon; Drawizon; Kayazinon; Kayazol; Meodinon; Dyzol; Nipsan; Diazinon ag 500; Knox-out; Delzinon; Dimpylatum; Dipofene; Dizictol; Neodinon; Optimizer; Bazudin; Dizinil; Srolex; Basudin 10 G; Geigy 24480; Basudin S; Knox Out 2FM; Diagran; Fezudin; NCI-C08673; AG-500; ENT 19,507; Isopropylmethylpyrimidyl diethyl thiophosphate; G-24480; Diziktol; O,O-Diethyl 2-isopropyl-4-methylpyrimidyl-6-thiophosphate; G 301; O,O-Diethyl O-(2-isopropyl-6-methyl-4-pyrimidinyl) phosphorothioate; UNII-YUS1M1Q929; 4-Pyrimidinol, 2-isopropyl-6-methyl-, O-ester with O,O-diethyl phosphorothioate; Diethyl 4-(2-isopropyl-6-methylpyrimidinyl)phosphorothionate; O-2-Isopropyl-4-methylpyrimidyl-O,O-diethyl phosphorothioate; O,O-Diethyl O-(2-isopropyl-4-methyl-6-pyrimidyl) thionophosphate; CHEBI:34682; O,O-Diethyl O-6-methyl-2-isopropyl-4-pyrimidinyl phosphorothioate; Phosphorothioate, O,O-diethyl O-6-(2-isopropyl-4-methylpyrimidyl); Thiophosphate de O,O-diethyle et de O-2-isopropyl-4-methyl-6-pyrimidyle; Phosphorothioic acid, O,O-diethyl O-(6-methyl-2-(1-methylethyl)-4-pyrimidinyl) ester; YUS1M1Q929; Diethyl 2-isopropyl-4-methyl-6-pyrimidinyl phosphorothionate; NSC8938; O,O-Diethyl-O-(2-isopropyl-4-methyl-pyrimidin-6-yl)-monothiofosfaat; Phosphorothioic acid, O,O-diethyl O-(2-isopropyl-6-methyl-4-pyrimidinyl) ester; Diethyl 2-isopropyl-4-methyl-6-pyrimidyl thionophosphate; NCGC00091073-01; Bazudine; Neotsidol; O,O-Diethyl 2-isopropyl-6-methyl-4-pyrimidinylphosphorothioate; DSSTox_CID_407; O,O-Diethyl O-(2-isopropyl-4-methyl-6-pyrimidinyl) phosphorothioate; O,O-diethyl O-[6-methyl-2-(1-methylethyl)pyrimidin-4-yl] thiophosphate; Kleen-Dok; DSSTox_RID_75567; Phosphorothioic acid, O,O-diethyl O-[6-methyl-2-(1-methylethyl)-4-pyrimidinyl] ester; DSSTox_GSID_20407; Diazinon, analytical standard; KFM Blowfly Dressing; Compass (insecticide); Caswell No. 342; gardentox; Dimpilato; Diaterr-fos; Dimpylatum [INN-Latin]; O,O-Diaethyl-O-(2-isopropyl-4-methyl-pyrinidin-6-yl)-monothiophosphat; O,O-Diethyl O-(2-isopropyl-4-methyl-6-pyrimidyl) phosphorothioate; Cooper's Flystrike Powder; Dimpilato [INN-Spanish]; NSC 8938; Phosphorothioic acid, O,O-diethylO-[6-methyl-2-(1-methylethyl)-4-pyrimidinyl] ester; Diazinon [ANSI:BSI:ISO]; CAS-333-41-5; CCRIS 204; HSDB 303; Knox Out Yellow Jacket Contorl; OMS 469; EINECS 206-373-8; PT 265; EPA Pesticide Chemical Code 057801; BRN 0273790; Spertacide; Bazanon; Antlak; AI3-19507; Root guard; Diethyl dimpylatum; diethoxy-(6-methyl-2-propan-2-ylpyrimidin-4-yl)oxy-sulfanylidene-?^{5}-phosphane; Dimpylate, INN; Basudin 5G; Dimpylate (INN); Spectracide 25EC; G 24480; Agridin 60; Basudin 10G; Spectrum_001777; Dimpylate [INN:BAN]; New Z Diazinon (TN); SpecPlus_000344; O,O-Diethyl O-(2-isopropyl-6-methyl-4-pyrimidinyl)phosphorothioate; O,O-Diethyl-O-(2-isopropyl-4-methyl-6-pyrimidyl)phosphorothioate; Spectrum2_001226; Spectrum3_000802; Spectrum4_000642; Spectrum5_001929; Thiophosphoric acid 2-isopropyl-4-methyl-6-pyrimidyl diethyl ester; O,O-Diethyl-O-(2-isopropyl-4-methyl-6-pyrimidinyl)-phosphorothioate; Phosphorothioic acid, O,O-diethyl O-(isopropylmethylpyrimidinyl) ester; O,O-Diaethyl-O-(2-isopropyl-4-methyl)-6-pyrimidyl-thionophosphat [German]; O,O-Diaethyl-O-(2-isopropyl-4-methyl-pyrimidin-6-yl)-monothiophosphat [German]; O,O-Diethyl O-(6-methyl-2-(1-methylethyl)-4-pyrimidinyl)phosphorothioate; O,O-Diethyl-O-(2-isopropyl-4-methyl-pyrimidin-6-yl)-monothiofosfaat [Dutch]; O,O-Dietil-O-(2-isopropil-4-metil-pirimidin-6-il)-monotiofosfato [Italian]; Optimizer Insecticide (TN); Thiophosphate de O,O-diethyle et de O-2-isopropyl-4-methyl-6-pyrimidyle [French]; SCHEMBL17453; BSPBio_002263; KBioGR_000983; KBioSS_002258; 5-23-11-00187 (Beilstein Handbook Reference); MLS002207243; BIDD:ER0457; DivK1c_006440; SPBio_001072; CHEMBL388560; ZINC1309; DIAZINON (DIETHYL-D10); DTXSID9020407; FHIVAFMUCKRCQO-UHFFFAOYSA-; KBio1_001384; KBio2_002257; KBio2_004825; KBio2_007393; KBio3_001763; AMY3613; HMS3264I04; Pharmakon1600-00330017; EBD29972; HY-B1113; NSC-8938; O,O-Diaethyl-O-(2-isopropyl-4-methyl)-6-pyrimidyl-thionophosphat; o,o-diethyl o-2-isopropyl-6-methylpyrimidin-4-yl phosphorothioate; Diazinon 100 microg/mL in Acetone; Tox21_111077; Tox21_201409; Tox21_300730; BDBM50005409; CCG-39143; ENT 19507; NSC755893; O,O-Diaethyl-O-(2-isopropyl-4-methyl-pyrimidin-6-yl)-monothiophosphat; O,O-Dietil-O-(2-isopropil-4-metil-pirimidin-6-il)-monotiofosfato; Diazinon 10 microg/mL in Cyclohexane; Diazinon 1000 microg/mL in Toluene; AKOS025311513; Diazinon 1000 microg/mL in Methanol; diethoxy-(2-isopropyl-6-methyl-pyrimidin-4-yl)oxy-thioxo-$l^{5}-phosphane; O,O-diethyl O-[6-methyl-2-(propan-2-yl)pyrimidin-4-yl] phosphorothioate; Tox21_111077_1; CS-4712; Diazinon 10 microg/mL in Acetonitrile; Diazinon 100 microg/mL in Cyclohexane; NSC-755893; Diazinon 100 microg/mL in Acetonitrile; NCGC00091073-02; NCGC00091073-03; NCGC00091073-04; NCGC00091073-05; NCGC00091073-06; NCGC00091073-07; NCGC00254636-01; NCGC00258960-01; SMR000777921; SBI-0052498.P002; DB-048387; Diazinon, PESTANAL(R), analytical standard; FT-0603088; FT-0778116; C14324; D07856; AB00053004_04; 333D415; Q411202; SR-01000872734; Q-200952; SR-01000872734-1; BRD-K60567437-001-04-5; Diazinon, certified reference material, TraceCERT(R); 4-Pyrimidinol, O-ester with O,O-diethyl phosphorothioate; WLN: T6N CNJ BY1 & 1 DOPS & O2 & O2 F1; O, O-Diethyl 2-isopropyl-4-methylpyrimidyl-6-thiophosphate; O,O-Diethyl-O-(2-isopropyl-4-methylpyrimidyl)thiophosphate; o,o-Dietil-o-(2-isopropil-4-metil-pirimidin-il)-monotiofosato; Phosphorothioate,O-diethyl O-6-(2-isopropyl-4-methylpyrimidyl); O,O-Diethyl O-(2-isopropyl-6-methyl-4-primidinyl)phosphorothioate; O,O-Diethyl O-(2-isopropyl-6-methyl-4-pyrimidinyl) thiophosphate; O,O-Diethyl o-(2-isopropyl-6-methyl-4-pyrimidinyl) thiophosphate #; O,O-diethyl O-(2-isopropyl-6-methyl-4-pyrimidinyl)thio-phosphate; O,O-Diethyl-O-(2-isopropyl-4-methyl-6-pyrimidyl) thiophosphate; diethoxy-(6-methyl-2-propan-2-ylpyrimidin-4-yl)oxy-sulfanylidenephosphorane; o,o-Diethyl-O-(6-methyl-2-(1-methylethyl)-4-pyrimidinyl)phosophorothioate; Phosphorothioic acid, O,O-diethyl 2-isopropyl-6-methyl-4-pyrimidinyl ester; Phosphorothioic acid,O-diethyl O-(2-isopropyl-6-methyl-4-pyrimidinyl) ester; Diazinon solution, 100 mug/mL in acetonitrile, PESTANAL(R), analytical standard; diethoxy-(6-methyl-2-propan-2-ylpyrimidin-4-yl)oxy-sulfanylidene-$l^{5-phosphane; ethyl 6-methyl-2-(propan-2-yl)pyrimidin-4-yl ethoxy(sulfanylidene)phosphonite; Phosphorothioic acid, O,O-diethyl {O-[6-methyl-2-(1-methylethyl)-4-pyrimidinyl]} ester; PHOSPHOROTHIOIC ACID,O-DIETHYL O-[6-METHYL-2-(1-METHYLETHYL)-4-PYRIMIDINYL] ESTER; O,O-Diethyl O-2-isopropyl-4-methyl-6-pyrimidyl thiophosphate; O,O-Diethyl O-(6-methyl-2-(1-methylethyl)-4-pyrimidinyl) phosophorothioate	Small molecule	1S/C12H21N2O3PS/c1-6-15-18(19,16-7-2)17-11-8-10(5)13-12(14-11)9(3)4/h8-9H,6-7H2,1-5H3	FHIVAFMUCKRCQO-UHFFFAOYSA-N	CCOP(=S)(OCC)OC1=NC(=NC(=C1)C)C(C)C	C12H21N2O3PS	CAS 333-41-5	CHEBI:34682	.	.	.	.	.	.	.
DR2370	Azacitidine	CID: 9444	Azacitidina; Azacitidinum; Azacytidine; Ladakamycin; Mylosar; Vidaza; Mylo sar; Pharmion Brand of Azacitidine; A 2385; Antibiotic U 18496; U 18496; Wr 183027; Azacitidina [INN-Spanish]; Azacitidine [USAN:INN]; Azacitidinum [INN-Latin]; NS-17; Pyrimidine antimetabolite: inhibits nucleic acid replication; U-18496; Vidaz (TN); Vidaza (TN); WR-183027; Azacitidine (JAN/USAN/INN); S-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl-(8CI); 2-(beta-D-Ribofuranosyl)-4-amino-1,3,5-triazin-2-one; 4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-traizin-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazine-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one; 4-Amino-1-beta-d-ribofuranosyl-1,3,5-triazin-2(1H)-one; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triaz; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; 4-amino-1-beta-L-ribofuranosyl-1,3,5-triazin-2(1H)-one; 5 AZC; 5 Azacytidine; 5-AC; 5-AZAC; 5-AZCR; 5-aza-CR; 5-azacitidine; 5-azacytidine; 5-azacytidine, Mylosar, Ladakamycin, Vidaza, Azacitidine; 5AzaC	Small molecule	1S/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1	NMUSYJAQQFHJEW-KVTDHHQDSA-N	C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N	C8H12N4O5	CAS 320-67-2	CHEBI:2038	.	.	.	D09FAZ	.	.	.
DR2378	Uftoral	CID: 104747	Tegafur-Uracil; Ufur; Uftoral; 74578-38-4; UFT; Youfuding; Uracil-Tegafur; orzel; Tegafur - uracil mixture; Tegafur / uracil; UFT(R) drug; FT mixt. with uracil (1:4); Uracil mixt. with FT (4:1); Tegafur Mixture With With Uracil; Tegafur mixt. with uracil (1:4); Uracil mixt. with tegafur (4:1); Tegafur/uracil; Tegafur and uracil; Uftoral (TN); 1-(2-Tetrahydrofuryl)-5-fluorouracil mixt. with uracil (1:4); Uracil mixt. with 1-(2-tetrahydrofuryl)-5-fluorouracil (4:1); SCHEMBL8228; DTXSID3023635; Uracil, 5-fluoro-1-(tetrahydro-2-furyl)- mixt. with uracil (1:4); DB09327; 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-, mixt. with 2,4(1H,3H)-pyrimidinedione; D02131; 117638-EP2270505A1; 117638-EP2295426A1; 117638-EP2295427A1; 117638-EP2298768A1; Q27098002; 5-fluoro-1-(oxolan-2-yl)pyrimidine-2,4-dione;1H-pyrimidine-2,4-dione; 5-fluoro-1-(tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione - pyrimidine-2,4(1H,3H)-dione (1:1)	Small molecule	1S/C8H9FN2O3.C4H4N2O2/c9-5-4-11(6-2-1-3-14-6)8(13)10-7(5)12;7-3-1-2-5-4(8)6-3/h4,6H,1-3H2,(H,10,12,13);1-2H,(H2,5,6,7,8)	DHMYGZIEILLVNR-UHFFFAOYSA-N	C1CC(OC1)N2C=C(C(=O)NC2=O)F.C1=CNC(=O)NC1=O	C12H13FN4O5	CAS 74578-38-4	.	.	.	.	D0Y8PT	.	.	.
DR2391	Gemcitabine	CID: 60750	Gemcitabine hydrochloride; DDFC; DFdC; DFdCyd; Folfugem; GEO; Gamcitabine; GemLip; Gemcel; Gemcin; Gemcitabina; Gemcitabinum; Gemtro; Gemzar; Zefei; Gemcitabine HCl; Gemcitabine stereoisomer; LY 188011; LY188011; Gemcitabina [INN-Spanish]; Gemcitabinum [INN-Latin]; Gemzar (TN); Gemzar (hydrochloride); Inno-D07001; LY-188011; Gemcitabine (USAN/INN)	Small molecule	1S/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1	SDUQYLNIPVEERB-QPPQHZFASA-N	C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F	C9H11F2N3O4	CAS 95058-81-4	.	.	.	.	D03UVS	.	.	Gemcitabine
DR2426	Mexidol	CID: 122298	mexidol; 127464-43-1; 2-Ethyl-6-methylpyridin-3-ol succinate; Emoxypine succinate; UNII-2R985002CT; 2-Ethyl-3-hydroxy-6-methylpyridine Succinate; 2-Ethyl-6-methyl-3-pyridinol succinate; butanedioic acid, compd. with 2-ethyl-6-methyl-3-pyridinol (1:1); 2R985002CT; 2-Ethyl-6-methyl-3-hydroxypyridine succinate; Emicidine; Mexidole; Butanedioic acid 2-ethyl-6-methyl-3-pyridinol (1:1); ACMC-20a84f; Cambridge id 5110148; SCHEMBL1010987; DTXSID30155577; BCP13396; ANW-61453; MFCD00445612; AKOS003239209; AK-41005; DS-13730; E1069; FT-0660570; X0082; 2-Ethyl-6-methyl-3-pyridinol succinate (salt); butanedioic acid;2-ethyl-6-methylpyridin-3-ol; butanedioic acid; 2-ethyl-6-methyl-3-pyridinol; butanedioic acid; 2-ethyl-6-methyl-pyridin-3-ol; 647M960; A805706; Q-100116; Q27255507	Small molecule	1S/C8H11NO.C4H6O4/c1-3-7-8(10)5-4-6(2)9-7;5-3(6)1-2-4(7)8/h4-5,10H,3H2,1-2H3;1-2H2,(H,5,6)(H,7,8)	IKMNOGHPKNFPTK-UHFFFAOYSA-N	CCC1=C(C=CC(=N1)C)O.C(CC(=O)O)C(=O)O	C12H17NO5	CAS 127464-43-1	.	.	.	.	.	.	.	.
DR2430	Deoxynivalenol	CID: 40024	DEOXYNIVALENOL; 51481-10-8; Vomitoxin; Dehydronivalenol; 4-Deoxynivalenol; 4-Desoxynivalenol; Desoxynivalenol; UNII-JT37HYP23V; Rd toxin; JT37HYP23V; 3alpha,7alpha,15-Trihydroxy-12,13-epoxytrichothec-9-en-8-one; 3?,7?,15-Trihydroxy-12,13-epoxytrichothec-9-en-8-one; (3beta,7alpha)-3,7,15-Trihydroxy-12,13-Epoxytrichothec-9-En-8-One; Trichothec-9-en-8-one, 12,13-epoxy-3,7,15-trihydroxy-, (3a,7a)-; NSC 269144; CCRIS 7801; (3alpha,7alpha)-3,7,15-trihydroxy-12,13-epoxytrichothec-9-en-8-one; Deoxynivalenol 100 microg/mL in Acetonitrile; HSDB 7245; 12,13-Epoxy-3-alpha,7-alpha,15-trihydroxy-9-trichothecen-8-one; CHEMBL513300; SCHEMBL2694361; DTXSID3020382; CHEBI:10022; Deoxynivalenol, reference material; HY-N6684; ZINC5457778; CD0228; MFCD09039270; AKOS024457908; CS-W012154; Trichothec-9-en-8-one, 12,13-epoxy-3,7,15-trihydroxy-, (3-alpha,7-alpha)-; B7557; Q420518; (3beta,7alpha,12R)-3,7,15-trihydroxy-12,13-epoxytrichothec-9-en-8-one; 4-Deoxynivalenol in acetonitrile, IRMM(R) certified Reference Material; Deoxynivalenol solution, 100 mug/mL in acetonitrile, analytical standard; Deoxynivalenol solution, 200 mug/mL in ethyl acetate: methanol (95:5), analytical standard; 3J6; Deoxynivalenol solution, certified reference material, 200 mug/mL in ethyl acetate: methanol (95:5), ampule of 1 mL	Small molecule	1S/C15H20O6/c1-7-3-9-14(5-16,11(19)10(7)18)13(2)4-8(17)12(21-9)15(13)6-20-15/h3,8-9,11-12,16-17,19H,4-6H2,1-2H3/t8-,9-,11-,12-,13-,14-,15+/m1/s1	LINOMUASTDIRTM-QGRHZQQGSA-N	CC1=CC2C(C(C1=O)O)(C3(CC(C(C34CO4)O2)O)C)CO	C15H20O6	CAS 51481-10-8	CHEBI:10022	.	.	.	.	.	.	.
DR2449	Phenylephrine	CID: 6041	phenylephrine; L-Phenylephrine; 59-42-7; Metasympatol; Mezaton; Metasynephrine; Neosynephrine; Metaoxedrin; m-Oxedrine; Metaoxedrine; Mesaton; Mesatone; Visadron; m-Sympatol; Isophrin; m-Synephrine; m-Sympathol; R(-)-Phenylephrine; Metaoxedrinum; Mesatonum; Neo-Synephrine; Fenilefrina; Phenylephrinum; m-Methylaminoethanolphenol; Isophrim; Ak-dilate; 3-[(1R)-1-hydroxy-2-(methylamino)ethyl]phenol; Mydfrin; Nostril; Cyclomydril; Alcon Efrin; l-(3-Hydroxyphenyl)-N-methylethanolamine; Dionephrine; Adrianol; Biomydrin; Neophryn; Prefrin; Rhinall; Isopto Frin; Prefrin Liquifilm; (-)-m-Hydroxy-alpha-(methylaminomethyl)benzyl alcohol; (R)-3-(1-hydroxy-2-(methylamino)ethyl)phenol; Duo-Medihaler; l-1-(m-Hydroxyphenyl)-2-methylaminoethanol; UNII-1WS297W6MV; R(-)-Mezaton; CHEBI:8093; R-PHENYLEPHRINE; Benzenemethanol, 3-hydroxy-alpha-((methylamino)methyl)-, (R)-; 1WS297W6MV; Benzyl alcohol, m-hydroxy-alpha-((methylamino)methyl)-, (-)-; Phenylephrine Tannate; Ah-Chew; 1416-03-1; Spersaphrine; Dilatair; Doktors; Duration; Neofrin; Ocugestrin; Phenoptic; Fenilefrina [INN-Spanish]; Phenylephrinum [INN-Latin]; Benzenemethanol, 3-hydroxy-.alpha.-[(methylamino)methyl]-, (R)-; Ak-nefrin; I-Phrine; 61-76-7; Phenylephrine, l-; Nostril Spray Pump; Phenylephrine [INN:BAN]; Minims Phenylephrine; Hemorid; Nostril Spray Pump Mild; Alconefrin Nasal Drops 12; Alconefrin Nasal Drops 25; Alconefrin Nasal Drops 50; Alconefrin Nasal Spray 25; Neo-Synephrine Nasal Drops; Neo-Synephrine Nasal Jelly; Neo-Synephrine Nasal Spray; Ocu-Phrin Sterile Eye Drops; (-)-phenylephrine; (-)-m-Oxedrine; (R)-(-)-phenylephrine; Relief Eye Drops for Red Eyes; Phenylephrine (INN); (R)-(-)-Phenylephrine hydrochloride; HSDB 3383; UNII-DU5ATO7HYP; EINECS 200-424-8; Phenylephrine Minims (TN); phenylene; l-m-Hydroxy-alpha-((methylamino)methyl)benzyl alcohol; AI3-02402; CCRIS 8464; l-alpha-Hydroxy-beta-methylamino-3-hydroxy-L-ethylbenzene; Phenylephrine HCI; Phenylephrine mixture with Tannins; EINECS 215-810-1; Mydfrin (Salt/Mix); Nostril (Salt/Mix); Prefrin (Salt/Mix); Adrianol (Salt/Mix); Neophryn (Salt/Mix); Biomydrin (Salt/Mix); R-(-)-Phenylephrine; Spectrum_001101; Ak-dilate (Salt/Mix); Ak-nefrin (Salt/Mix); DU5ATO7HYP; Alcon efrin (Salt/Mix); Spectrum2_001280; Spectrum3_000770; Spectrum4_000967; Spectrum5_001411; Lopac-P-6126; EC 200-424-8; Tannins, compds. with (R)-3-hydroxy-alpha-((methylamino)methyl)benzenemethanol; SCHEMBL4711; CHEMBL1215; Lopac0_000920; BSPBio_002420; GTPL485; KBioGR_001313; KBioSS_001581; BIDD:GT0157; DivK1c_000597; SPBio_001280; Benzyl alcohol, m-hydroxy-.alpha.-((methylamino)methyl)-, (-)-; (R)-2-Hydroxy-2-(3-hydroxyphenyl)-N-methylethylamine; component of Entex (Salt/Mix); component of Relief (Salt/Mix); DTXSID9023465; component of Comhist (Salt/Mix); component of Demazin (Salt/Mix); KBio1_000597; KBio2_001581; KBio2_004149; KBio2_006717; KBio3_001640; AB-101 (PHENYLEPHRINE); component of Vasosulf (Salt/Mix); component of Zincfrin (Salt/Mix); NINDS_000597; ZINC113355; component of Cerose dm (Salt/Mix); component of Prefrin-a (Salt/Mix); HY-B0769; component of Cyclomydril (Salt/Mix); ANW-42493; BDBM50067212; MFCD00044749; Neo-Synephrine Pediatric Nasal Drops; PDSP1_001108; PDSP2_001092; component of Decongestant (Salt/Mix); component of Dristan cold (Salt/Mix); Ocu-Phrin Sterile Ophthalmic Solution; AKOS006282042; CCG-205002; CS-6187; DB00388; J8.601K; MCULE-8302708533; SDCCGSBI-0050895.P005; component of Histalet forte (Salt/Mix); component of Ru-tuss liquid (Salt/Mix); IDI1_000597; component of Pv tussin syrup (Salt/Mix); component of Ru-tuss tablets (Salt/Mix); NCGC00015825-01; NCGC00015825-02; NCGC00024257-03; NCGC00024257-05; NCGC00024257-06; NCGC00024257-07; NCGC00024257-19; AM100999; AS-13635; R780; component of Hycomine compound (Salt/Mix); SBI-0050895.P004; AB0018328; component of Dristan nasal mist (Salt/Mix); P0395; 1400-EP2281815A1; 1400-EP2295409A1; 1400-EP2301933A1; 1400-EP2305640A2; 1400-EP2311827A1; 1400-EP2314590A1; 3-[(1R)-1-hydroxy-2-methylaminoethyl]phenol; C07441; D08365; J10016; M-2869; AB00053522_11; AB00053522_12; 044P749; 3-[1-Hydroxy-2-(methylamino)ethyl]phenol, (R)-; A832309; AT-057/40243664; Q421910; 3-[(1R)-2-(methylamino)-1-oxidanyl-ethyl]phenol; Q-201560; (-)-m-Hydroxy-.alpha.-(methylaminomethyl)benzyl alcohol; l-m-Hydroxy-.alpha.-((methylamino)methyl)benzyl alcohol; (R)-3-Hydroxy-.alpha.-[(methylamino)methyl]benzenemethanol; UNII-RH8FKZ05H0 component SONNWYBIRXJNDC-VIFPVBQESA-N; 3-[(1R)-1-Hydroxy-2-(methylamino)ethyl]phenol, AldrichCPR; l-.alpha.-Hydroxy-.beta.-methylamino-3-hydroxy-l-ethylbenzene; (-)- m-Hydroxy-a-[(methylamino)methyl]benzyl alcohol hydrochloride; Benzenemethanol, 3-hydroxy-a-[(methylamino)methyl]-, (.alpha.R)-; Benzenemethanol, 3-hydroxy-alpha-((methylamino)methyl)-, (R)- (9CI); 1228015-39-1	Small molecule	1S/C9H13NO2/c1-10-6-9(12)7-3-2-4-8(11)5-7/h2-5,9-12H,6H2,1H3/t9-/m0/s1	SONNWYBIRXJNDC-VIFPVBQESA-N	CNCC(C1=CC(=CC=C1)O)O	C9H13NO2	CAS 61-76-7	CHEBI:8093	.	.	.	D0O6IU	.	.	.
DR2461	Ganciclovir	CID: 135398740	ganciclovir; 82410-32-0; Cytovene; Gancyclovir; Vitrasert; Zirgan; RS-21592; Ganciclovirum; Cymevene; BW-759U; 2-Amino-9-(((1,3-dihydroxypropan-2-yl)oxy)methyl)-1H-purin-6(9H)-one; Virgan; BW 759U; 2'-NDG; 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine; UNII-P9G3CKZ4P5; 9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine; MFCD00870588; 9-(1,3-DIHYDROXY-PROPOXYMETHANE)GUANINE; GA2; CHEBI:465284; 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-3H-purin-6-one; 9-((1,3-Dihydroxy-2-propoxy)methyl)guanine; Guanine, 9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-; Hydroxyacyclovir; P9G3CKZ4P5; 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-1,9-dihydro-6H-purin-6-one; MLS000028481; 2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol; 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one; Ganciclovir, 98%; NCGC00015471-02; HHEMG; SMR000058324; 2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-1H-purin-6-one; Biolf 62; Ganciclovirum [Latin]; 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol; CAS-82410-32-0; 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one; 2-Amino-9-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)-1,9-dihydro-purin-6-one; 2-amino-9-(2-hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone; DSSTox_CID_21032; DSSTox_RID_79613; DSSTox_GSID_41032; 2'-Nor-2'-deoxyguanosine; BIOLF-62; 9-[[2-Hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine; Citovirax; Cymevan; Cymeven; BW-B 759U; 2-(2-Amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol; DRG-0018; 2-amino-9-(((1,3-dihydroxypropan-2-yl)oxy)methyl)-1,9-dihydro-6H-purin-6-one; Vitrasert (TN); BW 759; Cytovene (TN); CCRIS 9212; HSDB 6512; SR-01000075894; GCV & MSL; Ganciclovir (JAN/USP/INN); 2-amino-9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-1H-purin-6-one; Ganciclovir,(S); 2-Amino-1,9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-6-H-purin-6-one; BW-795; MB3795; Prestwick_1068; ST-605; Zirgan (TN); 6H-Purin-6-one, 2-amino-1,9-dihydro-9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-; GCV & 1110U81; Ganciclovir [USAN:USP:INN:BAN:JAN]; Opera_ID_284; 2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-3H-purin-6-one; Prestwick0_000839; Prestwick1_000839; Prestwick2_000839; Prestwick3_000839; Lopac-G-2536; CHEMBL182; EC 627-054-3; G 2536; SCHEMBL3033; Lopac0_000539; BSPBio_000797; MLS001077349; BIDD:GT0783; SPBio_002718; BPBio1_000877; ZINC1505; DTXSID8041032; methyl)-1H-purin-6(9H)-one; SCHEMBL14491348; BDBM85707; HMS1570H19; HMS2090K08; HMS2097H19; HMS2235C21; HMS3259B13; HMS3261L19; HMS3371H01; HMS3604L19; HMS3655M18; HMS3714H19; Pharmakon1600-01502362; ACT03317; BCP12705; NSC_3454; Tox21_110160; Tox21_500539; ANW-47031; BBL029078; BDBM50237614; NSC759656; PDSP1_000816; PDSP2_000803; s1878; SBB066292; STK801910; STL514515; 2-amino-9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-3H-purin-6-one; AKOS004119898; AKOS026749928; AKOS037492029; Tox21_110160_1; Valganciclovir hydrochloride impurity a; AC-8069; CCG-204629; CS-2014; DB01004; Ganciclovir, >=99% (HPLC), powder; KS-1065; LP00539; MCULE-9512761592; NC00647; NE60398; NSC 759656; NSC-759656; SDCCGSBI-0050522.P002; 2-Amino-1,9-dihydro-9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-6H-purin-6-one; 2-Amino-9-(((1,3-dihydroxypropan-2-yl)oxy)methyl)-6,9-dihydro-1H-purin-6-one; SMP2_000038; NCGC00015471-01; NCGC00015471-03; NCGC00015471-04; NCGC00015471-05; NCGC00015471-06; NCGC00015471-08; NCGC00015471-16; NCGC00093928-01; NCGC00093928-02; NCGC00168567-01; NCGC00188980-01; NCGC00261224-01; 9-(1,3-dihydroxy-2propoxymethyl)guanine; AK-76645; HY-13637; SY027981; 9-(1,3-dihydroxy-2-propoxymethyl)guanine; AB0012496; CAS_82410-32-0; 2-amino-9-((1,3-dihydroxypropan-2-yloxy); 9-(1,3-dihydroxy-2-propoxymethyl)-guanine; EU-0100539; FT-0611007; FT-0668948; G0315; SW197135-3; EN300-49857; A11645; C07019; D00333; J10127; 40034-EP2377510A1; Ganciclovir 100 microg/mL in Acetonitrile:Water; 410G320; 9-[[(1,3-Dihydroxy-2-propyl)oxy]methyl]guanine; A840322; Ganciclovir, Antibiotic for Culture Media Use Only; Q417640; SR-01000721941; Q-201148; SR-01000075894-1; SR-01000075894-4; SR-01000721941-3; Z1259084907; Ganciclovir, European Pharmacopoeia (EP) Reference Standard; 2-[(2-amino-6-hydroxy-9H-purin-9-yl)methoxy]propane-1,3-diol; 2-azanyl-9-[1,3-bis(oxidanyl)propan-2-yloxymethyl]-3H-purin-6-one; Ganciclovir, United States Pharmacopeia (USP) Reference Standard; 2-amino-9-{[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl}hydropurin-6-one; Ganciclovir, Pharmaceutical Secondary Standard; Certified Reference Material; 2-amino-9-{[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl}-1,9-dihydro-6H-purin-6-one; Ganciclovir, 1.0 mg/mL (1% 1M HCl in Methanol), certified reference material; Guanine, 9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)- and MSL, neutralizing monoclonal antibody	Small molecule	1S/C9H13N5O4/c10-9-12-7-6(8(17)13-9)11-3-14(7)4-18-5(1-15)2-16/h3,5,15-16H,1-2,4H2,(H3,10,12,13,17)	IRSCQMHQWWYFCW-UHFFFAOYSA-N	C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N	C9H13N5O4	CAS 82410-32-0	CHEBI:465284	.	.	.	D05ARP	.	.	.
DR2477	Napabucasin	CID: 10331844	Napabucasin; 83280-65-3; BBI608; 2-acetylnaphtho[2,3-b]furan-4,9-dione; 2-Acetylfuro-1,4-naphthoquinone; BBI-608; 2-acetylbenzo[f][1]benzofuran-4,9-dione; UNII-Z1HHM49K7O; BBI 608; 2-Acetylfuranonaphthoquinone; Z1HHM49K7O; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; Napabucasin [USAN:INN]; FNQ; Napabucasin; BBI608; Napabucasin (BBI608); CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; GTPL11358; AMY27812; BCP07628; EX-A1314; BDBM50366597; MFCD28155270; NSC788900; s7977; ZINC13306865; AKOS027470201; ACN-053294; CCG-266871; CS-1747; DB12155; NSC-788900; AC-32935; AK547981; AS-60519; HY-13919; 2-Acetyl-naphtho[2,3-b]furan-4,9-dione; A13474; D10717; Q27294876	Small molecule	1S/C14H8O4/c1-7(15)11-6-10-12(16)8-4-2-3-5-9(8)13(17)14(10)18-11/h2-6H,1H3	DPHUWDIXHNQOSY-UHFFFAOYSA-N	CC(=O)C1=CC2=C(O1)C(=O)C3=CC=CC=C3C2=O	C14H8O4	CAS 83280-65-3	.	.	.	.	D01IGZ	.	.	.
DR2507	Trolox	CID: 40634	trolox; 53188-07-1; 6-Hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid; TROLOX C; 3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-carboxylic acid; 6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid; 2H-1-Benzopyran-2-carboxylic acid, 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-; MFCD00006846; 56305-04-5; CHEBI:82625; (+/-)-6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid; Trolox(R), 97%; 6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromene-2-carboxylic acid; 6-hydroxy-2,5,7,8-tetramethyl-chromane-2-carboxylic acid; EINECS 258-422-8; BRN 5052542; Trolox?; Trolox; Trolox(TM); Prestwick_855; ACMC-20apju; ACMC-1ATBW; Prestwick0_000530; Prestwick1_000530; Prestwick2_000530; Prestwick3_000530; CHEMBL153; SCHEMBL3226; 2H-1-Benzopyran-2-carboxylic acid, 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-, (+-)-; Oprea1_727377; BSPBio_000519; MLS002153860; SPBio_002440; BPBio1_000571; DTXSID60866306; HMS1569J21; HMS2096J21; HMS2230A15; HMS3369E20; HMS3713J21; HMS3885K19; BCP16474; 6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromene-2-carboxylic acid; ANW-31653; BBL103047; BDBM50359629; GEO-03688; s3665; SBB005933; STL556856; 6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid; AKOS015856256; CCG-207912; CS-8035; MCULE-8649288753; NCGC00179534-01; AK116067; AS-30121; SMR001233218; ST057520; DB-052268; DB-071631; HY-101445; FT-0621156; FT-0770514; Q245489; SR-01000841227; SR-01000841227-2; BRD-A17846016-001-03-0; BRD-A17846016-001-07-1; 6-hydroxy-2,5,7,8-tetramethychroman-2-carboxylic acid; 6-Hydroxy-2,5,7,8-tetramethyl-2-chromancarboxylic acid; 6-Hydroxy-2,5,7,8-tetramethyl-2-chromanecarboxylic acid #; 6-Hydroxy-2,5,7,8-tetramethyl-chroman-2-carboxylic acid; (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)carboxylic acid; (+/-)- 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid; (+/-)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid; (+/-)-6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid, 97%; (S)-(-)-6-HYDROXY-2,5,7,8-TETRAMETHYLCHROMAN-2-CARBOXYLICACID; 3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzo-pyran-2-carboxylic Acid; 3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-carboxylic Acid;; 6-hydroxy-3,4-dihydro-2,5,7,8-tetramethyl-2H-1-benzopyran-2-carboxylic acid	Small molecule	1S/C14H18O4/c1-7-8(2)12-10(9(3)11(7)15)5-6-14(4,18-12)13(16)17/h15H,5-6H2,1-4H3,(H,16,17)	GLEVLJDDWXEYCO-UHFFFAOYSA-N	CC1=C(C2=C(CCC(O2)(C)C(=O)O)C(=C1O)C)C	C14H18O4	CAS 53188-07-1	CHEBI:82625	.	.	.	.	.	.	.
DR2520	Dextran sulfate sodium	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR2521	Mevastatin	CID: 64715	Mevastatin; compactin; 73573-88-3; ML-236B; Mevastatina; Mevastatine; Mevastatinum; Mevastatinum [INN-Latin]; Antibiotic ML 236B; CS 500; UNII-1UQM1K0W9X; ML 236 B; 1UQM1K0W9X; CHEMBL54440; [(1S,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate; CHEBI:34848; MFCD05662341; Mevastatin (Compactin); Mevastatin [INN]; Compactin (penicillium); Mevastatine [INN-French]; Mevastatina [INN-Spanish]; (1S,7S,8S,8aR)-8-(2-((2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-7-methyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (S)-2-methylbutanoate; (S)-((1S,7S,8S,8aR)-8-(2-((2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-7-methyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl) 2-methylbutanoate; Butanoic acid, 2-methyl-, (1S,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-7-methyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester, (2S)-; SMR000336944; CCRIS 4505; kompaktin; NCGC00095942-01; EC 700-442-0; SCHEMBL1116; DSSTox_CID_20684; DSSTox_RID_79540; DSSTox_GSID_40684; Lopac0_000754; MLS000721804; MLS000759452; MLS001424284; MLS002207227; GTPL3031; DTXSID4040684; Mevastatin, >=96% (HPLC); HMS2052P07; HMS2089D10; HMS2232N09; HMS3262G10; HMS3268A19; HMS3412H15; HMS3676H15; HMS3713B06; ZINC3833876; Tox21_111540; Tox21_500754; ANW-41687; BDBM50011036; CS-500; NSC779705; s4223; AKOS015994712; Mevastatin, >=95% (HPLC), powder; CCG-101174; CS-1234; DB06693; KS-1085; LP00754; NC00424; NSC 759322; NSC-779705; SDCCGSBI-0050732.P002; 7-(1,2,6,7,8,8a-Hexahydro-2-methyl-8-(2-methylbutyryloxy)naphthyl)-3-hydroxyheptan-5-olide; SMP1_000077; NCGC00025202-04; NCGC00261439-01; (1S,7S,8S,8aR)-8-(2-((2R,4R)-4-Hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-7-methyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl(2S)-2-methylbutanoate; Butanoic acid, 2-methyl-, (1S,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-7-methyl-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, (2S)-; Butanoic acid, 2-methyl-, 1,2,3,7,8,8a-hexahydro-7-methyl-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, (1S-(1-alpha(R*),7-beta,8-beta(2S*,4S*),8a-beta))-; HY-17408; I518; Mevastatin 100 microg/mL in Acetonitrile; AB0013739; CAS-73573-88-3; B1788; EU-0100754; M2275; C13963; M 2537; W-5323; AB00588266-06; AB00588266-08; AB00588266_09; 573M883; Q414407; SR-01000729493; L-637312; SR-01000729493-4; BRD-K94441233-001-03-1; BRD-K94441233-001-17-1; (1S,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-7-methyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate; (S)-((1S,7S,8S,8aR)-8-(2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-2H-pyran-2-yl)ethyl)-7-methyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl) 2-methylbutanoate; (S)-2-Methyl-butyric acid (1S,7S,8S,8aR)-8-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-7-methyl-1,2,3,7,8,8a-hexahydro-naphthalen-1-yl ester; 2-Methyl-butyric acid 8-[2-(4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-7-methyl-1,2,3,7,8,8a-hexahydro-naphthalen-1-yl ester; 2-Methyl-butyric acid 8-[2-(4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-7-methyl-1,2,3,7,8,8a-hexahydro-naphthalen-1-yl ester((+)-compactin); 2-Methyl-butyric acid 8-[2-(4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-7-methyl-1,2,3,7,8,8a-hexahydro-naphthalen-1-yl ester(compactin)	Small molecule	1S/C23H34O5/c1-4-14(2)23(26)28-20-7-5-6-16-9-8-15(3)19(22(16)20)11-10-18-12-17(24)13-21(25)27-18/h6,8-9,14-15,17-20,22,24H,4-5,7,10-13H2,1-3H3/t14-,15-,17+,18+,19-,20-,22-/m0/s1	AJLFOPYRIVGYMJ-INTXDZFKSA-N	CCC(C)C(=O)OC1CCC=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O	C23H34O5	CAS 73573-88-3	CHEBI:34848	.	.	.	D0J9GD	.	.	.
DR2568	Germacrone	CID: 6436348	Germacrone; 6902-91-6; (3E,7E)-3,7-Dimethyl-10-(propan-2-ylidene)cyclodeca-3,7-dienone; Germacron; (3E,7E)-3,7-dimethyl-10-propan-2-ylidenecyclodeca-3,7-dien-1-one; Germacrone,(S); Germacrol (obsol;); Germacrone, analytical standard; SCHEMBL2551615; SCHEMBL14215872; CHEBI:80830; HY-N0440; MFCD00210050; s9311; ZINC31308583; AKOS016009673; CCG-266711; CS-0008961; G0519; N1500; V0249; (E,E)-Germacra-3,7(11),9-trien-6-one; C16966; 902G916; Q-100776; Q15410959; trans,trans-3,7-dimethyl-10-isopropylidene-3,7-cyclodecadien-1-one	Small molecule	1S/C15H22O/c1-11(2)14-9-8-12(3)6-5-7-13(4)10-15(14)16/h7-8H,5-6,9-10H2,1-4H3/b12-8+,13-7+	CAULGCQHVOVVRN-SWZPTJTJSA-N	CC1=CCC(=C(C)C)C(=O)CC(=CCC1)C	C15H22O	CAS 6902-91-6	CHEBI:80830	.	.	.	.	.	.	.
DR2569	Crizotinib	CID: 11626560	Crizotinib; 877399-52-5; Xalkori; PF-02341066; (R)-crizotinib; PF-2341066; PF 2341066; Crizotinib (PF-02341066); 3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-pyridinamine; PF 02341066; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; UNII-53AH36668S; PF2341066; CHEMBL601719; Crizotinib (PF-2341066); CHEBI:64310; 877399-52-5 (free base); 53AH36668S; 3-[(1R)-1-(2,6-DICHLORO-3-FLUOROPHENYL)ETHOXY]-5-[1-(4-PIPERIDINYL)-1H-PYRAZOL-4-YL]PYRIDIN-2-AMINE; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-amine; 3-[(1r)-1-(2,6-Dichloro-3-Fluorophenyl)ethoxy]-5-(1-Piperidin-4-Yl-1h-Pyrazol-4-Yl)pyridin-2-Amine; (R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; Xalkori (TN); C21H22Cl2FN5O; Crizotinib [USAN:INN]; crizotinibum; VGH; PubChem19322; PF02341066; SCHEMBL93829; PF-2341066,Crizotinib; cc-190; Crizotinib (JAN/USAN/INN); PF-2341066(Crizotinib); GTPL4903; QCR-32; Crizotinib, >=98% (HPLC); PF-2341066 (Crizotinib); PF-2341066 - Crizotinib; AOB2688; EX-A096; SYN1139; PF-02341066 (Crizotinib); BCPP000116; DTXSID701009329; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine; AMY10313; ABP000131; ANW-47749; BDBM50306682; MFCD12407409; NSC749005; NSC749769; NSC800080; ZINC35902489; AKOS015901233; AKOS015995207; CCG-264803; DB08865; GS-6178; NSC 756645; NSC-749005; NSC-749769; NSC-800080; PB11015; NCGC00250400-01; NCGC00250400-02; NCGC00250400-09; NCGC00250400-12; 2-Pyridinamine, 3-((1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(4-piperidinyl)-1H-pyrazol-4-yl)-; HY-50878; AB0027203; BB 0261738; SW202555-3; W9013; D09731; Q-3209; 399P525; J-510370; Q5186964; BRD-K78431006-001-01-1; BRD-K78431006-001-03-7; 877399-52-5, 877399-53-6 (acetate); 3-(2,6-dichloro-3-fluorobenzyloxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-am ine; 3-(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy-5-1-(4-piperidinyl)-1H-pyrazol-4-yl-2-Pyridinamine; 3-[(R)-1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine	Small molecule	1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1	KTEIFNKAUNYNJU-GFCCVEGCSA-N	CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N	C21H22Cl2FN5O	CAS 877399-52-5	CHEBI:64310	.	.	.	D03ZBT	.	.	.
DR2599	Vecuronium	CID: 39765	Vecuronium; 86029-43-8; CHEBI:9939; UNII-5438723848; Piperidinium, 1-((2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)-2-(1-piperidinyl)androstan-16-yl)-1-methyl-; 50700-72-6; ORG-NC 45; 1-[(1S,2S,4S,5S,7S,10R,11S,13S,14R,15S)-5,14-bis(acetyloxy)-2,15-dimethyl-4-(piperidin-1-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-13-yl]-1-methylpiperidin-1-ium; NCGC00167467-01; Musculax; Vecuronium cation; Epitope ID:116647; GTPL4002; CHEMBL1201219; DTXSID1044146; SCHEMBL13575838; HMS2090D22; ZINC4097404; BDBM50424713; ORG NC 45 / ORG-NC 45; AKOS025290368; DB01339; MCULE-4520566918; (2beta,3alpha,5alpha,16beta,17beta)-3,17-diacetoxy-16-(1-methylpiperidinium-1-yl)-2-(piperidin-1-yl)androstane; C07553; AB00698366-05; AB00698366-07; AB00698366_08; Q421224; BRD-K20168442-004-06-3	Small molecule	1S/C34H57N2O4/c1-23(37)39-31-20-25-12-13-26-27(34(25,4)22-29(31)35-16-8-6-9-17-35)14-15-33(3)28(26)21-30(32(33)40-24(2)38)36(5)18-10-7-11-19-36/h25-32H,6-22H2,1-5H3/q+1/t25-,26+,27-,28-,29-,30-,31-,32-,33-,34-/m0/s1	BGSZAXLLHYERSY-XQIGCQGXSA-N	CC(=O)OC1CC2CCC3C(C2(CC1N4CCCCC4)C)CCC5(C3CC(C5OC(=O)C)[N+]6(CCCCC6)C)C	C34H57N2O4+	CAS 86029-43-8	CHEBI:9939	.	.	.	D0Z8HG	.	.	.
DR2609	Fenretinide	CID: 5288209	RT-101; ST-602; SYT-101; Fenretinide (pulmonary Pseudomonas aeruginosa infections in cystic fibrosis), McGill University; LXS/4-HPR; Fenretinide (Ewing's sarcoma), Cancer Research UK; Fenretinide (ILE formulation), Children's Hospital LA; Fenretinide (intralipid emulsion formulation), Children's Hospital of Los Angeles; Fenretinide (intravenous, cancer), SciTech Development; Fenretinide (iv), Children's Hospital LA; Fenretinide (oral, AMD), Sytera; Fenretinide (soft gel capsule, AMD), ReVision Therapeutics; Fenretinide (soft gel capsule, AMD), Sirion; Fenretinide (topical, actinic keratosis and cancer), SciTech Development; N-(4-hydroxyphenyl)retinamide; Fenretinide (intravenous emulsion, lymphoma/solid tumors/pediatric neuroblastomas/pediatric leukemia), CerRx; Fenretinide (oral powder/Lym-X-Sorb, neuroblastoma), BioMolecular Products; 4-HPR	Small molecule	1S/C26H33NO2/c1-19(11-16-24-21(3)10-7-17-26(24,4)5)8-6-9-20(2)18-25(29)27-22-12-14-23(28)15-13-22/h6,8-9,11-16,18,28H,7,10,17H2,1-5H3,(H,27,29)/b9-6+,16-11+,19-8+,20-18+	AKJHMTWEGVYYSE-FXILSDISSA-N	CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)NC2=CC=C(C=C2)O)C)C	C26H33NO2	CAS 65646-68-6	.	.	.	.	D08JAC	.	.	.
DR2625	BMS-231974	CID: 10092292	SCHEMBL6813836; SCHEMBL6813842; BMS-231974; 4-[(E)-2-[8-(3,3-dimethylbut-1-ynyl)-5,5,7-trimethyl-6H-naphthalen-2-yl]ethenyl]benzoic Acid	Small molecule	1S/C28H30O2/c1-19-18-28(5,6)25-14-11-21(17-24(25)23(19)15-16-27(2,3)4)8-7-20-9-12-22(13-10-20)26(29)30/h7-14,17H,18H2,1-6H3,(H,29,30)/b8-7+	DQRQOOAPWNLJRO-BQYQJAHWSA-N	CC1=C(C2=C(C=CC(=C2)C=CC3=CC=C(C=C3)C(=O)O)C(C1)(C)C)C#CC(C)(C)C	C28H30O2	.	.	.	.	.	.	.	.	.
DR2632	Vorinostat	CID: 5311	NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)	Small molecule	1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)	WAEXFXRVDQXREF-UHFFFAOYSA-N	C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO	C14H20N2O3	CAS 149647-78-9	.	.	.	.	D0E7PQ	.	.	Vorinostat
DR2639	Venetoclax	CID: 49846579	Venclexta	Small molecule	1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)	LQBVNQSMGBZMKD-UHFFFAOYSA-N	CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C	C45H50ClN7O7S	CAS 1257044-40-8	.	.	.	.	D00PBX	.	.	Venetoclax
DR2724	Sodium selenite	CID: 24934	Disodium selenite; 10102-18-8; Natriumselenit; disodium;selenite; UNII-HIW548RQ3W; MFCD00003489; Selenious acid, sodium salt (1:2); Sodium selenite, anhydrous; HIW548RQ3W; CHEBI:48843; 10102-18-8(disodiumsalt)7782-82-3(monosodiumsalt); Natriumselenit [German]; Selenite sodium; Selenious Acid Disodium Salt; Sodium selenite, 44-46% Se, anhydrous; CCRIS 1260; HSDB 768; EINECS 233-267-9; NA2630; Sodium-selenite; H2-O3-Se.1/2Na; Aselend (TN); Selenious acid, sodium salt (2:1); Sodium Selenite,(S); Sodium selenite (JAN); Sodium selenite anhydrous; EC 233-267-9; DSSTox_CID_12077; DSSTox_RID_78904; DSSTox_GSID_32077; CHEMBL112302; DTXSID0032077; Tox21_202977; AKOS015912461; Sodium selenite [NA2630]  [Poison]; NCGC00260523-01; 14013-56-0; CAS-10102-18-8; D10530; SODIUM SELENITE HIGH PURITY GRADE 100G; Q414626	Small molecule	1S/2Na.H2O3Se/c;;1-4(2)3/h;;(H2,1,2,3)/q2*+1;/p-2	BVTBRVFYZUCAKH-UHFFFAOYSA-L	[O-][Se](=O)[O-].[Na+].[Na+]	Na2O3Se	CAS 10102-18-8	.	.	.	.	.	.	.	.
DR2728	17-beta estradiol	CID: 66795326	Ostradiol.Ostradiol; Beta Estradiol Anhydrate; SCHEMBL772341	Small molecule	1S/2C18H24O2/c2*1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h2*3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t2*14-,15-,16+,17+,18+/m11/s1	DWMXQLDCXDJLRZ-ZFOCPYFBSA-N	CC12CCC3C(C1CCC2O)CCC4=C3C=CC(=C4)O.CC12CCC3C(C1CCC2O)CCC4=C3C=CC(=C4)O	C36H48O4	.	.	.	.	.	.	.	.	.
DR2742	Celecoxib	CID: 2662	CEL; Celebra; Celebrex; Celecox; Celecoxi; Celocoxib; Eurocox; Medicoxib; Onsenal; Solexa; Xilebao; Celecoxib [Old RN]; Celecoxib [USAN]; Pfizer brand of celecoxib; SC 58635; SC58635; YM 177; YM177; AI-525; CEP-33222; Celebra (TN); Celebrex (TN); SC-58635; TPI-336; YM-177; Celebrex, Celebra, Celecoxib; Celecoxib (SC-58635); Celecoxib (JAN/USAN/INN); SC-58553, SC-58635; P-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide; Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl); 4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide	Small molecule	1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)	RZEKVGVHFLEQIL-UHFFFAOYSA-N	CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F	C17H14F3N3O2S	CAS 169590-42-5	CHEBI:41423	.	.	.	D03RTS	.	.	.
DR2744	Deprenyl	CID: 5195	Deprenyl; Deprenil; 2323-36-6; PHENETHYLAMINE, N,alpha-DIMETHYL-N-2-PROPYNYL-; CHEBI:50217; methyl(1-phenylpropan-2-yl)(prop-2-yn-1-yl)amine; (+-)-Deprenyl; Selegilinum [INN-Latin]; Selegilina [INN-Spanish]; dl-Deprenyl; UNII-DPF682Q08V; Selegiline D5; DPF682Q08V; N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine;hydrochloride; (+/-)-Deprenyl; (.+/-.)-Deprenyl; N,alpha-Dimethyl-N-2-propynylphenethylamine; 1,N-Dimethyl-N-propargyl-2-phenylethylamine; N,alpha-Dimethyl-N-2-propynylbenzeneethanamine; CHEMBL8663; SCHEMBL74753; cid_92913; BDBM39862; DTXSID60860142; HMS2089B08; MCULE-3188554308; NCGC00015624-03; NCGC00016708-02; NCGC00162273-01; SBI-0206908.P001; FT-0665904; N,.alpha.-Dimethyl-N-2-propynylphenethylamine; AB00489975_10; DEP_188.1433_10.1; Phenethylamine, N,.alpha.-dimethyl-N-2-propynyl-; Q402633; Benzeneethanamine, N,.alpha.-dimethyl-N-2-propynyl-; BRD-A28545468-003-10-9; N-methyl-N-(1-methyl-2-phenylethyl)prop-2-yn-1-amine; Benzeneethanamine, N,alpha-dimethyl-N-2-propynyl- (9CI); N-Methyl-N-(1-methyl-2-phenylethyl)-2-propyn-1-amine #; methyl-(1-methyl-2-phenyl-ethyl)-propargyl-amine;hydrochloride; N-methyl-1-phenyl-N-prop-2-ynyl-2-propanamine;hydrochloride; N-methyl-1-phenyl-N-prop-2-ynyl-propan-2-amine;hydrochloride; METHYL-(1-METHYL-2-PHENYL-ETHYL)-PROP-2-YNYL-AMINE HYDROCHLORIDE	Small molecule	1S/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3	MEZLKOACVSPNER-UHFFFAOYSA-N	CC(CC1=CC=CC=C1)N(C)CC#C	C13H17N	CAS 2323-36-6	CHEBI:50217	.	.	.	D0Y8AN	.	.	.
DR2755	Penicillin G	CID: 5904	penicillin g; Benzylpenicillin; Benzylpenicillinic acid; Free penicillin II; Pfizerpen; Benzyl penicillin; Bencilpenicilina; Benzylpenicillinum; 61-33-6; Benzylpenicilline; Benzylpenicillin G; 6-(2-Phenylacetamido)penicillanic acid; Free penicillin G; Benzopenicillin; Dropcillin; Gelacillin; Liquacillin; Pharmacillin; Cilopen; Pradupen; Specilline G; Benzylpenicillin potassium; (5R,6R)-Benzylpenicillin; Penicillin, (phenylmethyl)-; Galofak; Free benzylpenicillin; Penicillin-G potassium; Compocillin G; bensylpenicillin; benzyl benicillin; Pfizerpen-AS; Penicillinic acid, (phenylmethyl)-; Phenylacetamidopenicillanic acid; Pencillin G; UNII-Q42T66VG0C; Cilloral; Cosmopen; PENICILLIN-2; CHEBI:18208; Benzyl-6-aminopenicillinic acid; Penicillinic acid, benzyl-; (Phenylmethyl)penicillin; Q42T66VG0C; (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-(2-phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Ursopen; (Phenylmethyl)penicillinic acid; 61-33-6 (FREE ACID); (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-(2-phenylacetamido)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-((phenylacetyl)amino)- (2S-(2alpha,5alpha,6beta))-; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-(phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-(2-phenylacetamido)-; Cillora; PenicillinG; Bencilpenicilina [Spanish]; Benzylpenicilline [French]; Benzylpenicillinum [Latin]; Benzylpenicillin [INN:BAN]; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[(phenylacetyl)amino]- [2S-(2alpha,5alpha,6beta)]-; PNN; SMR000538912; HSDB 3166; EINECS 200-506-3; NSC 193396; BRN 0044740; NSC-193396; J01CE01; Penicillin,(S); 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-(2-phenylacetamido)-; PENICILLIN-G; Spectrum_000933; Benzylpenicillin (INN); CHEMBL29; Prestwick0_001078; Prestwick1_001078; Prestwick2_001078; Prestwick3_001078; Spectrum2_000518; Spectrum3_000542; Spectrum4_000471; Spectrum5_001108; Epitope ID:114070; SCHEMBL3783; BSPBio_001096; BSPBio_002183; KBioGR_000942; KBioSS_001413; 4-27-00-05861 (Beilstein Handbook Reference); 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-((phenylacetyl)amino)-, (2S-(2alpha,5alpha,6beta))-; MLS000766897; MLS001032123; MLS001173382; DivK1c_000316; SPBio_000475; SPBio_002998; BPBio1_001206; GTPL4796; DTXSID5046934; KBio1_000316; KBio2_001413; KBio2_003981; KBio2_006549; KBio3_001683; NINDS_000316; HMS2875L09; ZINC3871701; BDBM50022787; Phenylacetyl-6-aminopenicillanic acid; AKOS005203091; DB01053; IDI1_000316; NCGC00159348-02; NCGC00159348-03; (2S,5R,6R)-3,3-DIMETHYL-7-OXO-6-[(PHENYLACETYL)AMINO]-4-THIA-1-AZABICYCLO[3.2.0]HEPTANE-2-CARBOXYLIC ACID; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6- (2-phenylacetamido)-; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[(phenylacetyl)amino]- (2S,5R,6R)-; SBI-0051476.P003; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-; Bicillin (*Benzathine Salt, Tetrahydrate*); C05551; D02336; (2-phenylacetamido)-4-thia-1-azabicyclo[3.2.0]; 061P336; Q258450; W-109262; BRD-K55191674-236-03-7; BRD-K55191674-237-02-7; BRD-K55191674-237-12-6; Benzylpenicillin, Antibiotic for Culture Media Use Only; 2,2-dimethyl-6beta-(phenylacetamido)penam-3alpha-carboxylic acid; (+)-3,3-Dimethyl-7-oxo-6-phenylacetylamino-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid(penicillin G); (2S,5R,6R)-3,3-dimethyl-7-oxo-6-(2-phenylacetamido)-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-phenylacetylamino-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid; 3,3-Dimethyl-7-oxo-6-phenylacetylamino-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid; 3,3-Dimethyl-7-oxo-6-phenylacetylamino-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid anion (Penicillin G); 3,3-Dimethyl-7-oxo-6-phenylacetylamino-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid(penicillin G); 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-(2-phenylacetamido)- (8CI); 4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[(phenylacetyl)amino]-, (2S,5R,6R)-	Small molecule	1S/C16H18N2O4S/c1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22)/t11-,12+,14-/m1/s1	JGSARLDLIJGVTE-MBNYWOFBSA-N	CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C	C16H18N2O4S	CAS 61-33-6	CHEBI:18208	.	.	.	D00QAR	.	.	.
DR2765	AT101	CID: 227456	Gossypol acetic acid; gossypol-Acetic acid; 12542-36-8; Gossypol acetate; Acetate gossypol; 866541-93-7; Gossypol (acetic acid); (-)-Gossypol acetic acid; GOSSYPOL-ACETIC ACID COMPLEX; AT101; 5453-04-3; (S)-Gossypol (acetic acid); NSC 19048; 1189561-66-7; Gossypol acetic acid clathrate; MLS000028630; MLS002702979; NSC19048; SMR000058743; 12542-36-8 (ACETIC ACID); acetic acid compound with (S)-1,1',6,6',7,7'-hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-[2,2'-binaphthalene]-8,8'-dicarbaldehyde (1:1); acetic acid;7-(8-formyl-1,6,7-trihydroxy-3-methyl-5-propan-2-ylnaphthalen-2-yl)-2,3,8-trihydroxy-6-methyl-4-propan-2-ylnaphthalene-1-carbaldehyde; (+/-)-Gossypol-acetic acid;BL 193 (acetic acid); (R)-Gossypol acetic acid; (S)-Gossypol acetic acid; NSC-19048; Gossypol acetate, (R)-; UNII-U9GNI6VT5N; Gossypol acetic acid, R-; AT-101 (acetic acid); R-(-)-gossypol acetic acid; Gossypol acetic acid, (R)-; Acetate-gossypol; Aceticacidgossypol; Gossypol xAcetate; Gossypol AcOH Salt; GOSSYPOLACETATE; AT 101 acetic acid; Opera_ID_1014; U9GNI6VT5N; SCHEMBL352576; (R)-Gossypol acetic acid salt; (S)-Gossypol acetic acid salt; CHEMBL1516388; HMS500I15; DTXSID90921593; HMS3651H13; BCP09006; BCP24040; C32H34O10; CCG-39212; CG0045; MFCD00058385; NSC727858; s2303; s2812; AKOS022188380; AT-101 (AT101); NSC-727858; NCGC00178279-01; (2,2'-Binaphthalene)-8,8'-dicarboxaldehyde, 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-(R)-5,5'-bis(1-methylethyl)-, (2R)-, compd. with acetic acid (1:1); AS-15487; HY-17510; P562; AB0017083; DB-081879; FT-0686636; FT-0768953; N2134; SW197103-3; A13578; A14795; A16323; 542G368; A800636; J-005228; (+/-)-Gossypol-acetic acid, analytical standard, crystalline complex consisting of equimolar quantities of gossypol and acetic acid, ~95%; 115038-46-5; 732279-26-4; acetic acid compound with 1,1',6,6',7,7'-hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-2,2'-binaphthyl-8,8'-dicarbaldehyde (1:1); Acetic acid--1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-di(propan-2-yl)[2,2'-binaphthalene]-8,8'-dicarbaldehyde (1/1); acetic acid; 7-(8-formyl-1,6,7-trihydroxy-3-methyl-5-propan-2-yl-2-naphthalenyl)-2,3,8-trihydroxy-6-methyl-4-propan-2-yl-1-naphthalenecarboxaldehyde; AT 101 acetic acid; AT101 acetic acid;AT-101 acetic acid; (-)-Gossypol acetic acid; (R)-Gossypol acetic acid; Gossypol acetic acid; ethanoic acid; 7-[8-methanoyl-3-methyl-1,6,7-tris(oxidanyl)-5-propan-2-yl-naphthalen-2-yl]-6-methyl-2,3,8-tris(oxidanyl)-4-propan-2-yl-naphthalene-1-carbaldehyde	Small molecule	1S/C30H30O8.C2H4O2/c1-11(2)19-15-7-13(5)21(27(35)23(15)17(9-31)25(33)29(19)37)22-14(6)8-16-20(12(3)4)30(38)26(34)18(10-32)24(16)28(22)36;1-2(3)4/h7-12,33-38H,1-6H3;1H3,(H,3,4)	NIOHNDKHQHVLKA-UHFFFAOYSA-N	CC1=CC2=C(C(=C(C(=C2C(C)C)O)O)C=O)C(=C1C3=C(C4=C(C=C3C)C(=C(C(=C4C=O)O)O)C(C)C)O)O.CC(=O)O	C32H34O10	CAS 866541-93-7	.	.	.	.	.	.	.	.
DR2770	Arsenite	.	.	.	.	.	.	.	.	.	.	.	.	D0X8KC	.	.	.
DR2806	Bacillus Calmette-Guerin	CID: 6451	Bromocresol green; 76-60-8; BROMCRESOL GREEN; bromo cresol green; 3,3-Bis(3,5-dibromo-4-hydroxy-2-methylphenyl)-3H-benzo[c][1,2]oxathiole 1,1-dioxide; Tetrabromo-m-cresolphthalein sulfone; 3',3'',5',5''-Tetrabromo-m-cresolsulfonephthalein; Bromocresol blue; NSC 7817; UNII-8YGN0Y942M; EINECS 200-972-8; BRN 0372527; CHEMBL145704; 8YGN0Y942M; Bromocresol Green, ACS reagent; NSC7817; FRPHFZCDPYBUAU-UHFFFAOYSA-N; MFCD00005874; o-Toluenesulfonic acid, alpha-hydroxy-, gamma-sultone; BROMOCRESOL GREEN, ACS; Phenol, 4,4'-(3H-2,1-benzox	Small molecule	1S/C21H14Br4O5S/c1-9-12(7-14(22)19(26)17(9)24)21(13-8-15(23)20(27)18(25)10(13)2)11-5-3-4-6-16(11)31(28,29)30-21/h3-8,26-27H,1-2H3	FRPHFZCDPYBUAU-UHFFFAOYSA-N	CC1=C(C(=C(C=C1C2(C3=CC=CC=C3S(=O)(=O)O2)C4=CC(=C(C(=C4C)Br)O)Br)Br)O)Br	C21H14Br4O5S	CAS 76-60-8	.	.	.	.	D0KO9R	.	.	.
DR2819	Hydrochlorothiazide	CID: 3639	hydrochlorothiazide; 58-93-5; HCTZ; Esidrix; Hypothiazide; Oretic; Dichlotiazid; Hidrotiazida; Hydrochlorothiazid; Hydrochlorthiazide; Hydrodiuretic; Hydrosaluric; Servithiazid; Aquarills; Aquarius; Dichlotride; Diclotride; Disalunil; Hypothiazid; Idrotiazide; Maschitt; Megadiuril; Newtolide; Thiuretic; Vetidrex; Drenol; Esidrex; Hidril; Hydril; Nefrix; Chlorosulthiadil; Hidrochlortiazid; Hydro-Diuril; Hydro-Aquil; Dihydrochlorothiazide; Jen-Diril; HydroDIURIL; Dihydrochlorothiazid; Dihydrochlorothiazidum; Apresazide; Carozide; Chlorzide; Dichlorosal; Hidroronol; Hydrothide; Hydrozide; Moduretic; Neoflumen; Urodiazin; Bremil; Cidrex; Diaqua; Direma; Dyazide; Fluvin; Ivaugan; Panurin; Ro-hydrazide; Neo-codema; Acuretic; Caplaril; Hydrocot; Microzide; Thlaretic; Timolide; Aquazide H; Lotensin HCT; 6-Chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3,4-Dihydrochlorothiazide; Thiaretic; Vaseretic; Ziac; Zide; Apo-Hydro; Lopressor HCT; Hydro-D; Hydrochlorothiazidum; Unipres; Dihydrochlorurit; Dihydrochlorurite; Hidroclorotiazida; Su 5879; Aldactazide; Inderide; Maxzide; Prinzide; Hydrochlorothiazide Intensol; NCI-C55925; component of Cyclex; component of Esimil; Esidrix (TN); Ser-Ap-Es; C7H8ClN3O4S2; component of Aldoril; component of Dyazide; component of Caplaril; HCZ; Chlorsulfonamidodihydrobenzothiadiazine dioxide; component of Aldactazide; UNII-0J48LPH2TH; component of Butizide Prestabs; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-, 1,1-dioxide; Dichlothiazide; MFCD00051765; Diu-melusin; 0J48LPH2TH; 6-chloro-1,1-dioxo-3,4-dihydro-2H-1$l^{6},2,4-benzothiadiazine-7-sulfonamide; 6-Chloro-3,4-dihydro-(2H)-1,2,4-benzothiadiazine-7-sulfonamide 1,1-Dioxide; MLS000069619; CHEBI:5778; Chlorizide; Disothiazid; Hidrosaluretil; Novodiurex; Spironazide; Acesistem; Acuilix; Aldazida; Briazide; Catiazida; Chlothia; Clorana; Condiuren; Dihydran; Diurogen; Dixidrasi; Esoidrina; H.H. 25/25; H.H. 50/50; Hyclosid; Indroclor; Manuril; Medozide; Mictrin; Mikorten; Modurcen; Natrinax; Pantemon; Saldiuril; Selozide; Tandiur; Urozide; Didral; Hytrid; Nefrol; Unazid; Hidro-Niagrin; Hydro-Saluric; Raunova Plus; 3,4-Dihydro-6-chloro-7-sulfamyl-1,2,4-benzothiadiazine-1,1-dioxide; 6-Chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; Concor Plus; Aquazide-H; Neo-Flumen; Neo-Minzil; 6-Chloro-3,4-dihydro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-Chloro-7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide; Hydro Par; NSC53477; Hydro-T; Hydrochlorthiazidum; NSC-53477; HCT; HCT-Isis; CAS-58-93-5; Mazide 25 mg; NCGC00015508-08; Hydrochlorat; Hydrochlorot; SMR000035778; Idroclorotiazide; Diu 25 Vigt; Hydrex-semi; Aldactazide 25/25; Aldectazide 50/50; Dihydroxychlorothiazidum; DSSTox_CID_713; Inderide 80/25; Hydrochlorothiazide form II; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-,1,1-dioxide; 6-chloro-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide; 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide-1,1-dioxide; 6-chloro-3,4-dihydro-2H-benzo[e][1,2,4]thiadiazine-7-sulfonamide 1,1-dioxide; Idroclorotiazide [DCIT]; DSSTox_RID_75752; DSSTox_GSID_20713; Hydrochlorzide; Ezide; Hydrozide Injection, Veterinary; Hidroclorotiazida [INN-Spanish]; Hydrochlorothiazidum [INN-Latin]; 6-Chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide; 6-chloro-1,1-dioxo-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide; Microzide (TN); CCRIS 2082; HSDB 3096; SR-01000000119; EINECS 200-403-3; NSC 53477; BRN 0625101; Hydrokraft; Idrodiuvis; Aquazide; Manschitt; Urirex; HydroPar; 6-chloro-1,1-dioxo-2H,3H,4H-benzo[e]1,2,4-thiadiazine-7-sulfonamide; 6-chloro-1,1-dioxo-3,4-dihydro-2H-1?^{6},2,4-benzothiadiazine-7-sulfonamide; Prestwick_263; Hydrochloro Thiazide; Hyzaar (Salt/Mix); Aldoril (Salt/Mix); Dutoprol (Salt/Mix); Inderide (Salt/Mix); Prinzide (Salt/Mix); Accuretic (Salt/Mix); Hydropres (Salt/Mix); Thiazide, hydrochloro-; Hydrochlorothiazide [USP:INN:BAN:JAN]; Spectrum_000877; Opera_ID_168; Maybridge1_004336; Prestwick0_000009; Prestwick1_000009; Prestwick2_000009; Prestwick3_000009; Spectrum2_001040; Spectrum3_000456; Spectrum4_000006; Spectrum5_000824; Lopac-H-4759; CHEMBL435; Tekturna HCT (Salt/Mix); 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-, 1, 1-dioxide; H 4759; cid_3639; SCHEMBL9349; Hydrochlorothiazide-13C-d2; Lopac0_000614; Oprea1_357174; BSPBio_000017; BSPBio_002132; KBioGR_000351; KBioSS_001357; AF-614/30832002; ARONIS24316; BIDD:GT0153; DivK1c_000289; SPECTRUM1500335; BMCL182567 Compound 6a; SPBio_001259; SPBio_001938; BPBio1_000019; GTPL4836; Hydrochlorothiazide, crystalline; DTXSID2020713; BDBM13076; component of Dyazide (Salt/Mix); HMS500O11; HMS553N04; KBio1_000289; KBio2_001357; KBio2_003925; KBio2_006493; KBio3_001352; component of Caplaril (Salt/Mix); NINDS_000289; HMS1568A19; HMS1920D19; HMS2091L05; HMS2095A19; HMS2235I09; HMS3259O17; HMS3261L10; HMS3370P11; HMS3428A05; HMS3655M21; HMS3712A19; Pharmakon1600-01500335; ZINC896569; BCP22001; EBD18905; HY-B0252; JFD00715; Tox21_110165; Tox21_201565; Tox21_300292; Tox21_500614; 3,4-dihydro-6-chloro-7-sulfamoyl-1,2,4-benzothiadiazine-1,1-dioxide; CCG-40240; NSC757059; s1708; SBB056984; STK315354; 3,2,4-benzothiadiazine-1,1-dioxide; Hydrochlorothiazide (JP17/USP/INN); AKOS000121373; Tox21_110165_1; AC-8114; DB00999; LP00614; MCULE-6585933943; NC00510; NSC-757059; PS-3162; SDCCGSBI-0050596.P005; SU-5879; IDI1_000289; WLN: T66 BSWM EM DHJ HG ISZW; NCGC00015508-01; NCGC00015508-02; NCGC00015508-03; NCGC00015508-04; NCGC00015508-05; NCGC00015508-06; NCGC00015508-07; NCGC00015508-09; NCGC00015508-10; NCGC00015508-11; NCGC00015508-12; NCGC00015508-13; NCGC00015508-14; NCGC00015508-16; NCGC00015508-17; NCGC00015508-25; NCGC00021906-03; NCGC00021906-04; NCGC00021906-05; NCGC00021906-06; NCGC00021906-07; NCGC00021906-08; NCGC00254017-01; NCGC00259114-01; NCGC00261299-01; NCI60_004317; ST033548; component of Butizide Prestabs (Salt/Mix); Hydrochlorothiazide 1.0 mg/ml in Methanol; SBI-0050596.P004; AB00052012; EU-0100614; FT-0650564; SW196569-3; 6-Chloro-3,2,4-benzothiadiazine 1,1-dioxide; A19550; C07041; D00340; J10079; AB00052012-15; AB00052012_16; AB00052012_17; 051H765; Hydrochlorothiazide 100 microg/mL in Acetonitrile; Q423930; Hydrochlorothiazide, meets USP testing specifications; Q-201210; SR-01000000119-2; SR-01000000119-4; SR-01000000119-6; BRD-K13078532-001-05-2; Z56347248; 6-Chloro-3,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-7-sulfamoyl-3,2,4-benzothiadiazine 1,1-dioxide; Hydrochlorothiazide, drug standard, 1.0 mg/mL in methanol; 6-chloro-3,4-dihydro-1,1-dioxo-7-sulfamoyl-1,2,4-benzothiadiazine; Hydrochlorothiazide, British Pharmacopoeia (BP) Reference Standard; Hydrochlorothiazide, European Pharmacopoeia (EP) Reference Standard; 3,4-Dihydro-6-chloro-7-sulfamyl-1,2, 4-benzothiadiazine-1,1-dioxide; 6-chloro-3,4-dihydro-2h-1,2,4-benzothiadiazine-7-sulphonamide-1,1-dioxide; 6-Chloro-3,4-dihydro-7-sulfamoyl-2H-1,2, 4-benzothiadiazine 1,1-dioxide; 6-Chloro-7-sulfamoyl-3, 4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-Chloro-7-sulfamoyl-3,4-dihydro-(2H)-1,2,4-benzothiadiazine 1,1-Dioxide; 6-Chloro-7-sulfamoyl-3,4-dihydrobenzo-1,2,4-thiadiazine-1,1-dioxide; Hydrochlorothiazide, United States Pharmacopeia (USP) Reference Standard; 2H-1,2, 4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-, 1, 1-dioxide; 2H-1,2,4-Benzothiadiazine, 6-chloro-3,4-dihydro-7-sulfamoyl-2, 1,1-dioxide; 2H-1,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-, 1,1-dioxide; 6-chloro-1,1-dioxo-1,2,3,4-tetrahydro-1lambda,2,4-benzothiadiazine-7-sulfonamide; 6-chloro-1,1-dioxo-3,4-dihydro-2H-1$l^{6,2,4-benzothiadiazine-7-sulfonamide; 6-Chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1, 1-dioxide; 7-(Aminosulfonyl)-6-chloro-3,4-dihydro-(2H)-1,2,4-benzothiadiazine 1,1-Dioxide; Hydrochlorothiazide for peak identification, European Pharmacopoeia (EP) Reference Standard; Hydrochlorothiazide, Pharmaceutical Secondary Standard; Certified Reference Material; 125727-50-6; 3,4-Dihydro-6-chloro-7-sulfamoyl-1,2,4-benzothiadiazine-1,1-dioxide; 6-Chloro-3,4-dihydro-7-sulfamoyl-2H-1,2,4-benzothiadiazine-1,1-dioxide; 3,4-Dihydrochlorothiazide; Hydrochlorothiazide solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material	Small molecule	1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)	JZUFKLXOESDKRF-UHFFFAOYSA-N	C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl	C7H8ClN3O4S2	CAS 58-93-5	CHEBI:5778	.	.	.	D0U4UQ	.	.	.
DR2830	Rev-caspase-3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR2851	Telbivudine	CID: 159269	Telbivudine; Epavudine; 2'-Deoxy-L-thymidine; L-Thymidine; beta-L-Thymidine; 3424-98-4; Telbivudin; Tyzeka; L-dT; L-Deoxythymidine; Sebivo; NV-02B; LDT600; beta-L-2'-Deoxythymidine; LdT; NV 02B; UNII-2OC4HKD3SF; CHEBI:63624; LDT-600; 1-(2-Deoxy-beta-L-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione; 2OC4HKD3SF; 26879-47-0; 1-((2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; 1-(2-deoxy-beta-L-ribofuranosyl)-5-methyluracil; MFCD02683612; 1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione; LLT; Tyzeka (TN); Telbivudine (USAN/INN); Telbivudine [USAN:INN:BAN]; 5-methyl-l-uridine; b-L-2'-deoxy-thymidine; SCHEMBL124279; Telbivudine (Sebivo, Tyzeka); CHEMBL374731; Epavudine;L-Thymidine;NV 02B; Thymine, 1-(2-deoxy-beta-L-erythro-pentofuranosyl)-; ZINC2159; Telbivudine, >=98% (HPLC); DTXSID30187813; AMY23971; HY-B0017; BDBM50088372; s1651; AKOS025117349; AC-5632; CCG-266887; CS-1934; DB01265; SB20806; 1-(2-Deoxy-beta-L-erythro-pentofuranosyl)-5-methyl-2,4(1H,3H)-Pyrimidinedione; 2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy-b-L-erythro-pentofuranosyl)-5-methyl-; 2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy-beta-L-erythro-pentofuranosyl)-5-methyl-; NCGC00346560-01; NCGC00346560-06; 1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione; AS-35209; SW220236-1; D06675; AB01274717-01; AB01274717_02; Q413621; BRD-K15976406-001-01-7; Thymine, 1-(2-deoxy-.beta.-L-erythro-pentofuranosyl)-; Z2574360267; 1-[(2s,4r,5s)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-pyrimidine-2,4-dione; 1-((2S,4S,5S)-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; L-thymidine; beta-L-thymidine; L-dT; 2'-deoxy-L-thymidine; 1-(2-deoxy-beta-L-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione	Small molecule	1S/C10H14N2O5/c1-5-3-12(10(16)11-9(5)15)8-2-6(14)7(4-13)17-8/h3,6-8,13-14H,2,4H2,1H3,(H,11,15,16)/t6-,7+,8+/m1/s1	IQFYYKKMVGJFEH-CSMHCCOUSA-N	CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)O	C10H14N2O5	CAS 3424-98-4	CHEBI:63624	.	.	.	D0CL9S	.	.	.
DR2863	Procarbazine	CID: 4915	procarbazine; 671-16-9; Procarbazin; Ibenzmethyzin; Natulan; Ibenzmethyzine; Procarbazin [German]; Procarbazina; Procarbazinum; Procarbazinum [INN-Latin]; Procarbazina [INN-Spanish]; N-Isopropyl-4-((2-methylhydrazinyl)methyl)benzamide; 2-(p-Isopropylcarbamoylbenzyl)-1-methylhydrazine; p-(2-Methylhydrazinomethyl)-N-isopropylbenzamide; 1-Methyl-2-(p-(isopropylcarbamoyl)benzyl)hydrazine; 4-((2-Methylhydrazino)methyl)-N-isopropylbenzamide; Benzamide, N-(1-methylethyl)-4-[(2-methylhydrazino)methyl]-; Ro 4-6467; N-4-Isopropylcarbamoylbenzyl-N'-methylhydrazine; N-(1-Methylethyl)-4-((2-methylhydrazino)methyl)benzamide; N-Isopropyl-p-(2-methylhydrazinomethyl)-benzamide; N-Isopropyl-alpha-(2-methylhydrazino)-p-toluamide; N-Isopropyl-4-[(2-methylhydrazino)methyl]benzamide; CB 400-497; MIH; Procarbazine free base; UNII-35S93Y190K; 4-[(2-methylhydrazinyl)methyl]-N-propan-2-ylbenzamide; N-(1-Methylethyl)-4-[(2-methylhydrazino)methyl]benzamide; PCX; Ro 4-6467/1; 671-16-9 (free base); Benzamide, N-(1-methylethyl)-4-((2-methylhydrazino)methyl)-; CHEBI:71417; 35S93Y190K; CB 400-497; Ibenzmethyzine; MIH; p-Toluamide, N-isopropyl-.alpha.-(2-methylhydrazino)-; Procarbazine [INN:BAN]; 4-[(2-methylhydrazin-1-yl)methyl]-N-(propan-2-yl)benzamide; Procarbazine (INN); CCRIS 2389; HSDB 3250; NCGC00016438-01; Ro-4646711; CAS-366-70-1; EINECS 211-582-2; p-(N'-Methylhydrazinomethyl)-N-isopropylbenzamide; BRN 0958270; SR-01000763375; Procarbazine-[d3]; p-Toluamide, N-isopropyl-alpha-(2-methylhydrazino)-; SRI-10847; MBH (Salt/Mix); Matulane (Salt/Mix); Nathulane (Salt/Mix); Natunalar (Salt/Mix); Prestwick0_001112; Prestwick1_001112; Prestwick2_001112; Prestwick3_001112; DSSTox_CID_1189; SCHEMBL4656; CHEMBL1321; DSSTox_RID_75999; NCIOpen2_004074; DSSTox_GSID_21189; BSPBio_001244; BIDD:GT0183; SPBio_003112; BPBio1_001369; GTPL7278; DTXSID4021189; 4-[(2-methylhydrazinyl)methyl]-N-(propan-2-yl)benzamide; HMS2090J09; Pharmakon1600-01502326; RO-4-6467 FREE BASE; BCP12198; Tox21_301738; 0319AC; NSC759626; STL483417; ZINC19166988; AKOS015891211; AC-4547; CCG-213031; DB01168; MCULE-9065058360; NSC-759626; NCGC00016438-02; NCGC00016438-05; NCGC00255280-01; CAS-671-16-9; NCI60_041703; Ro-4-6467/1; SRI-10847-09; SRI-10847-10; SRI-10847_11; SRI-10847_13; DB-082065; RO-4-6467; FT-0737820; C07402; D08423; 671P169; Q418656; N-Isopropyl-.alpha.-(2-methylhydrazino)-p-toluamide; SR-01000763375-3; N-Isopropyl-4-[(2-methylhydrazino)methyl]benzamide #; Benzamide, N-(1-methylethyl)-4-((2-methylhydrazino)methyl)- (9CI)	Small molecule	1S/C12H19N3O/c1-9(2)15-12(16)11-6-4-10(5-7-11)8-14-13-3/h4-7,9,13-14H,8H2,1-3H3,(H,15,16)	CPTBDICYNRMXFX-UHFFFAOYSA-N	CC(C)NC(=O)C1=CC=C(C=C1)CNNC	C12H19N3O	CAS 671-16-9	CHEBI:71417	.	.	.	D08GYO	.	.	.
DR2875	Hydrocinchonine	CID: 11630759	Hydrocinchonine; 485-65-4; Dihydrocinchonine; (1S)-((2R,4S,5R)-5-Ethylquinuclidin-2-yl)(quinolin-4-yl)methanol; UNII-ZPF9J31NM8; (+)-hydrocinchonine; TCMDC-125880; ZPF9J31NM8; (9S)-10,11-Dihydrocinchonan-9-ol; (S)-[(2R,4S,5R)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]-quinolin-4-ylmethanol; EINECS 207-621-8; (+)-Dihydrocinchonine; SCHEMBL192607; CHEMBL548921; DTXSID30878431; CHEBI:174145; 6625AB; ZINC13826669; AC-30195; (+)-Dihydrocinchonine, analytical standard; Q27295839; Hydrocinchonine, >=95.0% (sum of enantiomers, HPLC); (S)-((2R,4S,5R)-5-ethylquinuclidin-2-yl)(quinolin-4-yl)methanol	Small molecule	1S/C19H24N2O/c1-2-13-12-21-10-8-14(13)11-18(21)19(22)16-7-9-20-17-6-4-3-5-15(16)17/h3-7,9,13-14,18-19,22H,2,8,10-12H2,1H3/t13-,14-,18+,19-/m0/s1	WFJNHVWTKZUUTR-QAMTZSDWSA-N	CCC1CN2CCC1CC2C(C3=CC=NC4=CC=CC=C34)O	C19H24N2O	CAS 485-65-4	CHEBI:174145	.	.	.	.	.	.	.
DR2889	Tolfenamic acid	CID: 610479	Clotam; Tolfedine; 2-[(3-Chloro-2-methylphenyl)amino]benzoic Acid; N-(3-Chloro-2-methylphenyl)anthranilic acid; GEA 6414; Acido tolfenamico; Acide tolfenamique; Acidum tolfenamicum; 2-((3-Chloro-2-methylphenyl)amino)benzoic acid; 2-(3-Chloro-2-methylanilino)benzoic acid; N-(2-Methyl-3-chlorophenyl)anthranilic acid; UNII-3G943U18KM; N-(3-Chloro-o-tolyl)-anthranilic acid; Benzoic acid, 2-[(3-chloro-2-methylphenyl)amino]-; Anthranilic acid, N-(3-chloro-o-tolyl)-; N-(3-Chloro-ortho-tolyl) anthranilic acid; CHEBI:32243; 3G943U18KM; NCGC00016705-05; Bifenac; CAS-13710-19-5; DSSTox_CID_25409; DSSTox_RID_80860; DSSTox_GSID_45409; Tolfine; tolfenamic-acid; 2-([3-Chloro-2-methylphenyl]amino)benzoic acid; SR-01000000102; N-(3-Chloro-o-tolyl)anthranilic acid; Tolfenamic; Acide tolfenamique [INN-French]; Acido tolfenamico [INN-Spanish]; Acidum tolfenamicum [INN-Latin]; Tolfenamic acid [INN:BAN:JAN]; Prestwick_579; EINECS 237-264-3; Clotam (TN); TOLFENAMICACID; BRN 0657821; Spectrum_001263; ACMC-209cat; Tolfenamic Acid-13C6; Tolfenamic acid, NSAID; Prestwick0_000205; Prestwick1_000205; Prestwick2_000205; Prestwick3_000205; Spectrum2_001446; Spectrum3_001762; Spectrum4_000238; Spectrum5_001143; Oprea1_692996; SCHEMBL25190; Tolfenamic acid (JAN/INN); BSPBio_000189; BSPBio_003223; KBioGR_000935; KBioSS_001743; flufenamic acid analogue, 32; MLS000028531; BIDD:GT0343; SPECTRUM1501198; SPBio_001311; SPBio_002110; BPBio1_000209; CHEMBL121626; cid_610479; GTPL8769; ZINC2188; DTXSID1045409; BDBM35905; KBio2_001743; KBio2_004311; KBio2_006879; KBio3_002723; YEZNLOUZAIOMLT-UHFFFAOYSA-; HMS1568J11; HMS1921P13; HMS2090D04; HMS2095J11; HMS2230J13; HMS3370A02; HMS3651E06; HMS3712J11; HMS3884M16; Pharmakon1600-01501198; HY-B0335; Tox21_110570; ANW-20211; CCG-39189; MFCD00133865; NSC757873; s1959; SBB058187; AKOS012836098; Tox21_110570_1; 2-(3-Chloro-o-toluidino)benzoic Acid; DB09216; MCULE-9901889833; NSC-757873; 2(3-Chloro-2-methylanilino)benzoic acid; NCGC00016705-01; NCGC00016705-02; NCGC00016705-03; NCGC00016705-04; NCGC00016705-06; NCGC00016705-07; NCGC00016705-10; NCGC00022587-03; NCGC00022587-04; NCGC00022587-05; AK305709; AS-13748; DA-11289; n-(3-chloro-ortho-tolyl)anthranilic acid; SMR000058289; SBI-0051687.P002; AB0032595; 2-(3-Chloro-2-methylanilino)benzoic acid #; AB00052244; FT-0652603; ST51015128; SW196753-3; UNM000001237003; X5948; 2-(3-chloro-2-methylphenylamino)benzoic acid; D01183; J10240; Q59412; AB00052244-15; AB00052244_16; AB00052244_17; A807198; Benzoic acid, 2-(3-chloro-2-methylphenylamino)-; 2-[(3-chloranyl-2-methyl-phenyl)amino]benzoic acid; J-006962; SR-01000000102-2; SR-01000000102-3; Tolfenamic acid, VETRANAL(TM), analytical standard; BRD-K50133271-001-05-4; BRD-K50133271-001-10-4; Benzoic acid, 2-((3-chloro-2-methylphenyl)amino)- (9CI); Tolfenamic acid, European Pharmacopoeia (EP) Reference Standard; Tolfenamic Acid, Pharmaceutical Secondary Standard; Certified Reference Material	Small molecule	1S/C14H12ClNO2/c1-9-11(15)6-4-8-12(9)16-13-7-3-2-5-10(13)14(17)18/h2-8,16H,1H3,(H,17,18)	YEZNLOUZAIOMLT-UHFFFAOYSA-N	CC1=C(C=CC=C1Cl)NC2=CC=CC=C2C(=O)O	C14H12ClNO2	CAS 13710-19-5	.	.	.	.	.	.	.	.
DR2911	Lidocaine	CID: 3676	lidocaine; 137-58-6; Lignocaine; Xylocaine; 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide; Lidoderm; Anestacon; Esracaine; Duncaine; Alphacaine; Cappicaine; Gravocain; Isicaina; L-Caine; Leostesin; Maricaine; Xylocain; Xylocitin; Solcain; Isicaine; Xylestesin; Rucaina; Xilina; Xycaine; Xylotox; Cito optadren; Lida-Mantle; Dalcaine; 2-(Diethylamino)-2',6'-acetoxylidide; Xyloneural (free base); Cuivasil; Jetocaine; Remicaine; Xilocaina; 2-Diethylamino-N-(2,6-dimethylphenyl)acetamide; Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)-; Diethylaminoaceto-2,6-xylidide; ELA-Max; 2',6'-Acetoxylidide, 2-(diethylamino)-; alpha-Diethylamino-2,6-dimethylacetanilide; Lidocaton; alfa-Dietilamino-2,6-dimetilacetanilide; CHEBI:6456; UNII-98PI200987; Xylocaine (TN); CHEMBL79; LIDOPEN; N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide; MLS000069724; Dentipatch; Lignocainum; Xllina; NSC-40030; N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide; Lidocaine (VAN); .alpha.-Diethylaminoaceto-2,6-xylidide; NCGC00015611-10; Xilocaina [Italian]; Dilocaine; Lidocaina; Lidocaine, 97.5%; Lidocainum; SMR000058189; .alpha.-(Diethylamino)-2,6-acetoxylidide; Lidocaine Base; .alpha.-Diethylamino-2,6-dimethylacetanilide; .omega.-Diethylamino-2,6-dimethylacetanilide; 2-(Diethylamino)-N-(2,6-dimethylphenyl)-acetamide; 98PI200987; Lidocainum [INN-Latin]; DSSTox_CID_25166; DSSTox_RID_80716; DSSTox_GSID_45166; Lidocaina [INN-Spanish]; N-(2,6-Dimethylphenyl)-N2,N2-diethylglycinamide; 2-(Diethylamino)-N-(2,6-Dimethylphenyl)ethanamide; EMBOLEX; Versatis; Ztilido; ZTlido; Dentipatch (TN); CAS-137-58-6; LQZ; HSDB 3350; EINECS 205-302-8; NSC 40030; alfa-Dietilamino-2,6-dimetilacetanilide [Italian]; BRN 2215784; Qualigens; Xyline; Lignocaine base; LidocaineHClH2O; Lidocaine [USP:INN:BAN:JAN]; Lidocaine, powder; Lidocaine-D10; 2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide; N1-(2,6-dimethylphenyl)-N2,N2-diethylglycinamide; Zingo (Salt/Mix); MFCD00026733; 851528-09-1; CDS1_000283; Lidocaine (Alphacaine); Spectrum_001118; Lidothesin (Salt/Mix); Xyloneural (Salt/Mix); Opera_ID_385; Maybridge1_002571; Prestwick0_000050; Prestwick1_000050; Prestwick2_000050; Prestwick3_000050; Spectrum2_001343; Spectrum3_001392; Spectrum4_000070; Spectrum5_001549; Lopac-L-5647; Lidaform HC (Salt/Mix); Epitope ID:116205; Lidamantle HC (Salt/Mix); 2', 2-(diethylamino)-; Neosporin Plus (Salt/Mix); Lopac0_000669; SCHEMBL15689; BSPBio_000179; BSPBio_001359; BSPBio_003004; KBioGR_000079; KBioGR_000599; KBioSS_000079; KBioSS_001598; 4-12-00-02538 (Beilstein Handbook Reference); MLS000758263; MLS001074177; MLS001423964; ARONIS23855; BIDD:GT0342; Diethylaminoacet-2,6-xylidide; DivK1c_000174; DivK1c_001323; Lidocaine, analytical standard; SPBio_001525; SPBio_002100; Lidocaine (JP17/USP/INN); ALGRX 3268; ALGRX-3268; BPBio1_000197; GTPL2623; DTXSID1045166; SCHEMBL17967359; HMS548M19; KBio1_000174; KBio2_000079; KBio2_001598; KBio2_002647; KBio2_004166; KBio2_005215; KBio2_006734; KBio3_000157; KBio3_000158; KBio3_002224; ZINC20237; Lidocaine 1.0 mg/ml in Methanol; NINDS_000174; Bio1_000379; Bio1_000868; Bio1_001357; Bio2_000079; Bio2_000559; HMS1791D21; HMS1989D21; HMS2051C21; HMS2089E15; HMS2235O14; HMS3371J04; HMS3393C21; HMS3428O07; HMS3651G09; AMY25560; BCP09081; HY-B0185; NSC40030; Tox21_110183; ANW-42187; BBL005525; BDBM50017662; NSC789222; s1357; SBB080556; STK552033; AKOS001026768; Tox21_110183_1; CCG-100824; CS-2070; DB00281; MCULE-9294700940; NC00074; NSC-789222; SB19118; SDCCGSBI-0050648.P005; WLN: 2N2 & 1VMR B1 F1; .alpha.-Diethylamino-2,6-acetoxylidide; CAS-73-78-9; IDI1_000174; IDI1_033829; NCGC00015611-01; NCGC00015611-02; NCGC00015611-03; NCGC00015611-04; NCGC00015611-05; NCGC00015611-06; NCGC00015611-07; NCGC00015611-08; NCGC00015611-09; NCGC00015611-11; NCGC00015611-12; NCGC00015611-13; NCGC00015611-14; NCGC00015611-15; NCGC00015611-16; NCGC00015611-18; NCGC00015611-31; NCGC00022176-05; NCGC00022176-06; NCGC00022176-07; NCGC00022176-08; NCGC00022176-09; AC-10282; AS-13718; M620; ST023341; 2-(Diethylamino)-2'',6''-acetoxylidide; SBI-0050648.P004; AB00053581; L0156; SW196598-4; A18187; C07073; D00358; J10173; K-4450; M06299; AB00053581-27; AB00053581-28; AB00053581_29; AB00053581_30; Q216935; (2,6-dimethylphenyl)carbamoylmethyl-diethyl-azanium; N1-(2,6-dimethylphenyl)-2-(diethylamino)acetamide; W-108233; 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide #; BRD-K52662033-001-02-6; BRD-K52662033-003-05-5; BRD-K52662033-003-14-7; Z55135799; Lidocaine, British Pharmacopoeia (BP) Reference Standard; Lidocaine, European Pharmacopoeia (EP) Reference Standard; N~1~-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide; Lidocaine, United States Pharmacopeia (USP) Reference Standard; Lidocaine, Pharmaceutical Secondary Standard; Certified Reference Material; Lidocaine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; 91484-71-8	Small molecule	1S/C14H22N2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17)	NNJVILVZKWQKPM-UHFFFAOYSA-N	CCN(CC)CC(=O)NC1=C(C=CC=C1C)C	C14H22N2O	CAS 137-58-6	CHEBI:6456	.	.	.	D0X4RN	.	.	.
DR2915	Abivertinib	CID: 72734520	Avitinib; 1557267-42-1; N-(3-((2-((3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; Avitinib free base; SCHEMBL15453394; KS-00000TON; EX-A783; MolPort-042-663-560; Avitinib(AC0010/AC0010MA); ZINC142081723; AKOS030632728; CS-W008904; N-(3-{2-[3-Fluoro-4-(4-methyl-piperazin-1-yl)-phenylamino]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy}-phenyl)-acrylamide; DS-19269; AK543905; 2-Propenamide, N-[3-[[2-[[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-	Small molecule	1S/C26H26FN7O2/c1-3-23(35)29-17-5-4-6-19(15-17)36-25-20-9-10-28-24(20)31-26(32-25)30-18-7-8-22(21(27)16-18)34-13-11-33(2)12-14-34/h3-10,15-16H,1,11-14H2,2H3,(H,29,35)(H2,28,30,31,32)	UOFYSRZSLXWIQB-UHFFFAOYSA-N	CN1CCN(CC1)C2=C(C=C(C=C2)NC3=NC4=C(C=CN4)C(=N3)OC5=CC=CC(=C5)NC(=O)C=C)F	C26H26FN7O2	CAS 1557267-42-1	.	.	.	.	D0FV3K	.	.	.
DR2918	Salazosulfapyridine	CID: 5339	sulfasalazine; 599-79-1; Azulfidine; Salicylazosulfapyridine; Salazosulfapyridine; Sulphasalazine; Salazopyrin; Asulfidine; Salazopyridin; Accucol; Azopyrin; Sulcolon; Colo-Pleon; Salazopiridazin; Azopyrine; Benzosulfa; Reupirin; Salisulf; Salazosulfapyridin; w-t Sasp oral; Sulfasalazin; Azulfidine EN; Sulfasalazina; Sulfasalazinum; Sulfazalazine; Azulfidine EN-tabs; Salazosulfapiridina; Salazosulfapyridinum; Sas-500; SASP; 5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid; S.A.S.-500; 5-(4-(2-Pyridylsulfamoyl)phenylazo)-2-hydroxybenzoic acid; 4-(Pyridyl-2-amidosulfonyl)-3'-carboxy-4'-hydroxyazobenzene; 5-((p-(2-Pyridylsulfamoyl)phenyl)azo)salicylic acid; 2-Hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)benzoic acid; NSC 667219; CHEBI:9334; NSC 203730; S.A.S. 500; C18H14N4O5S; UNII-3XC8GUZ6CB; 5-[4-(2-Pyridylsulfamoyl)phenylazo]salicylic Acid; MFCD00057363; Benzoic acid, 2-Hydroxy-5-[[4-[(2-pyridinylamino)sulfonyl]phenyl]azo]-; (E)-2-hydroxy-5-((4-(N-(pyridin-2-yl)sulfamoyl)phenyl)diazenyl)benzoic acid; 3XC8GUZ6CB; Sulfasalazine (Azulfidine); CHEMBL421; Benzoic acid, 2-hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)-; S.A.S.; Azosulfidin; 2-hydroxy-5-{[4-(pyridin-2-ylsulfamoyl)phenyl]diazenyl}benzoic acid; 5-[p-(2-Pyridylsulfamoyl)phenylazo]salicylic acid; 2-HYDROXY-(5-([4-(2-PYRIDINYLAMINO)SULFONYL]PHENYL)AZO)BENZOIC ACID; NSC203730; NSC667219; NSC-203730; NSC-667219; (3Z)-6-Oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid; Salicylic acid, 5-((p-(2-pyridylsulfamoyl)phenyl)azo)-; SSZ; NCGC00090903-01; Salazo-sulfapyridinum; CAS-599-79-1; 2-Hydroxy-5-[[4-[(2-pyridinylamino)sulfonyl]phenyl]azo]benzoic acid; DSSTox_CID_1256; 2-hydroxy-5-[(E)-{4-[(pyridin-2-ylamino)sulfonyl]phenyl}diazenyl]benzoic acid; DSSTox_RID_76043; 5-[p-(2-Pyridylsulfamyl)phenylazo]salicylic acid; DSSTox_GSID_21256; Q63398427; Sulfasalazinum [INN-Latin]; Sulfasalazina [INN-Spanish]; Salicylic acid, 5-[[p-(2-pyridylsulfamoyl)phenyl]azo]-; 2-Hydroxy-5-[4-(pyridin-2-ylsulfamoyl)-phenylazo]-benzoic acid; Salazosulfapyridinum [INN-Latin]; Salazosulfapiridina [INN-Spanish]; SI-88; 2-Hydroxy-5-((4-(N-(pyridin-2-yl)sulfamoyl)phenyl)diazenyl)benzoic acid; 2-hydroxy-5-(2-{4-[(pyridin-2-yl)sulfamoyl]phenyl}diazen-1-yl)benzoic acid; Azulfidine (TN); 6-oxo-3-[[4-(2-pyridinylsulfamoyl)phenyl]hydrazinylidene]-1-cyclohexa-1,4-dienecarboxylic acid; 737754-28-8; SMR000059146; Sulphasalazine, N-; CCRIS 4713; HSDB 3395; 13gs; 5-(p-(2-Pyridylsulfamoyl)phenylazo)salicylic acid; SR-05000001721; EINECS 209-974-3; 5-[[p-(2-Pyridylsulfamoyl)phenyl]azo]salicylic acid; Sulfasalazine (USP/INN); BRN 0356241; Iwata; 2-hydroxy-5-({4-[(2-pyridylamino)sulfonyl]phenyl}diazenyl)benzoic acid; Prestwick_848; Sulfasalazine [USAN:USP:INN:BAN]; Spectrum_000998; Prestwick0_000520; Prestwick1_000520; Prestwick2_000520; Prestwick3_000520; Spectrum2_001216; Spectrum3_001364; Spectrum4_000347; Spectrum5_001443; Epitope ID:122672; SCHEMBL4514; SCHEMBL4515; Salazosulfapyridine (JP17); SCHEMBL18490; BSPBio_000479; BSPBio_002888; KBioGR_000753; KBioGR_002314; KBioSS_001478; KBioSS_002316; 5-22-08-00433 (Beilstein Handbook Reference); MLS000759399; MLS001424109; MLS006011702; BIDD:GT0161; DivK1c_000860; SPECTRUM1500552; SPBio_001032; SPBio_002400; BPBio1_000527; CHEMBL100848; CHEMBL242373; GTPL4840; SCHEMBL1079598; SCHEMBL1229516; CHEMBL1206016; DTXSID0021256; SCHEMBL10289061; CHEBI:94500; HMS502K22; KBio1_000860; KBio2_001478; KBio2_002314; KBio2_004046; KBio2_004882; KBio2_006614; KBio2_007450; KBio3_002108; KBio3_002794; cMAP_000018; NINDS_000860; HMS1569H21; HMS1921C05; HMS2051J21; HMS2090P13; HMS2092K07; HMS2096H21; HMS2232H07; HMS3370D16; HMS3393J21; HMS3655G07; HMS3713H21; HMS3871J13; HMS3884E21; Pharmakon1600-01500552; ALBB-033361; BCP13311; ZINC3831490; Tox21_111037; Tox21_201239; Tox21_300541; ANW-43676; BDBM50097125; BDBM50103596; CCG-39145; DL-510; KM0360; NSC757330; s1576; SBB058178; ZINC14768602; ZINC85550135; AKOS002311709; AKOS025116975; AKOS026749974; Tox21_111037_1; WLN: T6NJ BSWMR DNUNR DQ CVQ; ZINC100030102; ZINC100031653; CCG-100987; DB00795; HS-0062; MCULE-7533021815; NC00237; NSC-757330; VA11798; IDI1_000860; SMP2_000059; NCGC00016518-01; NCGC00090903-02; NCGC00090903-03; NCGC00090903-04; NCGC00090903-05; NCGC00090903-06; NCGC00090903-07; NCGC00090903-08; NCGC00090903-09; NCGC00090903-11; NCGC00186644-01; NCGC00254313-01; NCGC00258791-01; (3E)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid; 6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid; AC-20497; AK163126; H881; HY-14655; SMR004703430; SY052318; SBI-0051526.P003; AB0013330; DB-017797; FT-0603483; FT-0674746; S0580; ST50767935; SW196979-4; C07316; D00448; J10488; AB00052101-04; AB00052101-06; AB00052101_07; AB00052101_08; 599S791; Q420035; Q-201769; SR-05000001721-1; SR-05000001721-2; SR-05000001721-3; Sulfasalazine, analytical standard, >=98% (HPLC); 5-[[4-(2-Pyridylsulfamoyl)phenyl]azo]salicylic acid; BRD-K10670311-001-06-4; BRD-K10670311-001-08-0; Q27166356; Sulphasalazine, Antibiotic for Culture Media Use Only; F2173-1125; Z2030502809; 4-(Pyridyl-2-amidosulfonyl)-3''-carboxy-4''-hydroxyazobenzene; Sulfasalazine, European Pharmacopoeia (EP) Reference Standard; 2-hydroxy-5-[(E)-[4-(2-pyridylsulfamoyl)phenyl]azo]benzoic acid; 5-{4-[(2-pyridylideneamino)sulfonyl]phenyldiazenyl}salicylic acid; Sulfasalazine, United States Pharmacopeia (USP) Reference Standard; (E)-2-hydroxy-5-((4-(N-pyridin-2-ylsulfamoyl)phenyl)diazenyl)benzoic acid; 2-hydroxy-5-((4-(N-pyridin-2-ylsulfamoyl)phenyl)diazenyl)benzoic acid; 2-Hydroxy-5-((4-[(2-pyridinylamino)sulfonyl]phenyl)diazenyl)benzoic acid #; 2-hydroxy-5-{(E)-[4-(pyridin-2-ylsulfamoyl)phenyl]diazenyl}benzoic acid; 2-hydroxy-5-[(E)-2-{4-[(pyridin-2-yl)sulfamoyl]phenyl}diazen-1-yl]benzoic acid; 6-oxo-3-(2-[4-(n-pyridin-2-ylsulfamoyl)phenyl]hydrazono)cyclohexa-1,4-dienecarboxylic acid; 6-oxo-3-((4-(pyridin-2-ylsulfamoyl)phenyl) hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid	Small molecule	1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25)	NCEXYHBECQHGNR-UHFFFAOYSA-N	C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O	C18H14N4O5S	CAS 599-79-1	CHEBI:9334	.	.	.	D02ZTJ	.	.	.
DR2919	Rabeprazole	CID: 5029	rabeprazole; 117976-89-3; Aciphex; Habeprazole; Pariets; 2-(((4-(3-Methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; CHEBI:8768; LY307640; Sodium rabeprazole; 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole; 2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole; Rabeprazole [INN:BAN]; 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-; rabeprazol; Rabeloc; 1H-Benzimidazole, 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-; Rabeprazole (INN); Eraloc (TN); HSDB 7321; 2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl}methylsulfinyl]-1H-benzimidazole; 2-{[4-(3-Methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl}-1H-benzimidazole; 2-(((4-(3-Methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole; 2--1H-benzimidazole; 2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1H-benzo[d]imidazole; LY 307640; CHEMBL1219; SCHEMBL23336; MLS001401446; BIDD:GT0019; GTPL7290; DTXSID3044122; HMS2052P03; HMS3394P03; AMY10338; BCP06638; HY-B0656; ANW-57672; BDBM50070209; E-3810 (PPI); MFCD00868879; s4845; STL186112; AKOS015895259; CCG-101158; DB01129; MCULE-7848941080; NC00408; PB21725; 2-{[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methanesulfinyl}-1H-1,3-benzodiazole; NCGC00388029-07; NCGC00388029-09; AK-55871; AS-34993; SMR000469174; SBI-0206867.P001; AB0107093; DB-020298; DS-002860; FT-0602569; FT-0674301; FT-0674302; Q3515; C07864; D08463; Q-1236; AB00698237-06; 976R893; A803856; SR-01000763041; J-003691; SR-01000763041-3; BRD-A39390670-236-04-0; (R)-2-(((4-(3-Methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; (S)-2-(((4-(3-Methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; 1H-benzimidazole,2-[(r)-[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-; 2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methane}sulfinyl)-1H-1,3-benzodiazole; 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl] sulfinyl]-1H-benzimidazole; 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1H-benzimidazole; 2-[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methylsulfinyl]-1H-benzimidazole; 2-[[4-(3-methoxypropoxy)-3-methyl-pyridin-2-yl]methylsulfinyl]-1H-benzimidazole; 2-{[(3-Methyl-4-(3-methoxypropoxy)-2-pyridinyl)methyl]sulphinyl}1H-benzimidazole; 2-{4-(3-Methoxypropoxy)-3-methylpyridine-2-yl}methylsulfinyl-1H-benzimidazole	Small molecule	1S/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21)	YREYEVIYCVEVJK-UHFFFAOYSA-N	CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCCCOC	C18H21N3O3S	CAS 117976-89-3	CHEBI:8768	.	.	.	D0KL4J	.	.	.
DR2951	Betamethasone dipropionate	CID: 21800	BETAMETHASONE DIPROPIONATE; Diprolene; Diprosone; Diprolene AF; 5593-20-4; Alphatrex; Diproderm; Maxivate; Betamethasone 17,21-dipropionate; Diprosis; Psorion; Sch 11460; Betamethasone-17,21-dipropionate; Sch-11460; UNII-826Y60901U; S-3440; CHEBI:31276; beta-Methasone 17,21-dipropionate; 826Y60901U; Rinderon DP; Sernivo; (11-beta,16-beta)-9-Chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 9-fluoro-11beta-hydroxy-16beta-methyl-3,20-dioxopregna-1,4-diene-17,21-diyl dipropanoate; (8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-(2-(propionyloxy)acetyl)-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl propionate.; [2-[(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-propanoyloxy-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate; 2-((2S,10S,11S,13S,15S,17S,1R,14R)-1-fluoro-17-hydroxy-2,13,15-trimethyl-5-oxo -14-propanoyloxytetracyclo[8.7.0.0<2,7>.0<11,15>]heptadeca-3,6-dien-14-yl)-2-o xoethyl propanoate; 9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione-17,21-dipropionate; EINECS 227-005-2; BRN 3638108; Betamethasone Dipropionate (Diprolene); S 3440; Diprolene (TN); NCGC00159360-02; NCGC00159443-02; Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)-, (11.beta.,16.beta.)-; Sernivo (TN); Rinderon-DP (TN); Betamethasone dipropionate [USAN:USP:JAN]; betamethasone-dipropionate; DSSTox_CID_2672; BETAMETHASONE DIPROP; SCHEMBL7519; 9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate; DSSTox_RID_76683; DSSTox_GSID_22672; 9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17,21-di(propionate); CHEMBL1200384; DTXSID2022672; component of Betasone (Salt/Mix); component of Alphatrex (Salt/Mix); AMY22130; ZINC4212137; Tox21_113343; BDBM50421892; s1688; AKOS015969733; Betamethasone dipropionate (JP17/USP); CCG-269732; CS-7549; EBD2157850; KS-5303; NSC 758415; NCGC00159443-01; NCGC00159443-05; (11beta,16beta)-9-fluoro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-diene-17,21-diyl dipropanoate; HY-13571; Pregna-1,4-diene-3,20-dione, 9-fluoro-11-beta,17,21-trihydroxy-16-beta-methyl-, 17,21-dipropionate; Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)-, (11beta,16beta); ST024761; CAS-5593-20-4; B3166; D01637; AB01274713-01; AB01274713_02; Q4897349; BRD-K58148589-001-03-6; Betamethasone-17,21-dipropionate 100 microg/mL in Acetonitrile; (11.beta.,16.beta.)-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate; 9-Fluoro-11.beta.,17,21-trihydroxy-16.beta.-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate; 9-Fluoro-11.beta.-hydroxy-16.beta.-methyl-3,20-dioxo-17-(propionyloxy)pregna-1,4-dien-21-yl propionate #; 9alpha-Fluoro-11beta,17alpha,21-trihydroxy-16beta-methyl-1,4-pregnadiene-3,20-dione 17,21-Dipropionate; 9alpha-fluoro-11beta,17alpha,21-trihydroxy-16beta-methyl-3,20-dioxopregna-1,4-diene- 17,21-diyl dipropionate; Pregna-1,4-diene-3,20-dione, 9-fluoro-11-.beta.,17,21-trihydroxy-16-.beta.-methyl-,17,21-dipropionate	Small molecule	1S/C28H37FO7/c1-6-23(33)35-15-22(32)28(36-24(34)7-2)16(3)12-20-19-9-8-17-13-18(30)10-11-25(17,4)27(19,29)21(31)14-26(20,28)5/h10-11,13,16,19-21,31H,6-9,12,14-15H2,1-5H3/t16-,19-,20-,21-,25-,26-,27-,28-/m0/s1	CIWBQSYVNNPZIQ-XYWKZLDCSA-N	CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)OC(=O)CC	C28H37FO7	CAS 5593-20-4	CHEBI:31276	.	.	.	D0MD6C	.	.	.
DR2980	Simvastatin	CID: 54454	simvastatin; 79902-63-9; Zocor; Synvinolin; Sinvacor; Denan; Lipex; MK-733; Sivastin; Lodales; Simvastatine; Cholestat; Colemin; Simovil; Medipo; Pantok; Simvastatina; Simvastatinum; Velostatin; Zocord; Zorced; Simvastatin lactone; Simvastatin (Zocor); Lipovas; Simcard; Simvacor; Simvoget; Rechol; Simlup; (1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-Hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate; MK-0733; UNII-AGG2FN16EV; 2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one; AGG2FN16EV; CHEBI:9150; (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate; [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate; Labistatin; Coledis; Corolin; Nivelipol; Rendapid; Vasotenal; Simcor; Simvastatin, 98%; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; C25H38O5; Simvastatine [French]; Simvastatinum [Latin]; Simvastatina [Spanish]; DSSTox_CID_3581; DSSTox_RID_77090; DSSTox_GSID_23581; (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester; Zosta; Simvast CR; DRG-0320; [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxo-tetrahydropyran-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate; SMR000718785; MK 0733; CCRIS 7558; Zocor (TN); HSDB 7208; Simvastatin & Primycin; SR-05000001894; MK 733; L 644128-000U; BRN 4768037; Kolestevan; Lipinorm; Modutrol; Simvotin; Sinvascor; Valemia; Eucor; MFCD00072007; Nor-Vastina; Simvastatin,(S); C10AA01; simvastatin predrug; (+)-Simvastatin; NCGC00016940-01; inactive simvastatin; 8-[2-((2R,4R)-4-hydroxy-6-oxo(2H-3,4,5-trihydropyran-2-yl))ethyl](1S,7S,8S,3R, 8aR)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthyl 2,2-dimethylbutanoate; Simvastatin [USAN:USP:INN:BAN]; TNP00259; Prestwick_171; CAS-79902-63-9; KS-1113; Spectrum_001717; SpecPlus_000895; Prestwick0_000865; Prestwick1_000865; Prestwick2_000865; Prestwick3_000865; Spectrum2_001671; Spectrum3_000669; Spectrum4_000632; Spectrum5_001428; SCHEMBL2471; CHEMBL1064; BSPBio_000909; BSPBio_002337; KBioGR_001244; KBioSS_002197; MLS001304029; MLS001333077; MLS001333078; MLS002154038; MLS006011866; ARONIS24119; BIDD:GT0769; DivK1c_006991; SPECTRUM1504236; SPBio_001881; SPBio_002830; BPBio1_001001; GTPL2955; Simvastatin (JP17/USP/INN); Simvastatin, analytical standard; DTXSID0023581; BCBcMAP01_000007; KBio1_001935; KBio2_002197; KBio2_004765; KBio2_007333; KBio3_001557; RYMZZMVNJRMUDD-HGQWONQESA-; HMS1570N11; HMS1922H13; HMS2089D12; HMS2093E06; HMS2097N11; HMS2231N22; HMS3259B12; HMS3412P08; HMS3676P08; HMS3714N11; HMS3884G10; Pharmakon1600-01504236; ZINC3780893; Tox21_110696; Tox21_300400; BBL024390; BDBM50139181; CCG-39069; NSC633782; NSC758706; s1792; SBB080618; STK801938; AKOS005111006; AKOS015842733; Simvastatin, >=97% (HPLC), solid; Tox21_110696_1; AC-1530; AT-7048; DB00641; MCULE-8390617062; NC00719; NSC 758706; NSC-633782; NSC-758706; MRF-0000729; NCGC00017324-01; NCGC00017324-02; NCGC00017324-03; NCGC00017324-04; NCGC00017324-05; NCGC00017324-07; NCGC00017324-08; NCGC00017324-09; NCGC00254418-01; 2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; Butanoic acid, 2,2-dimethyl-, 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, (1S-(1alpha,3alpha,7beta,8beta(2S*,4S*),8abeta))-; HY-17502; ST057168; SBI-0206773.P001; Simvastatin 100 microg/mL in Acetonitrile; AB0069097; D00434; J10128; W-3044; 28049-EP2269989A1; 28049-EP2269990A1; 28049-EP2270011A1; 28049-EP2270505A1; 28049-EP2272825A2; 28049-EP2272841A1; 28049-EP2277865A1; 28049-EP2280001A1; 28049-EP2280006A1; 28049-EP2281813A1; 28049-EP2284158A1; 28049-EP2287165A2; 28049-EP2287166A2; 28049-EP2292620A2; 28049-EP2295406A1; 28049-EP2295409A1; 28049-EP2295417A1; 28049-EP2295422A2; 28049-EP2298731A1; 28049-EP2298742A1; 28049-EP2298745A1; 28049-EP2298769A1; 28049-EP2298772A1; 28049-EP2298776A1; 28049-EP2298779A1; 28049-EP2301923A1; 28049-EP2301931A1; 28049-EP2301936A1; 28049-EP2305219A1; 28049-EP2305648A1; 28049-EP2308839A1; 28049-EP2308878A2; 28049-EP2314588A1; 96639-EP2287163A1; 96639-EP2305678A1; 99548-EP2270011A1; 99548-EP2298779A1; 99548-EP2301923A1; 99548-EP2301931A1; AB00053395-07; AB00053395-08; AB00053395-10; AB00053395_11; AB00053395_13; 902S639; Q670131; SR-05000001894-1; SR-05000001894-2; BRD-K22134346-001-05-8; BRD-K22134346-001-11-6; BRD-K22134346-001-15-7; Z1741982918; Simvastatin, British Pharmacopoeia (BP) Reference Standard; Simvastatin, European Pharmacopoeia (EP) Reference Standard; Simvastatin, United States Pharmacopeia (USP) Reference Standard; Simvastatin, Pharmaceutical Secondary Standard; Certified Reference Material; Simvastatin for peak identification, European Pharmacopoeia (EP) Reference Standard; (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyly-2,2-dimethyl butanoate; (1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-Hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbu; (1S,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate	Small molecule	1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1	RYMZZMVNJRMUDD-HGQWONQESA-N	CCC(C)(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C	C25H38O5	CAS 79902-63-9	CHEBI:9150	.	.	.	D0H0ND	.	.	.
DR3007	Dapsone	CID: 2955	dapsone; 80-08-0; 4,4'-Sulfonyldianiline; Diaphenylsulfone; Dapson; 4,4'-Diaminodiphenyl sulfone; 4-Aminophenyl sulfone; 4,4'-Diaminodiphenylsulfone; Diaphenylsulfon; Sulfona; DADPS; Avlosulfone; Diphenasone; Sulfadione; Sulphadione; Disulone; Udolac; p-Aminophenyl sulfone; Bis(4-aminophenyl) sulfone; Avlosulfon; Croysulfone; Dapsonum; Dumitone; Novophone; Aczone; Diphone; Eporal; Diaphenylsulphon; Diaphenylsulphone; Metabolite C; Sulfonyldianiline; Sumicure S; Bis(p-aminophenyl) sulfone; Sulphonyldianiline; p,p-Sulphonylbisbenzamine; Sulfona-MAE; Avlosulphone; Croysulphone; Dubronax; 4,4'-Dapsone; Diaminodiphenyl sulfone; Tarimyl; p,p-Sulphonylbisbenzenamine; Sulfone ucb; 4,4'-Sulfonylbisaniline; p,p'-Diaminodiphenyl sulfone; 4-(4-aminophenyl)sulfonylaniline; Dapsona; Benzenamine, 4,4'-sulfonylbis-; Diaminodiphenylsulfone; Di(p-aminophenyl)sulphone; Bis(4-aminophenyl)sulfone; Di(p-aminophenyl) sulfone; p,p-Sulphonyldianiline; 4,4'-Sulfonylbisbenzamine; Di(4-aminophenyl) sulfone; p,p'-sulfonyldianiline; NSC-6091; 4,4'-Sulfonylbisbenzenamine; p,p-Sulfonylbisbenzamine; Diaminodifenilsulfona; DDS, pharmaceutical; p,p-Sulfonylbisbenzenamine; Araldite HT 976; Bis(p-aminophenyl)sulphone; Di(4-aminophenyl)sulphone; Bis(4-aminophenyl)sulphone; p,p-Diaminodiphenyl sulphone; N,N'-Diphenyl sulfondiamide; 1,1'-Sulfonylbis(4-aminobenzene); 4,4'-Sulphonyldianiline; 4,4'-Sulphonylbisbenzamine; 4,4'-Sulphonylbisbenzenamine; DDS; 4,4'-Diaminodiphenyl sulphone; WR 448; 4,4-Diaminodifenylsulfon; Diamino-4,4'-diphenyl sulfone; Diamino-4,4'-diphenyl sulphone; NSC 6091D; NCI-C01718; 1,1'-Sulfonylbis[4-aminobenzene]; 1,1'-Sulphonylbis(4-aminobenzene); Aniline, 4,4'-sulfonyldi-; HT 976; 4,4'-diamino diphenyl sulphone; F 1358; 4,4'-Sulfonyldianiline (Dapsone); 1358F; 4-[(4-aminobenzene)sulfonyl]aniline; MFCD00007887; 4,4'-Sulfonylbisbenzeneamine; 4,4'-Sulfonyldianilin; UNII-8W5C518302; 4-[(4-aminophenyl)sulfonyl]aniline; CHEMBL1043; 4-Aminophenyl sulfone, 97%; MLS000069409; CHEBI:4325; DTXSID4020371; Sulfanona-mae; NSC6091; Sulfon-mere; 4,4'-DDS; Di(4-aminophenyl)sulfone; 4-[(4-Aminophenyl)sulfonyl]phenylamine; 4-(4-amino-benzenesulfonyl)-phenylamine; NCGC00016322-08; SMR000059064; Hardener HT 976; DDS (pharmaceutical); Sulphon-mere; DSSTox_CID_371; 8W5C518302; Dapsonum [INN-Latin]; Dapsona [INN-Spanish]; DSSTox_RID_75547; DSSTox_GSID_20371; DSS (VAN); 4-Aminophenylsulfone; DDS, diaphenylsulfone; 4,4'-Diaminodiphenyl suphone; Atrisone; Diaminodifenilsulfona [Spanish]; 4,4-Diaminodifenylsulfon [Czech]; CAS-80-08-0; HY 976; CCRIS 192; Dapsone (USP); Aczone (TN); HSDB 5073; Diaphenylsulfone (JAN); SR-01000002976; NSC 6091; Sulfone, diphenyl, 4,4'-diamino-; EINECS 201-248-4; (4-sulfanilylphenyl)amine; AZT + Dapsone cominbation; BRN 0788055; Servidapson; AI3-08087; diaphenylsulfone;; Diaphenyl sulfone; Dapsone [USAN:USP:INN:BAN]; Dapsone-d8; Dapsone,(S); Prestwick_152; ALBB-005917; Dapsone-[d4]; IN-201; 1632119-29-9; Dapsone-13C12; BIS SULFONE; 4,4''-dapsone; Dapsone-[15N2]; Spectrum_000888; ACMC-209piw; Aniline,4'-sulfonyldi-; Opera_ID_1950; Prestwick0_000035; Prestwick1_000035; Prestwick2_000035; Prestwick3_000035; Spectrum2_001133; Spectrum3_000375; Spectrum4_000310; Spectrum5_000825; WLN: ZR DSWR DZ; 4,4''-sulfonyldianiline; 4,4''-sulfonylbisaniline; 4'-Diaminodiphenyl sulfone; EC 201-248-4; 4,4'-Sulfonyldiphenylamine; Benzenamine,4'-sulfonylbis-; Oprea1_143052; SCHEMBL21428; BSPBio_000129; BSPBio_002129; CBDivE_013582; Dianiline, 4,4'-sulfonyl-; KBioGR_000900; KBioSS_001368; MLS001055349; MLS001076146; 4,4''-Sulfonylbisbenzenamine; 4,4'-Sulfonylbis-benzenamine; 4,4'-Sulfonylbis[benzamine]; BIDD:GT0770; DivK1c_000573; p,p''-diaminodiphenyl sulfone; SPECTRUM1500222; SPBio_001025; SPBio_002050; 4,4''-diaminodiphenyl sulfone; 4,4'-diamino diphenyl sulfone; BPBio1_000143; ZINC6310; GTPL10934; HMS501M15; KBio1_000573; KBio2_001368; KBio2_003936; KBio2_006504; KBio3_001349; NSC-6091D; 4-(4-aminophenylsulfonyl)aniline; J04BA02; NINDS_000573; HMS1568G11; HMS1920C14; HMS2091K04; HMS2095G11; HMS2231G09; HMS3259C13; HMS3369B11; HMS3712G11; Pharmakon1600-01500222; ACT07431; AMY40781; EBD28910; HY-B0688; 1,1''-sulfonylbis(4-aminobenzene); Tox21_110371; Tox21_201347; Tox21_300558; 4-(4-aminophenylsulfonyl)benzenamine; ANW-37350; BBL002412; BDBM50029764; CCG-40260; CD0112; NSC756716; s4612; SBB003168; STK387118; AKOS000119322; Tox21_110371_1; DB00250; HT 9664; KS-1450; LS10738; MCULE-7294380437; NC00488; NSC-756716; IDI1_000573; NCGC00016322-01; NCGC00016322-02; NCGC00016322-03; NCGC00016322-04; NCGC00016322-05; NCGC00016322-06; NCGC00016322-07; NCGC00016322-09; NCGC00016322-10; NCGC00016322-13; NCGC00023946-03; NCGC00023946-04; NCGC00023946-05; NCGC00023946-06; NCGC00254533-01; NCGC00258899-01; AC-10922; AK175100; 4-[(4-Aminophenyl)sulfonyl]phenylamine #; SBI-0051331.P003; DB-056406; AB00051962; D0089; Dapsone, VETRANAL(TM), analytical standard; FT-0624447; FT-0665473; R1186; ST50308134; 4 inverted exclamation marka-Sulfonyldianiline; C07666; D00592; AB00051962_19; A839828; Q422226; 4 inverted exclamation marka-Diaminodiphenyl sulfone; Q-200435; SR-01000002976-2; SR-01000002976-4; BRD-K62363391-001-05-8; BRD-K62363391-001-15-7; 4 4-Diamino Diphenyl Sulfone 99.5%min Cas:80-08-8; Dapsone, British Pharmacopoeia (BP) Reference Standard; Dapsone, European Pharmacopoeia (EP) Reference Standard; F0266-3067; 2-(PIPERAZIN-1-YL)-ACETICACIDN-(2-PHENYLETHYL)-AMIDE; Dapsone, United States Pharmacopeia (USP) Reference Standard; Dapsone, Pharmaceutical Secondary Standard; Certified Reference Material	Small molecule	1S/C12H12N2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H,13-14H2	MQJKPEGWNLWLTK-UHFFFAOYSA-N	C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)N	C12H12N2O2S	CAS 80-08-0	CHEBI:4325	.	.	.	D0MA9N	.	.	.
DR3046	Raltitrexed	CID: 135400182	Raltitrexed; Tomudex; 112887-68-0; ZD1694; ZD-1694; ICI-D1694; D-1694; ICI D1694; UNII-FCB9EGG971; D1694; CHEBI:5847; C21H22N4O6S; Raltitrexed (Tomudex); ZD-16; FCB9EGG971; ZD 1694; CHEMBL225071; N-(5-(N-(3,4-Dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino)-2-thenoyl)-L-glutamic acid; ICI-D-1694; NSC-639186; NCGC00229704-01; DSSTox_CID_26482; DSSTox_RID_81653; DSSTox_GSID_46482; (S)-2-(5-(Methyl((2-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)-methyl)amino)thiophene-2-carboxamido)pentanedioic acid; (S)-2-(5-(methyl((2-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)methyl)amino)thiophene-2-carboxamido)pentanedioic acid; N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl)-L-glutamic acid; (2S)-2-[(5-{methyl[(2-methyl-4-oxo-1,4-dihydroquinazolin-6-yl)methyl]amino}thiophen-2-yl)formamido]pentanedioic acid; (S)-2-(5-(methyl((2-methyl-4-oxo-1,4-dihydroquinazolin-6-yl)methyl)amino)thiophene-2-carboxamido)pentanedioic acid; D16; Tomudex (TN); D 1694; CAS-112887-68-0; Raltitrexed (JAN/USAN/INN); (2S)-2-[[5-[methyl-[(2-methyl-4-oxo-1H-quinazolin-6-yl)methyl]amino]thiophene-2-carbonyl]amino]pentanedioic acid; 1hvy; 2kce; 2tsr; ZN-D1694; KS-5069; ZD1694; Raltitrexed; SCHEMBL7438; MLS001424225; MLS006010125; N-(5-(((3,4-Dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl)methylamino)-2-thenoyl)-L-glutamic acid; Raltitrexed [USAN:INN:BAN]; GTPL7403; DTXSID0046482; BDBM18795; QCR-125; 1i00; HMS2052I03; HMS3715P08; AMY42113; ZINC3832372; Tox21_112237; BDBM50027655; MFCD00864168; NSC639186; s1192; AKOS015894877; AKOS015994729; Tox21_112237_1; CCG-101075; CCG-221273; DB00293; NC00325; NCGC00263534-02; HY-10821; L-Glutamic acid, N-((5-(((1,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl)methylamino)-2-thienyl)carbonyl)-; L-Glutamic acid, N-[[5-[[(3,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]methylamino]-2-thienyl]carbonyl]-; NCI60_013008; SMR000469217; SMR002529608; BCP0726000267; SW197705-2; C11372; D01064; S-7682; AB00698356-05; 134189-EP2275102A1; 134189-EP2292233A2; 887R680; SR-01000763351; J-524216; SR-01000763351-3; BRD-K89839824-001-01-2; Q15304877; (2S)-2-[[5-[methyl-[(2-methyl-4-oxo-3H-quinazolin-6-yl)methyl]amino]thiophene-2-carbonyl]amino]pentanedioic acid; N-[(5-{methyl[(2-methyl-4-oxo-1,4-dihydroquinazolin-6-yl)methyl]amino}thiophen-2-yl)carbonyl]-L-glutamic acid; N-[[5-[[(1,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]methylamino]-2-thienyl]carbonyl]-L-glutamic acid	Small molecule	1S/C21H22N4O6S/c1-11-22-14-4-3-12(9-13(14)19(28)23-11)10-25(2)17-7-6-16(32-17)20(29)24-15(21(30)31)5-8-18(26)27/h3-4,6-7,9,15H,5,8,10H2,1-2H3,(H,24,29)(H,26,27)(H,30,31)(H,22,23,28)/t15-/m0/s1	IVTVGDXNLFLDRM-HNNXBMFYSA-N	CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1	C21H22N4O6S	CAS 112887-68-0	CHEBI:5847	.	.	.	D01KKQ	.	.	.
DR3065	Macitentan	CID: 16004692	Macitentan; 441798-33-0; Opsumit; ACT-064992; ACT 064992; UNII-Z9K9Y9WMVL; ACT064992; N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide; Z9K9Y9WMVL; CHEBI:76607; Actelion-1; 5-(4-bromophenyl)-6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-N-(propylsulfamoyl)pyrimidin-4-amine; N-[5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}pyrimidin-4-yl]-N'- propylsulfamide; Macitentan [USAN:INN]; macitentanum; zlchem 5; Opsumit (TN); Macitentan (JAN/USAN); (non-labelled)Macitentan-d7; MLS006011174; C19H20Br2N6O4S; GTPL7352; SCHEMBL1445625; CHEMBL2103873; DTXSID50196063; EX-A544; ZLA0005; HMS3653N06; HMS3747E09; cas:441798-33-0;Macitentan; AOB87765; BCP05309; ABP001066; BDBM50395626; MFCD17167076; s8051; ZINC43202140; AKOS024463406; ACN-034475; AM81244; CCG-270155; CS-0686; DB08932; SB14841; Macitentan (Actelion-1,ACT-064992); NCGC00346456-01; NCGC00346456-05; AC-30102; AK162704; AS-74590; HY-14184; n-(5-(4-bromophenyl)-6-(2-(5-bromopyrimidin-2-yloxy)ethoxy)pyrimidin-4-yl)-n'-propylaminosulfonamide; QC-10426; SMR004702943; AB0007893; DB-070519; FT-0696675; SW219473-1; X6162; A11492; ACT 064992; ACT-064992; D10135; S-7749; Q6724151; {[5-(4-BROMOPHENYL)-6-{2-[(5-BROMOPYRIMIDIN-2-YL)OXY]ETHOXY}PYRIMIDIN-4-YL]SULFAMOYL}(PROPYL)AMINE; N-(5-(4-Bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)-N'-propylsulfamide; N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)-oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide; n-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-n'-propyl-sulfamide; N-[5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}pyrimidin-4-yl]-N'-propylsulfuric diamide; Sulfamide, N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propyl-	Small molecule	1S/C19H20Br2N6O4S/c1-2-7-26-32(28,29)27-17-16(13-3-5-14(20)6-4-13)18(25-12-24-17)30-8-9-31-19-22-10-15(21)11-23-19/h3-6,10-12,26H,2,7-9H2,1H3,(H,24,25,27)	JGCMEBMXRHSZKX-UHFFFAOYSA-N	CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br	C19H20Br2N6O4S	CAS 441798-33-0	CHEBI:76607	.	.	.	D0S7JH	.	.	.
DR3078	1,25-dihydroxyvitamin D3	CID: 5280453	calcitriol; Rocaltrol; 32222-06-3; Calcijex; Topitriol; 1alpha,25-Dihydroxyvitamin D3; Silkis; Soltriol; 1alpha,25-Dihydroxycholecalciferol; Calcitriolum; Dihydroxyvitamin D3; 1,25-DHCC; 1,25-Dihydroxyvitamin D; Vectical; 1,25-DIHYDROXYCHOLECALCIFEROL; 1,25-Dihydroxyvitamin D3; 1alpha,25-Dihydroxyvitamin D; 1-alpha,25-Dihydroxyvitamin D3; Calcitriolum [INN-Latin]; UNII-FXC9231JVH; 1alpha,25(OH)2D3; DN-101; 1,25-Dihydroxycholecaliferol; CCRIS 5522; Ro 21-5535; HSDB 3482; 1-alpha,25-Dihydroxycholecalciferol; EINECS 250-963-8; DN 101; Calcitriol (chemotherapy-induced alopecia); Calcitriol (chemotherapy-induced alopecia), Cytotech Labs; Calcitriol (API-31543, drug-induced alopecia), Cytotech Labs; 1alpha,25 dihydroxyvitamin D(3)	Small molecule	1S/C27H44O3/c1-18(8-6-14-26(3,4)30)23-12-13-24-20(9-7-15-27(23,24)5)10-11-21-16-22(28)17-25(29)19(21)2/h10-11,18,22-25,28-30H,2,6-9,12-17H2,1,3-5H3/b20-10+,21-11-/t18-,22-,23-,24+,25+,27-/m1/s1	GMRQFYUYWCNGIN-NKMMMXOESA-N	CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C	C27H44O3	CAS 32222-06-3	.	.	.	.	D0T2PL	.	.	.
DR3085	PKRI	.	dsRNA-dependent protein kinase inhibitor	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR3098	6-mercaptopurine	CID: 667490	6-Mercaptopurine; mercaptopurine; 50-44-2; Purinethol; Mercapurin; 6-Thiopurine; Leukerin; Leupurin; Mercaleukin; 6-Thioxopurine; Puri-Nethol; Ismipur; 7H-purine-6-thiol; Mern; 6-Thiohypoxanthine; 6-Mercaptopurin; 6-Purinethiol; Purimethol; Purinethiol; 6-MP; 1,9-dihydro-6H-purine-6-thione; Purine-6-thiol; 3H-Purine-6-thiol; 6 MP; Mercaleukim; 9H-Purine-6-thiol; 1,7-Dihydro-6H-purine-6-thione; Hypoxanthine, thio-; Mercaptopurine (6-MP); 3,7-dihydropurine-6-thione; 6H-Purine-6-thione, 1,7-dihydro-; Mercaptopurin; Mercaptopurina; Mercaptopurinum; Merkaptopuryna; Xaluprine; 6-Merkaptopurin; Purine, 6-mercapto-; 9H-Purine-6(1H)-thione; Mercaptopurine anhydrous; Purine-6(1H)-thione; NCI-C04886; 7-Mercapto-1,3,4,6-tetrazaindene; 1H-Purine, 6-mercapto-; NSC 755; U-4748; NSC-755; UNII-PKK6MUZ20G; Mercaptopurine;6-MP; NSC755; 3,7-dihydro-6H-purine-6-thione; Purinethol (TN); PKK6MUZ20G; 1,9-dihydropurine-6-thione; 1H-purine-6(7H)-thione.; CHEBI:2208; 157930-13-7; Mercaptopurine (VAN); DSSTox_CID_810; Mercaptopurin [German]; Merkaptopuryna [Polish]; 6-Merkaptopurin [Czech]; DSSTox_RID_75801; DSSTox_GSID_20810; Mercaptopurine (anhydrous); 157930-14-8; Mercaptopurinum [INN-Latin]; Mercaptopurina [INN-Spanish]; Purixan; thiohypoxanthine; Purine-6-thiol, monohydrate; CAS-50-44-2; SMR000544948; Mercaptopurine, 6-; CCRIS 2761; Mercaptopurine (INN); HSDB 3235; SR-05000001925; 1194-62-3; EINECS 200-037-4; NCIMech_000025; 9H-Purin-6-yl hydrosulfide; a thiopurine; Mercaptopurine;; Mercaptopurine [USAN:USP:INN]; PubChem9680; Spectrum_000921; ACMC-1AUNA; Spectrum2_000060; Spectrum3_000491; Spectrum4_000857; Spectrum5_000950; M0063; H-Purine-6(1H)-thione; Azathioprine EP Impurity B; SCHEMBL3893; CHEMBL1425; BSPBio_001981; KBioGR_001493; KBioGR_002363; KBioSS_001401; KBioSS_002366; AG-670/31547064; MLS001066623; MLS001304020; MLS001304953; MLS006011869; ARONIS27054; DivK1c_000493; SPECTRUM1500387; SPBio_000219; GTPL7226; SCHEMBL2790086; 7H-Purin-6-yl hydrosulfide #; DTXSID0020810; SCHEMBL12683725; CHEBI:50667; CHEBI:94796; HMS501I15; KBio1_000493; KBio2_001401; KBio2_002363; KBio2_003969; KBio2_004931; KBio2_006537; KBio2_007499; KBio3_001481; KBio3_002842; 7-Mercapto-1,4,6-tetrazaindene; cMAP_000033; NINDS_000493; 6,7-dihydro-3H-purine-6-thione; HMS1920L07; HMS2091B20; HMS2236L06; HMS3259N03; HMS3369M05; HMS3651G07; HMS3713N10; HMS3747A17; HMS3872N13; Pharmakon1600-01500387; ACT11542; EBD16256; ZINC4658290; [S]C1=NC=NC2=C1NC=N2; Tox21_111158; Tox21_202591; 6450AJ; ANW-30999; ANW-57555; BBL033743; BDBM50423778; CCG-35344; CCG-39915; EBD540779; MFCD00233552; NSC759614; s1305; SBB037953; STK727062; STL257085; 6-Mercaptopurine, analytical standard; WLN: T56 BM DN FN HNJ ISH; AKOS000170222; AKOS000275858; AKOS005224624; AKOS008901311; AKOS016903205; Tox21_111158_1; AM81386; CCG-266232; CS-1499; DB01033; LS20858; MCULE-4811219863; NC00613; NSC-759614; IDI1_000493; NCGC00091641-02; NCGC00091641-03; NCGC00091641-04; NCGC00094717-01; NCGC00094717-02; NCGC00094717-03; NCGC00094717-05; NCGC00094717-06; NCGC00188973-01; NCGC00188973-02; NCGC00260139-01; AC-11464; AS-13109; H348; HY-13677; NCI60_041653; SMR004703503; ST086505; ST086506; SBI-0051437.P004; AB0013000; AB0119973; DB-026398; BB 0241023; FT-0621175; SW199090-2; EN300-61517; 1766-EP2270008A1; 1766-EP2272827A1; 1766-EP2272832A1; 1766-EP2277876A1; 1766-EP2292614A1; 1766-EP2292617A1; 1766-EP2295409A1; 1766-EP2295426A1; 1766-EP2295427A1; 1766-EP2298768A1; 1766-EP2298778A1; 1766-EP2308833A2; 1766-EP2308855A1; 1766-EP2308861A1; 1766-EP2314590A1; 1766-EP2316834A1; 1766-EP2374454A1; 50M442; C01756; C02380; D04931; W-5114; 15150-EP2272827A1; 15150-EP2275420A1; 15150-EP2295055A2; 15150-EP2295416A2; 15150-EP2298748A2; 15150-EP2298764A1; 15150-EP2298765A1; 15150-EP2305642A2; 15150-EP2305679A1; 15150-EP2308833A2; 15150-EP2311453A1; 15150-EP2311825A1; 15150-EP2311840A1; 15150-EP2311842A2; 15150-EP2316832A1; 15150-EP2316833A1; 21414-EP2270006A1; 21414-EP2270014A1; 21414-EP2272509A1; 21414-EP2272847A1; 21414-EP2275413A1; 21414-EP2277874A1; 21414-EP2284158A1; 21414-EP2287156A1; 21414-EP2287159A1; 21414-EP2295439A1; 21414-EP2311818A1; 21414-EP2314295A1; AB00171799_05; AB00641894-03; AB00641894-04; AB00641894_05; AB00876276-13; 233D552; 462M721; 599M524; A828129; Q418529; SR-05000001925-1; SR-05000001925-2; W-105961; purine antimetabolite: inhibits nucleic acid replication; 1,9-Dihydropurine-6-thione DISCONTINUED, see M225450; Mercaptopurine; 7H-Purine-6-thiol; Azathioprine BP Impurity B; 157930-11-5	Small molecule	1S/C5H4N4S/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H2,6,7,8,9,10)	GLVAUDGFNGKCSF-UHFFFAOYSA-N	C1=NC2=C(N1)C(=S)N=CN2	C5H4N4S	CAS 50-44-2	CHEBI:2208	.	.	.	D09UZO	.	.	.
DR3103	Gemigliptin	CID: 11953153	Gemigliptin; 911637-19-9; UNII-5DHU18M5D6; LC15-0444; 5DHU18M5D6; 911637-19-9 (free base); (S)-1-(2-amino-4-(2,4-bis(trifluoromethyl)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)-4-oxobutyl)-5,5-difluoropiperidin-2-one; LC-15-0444; (S)-1-(2-Amino-4-(2,4-bis(trifluoromethyl)-5,6-dihydropyrido[3,4-d]pyrimidin-7(8H)-yl)-4-oxobutyl)-5,5-difluoropiperidin-2-one; Gemigliptin [INN]; Gemigliptin (prop.INN); SCHEMBL1262740; CHEMBL3707235; CHEBI:134731; ZINC68245464; AKOS025290873; DB12412; PB11419; 2-Piperidinone, 1-((2S)-2-amino-4-(5,8-dihydro-2,4-bis(trifluoromethyl)pyrido(3,4-d)pyrimidin-7(6H)-yl)-4-oxobutyl)-5,5-difluoro-; HY-14892; Pyrido(3,4-d)pyrimidine, 7-((3S)-3-amino-4-(5,5-difluoro-2-oxo-1-piperidinyl)-1-oxobutyl)-5,6,7,8-tetrahydro-2,4-bis(trifluoromethyl)-; LC-150444; CS-0003618; D10502; Q5530612; 1-((2S)-2-Amino-4-(2,4-bis(trifluoromethyl)-5,8-dihydropyrido(3,4-d)pyrimidin-7(6H)-yl)-4-oxobutyl-5,5-difluoropiperidin-2-one; 1-[(2S)-2-amino-4-[2,4-bis(trifluoromethyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-5,5-difluoropiperidin-2-one	Small molecule	1S/C18H19F8N5O2/c19-16(20)3-1-12(32)31(8-16)6-9(27)5-13(33)30-4-2-10-11(7-30)28-15(18(24,25)26)29-14(10)17(21,22)23/h9H,1-8,27H2/t9-/m0/s1	ZWPRRQZNBDYKLH-VIFPVBQESA-N	C1CC(CN(C1=O)CC(CC(=O)N2CCC3=C(C2)N=C(N=C3C(F)(F)F)C(F)(F)F)N)(F)F	C18H19F8N5O2	CAS 911637-19-9	CHEBI:134731	.	.	.	D0ZD3C	.	.	.
DR3141	N-(4-hydroxyphenyl) retinamide	.	.	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.
DR3168	Phentolamine	CID: 5775	phentolamine; Regitine; 50-60-2; Regitin; Fentolamin; Dibasin; Rogitine; Phentolaminum; Fentolamina; C 7337 Ciba; 3-[(4,5-dihydro-1H-imidazol-2-ylmethyl)(4-methylphenyl)amino]phenol; 2-(N-(m-Hydroxyphenyl)-p-toluidinomethyl)imidazoline; 3-(((4,5-Dihydro-1H-imidazol-2-yl)methyl)(p-tolyl)amino)phenol; Phentolamine mesylas; C 7337; UNII-Z468598HBV; 2-(m-Hydroxy-N-p-tolylanilinomethyl)-2-imidazoline; Phenol, 3-(((4,5-dihydro-1H-imidazol-2-yl)methyl)(4-methylphenyl)amino)-; 2-((N-(m-Hydroxyphenyl)-p-toluidino)methyl)-2-imidazoline; 2-(N'-p-Tolyl-N'-m-hydroxyphenylaminomethyl)-2-imidazoline; Phenol, m-(N-(2-imidazolin-2-ylmethyl)-p-toluidino)-; MLS000040874; CHEBI:8081; 2-Imidazoline, 2-((N-(m-hydroxyphenyl)-p-toluidino)methyl)-; Z468598HBV; NCGC00016311-10; Phenotolamine; Phentalamine; Regitipe; SMR000058051; DSSTox_CID_3462; Phenol, 3-[[(4,5-dihydro-1H-imidazol-2-yl)methyl](4-methylphenyl)amino]-; DSSTox_RID_77036; DSSTox_GSID_23462; Phentolamine [INN:BAN]; Fentolamina [INN-Spanish]; Phentolaminum [INN-Latin]; Fentolamine; CAS-50-60-2; Phentolamine (INN); HSDB 3382; EINECS 200-053-1; BRN 0272944; C-7337; Regitina; phentol amine; Rogitine (Salt/Mix); Spectrum_000077; Opera_ID_116; 3-[N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-4-methylanilino]phenol; Prestwick0_000230; Prestwick1_000230; Prestwick2_000230; Prestwick3_000230; Spectrum3_000788; Spectrum4_000899; Spectrum5_001704; CHEMBL597; cid_5775; SCHEMBL5653; Lopac0_000982; BSPBio_000279; BSPBio_001435; BSPBio_002496; GTPL502; KBioGR_001338; KBioSS_000477; 5-25-09-00365 (Beilstein Handbook Reference); cid_91430; MLS001201741; DivK1c_000807; SPBio_002200; BPBio1_000307; PHE035; DTXSID4023462; BCBcMAP01_000014; BDBM31046; KBio1_000807; KBio2_000477; KBio2_003045; KBio2_005613; KBio3_001716; ZINC20251; NINDS_000807; HMS1791H17; HMS1989H17; HMS2089E03; HMS2235D17; HMS3372H21; HMS3402H17; Tox21_110364; BBL010978; STK802099; AKOS004119917; Tox21_110364_1; CCG-205062; DB00692; SDCCGSBI-0050955.P005; CAS-73-05-2; IDI1_000807; SMP1_000236; NCGC00016311-01; NCGC00016311-02; NCGC00016311-03; NCGC00016311-04; NCGC00016311-05; NCGC00016311-06; NCGC00016311-07; NCGC00016311-08; NCGC00016311-09; NCGC00016311-11; NCGC00016311-12; NCGC00016311-13; NCGC00016311-14; NCGC00016311-15; NCGC00016311-16; NCGC00016311-17; NCGC00016311-19; NCGC00016311-33; NCGC00021804-06; NCGC00021804-07; NCGC00021804-08; NCGC00021804-09; NCGC00021804-10; SBI-0050955.P004; DB-050268; FT-0603219; EN300-51916; D08362; AB00053768-28; AB00053768_29; AB00053768_30; 242P985; L001116; Q420360; m-[N-(2-Imidazolin-2-ylmethyl)-p-toluidino]phenol; W-105944; BRD-K90333595-001-02-8; BRD-K90333595-003-04-0; 2-[N-(3-Hydroxyphenyl)-p-toluidinomethyl]-2-imidazolidine; 3-[(4,5-Dihydro-1H-imidazol-2-ylmethyl)-4-methylanilino]phenol #; 3-[4,5-dihydro-1H-imidazol-2-ylmethyl-(4-methylphenyl)amino]phenol; 3-[N-(2-imidazolin-2-ylmethyl)-4-methyl-anilino]phenol;hydrochloride; 3-[N-(2-imidazolin-2-ylmethyl)-4-methyl-anilino]phenol;mesylic acid; 3-[4,5-dihydro-1H-imidazol-2-ylmethyl-(4-methylphenyl)amino]phenol;methanesulfonic acid	Small molecule	1S/C17H19N3O/c1-13-5-7-14(8-6-13)20(12-17-18-9-10-19-17)15-3-2-4-16(21)11-15/h2-8,11,21H,9-10,12H2,1H3,(H,18,19)	MRBDMNSDAVCSSF-UHFFFAOYSA-N	CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O	C17H19N3O	CAS 50-60-2	CHEBI:8081	.	.	.	D01JUF	.	.	.
DR3220	Volasertib	CID: 10461508	Volasertib; 755038-65-4; BI 6727; Volasertib (BI 6727); BI6727 (Volasertib); BI-6727; UNII-6EM57086EA; BI6727; 6EM57086EA; N-((1s,4S)-4-(4-(cyclopropylmethyl)piperazin-1-yl)cyclohexyl)-4-(((R)-7-ethyl-8-isopropyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-methoxybenzamide; N-(Trans-4-(4-(cyclopropylMethyl)piperazin-1-yl)cyclohexyl)-4-(((R)-7-ethyl-8-isopropyl-5-Methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)aMino)-3-MethoxybenzaMide; N-[4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl]-4-[[(7R)-7-ethyl-5-methyl-6-oxo-8-propan-2-yl-7H-pteridin-2-yl]amino]-3-methoxybenzamide; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI 6727 (Volasertib); BI6727 (Volasertib)/; cc-629; MLS006011195; SCHEMBL738946; GTPL7947; SCHEMBL2169101; SCHEMBL9888052; CHEMBL1233528; CHEMBL4284151; SCHEMBL21916558; BCPP000341; C34H50N8O3; AOB87138; BCP02405; EX-A1364; ABP000330; BDBM50402023; MFCD20926414; NSC757149; NSC800965; s2235; ZINC39716290; AKOS030257530; ZINC100071772; ZINC248087828; BCP9000403; CCG-264952; CS-0274; DB12062; NSC-757149; NSC-800965; PB19742; NCGC00263087-01; NCGC00263087-02; NCGC00263087-03; NCGC00263087-12; NCGC00263087-15; NCGC00485964-01; AC-32844; AS-16996; HY-12137; SMR004702964; SW218140-2; X7437; D10182; Q-4502; SR-03000003275; Q7939986; SR-03000003275-1; Benzamide, N-(trans-4-(4-(cyclopropylmethyl)-1-piperazinyl)cyclohexyl)-4-(((7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl)amino)-3-methoxy-; N-((trans)-4-(4-(cyclopropylmethyl)piperazin-1-yl)cyclohexyl)-4-((R)-7-ethyl-8-isopropyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-ylamino)-3-methoxybenzamide; n-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide; n-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxybenzamide	Small molecule	1S/C34H50N8O3/c1-6-28-33(44)39(4)29-20-35-34(38-31(29)42(28)22(2)3)37-27-14-9-24(19-30(27)45-5)32(43)36-25-10-12-26(13-11-25)41-17-15-40(16-18-41)21-23-7-8-23/h9,14,19-20,22-23,25-26,28H,6-8,10-13,15-18,21H2,1-5H3,(H,36,43)(H,35,37,38)/t25?,26?,28-/m1/s1	SXNJFOWDRLKDSF-XKHVUIRMSA-N	CCC1C(=O)N(C2=CN=C(N=C2N1C(C)C)NC3=C(C=C(C=C3)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)OC)C	C34H50N8O3	CAS 755038-65-4	.	.	.	.	D00BYM	.	.	.
DR3226	Bis-chloroethylnitrosourea	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR3231	Busulfan	CID: 2478	Busulfano; Busulfanum; Busulfex; Busulphan; Busulphane; Butanedioldimethanesulfonate; Buzulfan; Citosulfan; Glyzophrol; Leucosulfan; Mablin; Methanesulfonic; Mielevcin; Mielosan; Mielucin; Milecitan; Mileran; Misulban; Mitosan; Mitostan; Myeleukon; Myeloleukon; Myelosan; Myelosanum; Mylecytan; Myleran; Mylerlan; Sulfabutin; Sulphabutin; Busulfan GlaxoSmithKline Brand; Busulfan Orphan Brand; Busulfan Wellcome; Busulfan Wellcome Brand; Glaxo Wellcome Brand of Busulfan; GlaxoSmithKline Brand of Busulfan; Myleran tablets; Orphan Brand of Busulfan; Tetramethylene bis[methanesulfonate]; Tetramethylene dimethane sulfonate; Tetramethylenester kyseliny methansulfonove; Tetramethylenester kyseliny methansulfonove[Czech]; Wellcome Brand of Busulfan; AN 33501; CB 2041; GT 2041; GT 41; X 149; Acid, tetramethylene ester; Alkylating agent: crosslinks guanine residues; Busulfan [INN:JAN]; Busulfano [INN-Spanish]; Busulfanum [INN-Latin]; MYLERAN (TN); Methanesulfonic acid, tetram ethylene ester; Methanesulfonic acid, tetramethylene ester; Myleran (TN); Sulfabutin (VAN); Tetramethylene bis(methanesulfonate); Tetramethylene {bis[methanesulfonate]}; Wellcome, Busulfan; C.B. 2041; G.T. 41; Myleran, Busulfex, Busulfan; Busulfan (JP15/USP/INN); Butane-1,4-diyl dimethanesulfonate; BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE); N-Butane-1,3-di(methylsulfonate); 1,4-BUTANEDIOL DIMETHANESULFONATE; 1,4-Bis(methanesulfonoxy)butane; 1,4-Bis(methanesulfonyloxy)butane; 1,4-Bis[methanesulfonoxy]butane; 1,4-Butanedi yl dimethanesulfonate; 1,4-Butanediol dimethanesulphonate; 1,4-Butanediol dimethylsulfonate; 1,4-Butanediol, dimethanesulfonate; 1,4-Butanediol, dimethanesulphonate; 1,4-Butanediyl dimethanesulfonate; 1,4-Di(methylsulfonoxy)butane; 1,4-Dimesyloxybutane; 1,4-Dimethane sulfonyl oxybutane; 1,4-Dimethanesulfonoxybutane; 1,4-Dimethanesulfonoxylbutane; 1,4-Dimethanesulfonyloxybutane; 1,4-Dimethanesulphonyloxybutane; 1,4-Dimethylsulfonoxybutane; 1,4-Dimethylsulfonyloxybutane; 1,{4-Bis[methanesulfonoxy]butane}; 4-((Methylsulfonyl)oxy)butyl methanesulfonate; 4-methylsulfonyloxybutyl methanesulfonate	Small molecule	1S/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3	COVZYZSDYWQREU-UHFFFAOYSA-N	CS(=O)(=O)OCCCCOS(=O)(=O)C	C6H14O6S2	CAS 55-98-1	CHEBI:28901	.	.	.	D07SUG	.	.	.
DR3243	Clofarabine	CID: 119182	CAFdA; CFB; Clofarabina; Clofarabinum; Clofarex; Clolar; Evoltra; Clofarabine [USAN]; Clolar (TN); Evoltra (TN); Clofarabine (USAN/INN); Clolar, Evoltra, Clofarabine; Cl-F-Ara-A; (2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol; 2-Chloro-9-(2-deoxy-2-fluoro-b-D-arabinofuranosyl)-9H-purin-6-amine; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine; 2-Cl-2'-F-araA; 2-chloro-9-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)adenine; 3S211048	Small molecule	1S/C10H11ClFN5O3/c11-10-15-7(13)5-8(16-10)17(2-14-5)9-4(12)6(19)3(1-18)20-9/h2-4,6,9,18-19H,1H2,(H2,13,15,16)/t3-,4+,6-,9-/m1/s1	WDDPHFBMKLOVOX-AYQXTPAHSA-N	C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)F)Cl)N	C10H11ClFN5O3	CAS 123318-82-1	.	.	.	.	D0R5RR	.	.	.
DR3248	Imipramine	CID: 3696	imipramine; Melipramine; Imidobenzyle; 50-49-7; Antideprin; Berkomine; Dimipressin; Melipramin; Tofranil; Intalpram; Nelipramin; Dynaprin; Janimine; Timolet; Irmin; Dpid; Dyna-zina; Impramine; Promiben; Censtim; Censtin; Imiprin; Iramil; Imipramina; Declomipramine; Eupramin; Imipramin; Imipraminum; Psychoforin; 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; Imavate; Imizine; Surplix; Imizin; Tofranil, base; Imipramine Hcl; Tofranil-PM; Imizinum; Pramine; N-(gamma-Dimethylaminopropyl)iminodibenzyl; N-(3-Dimethylaminopropyl)-o-iminodibenzyl; 2,2'-(3-Dimethylaminopropylimino)bibenzyl; 2,2'-(3-Dimethylaminopropylimino)dibenzyl; Tofranil (free base); SK-Pramine; UNII-OGG85SX4E4; NSC 169866; CHEMBL11; 1-(3-Dimethylaminopropyl)-4,5-dihydro-2,3,6,7-dibenzazepine; 10,11-Dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine; 5,6-Dihydro-N-(3-(dimethylamino)propyl)-11H-dibenz(b,e)azepine; 5-(3-(Dimethylamino)propyl)-10,11-dihydro-5H-dibenz(b,f)azepine; 5-(3-Dimethylaminopropyl)-10,11-dihydro-5H-dibenzo(b,f)azepine; OGG85SX4E4; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine; CHEBI:47499; 5,e)azepine; 5,e]azepine; 5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(dimethylamino)propyl)-; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-; 5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-; Imipramine-d6; Imidol; NSC-169866; 113-52-0 (HCl); NCGC00015563-07; Imipramina [Italian]; Tofranil (TN); 10,11-Dihydro-5-(3-(dimethylamino)propyl)-5H-dibenz[b,f]azepine; 3-(5H-DIBENZO[B,F]AZEPIN-5-YL)-N,N-DIMETHYLPROPAN-1-AMINE; N-(.gamma.-Dimethylaminopropyl)iminodibenzyl; 5H-Dibenz(b,f)azepine, 5-(3-(dimethylamino)propyl)-10,11-dihydro-; 3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethyl-1-propanamine; Imipramine [INN:BAN]; DSSTox_CID_23881; DSSTox_RID_80080; DSSTox_GSID_43881; Imipraminum [INN-Latin]; Imipramina [INN-Spanish]; 3-(10,11-dihydro-5h-dibenz[b,f]azepin-5-yl)propyldimethylamine; G-22355; 5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine; 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine  hydrochloride; CAS-50-49-7; 3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine;3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; Imipramine (INN); CCRIS 9173; HSDB 3100; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethyl-propan-1-amine; Janimine (hydrochloride); Tofranil (hydrochloride); CAS-113-52-0; EINECS 200-042-1; BRN 0256892; 5H-Dibenz(b, 5-(3-(dimethylamino)propyl)-10,11-dihydro-; 5H-Dibenz[b, 5-[3-(dimethylamino)propyl]-10,11-dihydro-; Tofranil base; 5H-Dibenz[b,f]azepine, 5-[3-(dimethylamino)propyl]-10,11-dihydro-; Imipramine-d3 HCl; Imizin (Salt/Mix); Imavate (Salt/Mix); Imizine (Salt/Mix); Surplix (Salt/Mix); Eupramin (Salt/Mix); Imizinum (Salt/Mix); Tofranil (Salt/Mix); PubChem21397; Spectrum_000915; Psychoforin (Salt/Mix); Prestwick0_000072; Prestwick1_000072; Prestwick2_000072; Prestwick3_000072; SK-Pramine (Salt/Mix); Spectrum2_000990; Spectrum3_000466; Spectrum4_000016; Spectrum5_000864; Lopac-I-7379; Lopac0_000702; Oprea1_200908; SCHEMBL34282; BSPBio_000283; BSPBio_002172; GTPL357; KBioGR_000391; KBioSS_001395; BIDD:GT0116; DivK1c_000559; SPBio_001059; SPBio_002204; G-22355 (Salt/Mix); BPBio1_000313; Clomipramine HCl EP Impurity B; DTXSID1043881; KBio1_000559; KBio2_001395; KBio2_003963; KBio2_006531; KBio3_001392; ZINC20245; NINDS_000559; HMS2089G08; ORG-2463; Tox21_110174; BDBM50010859; CCG-36485; MFCD31699979; NSC169866; STL416211; AKOS016010320; N,N-Dimethyl-10,11-dihydro-5H-dibenzo[b,f]azepine-5-propanamine-2,8-D2; Tox21_110174_1; DB00458; MCULE-9471074673; SDCCGSBI-0050680.P005; IDI1_000559; MRF-0000592; NCGC00015563-01; NCGC00015563-02; NCGC00015563-03; NCGC00015563-04; NCGC00015563-05; NCGC00015563-06; NCGC00015563-08; NCGC00015563-09; NCGC00015563-10; NCGC00015563-11; NCGC00015563-13; NCGC00015563-25; NCGC00024253-03; NCGC00024253-04; 112898-42-7; 2241983-10-6; 5-(3-Dimethylaminopropyl)-10,f)azepine; SY246340; Trimipramine maleate impurity, imipramine-; SBI-0050680.P004; WLN: T C676 BN&T&J B3N1&1; 5-(3-(Dimethylamino)propyl)-10,f)azepine; AB00053486; FT-0670319; FT-0697093; W0042; 5H-Dibenz[b, 10,11-dihydro-N,N-dimethyl-; C07049; D08070; Q58396; AB00053486-15; AB00053486_16; AB00053486_17; 1-(3-Dimethylaminopropyl)-4,3,6,7-dibenzazepine; L000739; W-109253; BRD-K38436528-003-05-5; BRD-K38436528-003-15-4; 5H-Dibenz(b, 10,11-dihydro-5-(3-(dimethylamino)propyl)-; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl- (9CI); 3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethyl-1-propanamine #; 5H-Dibenz(b,5-[3-(dimethylamino)propyl]-10,11-dihydro-mixed with ethyl alcohol; Clomipramine EP Impurity B; 10,11-Dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine; (3-{2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl}propyl)dimethylamine; 5-(3-(dimethylamino)propyl)-10,11-dihydro-5H-dibenz[b,f]azepine;10,11-Dehydroimipramine;Depramine	Small molecule	1S/C19H24N2/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21/h3-6,8-11H,7,12-15H2,1-2H3	BCGWQEUPMDMJNV-UHFFFAOYSA-N	CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31	C19H24N2	CAS 50-49-7	CHEBI:47499	.	.	.	D06ZUK	.	.	.
DR3286	FTY720	CID: 107969	Fingolimod hydrochloride; 162359-56-0; FTY720; Fingolimod HCl; Gilenya; Gilenia; Fty 720; Fty-720; Fingolimod (hydrochloride); Fingolimod (FTY720) HCl; 2-Amino-2-(4-octylphenethyl)propane-1,3-diol hydrochloride; 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride; UNII-G926EC510T; FTY720 free base; CHEBI:63112; 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride; 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol;hydrochloride; G926EC510T; MFCD00939512; Gilenya (TN); 1,3-Propanediol, 2-amino-2-[2-(4-octylphenyl)ethyl]-, hydrochloride; 2-AMINO-2-[2-(4-OCTYL-PHENYL)-ETHYL]-PROPANE-1,3-DIOL HCL; 1,3-Propanediol, 2-amino-2-[2-(4-octylphenyl)ethyl]-, hydrochloride (1:1); FTY720 hydrochloride; Fingolimod-d4 Hydrochloride; 2-amino-2-(4-octylphenethyl)propane-1,3-diol hydrochloride.; 1,3-Propanediol, 2-amino-2-(2-(4-octylphenyl)ethyl)-, hydrochloride; 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol hydrochloride; 2-Amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol, hydrochloride; Fingolimod hydrochloride [USAN]; Fingolimod (FTY720); Imusera; 2-Amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol hydrochloride; Fingolimod, HCl; FTY720,Fingolimod; Fin;limod hydrochloride; PubChem23815; FTY720 - Fingolimod; Fingolimod HClFTY-720; Epitope ID:156573; SCHEMBL81362; cc-329; MLS006010179; Fingolimod (FTY-720 HCl); FTY-720 HYDROCHLORIDE; CHEMBL544665; FTY-720A; Fingolimod hydrochloride FTY720; AOB7477; DTXSID00167364; EX-A960; TDI-132; 2-Amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol, HCl; BCPP000225; BCP01808; Fingolimod hydrochloride (JAN/USAN); s5002; AKOS005145784; AC-1929; AM84549; BCP9000705; CCG-265016; CS-0114; KS-1172; AK-33554; HY-12005; SMR004701287; SY057854; AB0018286; DB-014816; A8548; F1018; FT-0643569; SW219384-1; 162359-56-0 (HCl); EC-000.2314; A25158; D04187; J10426; W-5231; 359F560; SR-01000942237; Q-101363; SR-01000942237-2; Q27132395; 2-(4-octylphenethyl)-2-aminopropane-1,3-diol hydrochloride; 2-amino-2-[2-(4-octylphenyl) ethyl]-1,3-propanediol hydrochloride; 2-Amino-2-[2-(4-octylphenyl)-ethyl]-1,3-propanediol hydrochloride; 2-Amino-2-[2-(4-n-octylphenyl)ethyl]propane-1,3-diol Hydrochloride; 2-Amino-2-[2-(4-octyl-phenyl)-ethyl]-propane -1,3-diol hydrochloride; 2-Amino-2-[2-(4-octyl-phenyl)-ethyl]-propane-1,3-diol hydrochloride	Small molecule	1S/C19H33NO2.ClH/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22;/h9-12,21-22H,2-8,13-16,20H2,1H3;1H	SWZTYAVBMYWFGS-UHFFFAOYSA-N	CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl	C19H34ClNO2	CAS 162359-56-0	CHEBI:63112	.	.	.	D0HI1K	.	.	.
DR3313	Isoniazid	CID: 3767	isoniazid; 54-85-3; Isonicotinic acid hydrazide; Isonicotinohydrazide; pyridine-4-carbohydrazide; Isoniazide; Nydrazid; Rimifon; Isonicotinic hydrazide; Laniazid; Isonicotinylhydrazine; Andrazide; Cotinazin; Dinacrin; Hydrazid; Neoteben; Nicizina; Nicotibina; Nicozide; Pycazide; Tubazide; Ditubin; Iscotin; Isolyn; Isonex; Mybasan; Niconyl; Hyzyd; Isonicotinhydrazid; Antimicina; Atcotibine; Chemiazid; Hidranizil; Hidrasonil; Hydrazide; Isobicina; Isocidene; Isohydrazide; Isonicotan; Isonicotil; Isonidrin; Isonikazid; Isonindon; Isonizide; Isotebezid; Neumandin; Pyricidin; Pyrizidin; Stanozide; Armazid; Armazide; Cemidon; Chemidon; Defonin; Diforin; Ebidene; Ertuban; Eutizon; Fimalene; Hidrulta; Hycozid; Idrazil; Isidrina; Ismazide; Isocotin; Isonerit; Isonicid; Isonico; Isonide; Isonilex; Isonirit; Isoniton; Isozide; Niadrin; Nicetal; Nidaton; Nidrazid; Nikozid; Nitadon; Nyscozid; Pelazid; Raumanon; Retozide; Rimicid; Rimitsid; Tubazid; Azuren; Cedin; Eralon; Evalon; Hidrun; Inizid; Isocid; Isonin; Isozyd; Neoxin; Nevin; Niplen; Antituberkulosum; Inah; Ido-tebin; 4-Pyridinecarboxylic acid, hydrazide; Bacillin; Isoniacid; Isotinyl; Nicazide; Nicotibine; Nicotisan; Phthisen; Pyreazid; Rimiphone; Tubilysin; Isotebe; Percin; Razide; Tyvid; Isoniazid SA; Neo-Tizide; GINK; Armacide; Cortinazine; Cotinizin; Isonicazide; Isotamine; Robisellin; Sauterazid; Teebaconin; Tibinide; Unicozyde; Vazadrine; Zonazide; Dibutin; Hyozid; Isonicotinoyl hydrazide; Tebecid; Tekazin; Tubeco; Tubicon; Tubomel; Vederon; Zinadon; Preparation 6424; Isonicotinyl hydrazide; TB-Razide; Sanohidrazina; Tisiodrazida; Laniozid; Niteban; Pyridicin; Robiselin; Roxifen; Sauterzid; Tebenic; Tebexin; Tebilon; Tibazide; Tibison; Tibivis; Tibizide; Tibusan; Tuberian; Tubizid; Unicocyde; Tebos; Tisin; Tizide; 4-Pyridinecarboxylic acid hydrazide; Dow-Isoniazid; FSR 3; TB-Vis; Inh-Burgthal; INH; TB-Phlogin; Zidafimia; Isokin; Nitebannsc 9659; In-73; RU-EF-Tb; isonicotinoylhydrazide; Isonicotinoylhydrazine; 4-Pyridinecarbonylhydrazine; BP 5015; FSR-3; Isonicotinsaeurehydrazid; 4-(Hydrazinocarbonyl)pyridine; 4-pyridinecarbohydrazide; 4-Pyridylcarbonylhydrazide; NSC 9659; MFCD00006426; HIA; RP-5015; UNII-V83O1VOZ8L; pyridine-4-carboxylic acid hydrazide; Isonicotinylhydrazide; L 1945; 5015 RP; CHEBI:6030; isonicotinate hydrazide; 5015 R.P.; CHEMBL64; V83O1VOZ8L; MLS000069444; Isozid; NSC9659; Isoniazid-d4; NSC-9659; Cedin (Aerosol); CAS-54-85-3; bacillen; tebemid; tubercid; NCGC00016244-09; Continazine; Isoniazidum; Tubecotubercid; Abdizide; Anidrasona; Isoniazida; Isonizida; SMR000059082; Tibemid; Tibiazide; Fetefu; Hydra; DSSTox_CID_755; DSSTox_RID_75771; DSSTox_GSID_20755; LANIZID; 4-Pyridinecarboxylic hydrazide; Isonicotinic acid hydrazide, 99%; RY-EF-Tb; Isoniazidum [INN-Latin]; Isoniazida [INN-Spanish]; AZT + Isoniazid; FRS-3; Isoniazid(Tubizid); Laniazid (TN); CCRIS 351; Usaf cb-2; HSDB 1647; Isonicotinsaeurehydrazid [German]; INHd20; SR-01000003025; EINECS 200-214-6; RP 5015; Mayambutol; AI3-23936; I.A.I.; Idrazide dell'acido isonicotinico [Italian]; isoniazid (inh); Isoniazid/INH; Idrazide dell'acido isonicotinico; Isoniazid [USP:INN:BAN:JAN]; isonicotinhydrazide; Soniazid,(S); NIZ; Prestwick_578; Isoniazid (Tubizid); Rifater (Salt/Mix); Isonicotinic acid hydrazide (Isoniazid); Spectrum_000853; ACMC-209ljq; Opera_ID_454; isonicotinicacid hydrazide; isonicotinic acid hydrazid; Prestwick0_000161; Prestwick1_000161; Prestwick2_000161; Prestwick3_000161; Spectrum2_000107; Spectrum3_000472; Spectrum4_000022; Spectrum5_000876; I0138; WLN: T6NJ DVMZ; isonicotinic acid hydrazone; SCHEMBL228; Biomol-NT_000288; Epitope ID:141801; 4-Pyridylcarbonyl hydrazide; Oprea1_396155; BSPBio_000021; BSPBio_002204; KBioGR_000423; KBioSS_001333; MLS001055327; ARONIS25141; BIDD:GT0140; DivK1c_000070; SPECTRUM1500355; SPBio_000094; SPBio_001942; Isoniazid (JP17/USP/INN); BPBio1_000025; BPBio1_001322; SCHEMBL2998929; ZINC1590; component of Niadox (Salt/Mix); DTXSID8020755; HMS500D12; KBio1_000070; KBio2_001333; KBio2_003901; KBio2_006469; KBio3_001424; NINDS_000070; HMS1568B03; HMS1920H09; HMS2089I16; HMS2091N19; HMS2095B03; HMS2234G04; HMS3259E19; HMS3373O01; HMS3655L03; HMS3712B03; KUC109571N; Pharmakon1600-01500355; 4-pyridinecarbohydrazide(Isoniazid); BCP13791; HY-B0329; STR00210; [(4-Pyridinylcarbonyl)oxy]hydrazine; Anti-TNF monoclonal antibody & INH; Tox21_113640; Tox21_201367; Tox21_300193; ANW-32196; BBL008409; BDBM50336507; CCG-39710; NSC757078; s1937; SBB004195; STK086288; AKOS000119062; Isonicotinic acid hydrazide(Isoniazid); Tox21_113640_1; DB00951; KSC-27-048; MCULE-6324947959; NC00513; NSC-757078; PS-4129; IDI1_000070; UPCMLD0ENAT5791176:001; NCGC00016244-01; NCGC00016244-02; NCGC00016244-03; NCGC00016244-04; NCGC00016244-05; NCGC00016244-06; NCGC00016244-07; NCGC00016244-08; NCGC00016244-10; NCGC00016244-11; NCGC00016244-12; NCGC00016244-14; NCGC00016244-15; NCGC00022648-03; NCGC00022648-04; NCGC00022648-05; NCGC00022648-06; NCGC00022648-07; NCGC00254094-01; NCGC00258919-01; AK-46317; ST078858; SY010614; Isoniazid, Vetec(TM) reagent grade, 98%; SBI-0051419.P003; [NH-]NC(=[OH+])C1=CC=NC=C1; AB00052025; BB 0240534; FT-0627424; FT-0670476; SW196752-3; T7976; ISONICOTINIC ACID HYDRAZIDE(ISONIAZIDE); C07054; D00346; Isoniazid, analytical standard, >=99% (TLC); 10319-EP2272972A1; 10319-EP2272973A1; 10319-EP2274983A1; 10319-EP2275102A1; 10319-EP2275401A1; 10319-EP2277872A1; 10319-EP2280000A1; 10319-EP2280012A2; 10319-EP2281563A1; 10319-EP2289510A1; 10319-EP2289876A1; 10319-EP2295407A1; 10319-EP2295411A1; 10319-EP2295416A2; 10319-EP2295433A2; 10319-EP2298312A1; 10319-EP2298736A1; 10319-EP2298747A1; 10319-EP2298748A2; 10319-EP2301536A1; 10319-EP2301538A1; 10319-EP2301924A1; 10319-EP2305640A2; 10319-EP2305642A2; 10319-EP2305808A1; 10319-EP2308852A1; 10319-EP2311455A1; 10319-EP2311824A1; 10319-EP2311830A1; 10319-EP2314584A1; 10319-EP2316452A1; 10319-EP2316459A1; 10319-EP2380872A1; 40687-EP2298761A1; 40687-EP2311830A1; AB00052025-20; AB00052025-21; AB00052025_22; AB00052025_23; AB00052025_24; AB00052025_25; 101033-EP2272832A1; 101033-EP2272972A1; 101033-EP2272973A1; 101033-EP2277872A1; 101033-EP2295053A1; 101033-EP2298776A1; 101033-EP2301544A1; AE-641/02310003; Q423169; SR-01000003025-2; SR-01000003025-3; BRD-K87202646-001-26-8; Isoniazid, certified reference material, TraceCERT(R); Z58981801; F0391-0007; Isoniazid, European Pharmacopoeia (EP) Reference Standard; Isoniazid, United States Pharmacopeia (USP) Reference Standard; Isoniazid, Pharmaceutical??Secondary??Standard;??Certified??Reference??Material	Small molecule	1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)	QRXWMOHMRWLFEY-UHFFFAOYSA-N	C1=CN=CC=C1C(=O)NN	C6H7N3O	CAS 54-85-3	CHEBI:6030	.	.	.	D09XQF	.	.	.
DR3320	Caspofungin	CID: 2826718	Caspofungin; Cancidas; L-743,872; CHEBI:474180; MK-991; Cancidas (TN); L-743872; MK-0991; Caspofungin (INN); CHEMBL499808; SCHEMBL6726364; N-[(2-aminoethylamino)-[(1R)-3-amino-1-hydroxy-propyl]-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-trihydroxy-[(1R)-1-hydroxyethyl]-hexaoxo-[?]yl]-10,12-dimethyl-tetradecanamide; BDBM50478215; NSC754342; NSC-754342; D07626; Q420875; Pneumocandin B0, 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-(threo-3-hydroxy-L-ornithine)-; Pneumocandin B0, 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]- (9CI)	Small molecule	1S/C52H88N10O15/c1-5-28(2)24-29(3)12-10-8-6-7-9-11-13-39(69)56-34-26-38(68)46(55-22-21-54)60-50(75)43-37(67)19-23-61(43)52(77)41(36(66)18-20-53)58-49(74)42(45(71)44(70)31-14-16-32(64)17-15-31)59-48(73)35-25-33(65)27-62(35)51(76)40(30(4)63)57-47(34)72/h14-17,28-30,33-38,40-46,55,63-68,70-71H,5-13,18-27,53-54H2,1-4H3,(H,56,69)(H,57,72)(H,58,74)(H,59,73)(H,60,75)/t28?,29?,30-,33-,34+,35+,36-,37+,38-,40+,41+,42+,43+,44+,45+,46+/m1/s1	JYIKNQVWKBUSNH-OGZDCFRISA-N	CCC(C)CC(C)CCCCCCCCC(=O)NC1CC(C(NC(=O)C2C(CCN2C(=O)C(NC(=O)C(NC(=O)C3CC(CN3C(=O)C(NC1=O)C(C)O)O)C(C(C4=CC=C(C=C4)O)O)O)C(CCN)O)O)NCCN)O	C52H88N10O15	CAS 162808-62-0	CHEBI:474180	.	.	.	D00ZCN	.	.	.
DR3335	Dichloroacetate	CID: 25975	Dichloroacetate; 2,2-dichloroacetate; Dichloracetate; Dichloroacetate ion; 13425-80-4; Dichloroacetic acid ion(1-); DCA; BRN 3903873; 2q8h; ACETIC ACID, DICHLORO-, ION(1-); 2,2-bis(chloranyl)ethanoate; GTPL4518; CHEBI:28240; DTXSID40158610; STL483470; NCGC00241105-01; 68626-EP2292227A2; 68626-EP2292628A2; 68626-EP2298776A1; 68626-EP2308861A1; 68626-EP2374454A1; A839686; Q27077050	Small molecule	1S/C2H2Cl2O2/c3-1(4)2(5)6/h1H,(H,5,6)/p-1	JXTHNDFMNIQAHM-UHFFFAOYSA-M	C(C(=O)[O-])(Cl)Cl	C2HCl2O2-	CAS 13425-80-4	CHEBI:28240	.	.	.	D7I9JH	.	.	.
DR3388	Daratumumab	.	.	Antibody	.	.	.	.	.	.	.	.	.	D0RV4P	.	.	.
DR3439	Apatinib	CID: 11315474	Apatinib mesylate; VEGF receptor inhibitor (cancer), Advenchen; VEGFR2 receptor inhibitor (cancer), LSK/ Jiangsu Henrui/ Bukwang	Small molecule	1S/C24H23N5O/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30)	WPEWQEMJFLWMLV-UHFFFAOYSA-N	C1CCC(C1)(C#N)C2=CC=C(C=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4	C24H23N5O	CAS 811803-05-1	.	.	.	.	D0SZ6E	.	.	Apatinib
DR3472	Mifepristone	CID: 55245	mifepristone; 84371-65-3; Mifegyne; Mifeprex; RU-486; Corlux; Korlym; RU486; RU 486; RU 38486; Mifepriston; RU-38486; UNII-320T6RNW1F; MLS000069785; 320T6RNW1F; VGX-410C; CHEBI:50692; VGX-410; Mifepristone, 98%; NCGC00025179-05; SMR000058481; Mifepristonum [Latin]; Mifepristona [Spanish]; DSSTox_CID_3322; DSSTox_RID_76976; DSSTox_GSID_23322; (8S,11R,13S,14S,17S)-11-(4-(dimethylamino)phenyl)-17-hydroxy-13-methyl-17-(prop-1-yn-1-yl)-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one; (8S,11R,13S,14S,17S)-11-(4-dimethylaminophenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; (8S,11R,13S,14S,17S)-11-[4-(dimethylamino)phenyl]-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; 11-(4-DIMETHYLAMINO-PHENYL)-17-HYDROXY-13-METHYL-17-PROP-1-YNYL-1,2,6,7,8,11,12,13,14,15,16,17-DODEC AHYDRO-CYCLOPENTA[A]PHENANTHREN-3-ONE; Mifepristona; Mifepristonum; (11beta,17beta)-11-[4-(Dimethylamino)phenyl]-17-hydroxy-17-(1-propyn-1-yl)estra-4,9-dien-3-one; (11beta,17beta)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-prop-1-yn-1-ylestra-4,9-dien-3-one; (8S,11R,13S,14S,17S)-11-(4-(dimethylamino)phenyl)-17-hydroxy-13-methyl-17-(prop-1-yn-1-yl)-6,7,8,11,12,13,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3(2H)-one; RU486 (tetramethyl-rhodamine conjugated); Mifepristone [USAN:INN:BAN]; HSDB 6841; SR-01000076011; R 38486; BRN 5779404; Pictovir; RU 486-6; CCRIS 9332; 1nhz; 11beta-(p-(Dimethylamino)phenyl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one; Mifeprex (TN); Pictovir (TM); Prestwick_570; CAS-84371-65-3; Korlym (TN); 2w8y; Mifepristone (Mifeprex); Mifepristone(Mifeprex)/; Opera_ID_562; Mifepristone, >=98%; Prestwick0_000299; Prestwick1_000299; Prestwick2_000299; Prestwick3_000299; Spectrum5_002045; 11beta-(4-(Dimethylamino)phenyl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-on; 17-beta-Hydroxy-11-beta-(4-dimethylaminophenyl-1)-17-alpha-(prop-1-ynyl)oestra-4,9-dien-3-one; BIDD:PXR0123; Lopac0_000801; SCHEMBL16087; BSPBio_000238; 11beta-(4-(Dimethylamino)phenyl)-17-hydroxy-21-methyl-19-nor-17alpha-pregna-4,9-dien-20-m-3-on; 11beta-(4-(N,N-Dimethylamino)phenyl)-17alpha-(prop-1-ynyl)-delta4,9-estradiene-17beta-ol-3-one; MLS001074115; MLS001424271; (non-labelled)Mifepristone-d3; ARONIS27015; SPBio_002457; RU-486; MIFEPRISTONE; BPBio1_000262; CHEMBL438575; GTPL2805; Mifepristone (JAN/USAN/INN); CHEMBL1276308; DTXSID5023322; BDBM18627; AOB6893; HMS1568L20; HMS2052L05; HMS2090L22; HMS2095L20; HMS2230P21; HMS3262B03; HMS3412D17; HMS3649J08; HMS3676D17; HMS3712L20; HMS3884D12; ACT02598; BCP02145; ZINC3831128; Tox21_110952; Tox21_301841; Tox21_500801; ABP000437; ANW-41472; BDBM50072024; HSCI1_000369; MFCD00867226; s2606; VX-410; AKOS015895416; Tox21_110952_1; CCG-101164; CI-1073; CS-1435; DB00834; LP00801; NC00414; NSC 759862; SDCCGSBI-0050778.P002; Mifepristone 1.0 mg/ml in Acetonitrile; NCGC00025179-06; NCGC00025179-07; NCGC00025179-08; NCGC00025179-09; NCGC00025179-12; NCGC00025179-13; NCGC00025179-23; NCGC00179632-01; NCGC00255152-01; NCGC00261486-01; (11beta,17beta)-11-(4-(Dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one; (11beta,17beta)-11-(4-(Dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one; AS-13938; CPD000058481; Estra-4,9-dien-3-one, 11-(4-(dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-, (11-beta,17-beta)-; HY-13683; RU486;C-1073; EU-0100801; C07652; D00585; M 8046; W-5163; 29523-EP2272827A1; 29523-EP2275420A1; 29523-EP2295055A2; 29523-EP2295416A2; 29523-EP2298748A2; 29523-EP2298764A1; 29523-EP2298765A1; 29523-EP2305642A2; 29523-EP2308880A1; 29523-EP2311453A1; 29523-EP2311808A1; 29523-EP2311829A1; 29523-EP2311842A2; 75603-EP2269977A2; 75603-EP2308880A1; 371M653; A840767; Q411240; SR-01000721888; Q-201405; SR-01000076011-1; SR-01000076011-3; SR-01000076011-5; SR-01000076011-9; SR-01000721888-4; BRD-K37270826-001-04-5; BRD-K37270826-001-31-8; Mifepristone, United States Pharmacopeia (USP) Reference Standard; (11?,17?)-11-[4-(Dimethylamino)phenyl]-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one; 11.beta.-[4-(Dimethylamino)phenyl]-17.beta.-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one; 11beta-(4-Dimethyl-amino)-phenyl-17beta-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one; 11ss-[p-(Dimethylamino)fenyl]-17ss-hydroxy- 17-(1-propynyl)estra-4,9-dien-3-on; (10S,11S,14S,15S,17R)-17-[4-(dimethylamino)phenyl]-14-hydroxy-15-methyl-14-(prop-1-yn-1-yl)tetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadeca-1,6-dien-5-one; (10S,11S,14S,15S,17R)-17-[4-(dimethylamino)phenyl]-14-hydroxy-15-methyl-14-(prop-1-yn-1-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-1,6-dien-5-one; (11R,13S,14S,17S)-11-(4-Dimethylamino-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one; (8S,11R,13S,14S,17S)-11-[4-(dimethylamino)phenyl]-13-methyl-17-oxidanyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; 122742-25-0; 83203-42-3; Estra-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propynyl)-, (11b,17b)-	Small molecule	1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1	VKHAHZOOUSRJNA-GCNJZUOMSA-N	CC#CC1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)O	C29H35NO2	CAS 84371-65-3	CHEBI:50692	.	.	.	D0Z4EI	.	.	.
DR3489	Irinotecan	CID: 60838	Biotecan; Camptosar; Irinotecanum; IRINOTECAN HYDROCHLORIDE Trihydrate; Irinotecan Hcl; Irinotecan hydrochloride; CP0; Biotecan (TN); Campto (TN); Camptosar (TN); Irinotecan (INN); Irinotecan [INN:BAN]; Irinotecanum [INN-Latin]; IRINOTECAN, CPT-11; Camptosar, Campto, CPT-11, Irinotecan; (+)-Irinotecan; (4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE; (4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate; Irinotecan (TOPO1 inhibitor); Onivyde	Small molecule	1S/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3/t33-/m0/s1	UWKQSNNFCGGAFS-XIFFEERXSA-N	CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7	C33H38N4O6	CAS 97682-44-5	.	.	.	.	D07HOB	.	.	Irinotecan
DR3490	Salmeterol	CID: 5152	Salmeterol; 89365-50-4; Serevent; Aeromax; Salmeterolum [Latin]; GR 33343X; SALMATEROL; 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol; Salmeterol free base; SN408D; 2-(hydroxymethyl)-4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)phenol; Astmerole; CHEBI:64064; 18910-65-1 (free base); GR 33343 X; Salmeterol Fluticasone Propionate Mixture; Salmeterolum; 4-hydroxy-alpha1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol; 4-(1-hydroxy-2-(6-(4-phenylbutoxy)hexylamino)ethyl)-2-(hydroxymethyl)phenol; 2-(hydroxymethyl)-4-[1-hydroxy-2-({6-[(4-phenylbutyl)oxy]hexyl}amino)ethyl]phenol; SMR000466295; HSDB 7315; SR-01000076139; Salmeterol (USAN/INN); Salmeterol [USAN:INN:BAN]; NCGC00025247-01; Fluticasonepropiponate; (+-)-4-Hydroxy-alpha'-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-alpha,alpha'-diol; (+-)-4-Hydroxy-alpha1-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-1,3-benzenedimethanol; CPD000466295; Prestwick3_000945; Salmeterol Dimer Impurity; ACMC-1C1VM; DSSTox_CID_3571; S 2692; SCHEMBL4767; CHEMBL1263; DSSTox_RID_77087; DSSTox_GSID_23571; Lopac0_001100; BSPBio_000910; GTPL559; cc-441; MLS000759000; MLS001424322; Salmeterol Related Compound H; BPBio1_001002; DTXSID6023571; BDBM25771; HMS2052H13; HMS2090E17; HMS2097N12; HMS3268K19; HMS3394H13; HMS3412P13; HMS3714N12; HMS3886G10; AMY37616; BCP04199; EX-A4409; Tox21_113584; CS0057; MFCD00867037; s5527; STK629186; AKOS005561914; CCG-101194; CCG-205176; DB00938; GR-33343-X; NC00444; SDCCGSBI-0633788.P001; 1,3-Benzenedimethanol, 4-hydroxy-.alpha.1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-; 1,3-Benzenedimethanol, 4-hydroxy-alpha1-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-, (+-)-; MRF-0000468; NCGC00015938-03; NCGC00025247-02; 1,3-Benzenedimethanol, 4-hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-, (+-)-; 1,3-Benzenedimethanol, 4-hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl-, (+-)-; AK173141; AS-56157; HY-14302; K590; Salmeterol 100 microg/mL in Acetonitrile; CAS-89365-50-4; AB00513972; FT-0674508; FT-0674509; C07241; D05792; AB00513972-07; 365S504; L000532; Q424333; Salmeterol Impurity H (Xinafoate Adduct Impurity); Q-101428; SR-01000076139-2; SR-01000076139-6; BRD-A01320529-001-05-9; 2-hydroxymethyl-4-{1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl}phenol; 4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)-2-(hydroxymethyl)phenol; 5-[2-[6-(4-Phenylbutoxy)hexylamino]-1-hydroxyethyl]-2-hydroxybenzenemethanol; ( inverted question mark) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol; GR 33343X; 1-hydroxy-2-naphthoic acid;4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]-2-methylol-phenol	Small molecule	1S/C25H37NO4/c27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21/h3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2	GIIZNNXWQWCKIB-UHFFFAOYSA-N	C1=CC=C(C=C1)CCCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O	C25H37NO4	CAS 89365-50-4	CHEBI:64064	.	.	.	D0L5YV	.	.	.
DR3524	Lithium chloride	CID: 433294	LITHIUM CHLORIDE; 7447-41-8; Lithium chloride (LiCl); Lithiumchloride; LiCl; chlorolithium; chlorure de lithium; MFCD00011078; Lithium Cholride; UNII-G4962QA067; CHEBI:48607; CHEMBL69710; Chlorku litu; NSC327172; G4962QA067; Lithiumchlorid; Lithium Chloride, Anhydrous; Lithium chloride, ultra dry; Chlorku litu [Polish]; Lithium chloride, 99%, extra pure; Luthium chloride; ClLi; Lithium chloride, 99+%, ACS reagent; Chlorure de lithium [French]; CCRIS 5924; Lithium chloride, 99%, for molecular biology; HSDB 4281; Lithium chloride, 99%, for analysis, anhydrous; Lithium chloride solution; EINECS 231-212-3; lithium(1+) ion chloride; NSC 327172; Lithium Chloride (2.3% in Tetrahydrofuran, ca. 0.5mol/L); lithim chloride; lithii chloridum; lithium;chloride; Lithium chloride, anhydrous, chunks, 99.99% trace metals basis; cloruro de litio; Lithium Chloride Salt; Lopac-L-4408; Lithium chloride (powder); MolMap_000071; WLN: LI G; EC 231-212-3; LithiumChlorideGr(Anhydrous); Lithium chloride, ACS grade; Lopac0_000604; Lithium chloride battery grade; Lithium chloride 1 M solution; Lithium chloride, ACS reagent; DTXSID2025509; Lithium chloride, 3-5% in THF; HMS3261J10; Tox21_500604; ANW-36491; BDBM50494542; AKOS015902822; AKOS015950647; AKOS024438070; Lithium chloride, 1M aqueous solution; CCG-204693; lithium chloride, gamma irradiated, 8m; LP00604; NSC-327172; SDCCGSBI-0050586.P002; Lithium chloride, ACS reagent, >=99%; Lithium chloride, ReagentPlus(R), 99%; NCGC00015607-01; NCGC00015607-02; NCGC00015607-03; NCGC00015607-04; NCGC00015607-07; NCGC00093980-01; NCGC00093980-02; NCGC00261289-01; AK323906; BP-13612; Lithium chloride, 200mM aqueous solution; SY002997; Lithium chloride solution, 1 M in ethanol; Lithium chloride solution, 2 M in ethanol; Lithium chloride, Vetec(TM) reagent grade; EU-0100604; FT-0627896; L0204; L0222; Lithium chloride, Trace metals grade 99.9%; W8215; L 4408; Lithium chloride, SAJ first grade, >=98.0%; Lithium chloride, for molecular biology, >=99%; Lithium chloride, SAJ special grade, >=99.0%; A838146; Lithium chloride, BioXtra, >=99.0% (titration); Q422930; SR-01000076252; SR-01000076252-1; Electrolyte solution, nonaqueous, 2 M LiCl in ethanol; Lithium chloride solution, 1 M in glacial acetic acid; Lithium chloride, powder, >=99.99% trace metals basis; Z1741960146; Electrolyte solution, nonaqueous, LiCl in ethanol (saturated); Lithium chloride solution, 0.5 M in anhydrous tetrahydrofuran; Lithium chloride solution, 8 M, for molecular biology, >=99%; Lithium chloride, puriss. p.a., anhydrous, >=99.0% (AT); Lithium chloride solution, 1 M in 1,3-dimethyl-2-imidazolidinone; Lithium chloride, anhydrous, beads, -10 mesh, >=99.9% trace metals basis; Lithium chloride, anhydrous, beads, -10 mesh, 99.998% trace metals basis; Lithium chloride, puriss. p.a., ACS reagent, anhydrous, >=99.0% (AT); Lithium chloride, anhydrous, free-flowing, Redi-Dri(TM), ACS reagent, >=99%; Lithium chloride, anhydrous, free-flowing, Redi-Dri(TM), ReagentPlus(R), 99%; Lithium chloride, BioUltra, for molecular biology, anhydrous, >=99.0% (AT); Lithium atomic spectroscopy standard concentrate 1.00 g Li, 1.00 g/L, for 1 l standard solution, analytical standard; Lithium standard solution, suitable for atomic absorption spectrometry, 1 mg/mL Li, 1000 ppm Li	Small molecule	1S/ClH.Li/h1H;/q;+1/p-1	KWGKDLIKAYFUFQ-UHFFFAOYSA-M	[Li+].[Cl-]	ClLi	CAS 7447-41-8	CHEBI:48607	.	.	.	D07WXT	.	.	.
DR3561	LY294002	CID: 3973	154447-36-6; LY294002; LY 294002; LY-294002; 2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; 2-morpholino-8-phenyl-4H-chromen-4-one; 2-morpholin-4-yl-8-phenyl-4H-chromen-4-one; UNII-31M2U1DVID; 2-(morpholin-4-yl)-8-phenyl-4H-chromen-4-one; NSC 697286; 31M2U1DVID; 2-MORPHOLIN-4-YL-7-PHENYL-4H-CHROMEN-4-ONE; CHEMBL98350; 4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl-; CHEBI:65329; LY2; 4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl; LY-294,002; 2-Morpholin-4-yl-8-phenyl-chromen-4-one; BMK1-D5; Lys 294002; 4azt; 2-morpholino-8-phenyl-chromen-4-one; 15447-36-6; SF 1101; Kinome_3543; PubChem16766; Tocris-1130; 1yi3; BiomolKI_000029; 2-(morpholin-4-yl)-8-phenylchromen-4-one; Lopac-L-9908; 8-Phenyl-2-(morpholin-4-yl)-chromen-4-one; BiomolKI2_000037; cc-58; CBiol_002046; Lopac0_000710; SCHEMBL94377; BSPBio_001223; KBioGR_000563; KBioSS_000563; MLS006010131; 2-Morpholino-8-phenylchromone; 2-(4-morpholino)-8-phenyl-4H-1-benzopyran-4-one; GTPL6004; ZINC6014; DTXSID6042650; BCBcMAP01_000117; BDBM12915; KBio2_000563; KBio2_003131; KBio2_005699; KBio3_001005; KBio3_001006; EX-A073; SYN1108; BCPP000177; Bio1_000332; Bio1_000821; Bio1_001310; Bio2_000442; Bio2_000922; HMS1362M05; HMS1792M05; HMS1990M05; HMS3229G17; HMS3403M05; HMS3649E04; HMS3654M21; AMY40921; BCP00195; HSCI1_000206; NSC697286; NSC755769; s1105; AKOS017344742; BCP9000880; CCG-100633; CS-0150; DB02656; NSC-697286; NSC-755769; QC-7260; SB10965; SDCCGSBI-0050688.P003; SF-1101; IDI1_002197; NCGC00015622-01; NCGC00015622-02; NCGC00015622-03; NCGC00015622-04; NCGC00015622-05; NCGC00015622-06; NCGC00015622-07; NCGC00015622-23; NCGC00025020-01; NCGC00025020-02; NCGC00025020-03; NCGC00025020-04; NCGC00179253-01; AC-30295; AK162301; AS-16252; HY-10108; NCI60_034712; SMR002530642; AB0033714; LY-924002; FT-0660382; M2410; SW217688-2; X7411; EC-000.2341; 2-Morpholino-8-phenyl-4-oxo-4H-1-benzopyran; C15195; K00235; S-7706; J-510126; Q4042503; SR-01000076245-7; 4H-1-Benzopyran-4-one,2-(4-morpholinyl)-8-phenyl-; BRD-K27305650-001-05-9; InSolution LY 294002 - CAS 154447-36-6; LY-294,002 hydrochloride, solid, >=98% (HPLC); LY 294002 - CAS 154447-36-6; 4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl- (9CI); H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl- (9CI); LY 294002; 2-(4-Morpholino)-8-phenyl-4H-1-benzopyran-4-one	Small molecule	1S/C19H17NO3/c21-17-13-18(20-9-11-22-12-10-20)23-19-15(7-4-8-16(17)19)14-5-2-1-3-6-14/h1-8,13H,9-12H2	CZQHHVNHHHRRDU-UHFFFAOYSA-N	C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4	C19H17NO3	CAS 154447-36-6	CHEBI:65329	.	.	.	D09SFV	.	.	.
DR3599	Atorvastatin	CID: 60823	atorvastatin; 134523-00-5; Cardyl; Lipitor; ATORVASTATIN CALCIUM; Torvast; (3R,5R)-7-(2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoic acid; UNII-A0JWA85V8F; 110862-48-1; CI 981; Lipitor (TN); Tozalip; Xavator; A0JWA85V8F; CHEMBL1487; (R-(R*,R*))-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid; CHEBI:39548; 134523-00-5 (free acid); (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; 134523-03-8; Atorvastatin [INN:BAN]; (3R,5R)-7-[2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid; 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, (R-(R*,R*))-; Atorvastatin calcium salt; atorvastatina; atorvastatine; atrovastin; Atofast; Atorcor; Atorlip; Lipilou; Lipinon; Atorin; Ator; Lipitor(TM); (3R,5R)-7-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid; (3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; Atorvastatin (INN); Sortis (TN); CCRIS 7159; MFCD00899261; C33H35FN2O5; HSDB 7039; NCGC00159458-03; atorvastatinum; rel-Atorvastatin; (betaR,deltaR)-2-(p-Fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoic acid; Atorvastatin & Primycin; DSSTox_CID_9868; SCHEMBL3831; DSSTox_RID_78825; DSSTox_GSID_29868; BIDD:GT0336; Atorvastatin (Relative Stereo); GTPL2949; DTXSID8029868; BDBM22164; DTXSID60274003; HMS3715L05; HMS3886C20; Lipilou; Tozalip; Torvast; Cardyl; ACT03225; HY-B0589; ZINC3920719; Tox21_302417; s5715; AKOS000281127; AC-9386; CCG-221172; DB01076; MCULE-2368532812; MRF-0000761; NCGC00159458-02; NCGC00159458-20; NCGC00255181-01; 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, (betaR,deltaR)-; 7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]- 3,5-DIHYDROXY-HEPTANOIC ACID; 7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID; AS-35260; H942; CAS-134523-00-5; C06834; D07474; S-2492; Y-8867; 28052-EP2269989A1; 28052-EP2269990A1; 28052-EP2270011A1; 28052-EP2270505A1; 28052-EP2272825A2; 28052-EP2272841A1; 28052-EP2280001A1; 28052-EP2284158A1; 28052-EP2287165A2; 28052-EP2287166A2; 28052-EP2292600A1; 28052-EP2292620A2; 28052-EP2295406A1; 28052-EP2295409A1; 28052-EP2295417A1; 28052-EP2295422A2; 28052-EP2298731A1; 28052-EP2298742A1; 28052-EP2298745A1; 28052-EP2298769A1; 28052-EP2298772A1; 28052-EP2298776A1; 28052-EP2298779A1; 28052-EP2301923A1; 28052-EP2301931A1; 28052-EP2301936A1; 28052-EP2308839A1; 28052-EP2308878A2; 28052-EP2314588A1; 523A005; Q668093; SR-01000872702; SR-01000872702-1; BRD-K69726342-001-02-6; UNII-36TN91XZ0V component XUKUURHRXDUEBC-KAYWLYCHSA-N; (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid; (3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-4-phenyl-2-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, (beta-R,delta-R)-;	Small molecule	1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1	XUKUURHRXDUEBC-KAYWLYCHSA-N	CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4	C33H35FN2O5	CAS 134523-00-5	CHEBI:39548	.	.	.	D01QIN	.	.	.
DR3619	Venlafaxine	CID: 5656	venlafaxine; 93413-69-5; Elafax; D,L-Venlafaxine; Venlafaxina; Venlafaxinum; Effexor; 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)cyclohexanol; 1-[2-(Dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol; 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol; Efectin; CHEBI:9943; Venlafaxine [INN:BAN]; NCGC00095109-01; Venlafaxinum [INN-Latin]; Venlafaxin; Venlafaxina [INN-Spanish]; Cyclohexanol, 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-; DSSTox_CID_3737; DSSTox_RID_77175; DSSTox_GSID_23737; Venlafexine; Efectin (TN); Venlafaxine (INN); CAS-93413-69-5; SR-01000762930; DL-Venlafaxine; Venflaxine EP; HSDB 6699; Venlafaxine-d6 HCl; Spectrum_001671; SpecPlus_000842; Spectrum2_000542; Spectrum3_000989; Spectrum4_001115; Spectrum5_001516; Venlafaxine EP Impurity H; CHEMBL637; EC 618-944-2; N,N,O-Didesmethylvenlafaxine; SCHEMBL35154; BSPBio_002657; KBioGR_001590; KBioSS_002151; MLS006011859; DivK1c_006938; SPECTRUM1504171; SPBio_000583; GTPL7321; DTXSID6023737; BDBM82071; KBio1_001882; KBio2_002151; KBio2_004719; KBio2_007287; KBio3_001877; HMS1922F05; HMS2090F04; HMS2093A12; HMS3714K11; HMS3886K14; Pharmakon1600-01504171; 1-{2-(dimethylamino)-1-[4-(methyloxy)phenyl]ethyl}cyclohexanol; AMY39116; HY-B0196; Tox21_111425; CCG-39577; MFCD00864385; N,N-dimethyl-2-(1-hydroxycyclohexyl)-2-(4-methoxyphenyl)ethylamine; NSC_62923; NSC758676; s5655; STK621394; AKOS005555049; Cyclohexanol, 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)-, (+-)-; Tox21_111425_1; AC-1547; AT-6375; DB00285; MCULE-6632261838; NSC 758676; NSC-758676; SDCCGSBI-0052740.P003; NCGC00095109-02; NCGC00095109-03; NCGC00095109-04; NCGC00095109-05; NCGC00095109-06; NCGC00095109-08; NCGC00095109-20; K700; SMR002204138; WY-45655; SBI-0052740.P002; CAS_93413-69-5; CAS_99300-78-4; DB-057399; FT-0642242; FT-0675793; FT-0675795; C07187; D08670; AB00053751-08; AB00053751-10; AB00053751-11; AB00053751_12; AB00053751_13; 413V695; Q898407; SR-01000762930-3; SR-01000762930-4; BRD-A51714012-001-02-3; BRD-A51714012-003-01-1; 1-[2-dimethylamino-1-(4-methoxylphenyl)ethyl]cyclohexanol; (RS)-1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol; 540726-98-5	Small molecule	1S/C17H27NO2/c1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14/h7-10,16,19H,4-6,11-13H2,1-3H3	PNVNVHUZROJLTJ-UHFFFAOYSA-N	CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O	C17H27NO2	CAS 93413-69-5	CHEBI:9943	.	.	.	D0P1UX	.	.	.
DR3634	Duloxetine	CID: 60835	duloxetine; 116539-59-4; (S)-Duloxetine; Cymbalta; Yentreve; (S)-N-Methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine; LY 248686; 136434-34-9; UNII-O5TNM5N07U; Ariclaim; Xeristar; LY248686; Yentreve (TN); (3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine; O5TNM5N07U; 2-Thiophenepropanamine, N-methyl-gamma-(1-naphthalenyloxy)-, (gammaS)-; N-Methyl-gama-(1-naphthalenyloxy)-2-thiophenepropanamine; CHEBI:36795; (3S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine; MFCD06801358; LY-248686; methyl[(3S)-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propyl]amine; (3s)-N-Methyl-3-(Naphthalen-1-Yloxy)-3-(Thiophen-2-Yl)propan-1-Amine; Duloxetine [INN:BAN]; Duloxetine (INN); SMR000449282; HSDB 7368; NCGC00164559-01; Duloxetine Boehringer Ingelheim; (S)-N-Methyl-gamma-(1-naphthalenyloxy)-2-thiophenepropanamine; 29E; CPD000449282; SCHEMBL8291; CHEMBL1175; GTPL202; cc-636; MLS000758267; MLS001423946; (S)-Duloxetine;LY248686; DTXSID6048385; BDBM84745; HMS2051I05; HMS3886K11; HY-B0161; ZINC1536779; (3S)-N-methyl-3-(naphthalen-1-yloxy)-3-(2-thienyl)propan-1-amine; 2-Thiophenepropanamine, N-methyl-gamma-(1-naphthalenyloxy)-, (S)-; ANW-63714; PDSP1_000969; PDSP1_001385; PDSP2_000953; PDSP2_001369; s5071; AKOS015851058; CCG-100763; CM14423; DB00476; NC00013; SB19317; VA11973; NCGC00164559-02; NCGC00164559-04; AC-15704; AS-35259; SBI-0206832.P001; CAS_136434-34-9; D07880; AB00639911-13; AB00639911_15; AB00639911_16; 539D594; Q411932; J-003455; J-523680; (+)-(S)-N-Methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamin; (S)-(+)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine; (S)-N-methyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine; (3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-yl-propan-1 amine; (3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-yl-propan-1-amine; (3s)-n-methyl-3-naphthalen-1-yloxy-3-thiophen-2-yl-propan-1amine; (S)-(+)-N-methyl-3-(1-naphthaleneoxy)-3-(2-thienyl)propanamine	Small molecule	1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1	ZEUITGRIYCTCEM-KRWDZBQOSA-N	CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32	C18H19NOS	CAS 116539-59-4	CHEBI:36795	.	.	.	D01AXB	.	.	.
DR3651	Micafungin	CID: 477468	Micafungin; Mycamine; 235114-32-6; UNII-R10H71BSWG; Micafungin [INN]; CHEBI:600520; R10H71BSWG; Micafungin (INN); Mycamine(TM); FK463; CHEMBL457547; SCHEMBL11893279; C56H71N9O23S; Pneumocandin A0, 1-((4R,5R)-4,5-dihydroxy-N2-(4-(5-(4-(pentyloxy)phenyl)-3-isoxazolyl)benzoyl]-L-ornithine)-4-((4S)-4-hydroxy-4-(4-hydroxy-3-(sulfooxy)phenyl)-L-threonine)-; BDBM50478216; DB01141; X7260; D08218; Z-3191; 114M326; J-015136; Q6827850; [5-[(1S,2S)-2-[[(1R)-3-amino-1-hydroxy-3-oxo-propyl]-tetrahydroxy-[(1R)-1-hydroxyethyl]-methyl-hexaoxo-[[4-[5-(4-pentoxyphenyl)isoxazol-3-yl]benzoyl]amino][?]yl]-1,2-dihydroxy-ethyl]-2-hydroxy-phenyl] hydrogen sulfate; 5.1:6-anhydro{(4R,5R)-4,5-dihydroxy-N(2)-(4-{5-[4-(pentyloxy)phenyl]isoxazol-3-yl}benzoyl)-L-ornithyl-L-threonyl-(4R)-4-hydroxy-L-prolyl-(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-(3R)-3-hydroxy-L-glutaminyl-(3S,4S)-3-hydroxy-4-methyl-L-proline}	Small molecule	1S/C56H71N9O23S/c1-4-5-6-17-86-32-14-11-28(12-15-32)39-21-33(63-87-39)27-7-9-29(10-8-27)49(75)58-34-20-38(70)52(78)62-54(80)45-46(72)25(2)23-65(45)56(82)43(37(69)22-41(57)71)60-53(79)44(48(74)47(73)30-13-16-36(68)40(18-30)88-89(83,84)85)61-51(77)35-19-31(67)24-64(35)55(81)42(26(3)66)59-50(34)76/h7-16,18,21,25-26,31,34-35,37-38,42-48,52,66-70,72-74,78H,4-6,17,19-20,22-24H2,1-3H3,(H2,57,71)(H,58,75)(H,59,76)(H,60,79)(H,61,77)(H,62,80)(H,83,84,85)/t25-,26+,31+,34-,35-,37+,38+,42-,43-,44-,45-,46-,47-,48-,52+/m0/s1	PIEUQSKUWLMALL-YABMTYFHSA-N	CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC(=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)C(CC(=O)N)O)C)O)O)O	C56H71N9O23S	CAS 235114-32-6	CHEBI:600520	.	.	.	D06TOE	.	.	.
DR3679	Sucralfate	CID: 121494085	Sucralfato; Ulcerban; Ulcogant; Ulsanic; Sucralfatum; Ulcerlmin; Ulcar; Sucralfatum [INN-Latin]; Sucralfato [INN-Spanish]; OGA-6J; UNII-XX73205DH5; HSDB 3926; XX73205DH5; EINECS 259-018-4; OS 202; DB00364; Sucralfate [USAN:USP:INN:BAN:JAN]; Aluminum, hexadeca-mu-hydroxytetracosahydroxy(mu8-(1,3,4,6-tetra-O-sulfo-beta-D-fructofuranosyl alpha-D-glucopyranoside tetrakis(hydrogen sulfato)(8-)))hexadeca-; Sucrose hydrogen sulfate basic aluminium salt; Sucrose octakis(hydrogen sulfate) aluminum complex; 1,2,3,3',4,4',6,6'-Octa-O-sulfo-beta-D-fructofuranosyl-alpha-D-glucopyranosid aluminium hydroxid-hydrat-salz; alpha-D-Glucopyranoside, beta-D-fructofuranosyl-, octakis(hydrogen sulfate), aluminum complex; Hexadeca-mu-hydroxytetracosahydroxy[mu8-[1,3,4,6-tetra-O-sulfo-beta-Dfructofuranosyl-alpha-D-glucopyranoside tetrakis(hydrogen sulfato)8-)]]hexadecaaluminum; Hexadeca-U-hydroxytetracosahydroxy-(U8-(1,3,4,6-tetra-O-sulfo-beta-D-fructofuranosyl-alpha-D-glucopyranoside tetrakis(hydrogen sulfato)(8-))) hexadecaaluminum	Small molecule	1S/C12H22O35S8.9Al.20H2O/c13-48(14,15)37-1-4-6(43-51(22,23)24)8(45-53(28,29)30)9(46-54(31,32)33)11(40-4)42-12(3-39-50(19,20)21)10(47-55(34,35)36)7(44-52(25,26)27)5(41-12)2-38-49(16,17)18;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/h4-11H,1-3H2,(H,13,14,15)(H,16,17,18)(H,19,20,21)(H,22,23,24)(H,25,26,27)(H,28,29,30)(H,31,32,33)(H,34,35,36);;;;;;;;;;20*1H2/q;;8*+1;;;;;;;;;;;;;;;;;;;;/p-8/t4-,5-,6-,7-,8+,9-,10+,11-,12+;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/m1............................./s1	YZPQNHUVIVIUCT-JTJNLBSYSA-F	C(C1C(C(C(C(O1)OC2(C(C(C(O2)COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al].O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Al]	C12H54Al9O55S8	CAS 54182-58-0	.	.	.	.	D06ULU	.	.	.
DR3681	Depsipeptide	CID: 5352062	Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone	Small molecule	1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20+/m1/s1	OHRURASPPZQGQM-GCCNXGTGSA-N	CC=C1C(=O)NC(C(=O)OC2CC(=O)NC(C(=O)NC(CSSCCC=C2)C(=O)N1)C(C)C)C(C)C	C24H36N4O6S2	CAS 128517-07-7	.	.	.	.	D0L7LC	.	.	.
DR3693	Lisinopril	CID: 5362119	lisinopril; Prinivil; Zestril; 76547-98-3; Linopril; Lysinopril; 83915-83-7; Acercomp; Inhibril; Lisipril; Noperten; Presiten; Sinopril; Tensopril; Acerbon; Carace; Vivatec; Coric; Lisinopril anhydrous; Lisinopril dihydrate; Alapril; Inopril; Lisinal; Lisoril; Lispril; Novatec; Sinopryl; Cipral; Linvas; Lipril; Loril; Prinil; Tensyn; Tersif; Lisinoprilum; Longes; Hipril; UNII-7Q3P4BS2FD; MK-521; Lisinopril (INN); [N2-[(S)-1-CARBOXY-3-PHENYLPROPYL]-L-LYSYL-L-PROLINE; Lisinopril (Zestril); C21H31N3O5; N2-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline; Zestril (TN); 7Q3P4BS2FD; CHEBI:43755; Lisinopril [INN]; Qbrelis; (S)-1-((S)-6-Amino-2-(((S)-1-carboxy-3-phenylpropyl)amino)hexanoyl)pyrrolidine-2-carboxylic acid; LPR; (S)-1-(N2-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline; Nanopril; Lisinoprilum [Latin]; (S)-1-(N(2)-(1-carboxy-3-phenylpropyl)-L-lysyl)-L-proline; MFCD01698825; CHEMBL1237; Lizinopril; Diroton; Lisitec; Lisopril; Listril; Lizonoton; Optimon; Prinvil; Skopryl; Vitopril; Amicor; Doneka; Irumed; Laaven; MLS002154258; MK 521; MK 522; (2S)-1-[(2S)-6-amino-2-{[(1S)-1-carboxy-3-phenylpropyl]amino}hexanoyl]pyrrolidine-2-carboxylic acid; SMR000544473; CCRIS 3568; SMR001233519; EINECS 278-488-1; BRN 4276619; lysinopryl; (S)-1-[N2-(1-carboxy-3-phenylpropyl)-L-lysyl]-L-proline; N-(1(S)-Carboxy-3-phenylpropyl)-L-lysyl-L-proline; N2-((S)-1-Carboxy-3-phenylpropyl)-L-lysyl-L-proline; HSDB 6852; (S)-1-(N(sup 2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline; (2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid; 77726-95-5; (S)-1-[N2-(1-carboxy-3-phenylpropyl)-L-lysyl]-L-proline dihydrate; 1-(N2-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline; L-Proline, N2-((1S)-1-carboxy-3-phenylpropyl)-L-lysyl-; Spectrum_000497; 1-[Nalpha-[(S)-1-Carboxy-3-phenylpropyl]-L-lysyl]-L-proline; Prestwick0_000301; Prestwick1_000301; Prestwick2_000301; Prestwick3_000301; Spectrum2_001456; Spectrum3_000941; Spectrum4_001040; Spectrum5_000995; SCHEMBL15680; BSPBio_000262; KBioGR_001599; KBioSS_000977; (2S)-1-[(2S)-6-amino-2-[[(2S)-1-hydroxy-1-oxo-4-phenylbutan-2-yl]amino]hexanoyl]pyrrolidine-2-carboxylic acid; MLS001306436; MLS001306481; BIDD:GT0755; DivK1c_001037; SPECTRUM1501217; SPBio_001351; SPBio_002481; BPBio1_000290; GTPL6360; ICI-209K; DTXSID6040537; BDBM66979; HMS503O15; KBio1_001037; KBio2_000977; KBio2_003545; KBio2_006113; KBio3_002002; L-Proline, 1-(N2-(1-carboxy-3-phenylpropyl)-L-lysyl)-; N(2)-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline; N~2~-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline; cid_22887897; NINDS_001037; HMS1921B14; HMS2090O14; HMS2092L21; HMS2850N20; Pharmakon1600-01501217; L-Proline, 1-(N2-(1-carboxy-3-phenylpropyl)-L-lysyl)-, (S)-; ZINC3812863; 1835AH; 2517AH; BDBM50367879; CCG-39190; DL-434; KM1776; NSC751176; NSC758151; s2076; AKOS015836369; AKOS015894970; L-Proline, 1-(N(sup 2)-(1-carboxy-3-phenylpropyl)-L-lysyl)-, (S)-; AB04852; BCP9000856; DB00722; MCULE-7813362088; NSC-751176; NSC-758151; IDI1_001037; NCGC00179623-01; HY-18206; SBI-0051692.P002; L0220; A11876; D08131; 54256-EP2270011A1; 54256-EP2272834A1; 54256-EP2277879A1; 54256-EP2287165A2; 54256-EP2287166A2; 54256-EP2292228A1; 54256-EP2292620A2; 54256-EP2298742A1; 54256-EP2298776A1; 54256-EP2298779A1; 54256-EP2301923A1; 54256-EP2301929A1; 54256-EP2301931A1; 54256-EP2301935A1; 54256-EP2305648A1; 54256-EP2305674A1; 54256-EP2308562A2; AB00052250-13; AB00052250_14; AB00052250_15; 547L983; A838743; Q412208; SR-05000001786; SR-05000001786-1; BRD-K67966701-335-03-5; Z2786051707; N-[N2 (1(S)-carboxy-3-phenylpropyl)-L-lysyl]-L-proline; N-[N2 -(1(S)-carboxy-3-phenylpropyl)-L-lysyl]-L-proline; (S)-1-[N2-(1-Carboxy-3-phenylpropyl)-lysyl-proline dihydrate; (2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenyl-propyl]amino]hexanoyl]proline;hydrate; (2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]-1-oxohexyl]-2-pyrrolidinecarboxylic acid; (2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]-1-oxohexyl]-2-pyrrolidinecarboxylic acid;hydrate; (2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid;hydrate; (2S)-1-[(2S)-6-azanyl-2-[[(2S)-1-oxidanyl-1-oxidanylidene-4-phenyl-butan-2-yl]amino]hexanoyl]pyrrolidine-2-carboxylic acid; (2S)-1-[(2S)-6-azanyl-2-[[(2S)-1-oxidanyl-1-oxidanylidene-4-phenyl-butan-2-yl]amino]hexanoyl]pyrrolidine-2-carboxylic acid;hydrate; (S)-1-((S)-6-amino-2-((S)-1-carboxy-3-phenylpropylamino)hexanoyl)pyrrolidine-2-carboxylic acid	Small molecule	1S/C21H31N3O5/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29)/t16-,17-,18-/m0/s1	RLAWWYSOJDYHDC-BZSNNMDCSA-N	C1CC(N(C1)C(=O)C(CCCCN)NC(CCC2=CC=CC=C2)C(=O)O)C(=O)O	C21H31N3O5	CAS 76547-98-3	CHEBI:43755	.	.	.	D07HGR	.	.	.
DR3720	3,3'-diindolylmethane	CID: 3071	diindolylmethane; di(1H-indol-3-yl)methane; 3,3'-Methylenebis-1H-indole; 3,3'-Methylenediindole; DIM; ARUNDINE; 1H-Indole, 3,3'-methylenebis-; Di(3-indolyl)methane; 3,3'-Di-indolylmethane; 3-(1H-indol-3-ylmethyl)-1H-indole; 3,3'-methylenebis(1H-indole); 3,3,-diindolylmethane; UNII-SSZ9HQT61Z; MFCD00195766; SSZ9HQT61Z; bis-1H-indol-3-ylmethane; CHEBI:50182; 3,3'-methanediylbis(1H-indole); 3-Diindolyl methane; 33'-Diindolylmethane; 3,3'-Diindolymethane; Diidolylmethane; Infemin; CCRIS 5806; Plant Indole; Di-3-indolylmethane; HB 236; NSC708486; PubChem8119; Spectrum2_001711; Spectrum3_001989; Spectrum5_001955; CBiol_001839; Oprea1_472633; Oprea1_740951; BSPBio_001290; BSPBio_003589; CBDivE_010856; KBioGR_000010; KBioSS_000010; MLS006011847; SCHEMBL325162; SPECTRUM1505331; SPBio_001722; ACMC-20976o; 3,3'-di(indol-3-yl)methane; BML3-F11; CHEMBL446452; 3,3'-Diindolylmethane (DIM); DTXSID8037047; GTPL11208; KBio2_000010; KBio2_002578; KBio2_005146; KBio3_000019; KBio3_000020; KBio3_003002; Bio1_000125; Bio1_000614; Bio1_001103; Bio2_000010; Bio2_000490; HMS1361A12; HMS1791A12; HMS1989A12; HMS3402A12; ZINC187911; 3,3'-diindolylmethane, AldrichCPR; ACT06989; ALBB-016048; BCP00470; ANW-13582; BBL015828; CCG-39861; GR-207; HSCI1_000069; s4728; STK263696; AKOS003627372; AM84671; CS-1652; DB11875; KS-5266; MCULE-3718375492; NSC-708486; SB16901; IDI1_033760; NCGC00095348-01; NCGC00095348-02; NCGC00095348-03; NCGC00095348-04; NCGC00095348-05; NCGC00095348-06; NCGC00095348-07; AC-11611; AK-45887; HY-15758; NCI60_038418; SMR001828114; SY038972; 3,3'-Diindolylmethane, >=98% (HPLC); 3,3'-Diindolylmethane, analytical standard; DB-011102; FT-0614061; M1399; A16321; D-3720; M-1632; 968D054; Q4634053; BRD-K37846922-001-05-2; BRD-K37846922-001-06-0; BRD-K37846922-001-09-4; C444299000	Small molecule	1S/C17H14N2/c1-3-7-16-14(5-1)12(10-18-16)9-13-11-19-17-8-4-2-6-15(13)17/h1-8,10-11,18-19H,9H2	VFTRKSBEFQDZKX-UHFFFAOYSA-N	C1=CC=C2C(=C1)C(=CN2)CC3=CNC4=CC=CC=C43	C17H14N2	CAS 1968-05-4	.	.	.	.	.	.	.	.
DR3731	Bevacizumab	.	Bevacizumab (ophthalmic slow-release tissue tablet)	Antibody	.	.	.	.	.	.	.	.	.	D04KBL	.	.	.
DR3743	Sucrose	CID: 5988	sucrose; 57-50-1; saccharose; Cane sugar; Table sugar; White sugar; D-Sucrose; sugar; Rohrzucker; Saccharum; Granulated sugar; Amerfand; Amerfond; Microse; Beet sugar; Rock candy; Confectioner's sugar; Sucrose, dust; Sucrose, pure; D(+)-Saccharose; sacarosa; D-(+)-Sucrose; Sucraloxum [INN-Latin]; beta-D-Fructofuranosyl alpha-D-glucopyranoside; beta-D-Fructofuranosyl-alpha-D-glucopyranoside; D-(+)-Saccharose; CCRIS 2120; HSDB 500; Sacharose; alpha-D-Glucopyranosyl beta-D-fructofuranoside; CHEBI:17992; D-Saccharose; AI3-09085; (alpha-D-Glucosido)-beta-D-fructofuranoside; D(+)-Sucrose; alpha-D-Glucopyranoside, beta-D-fructofuranosyl; Fructofuranoside, alpha-D-glucopyranosyl, beta-D; Glucopyranoside, beta-D-fructofuranosyl, alpha-D; UNII-C151H8M554; MFCD00006626; alpha-D-Glucopyranoside, beta-D-fructofuranosyl-; NCI-C56597; 1-alpha-D-glucopyranosyl-2-beta-D-fructofuranoside; C151H8M554; beta-D-Fruf-(2<->1)-alpha-D-Glcp; NCGC00164248-01; DSSTox_CID_1288; NSC 406942; DSSTox_RID_76060; DSSTox_GSID_21288; D(+)-Sucrose, ACS reagent; Sucraloxum; Sucrose [USAN:JAN]; (+)-Sucrose; CAS-57-50-1; (2R,3R,4S,5S,6R)-2-(((2S,3S,4S,5R)-3,4-Dihydroxy-2,5-bis(hydroxymethyl)tetrahydrofuran-2-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol; (2R,3R,4S,5S,6R)-2-{[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol; D(+)-Sucrose, 99.7%, for biochemistry; FICOLL; Sucrose [JAN:NF]; EINECS 200-334-9; GLC-(1-2)FRU; Sucrose,ultrapure; D(+)-Sucrose, 99+%, for biochemistry, DNAse, RNAse and protease free; Compressible sugar; NSC-406942; Sucrose, purified; Sucrose, AR; Sucrose, LR; Sucrose, ultrapure; Sucrose, USP; Sucrose ACS grade; Sucrose (TN); Sugar spheres (NF); Sugar,(S); Sucrose, ACS reagent; Sucrose, reagent grade; 1af6; Sucrose (JP17/NF); Glc(alpha1->2beta)Fru; Sucrose Biochemical grade; Sucrose, SAJ first grade; Sugar, compressible (NF); bmse000119; bmse000804; bmse000918; Epitope ID:153236; Sucrose, >=99.5%; Sucrose, JIS special grade; White soft sugar (JP17); Sucrose, analytical standard; Sucrose, cell culture tested; Sugar, confectioner's (NF); 1-alpha-D-glucopyranosyl-2-beta-D-fructofranoside; 25702-74-3; Sucrose, p.a., ACS reagent; CHEMBL253582; GTPL5411; DTXSID2021288; CHEBI:65313; Sucrose, 1.2M aqueous solution; Sucrose, Molecular Biology Grade; GNE-410; Sucrose, >=99.5% (GC); S-67F; alpha-D-Glc-(1-2)-beta-D-Fru; 2-{[3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol; HY-B1779; ZINC4217475; Tox21_112093; Tox21_201397; Tox21_300410; 5903AE; BDBM50108105; s3598; Sucrose, for electrophoresis, >99%; AKOS024306988; alpha-D-Glc-(1-->2)-beta-D-Fru; DB02772; MCULE-5933491732; Sucrose, BioXtra, >=99.5% (GC); a-D-Glucopyranosyl A-D-fructofuranoside; b -D-Fructofuranosyl a-D-glucopyranoside; NCGC00164248-02; NCGC00164248-03; NCGC00164248-05; NCGC00254237-01; NCGC00258948-01; 92004-84-7; Sucrose, meets USP testing specifications; Sucrose, Vetec(TM) reagent grade, 99%; D-Saccharose 1000 microg/mL in Methanol; alpha-D-Glucopyranosylbeta-D-fructofuranoside; CS-0013810; S0111; ST50308554; Sucrose, Grade I, plant cell culture tested; Sucrose, Grade II, plant cell culture tested; C00089; D00025; Sucrose, for molecular biology, >=99.5% (GC); Sucrose; ?-D-Fructofuranosyl ?-D-glucopyranoside; SR-01000883983; Sucrose, NIST(R) SRM(R) 17f, optical rotation; J-519846; Q4027534; SR-01000883983-1; Sucrose, for microbiology, ACS reagent, >=99.0%; alpha-D-glucopyranosyl-(1->2)-beta-D-fructofuranoside; Sucrose, British Pharmacopoeia (BP) Reference Standard; Sucrose, European Pharmacopoeia (EP) Reference Standard; Sucrose, Vetec(TM) reagent grade, RNase and DNase free; Z1601554751; alpha-D-Glucopyranoside, beta-D-fructofuranosyl, homopolymer; Sucrose, analytical standard, for enzymatic assay kit SCA20; UNII-YUH1C99228 component CZMRCDWAGMRECN-UGDNZRGBSA-N; Sucrose, anhydrous, free-flowing, Redi-Dri(TM), ACS reagent; Sucrose, BioUltra, for molecular biology, >=99.5% (HPLC); Sucrose, United States Pharmacopeia (USP) Reference Standard; Carbon isotopes in sucrose, NIST(R) RM 8542, IAEA-CH-6 sucrose; Compressible sugar, United States Pharmacopeia (USP) Reference Standard; Sucrose, puriss., meets analytical specification of Ph. Eur., BP, NF; WURCS=2.0/2,2,1/[ha122h-2b_2-5][a2122h-1a_1-5]/1-2/a2-b1; (2R,3R,4S,5S,6R)-2-((2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)tetrahydrofuran-2-ylhydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2R,3R,4S,5S,6R)-2-((2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)tetrahydrofuran-2-yloxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)tetrahydrofuran-2-yl]oxy-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol; 2-[(2S,3S,4S,5R)-2,5-bis(hydroxymethyl)-3,4-dihydroxyoxolan-2-yloxy](4S,5S,2R, 3R,6R)-6-(hydroxymethyl)-2H-3,4,5,6-tetrahydropyran-3,4,5-triol; 8027-47-2; 8030-20-4; 85456-51-5; 86101-30-6; 87430-66-8; Sucrose, BioReagent, suitable for cell culture, suitable for insect cell culture, >=99.5% (GC); Sucrose, Low Endotoxin, PharmaGrade, USP/NF, Ph Eur, Manufactured under appropriate GMP controls for pharma or biopharmaceutical production.	Small molecule	1S/C12H22O11/c13-1-4-6(16)8(18)9(19)11(21-4)23-12(3-15)10(20)7(17)5(2-14)22-12/h4-11,13-20H,1-3H2/t4-,5-,6-,7-,8+,9-,10+,11-,12+/m1/s1	CZMRCDWAGMRECN-UGDNZRGBSA-N	C(C1C(C(C(C(O1)OC2(C(C(C(O2)CO)O)O)CO)O)O)O)O	C12H22O11	CAS 57-50-1	CHEBI:17992	.	.	.	D08TCV	.	.	.
DR3755	Biphenyl dimethyl dicarboxylate	CID: 13099	792-74-5; Dimethyl biphenyl-4,4'-dicarboxylate; dimethyl [1,1'-biphenyl]-4,4'-dicarboxylate; Biphenyl dimethyl dicarboxylate; DIMETHYL 4,4'-BIPHENYLDICARBOXYLATE; [1,1'-Biphenyl]-4,4'-dicarboxylic acid, dimethyl ester; methyl 4-(4-methoxycarbonylphenyl)benzoate; Nissel; UNII-K61BXA0U9C; 4,4'-Biphenyldicarboxylic acid, dimethyl ester; K61BXA0U9C; 4,4'-Bibenzoic Acid Dimethyl Ester; MFCD00017201; methyl 4-[4-(methoxycarbonyl)phenyl]benzoate; Dimethyl (1,1'-biphenyl)-4,4'-dicarboxylate; (1,1'-Biphenyl)-4,4'-dicarboxylic acid, dimethyl ester; (1,1'-Biphenyl)-4,4'-dicarboxylic acid, 4,4'-dimethyl ester; 1219803-50-5; [1,1'-Biphenyl]-4,4'-dicarboxylic acid, 4,4'-dimethyl ester; HSDB 5754; EINECS 212-341-4; PubChem8961; ACMC-209pgt; Maybridge1_001712; 4,4-Dicarboxymethylbiphenyl; 4,4'-Dicarbomethoxybiphenyl; SCHEMBL68521; MLS000720058; CHEMBL4297409; DTXSID2061143; HMS546F18; ZINC132343; 4,4'-Bis(methoxycarbonyl)biphenyl; 4,4'-bis (methoxycarbonyl)biphenyl; ANW-37275; CCG-45472; SBB005981; AKOS001588888; DB12475; Dimethyl biphenyl-4,4''-dicarboxylate; LS10548; MCULE-5377004782; AK121980; O731; SMR000304587; ST023391; SY057043; TS-00900; HY-128854; 4,4-Biphenyldicarboxylic acid dimethyl ester; B1309; CS-0100928; Dimethyl biphenyl-4,4'-dicarboxylate, 99%; FT-0625049; 4,4'-Biphenyldicarboxylic Acid Dimethyl Ester; 92D745; Biphenyl 4,4'-dicarboxylic acid, dimethyl ester; A839634; SR-01000397421; 4-(4-methoxycarbonylphenyl)benzoic acid methyl ester; SR-01000397421-1; SR-01000397421-2; W-111708; 4,4'-dimethyl [1,1'-biphenyl]-4,4'-dicarboxylate; BRD-K33126632-001-02-1; Q27281994; Dimethyl 4,4 inverted exclamation mark -Biphenyldicarboxylate; Dimethyl biphenyl-4,4 inverted exclamation marka-dicarboxylate; Dimethyl 4,4 inverted exclamation marka-Biphenyl-d8-dicarboxylate; Biphenyl-4'4-dicarboxylic acid dimethyl ester  C16H14O4 270.29  212-216 degrees     792-74-5  212-341-4 MFCD00017201    Y	Small molecule	1S/C16H14O4/c1-19-15(17)13-7-3-11(4-8-13)12-5-9-14(10-6-12)16(18)20-2/h3-10H,1-2H3	BKRIRZXWWALTPU-UHFFFAOYSA-N	COC(=O)C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)OC	C16H14O4	CAS 792-74-5	.	.	.	.	.	.	.	.
DR3757	Torin 2	CID: 51358113	Torin 2; 1223001-51-1; Torin2; Torin-2; 9-(6-aminopyridin-3-yl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE; CHEMBL1765602; C24H15F3N4O; CHEBI:90682; 9-(6-Aminopyridin-3-Yl)-1-[3-(Trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2(1h)-One; 9-(6-AMINOPYRIDIN-3-YL)-1-(3-(TRIFLUOROMETHYL)PHENYL)BENZO[H][1,6]NAPHTHYRIDIN-2(1H)-ONE; 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)-phenyl)benzo[h][1,6]naphthyridin-2(1H)-one; BENZO[H]-1,6-NAPHTHYRIDIN-2(1H)-ONE, 9-(6-AMINO-3-PYRIDINYL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-; 9-(6-Amino-3-pyridinyl)-1-[3-(trifluoromethyl)phenyl]benzo[h]-1,6-naphthyridin-2(1H)-one; cc-275; MLS006011167; GTPL8839; SCHEMBL6876328; AOB3537; DTXSID00679917; EX-A431; HMS3265O05; HMS3265O06; HMS3265P05; HMS3265P06; HMS3651N13; BCP02612; ABP000908; BDBM50341209; MFCD18782652; NSC775727; s2817; ZINC71318831; AKOS024458055; CCG-265003; CS-0236; NSC-775727; PB34957; NCGC00263216-01; NCGC00263216-02; NCGC00263216-09; NCGC00263216-13; 9-(6-AMINO-PYRIDIN-3-YL)-1-(3-TRIFLUOROMETHYL-PHENYL)-1H-BENZO[H][1,6]NAPHTHYRIDIN-2-ONE; AC-31520; AK171126; AS-74405; HY-13002; SMR004702936; AB0035864; DB-084736; FT-0700124; SW218309-2; Y0293; Q-4148; J-519481; BRD-K68174511-001-01-7; Q27089008; 9-(6-amino-3-pyridyl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2-one; 17G; 9-(6-Amino-3-pyridinyl)-1-[3-(trifl uoromethyl)phenyl]-benzo[h]-1,6-naphthyridin-2(1H) -one; 9-(6-AMINOPYRIDIN-3-YL)-1-[3-(TRIFLUOROMETHYL)PHENYL]-1H,2H-BENZO[H]1,6-NAPHTHYRIDIN-2-ONE	Small molecule	1S/C24H15F3N4O/c25-24(26,27)17-2-1-3-18(11-17)31-22(32)9-6-16-13-29-20-7-4-14(10-19(20)23(16)31)15-5-8-21(28)30-12-15/h1-13H,(H2,28,30)	GUXXEUUYCAYESJ-UHFFFAOYSA-N	C1=CC(=CC(=C1)N2C(=O)C=CC3=CN=C4C=CC(=CC4=C32)C5=CN=C(C=C5)N)C(F)(F)F	C24H15F3N4O	CAS 1223001-51-1	CHEBI:90682	.	.	.	D2B7WM	.	.	.
DR3804	Cefuroxime	CID: 5479529	cefuroxime; Cephuroxime; Cefuroxim; Cefuroximo; 55268-75-2; Cefuroximum; Zinacef Danmark; Zinacef; Sharox; Cefuroximum [INN-Latin]; Cefuroximo [INN-Spanish]; UNII-O1R9FJ93ED; O1R9FJ93ED; CHEBI:3515; (6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Biofuroksym; Cefuril; Kefurox; Q63409033; (6r,7r)-3-[(Carbamoyloxy)methyl]-7-{[(2z)-2-(Furan-2-Yl)-2-(Methoxyimino)acetyl]amino}-8-Oxo-5-Thia-1-Azabicyclo[4.2.0]oct-2-Ene-2-Carboxylic Acid; Cefuroxime [USAN:INN:BAN]; C16H16N4O8S; (6R,7R)-3-[(carbamoyloxy)methyl]-7-[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(carbamoyloxy)methyl]-7-{[(2Z)-2-furan-2-yl-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; EINECS 259-560-1; BRN 5783190; Cefuroximine; Cefuroxime [USAN:BAN:INN]; 4kov; Cefuroxime (TN); Cefuroxime (USAN/INN); Prestwick3_000720; CHEMBL1436; BSPBio_000939; (6R,7R)-7-(2-(2-Furyl)glyoxylamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid 7(sup 2)-(Z)-(O-methyloxime) carbamate (ester); 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-7-((2-furanyl(methoxyimino)acetyl)amino)-8-oxo-, (6R-(6alpha,7beta(Z)))-; BIDD:GT0619; BPBio1_001033; SCHEMBL1821942; HY-B1256A; ZINC3830485; BDBM50422689; MFCD00864889; AKOS015962849; AC-4539; DB01112; KS-5162; P802; AB0010602; CS-0013520; EN300-53016; C06894; Cefuroxime, VETRANAL(TM), analytical standard; D00262; 268C752; A830563; Cefuroxime, Antibiotic for Culture Media Use Only; W-105575; BRD-K02733959-236-02-8; BRD-K02733959-236-07-7; (6R,7R)-3-((Carbamoyloxy)methyl)-7-((Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-(aminocarbonyloxymethyl)-7-[[(2Z)-2-(furan-2-yl)-2-methoxyimino-ethanoyl]amino]-8-oxidanylidene-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(2-furanyl)-2-methoxyimino-1-oxoethyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(2-furyl)-2-methoxyimino-acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[[(Aminocarbonyl)oxy]methyl]-7-[[(2Z)-2-(2-furanyl)-2-(methoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylic Acid; 3-[(carbamoyloxy)methyl]-7beta-[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-3,4-didehydrocepham-4-carboxylic acid; KEF; KOV	Small molecule	1S/C16H16N4O8S/c1-26-19-9(8-3-2-4-27-8)12(21)18-10-13(22)20-11(15(23)24)7(5-28-16(17)25)6-29-14(10)20/h2-4,10,14H,5-6H2,1H3,(H2,17,25)(H,18,21)(H,23,24)/b19-9-/t10-,14-/m1/s1	JFPVXVDWJQMJEE-IZRZKJBUSA-N	CON=C(C1=CC=CO1)C(=O)NC2C3N(C2=O)C(=C(CS3)COC(=O)N)C(=O)O	C16H16N4O8S	CAS 55268-75-2	CHEBI:3515	.	.	.	D0Y2IE	.	.	.
DR3806	Rifampicin	CID: 135398735	Rifampicin; rifampin; Rifadin; Rimactane; Rimactan; Rifamycin AMP; 13292-46-1; Rifaldazine; Rifaprodin; Riforal; Tubocin; Rifa; Rifampicinum; Archidyn; Rifoldin; Rifoldine; Rimactizid; Rifagen; Rimazid; Rifampicin SV; L-5103 Lepetit; R/AMP; Arficin; Benemicin; Doloresum; Eremfat; Fenampicin; Rifadine; Rifaldazin; Rifamor; Rifinah; Rifobac; Rimactazid; Sinerdol; Arzide; Rifcin; Rifam; Dione 21-acetate; Rifampicine [French]; Rifampicina; Rifampicinum [INN-Latin]; Ba 41166/E; Rifampicina [INN-Spanish]; 3-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV; CCRIS 551; Rifadin I.V.; HSDB 3181; C43H58N4O12; UNII-VJT6J7R4TR; BA-41166E; NSC113926; VJT6J7R4TR; NSC-113926; Rifampicine; Abrifam; Rifamycin, 3-(((4-methyl-1-piperazinyl)imino)methyl)-; RFP; CHEBI:28077; 3-(4-Methylpiperazinyliminomethyl)-rifamycin SV; 8-(4-Methylpiperazinyliminomethyl) rifamycin SV; L-5103; (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-{(E)-[(4-methylpiperazin-1-yl)imino]methyl}-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acetate; 8-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV; Rifamycin, 3-[[(4-methyl-1-piperazinyl)imino]methyl]-; Rifomycin SV, 8-(N-(4-methyl-1-piperazinyl)formidoyl)-; Rifaldin; DSSTox_CID_1244; DSSTox_RID_76035; DSSTox_GSID_21244; RIF; (7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-{(E)-[(4-methylpiperazin-1-yl)imino]methyl}-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.1(4,7).0(5,28)]triaconta-1(28),1(29),2,4,9,19,21,25,27-nonaen-13-yl acetate; CAS-13292-46-1; 3-(4-Methylpiperazinyliminomethyl)rifamycin SV; 3-([(4-Methyl-1-piperazinyl)imino]methyl)rifamycin SV; 8-[[(4-Methyl-1-piperazinyl)imino]methyl]rifamycin sv; rifamcin; [1,11,13]trienimino)naphto[2,1-b]furan-21-yl acetate; Rifomycin sv, 8-[N-(4-Methyl-1-piperazinyl)formidoyl]-; Rifamsolin; Rifampicin [INN:BAN:JAN]; Famcin; MFCD00151389; Rimactane (TN); NCGC00094777-01; AZT + Rifampin; Rifampin (USP); (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-5,6,9,17,19-Pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-[[(4-methylpiperazin-1-yl)imino]methyl]-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca; (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-{(E)-[(4-methylpiperazin-1-yl)imino]methyl}-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acet; (2S,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-5,6,9,17,19-Pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-{[(4-methylpiperazin-1-yl)imino]methyl}-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acetate; [pentahydroxy-methoxy-heptamethyl-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-dioxo-[?]yl] acetate; Rifampicin & EEP; Prestwick_833; EINECS 236-312-0; R-Cin; Rifadin (TN); NSC 113926; Piperine & Rifampicin; Rifampicin & Propolis; Reserpine & Rifampicin; Rifampin [USAN:USP]; Prestwick2_000525; Prestwick3_000525; Spectrum5_002018; 3-[[(4-Methyl-1-piperazinyl)imino]-methyl]rifamycin; Rifampicin (JP17/INN); SCHEMBL23490; BSPBio_000509; L-5103-LEPETIT; 8CI); BPBio1_000561; CHEMBL374478; DTXSID6021244; HMS1569J11; HMS2089F12; HMS2096J11; HMS3713J11; DRG-0109; Rifampicin, >=97.0% (HPLC); Rifampicin, powder, gamma-irradiated; Tox21_111329; Tox21_201385; Tox21_300550; Ba 41166; BDBM50370232; GR-306; NIH-10782; AKOS015951372; Rifampicin - CAS 13292-46-1; Rifampicin, >=97% (HPLC), powder; Tox21_111329_1; BA 411661E; CCG-208267; DB01045; NCGC00022678-03; NCGC00022678-04; NCGC00022678-05; NCGC00022678-06; NCGC00179536-02; NCGC00254537-01; NCGC00258936-01; 5,6,9,17,19,21-Hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-(N-(4-methyl-1-piperazinyl)formimidoyl)-2,7-(epoxypentadeca(1,11,13)trienimino)naphtho(2,1-b)furan-1,11(2H)-dione 21-acetate; M880; ST057531; C06688; D00211; J10110; Rifampicin, VETRANAL(TM), analytical standard; AB00383022_07; 292R461; SR-05000002118; 8-[[(4-Methyl-1-piperazinyl)imino[methyl]rifamycin; 8-[[(4-Methylpiperazinyl)imino]methyl]rifamycin sv; SR-05000002118-3; WLN: V1 WQ A&1 E&1 E1UN- AT6N DNTJ D1; 3-[(4-Methyl-1-piperazinyl)iminomethyl]rifamycin SV; Rifampicin, European Pharmacopoeia (EP) Reference Standard; Rifampin, United States Pharmacopeia (USP) Reference Standard; Rifampin, Pharmaceutical Secondary Standard; Certified Reference Material; 4,7>.0<5,28>]triaconta-1(28),2,4,9,1 9,21,25(29),26-octaen-13-yl acetate; Rifampicin, plant cell culture tested, BioReagent, >=97% (HPLC), crystalline; yl]-, (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-; (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-{(E)-[(4-methylpiperazin-1-yl)imino]methyl}-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl ac; (7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11- methoxy-3,7,12,14,16,18,22-heptamethyl-26-{(E)-[(4-methylpiperazin-1-yl)imino] methyl}-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1 (28),2,4,9,19,21,25(29),26-octaen-13-yl acetate; 2,11,13]trienimino)naphtho[2,1-b]furan-1,11(2H)-dione, 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-[N-(4-methyl-1-piperazinyl)formimidoyl]-, 21-acetate; 2,7-(epoxy[1,11,13]pentadecatrienoimino)naphtho[2,1-b]furan-1,11(2H)-dione, 21-(acetyloxy)-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-[(E)-[(4-methyl-1-piperazinyl)imino]meth; 2,7-(Epoxypentadeca(1,11,13)trienimino)naphtho(2,1-b)furan-1,11(2H)-dione, 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-(N-(4-methyl-1-piperazinyl)formimidoyl)-, 21-acetate (; 2,7-(Epoxypentadeca(1,11,13)trienimino)naphtho(2,1-b)furan-1,11(2H)-dione, 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-(N-(4-methyl-1-piperazinyl)formimidoyl)-, 21-acetate (8CI); 26-[(1E)-2-(4-methylpiperazinyl)-2-azavinyl](7S,11S,13S,17S,18S,12R,14R,15R,16 R)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-d ioxo-8,30-dioxa-24-azatetracyclo[23.3.1.1<; 5,6,9,17,19,21-Hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-(N-(4-methyl-1-piperazinyl)formimidoyl)-2,7-(epoxypentadeca(1,11,13)trienimino)naphtho(2,1-beta)furan-1,11(2H)-dione 21-acetate; 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-[N-(4-methyl-1-piperazinyl)formimidoyl]-, 21-acetate; Rifampicin in combination with actinonin, BB-3497, hydroxylamine hydrochloride, and 1,10-phenanthroline; RMP; Stereoisomer of 5,9,17,19,21-Hexahydroxy-23-methoxy-2,4,12,16,18,20,22-he@ptamethyl-8-[N-(4-methyl-1-piperazinyl)formimidoyl]-2,7-(epoxypentadeca[1,11,13]trienimino)naphtho[2,1-b]furan-1,11(2H)-dione 21-acetate	Small molecule	1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1	JQXXHWHPUNPDRT-WLSIYKJHSA-N	CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C=NN5CCN(CC5)C)C	C43H58N4O12	CAS 13292-46-1	CHEBI:28077	.	.	.	D0G3DL	.	.	.
DR3826	Donepezil	CID: 3152	donepezil; 120014-06-4; Aricept; 2-((1-Benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one; 2-[(1-benzyl-4-piperidyl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one; HSDB 7743; CHEMBL502; 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one; (S)-E2020 (free base); C24H29NO3; CHEBI:53289; 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one; 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-; donepezilo; Donepezil [INN:BAN]; 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-((1-(phenylmethyl)-4-piperidinyl)methyl)-; 142057-80-5; NSC 737535; NSC 758882; NCGC00167537-01; donepezilum; Domepezil; Donepezil (INN); Donaz (TN); PubChem22271; Spectrum_001664; Spectrum5_001662; SCHEMBL2149; Oprea1_188452; KBioSS_002144; BDBM8960; GTPL6599; SCHEMBL8265876; DTXSID8048317; KBio2_002144; KBio2_004712; KBio2_007280; AMY8939; CHEBI:145499; BCPP000253; HMS3886M11; BCP07590; EBD50998; MFCD00912833; s5073; STK003905; AKOS000277311; AKOS016842349; AC-6969; BCP9000622; CCG-268401; DB00843; MRF-0000323; AK-72906; HY-14566; I903; SBI-0206789.P001; AB0013927; FT-0601545; D07869; S-6065; 32288-EP2269989A1; 32288-EP2269990A1; 32288-EP2275420A1; 32288-EP2278970A1; 32288-EP2280010A2; 32288-EP2281815A1; 32288-EP2283811A1; 32288-EP2289882A1; 32288-EP2289886A1; 32288-EP2295417A1; 32288-EP2298758A1; 32288-EP2298759A1; 32288-EP2298761A1; 32288-EP2298772A1; 32288-EP2298776A1; 32288-EP2301933A1; 32288-EP2305640A2; 32288-EP2305664A1; 32288-EP2305675A1; 32288-EP2308839A1; 32288-EP2311823A1; 32288-EP2311827A1; AB00640013-07; AB00640013-08; AB00640013_09; AB00640013_10; 014D064; Q415081; Q-100098; BRD-A49160188-003-04-4; Z1741977105; 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one; (+/-)-2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-indan-1-one; 2-[(1-benzyl-4-piperidyl)methyl]- 5,6-dimethoxy-2,3-dihydroinden-1-one; 2,3-dihydro-5,6-dimethoxy-2 [[1-(phenyl methyl)-4-piperidinyl]methyl]-1H-inden-1-one; 2,3-dihydro-5,6-dimethoxy-2[[1-(phenyl methyl)-4-piperidinyl]methyl]-1H-inden-1-one; 5,6-dimethoxy-2-[[1-(phenylmethyl)piperidin-4-yl]methyl]-2,3-dihydroinden-1-one	Small molecule	1S/C24H29NO3/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18/h3-7,14-15,17,20H,8-13,16H2,1-2H3	ADEBPBSSDYVVLD-UHFFFAOYSA-N	COC1=C(C=C2C(=C1)CC(C2=O)CC3CCN(CC3)CC4=CC=CC=C4)OC	C24H29NO3	CAS 120014-06-4	CHEBI:53289	.	.	.	D0NS6H	.	.	.
DR3924	Bis(7)-tacrine	CID: 9959612	bis(7)-Tacrine; 224445-12-9; 9-Amino-1,2,3,4-tetrahydroacridine bis 1,7-heptylene dihydrochloride; Tacrine-Based Inhibitor 2f; N,N/'-bis(1,2,3,4-tetrahydroacridin-9-yl)heptane-1,7-diamine;dihydrochloride; C33H40N4.2HCl; CHEMBL3752685; DTXSID80433317; 1640AH; SR-01000946720; SR-01000946720-1; Bis(heptyl)-cognitin dihydrochloride, >=98% (HPLC); 9-Amino-1,2,3,4-tetrahydroacridine bis 1,7-heptylene dihydrochloride, >97%, solid	Small molecule	1S/C33H40N4.2ClH/c1(2-12-22-34-32-24-14-4-8-18-28(24)36-29-19-9-5-15-25(29)32)3-13-23-35-33-26-16-6-10-20-30(26)37-31-21-11-7-17-27(31)33;;/h4,6,8,10,14,16,18,20H,1-3,5,7,9,11-13,15,17,19,21-23H2,(H,34,36)(H,35,37);2*1H	RHKXINFBJWDTSK-UHFFFAOYSA-N	C1CCC2=NC3=CC=CC=C3C(=C2C1)NCCCCCCCNC4=C5CCCCC5=NC6=CC=CC=C64.Cl.Cl	C33H42Cl2N4	CAS 224445-12-9	.	.	.	.	.	.	.	.
DR3931	Amoxicillin	CID: 33613	amoxicillin; Amoxycillin; Amoxicillin anhydrous; 26787-78-0; Amoxicilline; p-Hydroxyampicillin; Amopenixin; Amolin; Moxal; D-Amoxicillin; Clamoxyl; Amoxil; Amoxicillinum; Amoxicilina; Imacillin; Hiconcil; Moxatag; Robamox; Amoxicilina [INN-Spanish]; Amoxicillin trihydrate; Amoxicilline [INN-French]; Amoxicillinum [INN-Latin]; alpha-Amino-p-hydroxybenzylpenicillin; Histocillin; Amoclen; Flemoxin; Unicillin; AMPC; Amoxycillin Trihydrate; BRL-2333; AMOXICILLIN CRYSTALLINE; 6-(p-Hydroxy-alpha-aminophenylacetamido)penicillanic acid; Amoxicillin (INN); Amoxicillin [INN]; CHEBI:2676; (2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; UNII-9EM05410Q9; Amoxicillin hydrate; Bristamox; Delacillin; Amoxiden; Amoxivet; Anemolin; Aspenil; Cemoxin; Efpenix; Piramox; Vetramox; Amoxi; Sumox; (2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Amoxi-Mast; Sawamox PM; Metafarma capsules; Metifarma capsules; (2S,5R,6R)-6-((R)-2-Amino-2-(4-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Ospamox; Amopen; Amoxicillin, 96%; 9EM05410Q9; NSC-277174; Amoxicaps; D-2-Amino-2-(4-hydroxyphenyl)acetamidopenicillanic acid; BRL 2333; Apo-Amoxi; AMOX; DSSTox_CID_17044; DSSTox_RID_79299; DSSTox_GSID_37044; AX; AMOXICILLIN PEDIATRIC; amoxicillanyl; Amoxicillin (anhydrous); AMOXICILLINTRIHYDRATE; BLP 1410; D-(-)-alpha-Amino-p-hydroxybenzylpenicillin; Amoxicillin (TN); (2S,5R,6R)-6-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; SMR000058707; Amoxicillin (Amoxycillin); Ro 10-8756; HSDB 3204; EINECS 248-003-8; BL-P 1410; 6-(D-(-)-p-Hydroxy-alpha-aminobenzyl)penicillin; NSC 277174; amoxycilin; Amoxi-Inject; Amoxi-Tabs; NSC277174; notoginsenoside-fe; 6-(D-(-)-alpha-Amino-p-hydroxyphenylacetamido)penicillanic acid; NCGC00016797-02; NCGC00094586-01; Prestwick_713; CAS-26787-78-0; (-)-6-(2-Amino-2-(P-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo-(3.2.0)heptane-2-carboxylic acid; MFCD00056860; Prestwick0_000357; Prestwick1_000357; Prestwick2_000357; Prestwick3_000357; Epitope ID:114241; Epitope ID:116054; EC 248-003-8; SCHEMBL3427; CHEMBL1082; BSPBio_000453; MLS000028632; MLS002222248; SPBio_002374; BPBio1_000499; DTXSID3037044; CHEBI:53712; GTPL10895; HY-B0467A; HMS1569G15; HMS2096G15; HMS2231K23; HMS3259P17; HMS3713G15; ZINC3830215; Tox21_111302; BDBM50350464; s3015; AKOS025395540; Tox21_111302_1; CCG-220357; DB01060; DS-3835; MCULE-5710225015; NC00670; NE41275; 6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carboxylic acid; NCGC00179554-01; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((2R)-amino(4-hydroxyphenyl)acetyl)amino)-3,3-dimethyl-7-oxo-, (2S,5R,6R)-; 4-Thia-1-azobicyclo(3.2.0)heptane-2-carboxylic acid, 6-((amino(4-hydroxyphenyl)acetyl)amino)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta(S)))-; AC-12263; Amoxicillin, potency: >=900 mug per mg; co-amoxiclav (amoxicillin + clavulanic acid); C06827; D07452; Q201928; SR-01000721886; SR-01000721886-2; BRD-K55044200-001-03-9; BRD-K55044200-001-15-3; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2-amino-2-(p-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-, D- (8CI); 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[amino (4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-, [2S-[2.alpha.,5.alpha.,6.beta.(S*)]]-	Small molecule	1S/C16H19N3O5S/c1-16(2)11(15(23)24)19-13(22)10(14(19)25-16)18-12(21)9(17)7-3-5-8(20)6-4-7/h3-6,9-11,14,20H,17H2,1-2H3,(H,18,21)(H,23,24)/t9-,10-,11+,14-/m1/s1	LSQZJLSUYDQPKJ-NJBDSQKTSA-N	CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=C(C=C3)O)N)C(=O)O)C	C16H19N3O5S	CAS 26787-78-0	CHEBI:2676	.	.	.	D0F6EO	.	.	.
DR3943	Carboplatin	CID: 426756	Azanide; Carbopaltin; Carboplatine; Carboplatino; Carboplatinum; Cbdca; Ercar; Paraplatin; Carboplatine [French]; Carboplatino [Spanish]; Carboplatinum [Latin]; C 2538; JM 8; Carboplatin (USAN); IUPAC: Azane; JM-8; Paraplatin (TN); Paraplatin, Carboplatin; Paraplatin-AQ; Cis-Diammine(cyclobutanedicarboxylato)platinumII; Platinum(+2) Cation; Carboplatin (JAN/USP/INN); Carboplatin [USAN:INN:BAN:JAN]; Cyclobutane-1,1-dicarboxylate; Cyclobutane-1,1-dicarboxylic acid; Diammine-1,1-cyclobutane dicarboxylate platinum II; Cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato) platinum; Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; Cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum; Diammine(1,1-cyclobutanedicarboxylato)platinum (II); Platinum, {diammine[1,1-cyclobut; Cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Platinum(II), (1, 1-cyclobutanedicar; Diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum; Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum; 1,1-Cyclobutanedicarboxylate diammine platinum (II); 1,1-Cyclobutanedicarboxylate diammine platinum(II)	Small molecule	1S/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6;;;/h1-3H2,(H,7,8)(H,9,10);2*1H2;/q;2*-1;+2	VSRXQHXAPYXROS-UHFFFAOYSA-N	C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]	C6H12N2O4Pt	CAS 41575-94-4	CHEBI:31355	.	.	.	D0X7HM	.	.	.
DR3952	MG132	CID: 462382	MG-132; 133407-82-6; Z-Leu-leu-leu-al; MG132; MG 132; Zlllal; Z-LLL-CHO; Zlll-cho; Z-Leu-leu-leucinal; Z-Leu-Leu-Leu-H; Carbobenzoxy-leucyl-leucyl-leucinal; UNII-RF1P63GW3K; Benzyloxycarbonyl-leu-leu-leu-aldehyde; Benzyloxycarbonyl-leucyl-leucyl-leucinal; Carbobenzoxyl-leucinyl-leucinyl-leucinal-H; Cbz-Leu-Leu-Leu-H; C26H41N3O5; Benzyloxycarbonylleucyl-leucyl-leucine aldehyde; Z-Leu-Leu-Leu-aldehyde; RF1P63GW3K; Carbobenzoxy-L-leucyl-L-leucyl-L-leucinal; CHEMBL64925; benzyl (S)-4-methyl-1-((S)-4-methyl-1-((S)-4-methyl-1-oxopentan-2-ylamino)-1-oxopentan-2-ylamino)-1-oxopentan-2-ylcarbamate; Cbz-L-Leu-L-Leu-L-Leu-CHO; CHEBI:75142; MFCD00674886; Benzyl ((S)-4-methyl-1-(((S)-4-methyl-1-(((S)-4-methyl-1-oxopentan-2-yl)amino)-1-oxopentan-2-yl)amino)-1-oxopentan-2-yl)carbamate; Lll cpd; (S)-N-((Phenylmethoxy)carbonyl)-L-leucyl-N-(1-formyl-3-methylbutyl)-L-leucinamide; N-[(Benzyloxy)carbonyl]-L-Leucyl-N-[(2s)-4-Methyl-1-Oxopentan-2-Yl]-L-Leucinamide; BRD0970; BRD-0970; Z-LLL; N-[(Phenylmethoxy)carbonyl]-L-leucyl-N-[(1S)-1-formyl-3-methylbutyl]-L-leucinamide; (R)-MG132; (S)-MG132; N-[(benzyloxy)carbonyl]-L-leucyl-N-[(1S)-1-formyl-3-methylbutyl]-L-leucinamide; Z-LLL-aldehyde; 1211877-36-9; Benzyl N-[(1S)-3-methyl-1-[[(1S)-3-methyl-1-[[(2S)-4-methyl-1-oxo-pentan-2-yl]carbamoyl]butyl]carbamoyl]butyl]carbamate; Z-LLLal; Cbz-Leu-Leu-Leu-al; Cbz-Leu-Leu-Leucinal; Z-LLL-H; Z-L-leu-L-leu-L-leu-H; BSPBio_001310; carbobenzoxy-Leu-Leu-leucinal; KBioGR_000030; KBioSS_000030; cc-245; MLS006011220; Cbz-L-Leu-L-Leu-L-Leu-H; SCHEMBL160925; GTPL8616; DTXSID3042639; BCBcMAP01_000028; KBio2_000030; KBio2_002598; KBio2_005166; KBio3_000059; KBio3_000060; AOB4946; QCR-183; benzyloxycarbonyl-Leu-Leu-leucinal; Bio2_000030; Bio2_000510; HMS1361B12; HMS1791B12; HMS1989B12; HMS3402B12; AMY40914; EX-A1500; ABP000958; BDBM50069985; NSC782153; PI-102; s2619; ZINC13476439; AKOS027420457; MG132/MG-132/; ACN-047884; CCG-207860; CCG-208036; CS-0471; NSC-782153; SB19111; compound 5b [PMID: 16686537]; IDI1_033780; NCGC00161679-01; NCGC00161679-02; NCGC00161679-03; NCGC00161679-04; Z-Leu-Leu-Leu-al, >=90% (HPLC); AS-55854; HY-13259; SMR002530629; AB0033810; SW219780-1; UNM000011053701; X7579; W-5117; InSolution MG-132 - CAS 133407-82-6; n-benzyloxycarbonyl-l-leucyl-l-leucyl-l-leucinal; Q3272916; SR-01000864598-1; BRD-K60230970-001-04-3; BRD-K60230970-001-05-0; BRD-K60230970-001-06-8; BRD-K60230970-001-07-6; BRD-K60230970-001-08-4; BRD-K60230970-001-10-0; MG-132 - CAS 133407-82-6; MG-132, >/=95% by HPLC - CAS 133407-82-6; L-Leucinamide, N-((phenylmethoxy)carbonyl)-L-leucyl-N-((1S)-1-formyl-3-methylbutyl)-; L-Leucinamide, N-((phenylmethoxy)carbonyl)-L-leucyl-N-(1-formyl-3-methylbutyl)-, (S)-; L-Leucinamide, N-[(phenylmethoxy)carbonyl]-L-leucyl-N1-[(1S)-1-formyl-3-methylbutyl]-; N-[(Phenylmethoxy)carbonyl]-L-leucyl-N-(1-formyl-3-methylbutyl)-(S)-L-leucinamide; (S)-4-methyl-2-(3-phenyl-propionylamino)-pentanoic acid [(S)-1-((S)-1-formyl-3-methyl-butylcarbamoyl)-3-methyl-butyl]-amide; {(S)-1-[(S)-1-((S)-1-Formyl-3-methyl-butylcarbamoyl)-3-methyl-butylcarbamoyl]-3-methyl-butyl}-carbamic acid benzyl ester; {1-[(S)-(S)-1-((S)-1-Formyl-3-methyl-butylcarbamoyl)-3-methyl-butylcarbamoyl]-3-methyl-butyl}-carbamic acid benzyl ester; {1-[1-(1-Formyl-3-methyl-butylcarbamoyl)-3-methyl-butylcarbamoyl]-3-methyl-butyl}-carbamic acid benzyl ester; benzyl N-[(1S)-1-[[(1S)-1-[[(1S)-1-formyl-3-methyl-butyl]carbamoyl]-3-methyl-butyl]carbamoyl]-3-methyl-butyl]carbamate; benzyl(S)-4-methyl-1-((S)-4-methyl-1-((S)-4-methyl-1-oxopentan-2-ylamino)-1-oxopentan-2-ylamino)-1-oxopentan-2-ylcarbamate; phenylmethyl N-[(2S)-4-methyl-1-[[(2S)-4-methyl-1-[[(2S)-4-methyl-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]carbamate	Small molecule	1S/C26H41N3O5/c1-17(2)12-21(15-30)27-24(31)22(13-18(3)4)28-25(32)23(14-19(5)6)29-26(33)34-16-20-10-8-7-9-11-20/h7-11,15,17-19,21-23H,12-14,16H2,1-6H3,(H,27,31)(H,28,32)(H,29,33)/t21-,22-,23-/m0/s1	TZYWCYJVHRLUCT-VABKMULXSA-N	CC(C)CC(C=O)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)OCC1=CC=CC=C1	C26H41N3O5	CAS 133407-82-6	CHEBI:75142	.	.	.	.	.	.	.
DR3991	Levetiracetam	CID: 5284583	Levetiracetam; 102767-28-2; Keppra; (S)-2-(2-Oxopyrrolidin-1-yl)butanamide; Keppra XR; ucb L059; UCB-L 059; (2S)-2-(2-oxopyrrolidin-1-yl)butanamide; UCB-L059; Levetiracetamum; Spritam; (S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; SIB-S1; (-)-(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; UNII-44YRR34555; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-, (alphaS)-; MFCD03265610; UCB-22059; Levetiracetamum [INN-Latin]; CHEBI:6437; Levetiracetam In Sodium Chloride; UCB 22059; 44YRR34555; Levroxa; (S)-(-)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide; (S)-2-(2-OXO-PYRROLIDIN-1-YL)-BUTYRAMIDE; matever; Leviteracetam; Levipil; Torleva; Elepsia XR; (S)-Levetiracetam; SMR000466303; Keppra (TN); Levesam 500; Etiracetam levo-isomer; SR-01000759400; Levetiracetame; E Keppra; HSDB 7528; N03AX14; Levetiracetam [USAN:USP:INN:BAN]; E keppra (TN); Levetiracetam solution; (S)-2-(2-Oxo-1-pyrrolidinyl)butyramide; L-059; 2(S)-(2-OXOPYRROLIDIN-1-YL)BUTYRAMIDE; CHEMBL1286; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-, (S)-; MLS000759403; MLS001424069; MLS006010215; BIDD:GT0242; SCHEMBL118843; GTPL6826; Levetiracetam (JAN/USP/INN); DTXSID9023207; AGB-101; Levetiracetam, >=98% (HPLC); Levetiracetam, analytical standard; HMS2051D07; HMS2089L20; HMS2235I18; HMS3262H11; HMS3713P16; HMS3884O11; Pharmakon1600-01502265; ACT02712; ALBB-027275; BCP11856; HY-B0106; ZINC1547851; Tox21_500835; ANW-41693; BDBM50422542; NSC760119; s1356; STL388027; Levetiracetam 1.0 mg/ml in Methanol; AKOS015841981; AB13957; AC-1479; CCG-100928; CS-1854; DB01202; KS-1176; LP00835; LS41261; MCULE-5120797917; NC00178; NSC 760119; NSC-760119; SDCCGSBI-0633760.P001; (2S)-(2-Oxopyrrolidin-1-yl)butyramide; NCGC00186028-01; NCGC00186028-13; NCGC00261520-01; (S)-2-(2-oxopyrrolidin-1-yl)butyramide; (s)-2-(2-oxopyrrolidin-1-yl) butyramide; (2S)-2-(2-oxo-1-pyrrolidinyl)butanamide; AB0012613; AM20070676; L0234; SW197558-3; C07841; D00709; M-2814; AB00639945-06; AB00639945_07; AB00639945_08; 767L282; A800616; (2S)-2-(2-oxidanylidenepyrrolidin-1-yl)butanamide; Q-201292; SR-01000759400-4; SR-01000759400-5; (ALPHAS)-ALPHA-ETHYL-2-OXO-1-PYRROLIDINEACETAMIDE; UNII-230447L0GL component HPHUVLMMVZITSG-LURJTMIESA-N; Levetiracetam, European Pharmacopoeia (EP) Reference Standard; (??S)???-??-???Ethyl-???2-???oxo-1-???pyrrolidineacetamide; Levetiracetam, United States Pharmacopeia (USP) Reference Standard; (-)-(S)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide (2S)-2-(2-Oxo-pyrrolidin-1-yl)butanamide; Levetiracetam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; Levitiracetam, Pharmaceutical Secondary Standard; Certified Reference Material	Small molecule	1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1	HPHUVLMMVZITSG-LURJTMIESA-N	CCC(C(=O)N)N1CCCC1=O	C8H14N2O2	CAS 102767-28-2	CHEBI:6437	.	.	.	D0E1XL	.	.	.
DR4000	Marbofloxacin	CID: 60651	Marbofloxacin; 115550-35-1; Zeniquin; Marbocyl; UNII-8X09WU898T; 8X09WU898T; MFCD00864820; 7H-Pyrido[3,2,1-ij][4,1,2]benzoxadiazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-; 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,3,4]oxadiazino[6,5,4-ij]quinoline-6-carboxylic acid; NCGC00166310-01; DSSTox_CID_26600; DSSTox_RID_81755; DSSTox_GSID_46600; 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-3,7-dihydro-2H-[1,3,4]oxadiazino[6,5,4-ij]quinoline-6-carboxylic acid; Marbofloxacine [INN-French]; Marbofloxacinum [INN-Latin]; 9-Fluoro-3,7-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2H-[1,3,4]oxadiazino[6,5,4-ij]quinoline-6-carboxylic Acid; Marbofloxacino [INN-Spanish]; CAS-115550-35-1; Marbofloxacin [INN:BAN]; Marbofloxacine/; CCRIS 8212; 9-Fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-pyrido[3,2,1-ij][4,1,2]benzoxadiazine-6-carboxylic acid; PubChem16145; Marbofloxacin (USP/INN); Oprea1_079403; 9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(3,2,1-ij)(4,1,2)benzoxadiazine-6-carboxylic acid; cc-422; SCHEMBL134860; CHEMBL478120; DTXSID4046600; CHEBI:94723; EX-A015; ZINC537947; HY-B0126; RKL10084; Tox21_112406; ABP000382; ANW-42471; s1464; AKOS015853291; Tox21_112406_1; BCP9000896; CCG-229989; CS-1892; DB11426; GS-3323; NCGC00166310-02; NCGC00166310-03; 7H-Pyrido(3,2,1-ij)(4,1,2)benzoxadiazine-6-carboxylic acid, 2,3-dihydro-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-; 9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-piperazino)-7-oxo-7H-pyrido[1,2,3-ij][1,2,4]benzoxadiazine-6-carboxylic acid; AC-24289; AK327608; AB0105713; DB-041275; FT-0628168; M2240; D08156; AB01566820_01; 550M351; Marbofloxacin, VETRANAL(TM), analytical standard; Q909359; SR-01000772975; Q-201338; SR-01000772975-2; Marbofloxacin, European Pharmacopoeia (EP) Reference Standard; Marbofloxacin for peak identification, European Pharmacopoeia (EP) Reference Standard; 7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1,2- diazatricyclo[7.3.1.0^5,13^]trideca-5,7,9(13),11-tetraene-11-carboxylic acid; 7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1,2-diazatricyclo[7.3.1.0^{5,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid; 7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1,2-diazatricyclo[7.3.1.0^{5,13}]trideca-5,7,9(13),11-tetraene-11-carboxylic acid; 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl -1-piperazinyl)-7-oxo-7H-pyrido[3,2,1-ij][4,1,2]benzoxadiazine-6-carboxylic acid; 9-fluoro-2,3-dihydro-3-methyl-10-(4-methylpiperazin-1-yl)- 7-oxo-7H-pyrido[1,2,3-ij][1,2,4]benzoxadiazine-6-carboxylic acid	Small molecule	1S/C17H19FN4O4/c1-19-3-5-21(6-4-19)14-12(18)7-10-13-16(14)26-9-20(2)22(13)8-11(15(10)23)17(24)25/h7-8H,3-6,9H2,1-2H3,(H,24,25)	BPFYOAJNDMUVBL-UHFFFAOYSA-N	CN1CCN(CC1)C2=C(C=C3C4=C2OCN(N4C=C(C3=O)C(=O)O)C)F	C17H19FN4O4	CAS 115550-35-1	CHEBI:94723	.	.	.	.	.	.	.
DR4025	Efonidipine	CID: 119171	Efonidipine; 111011-63-3; Efonidipine [INN]; Efonidipine (INN); NCGC00182046-01; NZ-105; 2-(Benzyl(phenyl)amino)ethyl 5-(5,5-dimethyl-2-oxido-1,3,2-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate; ( inverted exclamation markA)-2-[benzyl (phenyl) amino] ethyl 1,4-dihydro-2,6- dimethyl-5-(5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorinan-2-yl)-4-(3-nitrophenyl)-3-pyridinecarboxylate hydrochloride ethano; C34H38N3O7P; 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxido-1,3,2-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate; DSSTox_CID_23988; DSSTox_RID_80095; DSSTox_GSID_43988; SCHEMBL49637; CHEMBL2074922; DTXSID9043988; CHEBI:146221; HMS3886A09; ACT06293; BCP14772; EX-A3998; Tox21_113418; 3603AH; AC-389; MFCD00865899; s4977; AKOS015967143; CCG-270291; CS-3623; DB09235; 2-(N-Benzylanilino)ethyl (+-)-1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-5-phosphononicotinate, cyclic 2,2-dimethyltrimethylene ester; HY-12502; CAS-111011-63-3; FT-0748191; D07886; Q5347555; 2-(N-Benzylanilino)ethyl (- )-1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-5-phosphononicotinate, cyclic 2,2-dimethyltrimethylene ester.; 2-(N-benzylanilino)ethyl 5-(5,5-dimethyl-2-oxo-1,3,2$l^{5-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate; 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxo-1,3,2; E?-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate; 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxo-1,3,2lambda(5)-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate	Small molecule	1S/C34H38N3O7P/c1-24-30(33(38)42-19-18-36(28-15-9-6-10-16-28)21-26-12-7-5-8-13-26)31(27-14-11-17-29(20-27)37(39)40)32(25(2)35-24)45(41)43-22-34(3,4)23-44-45/h5-17,20,31,35H,18-19,21-23H2,1-4H3	NSVFSAJIGAJDMR-UHFFFAOYSA-N	CC1=C(C(C(=C(N1)C)P2(=O)OCC(CO2)(C)C)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OCCN(CC4=CC=CC=C4)C5=CC=CC=C5	C34H38N3O7P	CAS 111011-63-3	CHEBI:146221	.	.	.	.	.	.	.
DR4035	Exenatide	CID: 45588096	Exenatide; Exendin-4; 141758-74-9; Exenatide free base; UNII-9P1872D4OL; AC 2993; Exendin 4; Byetta; Bydureon; 9P1872D4OL; 141758-74-9 (free base); Bydureon Pen; ITCA 650; HSDB 7789; Exenatide [USAN:INN:BAN:JAN]; PT302; AC 2993A; DA 3091; Exenatide; Exendin-4; LY 2148568; SCHEMBL14634818; AKOS015994651; HS-2012; Y-100006; Exendin 3 (Heloderma horridum), 2-glycine-3-L-glutamic acid-	Small molecule	1S/C184H282N50O60S/c1-16-94(10)147(178(289)213-114(52-58-144(257)258)163(274)218-121(73-101-77-195-105-39-24-23-38-103(101)105)168(279)215-116(68-90(2)3)165(276)205-107(41-26-28-61-186)158(269)219-122(75-134(189)243)154(265)198-79-135(244)196-83-139(248)231-63-30-43-129(231)175(286)225-127(87-238)174(285)223-125(85-236)155(266)200-80-136(245)202-96(12)181(292)233-65-32-45-131(233)183(294)234-66-33-46-132(234)182(293)232-64-31-44-130(232)176(287)222-124(84-235)150(190)261)229-170(281)119(71-99-34-19-17-20-35-99)217-166(277)117(69-91(4)5)214-159(270)108(42-29-62-194-184(191)192)212-177(288)146(93(8)9)228-151(262)95(11)203-156(267)111(49-55-141(251)252)208-161(272)112(50-56-142(253)254)209-162(273)113(51-57-143(255)256)210-164(275)115(59-67-295-15)211-160(271)110(47-53-133(188)242)207-157(268)106(40-25-27-60-185)206-172(283)126(86-237)224-167(278)118(70-92(6)7)216-169(280)123(76-145(259)260)220-173(284)128(88-239)226-180(291)149(98(14)241)230-171(282)120(72-100-36-21-18-22-37-100)221-179(290)148(97(13)240)227-138(247)82-199-153(264)109(48-54-140(249)250)204-137(246)81-197-152(263)104(187)74-102-78-193-89-201-102/h17-24,34-39,77-78,89-98,104,106-132,146-149,195,235-241H,16,25-33,40-76,79-88,185-187H2,1-15H3,(H2,188,242)(H2,189,243)(H2,190,261)(H,193,201)(H,196,244)(H,197,263)(H,198,265)(H,199,264)(H,200,266)(H,202,245)(H,203,267)(H,204,246)(H,205,276)(H,206,283)(H,207,268)(H,208,272)(H,209,273)(H,210,275)(H,211,271)(H,212,288)(H,213,289)(H,214,270)(H,215,279)(H,216,280)(H,217,277)(H,218,274)(H,219,269)(H,220,284)(H,221,290)(H,222,287)(H,223,285)(H,224,278)(H,225,286)(H,226,291)(H,227,247)(H,228,262)(H,229,281)(H,230,282)(H,249,250)(H,251,252)(H,253,254)(H,255,256)(H,257,258)(H,259,260)(H4,191,192,194)/t94-,95-,96-,97+,98+,104-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,146-,147-,148-,149-/m0/s1	HTQBXNHDCUEHJF-XWLPCZSASA-N	CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC9=CNC=N9)N	C184H282N50O60S	CAS 141758-74-9	.	.	.	.	D00YVF	.	.	.
DR4059	Methylseleninic acid	CID: 161597	Methaneseleninic acid; Methylselenic acid; Methylseleninic acid; 28274-57-9; methylseleninate; UNII-9900C6V162; CHEBI:77012; 9900C6V162; Methyl seleninic acid; Methaneseleninic acid, 95%; SCHEMBL772883; CHEMBL399906; DTXSID9040550; AKOS025296197; C18902; Q6823570	Small molecule	1S/CH4O2Se/c1-4(2)3/h1H3,(H,2,3)	UEQANLFPOFICBH-UHFFFAOYSA-N	C[Se](=O)O	CH4O2Se	CAS 28274-57-9	CHEBI:77012	.	.	.	.	.	.	.
DR4093	Chlorambucil	CID: 2708	chlorambucil; 305-03-3; Ambochlorin; Chloroambucil; Leukeran; Chloraminophen; Chlorbutin; Chloraminophene; Chlorobutine; Amboclorin; Chlorbutine; Chlorobutin; Linfolizin; Linfolysin; Ecloril; Elcoril; Phenylbutyric acid nitrogen mustard; Chlocambucil; Lympholysin; Leukersan; Leukoran; 4-{4-[bis(2-chloroethyl)amino]phenyl}butanoic acid; Cb l348; NSC-3088; CB 1348; Phenylbuttersaeure-lost; Benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]-; NSC 3088; Rcra waste number U035; NCI-C03485; 4-[p-[Bis(2-chloroethyl)amino]phenyl]butyric acid; chlorambucilddv; 4-[4-[bis(2-chloroethyl)amino]phenyl]butanoic acid; N,N-Di-2-chloroethyl-gamma-p-aminophenylbutyric acid; 4-(Bis(2-chloroethyl)amino)benzenebutanoic acid; p-(N,N-Di-2-chloroethyl)aminophenyl butyric acid; 4-(p-Bis(beta-chloroethyl)aminophenyl)butyric acid; UNII-18D0SL7309; 4-(4-(Bis(2-chloroethyl)amino)phenyl)butanoic acid; CHEBI:28830; NSC3088; 4-[Bis(2-chloroethyl)amino]benzenebutyric acid; 4-[Bis(2-chloroethyl)amino]benzenebutanoic acid; CHEMBL515; gamma-[p-Di(2-chloroethyl)aminophenyl]butyric acid; Benzenebutanoic acid, 4-(bis(2-chloroethyl)amino)-; MLS000028443; Chloorambucol; Chlorbutinum; Elcorin; 4-(Bis(2-chloroethyl)amino)phenylbutyric acid; 4-(p-(Bis(2-chloroethyl)amino)phenyl)butyric acid; gamma-(p-Di(2-chloroethyl)aminophenyl)butyric acid; Butyric acid, 4-(p-bis(2-chloroethyl)aminophenyl)-; MFCD00021783; 18D0SL7309; Kyselina 4-(N,N-bis-(2-chlorethyl)-p-aminofenyl)maselna; NCGC00015199-08; Chlorambucilum; Clorambucile; Clorambucilo; CAS-305-03-3; SMR000058372; Clorambucile [DCIT]; DSSTox_CID_263; Leukeran tablets; 4-[Bis(2-chloroethyl)amino]phenylbutyric acid; DSSTox_RID_75472; DSSTox_GSID_20263; 4-(4-[Bis(2-chloroethyl)amino]phenyl)butyric acid; .gamma.-[p-Di(2-chloroethyl)aminophenyl]butyric acid; Butyric acid, 4-[p-[bis(2-chloroethyl)amino]phenyl]-; Chlorambucilum [INN-Latin]; Clorambucilo [INN-Spanish]; p-N,N-Di-(.beta.-chloroethyl)aminophenyl butyric acid; N,N-Di-2-chloroethyl-.gamma.-p-aminophenylbutyric acid; CB-1348; CCRIS 126; Phenylbuttersaeure-lost [German]; HSDB 3026; SR-01000000062; LEUKERAN (TN); 4-[4-[Bis(2-chloroethyl)amino]phenyl]butyric Acid; EINECS 206-162-0; .gamma.-(p-bis(2-chloroethyl)aminophenyl)butyric acid; .gamma.-[p-bis(2-chloroethyl)aminophenyl]butyric acid; 4-(p-Bis(.beta.-chloroethyl)aminophenyl)butyric acid; 4-[p-Bis(.beta.-chloroethyl)aminophenyl]butyric acid; RCRA waste no. U035; Butyric acid, 4-(p-[bis(2-chloroethyl)amino]phenyl)-; BRN 0999011; Chlorambucil [USP:INN:BAN]; AI3-26083; p-(N,N-Di-2-chlorethylaminophenyl)butyric acid; para-(Di(2-chloroethyl)aminophenyl)butyric acid; Chlorambucil,(S); gamma-(p-bis(2-chloroethyl)aminophenyl)butyricacid; Butanoic acid, 4-(bis(2-chloroethyl)amino) benzene; gamma-(p-Bis(2-chloroethyl)aminophenyl)butyric acid; phenyl)butanoic acid; p-N,N-Di-(beta-chloroethyl)aminophenyl butyric acid; Butyric acid, 4-(p-(bis(2-chloroethyl)amino)phenyl); para-N,N-Di(beta-chloroethyl)aminophenyl butyric acid; N,N-Di-2-chloroethyl-gamma-para-aminophenyl butyric acid; Opera_ID_51; PubChem21331; Spectrum_000118; Kyselina 4-(N,N-bis-(2-chlorethyl)-p-aminofenyl)maselna [Czech]; Prestwick0_001079; Prestwick1_001079; Prestwick2_001079; Prestwick3_001079; Spectrum2_000065; Spectrum3_000336; Spectrum4_000273; Spectrum5_000677; Lopac-C-0253; Epitope ID:139977; SCHEMBL4308; Lopac0_000227; WLN: QV3R DN2G2G; BSPBio_001098; BSPBio_001971; KBioGR_000766; KBioSS_000558; 4-14-00-01715 (Beilstein Handbook Reference); MLS001076130; DivK1c_000688; SPECTRUM1500171; Chlorambucil (JAN/USP/INN); SPBio_000249; SPBio_002999; BPBio1_001208; GTPL7143; ZINC1115; DTXSID7020263; HMS502C10; KBio1_000688; KBio2_000558; KBio2_003126; KBio2_005694; KBio3_001191; NINDS_000688; HMS1571G20; HMS1920M15; HMS2090M19; HMS2091A22; HMS2098G20; HMS2235A04; HMS3259I10; HMS3372O04; HMS3652P08; Pharmakon1600-01500171; 4-(4-(bis(2-chloroethyl)amino); AMY33445; BCP28394; NCI-3088; Tox21_110096; Tox21_201390; Tox21_302996; BDBM50003677; CCG-39872; NSC756674; s4288; AKOS024319346; Tox21_110096_1; Chlorambucil, purum, >=98.0% (T); CS-3118; DB00291; GS-6200; LP00227; MCULE-2575006904; NC00555; NSC-756674; SDCCGSBI-0050215.P005; IDI1_000688; NCGC00015199-01; NCGC00015199-02; NCGC00015199-03; NCGC00015199-04; NCGC00015199-05; NCGC00015199-06; NCGC00015199-07; NCGC00015199-09; NCGC00015199-10; NCGC00015199-11; NCGC00015199-12; NCGC00015199-13; NCGC00015199-14; NCGC00015199-15; NCGC00015199-16; NCGC00015199-17; NCGC00015199-19; NCGC00015199-20; NCGC00023250-00; NCGC00023250-03; NCGC00023250-04; NCGC00023250-05; NCGC00023250-06; NCGC00023250-07; NCGC00023250-08; NCGC00023250-09; NCGC00023250-10; NCGC00256464-01; NCGC00258941-01; AK327627; BP-24028; HY-13593; NCI60_002639; SBI-0050215.P004; AB0093202; DB-047794; AB00051938; EU-0100227; FT-0617365; ST50410766; SW197258-4; A14252; A18607; C 0253; C06900; D00266; AB00051938-14; AB00051938-15; AB00051938_16; 305C033; Q415939; 4[p-Bis(.beta.-chloroethyl)aminophenyl]butyric acid; Butanoic acid, 4-(bis(2-chloroethyl)amino)benzene-; SR-01000000062-2; SR-01000000062-4; SR-01000000062-7; W-106940; .gamma.-(p-bis(2-chloroethyl)aminophenyl)butyricacid; BRD-K29458283-001-04-2; BRD-K29458283-001-05-9; BRD-K29458283-001-17-4; 4-(4-[Bis(2-chloroethyl)amino]phenyl)butanoic acid #; Z1558572529; 4-[4-(N,N-bis(2-chloroethyl)-amino]phenyl)butanoic acid; Chlorambucil, European Pharmacopoeia (EP) Reference Standard; Chlorambucil, United States Pharmacopeia (USP) Reference Standard; Chlorambucil for system suitability, European Pharmacopoeia (EP) Reference Standard	Small molecule	1S/C14H19Cl2NO2/c15-8-10-17(11-9-16)13-6-4-12(5-7-13)2-1-3-14(18)19/h4-7H,1-3,8-11H2,(H,18,19)	JCKYGMPEJWAADB-UHFFFAOYSA-N	C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl	C14H19Cl2NO2	CAS 305-03-3	CHEBI:28830	.	.	.	D0V8QT	.	.	.
DR4137	Rapamycin	CID: 5284616	(-)-Rapamycin; 53123-88-9; AY 22989; AY-22989; I 2190A; I-2190A; I2190A; NSC 226080; RAPA; Rapammune; Rapamune; Rapamycin; SIIA 9268A; Sirolimus; Wy 090217; Rapamycin (Sirolimus); Antibiotic AY 22989; UNII-W36ZG6FT64; CHEBI:9168; W36ZG6FT64; WY-090217; DE-109; MFCD00867594; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; SILA 9268A; Supralimus; CAS-53123-88-9; sirolimusum; Perceiva; Cypher; CCRIS 9024; NSC226080; HSDB 7284; 1fkb; 1pbk; NSC-226080; NCGC00181146-01; LCP-Siro; RAP; S1039; PubChem16645; BiomolKI2_000084; Rapamycin C-7, analog 4; SCHEMBL3463; Rapamycin,Sirolimus,Rapamune; BIDD:PXR0165; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; MLS006010168; Sirolimus [USAN:INN:BAN]; GTPL6031; DTXSID5023582; BDBM36609; L04AA10; MS-R001; SYN1185; SM-88 COMPONENT SIROLIMUS; HMS2089A21; HMS3403F11; HMS3884C03; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; EX-A1044; Tox21_110870; Tox21_112750; AC-722; BDBM50064359; STL570275; AKOS015850976; AKOS015961618; ZINC169289388; ACN-035837; CCG-100684; CS-0063; DB00877; NCGC00021305-06; NCGC00021305-07; Rapamycin from Streptomyces hygroscopicus; AS-11687; HY-10219; SMR004701276; UNM-0000358684; A-275; R0097; Rapamycin, RAPA, Rapamune, Sirolimus, RPM; Rapamycin, VETRANAL(TM), analytical standard; EC 610-965-5; Q32089; S-7759; 123R889; Q-201659; 	Small molecule	1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1	QFJCIRLUMZQUOT-HPLJOQBZSA-N	CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC	C51H79NO13	CAS 53123-88-9	CHEBI:9168	.	.	.	D0T6DK	.	.	Rapamycin
DR4154	Thymidine kinase/ganciclovir	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR4171	Stilbenoids	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR4175	Domperidone	CID: 3151	domperidone; 57808-66-9; Motilium; Nauzelin; Domperidonum; Domperidona; 4-(5-Chloro-2-oxo-1-benzimidazolinyl)-1-[3-(2-oxobenzimidazolinyl)propyl]piperidine; R-33812; R 33,812; NSC299589; Domperidone (Motilium); 5-Chloro-1-(1-(3-(2-oxo-1-benzimidazolinyl)propyl)-4-piperidyl)-2-benzimidazolinone; R33812; UNII-5587267Z69; KW 5338; MLS000069343; CHEMBL219916; 5-Chloro-1-[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; CHEBI:31515; MFCD00069256; 6-chloro-3-[1-[3-(2-oxo-3H-benzimidazol-1-yl)propyl]piperidin-4-yl]-1H-benzimidazol-2-one; NSC 299589; NSC-299589; 5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; Motinorm; Costi; 5-Chloro-1-[1-[3-(2-oxo-1-benzimidazolinyl)propyl]-4-piperidyl]-2-benzimidazolinone; DSSTox_CID_25116; DSSTox_RID_80682; DSSTox_GSID_45116; 1-(3-(4-(5-chloro-2-oxo-2,3-dihydrobenzo[d]imidazol-1-yl)piperidin-1-yl)propyl)-1H-benzo[d]imidazol-2(3H)-one; 5-chloro-1-(1-(3-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)propyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one; 5-chloro-1-(1-(3-(2-oxo-2,3-dihydrobenzo[d]imidazol-1-yl)propyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one; 5-Chloro-1-{1-[3-(2-oxo-2,3-dihydro-benzoimidazol-1-yl)-propyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one; Domperidonum [INN-Latin]; Domperidona [INN-Spanish]; 5587267Z69; Motillium; Motilium (TN); SMR000326802; CAS-57808-66-9; KW-5338; Lopac-D-122; SR-01000003002; EINECS 260-968-7; BRN 0903774; Nauzelin OD; Domperidone,(S); 5-chloro-1-{1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinyl}-1,3-dihydro-2H-benzimidazol-2-one; Domperidone [USAN:INN:BAN:JAN]; Prestwick_794; NCI299589; HS-0067; PubChem15679; Spectrum_000391; Opera_ID_616; SpecPlus_000825; Prestwick0_000461; Prestwick1_000461; Prestwick2_000461; Prestwick3_000461; Spectrum4_000087; D-122; Biomol-NT_000022; NCIStruc1_001686; NCIStruc2_001819; Lopac0_000427; SCHEMBL43729; BSPBio_002350; GTPL965; KBioGR_000354; KBioSS_000871; 2H-Benzimidazol-2-one, 5-chloro-1-(1-(3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl)-4-piperidinyl)-1,3-dihydro-; 5-24-02-00402 (Beilstein Handbook Reference); MLS000859942; MLS001306482; MLS002222324; DivK1c_006921; SPECTRUM2300212; SPBio_002501; BPBio1_000620; BPBio1_001185; DTXSID1045116; Domperidone (JP17/USAN/INN); KBio1_001865; KBio2_000871; KBio2_003439; KBio2_006007; HMS1922N04; HMS2089C14; HMS2093N22; HMS2096C21; HMS2230N18; HMS3261E16; HMS3269O13; HMS3370L03; HMS3413F15; HMS3656M21; HMS3677F15; HMS3713C21; HMS3884N19; Pharmakon1600-02300212; BCP28265; Domperidone 1.0 mg/ml in Methanol; EBD46624; HY-B0411; ZINC4175569; Tox21_110056; Tox21_500427; ANW-42358; BBL028136; BDBM50241107; CCG-37870; CD0227; NCGC00014670; NSC759575; s2461; STK622843; AKOS005555858; Tox21_110056_1; AC-2037; DB01184; Domperidone, powder, >=98% (HPLC); LP00427; MCULE-4430288884; NSC 759575; NSC-759575; SDCCGSBI-0050412.P004; NCGC00014670-01; NCGC00014670-02; NCGC00014670-03; NCGC00014670-04; NCGC00014670-05; NCGC00014670-06; NCGC00014670-07; NCGC00014670-08; NCGC00014670-09; NCGC00014670-10; NCGC00014670-11; NCGC00014670-12; NCGC00014670-13; NCGC00014670-14; NCGC00014670-16; NCGC00014670-17; NCGC00014670-28; NCGC00015306-01; NCGC00021472-02; NCGC00021472-03; NCGC00021472-04; NCGC00021472-05; NCGC00021472-06; NCGC00021472-07; NCGC00021472-08; NCGC00097773-01; NCGC00261112-01; 2H-Benzimidazol-2-one, 1,3-dihydro-5-chloro-1-(1-(3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl)-4-piperidinyl)-; 5-chloro-1-(1-(3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl)-4-piperidinyl)-1,3-dihydro-2H-benzimidazol-2-one; 5-chloro-1-(1-(3-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)propyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one; NCI60_002512; SMR000058969; AB0110085; AB00052423; D4125; EU-0100427; FT-0625588; SW196931-3; D01745; AB00052423-06; AB00052423-07; AB00052423_08; AB00052423_09; 808D669; L000230; Q424238; R 33812; SR-01000003002-2; SR-01000003002-4; SR-01000003002-7; W-105440; BRD-K38305202-001-02-6; BRD-K38305202-001-08-3; Domperidone, European Pharmacopoeia (EP) Reference Standard; 5-Chloro-1-[1-[3-(2-oxo-1-benzimidazolyl)propyl]-4-piperidyl]benzimidazol-2-one; 2H-Benzimidazol-2-one,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinyl]-1,3-dihydro-; 5-Chloro-1-[1-[3-(2,3-dihydro-2-oxo -1H-benzimidazol-1-yl)propyl]-4-piperidinyl]-1,3-d ihydro-2H-benzimidazol-2-one; 5-Chloro-1-[1-[3-(2-oxo-2,3-dihydro-1H-benzimidazol-1- yl)propyl]piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one; 5-chloro-1-[1-[3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl]piperidine-4-yl]-1,3-dihydro-2H-benzimidazol-2-one;; 5-chloro-1-{1-[3(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinyl}-1,3-dihydro-2H-benzimidazol-2-one; 5-chloro-1-{1-[3-(1,3-dihydro-2-oxo-2H-benzimidazol-1-yl)propyl]-4-piperidinyl}-1,3-dihydro-2H-benzimidazol-2-one; 5-Chloro-1-{1-[3-(2-hydroxy-2,3-dihydro-benzoimidazol-1-yl)-propyl]-piperidin-4-yl}-2,3-dihydro-1H-benzoimidazol-2-ol; 5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-1H-1,3-benzodiazol-1-yl)propyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one; 5-Chloro-1-{1-[3-(2-oxo-2,3-dihydro-benzoimidazol-1-yl)-propyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one(domperidone); DOMPERIDONE5-Chloro-1-{1-[3-(2-oxo-2,3-dihydro-benzoimidazol-1-yl)-propyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one	Small molecule	1S/C22H24ClN5O2/c23-15-6-7-20-18(14-15)25-22(30)28(20)16-8-12-26(13-9-16)10-3-11-27-19-5-2-1-4-17(19)24-21(27)29/h1-2,4-7,14,16H,3,8-13H2,(H,24,29)(H,25,30)	FGXWKSZFVQUSTL-UHFFFAOYSA-N	C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O	C22H24ClN5O2	CAS 57808-66-9	CHEBI:31515	.	.	.	D0AV3G	.	.	.
DR4180	Nimustine hydrochloride	CID: 91657	Nimustine HCl; ACNU; Nidran hydrochloride; Nimustine (hydrochloride); Nimustina clorhidrato; CS 439 HCl; UNII-DFR965WKBU; NSC-245,382; DFR965WKBU; Nimustine hydrochloride [JAN]; CHEBI:7576; 52208-23-8; Nidran; MFCD01676942; 3-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-1-(2-chloroethyl)-1-nitrosourea hydrochloride; 3-((4-Amino-2-methylpyrimidin-5-yl)methyl)-1-(2-chloroethyl)-1-nitrosourea hydrochloride; 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride; 3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride; Urea, N'-((4-amino-2-methyl-5-pyrimidinyl)methyl)-N-(2-chloroethyl)-N-nitroso-, monohydrochloride (9CI); Nimustine hydrochloride (JAN); 1-[(4-Amino-2-methyl-5-pyrimidinyl)methyl]-3-(2-chloroethyl)-3-nitrosourea Hydrochloride; Nimustina clorhidrato [Spanish]; CS-439; 3-[(4-azanyl-2-methyl-pyrimidin-5-yl)methyl]-1-(2-chloroethyl)-1-nitroso-urea hydrochloride; Nidran (TN); Nimustine HCl(ACNU); nimustine monohydrochloride; 1-(2-Cloroetil)-1-nitroso-3-((2-metil-4-aminopirimidin-5-il)metil)urea clorhidrato [Spanish]; 1-(4-Amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride; 1-(4-Amino-2-methylpyrimidine-5-yl)methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride; N'-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-N-(2-chloroethyl)-N-nitrosourea HCl; N'-((4-Amino-2-metil-5-pirimidinil)metil)-N-(2-cloroetil)-N-nitrosourea clorhidrato [Spanish]; SCHEMBL98303; C9H14Cl2N6O2; MLS002153238; Nimustine hydrochloride, solid; CHEMBL1256616; DTXSID80204185; AMY23419; BCP11668; ANW-42405; HY-13703A; NSC245382; s5293; AKOS015895226; CCG-267570; MCULE-2422791904; NSC-245382; 1-(2-Cloroetil)-1-nitroso-3-((2-metil-4-aminopirimidin-5-il)metil)urea clorhidrato; 3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-1-(2-chloroethyl)-1-nitrosourea;hydrochloride; N'-((4-Amino-2-metil-5-pirimidinil)metil)-N-(2-cloroetil)-N-nitrosourea clorhidrato; AC-15840; AK683740; SMR001230702; Urea, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-1-(2-chloroethyl)-1-nitroso-, monohydrochloride; WLN: T6N CNJ B1 DZ E1MVNNO&2G; CS-0007733; FT-0630684; N0821; C11276; D01059; 208N238; A825909; A828980; A830740; Q27107532; Nimustine HCl; NSC-245,382; NSC245,382; NSC 245,382; 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-(2-chloroethyl)-3-nitrosourea; 1-[(4-amino-2-methylpyrimidin-5-yl)methyl]-3-(2-chloroethyl)-3-nitrosourea hydrochloride; N'-[(4-Amino-2-methyl-5-pyrimidinyl)methyl]-N-(2-chloroethyl)-N-nitrosourea hydrochloride; Urea, 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitroso-	Small molecule	1S/C9H13ClN6O2.ClH/c1-6-12-4-7(8(11)14-6)5-13-9(17)16(15-18)3-2-10;/h4H,2-3,5H2,1H3,(H,13,17)(H2,11,12,14);1H	KPMKNHGAPDCYLP-UHFFFAOYSA-N	CC1=NC=C(C(=N1)N)CNC(=O)N(CCCl)N=O.Cl	C9H14Cl2N6O2	CAS 55661-38-6	.	.	.	.	.	.	.	.
DR4184	Indomethacin	CID: 3715	indomethacin; 53-86-1; indometacin; Indocin; Indometacine; Indomethacine; Indocid; Metindol; Indomethazine; Imbrilon; Amuno; Tannex; Indomethacinum; Artracin; Artrinovo; Artrivia; Confortid; Idomethine; Indomecol; Indoptic; Indoptol; Inflazon; Infrocin; Metartril; Methazine; Mikametan; Reumacide; Sadoreum; Dolovin; Inacid; Indacin; Indomed; Indomee; Lausit; Metacen; Mobilan; Indo-rectolmin; Indo-tablinen; Inteban sp; Indometacyna; Indometicina; Mezolin; 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-; 2-(1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetic acid; Indometacina; Indometacinum; Dolcidium; Durametacin; Elmetacin; Indomethine; Indorektal; Catlep; Indoxen; Vonum; Indo-phlogont; Chibro-amuno; Rheumacin LA; Osmosin; 1-(p-Chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid; MFCD00057095; CCRIS 3502; 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid; HSDB 3101; 1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-3-indoleacetic acid; NCI-C56144; UNII-XXE1CET956; CHEMBL6; 1-(p-Chlorobenzoyl)-2-methyl-5-methoxyindole-3-acetic acid; IMN; Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl-; 1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid; Indo-Lemmon; [1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetic acid; Indocin Sr; XXE1CET956; N-p-Chlorbenzoyl-5-methoxy-2-methylindole-3-acetic acid; MLS000069402; Indomethacin (Indocid, Indocin); (1-p-Chlorobenzoyl-5-methoxy-2-methylindol-3-yl)acetic acid; CHEBI:49662; 1-(p-Chlorobenzoyl)-2-methoxy-3-methyl-1H-indole-3-acetic Acid; Indomet 140; alpha-(1-(p-Chlorobenzoyl)-2-methyl-5-methoxy-3-indolyl)acetic acid; {1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methyl-1H-indol-3-yl}acetic acid; CAS-53-86-1; 1-p-Cloro-benzoil-5-metoxi-2-metilindol-3-acido acetico; NCGC00015562-18; Indmethacine; Indomethancin; 1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolylacetic acid; Arthrexin; Bonidin; Bonidon; Indameth; Indomod; Miametan; SMR000058195; Indomo; Flexin continus; Hicin; Kwas 1-(p-chlorobenzoilo)-2-metylo-5-metoksy-3-indolilooctowy; Chrono-indicid; Chrono-indocid; Indometacyna [Polish]; DSSTox_CID_740; Bonidon Gel; Indometicina [Spanish]; 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetic acid; Dolcidium PL; Indo-Spray; Indolar SR; 2-{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methyl-1h-indol-3-yl}acetic acid; DSSTox_RID_75763; DSSTox_GSID_20740; Indometacine [INN-French]; Indometacinum [INN-Latin]; Indometacina [INN-Spanish]; 1-(4-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid; Tivorbex; Aconip; 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-indol-3-yl]acetic acid; 2-{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methylindol-3-yl}acetic acid; Indocin-SR; Indochron E-R; Indocin (TN); Aconip (TN); Indomethacin (USP); FLAM; NSC-77541; Indocid (pharmaceutical); SR-01000000014; EINECS 200-186-5; Indomethacin & MAP-30; Indomethacin [USAN:USP]; BRN 0497341; Indocollyre; Indonol; Innamit; Inteban; 2-{1-((4-chlorophenyl)carbonyl)-5-methoxy-2-methylindol-3-yl}acetic acid; 4kyk; Indomethacin,(S); Prestwick_597; Indometacin [INN]; Opera_ID_56; PubChem17620; Spectrum_000919; Tocris-1708; 1z9h; 1-(p-Chlorbenzoyl)-5-methoxy-2-methylindol-3-essigsaeure [German]; 1-p-Cloro-benzoil-5-metoxi-2-metilindol-3-acido acetico [Spanish]; Prestwick0_000272; Prestwick1_000272; Prestwick2_000272; Prestwick3_000272; Spectrum2_000970; Spectrum3_000468; Spectrum4_000018; Spectrum5_000868; Lopac-I-7378; Kwas 1-(p-chlorobenzoilo)-2-metylo-5-metoksy-3-indolilooctowy [Polish]; MolMap_000032; UPCMLD-DP023; EC 200-186-5; I 7378; Indometacin (JP17/INN); SCHEMBL9300; Lopac0_000692; Oprea1_686105; BSPBio_000144; BSPBio_001149; BSPBio_002176; KBioGR_000395; KBioGR_000489; KBioSS_000489; KBioSS_001399; 5-22-05-00239 (Beilstein Handbook Reference); MLS001074194; MLS006011845; ARONIS27005; BIDD:GT0132; DivK1c_000271; SPECTRUM1500350; SPBio_000979; SPBio_002363; BPBio1_000160; GTPL1909; DTXSID9020740; Indomethacin, >=99% (TLC); UPCMLD-DP023:001; BDBM17638; CGIGDMFJXJATDK-UHFFFAOYSA-; HMS500N13; KBio1_000271; KBio2_000489; KBio2_001399; KBio2_003057; KBio2_003967; KBio2_005625; KBio2_006535; KBio3_000897; KBio3_000898; KBio3_001396; 1-(p-Chlorbenzoyl)-5-methoxy-2-methylindol-3-essigsaeure; Indomethacin - CAS 53-86-1; NINDS_000271; Bio2_000405; Bio2_000885; HMS1362I11; HMS1568H06; HMS1792I11; HMS1920F21; HMS1990I11; HMS2089N19; HMS2091N09; HMS2095H06; HMS2231J10; HMS3262K05; HMS3268A14; HMS3374F07; HMS3403I11; HMS3414N13; HMS3430L03; HMS3649K17; HMS3655O04; HMS3678N11; HMS3712H06; HMS3747K21; HMS3884E08; Pharmakon1600-01500350; ZINC601283; ACT02579; BCP18951; Indomethacin, >=99.0% (TLC); Tox21_113109; Tox21_201791; Tox21_300266; Tox21_500692; AC-532; ANW-42683; CCG-40186; NSC757061; s1723; SBB057417; STL257874; AKOS000592893; Tox21_113109_1; DB00328; Indometacin 1.0 mg/ml in Acetonitrile; KS-5255; LP00692; MCULE-5636486088; NE11089; NSC 757061; NSC-757061; SDCCGSBI-0050670.P005; IDI1_000271; IDI1_002160; NCGC00015562-01; NCGC00015562-02; NCGC00015562-03; NCGC00015562-04; NCGC00015562-05; NCGC00015562-06; NCGC00015562-07; NCGC00015562-08; NCGC00015562-09; NCGC00015562-10; NCGC00015562-11; NCGC00015562-12; NCGC00015562-13; NCGC00015562-14; NCGC00015562-15; NCGC00015562-16; NCGC00015562-17; NCGC00015562-19; NCGC00015562-20; NCGC00015562-21; NCGC00015562-22; NCGC00015562-24; NCGC00015562-25; NCGC00015562-40; NCGC00024135-02; NCGC00024135-04; NCGC00024135-05; NCGC00024135-06; NCGC00024135-07; NCGC00024135-08; NCGC00024135-09; NCGC00024135-10; NCGC00024135-11; NCGC00024135-12; NCGC00024135-13; NCGC00024135-14; NCGC00024135-15; NCGC00254075-01; NCGC00259340-01; NCGC00261377-01; BP-30207; H911; HY-14397; NCI60_041708; SBI-0050670.P004; DB-052413; AB00052022; EU-0100692; FT-0603227; I0655; ST50320042; SW196768-5; Indomethacin, meets USP testing specifications; BIM-0050670.0001; C01926; D00141; J10170; S00108; AB00052022-20; AB00052022-21; AB00052022_23; AB00052022_24; L000959; Q409231; Indomethacin, Antibiotic for Culture Media Use Only; Q-201239; SR-01000000014-2; SR-01000000014-4; SR-01000000014-6; BRD-K57222227-001-06-1; BRD-K57222227-001-18-6; BRD-K57222227-001-27-7; SR-01000000014-10; SR-01000000014-16; Z56784896; 1-p-chlorobenzoyl-2-methyl-5-methoxyindol-3-acetic acid; 1-(p-chlorobenzoyl)-2-methyl-5-methoxy-3-indoleacetic acid; 1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indoleacetic acid; 1-(p-Chlorobenzoyl)-5-methoxy-2-methylindol-3-acetic acid; 1-(4-chloro-benzoyl)-5-methoxy-2-methyl-3-indolyl-acetic acid; 1-(4-Chlorobenzoyl)-2-methyl-5-methoxyindole-3-acetic acid; 1-(p-Chlorobenzoyl)-2-methyl-5-methoxy-3-indole-acetic acid; 1-(p-chlorobenzoyl)-2-methyl-5-methoxy-3-indolylacetic acid; 1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indol acetic acid; 1-(p-Chlorobenzoyl)-5-methoxy-2-methyl-Indole-3-acetic acid; Indomethacin, European Pharmacopoeia (EP) Reference Standard; N-(p-Chlorobenzoyl)-2-methyl-5-methoxy-3-indolylacetic acid; Indomethacin, United States Pharmacopeia (USP) Reference Standard; .alpha.-(1-(p-Chlorobenzoyl)-2-methyl-5-methoxy-3-indolyl)acetic acid; [1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetic acid #; 1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid & MAP-30; 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9CI); 2-{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2 methylindol-3-yl}acetic acid; 2-{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2methylindol-3-yl}acetic acid; Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8CI); Indomethacin, Pharmaceutical Secondary Standard; Certified Reference Material	Small molecule	1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)	CGIGDMFJXJATDK-UHFFFAOYSA-N	CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O	C19H16ClNO4	CAS 53-86-1	CHEBI:49662	.	.	.	D0R1RS	.	.	.
DR4185	Albendazole	CID: 2082	albendazole; 54965-21-8; Albenza; Eskazole; Valbazen; Zentel; Proftril; Albendazolum; SK&F 62979; SKF 62979; Methyl 5-(propylthio)-2-benzimidazolecarbamate; SK&F-62979; 5-(Propylthio)-2-carbomethoxyaminobenzimidazole; methyl N-(6-propylsulfanyl-1H-benzimidazol-2-yl)carbamate; Methyl [5-(Propylthio)benzimidazol-2-yl]carbamate; (5-(Propylthio)-1H-benzimidazol-2-yl)carbamic acid methyl ester; methyl N-[6-(propylsulfanyl)-1H-1,3-benzodiazol-2-yl]carbamate; O-Methyl N-(5-(propylthio)-2-benzimidazolyl)carbamate; MFCD00083232; NSC 220008; UNII-F4216019LN; Carbamic acid, [5-(propylthio)-1H-benzimidazol-2-yl]-, methyl ester; Albendazol; Bilutac; CHEMBL1483; CARBAMIC ACID, (5-(PROPYLTHIO)-1H-BENZIMIDAZOL-2-YL)-, METHYL ESTER; methyl [5-(propylsulfanyl)-1H-benzimidazol-2-yl]carbamate; ((Propylthio)-5 1H-benzimidazolyl-2) carbamate de methyle; [5-(Propylthio)benzimidazol-2-yl]carbamic Acid Methyl Ester; CHEBI:16664; Zental; Albendazole-D3; F4216019LN; NSC-220008; methyl 5-(propylthio)-1H-benzo[d]imidazol-2-ylcarbamate; methyl [6-(propylsulfanyl)-1H-benzimidazol-2-yl]carbamate; NCGC00016876-01; CAS-54965-21-8; DSSTox_CID_2563; Methyl 5-n-propylthio-2-benzimidazolecarbamate; DSSTox_RID_76632; DSSTox_GSID_22563; Albendazol [INN-Spanish]; Albendazolum [INN-Latin]; methoxy-N-(5-propylthiobenzimidazol-2-yl)carboxamide; methyl [5-(propylthio)-1H-benzimidazol-2-yl]carbamate; methyl N-(5-propylsulfanyl-1H-benzimidazol-2-yl)carbamate; SKF-62979; Andazol; Albenza (TN); Albendazole(Albenza); HSDB 7444; EINECS 259-414-7; Albendazole (JAN/USP/INN); Zenteltrade mark; Albenzatrade mark; Andazoltrade mark; Eskazoletrade mark; Albendazole,(S); ((Propylthio)-5 1H-benzimidazolyl-2) carbamate de methyle [French]; Prestwick_675; Albendazole (Albenza); Albendazole [USAN:USP:INN:BAN:JAN]; Spectrum_001532; CPD000036735; (5-Propylsulfanyl-1H-benzoimidazol-2-yl)-carbamic acid methyl ester; Prestwick0_000247; Prestwick1_000247; Prestwick2_000247; Prestwick3_000247; Spectrum4_000201; Spectrum5_001567; ChemDivAM_000003; ChemDiv1_000190; Oprea1_429292; Oprea1_585016; Oprea1_640007; SCHEMBL44682; BSPBio_000034; BSPBio_002548; KBioGR_000801; KBioSS_002012; MLS000069722; BIDD:GT0615; DivK1c_000704; SPECTRUM1503903; SPBio_002253; BPBio1_000038; DTXSID0022563; HMS502D06; HMS587I14; HXHWSAZORRCQMX-UHFFFAOYSA-; KBio1_000704; KBio2_002012; KBio2_004580; KBio2_007148; NINDS_000704; HMS1568B16; HMS1922K04; HMS2090G19; HMS2093K13; HMS2095B16; HMS2231O03; HMS3259B05; HMS3369C03; HMS3651C15; HMS3712B16; Pharmakon1600-01503903; [5-(Propythio)-1H-benzimidazol-2-yl]carbamic acid methyl ester; BCP12108; HY-B0223; Tox21_110659; Tox21_302300; AC-015; ANW-42170; BBL005883; BDBM50241293; CCG-39620; MFCD01220143; N-[6-(propylthio)-1H-benzimidazol-2-yl]carbamic acid methyl ester; NSC220008; NSC758644; s1640; SBB056658; STK387550; STL046130; ZINC17146904; AKOS000540882; AKOS005431684; AKOS005699352; Tox21_110659_1; CCG-220247; DB00518; KS-5159; MCULE-5872469561; NC00615; NE41026; NSC-758644; IDI1_000704; methyl [(2Z)-5-(propylsulfanyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]carbamate; NCGC00016876-02; NCGC00016876-03; NCGC00016876-04; NCGC00016876-05; NCGC00016876-06; NCGC00016876-07; NCGC00016876-08; NCGC00016876-09; NCGC00016876-10; NCGC00016876-12; NCGC00022896-03; NCGC00022896-04; NCGC00022896-05; NCGC00022896-06; NCGC00022896-07; NCGC00022896-08; NCGC00255250-01; AK405353; Albendazole, analytical standard, >=98%; H152; SMR000036735; ST012016; Albendazole 100 microg/mL in Acetonitrile; SBI-0051849.P002; AB0012898; DB-052669; AB00052377; FT-0621945; SW196830-3; T9034; EN300-49850; methyl 5-propylthio-2-benzimidazole carbamate; VU0239747-6; BIM-0051849.0001; C01779; D00134; J10424; AB00052377-13; AB00052377-14; AB00052377_15; AB00052377_16; A830429; Albendazole, Antibiotic for Culture Media Use Only; Q411629; SR-01000000171; SR-05000001875; methyl 5-(propylthio)-1H-benzimidazol-2-ylcarbamate; Q-200603; Q-200604; SR-01000000171-2; SR-05000001875-1; BRD-K79131256-001-04-7; BRD-K79131256-001-08-8; methyl 6-(propylthio)-1H-benzo[d]imidazol-2-ylcarbamate; Z1245635850; 2-[(Methoxycarbonyl)amino]-5-propylthio-1H-benzimidazole; Albendazole, European Pharmacopoeia (EP) Reference Standard; Methyl (6-(propylthio)-1H-benzo[d]imidazol-2-yl)carbamate; Methyl 5-(propylsulfanyl)-1H-benzimidazol-2-ylcarbamate #; Albendazole, United States Pharmacopeia (USP) Reference Standard; Albendazole, Pharmaceutical Secondary Standard; Certified Reference Material	Small molecule	1S/C12H15N3O2S/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16)	HXHWSAZORRCQMX-UHFFFAOYSA-N	CCCSC1=CC2=C(C=C1)N=C(N2)NC(=O)OC	C12H15N3O2S	CAS 54965-21-8	CHEBI:16664	.	.	.	D00KVO	.	.	.
DR4199	Alpelisib	CID: 56649450	alpelisib; 1217486-61-7; BYL-719; BYL719; NVP-BYL719; Piqray; Alpelisib (BYL719); (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide; UNII-08W5N2C97Q; BYL 719; (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide; CHEMBL2396661; 08W5N2C97Q; C19H22F3N5O2S; (2S)-1-N-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide; (2s)-N~1~-{4-Methyl-5-[2-(1,1,1-Trifluoro-2-Methylpropan-2-Yl)pyridin-4-Yl]-1,3-Thiazol-2-Yl}pyrrolidine-1,2-Dicarboxamide; (S)-N1-(4-methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide.; 1,2-Pyrrolidinedicarboxamide, N1-(4-methyl-5-(2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl)-2-thiazolyl)-, (2S)-; 1,2-PYRROLIDINEDICARBOXAMIDE, N1-[4-METHYL-5-[2-(2,2,2-TRIFLUORO-1,1-DIMETHYLETHYL)-4-PYRIDINYL]-2-THIAZOLYL]-, (2S)-; 4jps; Piqray (TN); Alpelisib [USAN:INN]; QCR-1; Alpelisib (JAN/USAN/INN); cc-697; GTPL7955; SCHEMBL1911869; CHEBI:93752; DTXSID70153355; EX-A405; BYL 719; BYL719; AOB87192; NVP-BYL719 (BYL719); 2294AH; BDBM50436459; MFCD22417085; NSC765974; NSC800065; s2814; ZINC68198368; AKOS022186315; CCG-269139; CS-0663; DB12015; NSC-765974; NSC-800065; SB16575; NCGC00346717-03; NCGC00346717-06; (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidine; (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-(4-methyl-5-(2-(2,2,2-trifluoro-1,1-dimethylethyl)-pyridin-4-yl)thiazol-2-yl)amide; 1217486-47-9; AS-16349; HY-15244; AB0094905; SW220128-1; cas:1217486-61-7;BYL-719; D11011; W-5917; J-004627; Q27074391; 1LT; BYL-719; ; ; (2S)-1-N-[4-Methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide	Small molecule	1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1	STUWGJZDJHPWGZ-LBPRGKRZSA-N	CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F	C19H22F3N5O2S	CAS 1217486-61-7	CHEBI:93752	.	.	.	D0W7HE	.	.	.
DR4213	Raloxifene	CID: 5035	raloxifene; 84449-90-1; Keoxifene; Evista; Raloxifenum [Latin]; Raloxifeno [Spanish]; Raloxifenum; Raloxifeno; LY 139481; LY-139481; UNII-YX9162EO3I; Optruma; CHEMBL81; Keoxifene; LY 139481;; CHEBI:8772; YX9162EO3I; RAL; LY139481; CCRIS 7129; HSDB 7460; NCGC00015889-05; CAS-82640-04-8; Pharoxifene; Raloxifene D4; Raloxifene, 6; Raloxifene (INN); Eviden (TN); Raxeto (TN); Lopac-R-1402; DSSTox_CID_3550; SCHEMBL6144; DSSTox_RID_77076; DSSTox_GSID_23550; Lopac0_001051; BSPBio_000903; KBioGR_002361; KBioSS_002364; BIDD:ER0216; BIDD:GT0795; SPBio_002824; BPBio1_000995; GTPL2820; DTXSID3023550; BDBM19441; KBio2_002361; KBio2_004929; KBio2_007497; KBio3_002840; cid_11071264; cMAP_000032; HMS2089F06; HMS3742O11; ZINC538275; BCP09772; Tox21_202603; MFCD00866415; NSC747974; NSC761389; s5781; AKOS015896267; AC-8399; CCG-205128; DB00481; MCULE-4598311006; NSC-747974; NSC-761389; SDCCGSBI-0051021.P003; MRF-0000684; SMP2_000095; AS-35086; HY-13738; J22.982B; SBI-0051021.P002; AB0073011; CAS-84449-90-1; CS-0007764; FT-0674305; VU0155042-3; C07228; D08465; 449R901; Q425223; BRD-K63828191-003-11-5; 	Small molecule	1S/C28H27NO4S/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29/h4-13,18,30-31H,1-3,14-17H2	GZUITABIAKMVPG-UHFFFAOYSA-N	C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O	C28H27NO4S	CAS 84449-90-1	.	.	.	.	D01XBA	.	.	.
DR4256	SU5416	CID: 5329098	Semaxanib; Semaxinib; SU 5416; 204005-46-9; Semoxind; Semaxanib (SU5416); SU-5416; 194413-58-6; TSU 16; Z-Semaxanib; UNII-71IA9S35AJ; VEGF Receptor 2 Kinase Inhibitor III; (Z)-3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)indolin-2-one; NSC-696819; (Z)-SU 5416; 71IA9S35AJ; CHEMBL276711; (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one; (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one; 3-(1-(3,5-Dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene)-2-oxo-2,3-dihydroindole; 3-((Z)-(3,5-Dimethylpyrrol-2-yl)methylene)-2-indolinone; Semaxnib; Sugen 5416; 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one; (3Z)-3-[(3,5-DIMETHYL-1H-PYRROL-2-YL)METHYLIDENE]-2,3-DIHYDRO-1H-INDOL-2-ONE; 3-[(2,4-Dimethylpyrrol-5-yl)methylidene]-indolin-2-one; SMR000568416; TSU-16; SR-01000076044; Semaxanib (USAN/INN); Semaxanib [USAN:INN]; methylene]-2H-indol-2-one; VEGFR2 Kinase Inhibitor III; 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-; NCGC00094381-03; 3-(2,4-dimethylpyrrol-5-yl)methylidene-indolin-2-one; NSC 696819; 2x2m; Semaxanib; SU5416; 1,3-Dihydro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2H-indol-2-one; H-Indol-2-one, 3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-1,3-dihydro-; S 8442; SCHEMBL8190; Lopac0_001110; SCHEMBL19571; 1,3-Dihydro-3-[(3,5-dimethyl-1H-pyrrol-2-yl); MLS001074896; MLS001332519; MLS001332520; BDBM4810; GTPL5056; QCR-86; 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]indolin-2-one; CHEBI:91083; cid_5329098; AOB6828; HMS2234L12; HMS3229O13; HMS3263M22; HMS3268J13; HMS3413H10; HMS3648O12; HMS3677H10; AMY10847; BCP06068; EX-A2158; Tox21 111271; Tox21_501110; 2033AH; 2712AH; HSCI1_000303; MFCD01940922; NSC696819; s2845; SU5146; ZINC12410091; 3-[(3,5-dimethyl-1h-pyrrol-2-yl)methylene]-1,3-dihydro-2h-indol-2-one; AKOS015994557; CCG-205186; CS-1225; DB06436; ES-0010; LP01110; SDCCGSBI-0051079.P003; NCGC00094381-01; NCGC00094381-02; NCGC00094381-04; NCGC00094381-05; NCGC00094381-19; NCGC00261795-01; HY-10374; QC-11357; SU005416; AB0094985; EU-0101110; SW219791-1; A12437; D05819; W-5403; 2H-Indol-2-one,5-dimethyl-2-pyrrolyl)methylene]-; J-013281; Q7449140; SR-01000076044-2; SR-01000076044-8; BRD-K63504947-001-05-5; 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-2-indolinon; 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone; 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-indolin-2-one; Semaxanib, Semoxind, TSU-16, NSC-696819, SU-5416; 3-[(3,5-Dimethyl-2H-pyrrol-2-ylidene)methyl]-1H-indol-2-ol; 3-[(3,5-Dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- 2H-indol-2-one; 2H-Indol-2-one, 3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-1,3-dihydro-, (3Z)-; 2H-Indol-2-one, 3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-1,3-dihydro-, (Z)-; 2H-Indol-2-one, 3-(3,5-dimethyl-1H-pyrrol-2-yl)methylene)- 1,3-dihydro-, (Z)-; 3-[1-(3,5-dimethyl-1h-pyrrol-2-yl)-meth-(z)-ylidene]-2-oxo-2,3-dihydro-indole	Small molecule	1S/C15H14N2O/c1-9-7-10(2)16-14(9)8-12-11-5-3-4-6-13(11)17-15(12)18/h3-8,16H,1-2H3,(H,17,18)/b12-8-	WUWDLXZGHZSWQZ-WQLSENKSSA-N	CC1=CC(=C(N1)C=C2C3=CC=CC=C3NC2=O)C	C15H14N2O	CAS 194413-58-6	.	.	.	.	D01PZD	.	.	.
DR4267	TRAIL/Apo2L 	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR4274	Recombinant vaccinia Neu vaccine	.	.	Vaccine	.	.	.	.	.	.	.	.	.	.	.	.	.
DR4283	5-LOX shRNA	.	.	Small hairpin RNA	.	.	.	.	.	.	.	.	.	.	.	.	.
DR4313	Ertugliflozin	CID: 44814423	Ertugliflozin; 1210344-57-2; PF-04971729; Steglatro; PF04971729; UNII-6C282481IP; 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-beta-L-idopyranose; CHEMBL1770248; 1210344-57-2 (free base); 6C282481IP; (1S,2S,3S,4R,5S)-5-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)octane-2,3,4-triol; (1S,2S,3S,4R,5S)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol; (1S,2S,3S,4R,5S)-5-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol; PF 04971729; Ertugliflozin [USAN:INN]; (1s,2s,3s,4r,5s)-5-[4-chloro-3-(4-ethoxybenzyl)phenyl]-1-hydroxymethyl-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol; MK-8835; Tube108; Ertugliflozin (USAN/INN); PF 04971729-00; PF-04971729-00; cc-212; SCHEMBL181047; GTPL8376; PF-04971729;Ertugliflozin; DTXSID40153120; EX-A407; AMY32613; ABP000359; BDBM50342885; MFCD21609259; s5413; ZINC68197809; AKOS025404928; CCG-269087; CS-0976; DB11827; SB11082; 5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)octane-2,3,4-triol; AC-29007; AS-35204; beta-L-Idopyranose, 1,6-anhydro-1-C-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-5-C-(hydroxymethyl)-; HY-15461; Y0303; D10313; W-5850; J-504029; PF-04971729/PF04971729/; Q27077223; (1S,2S,3S,4R,5S)-5-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-1-hydroxymethyl-6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol; (1S,2S,3S,4R,5S)-5-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-1-(hydroxymethyl)-6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol; (1S,5S)-1-(Hydroxymethyl)-5-[3-(4-ethoxybenzyl)-4-chlorophenyl]-6,8-dioxabicyclo[3.2.1]octane-2beta,3alpha,4beta-triol	Small molecule	1S/C22H25ClO7/c1-2-28-16-6-3-13(4-7-16)9-14-10-15(5-8-17(14)23)22-20(27)18(25)19(26)21(11-24,30-22)12-29-22/h3-8,10,18-20,24-27H,2,9,11-12H2,1H3/t18-,19-,20+,21-,22-/m0/s1	MCIACXAZCBVDEE-CUUWFGFTSA-N	CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C34C(C(C(C(O3)(CO4)CO)O)O)O)Cl	C22H25ClO7	CAS 1210344-57-2	.	.	.	.	D0Q3VE	.	.	.
DR4332	Chlorhexidine	CID: 9552079	chlorhexidine; 55-56-1; Rotersept; Fimeil; Hexadol; Soretol; Chlorhexidin; Chlorhexidinum; Chlorohexidine; Nolvasan; Cloresidina [DCIT]; Chlorhexidin [Czech]; Chlorhexidinum [INN-Latin]; Clorhexidina [INN-Spanish]; Hibistat; 1,6-Bis(p-chlorophenyldiguanido)hexane; 1,6-Di(4'-chlorophenyldiguanido)hexane; UNII-R4KO0DY52L; 1,6-Bis(5-(p-chlorophenyl)biguandino)hexane; Exidine; Tubulicid; 1,1'-Hexamethylenebis(5-(p-chlorophenyl)biguanide); 1,1'-Hexamethylene bis(5-(p-chlorophenyl)biguanide); 2,4,11,13-Tetraazatetradecanediimidamide, N,N''-bis(4-chlorophenyl)-3,12-diimino-; Sterilon; CHEMBL790; R4KO0DY52L; MLS001332388; CHEBI:3614; Cloresidina; Clorhexidina; 56-95-1; Biguanide, 1,1'-hexamethylenebis(5-(p-chlorophenyl)-; Chlorhexidine, 98%; CAS-55-56-1; NCGC00016246-03; SMR000857146; Sterido; Savlon babycare; N',N'''''-hexane-1,6-diylbis[N-(4-chlorophenyl)(imidodicarbonimidic diamide)]; DSSTox_CID_13314; DSSTox_RID_79062; N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide; DSSTox_GSID_33314; Chlorhexidine [INN:BAN]; Chlorhexidine dihydrochloride; MLS001304094; (1E)-2-[6-[[amino-[(E)-[amino-(4-chloroanilino)methylidene]amino]methylidene]amino]hexyl]-1-[amino-(4-chloroanilino)methylidene]guanidine; 1-(4-chlorophenyl)-3-[N-[6-[[N-[N-(4-chlorophenyl)carbamimidoyl]carbamimidoyl]amino]hexyl]carbamimidoyl]guanidine; N-(4-chlorophenyl)-1-3-(6-{N-[3-(4-chlorophenyl)carbamimidamidomethanimidoyl]amino}hexyl)carbamimidamidomethanimidamide; CCRIS 9230; Chlorhexidine (INN); C22H30Cl2N10; HSDB 7196; Merfen-incolore (TN); SR-01000799135; Nolvasan (*Diacetate*); 1,1'-Hexamethylenebis(5-[p-chlorophenyl]biguanide); SMR000718621; EINECS 200-238-7; Lisium (*Dihydrochloride*); BRN 2826432; 1,6-Di(N-p-chlorophenyldiguanido)hexane; Dentisept [veterinary] (TN); 1,6-Bis(N5-[p-chlorophenyl]-N1-biguanido)hexane; Prestwick_53; Chlorhexidine (1); Hibidil (Salt/Mix); Hibisol (Salt/Mix); Chlorhexidine diacetate salt hydrate; Hibitane (Salt/Mix); Hibiscrub (Salt/Mix); Hibispray (Salt/Mix); NSC526936; Spectrum_000237; Savloclens (Salt/Mix); Prestwick0_000143; Prestwick1_000143; Prestwick2_000143; Prestwick3_000143; Spectrum2_000135; Spectrum3_000339; Spectrum4_000277; Spectrum5_001322; chlorhexidine diacetate salt; EC 200-238-7; SCHEMBL3984; Chlorhexidine, >=99.5%; BSPBio_000246; BSPBio_001977; KBioGR_000774; KBioSS_000717; 4-12-00-01201 (Beilstein Handbook Reference); MLS001332387; MLS002154209; DivK1c_000761; SPBio_000210; SPBio_002185; BPBio1_000272; DTXSID2033314; BDBM51937; BDBM64773; cid_9552079; KBio1_000761; KBio2_000717; KBio2_003285; KBio2_005853; KBio3_001197; 2,4,11,13-Tetraazatetradecanediimidamide, N1,N14-bis(4-chlorophenyl)-3,12-diimino-; cid_12303047; NINDS_000761; REGID_for_CID_9552079; BDBM152706; HMS1568M08; HMS2095M08; HMS2233B16; HMS3712M08; HY-B1248; Tox21_110325; Tox21_201404; Tox21_303445; BDBM50170723; s5397; SBB057564; STK089248; AKOS005394319; Tox21_110325_1; CCG-220143; CS-4958; DB00878; EBD2224760; MCULE-4644073142; 2,4,11,13-Tetraazatetradecanediimidamide, N,N'-bis(4-chlorophenyl)-3,12-diimino-; IDI1_000761; N,N''''-hexane-1,6-diylbis[N'-(4-chlorophenyl)(imidodicarbonimidic diamide)]; N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradeca- nediimidamide; QTL1_000020; NCGC00016246-01; NCGC00016246-02; NCGC00016246-04; NCGC00016246-05; NCGC00016246-06; NCGC00016246-07; NCGC00016246-09; NCGC00016246-13; NCGC00091025-01; NCGC00091025-02; NCGC00091025-04; NCGC00247766-01; NCGC00257242-01; NCGC00258955-01; (1E)-2-[6-[[amino-[(E)-[amino-(4-chloroanilino)methylene]amino]methylene]amino]hexyl]-1-[amino-(4-chloroanilino)methylene]guanidine; AS-12648; Chlorhexidine, purum, >=99.0% (HPLC); SBI-0051301.P003; AB00053427; C06902; D07668; AB00053427-24; AB00053427-28; AB00053427_29; 009C673; Q-200828; SR-01000799135-5; 1,1''-Hexamethylene bis(5-(p-chlorophenyl)biguanide); BRD-K52256627-300-03-3; BRD-K52256627-300-05-8; SR-01000799135-10; SR-01000799135-11; Chlorhexidine, European Pharmacopoeia (EP) Reference Standard; 1,1'-(Hexane-1,6-diyl)bis[5-(4-chlorophenyl)biguanide] diacetate; Chlorhexidine, United States Pharmacopeia (USP) Reference Standard; Chlorhexidine, Pharmaceutical Secondary Standard; Certified Reference Material; N'',N''''''''''-hexane-1,6-diylbis[N-(4-chlorophenyl)(imidodicarbonimidic diamide)]; N,N''-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide; (1E)-2-[6-[[amino-[(E)-[amino-(4-chloroanilino)methylene]amino]methylene]amino]hexyl]-1-[amino-(4-chloroanilino)methylene]guanidine;hydrochloride; (1E)-2-[6-[[amino-[(E)-[amino-(4-chloroanilino)methylidene]amino]methylidene]amino]hexyl]-1-[amino-(4-chloroanilino)methylidene]guanidine;hydrochloride; (1E)-2-[6-[[azanyl-[(E)-[azanyl-[(4-chlorophenyl)amino]methylidene]amino]methylidene]amino]hexyl]-1-[azanyl-[(4-chlorophenyl)amino]methylidene]guanidine; (1E)-2-[6-[[azanyl-[(E)-[azanyl-[(4-chlorophenyl)amino]methylidene]amino]methylidene]amino]hexyl]-1-[azanyl-[(4-chlorophenyl)amino]methylidene]guanidine;hydrochloride; {[(4-chlorophenyl)amino]iminomethyl}{[(6-{[({[(4-chlorophenyl)amino]iminomethy l}amino)iminomethyl]amino}hexyl)amino]iminomethyl}amine; 2-[amino-[6-[[amino-[(E)-[amino-(4-chloroanilino)methylidene]amino]methylidene]amino]hexylimino]methyl]-1-(4-chlorophenyl)guanidine; 2-[amino-[6-[[amino-[(E)-[amino-(4-chloroanilino)methylidene]amino]methylidene]amino]hexylimino]methyl]-1-(4-chlorophenyl)guanidine;hydrochloride	Small molecule	1S/C22H30Cl2N10/c23-15-5-9-17(10-6-15)31-21(27)33-19(25)29-13-3-1-2-4-14-30-20(26)34-22(28)32-18-11-7-16(24)8-12-18/h5-12H,1-4,13-14H2,(H5,25,27,29,31,33)(H5,26,28,30,32,34)	GHXZTYHSJHQHIJ-UHFFFAOYSA-N	C1=CC(=CC=C1NC(=NC(=NCCCCCCN=C(N)N=C(N)NC2=CC=C(C=C2)Cl)N)N)Cl	C22H30Cl2N10	CAS 55-56-1	CHEBI:3614	.	.	.	D0V4GY	.	.	.
DR4368	Acetazolamide	CID: 1986	acetazolamide; 59-66-5; Diamox; N-(5-Sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide; Acetazolamid; Acetamox; Diacarb; Glaupax; Defiltran; Nephramide; Cidamex; Diluran; Edemox; Dehydratin; Diuramid; Diutazol; Duiramid; Eumicton; Natrionex; Nephramid; Phonurit; Diakarb; Donmox; Fonurit; Glupax; Vetamox; Didoc; SK-acetazolamide; 5-Acetamido-1,3,4-thiadiazole-2-sulfonamide; Diuriwas; Acetazoleamide; Acetozalamide; Diureticum-holzinger; Acetamidothiadiazolesulfonamide; Acetazolamida; Acetazolamidum; 4-Diamox; Acetamide, N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]-; Carbonic Anhydrase Inhibitor No. 6063; 2-Acetylamino-1,3,4-thiadiazole-5-sulfonamide; N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]acetamide; C4H6N4O3S2; 2-Acetamido-5-sulfonamido-1,3,4-thiadiazole; Carbonic anhydrase inhibitor 6063; UNII-O3FX965V0I; MFCD00003105; NSC 145177; 1,3,4-Thiadiazole-2-sulfonamide, 5-acetamido-; 5-Acetamide-1,3,4-thiadiazole-2-sulfonamide; CHEMBL20; Diamox (TN); N-(5-(Aminosulfonyl)-1,3,4-thiadiazol-2-yl)acetamide; MLS000028435; O3FX965V0I; CHEBI:27690; Acetamide, N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)-; NSC-145177; CAS-59-66-5; N-[5-(Aminosulfonyl)-1,3,4-thiadiozol-2-yl]-Acetamide; NCGC00015074-10; Acetazolamine; Acetamide, N-(5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl)-; Atenezol; Glaumox; SMR000058394; Diamox Sequels; DSSTox_CID_2544; 5-acetylamino-1,3,4-thiadiazole-2-sulfonamide; DSSTox_RID_76621; DSSTox_GSID_22544; Acetazolamidum [INN-Latin]; Acetazolamida [INN-Spanish]; N-(5-[Aminosulfonyl]-1,3,4-thiadiazol-2-yl)acetamide; N-[5-(aminosulfonyl)-1,3,5-thiadiazol-2-yl]acetamide; CCRIS 5811; Acetazolamide (AAZ); HSDB 3002; SR-01000000065; EINECS 200-440-5; AI3-52458; Prestwick_4; 1azm; 1yda; 1ydb; 1ydd; 1zsb; 2xtk; 3czv; 3ucj; Acetazolamide, 5; Acetazolamide [USP:INN:BAN:JAN]; Acerazolamide, AAZ; Acetazolamide, AAZ; Acetazolamide, AZA; Acetazolamide, AZM; ACMC-20gwkd; PubChem12858; Spectrum_000018; 1jd0; 2h4n; 2uy4; 3dc3; 3hs4; 3ml5; 4g0c; Opera_ID_288; AZA2; Prestwick0_000003; Prestwick1_000003; Prestwick2_000003; Prestwick3_000003; Spectrum2_000082; Spectrum3_000284; Spectrum4_000139; Spectrum5_000738; Lopac-A-6011; A 6011; Lopac0_000039; SCHEMBL23219; BSPBio_000005; BSPBio_001788; KBioGR_000558; KBioSS_000358; MLS001148438; BIDD:GT0643; DivK1c_000017; SPECTRUM1500102; N-(5-Sulfamoyl-[1,3,4]thiadiazol-2-yl)-acetamide; SPBio_000004; SPBio_001926; BPBio1_000007; GTPL6792; (non-d)Acetazolamide-13C2-d3; Acetazolamide, >=99%, powder; DTXSID7022544; SCHEMBL11049053; BDBM10880; BZKPWHYZMXOIDC-UHFFFAOYSA-; HMS500A19; KBio1_000017; KBio2_000358; KBio2_002926; KBio2_005494; KBio3_001288; Acetazolamide (JP17/USP/INN); AMY3289; Acetazolamide, analytical standard; NINDS_000017; HMS1568A07; HMS1920A05; HMS2091G05; HMS2095A07; HMS2232G23; HMS3259I13; HMS3260G19; HMS3370P01; HMS3712A07; HMS3744A21; Pharmakon1600-01500102; WLN: T5NN DSJ CSZW EMV1; ALBB-023617; BCP29616; EBD55026; HY-B0782; ZINC3813042; Tox21_110078; Tox21_201559; Tox21_302773; Tox21_500039; CCG-38900; NSC145177; NSC755854; s4506; SBB056640; AKOS000715163; Tox21_110078_1; CS-3568; DB00819; LP00039; MCULE-4029778803; NC00491; NSC-755854; SDCCGSBI-0050028.P005; Acetazolamide Related Compound (5-acetamido-1,3,4-thiadiazole-2-sulfonic acid); IDI1_000017; NCGC00015074-01; NCGC00015074-02; NCGC00015074-03; NCGC00015074-04; NCGC00015074-05; NCGC00015074-06; NCGC00015074-07; NCGC00015074-08; NCGC00015074-09; NCGC00015074-11; NCGC00015074-12; NCGC00015074-14; NCGC00015074-15; NCGC00015074-22; NCGC00023455-03; NCGC00023455-04; NCGC00023455-05; NCGC00023455-06; NCGC00023455-07; NCGC00256374-01; NCGC00259108-01; NCGC00260724-01; AC-12779; AK324920; AS-13169; H501; SBI-0050028.P004; 2-Acetamido-5-sulfonamido-1,4-thiadiazole; 5-Acetamide-1,4-thiadiazole-2-sulfonamide; DB-053437; 5-Acetamido-1,3,4-thiadiazol-2-sulfonamide; AB00051906; EU-0100039; R1055; ST45022057; 1,4-Thiadiazole-2-sulfonamide, 5-acetamido-; C06805; D00218; J10059; 20506-EP2269989A1; 20506-EP2275420A1; 20506-EP2280008A2; 20506-EP2295406A1; 20506-EP2298772A1; 20506-EP2308562A2; 20506-EP2308839A1; 20506-EP2314585A1; AB00051906_15; 003A105; A832415; N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)ethanamide; Q413690; L 579486; Q-200579; Q-200580; SR-01000000065-2; SR-01000000065-4; SR-01000000065-6; BRD-K43457670-001-22-9; BRD-K43457670-001-26-0; Z277559108; Acetazolamide, European Pharmacopoeia (EP) Reference Standard; 2,2,2-trideuterio-N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide; Acetazolamide, United States Pharmacopeia (USP) Reference Standard; N - (5 - Sulfamoyl - 1,3, 4 - thiadiazol - 2 - yl) acetamide; Acetazolamide for system suitability, European Pharmacopoeia (EP) Reference Standard; Acetazolamide, Pharmaceutical Secondary Standard; Certified Reference Material; 124442-28-0; 2-Acetamido-5-sulfamoyl-1,3,4-thiadiazole; 2-Acetylamino-1,3,4-thiadiazole-5-sulfonamide; 5-Acetamido-1,3,4-thiadiazole-2-sulfonamide	Small molecule	1S/C4H6N4O3S2/c1-2(9)6-3-7-8-4(12-3)13(5,10)11/h1H3,(H2,5,10,11)(H,6,7,9)	BZKPWHYZMXOIDC-UHFFFAOYSA-N	CC(=O)NC1=NN=C(S1)S(=O)(=O)N	C4H6N4O3S2	CAS 59-66-5	CHEBI:27690	.	.	.	D0E1SW	.	.	.
DR4377	Rasagiline	CID: 3052776	rasagiline; 136236-51-6; (R)-N-(2-Propynyl)-2,3-dihydroinden-1-amine; Azilect; (R)-N-2-Propynyl-1-indanamine; (R)-2,3-dihydro-N-2-propynyl-1H-inden-1-amine; 1-Indanamine, N-2-propynyl-, (R)-; (1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine; UNII-003N66TS6T; TV-1030; Azilect (TN); RAS; CHEMBL887; (1R)-N-propargylindan-1-amine; CHEBI:63620; 003N66TS6T; (R)-Indan-1-yl-prop-2-ynyl-amine; 1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R)-; (R)-N-(prop-2-ynyl)-2,3-dihydro-1H-inden-1-amine; (1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine; Rasagiline [USAN:INN]; MFCD00866571; HSDB 7699; (1R)-N-prop-2-ynylindan-1-amine; 1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R); TV 1030; PubChem23269; Rasagiline (USAN/INN); SCHEMBL74699; cc-221; MLS006012042; N-propargyl-1-(R)aminoindan; GTPL6641; IND057; SCHEMBL2029054; DTXSID3041112; BDBM10989; HMS3264K12; HMS3715L12; HMS3886N03; Pharmakon1600-01502333; AC-723; ANW-49399; HY-14605A; NSC759639; NSC789038; s5795; ZINC19875504; AKOS006271452; AKOS015837675; AM84542; CCG-213034; DB01367; FS-3130; MCULE-4385913742; NSC 759639; NSC-759639; NSC-789038; SMR002533187; (1R)-N-(prop-2-yn-1-yl)indan-1-amine; AB0035569; DB-001111; A2916; X9941; D08469; S-3541; AB01562963_01; AB01562963_02; Q420685; SR-00000006359; SR-00000006359-3; 1204184-69-9	Small molecule	1S/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2/t12-/m1/s1	RUOKEQAAGRXIBM-GFCCVEGCSA-N	C#CCNC1CCC2=CC=CC=C12	C12H13N	CAS 136236-51-6	CHEBI:63620	.	.	.	D06OMW	.	.	.
DR4436	Oxacillin	CID: 6196	oxacillin; Oxazocillin; MPI-penicillin; 66-79-5; Bactocill; Prostaphlin; OXACILLIN SODIUM; 5-Methyl-3-phenyl-4-isoxazolyl-penicillin; UNII-UH95VD7V76; CHEBI:7809; C19H19N3O5S; (5-methyl-3-phenyl-4-isoxazolyl)penicillin; (2S,5R,6R)-3,3-dimethyl-6-[(5-methyl-3-phenyl-1,2-oxazole-4-carbonyl)amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Penicillin, (5-methyl-3-phenyl-4-isoxazolyl)-; 6beta-(5-methyl-3-phenylisoxazol-4-yl)penicillanic acid; UH95VD7V76; (2S,5R,6R)-3,3-dimethyl-6-{[(5-methyl-3-phenylisoxazol-4-yl)carbonyl]amino}-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Ossacillina; Oxacilline; Oxacillinum; Prostaphlyn; Oxacilina; Ossacillina [DCIT]; MPi-PC; Oxacillin [INN:BAN]; Oxacilina [INN-Spanish]; Oxacilline [INN-French]; Oxacillinum [INN-Latin]; 1173-88-2; Oxacilina (TN); Oxacillin (INN); EINECS 200-635-5; Oxacillin,(S); (2S,5R,6R)-3,3-dimethyl-6-[(5-methyl-3-phenyl-isoxazole-4-carbonyl)amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-6-(((5-methyl-3-phenyl-4-isoxazolyl)carbonyl)amino)-7-oxo-, (2S-(2alpha,5alpha,6beta))-; CHEMBL819; Epitope ID:181859; SCHEMBL3817; DTXSID8023397; GTPL10943; phenylisoxazole-4-carboxamido)-7-; ZINC3875439; BDBM50350483; DB00713; 2,2-dimethyl-6beta-(5-methyl-3-phenyl-1,2-oxazole-4-carboxamido)penam-3alpha-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-6-(5-methyl-3-phenyl-1,2-oxazole-4-amido)-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-6-(5-methyl-3-phenyl-4-isoxazolecarboxamide)-7-oxo-; 5-Methyl-3-phenyl-4-isooxazolylpenicillin; oxo-4-thia-1-azabicyclo[3.2.0]heptane-; X6829; C07334; D08307; (2S,5R,6R)-3,3-dimethyl-6-(5-methyl-3-; Q418725; BRD-K96786677-236-01-6; BRD-K96786677-236-02-4; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-(((5-methyl-3-phenyl-4-isoxazolyl)carbonyl)amino)-7-oxo-, (2S-(2.alpha.,5.alpha.,6.beta.))-; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[[(5-methyl-3-phenyl-4-isoxazolyl)carbonyl]amino]-7-oxo-, (2S,5R,6R)-	Small molecule	1S/C19H19N3O5S/c1-9-11(12(21-27-9)10-7-5-4-6-8-10)15(23)20-13-16(24)22-14(18(25)26)19(2,3)28-17(13)22/h4-8,13-14,17H,1-3H3,(H,20,23)(H,25,26)/t13-,14+,17-/m1/s1	UWYHMGVUTGAWSP-JKIFEVAISA-N	CC1=C(C(=NO1)C2=CC=CC=C2)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)O	C19H19N3O5S	CAS 66-79-5	CHEBI:7809	.	.	.	D0MB8I	.	.	.
DR4455	Mizoribine	CID: 104762	mizoribine; 50924-49-7; Bredinin; HE-69; UNII-4JR41A10VP; MLS000028813; 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-hydroxy-1H-imidazole-4-carboxamide; 5-Hydroxy-1-beta-D-ribofuranosyl-1H-imidazole-4-carboxamide; SMR000058473; 5-Hydroxy-1-beta-D-ribofuranosylimidazole-4-carboxamide; 4JR41A10VP; Bredinine; 1H-Imidazole-4-carboxamide, 5-hydroxy-1-beta-D-ribofuranosyl-; MFCD00057221; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-hydroxyimidazole-4-carboxamide; 50524-49-7; NCGC00094087-01; Mizoribinum; Mizoribina; Mizoribine [INN:JAN]; DSSTox_CID_25777; DSSTox_RID_81119; DSSTox_GSID_45777; Mizoribinum [INN-Latin]; Mizoribina [INN-Spanish]; Bredinin (TN); 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-hydroxy-1H-imidazole-4-carboxamide; CAS-50924-49-7; SR-01000075989; BRN 4151713; 4-Carbamoyl-1-beta-D-ribofuranosyl-imidazolium-5-olate; HE 69; Anhydro-4-carbamoyl-5-hydroxy-1-beta-D-ribofuranosyl-imidazolium hydroxide; Mizoribine(Bredinin); NSC 289637; HS-0046; Mizoribine (Bredinin); Opera_ID_1558; Spectrum2_001559; Spectrum3_000739; Spectrum4_000220; Spectrum5_001671; Mizoribine (JP17/INN); M 3047; SCHEMBL7118; Lopac0_000745; BSPBio_002298; KBioGR_000859; 1H-Imidazole-4-carboxamide, 5-hydroxy-1-b-D-ribofuranosyl-; MLS001076272; MLS006010038; DivK1c_000948; SPBio_001438; CHEMBL245019; cid_104762; Mizoribine, >=98% (TLC); DTXSID8045777; BDBM68669; CHEBI:31858; HMS502P10; KBio1_000948; KBio3_001518; N'-(beta-D-Ribofuranosyl)-5-hydroxyimidazole-4-carboxamide; NINDS_000948; HMS2230D04; HMS3262E12; N'-(beta-D-Ribofuranosyl)-5-hydroxy-imida-zole-4-carboxamide; EX-A2256; ZINC3812887; Tox21_111242; Tox21_500745; CCG-39778; QC-367; s1384; AKOS015994615; Tox21_111242_1; AC-5266; BCP9000933; CS-1823; DB12617; LP00745; SDCCGSBI-0050723.P004; IDI1_000948; SMP1_000195; NCGC00094087-02; NCGC00094087-03; NCGC00094087-04; NCGC00094087-05; NCGC00261430-01; HY-17470; Q571; BCP0726000318; SBI-0050723.P003; AB0017672; EU-0100745; M2399; A10597; A16794; D01392; AB00053323_12; AB00053323_13; 924M497; J-700185; Q6884708; SR-01000075989-1; SR-01000075989-4; 1-(beta-D-Ribofuranosyl)-5-hydroxyimidazole-4-carboxamide; 4-Carbamoyl-1-(beta-D-ribofuranosyl)-5-oxylatoimidazolium; 5-hydroxy-1-b-D-ribofuranosyl-1H-Imidazole-4-carboxamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-oxolanyl]-5-hydroxy-4-imidazolecarboxamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-hydroxy-imidazole-4-carboxamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methylol-tetrahydrofuran-2-yl]-5-hydroxy-imidazole-4-carboxamide; 1-[(2R,3R,4S,5R)-5-(hydroxymethyl)-3,4-bis(oxidanyl)oxolan-2-yl]-5-oxidanyl-imidazole-4-carboxamide; Bredinin; ; ; HE-69; ; ; NSC-289637; ; ; 1-[(2R,3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-hydroxyimidazole-4-carboxamide	Small molecule	1S/C9H13N3O6/c10-7(16)4-8(17)12(2-11-4)9-6(15)5(14)3(1-13)18-9/h2-3,5-6,9,13-15,17H,1H2,(H2,10,16)/t3-,5-,6-,9-/m1/s1	HZQDCMWJEBCWBR-UUOKFMHZSA-N	C1=NC(=C(N1C2C(C(C(O2)CO)O)O)O)C(=O)N	C9H13N3O6	CAS 50924-49-7	CHEBI:31858	.	.	.	D0G5AG	.	.	.
DR4469	Doxorubicin	CID: 31703	Adriacin; 25316-40-9; Doxorubicin HCl; ADRIAMYCIN HYDROCHLORIDE; Hydroxydaunorubicin hydrochloride; Doxorubicin (Adriamycin) HCl; UNII-82F2G7BL4E; ADRIAMYCIN, HYDROCHLORIDE; KW-125; Lipodox; MLS001401460; 82F2G7BL4E; SMR000058570; CPD000058570; DSSTox_RID_78854; DSSTox_RID_80678; DSSTox_CID_10636; DSSTox_GSID_30636; DSSTox_GSID_45111; CCRIS 740; CAS-NOCAS_45111	Small molecule	1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22+,27-/m0/s1	AOJJSUZBOXZQNB-TZSSRYMLSA-N	CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O	C27H29NO11	CAS 23214-92-8	CHEBI:28748	.	.	.	D07VLY	.	.	Doxorubicin
DR4508	Edetic acid	CID: 6049	EDTA; Edetic acid; Ethylenediaminetetraacetic acid; 60-00-4; Edathamil; Endrate; Versene; Havidote; Sequestrol; Titriplex; EDTA acid; Cheelox; Sequestric acid; Warkeelate acid; Gluma cleanser; Sequestrene aa; Komplexon ii; Quastal Special; Tetrine acid; Versene acid; Metaquest A; Trilon bw; Complexon II; Hamp-ene acid; Titriplex II; Cheelox BF acid; Trilon BS; Celon A; Chelest 3A; Questex 4H; Celon ATH; Chemcolox 340; Universne acid; Vinkeil 100; Dissolvine E; Nullapon B acid; Nullapon bf acid; Perma kleer 50 acid; Nervanaid B acid; Clewat TAA; (Ethylenedinitrilo)tetraacetic acid; EDTA (chelating agent); Versenate; Ethylenedinitrilotetraacetic acid; Calcium disodium versenate; Acidum edeticum; Acide edetique; Acido edetico; Caswell No. 438; Disodium EDTA; Chelaton 3; ICRF 185; Acetic acid, (ethylenedinitrilo)tetra-; Glycine, N,N'-1,2-ethanediylbis[N-(carboxymethyl)-; Cheladrate; SEQ 100; Edetate calcium; Ethylenebisiminodiacetic acid; YD 30; Acide edetique [INN-French]; Acido edetico [INN-Spanish]; Acidum edeticum [INN-Latin]; CCRIS 946; Edetate; ETHYLENEDIAMINE TETRAACETIC ACID; HSDB 809; Acide ethylenediaminetetracetique; Ethylenediamine-N,N,N',N'-tetraacetic acid; UNII-9G34HU7RV0; MFCD00003541; EPA Pesticide Chemical Code 039101; Edta disodium; Disodium edetate; Disodium versene; Endrate disodium; Kyselina ethylendiamintetraoctova; Sodium versenate; Edetic acid disodium salt; Ethylenediaminetetraacetate; Kyselina ethylendiamintetraoctova [Czech]; Acide ethylenediaminetetracetique [French]; Metaquest B; ethylene diamine tetraacetic acid; Kiresuto B; Chelaplex III; Complexon III; Diso-Tate; Titriplex III; 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid; 3,6-Diazaoctanedioic acid, 3,6-bis(carboxymethyl)-; AI3-17181; Chelaton III; Versene NA; Triplex III; Disodium versenate; Edathamil disodium; Trilon BD; Versene Na2; Disodium sequestrene; Disodium tetracemate; EDTA disodium salt; F 1 (complexon); EDTA, ion(4-); CHEMBL858; Sequestrene sodium 2; Acetic acid, 2,2',2'',2'''-(1,2-ethanediyldinitrilo)tetrakis-; N,N'-1,2-Ethanediylbis(N-(carboxymethyl)glycine); Glycine, N,N'-1,2-ethanediylbis(N-(carboxymethyl)-; {[-(BIS-CARBOXYMETHYL-AMINO)-ETHYL]-CARBOXYMETHYL-AMINO}-ACETIC ACID; Disodium salt of EDTA; 9G34HU7RV0; Perma Kleer Di Crystals; Calcium disodium versenate (TN); ethylene-diamine tetraacetic acid; 2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetic acid; CHEBI:42191; 2-({2-[bis(carboxymethyl)amino]ethyl}(carboxymethyl)amino)acetic acid; 4-04-00-02449 (Beilstein Handbook Reference); N,N'-1,2-Ethane diylbis-(N-(carboxymethyl)glycine); Ethylenediaminetetraacetic acid disodium salt; Edetate calcium disodium (USP); Sequestrene Na2; Trilon B; Selekton B2; Disodium ethylenediaminetetraacetate; (ethylenedinitrilo)tetraacetic acid, ion(4-); ETHYLENEDIAMINETETRAACETIC ACID-D16; Perma kleer 50 crystals disodium salt; Disodium (ethylenedinitrilo)tetraacetate; Disodium ethylenediaminetetraacetic acid; SODIUM ETHYLENEDIAMINETETRAACETATE; CBC 50152966; DR-16133; Ethylenediaminetetraacetate, disodium salt; Disodium diacid ethylenediaminetetraacetate; D'E.d.t.a. disodique; Disodium (ethylenedinitrilo)tetraacetic acid; Ethylenediamine-N,N,N',N'-tetraacetic Acid-13C4; 2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetate; Disodium dihydrogen ethylenediaminetetraacetate; Ethylenediaminetetraacetic acid, disodium salt; Disodium dihydrogen(ethylenedinitrilo)tetraacetate; 139-33-3; NSC2760; CaEDTA; Ethylenediaminetetraacetic acid, 99%, pure; 203805-96-3; C10H16N2O8; N,N'-1,2-ethanediylbis[N-(carboxymethyl)glycine]; NCGC00159485-02; 6381-92-6; EINECS 200-449-4; BRN 1716295; disodium-edta; Edetic acid [INN:BAN:NF]; Ethylenebis(iminodiacetic acid); (Ethylenedinitrilo)tetraacetic acid, disodium salt; 2-[2-(bis(carboxymethyl)amino)ethyl-(carboxymethyl)amino]acetic acid; Tricon bw; ([2-(Bis-carboxymethyl-amino)-ethyl]-carboxymethyl-amino)-acetic acid; {[2-(Bis-carboxymethyl-amino)-ethyl]-carboxymethyl-amino}-acetic acid; Calcium Disodium Edetate (JAN); Techrun DO; Zonon AO; EDTA, free acid; EDTA, free base; EDTA ACS grade; ACETIC ACID, (ETHYLENEDINITRILO)TETRA-, DISODIUM SALT; Versene acid (TN); Acroma DH 700; Spectrum_001018; ACMC-209mhe; Edetic acid (NF/INN); 53632-26-1; Spectrum2_000003; Spectrum3_000412; Spectrum4_000531; Spectrum5_000955; Edetic acid [BAN:INN]; DSSTox_CID_2977; EC 200-449-4; DSSTox_RID_76814; DSSTox_GSID_22977; ethylenediaminetetracetic acid; BSPBio_001964; Diaminoethanetetra-acetic acid; Ethylenediamineteraacetic Acid; KBioGR_001161; KBioSS_001498; ethylenediaminetetraacetic-acid; MLS001249457; BIDD:ER0565; DivK1c_000777; ethylenediamine tetracetic acid; SPBio_000005; ethylenediamine-tetraacetic acid; DTXSID6022977; EDTA, 500 mM Solution, pH 8.0, ULTROL Grade; KBio1_000777; KBio2_001498; KBio2_004066; KBio2_006634; KBio3_001184; EBD3431; (Ethylenedintrilo)tetraacetic acid; ethylen-ediamine tetra-acetic acid; NINDS_000777; STR08855; Tox21_202736; ANW-33408; BDBM50330325; s6350; SBB008807; STK386291; ZINC19364242; AKOS001574475; Glycine, (N,N'-1,2-ethanediylbis(N-(carboxymethyl)-, labeled with carbon-14; (ethane-1,2-diyldinitrilo)tetraacetate; DB00974; MCULE-1868494404; CAS-60-00-4; IDI1_000777; NCGC00159485-03; NCGC00159485-04; NCGC00260284-01; 688-55-1; AC-10615; AK109916; SMR000058776; ST072179; SBI-0051360.P003; DB-084840; DS-003836; B7197; E0084; Ethylenediaminetetraacetic acid, 2Na (EDTA); Ethylenediaminetetraacetic acid, LR, >=98%; FT-0626319; FT-0668253; FT-0668254; C00284; D00052; Ethylenediaminetetraacetic acid, p.a., 98.0%; ETHYLENEDIAMINETETRAACETIC ACID-D4 (CAR; AB00053468_03; Ethylenediaminetetraacetic acid solution, 0.02 N; Ethylenediaminetetraacetic acid, >=98.0% (KT); A832566; N,N'-1,2-Ethanediylbis[N-(carboxymethyl)]glycine; Q408032; SR-01000883946; Ethylenediaminetetraacetic acid, Cell Culture Reagent; J-610078; SR-01000883946-1; 37C3C5E7-D921-445F-82D6-FEBF1AE5AEF5; Ethylenediaminetetraacetic acid, 99.5%, ACS reagent; Ethylenediaminetetraacetic acid, Electrophoresis Grade; Z2688689169; Ethylenediaminetetraacetic acid, BioUltra, >=99.0% (KT); Ethylenediaminetetraacetic acid, 0.5M aq. solution, pH 8.0; Ethylenediaminetetraacetic acid, 99.995% trace metals basis; Ethylenediaminetetraacetic acid, SAJ special grade, >=99.0%; Ethylenediaminetetraacetic acid, Vetec(TM) reagent grade, 98%; [{2-[bis(carboxymethyl)amino]ethyl}(carboxymethyl)amino]acetic acid; 2,2',2'',2'''-(ethane-1,2-diylbis(azanetriyl))tetraacetic acid; Edetic acid, United States Pharmacopeia (USP) Reference Standard; Edetic acid; EDTA; (Ethylenedinitrilo)tetraacetic acid; Edathamil; Ethylenediaminetetraacetic acid, ACS reagent, 99.4-100.6%, powder; Ethylenediaminetetraacetic acid, purified grade, >=98.5%, powder; 2,2'',2'''',2''''''-(ethane-1,2-diylbis(azanetriyl))tetraacetic acid; Ethylenediaminetetraacetic acid, 0.5M aqueous solution, pH 8.0, autoclaved; Ethylenediaminetetraacetic acid, BioUltra, anhydrous, >=99% (titration); Glycine, N,N'-1, {2-ethanediylbis[N-(carboxymethyl)-,} disodium salt; {[2-(Bis-carboxymethyl-amino)-ethyl]-carboxymethyl-amino}-acetic acid(EDTA); 2-[2-[bis(2-hydroxy-2-oxoethyl)amino]ethyl-(2-hydroxy-2-oxoethyl)amino]ethanoic acid; Ethylenediaminetetraacetic acid, anhydrous, free-flowing, Redi-Dri(TM), >=98%; 124949-23-1; 470462-56-7; Ethylenediamine-N,N,N inverted exclamation mark ,N inverted exclamation mark -tetraacetic Acid-13C4 (; A-labels); Ethylenediaminetetraacetic acid solution, 0.02% in DPBS (0.5 mM), sterile-filtered, BioReagent, suitable for cell culture; Ethylenediaminetetraacetic acid solution, BioUltra, for molecular biology, pH 8.0, ~0.5 M in H2O; Ethylenediaminetetraacetic acid, anhydrous, crystalline, BioReagent, suitable for cell culture; Ethylenediaminetetraacetic acid, anhydrous, free-flowing, powder, Redi-Dri(TM), ACS reagent, 99.4-100.6%	Small molecule	1S/C10H16N2O8/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20)	KCXVZYZYPLLWCC-UHFFFAOYSA-N	C(CN(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O	C10H16N2O8	CAS 60-00-4	CHEBI:42191	.	.	.	D00KEP	.	.	.
DR4517	Tetramethylpyrazine	CID: 14296	2,3,5,6-Tetramethylpyrazine; TETRAMETHYLPYRAZINE; 1124-11-4; Ligustrazine; Pyrazine, tetramethyl-; Bs factor; Tetramethylpyrazin; Tetrapyrazine; Chuanxiongzine; Liqustrazine; Ligustizine; 2,3,5,6-Tetramethyl pyrazine; TMPZ; chuanxingzine; FEMA No. 3237; UNII-V80F4IA5XG; MFCD00006146; 2,3,5,6,-Tetramethyl-1,4-pyrazine; V80F4IA5XG; MLS000069594; FEMA 3237; Pyrazine, 2,3,5,6-tetramethyl-; SMR000059042; 2,5,6-Tetramethylpyrazine; EINECS 214-391-2; NSC 36080; NSC 46451; 2,3,5,6-Tetramethylpyrazine (natural); Ligustrazin; PubChem8617; Opera_ID_849; TMP?; ACMC-2099er; DSSTox_CID_27070; DSSTox_RID_82085; DSSTox_GSID_47070; SCHEMBL77624; CHEMBL303697; ZINC4042; 2,3,5,6-Tetramethyl-pyrazine; DTXSID6047070; FINHMKGKINIASC-UHFFFAOYSA-; CHEBI:133246; Pyrazine, 2,3,5,6-tetramethyl; HMS2235K03; HMS3371J08; Nat.2,3,5,6-Tetramethylpyrazine; ACN-S003305; HY-N0264; NSC36080; NSC46451; Tox21_302313; ANW-16465; BBL012277; CT0189; NSC-36080; NSC-46451; s3956; SBB085945; STL163591; 2,3,5,6-Tetramethylpyrazine, 98%; AKOS003398567; CCG-207974; CS-W023183; MCULE-2834033564; NCGC00247063-01; NCGC00256097-01; AC-10515; AK-47432; AS-13206; H601; SY011353; CAS-1124-11-4; DB-003786; AM20070299; FT-0609443; N1918; ST45025457; 2,3,5,6-Tetramethylpyrazine, >=98%, FG; M-4966; 2,3,5,6-Tetramethylpyrazine, analytical standard; A802574; AC-907/25014219; Q-100069; 2,3,5,6-Tetramethylpyrazine, natural, >=98%, FG; Q11319317; Z1741976694; 2,3,5,6-Tetramethylpyrazine, Vetec(TM) reagent grade, 98%	Small molecule	1S/C8H12N2/c1-5-6(2)10-8(4)7(3)9-5/h1-4H3	FINHMKGKINIASC-UHFFFAOYSA-N	CC1=C(N=C(C(=N1)C)C)C	C8H12N2	CAS 1124-11-4	CHEBI:133246	.	.	.	D09WFI	.	.	.
DR4666	PD98059	CID: 4713	PD98059; PD 98059; 2-(2-amino-3-methoxyphenyl)-4H-chromen-4-one; PD-98059; PD 98,059; 2-(2-amino-3-methoxyphenyl)chromen-4-one; 2-(2-Amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 2'-AMINO-3'-METHOXYFLAVONE; PD-098059; 4H-1-Benzopyran-4-one, 2-(2-Amino-3-methoxyphenyl)-; UNII-SJE1IO5E3I; SJE1IO5E3I; CHEMBL35482; C16H13NO3; CHEBI:77954; MFCD00671789; 2-(2-Amino-3-methoxy-phenyl)-chromen-4-one; SR-01000076097; PD 098059; 2-(2-Amino-3-methoxyphenyl)-chromen-4-one; Tocris-1213; PD098059; Lopac-P-215; BiomolKI_000001; 2-(2-amino-3-methoxy-phenyl)chromen-4-one; BiomolKI2_000011; PD 98,059, solid; Lopac0_001028; BMK1-B1; BSPBio_000996; KBioGR_000336; KBioSS_000336; 2-(2'-amino-3'-methoxyphenyl)oxanaphthalen-4-one; cc-461; MLS006010134; SCHEMBL157826; 4H-1-Benzopyran-4-one,2-(2-amino-3-methoxyphenyl)-; GTPL5241; QCR-14; 2''-amino-3''-methoxyflavone; BCBcMAP01_000049; KBio2_000336; KBio2_002904; KBio2_005472; KBio3_000671; KBio3_000672; AOB2598; DTXSID40168416; BCPP000123; Bio1_000475; Bio1_000964; Bio1_001453; Bio2_000338; Bio2_000818; HMS1362B17; HMS1792B17; HMS1990B17; HMS3229M08; HMS3263M17; HMS3267D03; HMS3403B17; HMS3412O09; HMS3649N14; HMS3654I16; HMS3676O09; BCP02423; EX-A2127; ZINC1420826; Tox21_501028; ABP000927; BDBM50108771; NSC679828; s1177; AKOS015995212; BCP9001060; CCG-100605; CS-0169; LP01028; NSC 679828; NSC-679828; SB16629; SDCCGSBI-0051000.P003; IDI1_002093; SMP2_000052; NCGC00015790-01; NCGC00015790-02; NCGC00015790-03; NCGC00015790-04; NCGC00015790-05; NCGC00015790-06; NCGC00015790-07; NCGC00015790-08; NCGC00025045-01; NCGC00025045-02; NCGC00025045-03; NCGC00025045-04; NCGC00025045-05; NCGC00179347-01; NCGC00261713-01; AC-28412; AK-60664; AS-19374; HY-12028; NCI60_028554; SMR001456459; AB0033706; EU-0101028; FT-0716482; P-215; PD-98059/PD98059/; SW218254-2; X7398; EC-000.2425; A25454; P-4313; PD 98059 & Z-100; InSolution PD 98059 - CAS 167869-21-8; J-505513; SR-01000076097-1; SR-01000076097-3; SR-01000076097-6; 2-(2-amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran; BRD-K62810658-001-05-6; BRD-K62810658-001-06-4; Q27088281; 2-(2-Amino-3-methoxy-phenyl)-chromen-4-one(PD98059); PD 98059 - CAS 167869-21-8; 4H-1-Benzopyran-4-one, 2-(2-amino-3-methoxyphenyl)- & Z-100	Small molecule	1S/C16H13NO3/c1-19-14-8-4-6-11(16(14)17)15-9-12(18)10-5-2-3-7-13(10)20-15/h2-9H,17H2,1H3	QFWCYNPOPKQOKV-UHFFFAOYSA-N	COC1=CC=CC(=C1N)C2=CC(=O)C3=CC=CC=C3O2	C16H13NO3	CAS 167869-21-8	.	.	.	.	.	.	.	.
DR4671	Zafirlukast	CID: 5717	zafirlukast; 107753-78-6; Accolate; Olmoran; ICI-204219; Cyclopentyl (3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methyl-1H-indol-5-yl)carbamate; Accoleit; ICI 204219; ICI 204,219; C31H33N3O6S; UNII-XZ629S5L50; Cyclopentyl 3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamate; Zafirlukast (Accolate); CHEMBL603; Aeronix; CHEBI:10100; XZ629S5L50; MFCD00864775; 4-(5-cyclopentyloxycarbonylamino-1-methyl-1H-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide; NCGC00164547-01; NCGC00164547-06; Vanticon; DSSTox_CID_3746; DSSTox_RID_77181; DSSTox_GSID_23746; cyclopentyl 3-[2-methoxy-4-(2-methylphenylsulfonylcarbamoyl)benzyl]-1-methyl-1H-indol-5-ylcarbamate; Zafirst; Respix; Accolate (TN); Cyclopentyl 3-{2-methoxy-4-[(o-tolylsulfonyl)carbamoyl]benzyl}-1-methyl-1H-indol-5-ylcarbamate; cyclopentyl N-{3-[(2-methoxy-4-{[(2-methylbenzene)sulfonyl]carbamoyl}phenyl)methyl]-1-methyl-1H-indol-5-yl}carbamate; N-[3-[[2-Methoxy-4-[[[(2-methylphenyl)sulfonyl]amino]carbonyl]phenyl]methyl]-1-methyl-1H-indol-5-yl]carbamic Acid Cyclopentyl Ester; SMR000466316; CAS-107753-78-6; SR-01000759386; Zafirlucast; Zafirlukast (JAN/USAN/INN); Zafirlukast [USAN:INN:BAN]; Zafirlukast(Accolate); PubChem18223; CPD000466316; ACMC-209wlw; cc-92; SCHEMBL4175; Carbamic acid, (3-((2-methoxy-4-((((2-methylphenyl)sulfonyl)amino)carbonyl)phenyl)methyl)-1-methyl-1H-indol-5-yl)-, cyclopentyl ester; MLS000759421; MLS001424064; MLS006011771; BIDD:GT0267; GTPL3322; DTXSID5023746; Zafirlukast, >=98% (HPLC); HMS2051F12; HMS2089J10; HMS3393F12; HMS3650A04; HMS3655E13; HMS3713J08; HMS3745K03; ZINC896717; BCP05226; Tox21_112176; ANW-46530; BDBM50009073; s1633; STK646780; AKOS005577888; Tox21_112176_1; AC-9018; CCG-101025; DB00549; MCULE-2053856450; NC00275; SB19079; NCGC00164547-02; NCGC00164547-03; NCGC00164547-04; NCGC00164547-05; AS-12943; cyclopentyl (1-methyl-3-{[2-(methyloxy)-4-({[(2-methylphenyl)sulfonyl]amino}carbonyl)phenyl]methyl}-1H-indol-5-yl)carbamate; cyclopentyl [3-(2-methoxy-4-{[(2-methylphenyl)sulfonyl]carbamoyl}benzyl)-1-methyl-1H-indol-5-yl]carbamate; cyclopentyl N-[3-[[2-methoxy-4-(o-tolylsulfonylcarbamoyl)phenyl]methyl]-1-methyl-indol-5-yl]carbamate; HY-17492; AB0012638; FT-0601575; MLS000759421-02; SW197655-3; C07206; D00411; 32256-EP2270008A1; 32256-EP2280006A1; 32256-EP2281813A1; 32256-EP2281815A1; 32256-EP2281819A1; 32256-EP2284166A1; 32256-EP2292617A1; 32256-EP2292619A1; 32256-EP2295409A1; 32256-EP2298415A1; 32256-EP2301933A1; 32256-EP2305640A2; 32256-EP2305659A1; 32256-EP2308562A2; 32256-EP2311818A1; 32256-EP2311827A1; AB00639922-06; AB00639922-08; AB00639922_09; 753Z786; A801752; L001011; Q928378; Q-201940; SR-01000759386-4; SR-01000759386-5; SR-01000759386-9; BRD-K71289571-001-06-4; Z1551429730; Cyclopentyl (3-(2-methoxy-4-((o-tolylsulfonyl)-carbamoyl)benzyl)-1-methyl-1H-indol-5-yl)carbamate; cyclopentyl 3-(2-methoxy-4-(o-tolylsulfonylcarbamoyl)benzyl)-1-methyl-1H-indol-5-ylcarbamate; cyclopentyl N-[3-({2-methoxy-4-[(2-methylbenzenesulfonyl)carbamoyl]phenyl}methyl)-1-methyl-1H-indol-5-yl]carbamate; cyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methyl-indol-5-yl]carbamate; Cyclopentyl N-[3-[[2-Methoxy-4-[[[(2-methylphenyl)sulfonyl]amino]carbonyl]phenyl]methyl]-1-methyl-1H-indol-5-yl]carbamate; N-[3-[[2-methoxy-4-[[(2-methylphenyl)sulfonylamino]-oxomethyl]phenyl]methyl]-1-methyl-5-indolyl]carbamic acid cyclopentyl ester; ZLK	Small molecule	1S/C31H33N3O6S/c1-20-8-4-7-11-29(20)41(37,38)33-30(35)22-13-12-21(28(17-22)39-3)16-23-19-34(2)27-15-14-24(18-26(23)27)32-31(36)40-25-9-5-6-10-25/h4,7-8,11-15,17-19,25H,5-6,9-10,16H2,1-3H3,(H,32,36)(H,33,35)	YEEZWCHGZNKEEK-UHFFFAOYSA-N	CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)NC(=O)OC5CCCC5)C)OC	C31H33N3O6S	CAS 107753-78-6	CHEBI:10100	.	.	.	D05DVP	.	.	.
DR4674	Voriconazole	CID: 71616	Voriconazole; 137234-62-9; Vfend; (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol; UK-109496; UK 109496; UK-109,496; UNII-JFU09I87TR; (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol; C16H14F3N5O; (+/-)-Voriconazole; VCZ; CHEMBL638; JFU09I87TR; CPD000466350; (R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; CHEBI:10023; (alphaR,betaS)-alpha-(2,4-Difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; 4-Pyrimidineethanol, alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-, (alphaR,betaS)-; VRC; Voriconazol; DSSTox_CID_26485; DSSTox_RID_81656; DSSTox_GSID_46485; (2R,3S)-2-(2,4-Difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-((1H)-1,2,4-triazol-1-yl)-butan-2-ol; (alphaR,betaS)-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; 4-Pyrimidineethanol, alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-, (R-(R*,S*))-; Voriconazolum; Vorikonazole; Voriconazole [USAN:INN:BAN]; 188416-29-7; DRG-0301; SMR000466350; CAS-137234-62-9; Vfend (TN); VFEND I.V.; Pfizer; MFCD00905717; NCGC00164622-01; Voriconazole solution; Voriconazole, 98%; Voriconazole - Vfend; Voriconazole in combination with MGCD290; Voriconazole, (+/-)-; SCHEMBL36233; 2R,3S-2-(2,4-Difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol; MLS000759464; MLS001424082; MLS006010028; DTXSID5046485; Voriconazole (JP17/USP/INN); ZINC14864; AMY8903; SYN3012; Voriconazole, >=98% (HPLC); BCPP000019; DTXSID201019420; HMS2051N09; HMS3260M22; HMS3713F12; Pharmakon1600-01502346; Tox21_112241; Tox21_500150; Voriconazole 2.0 mg/ml in Methanol; AC-823; BDBM50333117; MFCD20488064; NSC759888; s1442; AKOS005145705; Tox21_112241_1; CCG-100941; CS-1227; DB00582; KS-1157; NC00191; NSC 759888; NSC-759888; SB17419; NCGC00164622-02; NCGC00164622-04; NCGC00164622-06; NCGC00260835-01; HY-76200; I992; Voriconazole related compound A RS [USP]; AB0013963; SW197571-2; C07622; D00578; J10329; W-5208; AB00639948-04; AB00639948-06; AB00639948_07; AB00639948_08; Voriconazole, VETRANAL(TM), analytical standard; 234V629; Q412236; J-006986; Z2616414875; UNII-USG4B1CD29 component BCEHBSKCWLPMDN-MGPLVRAMSA-N; Voriconazole, European Pharmacopoeia (EP) Reference Standard; Voriconazole, United States Pharmacopeia (USP) Reference Standard; (2R,3S)-2,3-bis(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol; 2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl) butan-2-ol; Voriconazole, Pharmaceutical Secondary Standard: Certified Reference Material; (2R,3S)-2-(2,4-Difluoro-phenyl)-3-(5-fluoro-pyrimidin-4-yl)-1-[1,2,4]triazol-1-yl-butan-2-ol; (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1H-1,2,4-triazol-1-yl) butan-2-ol; (2R,3S)-2-(2,4-Difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol; (2r,3s)-2-(2,4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1h-1,2,4-triazol-1-yl)butan-2-ol; 4-Pyrimidineethanol, alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-, (alphaR,betaS)-rel-	Small molecule	1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1	BCEHBSKCWLPMDN-MGPLVRAMSA-N	CC(C1=NC=NC=C1F)C(CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O	C16H14F3N5O	CAS 188416-29-7	CHEBI:10023	.	.	.	D0N3VR	.	.	.
DR4698	Anti-CD25 monoclonal antibody	.	Humanized anti-Tac antibody (HAT)	Antibody	.	.	.	.	.	.	.	.	.	.	.	.	.
DR4718	Primaquin	CID: 4908	PRIMAQUINE; 90-34-6; 8-(4-Amino-1-methylbutylamino)-6-methoxyquinoline; Primachin; Neo-Quipenyl; Primaquin; Primachinum; Primaquinum; Primaquina; 1,4-Pentanediamine, N4-(6-methoxy-8-quinolinyl)-; 6-Methoxy-8-(4-amino-1-methylbutylamino)quinoline; SN 13,272; S. N. 13272; WR 2975; (RS)-primaquine; NSC 27296; CHEBI:8405; 4-N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; N-(5-aminopentan-2-yl)-6-methoxyquinolin-8-amine; 8-((4-Amino-1-methylbutyl)amino)-6-methoxyquinoline; N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; l-Primaquine; N4-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; NSC27296; NSC-27296; 1,4-Pentanediamine, N(4)-(6-methoxy-8-quinolinyl)-; 8-[(4-Amino-1-methylbutyl)amino]-6-methoxyquinoline; Primachina [DCIT]; Primachina; dl-Primaquine; Primaquine [INN:BAN]; BRN 0019337; Maliride; NSC 27296; Neo-Quipenyl; Primachin; N4-(6-methoxy-8-quinolyl)pentane-1,4-diamine; Primaquinum [INN-Latin]; Primaquina [INN-Spanish]; 6-Methoxy-8-[(4-amino-1-methylbutyl)amino]quinoline; N~4~-[6-(methyloxy)quinolin-8-yl]pentane-1,4-diamine; (+/-)-Primaquine; CHEMBL506; MLS001334045; (+)-Primaquine; (-)-Primaquine; Kanaprim (TN); Primaquine (INN); CCRIS 4109; HSDB 6516; 4-22-00-05817 (Beilstein Handbook Reference); 57152-58-6; NCGC00178754-06; N~4~-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; SMR000875314; EINECS 201-987-2; 6-Methoxy-8-((4-amino-1-methylbutyl)amino)quinoline; Quinoline, 8-((4-amino-1-methylbutyl)amino)-6-methoxy-; Quinoline, 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-; Quinoline, 8-(4-amino-1-methylbutylamino)-6-methoxy; TG1-296; TG1-297; Spectrum_000830; Prestwick0_000476; Prestwick1_000476; Prestwick2_000476; Prestwick3_000476; Spectrum2_000887; Spectrum3_000552; Spectrum4_000484; Spectrum5_001363; Epitope ID:131792; Oprea1_546209; SCHEMBL22207; BSPBio_000612; BSPBio_002223; KBioGR_000967; KBioSS_001310; DivK1c_000806; N(4)-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; SPBio_000674; SPBio_002551; (+)-N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; (-)-N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; BPBio1_000674; cid_359247; GTPL9952; Quinoline, 8-(4-amino-1-methylbutylamino)-6-methoxy-; DTXSID8023509; BDBM71542; KBio1_000806; KBio2_001310; KBio2_003878; KBio2_006446; KBio3_001723; NINDS_000806; HMS2090J17; BCP29271; ANW-50074; BBL011330; MFCD00598906; STL146416; 1, N4-(6-methoxy-8-quinolinyl)-; AKOS005721199; DB01087; MCULE-1557087031; WLN: T66 BNJ HO1 JMY1&3Z; WR-2975; IDI1_000806; SMP1_000263; NCGC00178754-01; NCGC00178754-02; NCGC00178754-03; AC-23007; AS-30679; NCI60_001035; NCI60_005887; SN-13272; SBI-0051491.P003; AB00053529; FT-0687514; W9302; C07627; D08420; S-4508; AB00053529-11; AB00053529_12; AB00053529_14; N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; 598P906; A843518; N4-(6-methoxy-8-quinolinyl)pentane-1,4-diamine; Q419834; BRD-A55913614-316-06-2; 1,4-Pentanediamine, N4-(6-methoxy-8-quinolinyl)- (9CI); N-[(S)-4-Amino-1-methylbutyl]-6-methoxy-8-quinolinamine; N4-(6-Methoxyquinolin-8-yl)pentane-1,4-diamine (2 H3PO4); N4-(6-methoxy-8-quinolinyl)pentane-1,4-diamine;phosphoric acid; N4-(6-methoxyquinolin-8-yl)pentane-1,4-diamine;phosphoric acid; (4-amino-1-methyl-butyl)-(6-methoxy-8-quinolyl)amine;phosphoric acid	Small molecule	1S/C15H21N3O/c1-11(5-3-7-16)18-14-10-13(19-2)9-12-6-4-8-17-15(12)14/h4,6,8-11,18H,3,5,7,16H2,1-2H3	INDBQLZJXZLFIT-UHFFFAOYSA-N	CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2	C15H21N3O	CAS 90-34-6	CHEBI:8405	.	.	.	D0T1LK	.	.	.
DR4815	PX-478	CID: 11234794	PX-478; 685898-44-6; PX-478 2HCl; UNII-T23U22X160; PX478; PX 478; PX-478 HCl; CHEMBL4061538; (S)-4-(2-amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline oxide dihydrochloride; T23U22X160; L-Phenylalanine, 4-[bis(2-chloroethyl)oxidoaMino]-, (Hydrochloride) (1; 685898-44-6 (HCl); PX-478 dihydrochloride; 4-[Bis(2-chloroethyl)oxidoamino]-L-phenylalanine; Melphalan N-Oxide Impurity HCl; C13H18Cl2N2O3.2ClH; SCHEMBL18548830; DTXSID00218688; 4-[(2S)-2-amino-2-carboxyethyl]-N,N-bis(2-chloroethyl)benzeneamine oxide;dihydrochloride; EX-A4655; 2675AH; BDBM50231387; s7612; 2-Amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide; CCG-268582; CS-5164; DB06082; HY-10231; A14319; Z-3209; Q27289565; L-Phenylalanine, 4-(bis(2-chloroethyl)oxidoamino)-, dihydrochloride	Small molecule	1S/C13H18Cl2N2O3.2ClH/c14-5-7-17(20,8-6-15)11-3-1-10(2-4-11)9-12(16)13(18)19;;/h1-4,12H,5-9,16H2,(H,18,19);2*1H/t12-;;/m0../s1	GIGCDIVNDFQKRA-LTCKWSDVSA-N	C1=CC(=CC=C1CC(C(=O)O)N)[N+](CCCl)(CCCl)[O-].Cl.Cl	C13H20Cl4N2O3	CAS 685898-44-6	.	.	.	.	D06ZVO	.	.	.
DR4834	N-palmitoylethanolamine	CID: 4671	Palmitoylethanolamide; Palmidrol; 544-31-0; N-(2-Hydroxyethyl)hexadecanamide; Impulsin; Palmitoyl ethanolamide; N-palmitoylethanolamine; Palmitamide MEA; Hydroxyethylpalmitamide; N-(2-Hydroxyethyl)palmitamide; Palmitoyl-EA; Palmitic acid monoethanolamide; Loramine P 256; palmitylethanolamide; Palmidrolum; HEXADECANAMIDE, N-(2-HYDROXYETHYL)-; Palmidrol [INN]; Monoethanolamine palmitic acid amide; Anandamide (16:0); N-palmitoyl ethanolamine; Palmitinsaeure-beta-hydroxyethylamid; UNII-6R8T1UDM3V; NSC 23320; hexadecanoyl ethanolamide; N-hexadecanoylethanolamine; N-hexadecanoyl-ethanolamine; 6R8T1UDM3V; CHEBI:71464; Palmidrol (INN); MFCD00020562; NSC-23320; NCGC00015793-03; AM 3112;Loramine P 256;Mackpeart DR 14V; DSSTox_CID_22254; DSSTox_RID_79975; DSSTox_GSID_42254; MimyX; Palmidrolum [INN-Latin]; CAS-544-31-0; SR-01000076055; EINECS 208-867-9; N-(2-hydroxyethyl) hexadecanamide; Hexadecanamide,N-(2-hydroxyethyl)-; AM 3112; 2-Palmitoylaminoethanol; Palmdrol prodes (TN); Tocris-0879; N-hexadecyl-ethanolamine; Lopac-P-0359; Palmitoylethanolamide-[d4]; Palmityoletanolamide (PEA); CBiol_002043; Lopac0_000905; BSPBio_001454; KBioGR_000174; KBioSS_000174; MLS002153421; SCHEMBL120518; BML2-B10; CHEMBL417675; GTPL3622; DTXSID4042254; Palmidrol; N-palmitoylethanolamine; SCHEMBL19511663; BDBM29083; KBio2_000174; KBio2_002742; KBio2_005310; KBio3_000347; KBio3_000348; Bio1_000329; Bio1_000818; Bio1_001307; Bio2_000174; Bio2_000654; HMS1361I16; HMS1791I16; HMS1989I16; HMS2234L19; HMS3264C10; HMS3266N08; HMS3374K03; HMS3402I16; HMS3411B14; HMS3649L03; HMS3675B14; Pharmakon1600-01506156; Amides, C16-18 and C18-branched, unsatd., N-(hydroxyethyl); BCP29005; CS-D1253; NSC23320; ZINC8035017; Tox21_110222; LMFA08040013; NAE(16:0); NSC760371; s4708; STL454872; AKOS002676363; Tox21_110222_1; CCG-204987; DB14043; LP00905; NSC-760371; SDCCGSBI-0050880.P002; IDI1_033924; NCGC00015793-01; NCGC00015793-02; NCGC00015793-04; NCGC00015793-05; NCGC00015793-06; NCGC00015793-07; NCGC00015793-08; NCGC00015793-09; NCGC00015793-10; NCGC00024840-01; NCGC00024840-02; NCGC00024840-05; NCGC00024840-06; NCGC00024840-07; NCGC00024840-08; NCGC00024840-09; 71060-58-7; AK307896; AS-14094; HY-20685; SMR000058371; Hexadecanoic acid (2-hydroxy-ethyl)-amide; B6485; EU-0100905; FT-0778178; V1640; C16512; D08328; J90064; P 0359; AB00918319_06; Q2159860; SR-01000076055-1; SR-01000076055-3; SR-01000076055-7; BRD-K68095457-001-04-4; Z2687203832; UNII-3VVG2UI23S component HXYVTAGFYLMHSO-UHFFFAOYSA-N; UNII-C80684146D component HXYVTAGFYLMHSO-UHFFFAOYSA-N	Small molecule	1S/C18H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)19-16-17-20/h20H,2-17H2,1H3,(H,19,21)	HXYVTAGFYLMHSO-UHFFFAOYSA-N	CCCCCCCCCCCCCCCC(=O)NCCO	C18H37NO2	CAS 544-31-0	CHEBI:71464	.	.	.	D07ILQ	.	.	.
DR4854	Roscovitine	CID: 160355	Seliciclib; roscovitine; 186692-46-6; R-Roscovitine; (R)-roscovitine; CYC202; CYC-202; CYC 202; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; UNII-0ES1C2KQ94; Roscovitine (Seliciclib,CYC202); NSC 701554; AL-39256; CHEMBL14762; 0ES1C2KQ94; CHEBI:45307; NSC701554; NSC-701554; (2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; Rosco; M02443; BMK1-E12; CYC202, Seliciclib, R-roscovitine, Roscovitine; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-(R)-1-butanol; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine	Small molecule	1S/C19H26N6O/c1-4-15(11-26)22-19-23-17(20-10-14-8-6-5-7-9-14)16-18(24-19)25(12-21-16)13(2)3/h5-9,12-13,15,26H,4,10-11H2,1-3H3,(H2,20,22,23,24)/t15-/m1/s1	BTIHMVBBUGXLCJ-OAHLLOKOSA-N	CCC(CO)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NCC3=CC=CC=C3	C19H26N6O	CAS 186692-46-6	.	.	.	.	D05ADP	.	.	Roscovitine
DR4869	Endostar	.	Endu; Recombinant human endostatin (cancer); YH-16; Recombinant human endostatin (cancer), Shandong Simcere Medgenn	Protein	.	.	.	.	.	.	.	.	.	D05YAG	.	.	.
DR4889	Interferon alpha-2b	.	.	Protein	.	.	.	.	.	.	.	.	.	.	.	.	.
DR4912	Memantine	CID: 4054	memantine; 19982-08-2; 3,5-dimethyladamantan-1-amine; Namenda; 1-Amino-3,5-dimethyladamantane; Ebixa; 3,5-Dimethyl-1-adamantanamine; Memantina; Memantinum [INN-Latin]; Memantina [INN-Spanish]; Memantinum; 1,3-Dimethyl-5-adamantanamine; Memantine [INN]; 3,5-Dimethyl-1-aminoadamantane; UNII-W8O17SJF3T; 3,5-Dimethyl-1-adamantylamine; 3,5-Dimethyltricyclo(3.3.1.1(3,7))decan-1-amine; Tricyclo[3.3.1.13,7]decan-1-amine, 3,5-dimethyl-; CHEMBL807; 3,5-dimethyladamantanylamine; W8O17SJF3T; D-145; CHEBI:64312; Memantine (INN); alzantin; NCGC00015705-04; DSSTox_CID_25174; DSSTox_RID_80723; DSSTox_GSID_45174; D 145; Memantine [INN:BAN]; CAS-19982-08-2; HSDB 7327; 3,5-dimethyltricyclo[3.3.1.1~3,7~]decan-1-amine; DMAA [Antiparkinson Agent]; Retyliumtosylate; 1,3-Dimethyl-5-aminoadamantane; DRG 0267; DRG-0267; Exiba (TN); Spectrum_000607; Prestwick0_000978; Prestwick1_000978; Prestwick2_000978; Prestwick3_000978; Spectrum2_001408; Spectrum3_000923; Spectrum4_001022; Spectrum5_001355; CBMicro_020348; Biomol-NT_000209; SCHEMBL2688; Lopac0_000861; Oprea1_480562; BSPBio_001015; KBioGR_001543; KBioSS_001087; DivK1c_000068; SPBio_001456; SPBio_002926; 1-amino-3,5-dimethyladamantan; BPBio1_001117; BPBio1_001270; GTPL4253; DTXSID5045174; SCHEMBL13213676; HMS500D10; KBio1_000068; KBio2_001087; KBio2_003655; KBio2_006223; KBio3_001926; 1-amino-3,5-dimethyl adamantane; 1-amino-3,5-dimethyl-adamantane; Tricyclo(3.3.1.1(3,7))decan-1-amine, 3,5-dimethyl-; NINDS_000068; (3,5-Dimethyl-1-adamantyl)amine; 3,5-Dimethyl-adamantan-1-ylamine; ALBB-013872; BCP29702; Tox21_110199; 3,5-Dimethyl-1-aminoadamantane HCl; ANW-56451; BBL000737; BDBM50062599; SBB002574; STK520682; AKOS000113995; AKOS015953276; AKOS016340748; Tox21_110199_1; CCG-204092; DB01043; DS-3152; MCULE-3726352671; NSC 757843; SDCCGSBI-0020417.P005; IDI1_000068; NCGC00015705-03; NCGC00015705-05; NCGC00015705-07; NCGC00015705-09; NCGC00015705-16; NCGC00024782-02; NCGC00024782-03; D145 pound>>D 145 pound>>D-145; ST057652; SBI-0020417.P004; AB0212255; AB00053600; BB 0216388; EU-0053634; FT-0649142; AZ0001-0553; C13736; D08174; S-1686; AB00053600-13; AB00053600_14; AB00053600_15; Q412189	Small molecule	1S/C12H21N/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10/h9H,3-8,13H2,1-2H3	BUGYDGFZZOZRHP-UHFFFAOYSA-N	CC12CC3CC(C1)(CC(C3)(C2)N)C	C12H21N	CAS 19982-08-2	CHEBI:64312	.	.	.	D01JEU	.	.	.
DR4920	Tetracycline	CID: 54675776	tetracycline; 60-54-8; Tetracyclinum; Achromycin; Tetracyclin; Deschlorobiomycin; Sumycin; Abramycin; Tsiklomitsin; Achromycin V; Liquamycin; Panmycin; Tetracyn; Tetrazyklin; Ambramycin; Hostacyclin; Omegamycin; Tetradecin; Tetraverine; Tsiklomistsin; Vetacyclinum; Tetrafil; Tetracycline base; Cefracycline; Criseociclina; Abricycline; Agromicina; Ambramicina; Biocycline; Ciclibion; Copharlan; Democracin; Lexacycline; Limecycline; Mericycline; Micycline; Orlycycline; Polycycline; Polyotic; Purocyclina; Roviciclina; Solvocin; Tetrabon; Tetracycl; Amycin; Veracin; SK-Tetracycline; Tetracycline II; Tetra-Co; UNII-F8VB5M810T; Cyclomycin; Sustamycin; Sumycin syrup; Tetracycline I; Bio-tetra; (4S,4aS,5aS,6S,12aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; CHEBI:27902; Piracaps (base); Centet (base); Polycycline (VAN); 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)-; Cefracycline suspension; Liquamycin (Veterinary); Polycycline (antibiotic); F8VB5M810T; (4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide; Tetraciclina; Tetracycline (internal use); Supramycin; Vetquamycin-324 (free base); MFCD00151232; 60-54-8 (FREE BASE); NSC-108579; E701; Achromycin (naphthacene derivative); NSC 108579; T-125; HSDB 3188; 6-Methyl-1,11-dioxy-2-naphthacenecarboxamide; Tetracyclinum [INN-Latin]; Tetraciclina [INN-Spanish]; (4S,4aS,5aS,6S,12aR)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide; Sumycin (TN); 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S-(4alpha,4aalpha,5aalpha,6beta,12aalpha))-; 6416-04-2 (3H2O); Economycin; Vetquamycin; Brodspec; Tetracycline (JAN/USP/INN); CCRIS 9483; SR-01000000212; NSC108579; Tetrabid Organon; Ala-Tet; Tetracycline [USP:INN:BAN:JAN]; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-; EINECS 200-481-9; Spectrum_001034; Tetracycline, EP grade; Prestwick0_000140; Prestwick1_000140; Prestwick2_000140; Prestwick3_000140; Spectrum2_001329; Spectrum3_000565; Spectrum4_000352; Spectrum5_001112; DSSTox_CID_3645; EC 200-481-9; SCHEMBL3098; DSSTox_RID_77127; DSSTox_GSID_23645; BSPBio_000220; BSPBio_001950; KBioGR_000783; KBioSS_001514; BIDD:GT0653; DivK1c_000827; SCHEMBL537050; SPBio_001457; SPBio_002159; BPBio1_000242; SCHEMBL2116649; SCHEMBL2116661; DTXSID7023645; SCHEMBL21271987; GTPL10927; KBio1_000827; KBio2_001514; KBio2_004082; KBio2_006650; KBio3_001450; NINDS_000827; HMS2090B04; Tetracycline, >=98.0% (NT); HY-A0107; RKL10088; Tetracycline, >=88.0% (HPLC); Tox21_300150; BDBM50237605; s4490; ZINC84441937; AKOS024277860; AKOS026749977; ZINC100303069; ZINC102229720; CS-8188; DB00759; MCULE-3752961261; CAS-60-54-8; IDI1_000827; NCGC00017323-03; NCGC00017323-04; NCGC00017323-05; NCGC00017323-07; NCGC00017323-15; NCGC00142507-02; NCGC00254063-01; 4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,1 0,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide; ST019403; SBI-0051530.P003; 1369-EP2269978A2; 1369-EP2269985A2; 1369-EP2269991A2; 1369-EP2270008A1; 1369-EP2275420A1; 1369-EP2284150A2; 1369-EP2284151A2; 1369-EP2284152A2; 1369-EP2284153A2; 1369-EP2284155A2; 1369-EP2284156A2; 1369-EP2284164A2; 1369-EP2287140A2; 1369-EP2287148A2; 1369-EP2287150A2; 1369-EP2289871A1; 1369-EP2289891A2; 1369-EP2292088A1; 1369-EP2292590A2; 1369-EP2292612A2; 1369-EP2292617A1; 1369-EP2295402A2; 1369-EP2295419A2; 1369-EP2298732A1; 1369-EP2301534A1; 1369-EP2301912A2; 1369-EP2301913A1; 1369-EP2301914A1; 1369-EP2301916A2; 1369-EP2305637A2; 1369-EP2305640A2; 1369-EP2305662A1; 1369-EP2307027A1; 1369-EP2308832A1; 1369-EP2308863A1; 1369-EP2308883A1; 1369-EP2311451A1; 1369-EP2311796A1; 1369-EP2311797A1; 1369-EP2311798A1; 1369-EP2311799A1; 1369-EP2311822A1; 1369-EP2314583A1; 1369-EP2316450A1; 1369-EP2371797A1; 1369-EP2371798A1; 1369-EP2371800A1; 1369-EP2371804A1; C06570; D00201; AB00053550-04; AB00053550_05; AB00053550_06; Q193045; SR-01000000212-3; Z2144222809; (4S,4aS,5aS,6S,12aS)-2-[Amino(hydroxy)methylene]-4beta-(dimethylamino)-1,2,3,4,4a,5,5a,6,11,12a-decahydro-6alpha,10,12,12abeta-tetrahydroxy-6-methylnaphthacene-1,3,11-trione; (4S,4aS,5aS,6S,12aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide; (4S,6S,12aS,4aS,5aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,1 1-dioxo-4,5,6,12a,4a,5a-hexahydronaphthacene-2-carboxamide	Small molecule	1S/C22H24N2O8/c1-21(31)8-5-4-6-11(25)12(8)16(26)13-9(21)7-10-15(24(2)3)17(27)14(20(23)30)19(29)22(10,32)18(13)28/h4-6,9-10,15,25-26,29,31-32H,7H2,1-3H3,(H2,23,30)/t9-,10-,15-,21+,22-/m0/s1	NWXMGUDVXFXRIG-WESIUVDSSA-N	CC1(C2CC3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O	C22H24N2O8	CAS 60-54-8	CHEBI:27902	.	.	.	D08NQZ	.	.	.
DR4941	Ondansetron	CID: 4595	ondansetron; 99614-02-5; Zofran; Zudan; Zophren; 9-Methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-2,3-dihydro-1H-carbazol-4(9H)-one; Zuplenz; 116002-70-1; 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one; GR 38032X; GR 38032; CHEBI:7773; 99614-01-4; 1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-4H-carbazol-4-one; 9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one; NCGC00179341-02; DSSTox_CID_3393; 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one; 9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-1,2,3,9-tetrahydro-4H-carbazol-4-one; 9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-2,3,4,9-tetrahydro-1H-carbazol-4-one; DSSTox_RID_77011; DSSTox_GSID_23393; GR 38032 (hydrochloride);SN 307 (hydrochloride); ondansetron (Zofran); CAS-99614-02-5; Ondansetron (base and/or unspecified salts); Ondansetron Injection; EUR-1025; Zofran ODT (TN); DESMETHYLONDANSETRON; BRN 3622981; Ondansetron (JAN/USP/INN); Ondansetron [USP:INN:BAN]; SR-01000763250; 9-methyl-3-[(2-methylimidazolyl)methyl]-1,2,3,9-tetrahydro-4aH-carbazol-4-one; A04AA01; GR38032; CHEMBL46; Prestwick0_001058; Prestwick1_001058; Prestwick2_001058; Prestwick3_001058; Odansetron [common misspelling of ondansetron]; SCHEMBL4542; TimTec1_001750; (RS)-1,2,3,9-Tetrahydro-9-methyl-3-(2-methylimidazol-1-ylmethyl)carbazol-4-one; 4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-; Oprea1_435466; Oprea1_852372; BSPBio_001016; CBDivE_008994; MLS006011928; SPBio_002938; BPBio1_001118; GTPL2290; DTXSID8023393; BDBM85330; HSDB 8304; HY-B0002B; HMS2090H16; HMS3259H08; HMS3371E18; ACT02589; BCP28911; Tox21_113048; BBL010304; CAS_68647; MFCD00833882; NSC_68647; NSC791005; QC-660; s1996; SBB066158; STK370548; AKOS000599484; AKOS016340526; Tox21_113048_1; ACN-049703; BCP9001025; DB00904; KS-5227; MCULE-9438746800; NC00706; NSC 757870; NSC-791005; VA11441; 1,2,3,4-Tetrahydro-9-methyl-3-(2-methyl-1H-imidazol-1-ylmethyl)carbazol-4-one; NCGC00179341-04; NCGC00179341-07; NCGC00179341-12; AC-28927; AK-29654; GR-38032; I544; NCI60_022780; SMR001307702; ST077669; GR-38032F/GR-38032; AB0013753; GR 38032F;GR-C507/75; AB00373674; FT-0631004; 39O049; C07325; D00456; S-2116; AB00373674-15; AB00373674-17; AB00373674_18; AB00373674_19; L000456; Q410011; SR-01000763250-4; BRD-A19736161-001-01-8; BRD-A19736161-003-03-0; Z1741971217; 1,2,3,9,-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one; 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H- carbazol-4-one; 1,2,3,9-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1yl)methyl]-4H-carbazol-4-one; 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazole-1 -yl)methyl]-4H-carbazol-4-one; 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazole-1-yl)methyl]-4H-carbazol-4-one; 9-Methyl-3- (2-methyl-imidazol-1ylmethyl)-1,2,3,9-tetrahydro-carbazol-4-one; 9-Methyl-3-[(2-methyl-1H-imidazolyl)methyl]-1,2,3,9-tetrahydro-4H-carbazole-4-one; 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1~{H}-carbazol-4-one	Small molecule	1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3	FELGMEQIXOGIFQ-UHFFFAOYSA-N	CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C	C18H19N3O	CAS 99614-02-5	CHEBI:7773	.	.	.	D0K7WK	.	.	.
DR4974	Ketoconazole	CID: 456201	ketoconazole; 65277-42-1; (+)-Ketoconazole; (2R,4S)-ketoconazole; Kuric; Ketocanazole; CPD000058460; CHEMBL75; MFCD00058579; C26H28Cl2N4O4; SMR000058460; MLS000069784; MLS001146934; 1-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone; 1-acetyl-4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine; 142128-59-4; CHEBI:48336; DSSTox_CID_9879; DSSTox_RID_78829; DSSTox_GSID_29879; 1-(4-(4-(((2R,4S)-2-((1H-IMIDAZOL-1-YL)METHYL)-2-(2,4-DICHLOROPHENYL)-1,3-DIOXOLAN-4-YL)METHOXY)PHENYL)PIPERAZIN-1-YL)ETHANONE; R-41400; rac-trans-Ketoconazole; KTZ; SR-01000075626; SR-01000597381; Ketoconazole (k); Ketoconazole,(S); NCGC00016907-01; 83374-59-8; Prestwick_744; CAS-65277-42-1; Tocris-1103; Opera_ID_397; Prestwick0_000389; Prestwick1_000389; Prestwick2_000389; Prestwick3_000389; R 41,400; UPCMLD-DP138; SCHEMBL8407; Lopac0_000666; BSPBio_000577; MLS000758224; MLS001423987; MLS002207053; MLS002222255; BIDD:GT0696; US9150527, Ketoconazole; SPBio_002498; AMY917; BDBM8610; BPBio1_000635; DTXSID7029879; UPCMLD-DP138:001; BDBM60666; HY-B0105A; Ketoconazole, >=98% (HPLC); HMS1569M19; HMS2051A19; HMS2089N05; HMS2096M19; HMS2234H17; HMS3262E13; HMS3414J19; HMS3678J17; HMS3713M19; ZINC643138; BCP28528; Piperazine, (+/-)-1-acetyl-4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-, rel-; Ketoconazole 2.0 mg/ml in Methanol; Tox21_110676; Tox21_300267; Tox21_500666; EI-107; s1353; AKOS007930650; AB02344; CCG-100815; CS-1846; KS-1205; LP00666; MCULE-2726394491; NC00065; SDCCGSBI-0050645.P002; MRF-0000100; 24F2-1,25(OH)D3; NCGC00025000-01; NCGC00025000-02; NCGC00025000-03; NCGC00025000-04; NCGC00025000-05; NCGC00025000-06; NCGC00025000-07; NCGC00025000-08; NCGC00025000-09; NCGC00025000-10; NCGC00025000-14; NCGC00025000-16; NCGC00025000-28; NCGC00253967-01; NCGC00261351-01; (+/-)-cis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine; AC-15957; cis-1-Acetyl-4-[4-[[2-(2,4-; AB0090681; Ketoconazole 100 microg/mL in Acetonitrile; EU-0100666; K0045; SW196888-4; BIM-0050645.0001; J10202; K 1003; W-2941; 277K421; Ketoconazole, Antibiotic for Culture Media Use Only; Q-201267; SR-01000075626-1; SR-01000075626-4; SR-01000597381-1; SR-01000597381-6; BRD-K29113274-001-03-6; BRD-K29113274-001-11-9; BRD-K29113274-001-21-8; Q27121163; Ketoconazole, British Pharmacopoeia (BP) Reference Standard; UNII-R9400W927I component XMAYWYJOQHXEEK-OZXSUGGESA-N; Ketoconazole, European Pharmacopoeia (EP) Reference Standard; Ketoconazole, United States Pharmacopeia (USP) Reference Standard; dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-piperazine; Ketoconazole, Pharmaceutical Secondary Standard; Certified Reference Material; (+/-)-cis-1-Acetyl-4-(4-[(2-[2,4-dichlorophenyl]-2-[1H-imidazol-1-ylmethyl]-1,3-dioxolan-4-yl)-methoxy]phenyl)piperazine; (2R,4S)-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine; 1-(4-(4-(((2R,4S)-2-((1H-imidazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)ethan-1-one; 1-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]ethan-1-one; cis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl] methoxy]phenyl]piperazine; Ethanone, 1-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]-; KZ; Piperazine, (+)-1-acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-	Small molecule	1S/C26H28Cl2N4O4/c1-19(33)31-10-12-32(13-11-31)21-3-5-22(6-4-21)34-15-23-16-35-26(36-23,17-30-9-8-29-18-30)24-7-2-20(27)14-25(24)28/h2-9,14,18,23H,10-13,15-17H2,1H3/t23-,26-/m0/s1	XMAYWYJOQHXEEK-OZXSUGGESA-N	CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl	C26H28Cl2N4O4	CAS 65277-42-1	CHEBI:48336	.	.	.	D0B4IF	.	.	.
DR5040	KML001	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR5051	SP600125	CID: 8515	129-56-6; 1,9-Pyrazoloanthrone; SP600125; Pyrazolanthrone; Dibenzo[cd,g]indazol-6(2H)-one; Pyrazoleanthrone; SP 600125; Anthra[1,9-cd]pyrazol-6(2H)-one; SP-600125; Anthra-1,9-pyrazol-6-none; JNK Inhibitor II; 2H-Dibenzo[cd,g]indazol-6-one; C.I. 70300; ANTHRA(1,9-cd)PYRAZOL-6(2H)-ONE; NSC 75890; UNII-1TW30Y2766; NSC-75890; CHEMBL7064; MLS002693964; 2h-dibenzo(cd,g)indazol-6-one; CHEBI:90695; 1TW30Y2766; NCGC00015958-03; SAPK Inhibitor II; 1pmv; SMR000015440; SR-01000075840; NSC75890; EINECS 204-955-6; BRN 0746890; 2zmd; Kinome_3844; Tocris-1496; BiomolKI_000068; Lopac-S-5567; BiomolKI2_000072; cid_8515; DSSTox_CID_20525; DSSTox_RID_79502; CBiol_002049; DSSTox_GSID_40525; Lopac0_000473; BMK1-G8; BSPBio_001066; ChemBiol10705 Compound 4; KBioGR_000406; KBioSS_000406; cc-622; JMC517015 Compound 2; MLS002153267; MLS006011577; SCHEMBL170980; anthra[1,9-cd]pyrazol-6-one; GTPL5273; CHEMBL1725279; DTXSID2040525; SCHEMBL15583517; BCBcMAP01_000053; BDBM16018; dibenz[cd,g]indazol-6(2h)-one; KBio2_000406; KBio2_002974; KBio2_005542; KBio3_000771; KBio3_000772; Bio1_000335; Bio1_000824; Bio1_001313; Bio2_000373; Bio2_000853; HMS1362F07; HMS1667K13; HMS1792F07; HMS1990F07; HMS2250C03; HMS3229I16; HMS3261O08; HMS3267P06; HMS3295M01; HMS3403F07; HMS3412F05; HMS3654P10; HMS3676F05; HMS3747M19; ALBB-024051; AMY31086; Anthra[1,9cd]pyrazol-6(2H)-one; BCP05457; EX-A1998; Tox21_110267; Tox21_500473; Anthra[1-9-cd]pyrazol-6(2H)-one; ANW-68872; BDBM50024294; BDBM50433916; CCG-47500; Dibenzo[cd,g]indazol-6(2H)-one #; HSCI1_000136; MFCD00022289; NSC755773; s1460; SBB000595; ZINC96298875; AKOS000115584; Anthra[1,9-cd]pyrazol-6(2H)-one;; Anthrapyrazolone; 1,9-Pyrazoloanthrone; CCG-100672; CS-0196; DB01782; LP00473; MCULE-7820194475; NSC-755773; SDCCGSBI-0050458.P003; VA10299; 1,6-dihydrodibenzo[cd,g]indazol-6-one; 2,6-dihydrodibenzo[cd,g]indazol-6-one; IDI1_002128; QTL1_000077; SMP2_000240; NCGC00015958-01; NCGC00015958-02; NCGC00015958-04; NCGC00015958-05; NCGC00015958-06; NCGC00015958-07; NCGC00015958-08; NCGC00015958-22; NCGC00025186-01; NCGC00025186-02; NCGC00025186-03; NCGC00025186-04; NCGC00025186-05; NCGC00261158-01; WLN: T C6665 1A P IV OMNJ; 14,15-diazatetracyclo[7.6.1.0^{2,7}.0^{13,16}]hexadeca-1(15),2(7),3,5,9,11,13(16)-heptaen-8-one; AC-32051; AK-57219; AS-14374; CAS-129-56-6; HY-12041; JNK Inhibitor II - CAS 129-56-6; K914; SMR002530644; ST018684; DB-041928; EU-0100473; FT-0607068; SW218106-2; EN300-02083; Anthra[1,9-cd]pyrazol-6(2H)-one & Z-100; K00068; S 5567; SP600125, >=98% (HPLC); AB00075935-01; SP 600125 & Z-100; 129S566; Q4545713; SR-01000075840-1; SR-01000075840-2; SR-01000075840-4; SR-01000075840-6; SR-01000637108-1; W-108360; BRD-K01567962-001-04-0; BRD-K01567962-001-06-5; BRD-K01567962-001-08-1; BRD-K01567962-001-22-2; Z56785477; F1414-1245; 120093-15-4; 14,15-diazatetracyclo[7.6.1.0;{2,7}.0;{13,16}]hexadeca-1(15),2(7),3,5,9(16),10,12-heptaen-8-one	Small molecule	1S/C14H8N2O/c17-14-9-5-2-1-4-8(9)13-12-10(14)6-3-7-11(12)15-16-13/h1-7H,(H,15,16)	ACPOUJIDANTYHO-UHFFFAOYSA-N	C1=CC=C2C(=C1)C3=NNC4=CC=CC(=C43)C2=O	C14H8N2O	CAS 129-56-6	CHEBI:90695	.	.	.	D02PVB	.	.	.
DR5065	Alpha PD-L1 antibody	.	.	Antibody	.	.	.	.	.	.	.	.	.	.	.	.	.
DR5078	Cephalosporin	CID: 25058126	CEPHALOSPORIN; CHEMBL1235646; Q27465008; (2R)-2-[(R)-{[(6R)-6-amino-6-carboxyhexanoyl]amino}(carboxy)methyl]-5-methylidene-5,6-dihydro-2H-1,3-thiazine-4-carboxylic acid; REC	Small molecule	1S/C15H21N3O7S/c1-7-6-26-12(18-10(7)14(22)23)11(15(24)25)17-9(19)5-3-2-4-8(16)13(20)21/h8,11-12H,1-6,16H2,(H,17,19)(H,20,21)(H,22,23)(H,24,25)/t8-,11+,12-/m1/s1	JGKXEMYIHDYWCZ-JFUSQASVSA-N	C=C1CSC(N=C1C(=O)O)C(C(=O)O)NC(=O)CCCCC(C(=O)O)N	C15H21N3O7S	.	.	.	.	.	D07JVS	.	.	.
DR5094	Methylene blue	CID: 6099	methylene blue; 61-73-4; Basic blue 9; Methylthioninium chloride; Swiss Blue; Solvent blue 8; Chromosmon; 3,7-Bis(dimethylamino)phenothiazin-5-ium chloride; Methylene Blue N; Methylene Blue BB; Methylene Blue anhydrous; Bleu de methylene; Methylene Blue chloride; External Blue 1; Methylene Blue A; Methylene Blue B; Methylene Blue D; Methylene Blue G; C.I. Basic Blue 9; Calcozine Blue ZF; Methylene Blue BD; Methylene Blue BP; Methylene Blue BX; Methylene Blue BZ; Methylene Blue FZ; Methylene Blue GZ; Methylene Blue NZ; Methylene Blue SG; Methylene Blue SP; Methylene Blue ZF; Methylene Blue ZX; Tetramethylene Blue; Methylene Blue 2B; Methylenium ceruleum; Methylene Blue BBA; Methylene Blue BPC; Methylene Blue HGG; Methylene Blue IAD; Methylene Blue JFA; Sandocryl Blue BRL; Methylenblau; Methylene Blue 2BF; Methylene Blue 2BN; Methylene Blue 2BP; M-B Tabs; Rember; Mitsui Methylene Blue; Methylthionium chloride; Leather Pure Blue HB; Methylthionine chloride; Modr methylenova; Schultz No. 1038; Aizen Methylene Blue BH; Aizen Methylene Blue FZ; Methylene Blue polychrome; Methylene Blue Zinc Free; Yamamoto Methylene Blue B; D And C Blue Number 1; Tetramethylthionine chloride; Methylene Blue (Medicinal); Yamamoto Methylene Blue ZF; Ext D and C Blue No. 1; Methylene Blue I (Medicinal); Cloruro de metiltioninio; Methylene Blue NF (Medicinal); Methylthioninii chloridum; Hidaco Methylene Blue Salt Free; Methylene Blue BB (Zinc Free); Methylene Blue USP (Medicinal); Phenothiazin-5-ium, 3,7-bis(dimethylamino)-, chloride; Chlorure de methylthioninium; Methylene Blue USP XII (Medicinal); UNII-8NAP7826UB; Methylene Blue Chloride (Biological stain); C.I. 52015; X 138; 3,7-Bis(dimethylamino)phenazathionium chloride; MFCD00012111; 8NAP7826UB; CHEBI:6872; Urolene blue; Methylene Blue (C.I. 52015); CI 52015; azul de metileno; Phenothiazin-5-ium, 3,7-bis(dimethylamino)-, chloride (1:1); DSSTox_CID_3296; N-[7-(dimethylamino)-3H-phenothiazin-3-ylidene]-N-methylmethanaminium chloride; Ceruleum methylenum; DSSTox_RID_76963; DSSTox_GSID_23296; 12262-49-6; Methylenum coeruleum; CI-52015; CI Basic Blue 9; Caswell No. 567; Methylenblau [German]; Methylthionini chloridum; 3H-Phenothiazine, 3-methochloride; Modr Methylenova [Czech]; CHEMBL405110; Modr zasadita 9; Modr Zasadita 9 [Czech]; CAS-61-73-4; N-(7-(dimethylamino)-3H-phenothiazin-3-ylidene)-N-methylmethanaminium chloride; NSC3089; CCRIS 833; Metiltioninio cloruro [DCIT]; Metiltioninio cloruro; Modr Rozpoustedlova 8 [Czech]; 3H-Phenothiazine, 7-(dimethylamino)-3-(methylimino)-, 3-methochloride; Modr rozpoustedlova 8; NSC215213; NSC617593; C.I. 52 015; HSDB 1405; Methylene Blue, pure, certified, residual water; NSC-215213; NSC-617593; NCGC00167496-01; NCGC00167496-03; Phenothiazin-5-ium,7-bis(dimethylamino)-, chloride; EINECS 200-515-2; Methylthioninii chloridum [INN-Latin]; EPA Pesticide Chemical Code 039505; NSC 215213; Cloruro de metiltioninio [INN-Spanish]; WLN: T C666 BS EY INJ EUK1&1 MN1&1 &G &421; Provayblue; Chlorure de methylthioninium [INN-French]; [7-(dimethylamino)phenothiazin-3-ylidene]dimethylamine, chloride; Lowacryl blue 9; Methylene Azure II; Prestwick_326; Ehrlichs reagent III; Loefflers Methylene Blue; Methylene Blue (Inhibitor); SCHEMBL1351; MLS000719838; DOG (COUCH) GRASS Powder; DTXSID0023296; Methylthioninium chloride [INN]; C.I. Basic Blue 9 (8CI); HMS2598O03; Pharmakon1600-01505444; CI NO 52015; NSC-3089; Tox21_112497; Tox21_302087; NSC759135; s4535; SBB060907; STK018918; AKOS000486124; AKOS015916406; Tox21_112497_1; CCG-267696; DB09241; MCULE-7744087830; NSC-759135; 4-(1-HYDROXY-ETHYL)-BENZOICACID; NCGC00255351-01; 105504-42-5; AC-15225; AK326199; AS-35256; Basic Blue 9;Tetramethylthionine chloride; HY-14536; Methylene Blue, 1% w/v aqueous solution; SMR000304367; ST093058; SY076497; Methylthioninium Chloride (Methylene Blue); Methylene Blue (C.I. 52015) BioChemica; A0574; FT-0622580; M0501; ST50406802; C00220; 3,7-Bis(dimethylamino)-5-phenothiazinium Chloride; Q422134; 3,7-bis(dimethylamino)-phenothiazin-5-ium chloride salt; [7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium;chloride; [7-(dimethylamino)dibenzo[b,e]1,4-thiazin-3-yl]dimethylamine, chloride; 3-N,3-N,7-N,7-N-tetramethylphenothiazin-5-ium-3,7-diamine;chloride; 1341-90-8; 152071-32-4; 6476-03-5; 97130-83-1	Small molecule	1S/C16H18N3S.ClH/c1-18(2)11-5-7-13-15(9-11)20-16-10-12(19(3)4)6-8-14(16)17-13;/h5-10H,1-4H3;1H/q+1;/p-1	CXKWCBBOMKCUKX-UHFFFAOYSA-M	CN(C)C1=CC2=C(C=C1)N=C3C=CC(=[N+](C)C)C=C3S2.[Cl-]	C16H18ClN3S	CAS 61-73-4	CHEBI:6872	.	.	.	D09NYS	.	.	.
DR5145	Prednisolone	CID: 5755	prednisolone; 50-24-8; Metacortandralone; Hydroretrocortine; Predonine; Delta-Cortef; Deltacortril; Meticortelone; Deltahydrocortisone; Prenolone; Hydroretrocortin; PRDL; Deltacortenol; Hydrodeltalone; Hydrodeltisone; Codelcortone; Cortalone; Cotogesic; Decaprednil; Delcortol; Deltisilone; Dicortol; Donisolone; Dydeltrone; Erbacort; Erbasona; Estilsona; Fernisolone; Hydeltra; Hydeltrone; Lentosone; Paracortol; Paracotol; Precortancyl; Precortilon; Precortisyl; Prednelan; Prednicen; Predniliderm; Predonin; Rolisone; Scherisolon; Sterolone; Cordrol; Prednis; Prelone; Steran; Ulacort; Fernisolone P; Hostacortin H; Ultracorten H; Ultracortene-H; Delta-stab; Predne-Dome; Decortin H; CO-Hydeltra; Eazolin D; Meti-Derm; Di-adreson F; Delta F; Derpo PD; 1-Dehydrohydrocortisone; Solone; delta(1)-Hydrocortisone; delta(1)-Dehydrocortisol; Delta-Ef-Cortelan; Dexa-Cortidelt hostacortin H; 1,2-Dehydrohydrocortisone; Prednisolona; Prednisolonum; Prednisolonum [INN-Latin]; Prednisolona [INN-Spanish]; 1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione; (11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione; Ultracortene-hydrogen; Delta(1)-dehydrohydrocortisone; 1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol; UNII-9PHQ9Y1OLM; 3,20-Dioxo-11beta,17alpha,21-trihydroxy-1,4-pregnadiene; 11beta,17,21-Trihydroxypregna-1,4-diene-3,20-dione; K 1557; .DELTA.1-Cortisol; MFCD00003649; .DELTA.1-Hydrocortisone; 9PHQ9Y1OLM; (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one; .DELTA.1-Dehydrocortisol; CHEMBL131; CHEBI:8378; .DELTA.1-Dehydrohydrocortisone; 50-24-8 (free); Predniretard; Poly-Pred; .delta.-Cortef; 1-Dehydrocortisol; Neo-Delta-Cortef; Fernisolone-P; .delta.-Stab; NSC-9120; NSC-9900; Prednisolone, 99%; component of Ataraxoid; 11beta,17alpha,21-Trihydroxypregna-1,4-diene-3,20-dione; Cotolone; Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11b)-; DSSTox_CID_1184; component of K-Predne-Dome; DSSTox_RID_75996; DSSTox_GSID_21184; (1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-5-one; (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one; delta(1)-Cortisol; Deltasolone; Klismacort; Panafcortelone; delta(sup 1)-Cortisol; Bubbli-Pred; delta(sup 1)-Hydrocortisone; delta(sup 1)-Dehydrocortisol; SMR000718761; CCRIS 980; Prednisolone [INN:BAN:JAN]; Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11.beta.)-; HSDB 3385; delta(sup 1)-Dehydrohydrocortisone; MLS002638110; NSC 9120; Pregna-1,20-dione, 11.beta.,17,21-trihydroxy-; EINECS 200-021-7; Predisolone Sodium Phosphate; BRN 1354103; prednisolon; Preflam; Pregna-1,20-dione, 11,17,21-trihydroxy-, (11.beta.)-; CAS-50-24-8; Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-; NCGC00094764-01; delta-hydrocortisone; Prestwick_404; delta-dehydrocortisol; DELTA.1-Cortisol; Delta-Cortef (TN); 11-beta,17,21-Trihydroxypregna-1,4-diene-3,20-dione; T-Pred (Salt/Mix); 1,4-Pregnadien-11-beta,17-alpha,21-triol-3,20-dione; 1,4-Pregnadiene-11-beta,17-alpha,21-triol-3,20-dione; 1,4-Pregnadiene-3,20-dione-11-beta,17-alpha,21-triol; Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-; Prednisolone, >=99%; Prestwick0_000274; Prestwick1_000274; Prestwick2_000274; Prestwick3_000274; delta-dehydrohydrocortisone; EC 200-021-7; SCHEMBL3233; K-Predne-Dome (Salt/Mix); .DELTA.(sup 1)-Cortisol; BSPBio_000148; 4-08-00-03467 (Beilstein Handbook Reference); MLS001304083; MLS002154250; MLS002207037; MLS002548883; SPBio_002367; BPBio1_000164; GTPL2866; DTXSID9021184; .DELTA.(sup 1)-Hydrocortisone; BDBM19190; Prednisolone (JP17/USP/INN); NSC9120; NSC9900; .DELTA.(sup 1)-Dehydrocortisol; HMS1568H10; HMS2090J05; HMS2095H10; HMS2230P10; HMS3259E09; HMS3712H10; BCP09053; ZINC3833821; Tox21_111327; Tox21_201673; Tox21_302987; CP0099; LMST02030179; s1737; .DELTA.(sup 1)-Dehydrohydrocortisone; AKOS015894935; Tox21_111327_1; AC-1773; CCG-220274; DB00860; NC00473; NCGC00179649-01; NCGC00179649-02; NCGC00179649-03; NCGC00179649-04; NCGC00179649-06; NCGC00256577-01; NCGC00259222-01; AS-13665; HY-17463; P0637; EN300-53017; 5948-EP0930075A1; 5948-EP2272832A1; 5948-EP2277565A2; 5948-EP2277566A2; 5948-EP2277567A1; 5948-EP2277568A2; 5948-EP2277569A2; 5948-EP2277570A2; 5948-EP2277861A1; 5948-EP2277865A1; 5948-EP2281815A1; 5948-EP2292280A1; 5948-EP2295426A1; 5948-EP2295427A1; 5948-EP2298778A1; 5948-EP2301933A1; 5948-EP2305219A1; 5948-EP2305248A1; 5948-EP2305663A1; 5948-EP2308562A2; 5948-EP2308880A1; 5948-EP2311827A1; 5948-EP2314585A1; 5948-EP2314590A1; 5948-EP2316832A1; 5948-EP2316833A1; 5948-EP2371811A2; C07369; D00472; J10078; Prednisolone, VETRANAL(TM), analytical standard; 003P649; SR-01000837502; Q-201616; SR-01000837502-2; 11b,17,21-Trihydroxypregna-1,4-diene-3,20-dione; BRD-K98039984-001-03-0; BRD-K98039984-001-06-3; Q11426176; 11beta,17,21-trihydroxy-1,4-pregnadiene-3,20-dione; delta-1-Cortisol; Prednicarbate EP Imp A; Supercortisol; Prednisolone, British Pharmacopoeia (BP) Assay Standard; Z1245633279; 11-.beta.,17,21-Trihydroxypregna-1,4-diene-3,20-dione; 11beta,17alpha,21-Trihydroxy-1,4-pregnadiene-3,20-dione; (11alpha)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione; 1,4-Pregnadien-11-.beta.,17-.alpha.,21-triol-3,20-dione; 1,4-Pregnadiene-11-.beta.,17-.alpha.,21-triol-3,20-dione; 1,4-Pregnadiene-3,20-dione-11-.beta.,17-.alpha.,21-triol; Prednisolone, European Pharmacopoeia (EP) Reference Standard; Pregna-1,4-diene-3,20-dione, 11.beta.,17,21-trihydroxy-; 11,17,21-Trihydroxypregna-1,4-diene-3,20-dione, (11.beta.)-; 11-.beta.,17-.alpha.,21-Trihydroxy-1,4-pregnadiene-3,20-dione; 11-.beta.,17-.alpha.,21-Trihydroxypregna-1,4-diene-3,20-dione; 11.beta.,17.alpha.,21-Trihydroxypregna-1,4-diene-3,20-dione; Prednisolone, United States Pharmacopeia (USP) Reference Standard; Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8CI); Prednisolone for peak identification, European Pharmacopoeia (EP) Reference Standard; Prednisolone for system suitability, European Pharmacopoeia (EP) Reference Standard; Prednisolone, Pharmaceutical Secondary Standard; Certified Reference Material; (1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadeca-3,6-dien-5-one; Prednisolone solution, 100 mug/mL in acetonitrile, ampule of 1 mL, certified reference material; TUA	Small molecule	1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1	OIGNJSKKLXVSLS-VWUMJDOOSA-N	CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O	C21H28O5	CAS 50-24-8	CHEBI:8378	.	.	.	D0D1SG	.	.	.
DR5153	Spironolactone	CID: 5833	spironolactone; 52-01-7; Aldactone; Spirolactone; Verospiron; Euteberol; Spirolang; Verospirone; Spiroctan; Acelat; Aldactone A; Spironocompren; Melarcon; Spiresis; Spiridon; Uractone; Urusonin; Alderon; Spirone; Xenalon; Dira; Spiro-Tablinen; Spironolactone A; spironolattone; Aquareduct; Aldopur; Espironolactona; Spironolactonum; Aldace; Almatol; Deverol; Altex; Berlactone; SC 9420; SC-9420; UNII-27O7W4T232; MFCD00082250; CHEMBL1393; C24H32O4S; CHEBI:9241; Spiro(17H-cyclopenta(a)phenauthrene-17,2'-(3'H)-furan); Spironolattone [DCIT]; 27O7W4T232; NSC-150399; S-[(7R,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate; Spironolactone, 99%; Aldactide; Spiractin; Spironolactonum [INN-Latin]; Espironolactona [INN-Spanish]; DSSTox_CID_14186; DSSTox_RID_79120; DSSTox_GSID_34186; SC 15983; (1'S,2R,2'R,9'R,10'R,11'S,15'S)-9'-(acetylsulfanyl)-2',15'-dimethylspiro[oxolane-2,14'-tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan]-6'-ene-5,5'-dione; S-[(7R,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3,5'-dioxo-1,2,3,4',5',6,7,8,9,10,11,12,13,14,15,16-hexadecahydro-3'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-7-yl] ethanethioate; Spiro[17H-cyclopenta[a]phenauthrene-17,2'-(3'H)-furan]; Diatense; Aldactone (TN); 17-Hydroxy-7-alpha-mercapto-3-oxo-17-alpha-pregn-4-ene-21-carboxylic acid-gamma-lactone-7-acetate; SMR000471892; HSDB 3184; EINECS 200-133-6; NSC 150399; BRN 0057767; spirotone; Spiranolactone; Carospir; 2oax; 3vhu; CAS-52-01-7; NCGC00015948-02; 3-(3-Keto-7.alpha.-acetylthio-17.beta.-hydroxy-4-androsten-17.alpha.-yl)propionic acid lactone; 7-.alpha.-(acetylthio)-17-.alpha.-hydroxy-3-oxopregn-4-ene-21-carboxylic acid, .gamma.-lactone; 7-alpha-Acetylthio-3-oxo-17-alpha-pregn-4-ene-21,17-beta-carbolactone; S-((7R,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3,5'-dioxo-1,2,3,4',5',6,7,8,9,10,11,12,13,14,15,16-hexadecahydro-3'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-7-yl) ethanethioate; Spironolactone [USP:INN:BAN:JAN]; Pregn-4-ene-21-carboxylic acid, 7-(acetylthio)-17-hydroxy-3-oxo-, gamma-lactone, (7alpha,17alpha)-; Prestwick0_000128; Prestwick1_000128; Prestwick2_000128; Prestwick3_000128; 17-Hydroxy-7alpha-mercapto-3-oxo-17alpha-pregn-4-ene-21-carboxylic acid, gamma-lactone acetate; 3'-(3-Oxo-7-alpha-acetylthio-17-beta-hydroxyandrost-4-en-17-beta-yl)propionic acid lactone; 3-(3-Keto-7-alpha-acetylthio-17-beta-hydroxy-4-androsten-17-alpha-yl)propionic acid lactone; BIDD:PXR0071; SCHEMBL20939; BSPBio_000176; 17alpha-Pregn-4-ene-21-carboxylic acid, 17-hydroxy-7alpha-mercapto-3-oxo-, gamma-lactone, acetate; 4-18-00-01601 (Beilstein Handbook Reference); MLS001074672; MLS001333253; MLS001333254; MLS002153245; MLS002207058; MLS002548846; SPBio_002115; BPBio1_000194; GTPL2875; DTXSID6034186; Spironolactone (JP17/USP/INN); HMS1568I18; HMS2090N21; HMS2095I18; HMS2236E06; HMS3259G11; HMS3712I18; ACT02596; AMY40521; HY-B0561; Spironolactone, 97.0-103.0%; ZINC3861599; Tox21_113047; Tox21_302154; 7alpha-(acetylsulfanyl)-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone; BDBM50228080; NSC150399; s4054; 4-Pregnen-21-oic acid-17alpha-ol-3-one-7alpha-thiol gamma-lactone 7-acetate; AKOS015896401; AC-4214; CCG-220128; DB00421; KS-5234; MCULE-4394091100; NC00482; NCGC00164397-01; NCGC00164397-02; NCGC00164397-03; NCGC00164397-05; NCGC00255229-01; 17-alpha-Pregn-4-ene-21-carboxylic acid, 17-hydroxy-7-alpha-mercapto-3-oxo-, gamma-lactone acetate; AK546740; CPD000471892; H490; Spironolactone 1.0 mg/ml in Acetonitrile; AB00513806; S0260; 7080-EP2269989A1; 7080-EP2270011A1; 7080-EP2272841A1; 7080-EP2295406A1; 7080-EP2298772A1; 7080-EP2298776A1; 7080-EP2301936A1; 7080-EP2308562A2; 7080-EP2308839A1; C07310; D00443; AB01275520-01; AB01275520_02; 082S250; Q422188; SR-01000765419; SR-05000000452; Q-201737; SR-01000765419-2; SR-05000000452-2; BRD-K90027355-001-03-4; BRD-K90027355-001-19-0; Z1551900341; Spironolactone, European Pharmacopoeia (EP) Reference Standard; WLN: L E5 B666 FX OV MUTJ A1 E1 KSV1 F-& CT5VOXTJ; 17.alpha.-Pregn-4-ene-21-carboxylic acid, .gamma.-lactone acetate; Spironolactone, United States Pharmacopeia (USP) Reference Standard; 17.alpha.-Pregn-4-ene-21-carboxylic acid, .gamma.-lactone, acetate; Pregn-4-ene-21-carboxylic acid, .gamma.-lactone, (7.alpha.,17.alpha.)-; (7?,17?)-7-(Acetylthio)-17-hydroxy-3-oxopregn-4-ene-21-carboxylic acid ?-lactone; 7alpha-(Acetylthio)-17alpha-hydroxy-3-oxopregn-4-ene-21-carboxylic acid gamma-lactone; Spironolactone for system suitability, European Pharmacopoeia (EP) Reference Standard; 17-HYDROXY-7ALPHA-MERCAPTO-3-OXO-17ALPHA-PREGN-4-ENE-21- CARBOXYLIC ACID; GAMMA-LACTONE ACETATE; 2'',15''-dimethyl-5,5''-dioxo-(9''R)-spiro[tetrahydrofuran-2,14''-tetracyclo[8.7.0.02,7.011,15]heptadec-6''-ene]-9-yl ethanethioate; 2'',15''-dimethyl-5,5''-dioxospiro[tetrahydrofuran-2,14''-tetracyclo[8.7.0.02,7.011,15]heptadec-6''-ene]-9-yl ethanethioate; 2'',15''-dimethyl-5,5''-dioxospiro[tetrahydrofuran-2,14''-tetracyclo[8.7.0.02,7.011,15]heptadec-6''-ene]-9-yl ethanethioate(Spiranolactone); 7-alpha-(acetylthio)-17-alpha-hydroxy-3-oxopregn-4-ene-21-carboxylic acid, gamma-lactone (9CI); S-(2''R,7R,8R,9S,10R,13S,14S)-10,13-dimethyl-3,5''-dioxo-1,2,3,4'',5'',6,7,8,9,10,11,12,13,14,15,16-hexadecahydro-3''H-spiro[cyclopenta[a]phenanthrene-17,2''-furan]-7-yl ethanethioate	Small molecule	1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1	LXMSZDCAJNLERA-ZHYRCANASA-N	CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C	C24H32O4S	CAS 52-01-7	CHEBI:9241	.	.	.	D0EP0C	.	.	.
DR5175	Difluoromethylornithine	CID: 3009	EFLORNITHINE; 70052-12-9; Ornidyl; 2-(Difluoromethyl)ornithine; dfmo; Difluoromethylornithine; 2,5-diamino-2-(difluoromethyl)pentanoic acid; Vaniqa; alpha-Difluoromethylornithine; alpha-(Difluoromethyl)-DL-ornithine; 67037-37-0; 2-(Difluoromethyl)-DL-ornithine; Difluromethylornithine; Eflornithine free base; RMI 71782; (RS)-eflornithine; DL-.alpha.-Difluoromethylornithine; CHEMBL830; DFMO HCl; CHEBI:41948; 70052-12-9 (free base); NSC337250; Eflornithinum; Eflornitina; Eflornithinum [Latin]; Eflornitina [Spanish]; 2,5-diamino-2-(difluoromethyl)pentanoic acid.; .alpha.-DFMO HCl; DFMO (growth regulator); Eflornithine [INN:BAN]; L-DFMO;L-RMI71782;L-alpha-difluoromethylornithine; DL-alpha-(Difluoromethyl)ornithine; DL-Ornithine, monohydrochloride; MDL 71782; Eflornithine (INN); CCRIS 3295; Ornithine, 2-(difluoromethyl)-; NSC-337250; 70050-56-5; DL-Ornithine, 2-(difluoromethyl)-; BRN 2250529; alpha,delta-Diamino-alpha-(difluoromethyl)valeric acid; D-Ornithine, 2-(difluoromethyl)-; C6H12F2N2O2; HSDB 7923; alpha-DFMO; 66640-93-5; RFI 7178; ACMC-20m6r1; Lopac0_000429; SCHEMBL26327; GTPL5176; 2-(difluoromethyl)-L-ornithine; alpha-difluoromethyl-dl-ornithine; DTXSID3020467; H-DL-(a-Difluoromethyl)Orn-OH; BCP10516; HY-B0744; 2-(difluoromethyl)ornithine (DMFO); BDBM50028197; HSCI1_000267; KM1060; MFCD00221766; AKOS006281180; CCG-204521; DB06243; SDCCGSBI-0050414.P002; NCGC00015316-02; NCGC00015316-03; NCGC00015316-06; NCGC00015316-15; NCGC00162152-01; K100; 2-difluoromethyl-2,5-diaminopentanoic acid; DB-055371; FT-0630795; FT-0720946; FT-0775156; 2-(difluoromethyl)-2,5-diaminopentanoic acid;; C07997; D07883; 020E916; Q424751; (RS)-2,5-diamino-2-(difluoromethyl)pentanoic acid; DFMO;MDL71782;RMI71782;; A-difluoromethylornithine	Small molecule	1S/C6H12F2N2O2/c7-4(8)6(10,5(11)12)2-1-3-9/h4H,1-3,9-10H2,(H,11,12)	VLCYCQAOQCDTCN-UHFFFAOYSA-N	C(CC(C(F)F)(C(=O)O)N)CN	C6H12F2N2O2	CAS 70052-12-9	CHEBI:41948	.	.	.	D0X7JR	.	.	.
DR5200	Glibenclamide	CID: 3488	glyburide; Glibenclamide; 10238-21-8; Glybenclamide; Glynase; Micronase; Diabeta; Daonil; Euglucon; Maninil; Semi-daonil; Apo-Glibenclamide; Euglucon 5; Azuglucon; Bastiverit; Benclamin; Betanase; Duraglucon; Euglucan; Euglykon; Glibenil; Glucolon; Orabetic; Prodiabet; Renabetic; Yuglucon; Dibelet; Gilemal; Glibens; Glibil; Glimel; Glimide; Humedia; Libanil; Suraben; Tiabet; Adiab; Glybenzcyclamide; Melix; Pira; Med-Glionil; Glibenclamida; Glibenclamidum; 5-Chloro-N-(4-(N-(cyclohexylcarbamoyl)sulfamoyl)phenethyl)-2-methoxybenzamide; Glibenclamidum [INN-Latin]; Glibenclamida [INN-Spanish]; HB 419; glyburide (glibenclamide); C23H28ClN3O5S; UR 606; UNII-SX6K58TVWC; 1-(p-(2-(5-Chloro-2-methoxybenzamido)ethyl)benzenesulfonyl)-3-cyclohexylurea; 1-((p-(2-(5-Chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexylurea; Neogluconin; 5-Chloro-N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-methoxybenzamide; U 26452; 5-chloro-N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide; Gewaglucon; Glibenbeta; Glidiabet; Glucobene; Glucohexal; Glucoremed; Hexaglucon; Lederglib; Lisaglucon; Normoglucon; Praeciglucon; Calabren; Cytagon; Euclamin; Glamide; Glibesyn; Glibetic; Gliboral; Glisulin; Glitisol; Glubate; Glucomid; Glucoven; Glycomin; MFCD00056625; Miglucan; Debtan; Gliban; Gliben; Glibet; Glicem; Gluben; Glyben; Nadib; Sugril; SX6K58TVWC; CHEMBL472; Novo-Glyburide; Glibenclamid AL; Gen-Glybe; Norglicem 5; Betanese 5; N-(4-(2-(5-Chloro-2-methoxybenzamido)ethyl)phenylsulfonyl)-N'-cyclohexylurea; Glibenclamid Fabra; MLS000069721; CHEBI:5441; Glibenclamid Basics; Glibenclamid-Cophar; Glibenclamid Heumann; Semi-Euglucon; Glibenclamid Genericon; Hemi-Daonil; Glibenclamid-Ratiopharm; 5-chloro-N-(2-{4-[(cyclohexylcarbamoyl)sulfamoyl]phenyl}ethyl)-2-methoxybenzamide; Urea, 1-(p-(2-(5-chloro-2-methoxybenzamido)ethyl)benzenesulfonyl)-3-cyclohexyl-; Benzamide, 5-chloro-N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-methoxy-; NCGC00015467-11; Abbenclamide; Diabiphage; Glibadone; SMR000058229; Semi-Gliben-Puren N; GBN 5; CAS-10238-21-8; Glibenclamid Riker M.; Glyburide (micronized); 5-Chloro-N-[4-(cyclohexylureidosulfonyl)phenethyl]-2-methoxybenzamide; Urea, 1-((p-(2-(chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexyl-; 5-chloro-N-[2-(4-{[(cyclohexylcarbamoyl)amino]sulfonyl}phenyl)ethyl]-2-methoxybenzamide; 5-Chloro-N-[2-[4-[[[(cyclohexylamino)carbonyl]-amino]sulfonyl]phenyl]-ethyl]-2-methoxybenzamide; DSSTox_CID_17237; DSSTox_RID_79313; DSSTox_GSID_37237; Benzamide, 5-chloro-N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-methoxy-; Micronized glyburide; U-26,452; Glycron; 1-[[p-[2-(5-Chloro-o-anisamido)ethyl]phenyl]sulfonyl]-3-cyclohexylurea; 5-chloro-N-(2-{4-[N-(N-cyclohexylcarbamoyl)sulfamoyl]phenyl}ethyl)-2-methoxybenzamide; 5-Chloro-N-(4-(N-(cyclohexylcarbamoyl)sulfamoyl)-phenethyl)-2-methoxybenzamide; Glyburide (USP); Micronase (TN); HB-419; 1-{4-[2-(5-chloro-2-methoxybenzamido)ethyl]benzenesulfonyl}-3-cyclohexylurea;1-{4-[2-(5-chloro-2-methoxybenzamido)ethyl]benzenesulfonyl}-3-cyclohexylurea; Diabeta (TN); Glynase (TN); SR-01000000196; Glyburide [USAN:USP]; EINECS 233-570-6; BRN 2230085; Amglidia; Delmide; 5-chloro-N-(4-[N-(cyclohexylcarbamoyl)sulfamoyl]phenethyl)-2-methoxybenzamide; Glibenclamide,(S); GBM; Prestwick_569; Glibenclamide B.P.; Glyburide (Diabeta); Glibenclamide [INN]; RP-1127; Spectrum_000250; Tocris-0911; Glybenzcyclamide, 99%; Glibenclamide; Glyburide; Opera_ID_801; Prestwick0_000316; Prestwick1_000316; Prestwick2_000316; Prestwick3_000316; Spectrum2_001816; Spectrum3_001327; Spectrum4_001199; Spectrum5_001631; Lopac-G-0639; ACMC-20a66i; Probes1_000431; Probes2_000378; UPCMLD-DP006; G 0639; Glibenclamide (JP17/INN); N-(4-(beta-(2-Methoxy-5-chlorbenzamido)-aethyl)-benzolsulfonyl)-N'-cyclohexyl-harnstoff; CBiol_001790; Lopac0_000499; Oprea1_764617; SCHEMBL22009; U-26452; BSPBio_000312; BSPBio_001351; BSPBio_003053; KBioGR_000071; KBioGR_001897; KBioSS_000071; KBioSS_000730; MLS001077262; BIDD:GT0239; DivK1c_000481; SPECTRUM2300229; SPBio_001831; SPBio_002531; BPBio1_000344; GTPL2414; DTXSID0037237; UPCMLD-DP006:001; HMS501I03; KBio1_000481; KBio2_000071; KBio2_000730; KBio2_002639; KBio2_003298; KBio2_005207; KBio2_005866; KBio3_000141; KBio3_000142; KBio3_002273; AOB6214; SYN3026; Glybenclamide, >=99% (HPLC); NINDS_000481; Bio1_000076; Bio1_000565; Bio1_001054; Bio2_000071; Bio2_000551; HMS1361D13; HMS1568P14; HMS1791D13; HMS1922L08; HMS1989D13; HMS2089L06; HMS2093P04; HMS2095P14; HMS3259O12; HMS3261D19; HMS3267A15; HMS3402D13; HMS3411F16; HMS3428D15; HMS3651E17; HMS3675F16; HMS3712P14; Pharmakon1600-02300229; ZINC537805; BCP05327; Tox21_110158; Tox21_300758; Tox21_500499; ANW-58936; BDBM50012957; CCG-39618; HD 419; NSC759618; SBB057426; STK362992; Glyburide - CAS 10238-21-8; AKOS001487495; N-p-[2-(5-Chloro-2-methoxybenzamido)ethyl]benzenesulfonyl-N'-cyclohexylurea; Tox21_110158_1; BCP9000729; CS-1075; DB01016; KS-5326; LP00499; MCULE-2351642942; NC00566; NSC 759618; NSC-759618; SB17414; SDCCGSBI-0050483.P004; IDI1_000481; IDI1_033821; Glibenclamide 1.0 mg/ml in Acetonitrile; NCGC00015467-01; NCGC00015467-02; NCGC00015467-03; NCGC00015467-04; NCGC00015467-05; NCGC00015467-06; NCGC00015467-07; NCGC00015467-08; NCGC00015467-09; NCGC00015467-10; NCGC00015467-12; NCGC00015467-13; NCGC00015467-14; NCGC00015467-15; NCGC00015467-16; NCGC00015467-17; NCGC00015467-18; NCGC00015467-20; NCGC00015467-21; NCGC00015467-36; NCGC00015467-37; NCGC00016689-01; NCGC00023447-02; NCGC00023447-04; NCGC00023447-05; NCGC00023447-06; NCGC00023447-07; NCGC00023447-08; NCGC00023447-09; NCGC00023447-10; NCGC00023447-11; NCGC00023447-12; NCGC00254662-01; NCGC00261184-01; HY-15206; ST024780; SBI-0050483.P003; AB0012611; Glyburide, meets USP testing specifications; AB00051949; EU-0100499; FT-0601608; G-150; G0382; S1716; SW195828-5; A19539; C07022; D00336; J10021; W-5054; 78637-EP2270001A1; 78637-EP2270011A1; 78637-EP2272825A2; 78637-EP2272841A1; 78637-EP2275414A1; 78637-EP2287165A2; 78637-EP2287166A2; 78637-EP2292620A2; 78637-EP2298750A1; 78637-EP2298776A1; 78637-EP2298779A1; 78637-EP2301923A1; 78637-EP2301936A1; 78637-EP2305648A1; 78637-EP2308847A1; AB00051949-16; AB00051949-17; AB00051949_18; AB00051949_19; Q420626; U-26,45; SR-01000000196-2; SR-01000000196-4; SR-01000000196-5; SR-01000000196-6; SR-01000000196-8; W-108874; BRD-K36927236-001-06-0; BRD-K36927236-001-17-7; Z277540138; Glybenclamide, European Pharmacopoeia (EP) Reference Standard; Glyburide, United States Pharmacopeia (USP) Reference Standard; 1-((p-(2-(5-Chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexyl urea; 5-Chloro-N-[4-(3-cyclohexylureidosulfonyl)phenethyl]-2-methoxybenzamide; 5-chloro-N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide.; 5-chloro-N-[4-({[(cyclohexylamino)carbonyl]amino}sulfonyl)phenethyl]-2-methoxybenzamide; Glibenclamide for peak identification, European Pharmacopoeia (EP) Reference Standard; Glyburide (Glibenclamide), Pharmaceutical Secondary Standard; Certified Reference Material; N-(4-(.beta.-(2-Methoxy-5-chlorbenzamido)-aethyl)-benzolsulfonyl)-N'-cyclohexyl-harnstoff; N1-[4-({[(cyclohexylamino)carbonyl]amino}sulfonyl)phenethyl]-5-chloro-2-methoxybenzamide; (5-chloro-2-methoxyphenyl)-N-[2-(4-{[(cyclohexylamino)carbonylamino]sulfonyl}p henyl)ethyl]carboxamide; 5-Chloro-N-(2-[4-(([(cyclohexylamino)carbonyl]amino)sulfonyl)phenyl]ethyl)-2-methoxybenzamide #; 5-Chloro-N-[2-[4-[[[(Cylcohexylamino)carbonyl]amino]sulphonyl]phenyl]ethyl]-2-methoxybenzamide; N-[(4-{2-[(5-chloro-2-methoxyphenyl)carbonylamino]ethyl}phenyl)sulfonyl](cyclo hexylamino)carboxamide	Small molecule	1S/C23H28ClN3O5S/c1-32-21-12-9-17(24)15-20(21)22(28)25-14-13-16-7-10-19(11-8-16)33(30,31)27-23(29)26-18-5-3-2-4-6-18/h7-12,15,18H,2-6,13-14H2,1H3,(H,25,28)(H2,26,27,29)	ZNNLBTZKUZBEKO-UHFFFAOYSA-N	COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3	C23H28ClN3O5S	CAS 10238-21-8	CHEBI:5441	.	.	.	D05LYX	.	.	.
DR5221	Cetuximab	.	Erbitux; Cetuximab (genetical recombination); Erbitux (TN); Cetuximab (USAN/INN); Cetuximab (genetical recombination) (JAN); novel EGFR mAb inhibitors	Antibody	.	.	.	.	.	.	.	.	.	D0N5OV	.	.	Cetuximab
DR5269	Hypothermia	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR5291	4-hydroxy-tamoxifen	CID: 5284643	4'-hydroxytamoxifen; 82413-23-8; 4-Hydroxy-tamoxifen; (Z)-4'-hydroxytamoxifen; CHEMBL10041; trans-Hydroxytamoxifen; 4-[(Z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol; 4-HT; 4-{(1Z)-1-[{4-[2-(dimethylamino)ethoxy]phenyl}(phenyl)methylene]propyl}phenol; 4Hydroxy Tamoxifen; NCGC00091028-01; GTPL2817; SCHEMBL2165503; DTXSID00873019; ZINC8602413; BDBM50180684; NCGC00091028-02; Q27073761; 4 inverted exclamation mark -Hydroxy Tamoxifen (contains up to 10% E isomer); 4-[(Z)-1-[4-(2-dimethylaminoethyloxy)phenyl]-1-phenylbut-1-en-2-yl] phenol; 4HT	Small molecule	1S/C26H29NO2/c1-4-25(20-10-14-23(28)15-11-20)26(21-8-6-5-7-9-21)22-12-16-24(17-13-22)29-19-18-27(2)3/h5-17,28H,4,18-19H2,1-3H3/b26-25-	DODQJNMQWMSYGS-QPLCGJKRSA-N	CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCN(C)C)C3=CC=C(C=C3)O	C26H29NO2	CAS 82413-23-8	.	.	.	.	D0B4VV	.	.	.
DR5354	Triptorelin	CID: 25074470	TRIPTORELIN; 57773-63-4; Triptoreline; Decapeptyl; (D-Trp6)-GnRH; Triptorelina; Triptorelinum; Trelstar; Triptodur; Diphereline; (6-D-Tryptophan)luteinizing hormone-releasing hormone; CL 118532; CL-118532; pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2; AY-25650; Luteinizing hormone-releasing factor (pig), 6-D-tryptophan; CL 118,532; CHEBI:63633; Pamorelin; Trelstar depot; 5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-L-prolylglycinamide; Trelstar LA; Arvekap; Diferelin; Luteinizing hormone-releasing factor (swine), 6-D-tryptophan-; UNII-08AN7WA2G0; 08AN7WA2G0; D-Tryptophan-LH-RH; Wy 42462; Triptoreline [INN-French]; Triptorelinum [INN-Latin]; Triptorelina [INN-Spanish]; AY 25650; Salvacyl; Trellasar; Moapar; Triptorelin [USAN:INN:BAN]; Decapeptyl SR; Pamorelin LA; UNII-9081Y98W2V; Triptorelin (swine); BIM 21003; Wy 42422; Wy-42462; D-Trp6-LHRH; Debio-8206; Triptorelin (USAN/INN); (D-Trp6)-LH-RH; GTPL1177; SCHEMBL5079698; CHEMBL1201334; SCHEMBL22289009; HMS2090C17; EX-A3857; BIM-21003; AKOS030213249; 9081Y98W2V; CS-5745; DB06825; NCGC00167301-01; NCGC00167301-02; AK552887; AS-71149; BN-52014; HY-12551; 73T634; D06247; [D-Trp6]-LH-RH, >=97% (HPLC), powder; AB01275488-01; pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-GlyNH2; Q1992452; (S)-1-((3S,6S,9S,12S,15R,18S,21S)-3-((1H-imidazol-5-yl)methyl)-6,15-bis((1H-indol-3-yl)methyl)-21-(3-guanidinopropyl)-12-(4-hydroxybenzyl)-9-(hydroxymethyl)-18-isobutyl-1,4,7,10,13,16,19-heptaoxo-1-((S)-5-oxopyrrolidin-2-yl)-2,5,8,11,14,17,20-heptaazadocosan-22-oyl)-N-(2-amino-2-oxoethyl)pyrrolidine-2-carboxamide	Small molecule	1S/C64H82N18O13/c1-34(2)23-46(56(88)75-45(13-7-21-69-64(66)67)63(95)82-22-8-14-52(82)62(94)72-31-53(65)85)76-58(90)48(25-36-28-70-42-11-5-3-9-40(36)42)78-57(89)47(24-35-15-17-39(84)18-16-35)77-61(93)51(32-83)81-59(91)49(26-37-29-71-43-12-6-4-10-41(37)43)79-60(92)50(27-38-30-68-33-73-38)80-55(87)44-19-20-54(86)74-44/h3-6,9-12,15-18,28-30,33-34,44-52,70-71,83-84H,7-8,13-14,19-27,31-32H2,1-2H3,(H2,65,85)(H,68,73)(H,72,94)(H,74,86)(H,75,88)(H,76,90)(H,77,93)(H,78,89)(H,79,92)(H,80,87)(H,81,91)(H4,66,67,69)/t44-,45-,46-,47-,48+,49-,50-,51-,52-/m0/s1	VXKHXGOKWPXYNA-PGBVPBMZSA-N	CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8	C64H82N18O13	CAS 57773-63-4	CHEBI:63633	.	.	.	D03QRS	.	.	.
DR5364	Alogliptin	CID: 11450633	Alogliptin; 850649-61-5; UNII-JHC049LO86; Alogliptin (SYR-322); (R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile; 2-({6-[(3r)-3-Aminopiperidin-1-Yl]-3-Methyl-2,4-Dioxo-3,4-Dihydropyrimidin-1(2h)-Yl}methyl)benzonitrile; JHC049LO86; CHEBI:72323; 2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl}methyl)benzonitrile; alogliptina; vipidia; 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]benzonitrile; Alogliptin [INN]; alogliptine; alogliptinum; SYR322; HSDB 8203; SCHEMBL121028; CHEMBL376359; GTPL6319; BDBM16285; HY-A0023A; DTXSID90234130; AMY22119; Alogliptin pound SYR-322 pound(c); MFCD09833196; s2868; s5365; ZINC14961096; AKOS025149226; CCG-267914; CCG-267915; CS-1617; DB06203; SB20301; 2-((6-((3R)-3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl) benzonitrile; AC-26300; AS-19582; SW219186-1; Y1123; Q-4517; Q4734170; BRD-K83003151-057-02-4; 2-{6-[3(R)-Amino-piperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl}-benzonitrile	Small molecule	1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1	ZSBOMTDTBDDKMP-OAHLLOKOSA-N	CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCCC(C3)N	C18H21N5O2	CAS 850649-61-5	CHEBI:72323	.	.	.	D0NJ5H	.	.	.
DR5410	Recombinant mutant human TRAIL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR5481	3-bromopyruvate	CID: 70684	3-bromopyruvic acid; bromopyruvic acid; 1113-59-3; 3-bromo-2-oxopropanoic acid; 3-Bromo-2-oxopropionic acid; bromopyruvate; 3-bromopyruvate; Bromopyruvicacid; Pyruvic acid, bromo-; Propanoic acid, 3-bromo-2-oxo-; UNII-63JMV04GRK; MFCD00002587; .beta.-Bromopyruvic acid; 63JMV04GRK; 3-bromo-2-oxo-propionic acid; C3H3BrO3; 3-BrPA; EINECS 214-206-5; NSC 11731; NSC 62343; BRN 1746786; BPV; bromo-2-oxopropanoic acid; ACMC-1C0WT; SCHEMBL8126; NCIOpen2_000241; 3-BP; 3-bromo-2-keto-propionic acid; CHEMBL177837; 3-Bromo-2-oxopropanoic acid #; 3-Bromopyruvic acid hydrate,98; DTXSID7040940; CHEBI:95046; CHEBI:131461; Hexokinase II Inhibitor II;3-BP; HMS3741K19; HMS3866H13; ACT09279; NSC11731; NSC62343; ZINC1718542; ANW-43645; NSC-11731; NSC-62343; NSC782120; s5426; SBB053571; Bromopyruvic acid, >=97.0% (T); AKOS015892643; AM84337; CCG-266336; CS-5517; MCULE-4768170572; NSC-782120; AS-16146; DA-15474; HY-19992; S691; AK00558616; B1153; FT-0623262; ST51037166; EN300-67360; A-2150; Bromopyruvic acid; 3-bromo-2-oxopropanoic acid; J-511892; J-650255; Q3608257; BRD-K92980438-001-01-7; Hexokinase II Inhibitor II, 3-BP - CAS 1113-59-3; Z2690354216	Small molecule	1S/C3H3BrO3/c4-1-2(5)3(6)7/h1H2,(H,6,7)	PRRZDZJYSJLDBS-UHFFFAOYSA-N	C(C(=O)C(=O)O)Br	C3H3BrO3	CAS 1113-59-3	CHEBI:95046	.	.	.	.	.	.	.
DR5502	BIIB021	CID: 16736529	BIIB021; 848695-25-0; 6-chloro-9-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-9H-purin-2-amine; BIIB-021; CNF2024; BIIB 021; UNII-851B9FQ7Q0; CNF-2024; 6-Chloro-9-[(4-Methoxy-3,5-Dimethylpyridin-2-Yl)methyl]-9h-Purin-2-Amine; CHEMBL467399; CHEBI:90687; 851B9FQ7Q0; 6-chloro-9-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]purin-2-amine; CNF 2024; 848695-25-0 (free base); (6-Chloro-9-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-9h-purin-2-yl)amine; [6-Chloro-9-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-9H-purin-2-yl]amine; 6-chloro-9-((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)-9h-purin-2-amine; 6-chloro-9-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethyl)-9H-purin-2-ylamine; 6-Chloro-9-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-9h-purin-2-amine; 94M; 3qdd; BIIB021, Free Base; cc-544; MLS006011080; GTPL9258; SCHEMBL1791028; BIIB021,CNF2024; BIIB021/CNF2024; BDBM20800; AOB4502; EX-A681; QCR-185; BIIB021(CNF2024); BIIB021; CNF2024; BCPP000335; HMS3654G16; BCP02111; 2-amino-6-halopurine analogue, 20; ABP000837; ANW-70835; MFCD15528939; NSC773265; s1175; ZINC14974583; 9H-purin-2-amine, 6-chloro-9-((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)-; AKOS015969048; BCP9000411; CCG-264848; CS-0168; DB12359; NSC-773265; SB16641; NCGC00247877-01; AC-32860; AK104952; AS-55914; HY-10212; SMR004702868; AB0008087; FT-0696777; SW220186-1; X7555; W-5597; J-518605; BRD-K51967704-001-01-0; Q27075249	Small molecule	1S/C14H15ClN6O/c1-7-4-17-9(8(2)11(7)22-3)5-21-6-18-10-12(15)19-14(16)20-13(10)21/h4,6H,5H2,1-3H3,(H2,16,19,20)	QULDDKSCVCJTPV-UHFFFAOYSA-N	CC1=CN=C(C(=C1OC)C)CN2C=NC3=C2N=C(N=C3Cl)N	C14H15ClN6O	CAS 848695-25-0	CHEBI:90687	.	.	.	D05HWN	.	.	.
DR5586	Gamma-ray irradiation	.	.	Radiotherapy	.	.	.	.	.	.	.	.	.	.	.	.	.
DR5598	Amphotericin B	CID: 5280965	amphotericin b; 1397-89-3; Amphotericine B; Amphotericin; Fungizone; Amfotericina B; Amphotericinum B; AMPH-B; Liposomal Amphotericin B; Amphotericin-B; Ambisome; Fungilin; Abelcet; Ampho-Moronal; UNII-7XU7A7DROE; Amphotec; MFCD00877763; 7XU7A7DROE; NCGC00090808-01; Abelecet; Halizon; DSSTox_CID_2601; DSSTox_RID_76653; DSSTox_GSID_22601; (1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-[(3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy]-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid; Amphotericin B trihydrate; C47H73NO17; Amphortericin B; Anfotericine B; Amphotericin b deoxycholate; IAB; NSC 527017; Fungisome; Amfotericina B [INN-Spanish]; Amphotericine B [INN-French]; Amphotericinum B [INN-Latin]; CCRIS 5963; HSDB 3008; Amphotericin B [USP:INN:JAN]; Fungizone (TN); Amphotec (TN); (1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-(((2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid; (1S,3R,4E,6E,8E,10E,12E,14E,16E,18S,19R,20R,21S,25R,27R,30R,31R,33S,35R,37S,38R)-3-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,12,14,16-heptaene-38-carboxylic acid; AmBisome (TN); Amp B; CAS-1397-89-3; EINECS 215-742-2; NS 718; BRN 0078342; AI3-26528; Prestwick3_000410; Amphotericin B solubilized; SCHEMBL17973; BSPBio_000340; 5-18-10-00525 (Beilstein Handbook Reference); BIDD:GT0351; BPBio1_000374; NKTR-024; Amphotericin B and cinnamon oil; DTXSID9022601; HMS2096A22; HMS3713A22; Amphotericin B (JP17/USP/INN); HY-B0221; Amphotericin B, Streptomyces nodosus; Tox21_111027; Tox21_202484; Amphotericin B from Streptomyces sp.; BRL-49594; LMPK06000002; s1636; AKOS024464746; ZINC253387843; CCG-220410; DB00681; NCGC00260033-01; (1R-(1R*,3S*,5R*,6R*,9R*,11R*,15S*,16R*,17R*,18S*,19E,21E,23E,25E,27E,29E,31E,33R*,35S*,36R*,37S*))-33-((3-Amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy)-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo(33.3.1)nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid; 14,39-Dioxabicyclo(33.3.1)nonatriaconta-19,21,23,25,2 7,29,31-heptaene-36-carboxylic acid, 33-((3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy)-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-(1R-(1R*,3S*,5R*,6R*,9R*,11R*,15S*,16R*,17R*,18S*,19E,21E,23E, 25E-27E,29E,31E,33R*,35S*,36R*,37S*))-; AB00513832; C06573; D00203; J10140; AB00513832_02; 397A893; Q412223; 1397-89-3, C47H73NO17; Amphotericin B from Streptomyces sp., ~80% (HPLC), powder; Amphotericin B from Streptomyces sp., BioReagent, suitable for cell culture, ~80% (HPLC); Amphotericin B solubilized, powder, gamma-irradiated, BioXtra, suitable for cell culture; (1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid; (1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-[(3-Amino-3,6-dideoxy-?-D-mannopyranosyl)oxy]-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid; (1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-[(3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy]-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-he; (1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-[(3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy]-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-hept; (1S,3R,4E,6E,8E,10E,12E,14E,16E,18S,19R,20R,21S,25R,27R,30R,31R,33S,35R,37S,38R)-3-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-; 23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,12,14,16-heptaene-38-carboxylic acid; Amphotericin B from Streptomyces sp., Vetec(TM) reagent grade, BioReagent, suitable for cell culture, ~80%; Amphotericin B solution, 250 mug/mL in deionized water, sterile-filtered, BioReagent, suitable for cell culture	Small molecule	1S/C47H73NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-33(51)22-36(53)35(52)20-19-31(49)21-32(50)23-39(55)62-29(3)28(2)42(27)56/h5-18,27-38,40-44,46,49-54,56-58,61H,19-26,48H2,1-4H3,(H,59,60)/b6-5+,9-7+,10-8+,13-11+,14-12+,17-15+,18-16+/t27-,28-,29-,30+,31+,32+,33-,34-,35+,36+,37-,38-,40+,41-,42+,43+,44-,46-,47+/m0/s1	APKFDSVGJQXUKY-INPOYWNPSA-N	CC1C=CC=CC=CC=CC=CC=CC=CC(CC2C(C(CC(O2)(CC(CC(C(CCC(CC(CC(=O)OC(C(C1O)C)C)O)O)O)O)O)O)O)C(=O)O)OC3C(C(C(C(O3)C)O)N)O	C47H73NO17	CAS 1397-89-3	.	.	.	.	D02DWM	.	.	.
DR5601	Lovastatin	CID: 53232	lovastatin; 75330-75-5; mevinolin; Mevacor; MK-803; Altoprev; Lovalord; Nergadan; Artein; 6alpha-Methylcompactin; Lovalip; Monacolin K; Lovastatine [French]; Lovastatinum [Latin]; Lovastatina [Spanish]; 6-alpha-Methylcompactin; Lovastatine; Mevinacor; Altocor; Hipovastin; Lovasterol; Cholestra; Closterol; Colevix; Hipolip; Lestatin; Lipivas; Lipofren; Lovastin; Lozutin; Paschol; Rodatin; Rovacor; Tecnolip; Teroltrat; Belvas; Lipdip; Mevlor; Sivlor; Taucor; UNII-9LHU78OQFD; MLS000069585; MSD 803; MFCD00072164; 9LHU78OQFD; MK 803; 2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone; SMR000058779; (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate; (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate; CHEBI:40303; L-154803; Lovastatin, 98%; Lovastatin (Mevacor); (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-(2-(2R,4R)-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl (S)-2-methyl-butyrate; HSDB 6534; NCGC00023509-03; Lovastatina; Lovastatinum; C24H36O5; DSSTox_CID_784; butanoic acid, 2-methyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester, (2S)-; DSSTox_RID_75788; DSSTox_GSID_20784; Liposcler; 6 alpha-Methylcompactin; Rextat; Monakolin K; (1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (S)-2-methylbutanoate; (S)-(1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-Hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2-methylbutanoate; Mevacor (TN); CHEMBL503; Lovastatin & Primycin; Lovastatin (USP/INN); SR-05000001880; (1S-(1alpha(R*),3alpha,7beta,8beta(2S*,4S*),8abeta))-2-Methylbutanoic acid 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester; (S)-2-Methylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one; [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate; 1,2,6,7,8,8a-Hexahydro-beta,delta-dihydroxy-2,6-dimethyl-8-(2-methyl-1-oxobutyoxy)-1-naphthaleneheptanoic acid delta-lactone; BRN 3631989; Mevinolin from Aspergillus sp.; CCRIS 8092; 1cqp; Lovastatin,(S); ML-530B; Lovastatin [USAN:USP:INN:BAN]; (+)-mevinolin; (S)-((1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl) 2-methylbutanoate; [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxo-tetrahydropyran-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate; Prestwick_819; CAS-75330-75-5; Lovastatin [USAN]; Mevinolin (lovastatin); Opera_ID_1578; Prestwick0_000516; Prestwick1_000516; Prestwick2_000516; Prestwick3_000516; Spectrum3_001873; Spectrum5_001294; Lovastatin (MK-803); EC 616-212-7; SCHEMBL3136; US9115116, lovastatin; BIDD:PXR0113; BSPBio_000471; BSPBio_001265; BSPBio_003346; Butanoic acid, 2-methyl-, 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, (1S-(1alpha(R*),3alpha,7beta,8beta(2S*,4S*),8abeta))-; cid_53232; MLS001055358; MLS006011867; US9353061, Lovastatina; ARONIS24208; BIDD:GT0749; DivK1c_001032; SPECTRUM1503977; SPBio_002392; BPBio1_000519; GTPL2739; MEGxm0_000398; DTXSID5020784; SCHEMBL14227102; ACon0_000534; ACon1_000390; BDBM34168; HMS503O05; KBio1_001032; KBio3_002848; AOB5269; C10AA02; Simvastatin impurity, lovastatin-; NINDS_001032; HMS1569H13; HMS1792O07; HMS1923O13; HMS1990O07; HMS2089M06; HMS2093O03; HMS2096H13; HMS2236F07; HMS3039N16; HMS3259F10; HMS3268C03; HMS3403O07; HMS3412H19; HMS3676H19; HMS3713H13; HMS3884B03; Pharmakon1600-01503977; (S)-((1S,3R,7S,8S,8AR)-8-(2-((2R,4R)-4-HYDROXY-6-OXO-TETRAHYDRO-2H-PYRAN-2-YL)ETHYL)-3,7-DIMETHYL-1,2,3,7,8,8A-HEXAHYDRONAPHTHALEN-1-YL) 2-METHYLBUTANOATE; 2-Methyl-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl ester butanoic acid; ACT02620; ALBB-027272; Butanoic acid, 2-methyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, (2S)-; HY-N0504; MK-803; LOVALIP; MEVACOR; ZINC3812841; Tox21_110888; Tox21_201475; Tox21_300268; ANW-41686; BBL024473; CCG-39627; NSC633781; NSC758662; NSC779704; s2061; SBB080686; STK801953; AKOS005267139; Tox21_110888_1; CS-1990; DB00227; EBD2126857; KS-1082; MCULE-4740518260; MCULE-7087866108; Mevinolin from Aspergillus sp., powder; NC00713; NSC 758662; NSC-633781; NSC-758662; NSC-779704; IDI1_001032; NCGC00023509-04; NCGC00023509-05; NCGC00023509-06; NCGC00023509-07; NCGC00023509-08; NCGC00023509-09; NCGC00023509-10; NCGC00023509-11; NCGC00023509-13; NCGC00023509-14; NCGC00023509-16; NCGC00254157-01; NCGC00259026-01; 74133-25-8; AC-13961; Butanoic acid, 2-methyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, (2S)-; G226; SMR000673570; SBI-0051881.P002; AB0108514; L0214; N1632; EN300-52515; C07074; D00359; J10136; S-7779; 28048-EP2269989A1; 28048-EP2270011A1; 28048-EP2272825A2; 28048-EP2272841A1; 28048-EP2277507A1; 28048-EP2277865A1; 28048-EP2280006A1; 28048-EP2281813A1; 28048-EP2284158A1; 28048-EP2286795A1; 28048-EP2287165A2; 28048-EP2287166A2; 28048-EP2289892A1; 28048-EP2292620A2; 28048-EP2295406A1; 28048-EP2295409A1; 28048-EP2298742A1; 28048-EP2298745A1; 28048-EP2298772A1; 28048-EP2298776A1; 28048-EP2298779A1; 28048-EP2301923A1; 28048-EP2301931A1; 28048-EP2301936A1; 28048-EP2305648A1; 28048-EP2308839A1; 28048-EP2311808A1; 28048-EP2311829A1; 28048-EP2314588A1; 96638-EP2287163A1; 96638-EP2305678A1; AB00052400-17; AB00052400_18; AB00052400_19; Mevinolin from Aspergillus sp., >=98% (HPLC); 117141-EP2272825A2; 117141-EP2298776A1; 330L755; A838030; Q417740; SR-01000000123; SR-01000000123-3; SR-05000001880-1; SR-05000001880-2; BRD-K09416995-001-06-8; BRD-K09416995-001-21-7; Z1258578375; (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-Hexahydro-8-(2-((4R,6R)-4-hydroxy-2-oxo-2H-pyran-6-yl)ethyl)-3,7-dimethylnaphtyl(S)-2-methylbutyrat; (2S)-(1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl-2-methyl butanoate; (2S)-2-Methylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; (2S)-2-methylbutanoic acid [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxo-2-oxanyl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] ester; (S)-2-Methyl-butyric acid (1S,3R,7S,8S,8aR)-8-[2-((3R,5R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl ester; [(1S,3R,7S,8S,8aR)-3,7-dimethyl-8-[2-[(2R,4R)-4-oxidanyl-6-oxidanylidene-oxan-2-yl]ethyl]-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate; 1S,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate; 8-[2-((2R,4R)-4-hydroxy-6-oxo(2H-3,4,5-trihydropyran-2-yl))ethyl](1S,7S,8S,3R, 8aR)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthyl (2S)-2-methylbutanoate; 8-[2-(4-Hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydro-1-naphthale; Butanoic acid, 2-methyl-, 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydroxy-6-- oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, (1S-(1alpha(R*),3alpha,7beta,8beta(2S*,4S*),8abeta))-	Small molecule	1S/C24H36O5/c1-5-15(3)24(27)29-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-19-12-18(25)13-22(26)28-19/h6-7,10,14-16,18-21,23,25H,5,8-9,11-13H2,1-4H3/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1	PCZOHLXUXFIOCF-BXMDZJJMSA-N	CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C	C24H36O5	CAS 75330-75-5	CHEBI:40303	.	.	.	D06WTZ	.	.	.
DR5605	Polyinosinic acid-polycytidylic acid	CID: 135618150	Polyinosinic acid-polycytidylic acid; Poly(rI).poly(rC); 24939-03-5; Poly C poly I; Poly I:poly C; Poly(I).poly(C); Poly(rI).(rC); PI:C; Poly(I).poly(C) complex; Polyinosinate:polycytidylate; Poly IC; Polycytidylic-polyinosinic acid; Polyinosinic-polycytidylic acid; Polyinosinate-polycytidylate complex; Polyinosinic acid:polycytidylic acid; Polyinosinic-polycytidylic acid complex; Polyriboinosinic-polyribocytidylic acid; NSC-120949; Polyriboinosinic: polyribocytidylic acid; Poly(cytidylic acid)-poly(inosinic acid); Polyinosinic:polycytidylic acid; Polyinosinic acid:polycytidylic acid complex; Polyriboinosinic-polyribocytidylic acid complex; Polyribocytidylic acid-polyriboinosinic acid complex; Polyriboinosinic acid-polyribocytidylic acid complex; Poly(I:C) (VAN); NSC 123233; UNII-3R630IWW5I; UNII-O84C90HH2L; Poly(I).poly(C); Poly(I).poly(C) complex; Polyinosinic:polycytidylic acid copolymer; 3R630IWW5I; O84C90HH2L; DTXSID90947819; AKOS025402393; AC-8822; Q7226506; 5'-aInosinic acid, homopolymer, complex with 5'-acytidylic acid homopolymer (1:1); 5'-Inosinic acid, homopolymer, complex with 5'-cytidylic acid homopolymer (1:1) (9CI); 5'-Inosinic acid, polymers, complex with 5'-cytidylic acid polymers (1:1) (8CI); [(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate;[(2R,3S,4R,5R)-3,4-dihydroxy-5-(6-oxo-1H-purin-9-yl)oxolan-2-yl]methyl dihydrogen phosphate	Small molecule	1S/C10H13N4O8P.C9H14N3O8P/c15-6-4(1-21-23(18,19)20)22-10(7(6)16)14-3-13-5-8(14)11-2-12-9(5)17;10-5-1-2-12(9(15)11-5)8-7(14)6(13)4(20-8)3-19-21(16,17)18/h2-4,6-7,10,15-16H,1H2,(H,11,12,17)(H2,18,19,20);1-2,4,6-8,13-14H,3H2,(H2,10,11,15)(H2,16,17,18)/t4-,6-,7-,10-;4-,6-,7-,8-/m11/s1	ACEVNMQDUCOKHT-ZLOOHWKQSA-N	C1=CN(C(=O)N=C1N)C2C(C(C(O2)COP(=O)(O)O)O)O.C1=NC2=C(C(=O)N1)N=CN2C3C(C(C(O3)COP(=O)(O)O)O)O	C19H27N7O16P2	.	.	.	.	.	D0AY7O	.	.	.
DR5623	Ketamine	CID: 3821	ketamine; Ketaject; Ketalar; dl-Ketamine; CI 581 base; Special K; (+-)-Ketamine; Ketaminum; CLSTA 20; Ketanest; 6740-88-1; Ketalar base; 2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone; (+/-)-Ketamine; KETAMINE HCL; 2-(Methylamino)-2-(2-chlorophenyl)cyclohexanone; Ketolar; 2-(o-Chlorophenyl)-2-(methylamino)-cyclohexanone; 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one; NSC 70151; CHEMBL742; CHEBI:6121; Calypsol; 2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone; 2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone; Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-; NSC-70151; 100477-72-3; DEA No. 7285; NCGC00159480-02; NCGC00159480-03; Cetamina; Ketamine Base; Ketamine [INN:BAN]; DSSTox_CID_3187; Ketaminum [INN-Latin]; Cetamina [INN-Spanish]; DSSTox_RID_76912; Special K [street name]; DSSTox_GSID_23187; Ketoject; Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (+-)- (9CI); Ketamine (INN); PMI-150; CAS-6740-88-1; Tekam (TN); EINECS 229-804-1; (+/-)-2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone; BRN 2216965; ketamina; HSDB 2180; Ketolar (Salt/Mix); Vetalar (Salt/Mix); Kalipsol (Salt/Mix); Ketanest (Salt/Mix); Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+-)-; (.+/-.)-Ketamine; EC 229-804-1; Cyclohexanone, (.+-.)-; SCHEMBL16103; MLS001331674; DivK1c_000217; cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-; GTPL4233; (+/-)-2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone; DTXSID8023187; SCHEMBL17084881; KBio1_000217; NINDS_000217; HMS2272G05; NSC70151; Tox21_111703; Tox21_111704; BDBM50044140; DB01221; MCULE-4905246871; IDI1_000217; SMR000238141; C07525; D08098; Q243547; 2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone #; J-505587; (.+/-.)-2-(O-Chlorophenyl)-2-(methylamino)cyclohexanone; 2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone(Ketamine); Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)- (9CI); Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (+/-)-; Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (.+/-.)-; Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (.+/-.)-; Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+/-)- (8CI)	Small molecule	1S/C13H16ClNO/c1-15-13(9-5-4-8-12(13)16)10-6-2-3-7-11(10)14/h2-3,6-7,15H,4-5,8-9H2,1H3	YQEZLKZALYSWHR-UHFFFAOYSA-N	CNC1(CCCCC1=O)C2=CC=CC=C2Cl	C13H16ClNO	CAS 6740-88-1	CHEBI:6121	.	.	.	D0UM7O	.	.	.
DR5656	Loxoprofen	CID: 3965	Loxoprofen; 68767-14-6; 2-(4-((2-Oxocyclopentyl)methyl)phenyl)propanoic acid; Loxoprofene; Loxoprofeno; Koloxo; Loxoprofenum; Loxoprofen [INN]; 2-[4-[(2-oxocyclopentyl)methyl]phenyl]propanoic acid; UNII-3583H0GZAP; 2-{4-[(2-oxocyclopentyl)methyl]phenyl}propanoic acid; MFCD00864331; CHEMBL19299; 3583H0GZAP; Loxoprofen sodium hydrate; CHEBI:76172; CS-600; sodium loxoprofen; Loxoprofen (INN); Oxeno; NCGC00015594-02; DSSTox_CID_25164; DSSTox_RID_80714; DSSTox_GSID_45164; Loxoprofene [French]; Loxoprofenum [Latin]; Loxoprofeno [Spanish]; yl]-propionic acid; CAS-68767-14-6; 2-[4-(2-Oxo-cyclopentylmethyl)-phen; Loxoprofen, solid; 80382-23-6; Lopac0_000677; SCHEMBL24423; C15H17NaO3; (+-)-p-((2-Oxocyclopentyl)methyl)hydratropic acid; DTXSID1045164; alpha-Methyl-4-[(2-oxocyclopentyl)methyl]benzeneacetic acid; HMS3262G15; HMS3885N16; Loxoprofen (low-melting polymorph); BCP10971; EBD24378; HY-B0578; Loxoprofen (high-melting polymorph); Tox21_110178; Tox21_500677; ANW-43655; BDBM50140320; s4682; AKOS015906359; Tox21_110178_1; AC-8108; AT-7141; CCG-204763; DB09212; GS-3193; LP00677; SDCCGSBI-0050656.P002; NCGC00015594-03; NCGC00015594-04; NCGC00015594-08; NCGC00094037-01; NCGC00094037-02; NCGC00261362-01; NCGC00263577-01; AC-15776; AK-72809; H883; SY113439; AB0012364; DB-055188; EU-0100677; FT-0641207; L0244; CS-600; CS600; CS 600; D08149; L 0664; M-9376; (+-)-((2-oxocyclopentyl)methyl)hydratropic acid; 767L146; A836244; SR-01000075955; Q-201324; Q-300011; Q2759348; SR-01000075955-1; 2-[4-[(2-Oxocyclopentyl)methyl]phenyl]propionic Acid; 2-(4-((2-Oxocyclopentyl)methyl)-phenyl)propanoic acid; 2-[4-(2-Oxo-cyclopentylmethyl)-phenyl]-propionic acid; 2-[4-(2-oxocyclopentan-1-ylmethyl)phenyl]propionic acid; 2-[4-(2-Oxocyclopentan-1-ylmethyl)phenyl]-propionic Acid; 2-[4-[(2-oxidanylidenecyclopentyl)methyl]phenyl]propanoic acid; Benzeneacetic acid, alpha-methyl-4-((2-oxocyclopentyl)methyl)-; Benzeneacetic acid, .alpha.-methyl-4-[(2-oxocyclopentyl)methyl]-	Small molecule	1S/C15H18O3/c1-10(15(17)18)12-7-5-11(6-8-12)9-13-3-2-4-14(13)16/h5-8,10,13H,2-4,9H2,1H3,(H,17,18)	YMBXTVYHTMGZDW-UHFFFAOYSA-N	CC(C1=CC=C(C=C1)CC2CCCC2=O)C(=O)O	C15H18O3	CAS 68767-14-6	CHEBI:76172	.	.	.	.	.	.	.
DR5662	Pravastatin	CID: 54687	pravastatin; 81093-37-0; Pravastatina; Pravastatine; Pravastatinum; Pravachol; Pravastatin acid; PRAVASTATIN SODIUM; UNII-KXO2KT9N0G; KXO2KT9N0G; (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid; CHEMBL1144; (3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid; Eptastatin; CHEBI:63618; Pravastatine [French]; Pravastatinum [Latin]; Pravastatina [Spanish]; Pravastatin [INN:BAN]; (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid; Mevalothin; Pravator (TN); (+)-(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid; Pravastatin (INN); CCRIS 7557; C10AA03; 3beta-Hydroxycompactin; KS-5015; SCHEMBL1117; BIDD:GT0773; GTPL2953; DTXSID6023498; BDBM20688; HSDB 8368; HMS3715P11; ACT02637; HY-B0165; ZINC3798763; 1,4-Butanedisulfonicaciddisodiumsalt; LMFA05000695; s5713; AKOS015895229; CCG-221195; DB00175; NCGC00188962-01; NCGC00188962-02; 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1S-(1alpha(betaS*,deltaS*),2alpha,6alpha,8beta(R*),8aalpha))-1-Naphthaleneheptanoic acid; 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-((2S)-2-methyl-1-oxobutoxy)-, (betaR,deltaR,1S,2S,6S,8S,8aR)-; 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1S-(1alpha(betas*,deltas*),2alpha,6alpha,8beta(R*),8aalpha))-; C01844; D08410; 093P370; SR-01000781259; Q1240093; SR-01000781259-2; BRD-K60511616-236-01-4; BRD-K60511616-236-02-2; BRD-K60511616-236-08-9; (3R,5R)-3,5-dihydroxy-7-((1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-((S)-2-methylbutanoyloxy)-1,2,6,7,8,8a-hexahydronaphthalen-1-yl)heptanoic acid	Small molecule	1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1	TUZYXOIXSAXUGO-PZAWKZKUSA-N	CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC(CC(CC(=O)O)O)O)O	C23H36O7	CAS 81093-37-0	CHEBI:63618	.	.	.	D02RQU	.	.	.
DR5670	Ibuprofen	CID: 3672	ibuprofen; 15687-27-1; 2-(4-Isobutylphenyl)propanoic acid; Motrin; Brufen; Advil; Nurofen; Dolgit; Nuprin; Liptan; Ibuprocin; Buburone; Medipren; Butylenin; Ibumetin; Anflagen; Lamidon; Ebufac; Mynosedin; Trendar; Roidenin; Apsifen; Haltran; Epobron; Nobgen; Adran; Nobfen; Rufen; PediaProfen; Andran; Bluton; Nobfelon; Pantrop; Brufort; Suspren; Rebugen; Tabalon; Inabrin; (RS)-Ibuprofen; Urem; Anco; 2-[4-(2-methylpropyl)phenyl]propanoic acid; Ibu-slo; Napacetin; Brufanic; Ibuprohm; Ibufen; Ibren; 4-Isobutylhydratropic acid; p-Isobutylhydratropic acid; Actiprofen; Alaxan; Algofen; Amelior; Amersol; Amibufen; Anafen; Antagil; Antalfene; Antarene; Antiflam; Artofen; Artril; Balkaprofen; Betaprofen; Bloom; Brofen; Bruflam; Bufeno; Bufigen; Bukrefen; Bupron; Buracaps; Burana; Carol; Cesra; Citalgan; Cobo; Codral; Combiflam; Cunil; Daiprophen; Dalsy; Dansida; Dentigoa; Dibufen; Dignoflex; Dolgirid; Dolibu; Dolmaral; Dolocyl; Dolofen; Dolofin; Dolofort; Dologel; Dolomax; Doloren; Dolormin; Doltibil; Dolven; Dorival; Drin; Duafen; Duobrus; Dysdolen; Easifon; Emflam; Eputex; Ergix; Esprenit; Exneural; Faspic; Femadon; Femafen; Femapirin; Femidol; Fenbid; Fendol; Fenspan; Fibraflex; Gelufene; Gofen; Grefen; Gynofug; Ibol; Ibu; Ibubest; Ibubeta; Ibucasen; Ibudol; Ibudolor; Ibuflamar; Ibufug; Ibugel; Ibugen; Ibugesic; Ibuhexal; Ibulagic; Ibular; Ibulav; Ibuleve; Ibulgan; Ibumed; Ibumerck; Ibupirac; Ibuprin; Ibuprofene; Ibuprofeno; Ibuprofenum; Ibuprophen; Ibusal; Ibutid; Ifen; Inflam; Inoven; Ipren; Irfen; Isodol; Jenaprofen; Junifen; Kesan; Kratalgin; Lebrufen; Librofem; Lidifen; Lopane; Malafene; Manypren; Melfen; Mensoton; Midol; Moment; Narfen; Neobrufen; Nerofen; Noalgil; Nobafon; Noritis; Norton; Novadol; Novogent; Novoprofen; Nuprilan; Optifen; Opturem; Oralfene; Ostarin; Ostofen; Ozonol; Paduden; Panafen; Paxofen; Perofen; Proartinal; Profen; Proflex; Provon; Quadrax; Rafen; Ranofen; Relcofen; Rhinadvil; Rofen; Rufin; Rupan; Sadefen; Salivia; Salprofen; Seclodin; Sednafen; Seklodin; Seskafen; Siyafen; Solpaflex; Solufen; Stelar; Sugafen; Suprafen; Syntofene; Tatanal; Tempil; Tofen; Tonal; Unipron; Upfen; Uprofen; Zafen; Zofen; DOLO PUREN; Deep Relief; Donjust B; Motrin IB; Novogent N; Togal N; Adex 200; Artril 300; Brufen 400; I 4883; IP 82; IP82; Midol 200; RD 13621; Tabalon 400; U 18573; UCB 79171; VUFB 9649; Act-3; Advil (TN); Ak+C2278tren; Aktre (TN); Alaxan (TN); Algoflex (TN); Alivium (TN); Am-Fam 400; Apsifen-F; Arthrofen (TN); Bonifen (TN); Brufen (TN); Bugesic (TN); Burana (TN); Caldolor (TN); Calprofen (TN); Cap-Profen; Dalsy (TN); Dismenol (TN); Diverin (TN); Dolgit (TN); Dolo-Dolgit; Dolofen-F; Dolofort (TN); Doloraz (TN); Dolormin (TN); Dorival (TN); Dura-Ibu; Ebufac (TN); Emflam-200; EmuProfen (TN); Espidifen (TN); Eve (TN); Fenbid (TN); Fenpaed (TN); Finalflex (TN); Galprofen (TN); Hedex (TN); Herron Blue (TN); IB-100; IBUFEN (TN); IP-82; Ibalgin (TN); Ibu-Attritin; Ibu-Tab; Ibu-Tab 200; Ibu-slow; IbuHEXAL (TN); Ibugel (TN); Ibuleve (TN); Ibum (TN); Ibumax (TN); Ibumetin (TN); Ibuprom (TN); Ibuprosyn (TN); Ibux (TN); Ibuxin (TN); Ipren (TN); Kratalgin (TN); Medicol (TN); Moment (TN); Motrin (TN); Nagifen-D; Narfen (TN); Neo-Helvagit; Neo-Mindol; Neobrufen (TN); Neofen (TN); Norvectan (TN); Novo-Profen; Nuprin (TN); Nureflex (TN); Nurofen (TN); Orbifen (TN); Panafen (TN); Pedia-Profen; Perifar (TN); Profin (TN); Ratiodolor (TN); Retard (TN); Rimafen (TN); Salvarina (TN); Solpaflex (TN); Spedifen (TN); Speedpain NANO (TN); Spidifen (TN); Tab-Profen; U-18573; Upfen (TN); ACHES-N-PAIN; Act-3 (TN); Dolo-Spedifen (TN); I-profen (TN); IBU-Ratiopharm (TN); Ibu-Vivimed (TN); U-18,573; IBUPROPHEN	Small molecule	1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)	HEFNNWSXXWATRW-UHFFFAOYSA-N	CC(C)CC1=CC=C(C=C1)C(C)C(=O)O	C13H18O2	CAS 15687-27-1	CHEBI:5855	.	.	.	D0R1QE	.	.	.
DR5673	Nanoliposomal C6-ceramide	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR5679	Methioninase	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR5683	Montelukast	CID: 5281040	montelukast; 158966-92-8; Singulair; UNII-MHM278SD3E; (R-(E))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid; CHEMBL787; MHM278SD3E; CHEBI:50730; Cyclopropaneacetic acid, 1-((((1R)-1-(3-((1E)-2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)-; Montelukast [INN:BAN]; (R,E)-2-(1-(((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propyl)thio)methyl)cyclopropyl)acetic acid; 142522-28-9; Aerokast; Brondilat (TN); 1-[[[(1 R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropaneacetic acid; 2-[1-({[(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanyl}methyl)cyclopropyl]acetic acid; Montelukast (INN); SR-01000763441; HSDB 7582; 1-((((1R)-1-(3-((1E)-2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid; cc-91; SCHEMBL4486; SCHEMBL4487; {1-[({(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetic acid; BIDD:GT0394; GTPL3340; DTXSID9023334; CHEBI:94710; HMS2089D07; HMS3715N13; HMS3886L03; ACT04773; ZINC3831151; BDBM50052024; HY-13315A; AKOS025310659; CCG-221186; DB00471; SB19081; NCGC00188977-01; {1-[({(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetic acid; 2-[1-[[(1R)-1-[3-[(E)-2-(7-chloro-2-quinolyl)vinyl]phenyl]-3-[2-(1-hydroxy-1-methyl-ethyl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid; Cyclopropaneacetic acid, 1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)-, (R-(E))-; CS-0002595; S5783; 5306-EP2270008A1; 5306-EP2276739A1; 5306-EP2280006A1; 5306-EP2281813A1; 5306-EP2281815A1; 5306-EP2281819A1; 5306-EP2284166A1; 5306-EP2287154A1; 5306-EP2288595A2; 5306-EP2292617A1; 5306-EP2292619A1; 5306-EP2295409A1; 5306-EP2298415A1; 5306-EP2301933A1; 5306-EP2305640A2; 5306-EP2305659A1; 5306-EP2308562A2; 5306-EP2311818A1; 5306-EP2311827A1; 5306-EP2314590A1; C07482; D08229; AB01275454-01; 522M289; Q417767; SR-01000763441-3; SR-01000763441-5; BRD-K99673372-001-01-9; 1-[[[(R)-3-[2-(1-Hydroxy-1-methylethyl)phenyl]-1-[3-[2-(7-chloroquinoline-2-yl)ethenyl]phenyl]propyl]thio]methyl]cyclopropane-1-acetic acid; 1124196-02-6; r-(e)-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid	Small molecule	1S/C35H36ClNO3S/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39)/b15-10+/t32-/m1/s1	UCHDWCPVSPXUMX-TZIWLTJVSA-N	CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O	C35H36ClNO3S	CAS 158966-92-8	CHEBI:50730	.	.	.	D00QET	.	.	.
DR5708	PNC-27	.	.	.	.	.	.	.	.	.	.	.	.	D00GNN	.	.	.
DR5724	Ribavirin	CID: 37542	ribavirin; 36791-04-5; Tribavirin; Rebetol; Virazole; Copegus; Vilona; Ribavirine; Viramid; Ribamide; Ribamidil; Ribasphere; Ribavirina; Ribavirinum; Ribavirine [INN-French]; Ribavirinum [INN-Latin]; ICN-1229; Ribavirina [INN-Spanish]; 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide; 1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide; RTCA; RBV; SCH 18908; UNII-49717AWG6K; Ribamidyl; Ribavirin (Copegus); 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide; 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1H-1,2,4-triazole-3-carboxamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide; MFCD00058564; Rebetron; Varazid; Ribavirin Capsules; CHEBI:63580; 49717AWG6K; Ribavirin, 98%; 1-(beta-D-ribofuranosyl)-1H-1,2,4-triazole-3-carboxamide; Rebretron; Virazid; Virazide; Ribav; DSSTox_CID_3557; DSSTox_RID_77081; DSSTox_GSID_23557; RTC; 1-(beta-D-Ribofuranosyl)-1,2,4-triazole-3-carboxamide; Cotronak; Ravanex; Ribacine; NSC-163039; C-Virin; DRG-0028; Ribasphere (TN); Virazole (TN); SMR000058315; Copegus (TN); Rebetol (TN); HSDB 6513; SR-01000076112; BRN 0892462; Ribavirine;; NSC163039; Ribavirin [USAN:USP:INN:BAN]; Ribavirin,(S); NCGC00015904-02; Ribavirin, antiviral; CAS-36791-04-5; RG-964; PubChem14187; Ro-20-9963; Spectrum_001826; 1H-1,2,4-Triazole-3-carboxamide, 1-beta-D-ribofuranosyl-; 4pb1; ribofluranosyl carboxamide; Prestwick3_000993; Spectrum3_001876; Spectrum4_001252; Spectrum5_002075; R-964; R 9644; SCHEMBL3727; CHEMBL1643; Lopac0_001063; BSPBio_001085; BSPBio_003352; KBioGR_001804; KBioSS_002331; cid_37542; MLS000028486; MLS002222317; DivK1c_000782; SPECTRUM1503938; Ribavirin (JP17/USP/INN); BPBio1_001195; GTPL6842; 1,2,4-Triazole-3-carboxamide, 1-beta-D-ribofuranosyl-; 1-.beta.-D-Ribofuranosyl-1,2,4-triazolo-3-carboxamide; DTXSID8023557; HMS502H04; KBio1_000782; KBio2_002328; KBio2_004896; KBio2_007464; KBio3_002854; NINDS_000782; HMS2090L15; HMS2094O09; HMS2098G07; HMS2232P07; HMS3263E08; HMS3715G07; Pharmakon1600-01503938; HY-B0434; ZINC1035331; Tox21_110259; Tox21_200967; Tox21_501063; BDBM50154375; CCG-38985; NSC758650; s2504; SCH-18908; AKOS001715163; Tox21_110259_1; DB00811; GS-3572; LP01063; MCULE-9495128592; NSC-758650; SDCCGSBI-0051033.P004; IDI1_000782; SMP1_000261; NCGC00090726-01; NCGC00090726-03; NCGC00090726-04; NCGC00090726-05; NCGC00090726-06; NCGC00090726-07; NCGC00090726-08; NCGC00090726-09; NCGC00090726-12; NCGC00090726-25; NCGC00258520-01; NCGC00261748-01; 252269-50-4; AS-34178; BCP0726000138; SBI-0051033.P003; AB0068936; AB00430481; EU-0101063; R0077; EN300-59237; D00423; J10190; M-7546; AB00430481-15; AB00430481-16; AB00430481_17; AB00430481_18; 1-beta-Ribofuranosyl-1,2,4-triazole-3-carboamide; 791R045; Q421862; Ribavirin 100 microg/mL in Acetonitrile:Methanol; SR-01000721904; SR-01000076112-2; SR-01000076112-3; SR-01000076112-4; SR-01000721904-2; 1-??-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide; BRD-K60369935-001-02-7; BRD-K60369935-001-18-3; SR-01000076112-11; 1-?-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide; Ribavirin, British Pharmacopoeia (BP) Reference Standard; Z1522567185; 1-(beta -D-ribofuranosyl)-1,2,4-triazole-3-carboxamide; Ribavirin, European Pharmacopoeia (EP) Reference Standard; Ribavirin, United States Pharmacopeia (USP) Reference Standard; Ribavirin, Pharmaceutical Secondary Standard; Certified Reference Material; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,2,4-triazole-3-carboxamide	Small molecule	1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1	IWUCXVSUMQZMFG-AFCXAGJDSA-N	C1=NC(=NN1C2C(C(C(O2)CO)O)O)C(=O)N	C8H12N4O5	CAS 36791-04-5	CHEBI:63580	.	.	.	D0H3WI	.	.	.
DR5742	Caffeic acid phenethyl ester	CID: 5281787	Caffeic acid phenethyl ester; Phenethyl caffeate; 104594-70-9; CAPE; Phenylethyl caffeate; phenethyl 3-(3,4-dihydroxyphenyl)acrylate; Capeee; 115610-29-2; caffeic acid phenylethyl ester; PHENETHYL CAFFEATE (CAPE); UNII-G960R9S5SK; 2-phenylethyl caffeate; 2-phenylethyl (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate; CHEBI:8062; CHEMBL319244; G960R9S5SK; (E)-phenethyl 3-(3,4-dihydroxyphenyl)acrylate; MFCD00866470; 100981-80-4; 2-Phenylethyl (2e)-3-(3,4-Dihydroxyphenyl)prop-2-Enoate; 2-phenylethyl (2E)-3-(3,4-dihydroxyphenyl)acrylate; 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)-, 2-phenylethyl ester; SMR000326751; SR-01000075785; 2-phenylethyl 3-(3,4-dihydroxyphenyl)prop-2-enoate; caffeic-acid-phenethyl-ester; phenethyl 3,4-dihydroxycinnamate; 3-(3,4-Dihydroxyphenyl)-2-propenoic acid 2-phenylethyl ester; QAP; 2-phenylethyl 3-(3,4-dihydroxyphenyl)-2-propenoate; Caffeic Acid Phenethyl Ester, Synthetic; Phenethyl (E)-caffeate; caffeic acidphenethylester; caffeic acid phenethylester; caffeic acid phenylethylester; Lopac0_000269; BSPBio_001560; BSPBio_003586; MLS000859889; MLS002207297; SPECTRUM1502209; phenethyl (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate; ZINC1083; CHEBI:93478; DTXSID80861176; FR102; HMS1361N22; HMS1791N22; HMS1989N22; HMS2233J04; HMS3260F20; HMS3402N22; HMS3413D22; HMS3649C16; HMS3677D22; Phenylethyl 3,4-dihydroxycinnamate; Caffeic acid beta-phenylethyl ester; Trans-Caffeic Acid Phenethyl Ester; BCP27877; Caffeic acid phenethyl ester(CAPE); EBD26363; HY-N0274; Tox21_500269; BDBM50029207; Caffeic acid phenethyl ester (CAPE); CCG-39542; s7414; 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)-, 2-phenylethyl ester, (E)-; AKOS015888207; AC-8896; LP00269; SDCCGSBI-0050257.P002; IDI1_034030; QTL1_000016; NCGC00093727-01; NCGC00093727-02; NCGC00093727-03; NCGC00093727-04; NCGC00093727-05; NCGC00093727-06; NCGC00093727-07; NCGC00093727-08; NCGC00093727-09; NCGC00093727-16; NCGC00260954-01; AS-14021; I793; LS-14562; CS-0008774; EU-0100269; SW219156-1; B-6327; C 8221; C10484; 3,4-Dihydroxy-trans-cinnamic acid phenethyl ester; SR-01000075785-1; SR-01000075785-6; SR-01000075785-9; BRD-K84709232-001-02-6; BRD-K96188950-001-02-9; BRD-K96188950-001-04-5; Caffeic acid phenethyl ester, >=97% (HPLC), powder; Q15410860; 3-(3,4-Dihydroxy-phenyl)-acrylic acid phenethyl ester; Methanone, 1,1'-(1,2-cyclopropanediyl)bis[1-phenyl-; (E)-3-(3,4-Dihydroxy-phenyl)-acrylic acid phenethyl ester	Small molecule	1S/C17H16O4/c18-15-8-6-14(12-16(15)19)7-9-17(20)21-11-10-13-4-2-1-3-5-13/h1-9,12,18-19H,10-11H2/b9-7+	SWUARLUWKZWEBQ-VQHVLOKHSA-N	C1=CC=C(C=C1)CCOC(=O)C=CC2=CC(=C(C=C2)O)O	C17H16O4	CAS 115610-29-2	CHEBI:8062	.	.	.	D06YGF	.	.	.
DR5752	Androgen	CID: 5995	testosterone propionate; 57-85-2; Agovirin; Androlon; Androteston; Aquaviron; Hormoteston; Enarmon; Bio-testiculina; Androtest P; Androsteston; Sterandryl; Testonique; Andronate; Masenate; Orchiol; Orchistin; Pantestin; Propiokan; Solvotest; Synandrol; Synerone; Telipex; Testaform; Testodet; Testodrin; Testogen; Testolets; Testormol; Testosid; Testoxyl; Testrex; Tostrin; Uniteston; Nasdol; Vulvan; Enarmon-oil; Neo-Hombreol; Okasa-Mascul; Andrusol-P; Oreton propionate; Recthormone testosterone; NSC 9166; Testosteron propionate; 17beta-(Propionyloxy)androst-4-en-3-one; Testosterone-17-propionate; Homandren (amps); Androgen; UNII-WI93Z9138A; CHEMBL1170; CHEBI:9466; (17beta)-3-oxoandrost-4-en-17-yl propanoate; (17beta)-3-oxoandrost-4-en-17-yl propionate; Testosterone-17.beta.-propionate; WI93Z9138A; NSC-9166; Androst-4-en-3-one, 17-(1-oxopropoxy)-, (17b)-; [(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] propanoate; NCGC00016254-01; 17-propionyl-17beta-hydroxyandrost-4-en-3-one; DSSTox_CID_16515; DSSTox_RID_79286; DSSTox_GSID_36515; Orchisterone; Testosteroni propionas; CAS-57-85-2; CCRIS 575; Testoviron (ampule); testosteron-17-propionat; Testosterone-17beta propionate; Testosterone-17beta-propionate; Testosterone-17-beta-propionate; EINECS 200-351-1; Androst-4-en-3-one, 17-(1-oxopropoxy)-, (17.beta.)-; AI3-26378; 17beta-Hydroxyandrost-4-en-3-one propionate; 17beta-Hydroxy-4-androsten-3-one 17-propionate; Testosterone propionate [USP:JAN]; Androst-4-en-3-one, 17beta-hydroxy-, propionate; delta(sup 4)-Androstene-17-beta-propionate-3-one; Prestwick_432; 17beta-Hydroxyandrost-4-en-3-one-17beta-propionate; Testex (TN); 17.beta.-(Propionyloxy)androst-4-en-3-one; Androst-4-en-3-one, 17-(1-oxopropoxy)-, (17beta)-; .DELTA.4-androstene-17.beta.-propionate-3-one; 17.beta.-hydroxyandrost-4-en-3-one, propionate; 3-Oxoandrost-4-en-17-yl propionate, (17.beta.)-; Prestwick0_000401; Prestwick1_000401; Prestwick2_000401; Prestwick3_000401; Androst-4-en-3-one, 17.beta.-hydroxy-, propionate; 17-(1-Oxopropoxy)androst-4-en-3-one, (17.beta.)-; Testosterone propionate ciii; SCHEMBL4044; BSPBio_000322; MLS002153796; Testosterone propionate, solid; SPBio_002261; BPBio1_000356; GTPL7100; Testosterone-17.beta.propionate; DTXSID9036515; Testosterone propionate [Androgenic (anabolic) steroids]; NSC9166; HMS1569A04; HMS2096A04; HMS2272K06; HMS3713A04; Testosterone propionate (Agovirin); ZINC490791; HY-B1269; Tox21_110330; Tox21_302270; BBL029912; BDBM50215709; LMST02020076; MFCD00003653; NRB-03689; STK801834; Testosterone propionate (JP17/USP); AKOS005622513; AKOS015842719; Tox21_110330_1; CCG-220401; CS-4905; DB01420; MCULE-8627319345; NCGC00179602-01; NCGC00179602-03; NCGC00179602-06; NCGC00255481-01; AC-12172; AC-33160; SMR000058348; VS-09499; BCP0726000215; C08158; D00959; 003T653; Testosterone Propionate 1.0 mg/ml in Acetonitrile; Testosterone propionate, tested according to Ph.Eur.; W-105436; BRD-K90553655-001-03-6; Q10354588; WLN: L E5 B666 OV MUTJ A E FO52 -B&AEF; Androst-4-en-3-one, 17-(1-oxopropoxy)-(17.beta.)-; Testosterone propionate, British Pharmacopoeia (BP) Reference Standard; Testosterone propionate, European Pharmacopoeia (EP) Reference Standard; Testosterone propionate, United States Pharmacopeia (USP) Reference Standard; (1S,3aS,3bR,9aR,9bS,11aS)-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl propanoate; Propionic acid (8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl ester; Propionic acid 10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl ester; Propionic acid 10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl ester(Testosterone Propionate); Testosterone propionate for system suitability, European Pharmacopoeia (EP) Reference Standard	Small molecule	1S/C22H32O3/c1-4-20(24)25-19-8-7-17-16-6-5-14-13-15(23)9-11-21(14,2)18(16)10-12-22(17,19)3/h13,16-19H,4-12H2,1-3H3/t16-,17-,18-,19-,21-,22-/m0/s1	PDMMFKSKQVNJMI-BLQWBTBKSA-N	CCC(=O)OC1CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C	C22H32O3	CAS 57-85-2	CHEBI:9466	.	.	.	D0SP7S	.	.	.
DR5762	Trimetazidine	CID: 21109	TRIMETAZIDINE; 5011-34-7; 1-(2,3,4-Trimethoxybenzyl)piperazine; 1-[(2,3,4-trimethoxyphenyl)methyl]piperazine; 1-(2,3,4-Trimethoxy-benzyl)-piperazine; UNII-N9A0A0R9S8; Piperazine, 1-((2,3,4-trimethoxyphenyl)methyl)-; N9A0A0R9S8; Vasartel; Piperazine, 1-[(2,3,4-trimethoxyphenyl)methyl]-; Trimetazidina; Trimetazidinum; MLS001240268; Trimetazidinum [INN-Latin]; Trimetazidina [INN-Spanish]; Trimetazidine [INN:BAN:DCF]; 1,2,3-trimethoxy-4-(piperazinylmethyl)benzene; NCGC00016697-01; SMR000674573; EINECS 225-690-2; CAS-13171-25-0; Preductal; Vasorel; Preductal MB; Dilatan (TN); Trimetazidine (INN); BAS 06612844; Prestwick0_000549; Prestwick1_000549; Prestwick2_000549; Prestwick3_000549; Oprea1_279550; Piperazine,1-[(2,3,4-trimethoxyphenyl)methyl]-; BSPBio_000597; MLS001331735; SCHEMBL230374; SPBio_002518; BPBio1_000657; CHEMBL203266; DTXSID2048531; BDBM80613; CHEBI:94789; cid_9926449; HY-B0968A; HMS2230L07; HMS3374D04; ALBB-004703; BCP16534; BBL013084; MFCD00868263; s5779; SBB007020; STK315643; ZINC19358638; AKOS000308094; 4-(2,3,4-Trimethoxybenzyl)piperazine; DB09069; MCULE-9820869946; 1-(2,3,4-trimethoxy benzyl)piperazine; NCGC00016697-02; SMR000814701; 1-(2,3,4-trimethoxyphenyl)methylpiperazine; 1-(2,3,4-trimethoxyphenylmethyl)piperazine; AB0111344; DB-051731; BB 0220635; CS-0099250; R3927; ST45134749; EN300-14439; 71T250; A25088; D08642; A827982; A837947; Q674703; 1-(2,3,4-trimethoxybenzyl)piperazine;hydrochloride; 1-[2,3,4-trimethoxybenzyl] piperazine dihydrochloride; BRD-K88366685-300-03-7; BRD-K88366685-300-04-5; Z99601262; 1-[(2,3,4-trimethoxyphenyl)methyl]piperazine;hydrochloride; 1-((2,3,4-trimethoxyphenyl)methyl)-piperazindihydrochloride;1-(2,3,4-trimethoxybenzyl)-piperazindihydrochloride; 127881-54-3	Small molecule	1S/C14H22N2O3/c1-17-12-5-4-11(13(18-2)14(12)19-3)10-16-8-6-15-7-9-16/h4-5,15H,6-10H2,1-3H3	UHWVSEOVJBQKBE-UHFFFAOYSA-N	COC1=C(C(=C(C=C1)CN2CCNCC2)OC)OC	C14H22N2O3	CAS 5011-34-7	CHEBI:94789	.	.	.	D0Q4YI	.	.	.
DR5764	Desloratadine	CID: 124087	Desloratadine; 100643-71-8; Clarinex; Descarboethoxyloratadine; Desloratidine; Neoclarityn; Sch-34117; Aerius; Azomyr; Denosin; Sch 34117; Descarboethoxyoratidine; 8-Chloro-11-piperidin-4-ylidene-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; MFCD00871949; UNII-FVF865388R; CHEMBL1172; Loratadine related compound a; C19H19ClN2; 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)-; 8-chloro-11-(piperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 8-Chloro-6,11-dihydro-11-(4-piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine; MLS000559042; CHEBI:291342; FVF865388R; NCGC00159325-02; SMR000149358; Opulis; Allex; Clarinex RediTabs; 8-Chloro-6,11-dihydro-11-(4-piperidinylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; DSSTox_CID_24196; DSSTox_RID_80112; DSSTox_GSID_44196; Desalex; 5H-Benzo(5,6)cyclohepta(1,2-b)pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)-; 8-chloro-11-piperidin-4-ylidene-5,6-dihydrobenzo[1,2]cyclohepta[2,4-b]pyridine; 8-chloro-6,11-dihydro-11-(4-piperdinylidene)- 5H-benzo[5,6]cyclohepta[1,2-b]pyridine; Clarinex (TN); CAS-100643-71-8; SR-01000668962; Neoclaritin; Desloratadine [USAN:INN:BAN]; Clarinex(R); 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta(1,2-b]pyridin-11-ylidene)-piperidine; 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine; 4-{8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene}-piperidine; 4-{8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene}piperidine; Desloratadine-[d7]; MK-4117; CPD000149358; Opera_ID_1891; SCHEMBL4425; MLS000759406; MLS001201801; MLS001424247; BEN691; Desloratadine (JAN/USP/INN); GTPL7157; ZINC1261; DTXSID1044196; Loratadine related compound a rs; HMS2052H05; HMS2090C06; HMS2093F19; HMS3394H05; HMS3652O15; HMS3715J15; HMS3885C18; Pharmakon1600-01505393; ALBB-027276; BCP02340; HY-B0539; Tox21_111574; ANW-42359; BBL010777; BDBM50073179; CD0143; NSC675447; NSC759824; s4012; STK586537; AKOS000280921; Tox21_111574_1; AC-1279; CCG-101162; DB00967; KS-1048; MCULE-2975958622; NC00412; NSC 759824; NSC-675447; NSC-759824; SB17503; Desloratadine, powder, >=98% (HPLC); NCGC00159325-03; NCGC00159325-04; NCGC00159325-05; 13-chloro-2-(2,2,6,6-tetradeuteriopiperidin-4-ylidene)-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaene; AK163520; Loratadine EP Impurity D (Desloratadine); SBI-0206828.P001; AB0012600; D3787; FT-0602522; FT-0666048; R3930; SW197792-3; A19515; D03693; J10309; AB00456701-11; AB00456701-13; AB00456701_14; AB00456701_15; 643D718; L001025; Q418060; Q-200936; SR-01000668962-4; SR-01000668962-5; SR-01000668962-8; BRD-K82357231-001-13-4; Desloratadine, European Pharmacopoeia (EP) Reference Standard; Desloratadine, United States Pharmacopeia (USP) Reference Standard; 4-(8-chloro-5,6-dihydro-11 H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine; 4-(8-chloro-5,6-dihydro-11H-benzo-[5,6]cyclohepta(1,2-b]pyridin-11-ylidene)-piperidine; 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta [1,2-b]pyridin-11-ylidene) piperidine; 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene) piperidine; 8-chloro-11-(4-piperidinylidene)-6,11-dihydro-5H- benzo[4,5]cyclohepta[2,1-b]pyridine; 8-chloro-11-(4-piperidyliden)-6,11-dihydro-5H-benzo[5,6]cyclohepta [1,2-b]pyridine; 8-chloro-11-(4-piperidyliden)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 8-chloro-11-(4-piperidylidene)-6,11-dihydro-5h-benzo[5.6]cyclohepta[1,2-b]pyridine; 8-Chloro-6,11-dihydro-11-(4-piperidinylidene)-5H- benzo[5,6]cyclohepta[1,2,b]pyridine; 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; Desloratadine for system suitability, European Pharmacopoeia (EP) Reference Standard; Desloratidine, Pharmaceutical Secondary Standard; Certified Reference Material; Loratadine Related Compound A, United States Pharmacopeia (USP) Reference Standard; 13-chloro-2-(piperidin-4-ylidene)-4-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,12,14-hexaene; 8-CHLORO-11-(4-PIPERIDYLIDENE)-6,11-DIHYDRO-5H-BENZO[5,6]CYCLOHEPTA[1,2-b]PYRIDINE; 8-Chloro-11-(piperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine (Descarboethoxyloratadine; Desloratadine)	Small molecule	1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2	JAUOIFJMECXRGI-UHFFFAOYSA-N	C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4	C19H19ClN2	CAS 100643-71-8	CHEBI:291342	.	.	.	D01GBY	.	.	.
DR5773	Fernblock	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR5795	Verapamil	CID: 2520	VERAPAMIL; 52-53-9; Iproveratril; Vasolan; Dilacoran; Isoptin; Falicard; Finoptin; Isoptine; Calan; Lekoptin; Verapamilo; Verapamilum; Isotopin; Securon; Verelan; Calcan; Tarka; D-365; Cardibeltin; Izoptin; CP-16533-1; Covera-HS; Verpamil; Verelan PM; 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile; 5-((3,4-Dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; Cardiagutt; Berkatens; Dignover; Geangin; Veramex; Quasar; Univer; 5-((3,4-dimethoxyphenethyl)(methyl)amino)-2-(3,4-dimethoxyphenyl)-2-isopropylpentanenitrile; Novo-Veramil; Apo-Verap; Isoptin SR; Nu-Verap; Calan SR; Isoptimo; Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)-; (+/-)-Verapamil hydrochlorid; CHEBI:77733; Cardiabeltin; Cardioprotect; Durasoptin; Hexasoptin; Veratensin; Veroptinstada; Calaptin; Caveril; Civicor; Coraver; Corpamil; Harteze; Hormitol; Ikapress; Inselon; Isoptino; Jenapamil; Lodixal; Magotiron; Praecicor; Robatelan; Vasomil; Vasopten; Verabeta; Veracor; Verahexal; Veraloc; Veramil; Verapin; Verasal; Verasifar; Verdilac; Vetrimil; Akilen; Elthon; Flamon; Ikacor; Univex; Vortac; Anpec; Ormil; Rapam; Civicor Retard; Isoptin Retard; Manidon Retard; Valeronitrile, 5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropyl-; Vera-Sanorania; Verapamil Acis; Verapamil Atid; Verapamil Ebewe; Verapamil Riker; Verapamil Verla; (+/-)-Verapamil;CP-16533-1; Benzeneacetonitrile, .alpha.-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-.alpha.-(1-methylethyl)-; Verapamil Basics; Verapamil Nordic; Verapamil-AbZ; Novapamyl LP; Verapamil AL; Verapamil NM; Verapamil PB; Verapamil SR; Cordilox SR; Dilacoran HTA; Veracaps SR; Verapamil MSD; Verapamilum [INN-Latin]; Arpamyl LP; Hexasoptin Retard; Verapamil Henning; Verelan SR; NCGC00016083-09; Verapamilo [INN-Spanish]; 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile; Verapamil Injection; CP-16,533-1; Verapamil NM Pharma; Calaptin 240 SR; Verapress 240 SR; 5-[(3,4-Dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; DSSTox_CID_21152; DSSTox_RID_79636; DSSTox_GSID_41152; (+/-)-VERAPAMIL; Verapamil [USAN:INN:BAN]; dl-Verapamil; r,s-verapamil; CAS-52-53-9; CCRIS 6749; NSC272366; Verapamil (USAN/INN); EINECS 200-145-1; Ansyr; NSC 272306NA; EINECS 260-462-6; Calan (Salt/Mix); Akilen (Salt/Mix); alpha-((N-Methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile; Isoptin (Salt/Mix); alpha-(3-((2-(3,4-Dimethoxyphenyl)ethyl)-methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile; alpha-Isopropyl-alpha-((N-methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile; Cordilox (Salt/Mix); delta-365; Covera-HS (Salt/Mix); Prestwick0_000141; Prestwick1_000141; Prestwick2_000141; Prestwick3_000141; Spectrum2_001740; Spectrum4_000906; Spectrum5_001786; CP 16533-1; D 365; CHEMBL6966; Lopac0_001237; SCHEMBL16742; BSPBio_000242; BSPBio_001513; BSPBio_002358; KBioGR_000233; KBioGR_001372; KBioGR_002343; KBioSS_000233; KBioSS_002346; 56949-77-0; Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino) propyl)-3,4-dimethoxy-alpha-(1-methylethyl)-; MLS006011414; DivK1c_000399; SPBio_001820; SPBio_002181; BPBio1_000268; GTPL2406; CP 16533-1 (Verapamil); DTXSID9041152; SCHEMBL13287282; (A+/-)-Verapamil hydrochloride; BDBM81939; HSDB 3928; KBio1_000399; KBio2_000233; KBio2_002343; KBio2_002801; KBio2_004911; KBio2_005369; KBio2_007479; KBio3_000465; KBio3_000466; KBio3_002823; cMAP_000023; NINDS_000399; NSC-272306NA; Bio1_000425; Bio1_000914; Bio1_001403; Bio2_000233; Bio2_000713; HMS1791L15; HMS1989L15; HMS2089H17; HMS3402L15; Tox21_110300; NSC_62969; STK538085; AKOS005468962; Tox21_110300_1; CCG-205311; DB00661; MCULE-3016077278; SDCCGSBI-0051204.P005; CAS_52-53-9; IDI1_000399; IDI1_033983; NCGC00016083-04; NCGC00016083-05; NCGC00016083-06; NCGC00016083-07; NCGC00016083-08; NCGC00016083-10; NCGC00016083-11; NCGC00016083-13; NCGC00016083-14; NCGC00016083-15; NCGC00016083-16; NCGC00016083-17; NCGC00016083-18; NCGC00016083-20; NCGC00016083-25; NCGC00016083-34; NCGC00024710-04; NCGC00024710-05; NCGC00024710-06; NCGC00024710-07; NCGC00024710-08; NCGC00024710-09; NCGC00344584-01; 2-(3,4-Dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amino]-2-(1-methylethyl) pentanenitrile; 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amino]-2-isopropyl-pentanenitrile; AC-16016; BP-21223; HY-14275; NCI60_020143; SMR001550201; SBI-0051204.P003; CP-165331; AB00053495; CS-0002967; FT-0603225; FT-0675801; ST50826367; 1394-EP2270011A1; 1394-EP2272841A1; 1394-EP2272972A1; 1394-EP2272973A1; 1394-EP2275420A1; 1394-EP2277865A1; 1394-EP2277872A1; 1394-EP2280008A2; 1394-EP2298742A1; 1394-EP2298764A1; 1394-EP2298765A1; 1394-EP2298776A1; 1394-EP2298779A1; 1394-EP2301923A1; 1394-EP2301931A1; 1394-EP2301936A1; 1394-EP2305648A1; 1394-EP2314585A1; 1394-EP2316832A1; 1394-EP2316833A1; 52V114; C07188; D02356; AB00053495-20; AB00053495_21; L001330; Q410291; BRD-A09533288-001-02-7; BRD-A09533288-003-05-6; CP-165331 /  CP-16533-1; F2173-0851; VERAPAMIL, Dexverapamil, Verapamyl hydrochloride, VERAPAMIL HYDROCHLORIDE; .alpha.-((N-Methyl-N-homoveratryl)-.gamma.-aminopropyl)-3,4-dimethoxyphenylacetonitrile; (?)-alpha-[3-[[2-(3,4-Dimethoxyphenyl)ethyl](methyl)amino]propyl]-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile; 2-(3,4-Dimethoxyphenyl)-5-((2-(3,4-dimethoxyphenyl)ethyl)(methyl)amino)-2-isopropylpentanenitrile, (+/-)-; 2-(3,4-Dimethoxyphenyl)-5-[[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino]-2-isopropylpentanenitrile #; 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl]methylamino}-2-(methy lethyl)pentanenitrile	Small molecule	1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3	SGTNSNPWRIOYBX-UHFFFAOYSA-N	CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC	C27H38N2O4	CAS 52-53-9	CHEBI:77733	.	.	.	D0R0FE	.	.	.
DR5808	MG262	CID: 490002	MG-262; PS-III; MG262; UNII-549V4DP94W; 179324-22-2; CHEMBL114388; 549V4DP94W; boro-LLL; ((5S,8S,11R)-5,8-diisobutyl-13-methyl-3,6,9-trioxo-1-phenyl-2-oxa-4,7,10-triazatetradecan-11-yl)boronic acid; Z-Leu-Leu-Leu-B(OH)2 (MG262); [(1R)-1-[[(2S)-2-[[(2S)-2-(benzyloxycarbonylamino)-4-methyl-pentanoyl]amino]-4-methyl-pentanoyl]amino]-3-methyl-butyl]boronic acid; MG 262; SCHEMBL12384366; DTXSID80170795; BDBM50069984; ZINC169998630; [(1R)-3-methyl-1-[[(2S)-4-methyl-2-[[(2S)-4-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]amino]pentanoyl]amino]butyl]boronic acid; A8179; Q27261199; L-Leucinamide, N-[(phenylmethoxy)carbonyl]-L-leucyl-N1-[(1R)-1-borono-3-methylbutyl]-; (R)-1-((S)-2-((S)-2-(benzyloxycarbonyl)-4-methylpentanamido)-4-methylpentanamido)-3-methylbutylboronic acid	Small molecule	1S/C25H42BN3O6/c1-16(2)12-20(24(31)29-22(26(33)34)14-18(5)6)27-23(30)21(13-17(3)4)28-25(32)35-15-19-10-8-7-9-11-19/h7-11,16-18,20-22,33-34H,12-15H2,1-6H3,(H,27,30)(H,28,32)(H,29,31)/t20-,21-,22-/m0/s1	MWKOOGAFELWOCD-FKBYEOEOSA-N	B(C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)OCC1=CC=CC=C1)(O)O	C25H42BN3O6	CAS 179324-22-2	.	.	.	.	.	.	.	.
DR5834	Docosahexaenoic acid	CID: 445580	Docosahexaenoic acid; Doconexent; Cervonic acid; 6217-54-5; (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid; all-cis-DHA; Doconexento; Doconexentum; Doxonexent; Docosahexaenoate; cis-4,7,10,13,16,19-Docosahexaenoic acid; AquaGrow Advantage; all-Z-Docosahexaenoic acid; Martek DHA HM; Ropufa 60; UNII-ZAD9OKH9JC; all-cis-4,7,10,13,16,19-Docosahexaenoic acid; (4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid; Docosahexaenoic acid (all-Z); CCRIS 7670; ZAD9OKH9JC; all-cis-docosa-4,7,10,13,16,19-hexaenoic acid; DOCOSA-4,7,10,13,16,19-HEXAENOIC ACID; 4,7,10,13,16,19-Docosahexaenoic acid, (all-Z)-; CHEMBL367149; docosahexaenoic acid(DHA); CHEBI:28125; delta4,7,10,13,16,19-Docosahexaenoic acid; 4-cis,7-cis,10-cis,13-cis,16-cis,19-cis-Docosahexaenoic acid; 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic acid; (4Z,7Z,10Z,13Z,16Z,19Z)-4,7,10,13,16,19-Docosahexaenoic acid; (all-Z)-4,7,10,13,16,19-Docosahexaenoic acid; OMEGA-3 MARINE TRIGLYCERIDES; MFCD00065722; efalex; NCGC00161345-04; DOCOSAHEXAENOIC ACID (22:6 n-3); 22:6(n-3); cis-4,7,10,13,16,19-Docosahexanoic acid; 4,7,10,13,16,19-Docosahexaenoic acid; C22:6n-3,6,9,12,15,18; Monolife 50; Doconexent [INN]; Marinol D 50TG; 4,7,10,13,16,19-Docosahexaenoic acid, (4Z,7Z,10Z,13Z,16Z,19Z)-; SR-05000002130; Doconexentum [INN-Latin]; Doconexento [INN-Spanish]; DHA-[21,21,22,22,22-d5]; Cervonate; 1fdq; FA 22:6; Algal DHA; cis-4,7,13,16,19-docosahexaenoic acid; Omega 3 fatty acid; all-Z-Docosahexaenoate; Cervonic acid; ; ; DHA; Spectrum5_002062; Docosahexaenoic acid (6CI); DSSTox_CID_20465; DSSTox_RID_79498; DSSTox_GSID_40465; SCHEMBL19577; BSPBio_001298; Docoshexaenoic Acid (Powder); MLS004773950; BML3-B02; GTPL1051; Retriacyl (proposed trade name); DTXSID5040465; BCBcMAP01_000145; HMS1361A20; HMS1791A20; HMS1989A20; HMS3402A20; HMS3649J15; HY-B2167; ZINC4474564; Tox21_111992; BDBM50210259; LMFA01030185; AKOS015962159; AC-1010; CCG-207958; CCG-208135; CS-6261; DB03756; KL-0761; IDI1_033768; 4,7,10,13,16,19-Docosahexaenoate; NCGC00161345-01; NCGC00161345-02; NCGC00161345-03; NCGC00161345-05; NCGC00161345-07; all cis- Docosahexaenoic acid (cis-DHA); M355; SMR001881493; CAS-6217-54-5; cis-4,7,10,13,16,19-Docosahexanoate; D2226; S6454; C06429; AB01563379_01; 217D545; Q423345; SR-05000002130-1; SR-05000002130-4; BRD-K39965020-001-02-6; 4,7,10,13,16,19-Docosahexaenoic acid, (all cis)-; A320050000; cis-4,7,10,13,16,19-Docosahexaenoic acid, >=98%; z,z,z,z,z,z-docosa-4,7,10,13,16,19-hexaenoic acid; (all-Z)-4,7,10,13,16,19-Docosahexaenoic Acid, DHA; 800E8E72-BBF4-46F7-A60B-B8F2B54669C7; C22H32O2 (cis-4,7,10,13,16,19-docosahexaenoic acid); UNII-71M78END5S component MBMBGCFOFBJSGT-KUBAVDMBSA-N; UNII-96GS7P39SN component MBMBGCFOFBJSGT-KUBAVDMBSA-N; UNII-9B22238JYI component MBMBGCFOFBJSGT-KUBAVDMBSA-N; UNII-F85N2YHE4E component MBMBGCFOFBJSGT-KUBAVDMBSA-N; 4,7,10,13,16,19-Docosahexaenoic acid, (all-Z)- (8CI); cis-4,7,10,13,16,19-Docosahexaenoic acid, analytical standard; (4Z,7Z,10Z,13Z,16Z, 19Z)-docosa-4,7,10,13,16,19-hexaenoic acid; (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4, 7,10,13,16,19-hexaenoic acid; (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19- hexaenoic acid; cis-4,7,13,16,19-Docosahexaenoic acid (stabilized with vitamine E); 4,7,10,13,16,19-Docosahexaenoic acid, (4Z,7Z,10Z,13Z,16Z,19Z)- (9CI); 1024594-51-1; cis-4,7,10,13,16,19-Docosahexaenoic acid, 500 mug/mL in ethanol, certified reference material	Small molecule	1S/C22H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24/h3-4,6-7,9-10,12-13,15-16,18-19H,2,5,8,11,14,17,20-21H2,1H3,(H,23,24)/b4-3-,7-6-,10-9-,13-12-,16-15-,19-18-	MBMBGCFOFBJSGT-KUBAVDMBSA-N	CCC=CCC=CCC=CCC=CCC=CCC=CCCC(=O)O	C22H32O2	CAS 6217-54-5	CHEBI:28125	.	.	.	D0Q5XX	.	.	.
DR5849	Tazobactam	CID: 123630	Tazobactam; 89786-04-9; Tazobactam acid; Tazobactamum; YTR-830H; YTR 830H; UNII-SE10G96M8W; CHEMBL404; CL-298741; YTR 830; CHEBI:9421; SE10G96M8W; (2S,3S,5R)-3-((1H-1,2,3-triazol-1-yl)methyl)-3-methyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide; CL 298,741; YTR 830 H; 89786-04-9 (free acid); (2S,3S,5R)-3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide; (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4lambda6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,3S,5R)-3-Methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid 4,4-dioxide; SR-01000872598; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-, 4,4-dioxide, (2S,3S,5R)-; Tazobactamum [INN-Latin]; YTR830H; CCRIS 2203; YTR830; Tazobactam,(S); Tazobactam [USAN:USP:INN:BAN]; (2S,3S,5R)-3-METHYL-4,4,7-TRIOXO-3-(1H-1,2,3-TRIAZOL-1-YLMETHYL)-4-THIA-1-AZABICYCLO[3.2.0]HEPTANE-2-CARBOXYLIC ACID; (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4?^{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Cl 298741; BRN 4787943; CL298741; Tazobactum (Free acid); Tazobactam;Tazobactan acid; EC 618-303-7; BIDD:GT0212; SCHEMBL122302; CXA201; Tazobactam (JP17/USP/INN); DTXSID8023634; GTPL10789; HMS3714G17; (2S,3S,5S)-3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide; BCP09757; EX-A1377; HY-B1418; ZINC3787060; BDBM50053173; MFCD00867002; s3077; AKOS015960801; AC-7620; CCG-207890; CS-4914; DB01606; DS-8301; NSC 759887; (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,3S,5R)-3-Methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 4,4-dioxide; A-8312; C07771; D00660; T-1445; 786T049; A843310; Q423376; Tazobactam, Antibiotic for Culture Media Use Only; SR-01000872598-1; SR-01000872598-2; 89786-04-9, 89785-84-2 (sodium salt); BRD-K14312455-001-01-6; (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(1-triazolylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-[(1H-1,2,3-triazol-1-yl)methyl]-4lambda(6)-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,3S,5R)-3-Methyl-4,4,7-trioxo-3-[1,2,3]triazol-1-ylmethyl-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid; (2S,3S,5R)-3-Methyl-4,4,7-trioxo-3-[1,2,3]triazol-1-ylmethyl-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,3S,5R)-3-Methyl-4,4,7-trioxo-3-[1,2,3]triazol-1-ylmethyl-4lambda 6-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid; (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-[1,2,3]triazol-1-ylmethyl-4lambda6-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid; (2S,3S,5R)-3-methyl-4,4,7-tris(oxidanylidene)-3-(1,2,3-triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 3-Methyl-4,4,7-trioxo-3-[1,2,3]triazol-1-ylmethyl-4lambda*6*-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-, 4,4-dioxide, (2S-(2alpha,3beta,5alpha))-; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3-methyl-7- oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-, 4,4-dioxide, [2S- (2alpha,3beta,5alpha)]-	Small molecule	1S/C10H12N4O5S/c1-10(5-13-3-2-11-12-13)8(9(16)17)14-6(15)4-7(14)20(10,18)19/h2-3,7-8H,4-5H2,1H3,(H,16,17)/t7-,8+,10+/m1/s1	LPQZKKCYTLCDGQ-WEDXCCLWSA-N	CC1(C(N2C(S1(=O)=O)CC2=O)C(=O)O)CN3C=CN=N3	C10H12N4O5S	CAS 89786-04-9	CHEBI:9421	.	.	.	D0QQ7D	.	.	.
DR5851	Dasatinib	CID: 3062316	Sprycel (TN); BMS 354825; BMS-354825; BMS-354825, Sprycel, BMS354825, Dasatinib; BMS354825; Dasatinib (USAN); Dasatinib [USAN]; Dasatinib anhydrous; Dasatinib, BMS 354825; Dasatinibum; Sprycel; Spyrcel	Small molecule	1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)	ZBNZXTGUTAYRHI-UHFFFAOYSA-N	CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO	C22H26ClN7O2S	CAS 302962-49-8	CHEBI:49375	.	.	.	D0E6XR	.	.	Dasatinib
DR5858	Bcl-2 siRNA	.	.	Small interfering RNA	.	.	.	.	.	.	.	.	.	.	.	.	.
DR5892	GSK2041706	CID: 24964226	GPR119 agonist; 1037779-47-7; SCHEMBL2370813; ZINC95929383; 5-[4-[(2R)-4-(3-fluoro-4-methylsulfonylphenoxy)butan-2-yl]piperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole	Small molecule	1S/C21H30FN3O4S/c1-14(2)20-23-21(29-24-20)25-10-7-16(8-11-25)15(3)9-12-28-17-5-6-19(18(22)13-17)30(4,26)27/h5-6,13-16H,7-12H2,1-4H3/t15-/m1/s1	AJJISMLYIMQAKP-OAHLLOKOSA-N	CC(C)C1=NOC(=N1)N2CCC(CC2)C(C)CCOC3=CC(=C(C=C3)S(=O)(=O)C)F	C21H30FN3O4S	.	.	.	.	.	.	.	.	.
DR5893	Bezafibrate	CID: 39042	bezafibrate; 41859-67-0; Bezalip; Cedur; Bezafibrat; Befizal; Sklerofibrat; Azufibrat; Bezatol; Bezafibratum; Bezafibrato; Bezafibratum [INN-Latin]; Bezafibrato [INN-Spanish]; Bezatol SR (TN); BM-15.075; UNII-Y9449Q51XH; Difaterol; 2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid; BM 15.075; 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid; BM-15075; MLS000028533; CHEMBL264374; durabezur; Reducterol; Bezabeta; Bezacur; Bezamerck; Eulitop; Solibay; CHEBI:47612; Lipox; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]-2-methylpropanoic acid; Bezafibrat PB; Y9449Q51XH; Beza-Lande; Beza-Puren; Regadrin B; 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methyl-propanoic acid; Propanoic acid, 2-(4-(2-((4-chlorobenzoyl)amino)ethyl)phenoxy)-2-methyl-; Propanoic acid, 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methyl-; MFCD00078970; BM15075; NCGC00016850-01; SMR000058298; Bezafibrato [Spanish]; Bezalip Retard; CAS-41859-67-0; DSSTox_CID_9869; Propionic acid, 2-(4-(2-((4-chlorobenzoyl)amino)ethyl)phenoxy)-2-methyl-; DSSTox_RID_78826; DSSTox_GSID_29869; 2-(4-(2-(4-Chlorobenzamido)ethyl)phenoxy)-2-methylpropanoic acid; 2-{4-[2-(4-chlorobenzamido)ethyl]phenoxy}-2-methylpropanoic acid; BM 15075; LO 44; 2-(4-{2-[(4-chlorobenzoyl)amino]ethyl}phenoxy)-2-methylpropanoic acid; 2-(4-{2-[(4-chlorophenyl)formamido]ethyl}phenoxy)-2-methylpropanoic acid; 2-[P-[2-P-CHLOROBENZAMIDO)ETHYL]PHENOXY]-2-METHYLPROPIONIC ACID; BF-759; CCRIS 9085; SR-01000000106; EINECS 255-567-9; BRN 4267656; Bezalip SR; Bezafibrate,(S); Bezafibrate [USAN:INN:BAN:JAN]; PEM; Prestwick_724; BENAFIBRATE; PubChem4066; Spectrum_001443; Opera_ID_376; Prestwick0_000378; Prestwick1_000378; Prestwick2_000378; Prestwick3_000378; Spectrum2_000922; Spectrum3_001500; Spectrum4_000325; Spectrum5_001079; Spectrum5_001967; SCHEMBL16299; Bezafibrate-d6(dimethyl-d6); BSPBio_000535; BSPBio_001314; BSPBio_003119; KBioGR_000034; KBioGR_000669; KBioSS_000034; KBioSS_001923; MLS001148205; Bezafibrate, >=98%, solid; DivK1c_000092; SPECTRUM1502046; SPBio_000824; SPBio_002456; BPBio1_000589; GTPL2668; DTXSID3029869; BDBM28701; Bezafibrate (JP17/USAN/INN); HMS500E14; KBio1_000092; KBio2_000034; KBio2_001923; KBio2_002602; KBio2_004491; KBio2_005170; KBio2_007059; KBio3_000067; KBio3_000068; KBio3_002619; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]isobutyric Acid; NINDS_000092; Bio2_000034; Bio2_000514; HMS1361B16; HMS1569K17; HMS1791B16; HMS1921H16; HMS1989B16; HMS2089F04; HMS2092B12; HMS2096K17; HMS2233E22; HMS3261D21; HMS3369B13; HMS3402B16; HMS3650K22; HMS3652M22; HMS3713K17; Pharmakon1600-01502046; BCP03700; HY-B0637; ZINC3956919; Tox21_110645; Tox21_301845; Tox21_500500; ANW-42342; CCG-39683; NSC758174; s4159; AKOS005107743; Tox21_110645_1; AB03023; AC-6817; BCP9000398; DB01393; HS-0040; LP00500; MCULE-9775992840; NSC 758174; NSC-758174; SB17361; SDCCGSBI-0051715.P003; VA10400; IDI1_000092; IDI1_033784; NCGC00016850-02; NCGC00016850-03; NCGC00016850-04; NCGC00016850-05; NCGC00016850-06; NCGC00016850-07; NCGC00016850-08; NCGC00016850-09; NCGC00016850-10; NCGC00016850-11; NCGC00016850-12; NCGC00016850-15; NCGC00016850-25; NCGC00023317-03; NCGC00023317-04; NCGC00023317-05; NCGC00023317-06; NCGC00023317-07; NCGC00023317-08; NCGC00255376-01; NCGC00261185-01; Bezafibrate, analytical reference material; BCP0726000153; Bezafibrate 100 microg/mL in Acetonitrile; SBI-0051715.P002; 2-(4-(2-(4-chlorobenzamido)ethyl)phenoxy); AB00052265; B3346; FT-0622617; ST51014927; SW196871-4; D01366; K-8763; AB00052265-15; AB00052265_16; AB00052265_17; 859B670; Q577387; SR-01000000106-3; SR-01000000106-4; SR-01000000106-5; W-106291; BRD-K46018455-001-06-0; BRD-K46018455-001-17-7; SR-01000000106-10; Bezafibrate, European Pharmacopoeia (EP) Reference Standard; 2-(4-(2-parachlorobenzamidoethyl)phenoxy)-2-methylpropionic acid; 2-[4-[2-(4-chlorobezamide)ethyl]phenoxy]-2-methylpropanoic acid; 2-(4-{2-[(4-chlorophenyl)carbonylamino]ethyl}phenoxy)-2-methylpropanoic acid; 2-[4-(2-{[(4-chlorophenyl)carbonyl]amino}ethyl)phenoxy]-2-methylpropanoic acid; BF; 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methyl propanoic acid	Small molecule	1S/C19H20ClNO4/c1-19(2,18(23)24)25-16-9-3-13(4-10-16)11-12-21-17(22)14-5-7-15(20)8-6-14/h3-10H,11-12H2,1-2H3,(H,21,22)(H,23,24)	IIBYAHWJQTYFKB-UHFFFAOYSA-N	CC(C)(C(=O)O)OC1=CC=C(C=C1)CCNC(=O)C2=CC=C(C=C2)Cl	C19H20ClNO4	CAS 41859-67-0	CHEBI:47612	.	.	.	D00WCX	.	.	.
DR5916	Centchroman	CID: 154413	Cellulose sulfate gel, Polydex	Small molecule	1S/C30H35NO3/c1-30(2)29(23-9-5-4-6-10-23)28(26-16-15-25(32-3)21-27(26)34-30)22-11-13-24(14-12-22)33-20-19-31-17-7-8-18-31/h4-6,9-16,21,28-29H,7-8,17-20H2,1-3H3/t28-,29+/m0/s1	XZEUAXYWNKYKPL-URLMMPGGSA-N	CC1(C(C(C2=C(O1)C=C(C=C2)OC)C3=CC=C(C=C3)OCCN4CCCC4)C5=CC=CC=C5)C	C30H35NO3	CAS 31477-60-8	.	.	.	.	D0ER8I	.	.	.
DR5938	Ethambutol	CID: 14052	ethambutol; 74-55-5; Ethambutolum; Aethambutolum; D-Ethambutol; (+)-S,S-Ethambutol; Ethambutol Hydrochloride; (+)-ethambutol; (S,S)-ethambutol; Myambutol; (2S,2'S)-2,2'-(Ethane-1,2-diylbis(azanediyl))bis(butan-1-ol); Etambutolo [DCIT]; Tibutol; Etambutol [INN-Spanish]; Ethambutolum [INN-Latin]; S,S-Ethambutol; Diambutol; CHEBI:4877; UNII-8G167061QZ; (+)-2,2'-(Ethylenediimino)di-1-butanol; Purderal; (+)-N,N'-Bis(1-(hydroxymethyl)propyl)ethylenediamine; EMB; 8G167061QZ; 1-Butanol, 2,2'-(1,2-ethanediyldiimino)bis-, (2S,2'S)-; (2S,7S)-2,7-diethyl-3,6-diazaoctane-1,8-diol; (2S,2'S)-2,2'-(ethane-1,2-diyldiimino)dibutan-1-ol; Etambutolo; C10H24N2O2; Ebutol; D-2,2'-(Ethylenediimino)di-1-butanol; D-2,2'-(Ethylenediimino)bis(1-butanol); 1-Butanol, 2,2'-(1,2-ethanediyldiimino)bis-, (S-(R*,R*))-; Ethambutol, racemic mixture; 1-Butanol, 2,2'-(ethylenediimino)di-, (+)-; d,N,N'-Bis(1-hydroxymethylpropyl)ethylenediamine; D-N,N'-Bis(1-hydroxymethylpropyl)ethylenediamine; Ethambutol [INN:BAN]; (R)-2,2'-(1,2-Ethanediyldiimino)bis-1-butanol; NCGC00178864-03; 1-Butanol, 2,2'-(1,2-ethanediyldiimino)bis-, (R-(R*,R*))-; HSDB 3078; Servambutol (TN); 95E; Ethambutol (INN); EINECS 200-810-6; Spectrum_001058; Spectrum2_001014; Spectrum3_000426; Spectrum4_000545; Spectrum5_000702; 1-Butanol, 2,2'-(1,2-ethanediyldiimino)bis-, (R)-; Myambutol (dihydrochloride); SCHEMBL3399; BSPBio_002012; KBioGR_001209; KBioSS_001538; CHEMBL44884; DivK1c_000561; SPBio_001167; CL 40881 (dihydrochloride); DTXSID8023006; KBio1_000561; KBio2_001538; KBio2_004106; KBio2_006674; KBio3_001232; NINDS_000561; HY-B0535; 2860AH; BDBM50448407; ZINC19364219; DB00330; MCULE-9663372083; IDI1_000561; NCGC00178864-01; SBI-0051375.P003; C06984; D07925; E-3950; AB00053473_04; AB00053473_05; Q412318; (S,S)-2,2'-(1,2-Ethanediyldiimino)bis-1-butanol; BRD-K93231391-300-03-1; (+)-(S,S)-2,2'-(1,2-Ethylenediimino)-di-1-butanol; Ethambutol dihydrochloride, Antibiotic for Culture Media Use Only; (2S)-2-[(2-{[(2S)-1-hydroxybutan-2-yl]amino}ethyl)amino]butan-1-ol; (2S)-2-[2-[[(1S)-1-(hydroxymethyl)propyl]amino]ethylamino]butan-1-ol	Small molecule	1S/C10H24N2O2/c1-3-9(7-13)11-5-6-12-10(4-2)8-14/h9-14H,3-8H2,1-2H3/t9-,10-/m0/s1	AEUTYOVWOVBAKS-UWVGGRQHSA-N	CCC(CO)NCCNC(CC)CO	C10H24N2O2	CAS 74-55-5	CHEBI:4877	.	.	.	D08QME	.	.	.
DR5956	Dimethylaminoparthenolide	CID: 52945794	CHEMBL1270635	Small molecule	1S/C17H27NO3/c1-11-6-5-9-17(2)15(21-17)14-12(8-7-11)13(10-18(3)4)16(19)20-14/h6,12-15H,5,7-10H2,1-4H3/t12-,13?,14-,15+,17+/m0/s1	UJNSFDHVIBGEJZ-CALVTZMJSA-N	CC1=CCCC2(C(O2)C3C(CC1)C(C(=O)O3)CN(C)C)C	C17H27NO3	.	.	.	.	.	.	.	.	.
DR5958	SMC3	.	Smac mimetic compound 3	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR5963	Pyrroloquinoline quinone	CID: 1024	methoxatin; pyrroloquinoline quinone; 72909-34-3; 4,5-dioxo-4,5-dihydro-1H-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylic acid; Coenzyme pqq; Pyrrolo-quinoline quinone; UNII-47819QGH5L; Pyrroloquinoline-quinone; PQQ;Methoxatin; 4,5-dioxo-1H-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylic acid; PQQ; CHEBI:18315; 47819QGH5L; pyrroloquinolinedione tricarboxylic acid; 2,7,9-Tricarboxy-1H-pyrrolo(2,3-f)quinoline-4,5-dione; Pqq coenzyme; Pqq cofactor; 4,5-dioxo-1H,4H,5H-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylic acid; 4,5-Dihydro-4,5-dioxo-1H-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylic acid; 4,5-Dihydro-4,5-dioxo-1H-pyrrolo(2,3-f)quinoline-2,7,9-tricarboxylic acid; 1H-Pyrrolo(2,3-f)quinoline-2,7,9-tricarboxylic acid, 4,5-dihydro-4,5-dioxo-; Pyrroloquinolinequinone; 4,5-Dioxo-4,5-dihydro-1H-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylate; Methoxantin; Methoxatine; 2,7,9-Tricarboxypyrroloquinoline quinone; 1H-Pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylic acid, 4,5-dihydro-4,5-dioxo-; 2,4,6-tricarboxylic-pyrrolo[2,3-5,6]quinoline 8,9-quinone; Pyrroloquinoline dione; 4,5-dihydro-4,5-dioxo-1H-pyrrolo[2,3-5,6]quinoline-2,7,9-tricarboxylic acid; Pyrroloquinoline quinone/PQQ; SCHEMBL37975; Pyrroloquinoline quinone(PQQ); Pyrroloquinoline Quinone (PQQ); CHEMBL1235421; DTXSID3041162; SCHEMBL21049248; BCP06301; ZINC1532545; ANW-49082; MFCD00043125; AKOS015920260; CS-W009276; DB03205; GS-6613; QC-4272; VA11282; Pyrroloquinoline dione tricarboxylic acid; AK-76674; AB0026456; DB-055694; HY-100196; A9450; FT-0617182; Pyrroloquinoline quinone, >=95.0% (HPLC); Pyrroloquinoline quinone, >=97.0% (HPLC); W8127; C00113; S-7393; 909M343; Q414583; C(=O)(O)C1=CC=2C(C=3C(=CC(=NC=3C(C=2O)=O)C(=O)O)C(=O)O)=N1; 4,5-Dioxo-4,5-dihydro-1H-pyrrolo-[2,3-f]quinoline-2,7,9-tricarboxylic acid	Small molecule	1S/C14H6N2O8/c17-10-4-2-6(14(23)24)15-8(4)7-3(12(19)20)1-5(13(21)22)16-9(7)11(10)18/h1-2,15H,(H,19,20)(H,21,22)(H,23,24)	MMXZSJMASHPLLR-UHFFFAOYSA-N	C1=C(C2=C(C(=O)C(=O)C3=C2NC(=C3)C(=O)O)N=C1C(=O)O)C(=O)O	C14H6N2O8	CAS 72909-34-3	CHEBI:18315	.	.	.	.	.	.	.
DR5996	Sulindac sulfone	CID: 5472495	Aposulind; Aptosyn; FGN-1; Prevatac (former Brand Name); Exisulind; (Z)-5-Fluoro-2-methyl-1-[4-(methylsulfonyl)benzylidene]-1H-indene-3-acetic acid	Small molecule	1S/C20H17FO4S/c1-12-17(9-13-3-6-15(7-4-13)26(2,24)25)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9-	MVGSNCBCUWPVDA-MFOYZWKCSA-N	CC1=C(C2=C(C1=CC3=CC=C(C=C3)S(=O)(=O)C)C=CC(=C2)F)CC(=O)O	C20H17FO4S	CAS 59973-80-7	.	.	.	.	D0M9VE	.	.	.
DR6027	Bupropion	CID: 444	bupropion; Amfebutamone; 34911-55-2; 2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one; Amfebutamon; Wellbutrin; amfebutamonum; Amfebutamona; (+-)-Bupropion; 34841-39-9; Elontril; Wellbatrin; Zyban; AMFEBUTAMONE HCl; Bupropion SR; Bupropion hydrocloride; CHEMBL894; alpha-(tert-butylamino)-m-chloropropiophenone; CHEBI:3219; (+-)-1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone; Bupropion [INN:BAN]; Amfebutamonum [INN-Latin]; Amfebutamona [INN-Spanish]; 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]propan-1-one; UNII-01ZG3TPX31; Bupropion (INN); Bupropion (USAN); BW-323; NSC315851; bupropion (amfebutamone); BRN 2101062; 01ZG3TPX31; Bupropion-[d9]; Zyban (Salt/Mix); 150988-80-0; Budeprion (Salt/Mix); Spectrum_001663; Wellbutrin (Salt/Mix); SpecPlus_000954; (.+/-.)-Bupropion; 2-(Tert-Butylamino)-3'-chloropropiophenone; Prestwick0_000249; Prestwick1_000249; Prestwick2_000249; Prestwick3_000249; Spectrum2_001659; Spectrum3_000644; Spectrum4_000614; Spectrum5_001406; (+-)-2-(tert-Butylamino)-3'-chlorpropiophenon; Lopac0_000166; SCHEMBL38777; BSPBio_000038; BSPBio_002247; KBioGR_001168; KBioSS_002143; (+-)-2-(tert-Butylamino)-3'-chloropropiophenone; MLS001424015; DivK1c_007050; SPBio_001817; SPBio_002257; BPBio1_000042; GTPL7135; DTXSID7022706; HSDB 6988; KBio1_001994; KBio2_002143; KBio2_004711; KBio2_007279; KBio3_001467; HMS2051G10; HMS2089G14; HMS2232P04; HMS3369P11; HMS3393G10; 1-Propanone, 1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-; AMY32517; BCP24193; 8068AH; AC-197; BBL029065; BDBM50048392; STL373006; 1-Propanone, 1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-, (+-)-; AKOS015961770; CCG-100858; CCG-204261; DB01156; NC00108; NSC 758686; SDCCGSBI-0050154.P004; MRF-0000143; NCGC00015122-03; NCGC00015122-04; NCGC00015122-06; NCGC00015122-07; NCGC00015122-09; NCGC00015122-14; NCGC00015122-20; NCGC00089751-02; AM807634; NCI60_002714; SMR000472526; SBI-0050154.P003; DB-048697; AB00053756; .alpha.-(tert-Butylamino)-m-chloropropiophenone; 3'-Chloro-alpha-(tert-butylamino)propiophenone; C-6222; C06860; D07591; Propiophenone, 2-(tert-butylamino)-3'-chloro-; AB00053756-16; AB00053756-18; AB00053756-19; AB00053756_20; AB00053756_21; 2-tert-Butylamino-1-(3-chlorophenyl)propan-1-one; L000725; Q834280; (.+/-.)-2-(tert-Butylamino)-3'-chloropropiophenone; BRD-A05186015-003-05-7; BRD-A05186015-003-09-9; 2-(tert-Butylamino)-1-(3-chlorophenyl)-1-propanone #; 1-(3-Chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone; 1-Propanone, 1-(3-chlorophenyl)-2-[(1, 1-dimethylethyl)amino]-; 1-Propanone, 1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-, (.+/-.)-	Small molecule	1S/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3	SNPPWIUOZRMYNY-UHFFFAOYSA-N	CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C	C13H18ClNO	CAS 34911-55-2	CHEBI:3219	.	.	.	D0X4ZR	.	.	.
DR6052	Halofuginone	CID: 400772	7-bromo-6-chloro-3-(3-((2S,3R)-3-hydroxypiperidin-2-yl)-2-oxopropyl)quinazolin-4(3H)-one; empostatin; 7-bromo-6-chloro-3-(3-((2S,3R)-3-hydroxypiperidin-2-yl)-2-oxopropyl)quinazolin-4(3H)-one.; Halofuginone (INN); Halocur [veterinary] (TN); SCHEMBL25596; CHEMBL1199539; DTXSID0048260; BCBcMAP01_000063; BCBcMAP01_000107; AMY39119; HY-N1584; ZINC1849659; AKOS026669540; CS-5485; SB19686; 7-bromo-6-chloro-3-[3-[(2S,3R)-3-hydroxypiperidin-2-yl]-2-oxopropyl]quinazolin-4-one; NCI60_039464; D08034; 837H202; A830836; Q-201182; UNII-L31MM1385E component LVASCWIMLIKXLA-LSDHHAIUSA-N; 7-Bromo-6-chloro-3-[3-(3alpha-hydroxypiperidin-2beta-yl)-2-oxopropyl]quinazolin-4(3H)-one; 7-bromo-6-chloro-3-[3-[(2S,3R)-3-hydroxy-2-piperidinyl]-2-oxopropyl]-4-quinazolinone; 7-bromanyl-6-chloranyl-3-[2-oxidanylidene-3-[(2S,3R)-3-oxidanylpiperidin-2-yl]propyl]quinazolin-4-one; 7695-84-3	Small molecule	1S/C16H17BrClN3O3/c17-11-6-13-10(5-12(11)18)16(24)21(8-20-13)7-9(22)4-14-15(23)2-1-3-19-14/h5-6,8,14-15,19,23H,1-4,7H2/t14-,15+/m0/s1	LVASCWIMLIKXLA-LSDHHAIUSA-N	C1CC(C(NC1)CC(=O)CN2C=NC3=CC(=C(C=C3C2=O)Cl)Br)O	C16H17BrClN3O3	CAS 55837-20-2	.	.	.	.	.	.	.	.
DR6061	Lenalidomide	CID: 216326	Lenalidomide; 191732-72-6; Revlimid; Revimid; 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione; CC-5013; Lenalidomide (CC-5013); CDC 501; IMiD3; CC 5013; CDC-501; 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-; 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione; Revlimid (TN); CHEBI:63791; C13H13N3O3; MFCD07772307; 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline; NCGC00167491-01; 3-(4-amino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione; DSSTox_CID_26664; DSSTox_RID_81806; DSSTox_GSID_46664; Revlimid (lenalidomide); 3-(4-Amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione; CAS-191732-72-6; Lenalidomide (USAN/INN); Lenadoamide; Lenalidomide [USAN:INN:BAN]; (3S)-3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; ENMD 0997; ENMD-0997; HSDB 8220; IMID-5013; CDC-5013; ALBB-015321; 1227162-34-6; PubChem19113; CHEMBL848; Revlimid (TN) (Celgene); SCHEMBL32978; MLS003899194; GTPL7331; SCHEMBL1980410; 3-(4-Amino-1-oxo-2-isoindolinyl)piperidine-2,6-dione; DTXSID8046664; BDBM65454; 2,6-piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-, (3S)-; 3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione; BCPP000186; HMS3654G07; HMS3674C05; BCP01390; HY-A0003; Revlimid, Lenalidomide, CC-5013; SYP-1512; Tox21_112492; ABP001089; AC-914; NSC747972; s1029; STK639603; 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H- isoindol-2-yl)-; AKOS005146276; AKOS005174869; Tox21_112492_1; ACN-034469; BCP9000847; CCG-264781; CS-0125; DB00480; KS-1207; MCULE-9771679074; NSC 747972; NSC-747972; NCGC00167491-02; NCGC00167491-03; NCGC00167491-04; AK-47482; SMR002529986; SY047646; AB0017965; AM20050439; FT-0659651; FT-0670758; FT-0670759; SW218084-2; T5245; EC-000.2340; D04687; S-4172; AB01273975-01; AB01273975-02; AB01273975_03; 732L726; Q425681; SR-01000883999; Q-101410; SR-01000883999-1; Z1741976709; 2, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-; 3-(4-amino-1,3-dihydro-1-oxo-2h-isoindol-2-yl)-2,6-piperidinedione; 3-(4-amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)-2,6-dioxopiperidine; 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)-2,6-piperidinedione; 4-amino-2-(6-hydroxy-2-oxo-2,3,4,5-tetrahydropyridin-3-yl)-2,3-dihydro-1H-isoindol-1-one; 443912-14-9	Small molecule	1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)	GOTYRUGSSMKFNF-UHFFFAOYSA-N	C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N	C13H13N3O3	CAS 191732-72-6	CHEBI:63791	.	.	.	D0Q5NX	.	.	.
DR6066	Tanespimycin	CID: 6505803	Tanespimycin; 17-AAG; 75747-14-7; 17-(Allylamino)-17-demethoxygeldanamycin; 17-(Allylamino)geldanamycin; NSC-330507; 17-Allylaminogeldanamycin; KOS-953; 17-Demethoxy-17-allylamino geldanamycin; UNII-4GY0AVT3L4; Cp 127374; NSC 330507; 17AAG; CHEBI:64153; 17-AAG (Tanespimycin); BMS-722782; 4GY0AVT3L4; MFCD04973892; NCGC00163424-01; 17-N-allylamino-17-demethoxygeldanamycin; 17-demethoxy-17-(2-propenylamino)geldanamycin; Geldanamycin, 17-demethoxy-17-(2-propenylamino)-; NSC330507; (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-19-(prop-2-en-1-ylamino)-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate; [(3S,5S,6R,7S,8E,10R,11S,12E,14E)-6-Hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-8,12,14,18,21-pentaen-10-yl] carbamate; Tanespimycin [USAN:INN]; tanespimycina; tanespimycine; tanespimycinum; CCRIS 9401; 17-Demethoxy-17-allylaminogeldanamycin; C31H43N3O8; Tanespimycin (USAN); Geldanamycin, 17-(Allylamino)-17-demethoxy-; DSSTox_CID_26352; DSSTox_RID_81555; DSSTox_GSID_46352; BSPBio_001434; SCHEMBL2604976; DTXSID5046352; SCHEMBL13037468; SCHEMBL16226295; CHEBI:94756; CNF-101; CNF1010; HMS1361H16; HMS1791H16; HMS1989H16; HMS3402H16; (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(allylamino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate; CNF-1010; EX-A4668; NSC-330507D; Tox21_112054; BDBM50008057; s1141; AKOS024456643; ZINC100014666; BCP9000064; CCG-208039; CS-0161; DB05134; NSC-704057; IDI1_033904; NCGC00163424-02; NCGC00163424-04; NCGC00163424-05; NCGC00163424-06; NCGC00163424-07; HY-10211; Geldanamycin, des-O-methyl-17-allylamino-; CAS-75747-14-7; CP-127374; Geldanamycin, 17-allylamino-17-demethoxy-; X7553; D06650; W-5317; 747A147; Geldanamycin,17-demethoxy-17-(2-propenylamino)-; J-504153; BRD-K81473043-001-03-9; BRD-K81473043-001-08-8; 17-(Allylamino)-17-demethoxygeldanamycin, >=98% (HPLC), solid; (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-Hydroxy-8,14-dimethoxy-4,10,12,16- tetramethyl-3,20,22-trioxo-19-(prop-2-enylamino)-2-azabicyclo(16.3.1)docosa- 1(21),4,6,10,18-penten-9-yl carbamate; [(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-21-(allylamino)-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-19-(prop-2-enylamino)-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl] carbamate; 17-AAG; ; ; 17-(Allylamino)-17-demethoxy-geldanamycin; ; ; [(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-6-Hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate	Small molecule	1S/C31H43N3O8/c1-8-12-33-26-21-13-17(2)14-25(41-7)27(36)19(4)15-20(5)29(42-31(32)39)24(40-6)11-9-10-18(3)30(38)34-22(28(21)37)16-23(26)35/h8-11,15-17,19,24-25,27,29,33,36H,1,12-14H2,2-7H3,(H2,32,39)(H,34,38)/b11-9-,18-10+,20-15+/t17-,19+,24+,25+,27-,29+/m1/s1	AYUNIORJHRXIBJ-TXHRRWQRSA-N	CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCC=C)C)OC)OC(=O)N)C)C)O)OC	C31H43N3O8	CAS 75747-14-7	CHEBI:64153	.	.	.	D0SC2J	.	.	.
DR6077	Lapatinib	CID: 208908	FMM; Tycerb; Lapatinib Ditosylate; Lapatinib [INN]; Lapatinib tosilate hydrate; GSK 572016; GSK572016; GW 572016; GW 572016X; GW572016; Lapatinib (INN); Tykerb (TN); Lapatinib, Tykerb, GW572016; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine; N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine; N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine; 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline; Lapatinib (ERBB2 inhibitor)	Small molecule	1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)	BCFGMOOMADDAQU-UHFFFAOYSA-N	CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl	C29H26ClFN4O4S	CAS 231277-92-2	.	.	.	.	D08CDI	.	.	Lapatinib
DR6085	NL-101	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR6122	Enoxacin	CID: 3229	Almitil; Bactidan; Comprecin; Enoram; Enoxacine; Enoxacino; Enoxacinum; Enoxin; Enoxor; Flumark; Penetrex; Enoxacin Sesquihydrate; Enoxacine [French]; Enoxacino [Spanish]; Enoxacinum [Latin]; Faulding Brand of Enoxacin; Pierre Fabre Brand of Enoxacin Sesquihydrate; Rhone Poulenc Rorer Brand of Enoxacin Sesquihydrate; AT 2266; AT2266; CI919; CL23362; E0762; PD 107779; PD107779; AT-2266; Almitil (TN); Bactidan (TN); Bactidron (TN); Comprecin (TN); Enoksetin (TN); Enoxen (TN); Enoxin (TN); Enoxor (TN); Enroxil (TN); Flumark (TN); Gyramid (TN); PD-107779; Penetrex (TN); Rhone-Poulenc Rorer Brand of Enoxacin Sesquihydrate; Sesquihydrate, Enoxacin; Vinone (TN); Enoxacin (USAN/INN); Enoxacin [USAN:BAN:INN:JAN]; 1,8-Naphthyridine-3-carboxylic acid, 6-fluoro-1,4-dihydro-4-oxo-7-piperazinyl; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,8-naphthyridine-3-carboxylic acid	Small molecule	1S/C15H17FN4O3/c1-2-19-8-10(15(22)23)12(21)9-7-11(16)14(18-13(9)19)20-5-3-17-4-6-20/h7-8,17H,2-6H2,1H3,(H,22,23)	IDYZIJYBMGIQMJ-UHFFFAOYSA-N	CCN1C=C(C(=O)C2=CC(=C(N=C21)N3CCNCC3)F)C(=O)O	C15H17FN4O3	CAS 74011-58-8	.	.	.	.	D0R8ER	.	.	.
DR6126	Amifostine	CID: 2141	amifostine; 20537-88-6; Ethiofos; Gammaphos; Ethyol; Sapep; Apaetp; Aminopropylaminoethyl thiophosphate; WR 2721; NSC-296961; YM-08310; 2-(3-Aminopropylamino)ethyl thiophosphate; AU-95722; UNII-ILA426L95O; NSC296961; Amifostine (Hydrate); WR2721; NSC 296961; WR-2721; S-(2-(3-Aminopropylamino)ethyl) phosphorothioate; CHEBI:2636; ILA426L95O; WR 2721C; Amifostina; NCGC00015073-02; S-(2-((3-Aminopropyl)amino)ethyl) dihydrogen phosphorothioate; Ethanethiol, 2-[(3-aminopropyl)amino]-, 1-(dihydrogen phosphate); 2-((3-Aminopropyl)amino)-ethanethiol, dihydrogen phosphate ester (9CI); DSSTox_CID_2585; Ethiofos Anhydrous; DSSTox_RID_76644; DSSTox_GSID_22585; C5H15N2O3PS; ({2-[(3-aminopropyl)amino]ethyl}sulfanyl)phosphonic acid; S-{2-[(3-aminopropyl)amino]ethyl} dihydrogen thiophosphate; Amifostine Ethiofos; Amifostine Anhydrous; Amifostine [USAN:INN:BAN]; CAS-20537-88-6; S-[2-(3-Aminopropylamino)ethyl] phosphorothioate; SR-01000075680; BRN 2088122; YM 08310; S-[2-[(3-Aminopropyl)amino]ethyl] dihydrogen phosphorothioate; CCRIS 9316; HSDB 7560; Amifostine,(S); 2-(3-aminopropylamino)ethylsulfanylphosphonic acid; Amifostine disulfide; S,2-(3-Aminopropylamino)ethyl-phosphorothioic acid; S-2-(3-Aminopropylamino)ethyl phosphorothioic acid; Ethyol;WR2721; Spectrum_000332; S-omega-(3-Aminopropylamino)ethyl dihydrogen phosphorothioate; SpecPlus_000647; 2-(3-Aminopropyl)aminoethylphosphorothioate; Acide ((amino-3 propylamino)-2 ethyl)-S-phosphorothioique [French]; Spectrum5_001920; Lopac-A-5922; Ethanethiol, 2-((3-aminopropyl)amino)-, dihydrogen phosphate (ester); NCIMech_000622; S 8744; CHEMBL1006; Lopac0_000029; SCHEMBL18464; KBioSS_000812; cc-307; MLS000028473; S-2-(3-aminopropylamino)-ethylphosphorothioic acid; BIDD:GT0059; DivK1c_006743; WR-2721 TRIHYDRATE; DTXSID8022585; KBio1_001687; KBio2_000812; KBio2_003380; KBio2_005948; Acide ((amino-3 propylamino)-2 ethyl)-S-phosphorothioique; HMS2090I03; HMS3260E19; HMS3713C06; Pharmakon1600-01503081; Phosphorothioic acid, S-(2-(3-aminopropylamino)ethyl) ester; BCP08957; HY-B0639; Phosphorothioic acid, S-[2-[(3-aminopropyl)amino]ethyl] ester; Tox21_110077; Tox21_500029; CCG-35734; MFCD00233058; NSC758236; ZINC21992285; AKOS015895196; Tox21_110077_1; AC-1126; DB01143; LP00029; NSC-758236; SDCCGSBI-0050018.P005; SMP2_000335; NCGC00015073-01; NCGC00015073-03; NCGC00015073-04; NCGC00015073-05; NCGC00015073-15; NCGC00093549-01; NCGC00093549-02; NCGC00260714-01; AS-13020; Ethanethiol, dihydrogen phosphate (ester); NCI60_002485; SMR000058413; Ethanethiol, dihydrogen phosphate- (ester); SBI-0050018.P003; AB0012846; EU-0100029; FT-0622272; 37A886; A 5922; C06819; [2-(3-aminopropylamino)ethylthio]phosphonic acid; 33870-EP2275420A1; 33870-EP2295055A2; 33870-EP2295416A2; 33870-EP2295426A1; 33870-EP2295427A1; 33870-EP2298748A2; 33870-EP2298764A1; 33870-EP2298765A1; 33870-EP2305642A2; 33870-EP2311453A1; 33870-EP2311808A1; 33870-EP2311829A1; AB00053311-04; AB00053311-05; AB00053311_06; A814662; Q251698; {S-[2-(3-Aminopropylamino)ethyl]} phosphorothioate; 2-(3-azanylpropylamino)ethylsulfanylphosphonic acid; J-013390; J-519582; SR-01000075680-1; SR-01000075680-3; SR-01000075680-5; 2-(3-Aminopropyl)aminoethyl phosphorothioate; WR2721; BRD-K73947551-001-01-0; 2-[(3-aminopropyl)amino]ethanethiol dihydrogen phosphate; 2-(3-aminopropylamino)ethylsulfanylphosphonic acid,trihydrate; Phosphorothioic acid, S-[2-[(3-aminopropyl)amino]ethyl]ester; S-2-(3-aminopropylamino)ethyl O,O-dihydrogen phosphorothioate; {S-[2-[(3-Aminopropyl)amino]ethyl]} dihydrogen phosphorothioate; Ethanethiol, {S-[(3-aminopropyl)amino]-,} dihydrogen phosphate- (ester)	Small molecule	1S/C5H15N2O3PS/c6-2-1-3-7-4-5-12-11(8,9)10/h7H,1-6H2,(H2,8,9,10)	JKOQGQFVAUAYPM-UHFFFAOYSA-N	C(CN)CNCCSP(=O)(O)O	C5H15N2O3PS	CAS 20537-88-6	CHEBI:2636	.	.	.	D06CIE	.	.	.
DR6157	Ionizing radiation	.	.	Radiotherapy	.	.	.	.	.	.	.	.	.	.	.	.	.
DR6166	Regorafenib	CID: 11167602	BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]; 755037-03-7	Small molecule	1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)	FNHKPVJBJVTLMP-UHFFFAOYSA-N	CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F	C21H15ClF4N4O3	CAS 755037-03-7	CHEBI:68647	.	.	.	D09GDD	.	.	.
DR6219	Esmolol	CID: 59768	ESMOLOL; 81147-92-4; 103598-03-4; Brevibloc; ASL 8052-001; Methyl 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)benzenepropanoate; Benzenepropanoic acid, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, methyl ester; CHEBI:88206; (+-)-Esmolol; Esmolol [INN:BAN]; Esmolol (INN); NCGC00185766-01; BRN 5287174; SR-01000763706; Benzenepropanoic acid, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, methyl ester; (+/-)-esmolol; CHEMBL768; SCHEMBL3605; GTPL7178; DTXSID4022995; HMS2090P06; HMS3743M15; HMS3886F03; methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate; BDBM50404796; CE0048; methyl 3-(4-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)propanoate; methyl 3-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}propanoate; MFCD00864566; s5778; AKOS015960734; methyl 3-(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)propanoate; methyl 3-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]propanoate; DB00187; SL-8052; MRF-0000253; NCGC00185766-02; NCGC00185766-05; AC-12058; ASL-8052-001; DB-015362; E1106; FT-0630886; C06980; D07916; AB00698516-07; AB00698516-09; AB00698516_10; 147E924; L001332; Q418139; SR-01000763706-3; (+/-)-methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate; Methyl 3-[4-[2-Hydroxy-3-(isopropylamino)propoxy]phenyl]propionate; 3-[4-(2-Hydroxy-3-isopropylamino-propoxy)-phenyl]-propionic acid methyl ester; 3-[4-[2-Hydroxy-3-(isopropylamino)propoxy]phenyl]propionic Acid Methyl Ester; Methyl 3-[4-[2-Hydroxy-3-(isopropylamino)propoxy]phenyl]propionate / 3-[4-[2-Hydroxy-3-(isopropylamino)propoxy]phenyl]propionic Acid Methyl Ester	Small molecule	1S/C16H25NO4/c1-12(2)17-10-14(18)11-21-15-7-4-13(5-8-15)6-9-16(19)20-3/h4-5,7-8,12,14,17-18H,6,9-11H2,1-3H3	AQNDDEOPVVGCPG-UHFFFAOYSA-N	CC(C)NCC(COC1=CC=C(C=C1)CCC(=O)OC)O	C16H25NO4	CAS 81147-92-4	CHEBI:88206	.	.	.	D03XTC	.	.	.
DR6220	S-farnesylthiosalicylic acid	CID: 5469318	Salirasib; 162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; Farnesyl Thiosalicylic Acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; Benzoic acid, 2-[[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl]thio]-; 2-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)benzoic acid; Salirasib [USAN:INN]; Farnesylthiosalicyclic acid; Salirasib; FTS; S-trans,trans-farnesylthiosalicylic acid; Salirasib (INN/USAN); Lopac-F-8175; Lopac0_000517; MLS006010835; GTPL6281; Salirasib, >=98% (HPLC); AMY39921; BCP27978; EX-A1170; ONO-7056; trans,trans-Farnesylthiobenzoic acid; ZINC1650377; 2030AH; BDBM50034278; KD-032; MFCD00467723; NSC685986; NSC755771; s7684; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; AKOS024458453; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; CCG-204607; CS-0681; DB12681; NSC-685986; NSC-755771; NCGC00015448-01; NCGC00015448-02; NCGC00015448-03; NCGC00015448-11; NCGC00093912-01; NCGC00093912-02; AS-73028; HY-14754; SMR004701762; EU-0100517; D08995; F 8175; W-5109; Farnesylthiosalicylic acid, >98% (HPLC), solid; SR-01000075885; J-009946; SR-01000075885-1; Q27088685; 2-[(3,7,11-Trimethyl-2,6,10-dodecatrienyl)thio]benzoic acid; 2-((2E,6E)-3,7,11-Trimethyl-dodeca-2,6,10-trienylsulfanyl)-benzoic acid; 2-{[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]sulfanyl}benzoic acid; 166445-40-5	Small molecule	1S/C22H30O2S/c1-17(2)9-7-10-18(3)11-8-12-19(4)15-16-25-21-14-6-5-13-20(21)22(23)24/h5-6,9,11,13-15H,7-8,10,12,16H2,1-4H3,(H,23,24)/b18-11+,19-15+	WUILNKCFCLNXOK-CFBAGHHKSA-N	CC(=CCCC(=CCCC(=CCSC1=CC=CC=C1C(=O)O)C)C)C	C22H30O2S	CAS 162520-00-5	.	.	.	.	D00KTV	.	.	.
DR6224	Sodium orthovanadate	CID: 61671	Sodium orthovanadate; 13721-39-6; Trisodium vanadate; Sodium pervanadate; Sodium o-vanadate; Sodium vanadate (ortho); Trisodium tetraoxovanadate; Sodium vanadium oxide (Na3VO4); Sodium tetraoxovanadate(3-); Vanadic acid, trisodium salt; TRISODIUM ORTHOVANADATE; Vanadic acid (H3VO4), sodium salt; UNII-7845MV6C8V; trisodium trioxido(oxo)vanadium; trisodium;trioxido(oxo)vanadium; 7845MV6C8V; MFCD00003511; Sodium orthovanadate, 99%; CCRIS 9063; EINECS 237-287-9; NSC 79534; Vanadyl; Vanadate (VO43-), trisodium, (T-4)-; AI3-52157; Vanadate(VO4(3-)), trisodium; sodiumorthovanadate; Sodium Ortho Vanadate; Sodium vanadate(V) (Na3VO4) (6CI); Na3VO4; Vanadate (VO43-), trisodium, (beta-4)-; 3Na.O4V; sodium tetraoxidovanadate(V); sodium tetraoxidovanadate(3-); DTXSID2037269; CHEBI:35607; vanadate (VO4(3-)), trisodium; AKOS004910370; CCG-266460; Sodium orthovanadate, >=90% (titration); FT-0688138; X5030; Sodium orthovanadate, 100mM aqueous solution; Vanadic acid (H3VO4), trisodium salt (8CI); Sodium orthovanadate, 99.98% trace metals basis; J-006982; Q2156566	Small molecule	1S/3Na.4O.V/q3*+1;;3*-1;	IHIXIJGXTJIKRB-UHFFFAOYSA-N	[O-][V](=O)([O-])[O-].[Na+].[Na+].[Na+]	Na3O4V	CAS 13721-39-6	CHEBI:35607	.	.	.	D0C6RO	.	.	.
DR6231	Gilteritinib	CID: 49803313	Gilteritinib; 1254053-43-4; ASP2215; ASP-2215; Xospata; UNII-66D92MGC8M; ASP 2215; 6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide; 66D92MGC8M; Gilteritinib HCl; 1254053-43-4 (free base); 2-Pyrazinecarboxamide, 6-ethyl-3-((3-methoxy-4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)-; 2-Pyrazinecarboxamide, 6-ethyl-3-[[3-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-5-[(tetrahydro-2H-pyran-4-yl)amino]-; 6-ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide.; 6-ethyl-3-[[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]amino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide; 6-ethyl-3-[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide; Gilteritinib [USAN:INN]; Gilteritinib (ASP2215); gilteritinibum; C6F; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; CHEMBL3301622; CHEBI:145372; BDBM144315; C29H44N8O3; BCP28756; EX-A2775; 3694AH; MFCD28144685; NSC787846; NSC787854; NSC788454; NSC800106; s7754; ZINC113476229; CCG-270016; CS-3885; DB12141; NSC-787846; NSC-787854; NSC-788454; NSC-800106; SB16988; NCGC00481652-01; NCGC00481652-02; AC-29030; AS-35199; HY-12432; QC-11768; DB-108103; A14411; D10709; US8969336, 547; US8969336, 577; Q27077802; 6-ethyl-3-((3-methoxy-4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)-2-pyrazinecarboxamide; 6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide; 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide; 6-Ethyl-3-[3-methoxy-4-[4-(4-methylpiperazine-1-yl)piperidino]anilino]-5-[(tetrahydro-2H-pyran-4-yl)amino]pyrazine-2-carboxamide; 6-ethyl-3-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide; 6-ethyl-3-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-[(oxan-4-yl)amino]pyrazine-2-carboxamide	Small molecule	1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34)	GYQYAJJFPNQOOW-UHFFFAOYSA-N	CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5	C29H44N8O3	CAS 1254053-43-4	CHEBI:145372	.	.	.	D04KZY	.	.	.
DR6236	Nalidixic acid	CID: 4421	nalidixic acid; 389-08-2; Nalidixin; Nevigramon; Nalidixate; Uronidix; NegGram; Innoxalon; Nalidixan; Nalitucsan; Sicmylon; Unaserus; Nalidic acid; Nalidixinic acid; Wintomylon; Dixiben; Dixinal; Jicsron; Nalurin; Naxuril; Nogram; Urisal; Cybis; Nalix; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; Nalidicron; Betaxina; Kusnarin; Narigix; Nicelate; Specifen; Specifin; Uralgin; Uriclar; Urodixin; Negram; Poleon; Uriben; Uroman; Uroneg; Uropan; Acide nalidixique; Eucistin; Acide nalidixico; Acido nalidixico; Acidum nalidixicum; 1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; NSC-82174; Nalidixane; WIN 18,320; 1,4-Dihydro-1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; 1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; 3-Carboxy-1-ethyl-7-methyl-1,8-naphthyridin-4-one; NCI-C56199; MFCD00006884; 1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-1,4-dihydro-7-methyl-4-oxo-; 3-Carboxy-1-ethyl-7-methyl-1,8-naphthidin-4-one; UNII-3B91HWA56M; 1-Ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-carboxylic acid; 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure; Nalidixic acid (NegGram); MLS000028504; 3B91HWA56M; Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico; Win 18320; CHEBI:100147; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; NSC82174; NCGC00018181-08; SMR000058264; Wintron; DSSTox_CID_912; 1,4-Dihydro-1-ethyl-7-methyl-1,8-naphthyridin-4-one-3-carboxylic acid; Acido nalidissico; Nalidixic acid, 99.5%; DSSTox_RID_75859; DSSTox_GSID_20912; Acido nalidissico [DCIT]; Acide nalidixico [Italian]; Acide nalidixique [French]; Nalidixic; Acide nalidixique [INN-French]; Acido nalidixico [INN-Spanish]; Acidum nalidixicum [INN-Latin]; 1,8-Naphthyridine-3-carboxylic acid,1-ethyl-1,4-dihydro-7-methyl-4-oxo-; CAS-389-08-2; NegGram (TN); CCRIS 2365; HSDB 3241; EINECS 206-864-7; BRN 0750515; Innoxalomn; Eucisten; nalidixic-acid; SR-01000003086; 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure [German]; Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico [Italian]; WIN-18320; WIN 183203; CHEMBL5; Spectrum_000918; Nalidixic acid [USAN:USP:INN:BAN:JAN]; Maybridge1_007101; Opera_ID_1064; Prestwick0_000187; Prestwick1_000187; Prestwick2_000187; Prestwick3_000187; Spectrum2_001360; Spectrum3_000075; Spectrum4_000817; Spectrum5_001540; Nalidixic acid, >=98%; UPCMLD-DP129; N-1200; NCIOpen2_004342; Lopac0_000837; Oprea1_010545; SCHEMBL21736; BSPBio_000113; BSPBio_001889; KBioGR_001333; KBioSS_001398; 5-25-07-00384 (Beilstein Handbook Reference); MLS001148578; MLS002303041; MLS004820190; MLS006011875; 1-ethyl-7-methyl-4-oxo-1; BIDD:GT0529; DivK1c_000058; SPECTRUM1500756; SPBio_001579; SPBio_002034; BPBio1_000125; DTXSID3020912; UPCMLD-DP129:001; BDBM21691; HMS500C20; HMS561K17; KBio1_000058; KBio2_001398; KBio2_003966; KBio2_006534; KBio3_001109; ZINC57421; NINDS_000058; HMS1921G10; HMS2092K04; HMS2232H24; HMS3259O13; HMS3374G11; HMS3656K05; Pharmakon1600-01500756; Nalidixic acid (JP17/USP/INN); Nalidixic acid, analytical standard; ALBB-021275; HY-B0398; Tox21_110835; Tox21_201477; Tox21_302754; ANW-42195; BBL012279; CCG-39298; NSC757432; SBB002146; STK735579; 1,8-Naphthyridine-3-carboxylicacid, 1-ethyl-1,4-dihydro-7-methyl-4-oxo-; 1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxilic acid; AKOS000120074; Tox21_110835_1; DB00779; MCULE-6808033849; NC00494; NSC-757432; SDCCGSBI-0050814.P004; IDI1_000058; NCGC00018181-01; NCGC00018181-02; NCGC00018181-03; NCGC00018181-04; NCGC00018181-05; NCGC00018181-06; NCGC00018181-07; NCGC00018181-09; NCGC00018181-10; NCGC00018181-12; NCGC00018181-13; NCGC00021730-03; NCGC00021730-04; NCGC00021730-05; NCGC00021730-06; NCGC00021730-07; NCGC00256581-01; NCGC00259028-01; AK163550; AS-13289; H816; NCI60_041807; SMR004703506; WLN: T66 BN EV JNJ B2 DVQ I1; SBI-0050814.P003; AB0013282; DB-049349; 1, 1-ethyl-1,4-dihydro-7-methyl-4-oxo-; BB 0242389; FT-0603390; N0490; S2328; SW219624-1; 1-Ethyl-1,8-naphthyridine-3-carboxilic acid; 1-Ethyl-1,8-naphthyridine-3-carboxylic acid; Nalidixic acid 100 microg/mL in Acetonitrile; VU0239598-6; C05079; D00183; K-8443; Nalidixic acid, meets USP testing specifications; 389N082; Q281082; SR-01000003086-4; SR-01000003086-6; BRD-K47886988-323-03-0; Nalidixic acid, Antibiotic for Culture Media Use Only; SR-01000003086-10; F0850-6751; Z256708444; 1-Ethyl-7-methyl-1,8-naphthyridin-4-one-3-carboxylic acid; 1-ethyl-7-methyl-4-oxo-[1,8]naphthyridine-3-carboxylic acid; Nalidixic acid, European Pharmacopoeia (EP) Reference Standard; Nalidixic acid, United States Pharmacopeia (USP) Reference Standard; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naph thyridine-3-carboxylic acid; 1-ethyl-7-methyl-4-oxohydropyridino[2,3-b]pyridine-3-carboxylic acid; N-benzyl-4-[(5-cyclobutyl-1,2,4-oxadiazol-3-yl)methyl]-N-ethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-6-sulfonamide	Small molecule	1S/C12H12N2O3/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14/h4-6H,3H2,1-2H3,(H,16,17)	MHWLWQUZZRMNGJ-UHFFFAOYSA-N	CCN1C=C(C(=O)C2=C1N=C(C=C2)C)C(=O)O	C12H12N2O3	CAS 389-08-2	CHEBI:100147	.	.	.	D07JGT	.	.	.
DR6255	Synthetic lipid A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR6300	Trastuzumab	.	Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)	Antibody	.	.	.	.	.	.	.	.	.	D04WFL	.	.	.
DR6317	Eravacycline	CID: 54726192	ERAVACYCLINE; TP-434; Xerava; 1207283-85-9; UNII-07896928ZC; CHEMBL1951095; 07896928ZC; (4S,4aS,5aR,12aR)-4-(dimethylamino)-7-fluoro-1,10,11,12a-tetrahydroxy-3,12-dioxo-9-[(2-pyrrolidin-1-ylacetyl)amino]-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide; Eravacycline [USAN:INN]; TP434; YQM; TP434;Eravacycline; Eravacycline (USAN); CHEMBL4597183; SCHEMBL10040430; GTPL10805; EX-A751; MFCD28978145; ZINC200151468; CS-7564; DB12329; compound 17j [PMID: 2148514]; HY-16980; D10369; J-690064; Q15410941; 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline; (4S,4aS,5aR,12aR)-4-(dimethylamino)-7-fluoro-1,10,11,12a-tetrahydroxy-3,12-dioxo-9-[2-(pyrrolidin-1-yl)acetamido]-3,4,4a,5,5a,6,12,12a-octahydrotetracene-2-carboxamide; (4S,4aS,5aR,12aS)-4-(Dimethylamino)-7-fluoro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-((pyrrolidin-1-ylacetyl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; (4S,4aS,5aR,12aS)-4-(dimethylamino)-7-fluoro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[(2-pyrrolidin-1-ylacetyl)amino]-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide; 1-Pyrrolidineacetamide, N-((5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-4-fluoro-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl)-; 7-[6-(2-Hydroxy-2-propanyl)-3-pyridinyl]-1-(4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one; N-[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-4-fluoro-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-1-pyrrolidineacetamide	Small molecule	1S/C27H31FN4O8/c1-31(2)20-13-8-11-7-12-14(28)9-15(30-16(33)10-32-5-3-4-6-32)21(34)18(12)22(35)17(11)24(37)27(13,40)25(38)19(23(20)36)26(29)39/h9,11,13,20,34-35,38,40H,3-8,10H2,1-2H3,(H2,29,39)(H,30,33)/t11-,13-,20-,27-/m0/s1	AKLMFDDQCHURPW-ISIOAQNYSA-N	CN(C)C1C2CC3CC4=C(C=C(C(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)NC(=O)CN5CCCC5)F	C27H31FN4O8	CAS 1207283-85-9	.	.	.	.	D0LZ7E	.	.	.
DR6343	Lobeline	CID: 101616	lobeline; alpha-Lobeline; (-)-Lobeline; Lobnico; Lobelin; 8,10-Diphenyllobelionol; Lobelina; Lobelinum; 90-69-7; Inflatine; UNII-D0P25S3P81; 2-(6-(2-Hydroxy-2-phenylethyl)-1-methyl-2-piperidinyl)-1-phenylethanone; 2-{(2R,6S)-6-[(2S)-2-hydroxy-2-phenylethyl]-1-methylpiperidin-2-yl}-1-phenylethanone; CHEMBL122270; CHEBI:48723; 2-(6-(beta-Hydroxyphenethyl)-1-methyl-2-piperidyl)acetophenone; D0P25S3P81; NCGC00024378-05; Alpha-Lobeline HCl; Lobeline [INN:BAN]; Lobelinum [INN-Latin]; Lobelina [INN-Spanish]; SR-01000075960; Lobeline A; Lobeline (INN); L0B; EINECS 202-012-3; BRN 0091533; Prestwick0_000585; Prestwick1_000585; Prestwick2_000585; Prestwick3_000585; DSSTox_CID_3219; DSSTox_RID_76929; DSSTox_GSID_23219; Lopac0_000698; BSPBio_000430; 5-21-12-00627 (Beilstein Handbook Reference); Ethanone, 2-(6-(2-hydroxy-2-phenylethyl)-1-methyl-2-piperidinyl)-1-phenyl-, (2R-(2alpha,6alpha(S*)))-; SCHEMBL290803; SPBio_002649; BPBio1_000474; ZINC1624; DTXSID3023219; Tox21_110900; BDBM50080818; AKOS024278800; CCG-204783; DB05137; NSC 757421; SDCCGSBI-0050676.P002; 2-((2R,6S)-6-((S)-2-hydroxy-2-phenylethyl)-1-methylpiperidin-2-yl)-1-phenylethan-1-one; CAS-90-69-7; NCGC00024378-06; NCGC00024378-07; NCGC00024378-08; NCGC00024378-09; NCGC00024378-10; NCGC00024378-14; AB00489926; C07475; D02364; Q421905; SR-01000075960-5; BRD-K66206289-003-03-1; BRD-K66206289-003-09-8; UNII-73BJ3LA259 component MXYUKLILVYORSK-HBMCJLEFSA-N	Small molecule	1S/C22H27NO2/c1-23-19(15-21(24)17-9-4-2-5-10-17)13-8-14-20(23)16-22(25)18-11-6-3-7-12-18/h2-7,9-12,19-21,24H,8,13-16H2,1H3/t19-,20+,21-/m0/s1	MXYUKLILVYORSK-HBMCJLEFSA-N	CN1C(CCCC1CC(=O)C2=CC=CC=C2)CC(C3=CC=CC=C3)O	C22H27NO2	CAS 90-69-7	CHEBI:48723	.	.	.	D01IVE	.	.	.
DR6366	Fluconazole	CID: 3365	fluconazole; 86386-73-4; Diflucan; Triflucan; Biozolene; Elazor; Biocanol; Fluconazol; Fungata; Fluconazolum; Flucostat; 2-(2,4-DIFLUOROPHENYL)-1,3-DI(1H-1,2,4-TRIAZOL-1-YL)PROPAN-2-OL; UK 49858; Flusol; Zoltec; 2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol; UK-49858; 2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol; C13H12F2N6O; UNII-8VZV102JFY; 1H-1,2,4-Triazole-1-ethanol, alpha-(2,4-difluorophenyl)-alpha-(1H-1,2,4-triazol-1-ylmethyl)-; Pritenzol; Flucazol; Flukezol; Flunizol; Zonal; CHEMBL106; 2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)-2-propanol; 8VZV102JFY; 2,4-Difluoro-alpha,alpha-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol; alpha-(2,4-Difluorophenyl)-alpha-(1H-1,2,4-triazol-1-ylmethyl)-1H-1,2,4-triazole-1-ethanol; Alflucoz; Cryptal; Dimycon; Oxifugol; Canzol; CHEBI:46081; Forcan; Syscan; Baten; Mutum; Zemyc; 2-(2,4-Difluorophenyl)-1,3-di-1H-1,2,4-triazol-1-ylpropan-2-ol; Fluconazole, 98%; MFCD00274549; difluconazole; NCGC00095089-01; Flunazol; Fluconazol [Spanish]; Fluconazolum [Latin]; Loitin; UK-49,858; DSSTox_CID_627; DSSTox_RID_75701; DSSTox_GSID_20627; FLC; DRG-0005; Diflazon; Fuconal; Triconal; Trican; Diflucan (TN); SMR000471882; CAS-86386-73-4; FLCZ; CCRIS 7211; Fluconazole & hGCSF; DIFLUCAN IN SODIUM CHLORIDE 0.9%; HSDB 7420; SR-01000765440; Fluconazole in sodium chloride 0.9%; DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER; Flucoral; 2-(2,4-difluorophenyl)-1,3-di(1,2,4-triazolyl)propan-2-ol; Fluconazole & MC-510,011; Fluconazole (f); Fluconazole,(S); Fluconazole in dextrose 5% in plastic container; 2,4-Difluoro-alpha,alpha-1-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol; Fluzon [Antifungal]; Fluconazole [USAN]; KS-1059; Fluconazole [USAN:USP:INN:BAN:JAN]; Fluconazole in sodium chloride 0.9% in plastic container; Fluconazole in combination with MGCD290; Spectrum_001654; DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER; Spectrum2_001607; Spectrum3_001912; Spectrum4_000090; Spectrum5_001277; F0677; MGCD290 and Fluconazole; cid_3365; MG-3290 and Fluconazole; SCHEMBL3151; BSPBio_003504; KBioGR_000360; KBioSS_002134; 123631-92-5; MLS001066394; MLS001165780; MLS001195645; MLS001304713; MLS001306492; MLS006011884; BIDD:GT0799; DivK1c_001030; SPECTRUM1503975; SPBio_001613; ZINC4009; Fluconazole (JP17/USP/INN); DTXSID3020627; BDBM25817; HMS503M21; KBio1_001030; KBio2_002134; KBio2_004702; KBio2_007270; KBio3_003009; NINDS_001030; BAYT006267; HMS1922O10; HMS2090I20; HMS2093M21; HMS2230O22; HMS3259H13; HMS3373I19; HMS3654P15; HMS3715F21; HMS3748G19; Pharmakon1600-01503975; AMY23415; BAYT-006267; BCP28522; Fluconazole 2.0 mg/ml in Methanol; HY-B0101; 1,2,4-triazol-1-yl)propan-2-ol; Tox21_111419; Tox21_202240; Tox21_300581; 2-(2,4-Difluoro-phenyl)-1,3-bis-[1,2,4]triazol-1-yl-propan-2-ol; ABP001077; AC-428; ANW-42860; BBL005614; CCG-39065; CF0055; DL-407; Fluconazole & Human recombinant granulocyte colony stimulating factor; KM2402; NSC754343; NSC758661; s1331; SBB066063; STK619301; AKOS000280854; Tox21_111419_1; CS-1835; DB00196; Fluconazole, >=98% (HPLC), powder; MCULE-8641424658; NC00650; NSC 758661; NSC-754343; NSC-758661; IDI1_001030; NCGC00095089-02; NCGC00095089-04; NCGC00095089-05; NCGC00095089-06; NCGC00095089-07; NCGC00095089-08; NCGC00095089-09; NCGC00095089-10; NCGC00095089-11; NCGC00254412-01; NCGC00259789-01; 2-(2,4-difluorophenyl)-1,3-di(1H-; Fluconazole 100 microg/mL in Acetonitrile; SBI-0051880.P002; AB0008515; UK-049858; FT-0626437; ST51039043; SW199616-2; EN300-53634; C07002; D00322; J10407; AB00052399-07; AB00052399-08; AB00052399_09; AB00052399_10; 386F734; A841625; Q411478; 3-[4-(pyrrolidin-1-ylsulfonyl)phenyl]propanoicacid; Q-201120; SR-01000765440-2; SR-01000765440-4; SR-01000765440-8; UK-49858;UK 49858;UK49858; BRD-K05977355-001-02-6; BRD-K05977355-001-09-1; F2173-0496; Z235354561; Fluconazole, European Pharmacopoeia (EP) Reference Standard; 2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)-2-propanol; Fluconazole, United States Pharmacopeia (USP) Reference Standard; 2-[2,4-bis(fluoranyl)phenyl]-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol; Fluconazole, Pharmaceutical Secondary Standard; Certified Reference Material; Fluconazole for peak identification, European Pharmacopoeia (EP) Reference Standard; Fluconazole solution, 2.0 mg/mL in methanol, ampule of 1 mL, certified reference material; .alpha.-(2,4-Difluorophenyl)-.alpha.-(1H-1,2,4-triazol-1-ylmethyl)-1H-1,2,4-triazole-1-ethanol	Small molecule	1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2	RFHAOTPXVQNOHP-UHFFFAOYSA-N	C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O	C13H12F2N6O	CAS 86386-73-4	CHEBI:46081	.	.	.	D09LNI	.	.	.
DR6385	Nutlin-3	CID: 216345	nutlin-3A; nutlin 3; (+/-)-Nutlin3; CHEMBL211045; Nutlin 3(Random Configuration); MDM2 Antagonist, Nutlin-3, Racemic; 4-(4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one; 4-({4,5-bis(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one; 4-[4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazole-1-carbonyl]piperazin-2-one; 548472-68-0; 890090-75-2	Small molecule	1S/C30H30Cl2N4O4/c1-18(2)40-25-16-23(39-3)12-13-24(25)29-34-27(19-4-8-21(31)9-5-19)28(20-6-10-22(32)11-7-20)36(29)30(38)35-15-14-33-26(37)17-35/h4-13,16,18,27-28H,14-15,17H2,1-3H3,(H,33,37)	BDUHCSBCVGXTJM-UHFFFAOYSA-N	CC(C)OC1=C(C=CC(=C1)OC)C2=NC(C(N2C(=O)N3CCNC(=O)C3)C4=CC=C(C=C4)Cl)C5=CC=C(C=C5)Cl	C30H30Cl2N4O4	CAS 548472-68-0	.	.	.	.	D01QKK	.	.	Nutlin-3
DR6409	Glyoxalase I	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR6421	Fluvoxamine	CID: 5324346	fluvoxamine; 54739-18-3; Fluvoxaminum; Fluvoxamina; (Z)-Fluvoxamine; UNII-O4L1XPO44W; Fluvoxaminum [INN-Latin]; Fluvoxamina [INN-Spanish]; 2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine; CHEMBL814; O4L1XPO44W; CHEBI:5138; Fluvoxamine [INN:BAN]; (1E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one O-(2-aminoethyl)oxime; DSSTox_CID_24002; DSSTox_RID_80097; DSSTox_GSID_44002; (E)-5-Methoxy-1-(4-(trifluoromethyl)phenyl)-pentan-1-one O-(2-aminoethyl) oxime; 1-Pentanone, 5-methoxy-1-(4-(trifluoromethyl)phenyl)-, O-(2-aminoethyl)oxime, (E)-; Fluvoxamine (INN); CAS-54739-18-3; C15H21F3N2O2; N06AB08; (E)-5-Methoxy-1-(4-(trifluoromethyl)phenyl)pentan-1-one O-(2-aminoethyl) oxime; NCGC00018193-06; FVX; Prestwick2_000995; Prestwick3_000995; Lopac0_000495; SCHEMBL33983; BSPBio_001089; BIDD:GT0609; BPBio1_001199; DTXSID2044002; 2-[(Z)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine; HY-B0103; Tox21_110837; BDBM50028091; ZINC12466082; AKOS016003882; Tox21_110837_1; AC-1679; CCG-204586; CS-1840; DB00176; SDCCGSBI-0050479.P002; 2-[({(1E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene}amino)oxy]ethanamine; NCGC00018193-04; NCGC00018193-05; NCGC00018193-07; NCGC00018193-08; NCGC00018193-11; NCGC00018193-21; NCGC00021870-04; NCGC00021870-05; AS-15332; O893; AB0016707; AB00514702; 39F183; C07571; D07984; AB00513735_05; AB00513735_06; A830353; BRD-K53517854-050-03-2; Q27259474; (E)-5-Methoxy-4'-(trifluormethyl)valerophenon-O-(2-aminoethyl)oxim; (2-aminoethoxy)({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene})amine; 5-methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanone O-(2-aminoethyl)oxime; 1-Pentanone, 5-methoxy-1-[4-(trifluoromethyl)phenyl]-,O-(2-aminoethyl)oxime, (1E)-	Small molecule	1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14+	CJOFXWAVKWHTFT-XSFVSMFZSA-N	COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F	C15H21F3N2O2	CAS 54739-18-3	CHEBI:5138	.	.	.	D03HFG	.	.	.
DR6422	MST312	CID: 10385095	Telomerase Inhibitor IX; 368449-04-1; CHEMBL2170856; N-[3-[(2,3-dihydroxybenzoyl)amino]phenyl]-2,3-dihydroxybenzamide; N-[3-[[(2,3-dihydroxyphenyl)-oxomethyl]amino]phenyl]-2,3-dihydroxybenzamide; Benzamide, N,N'-1,3-phenylenebis[2,3-dihydroxy-; MST312; SCHEMBL17005794; CHEBI:95003; DTXSID90439103; ZINC3937611; BDBM50396097; MST-312, >=98% (HPLC); BRD-K19894101-001-01-6; Q27166764	Small molecule	1S/C20H16N2O6/c23-15-8-2-6-13(17(15)25)19(27)21-11-4-1-5-12(10-11)22-20(28)14-7-3-9-16(24)18(14)26/h1-10,23-26H,(H,21,27)(H,22,28)	MIQUEZGHEJGPJB-UHFFFAOYSA-N	C1=CC(=CC(=C1)NC(=O)C2=C(C(=CC=C2)O)O)NC(=O)C3=C(C(=CC=C3)O)O	C20H16N2O6	CAS 368449-04-1	.	.	.	.	.	.	.	MST312
DR6428	N-acetylcysteine	CID: 12035	N-Acetyl-L-cysteine; acetylcysteine; 616-91-1; N-Acetylcysteine; mercapturic acid; Acetadote; L-Acetylcysteine; Mucomyst; N-Acetyl-cysteine; Broncholysin; Fluimucil; Parvolex; Fluprowit; Acetein; Airbron; Fabrol; Fluimucetin; Flumucetin; Mucosolvin; Mucosil; Brunac; Fluimicil Infantil; Acetilcisteina; Acetylcysteinum; Lysomucil; Mucofilin; Respaire; Exomuc; Inspir; Ac-Cys-OH; Mucolyticum Lappe; Mucolytikum Lappe; (R)-2-Acetamido-3-mercaptopropanoic acid; N-Acetyl cysteine; Mucolyticum; LNAC; N-Acetyl-3-mercaptoalanine; N-Acetyl-L-(+)-cysteine; Neo-fluimucil; NAC-TB; Acetyl-L-cysteine; component of Naxid; Mercapturic acid, (R)-; Cysteine, N-acetyl-, L-; cysteine, N-acetyl-; L-Cysteine, N-acetyl-; (R)-mercapturic acid; Fluatox; Mucolator; Mucret; Tixair; N-acetylcystein; UNII-WYQ7N0BPYC; (2R)-2-acetamido-3-sulfanylpropanoic acid; (2R)-2-Acetamido-3-sulfanyl-propanoic acid; L-alpha-Acetamido-beta-mercaptopropionic acid; MFCD00004880; NSC 111180; Mucolyticum-Lappe; WYQ7N0BPYC; MLS000028419; CHEBI:28939; NSC-111180; RK-0202; NCGC00022304-05; SMR000058377; DSSTox_CID_21; (R)-2-acetylamino-3-mercaptopropanoic acid; (2R)-2-acetylamino-3-sulfanylpropanoic acid; (2R)-2-(acetylamino)-3-sulfanylpropanoic acid; DSSTox_RID_75324; DSSTox_GSID_20021; N-Acetyl-L-cysteine, 98%; Syntemucol; Cetylev; acetyl cysteine; Flumil; Ilube; Muco sanigen; MUCOSIL-10; MUCOSIL-20; Acetylcysteinum [INN-Latin]; CAS-616-91-1; Acetilcisteina [INN-Spanish]; CCRIS 3764; HSDB 3003; SR-01000075439; EINECS 210-498-3; Mucocedyl; AcCys; NSC111180; N-acetyl-l-cys; Sodium 2-acetamido-3-mercaptopropionate; SC2; Ilube (eye drops); N-A-C Sustain; N-acetyl-L-cystein; Naxid (Salt/Mix); N-Acety-L-Cysteine; L-N-acetyl-Cysteine; Acetyl Cysteine,(S); PubChem12963; Acetylcysteine [USAN:USP:INN:BAN:JAN]; N-acetyl-(R)-cysteine; Opera_ID_452; MUCOMYST (TN); Acetylcysteine Ph. Eur.; Spectrum2_000086; Spectrum3_000287; Spectrum4_000137; Spectrum5_000764; CHEMBL600; NAC & TNF; SCHEMBL5292; Lopac0_000081; BSPBio_001794; KBioGR_000554; MLS001076125; MLS006011563; SPECTRUM1500105; SPBio_000012; DTXSID5020021; GTPL10945; KBio3_001294; N-Acetyl-L-cysteine, USP grade; Acetylcysteine (JP17/USP/INN); HMS1920A11; HMS2091G11; HMS2234J22; HMS3260A04; HMS3655G11; HMS3715D03; HMS3884E04; HY-B0215; ZINC3589203; 2-Acetylamino-3-mercapto-propionate; Tox21_110877; Tox21_201078; Tox21_500081; acetylcysteine (n-acetyl-l-cysteine); ANW-33915; BDBM50420190; CCG-38902; s1623; AKOS015841009; Tox21_110877_1; CCG-204176; DB06151; GS-3121; LP00081; SDCCGSBI-0050069.P002; NCGC00015086-04; NCGC00022304-03; NCGC00022304-04; NCGC00022304-06; NCGC00022304-07; NCGC00022304-08; NCGC00022304-17; NCGC00258631-01; NCGC00260766-01; AC-16071; AC-24117; BP-12854; I630; SBI-0051272.P003; AB0013800; DB-038288; A0905; AM20100502; EU-0100081; ST50824849; SW199597-2; (2R)-2-acetylamino-3-mercapto-propionic acid; EN300-72028; 16A911; A 7250; A-1100; C06809; D00221; L-Cysteine, N-acetyl- & Tumor necrosis factor; N-Acetyl-L-cysteine, BioXtra, >=99% (TLC); 66233-EP2298305A1; 66233-EP2308851A1; AB00051908_02; AB00382974-12; AB00382974_13; L-.alpha.-Acetamido-.beta.-mercaptopropionic acid; Q375613; J-507685; N-Acetyl-L-cysteine & Tumor necrosis factor (TNF); N-Acetyl-L-cysteine 100 microg/mL in Acetonitrile; SR-01000075439-1; SR-01000075439-3; SR-01000075439-5; BRD-K59058747-001-20-9; N-Acetyl-L-cysteine, cell culture tested, BioReagent; N-Acetyl-L-cysteine, Vetec(TM) reagent grade, 98%; F1905-7178; CABC898A-E48B-4E13-9F72-98D0609A1854; N-Acetyl-L-cysteine, SAJ special grade, 98.0-102.0%; N-Acetyl-L-cysteine, Sigma Grade, >=99% (TLC), powder; UNII-2SPH1IMO2V component PWKSKIMOESPYIA-BYPYZUCNSA-N; Acetylcysteine, British Pharmacopoeia (BP) Reference Standard; Acetylcysteine, European Pharmacopoeia (EP) Reference Standard; Acetylcysteine, United States Pharmacopeia (USP) Reference Standard; N-Acetyl-L-cysteine, Pharmaceutical Secondary Standard; Certified Reference Material; N-Acetyl-L-cysteine, PharmaGrade, Ajinomoto, Manufactured under appropriate GMP controls for pharma or biopharmaceutical production, suitable for cell culture	Small molecule	1S/C5H9NO3S/c1-3(7)6-4(2-10)5(8)9/h4,10H,2H2,1H3,(H,6,7)(H,8,9)/t4-/m0/s1	PWKSKIMOESPYIA-BYPYZUCNSA-N	CC(=O)NC(CS)C(=O)O	C5H9NO3S	CAS 616-91-1	CHEBI:28939	.	.	.	D06XGW	.	.	.
DR6516	Temozolomide	CID: 5394	Methazolastone; Temodal; Temodar; Temozolamide; Temozolodida; Temozolomidum; Essex brand of temozolomide; Scheringbrand of temozolomide; Temozolodida [Spanish]; Temozolomidum [Latin]; M B 39831; MB 39831; Sch 52365; M & B 39831; M&B 39831; M-39831; Sch-52365; Schering-Plough brand of temozolomide; TMZ-Bioshuttle; Temodal (TN); Temodar (TN); Temozolomide [INN:BAN]; M&B-39831; Temozolomide (JAN/USAN/INN); 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide; 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide; 3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide; 3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide; 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; 8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one; TMZ	Small molecule	1S/C6H6N6O2/c1-11-6(14)12-2-8-3(4(7)13)5(12)9-10-11/h2H,1H3,(H2,7,13)	BPEGJWRSRHCHSN-UHFFFAOYSA-N	CN1C(=O)N2C=NC(=C2N=N1)C(=O)N	C6H6N6O2	CAS 85622-93-1	.	.	.	.	D0C8EU	.	.	Temozolomide
DR6609	Selumetinib	CID: 10127622	Selumetinib; 606143-52-6; AZD6244; AZD 6244; ARRY-142886; 5-[(4-BROMO-2-CHLOROPHENYL)AMINO]-4-FLUORO-N-(2-HYDROXYETHOXY)-1-METHYL-1H-BENZIMIDAZOLE-6-CARBOXAMIDE; AZD-6244; Selumetinib (AZD6244); ARRY 142886; AZD6244 (Selumetinib); ARRY-886; UNII-6UH91I579U; 5-((4-bromo-2-chlorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide; 5-(4-broMo-2-chlorophenylaMino)-4-fluoro-N-(2-hydroxyethoxy)-1-Methyl-1H-benzo[d]iMidazole-6-carboxaMide; CHEMBL1614701; CHEBI:90227; 6UH91I579U; NCGC00189073-01; NCGC00189073-02; C17H15BrClFN4O3; DSSTox_CID_28870; DSSTox_RID_83139; DSSTox_GSID_48944; 1H-Benzimidazole-6-carboxamide, 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-; 6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide; 6-[(4-bromo-2-chlorophenyl)amino]-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide; AZD 6244;5-((4-Bromo-2-chlorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide;6-(4-bromo-2-chlorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide; CAS-606143-52-6; ARRY142886; AZD6244(Selumetinib); Selumetinib [USAN:INN]; selumetinibum; Koselugo; 1H-Benzimidazole-6-carboxamide, 5-((4-bromo-2-chlorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-; 3EW; PubChem21092; AZD 6244 Selumetinib; Selumetinib (USAN/INN); AZD-6244(Selumetinib); AZD6244 - Selumetinib; AZD 6244 (Selumetinib); SCHEMBL155456; GTPL5665; QCR-91; Selumetinib, ARRY-142886; DTXSID3048944; EX-A020; SYN1016; BCPP000367; CC-49; HMS3244G03; HMS3244G04; HMS3244H03; HMS3265K01; HMS3265K02; HMS3265L01; HMS3265L02; HMS3654O03; NSC 741O78; AOB87732; BCP01739; Tox21_113362; ABP000918; ANW-45526; BDBM50355497; MFCD11977472; NSC741078; NSC800882; s1008; ZINC31773258; ARRY142886/AZD6244; AKOS015904255; Tox21_113362_1; ACN-031539; BCP9000354; CCG-264774; CS-0059; DB11689; EX-8621; NSC-741078; NSC-800882; SB14707; NCGC00189073-07; AC-25059; AK-40782; AM808016; AZD6244,Selumetinib, ARRY-142886; BC004624; HY-50706; AZD6244 (Selumetinib,ARRY-142886); AB0007973; FT-0674552; SW202561-3; X2640; D09666; S-7764; 143A526; Q-101405; Q7448840; BRD-K57080016-001-01-9; 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-1,3-benzodiazole-6-carboxamide; 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy -ethoxy)-amide; 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide; 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid(2-hydroxy-ethoxy)-amide; 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethoxy)-amide; 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid(2-hydroxyethoxy)-amide; 6-(4-bromo-2-chlorophenylamino)-N-(2-hydroxyethoxy)-3,7-dimethyl-3H-benzo[d]imidazole-5-carboxamide; 6-(4-bromo-2chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide	Small molecule	1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)	CYOHGALHFOKKQC-UHFFFAOYSA-N	CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO	C17H15BrClFN4O3	CAS 606143-52-6	CHEBI:90227	.	.	.	D0T5DP	.	.	.
DR6631	ABT-737	CID: 11228183	ABT 737; ABT737; UNII-Z5NFR173NV; Z5NFR173NV; 4-[4-[(4'-Chloro[1,1'-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]benzamide; CHEMBL376408; C42H45ClN6O5S2; 4-{4-[(4'-Chlorobiphenyl-2-Yl)methyl]piperazin-1-Yl}-N-{[4-({(1r)-3-(Dimethylamino)-1-[(Phenylthio)methyl]propyl}amino)-3-Nitrophenyl]sulfonyl}benzamide	Small molecule	1S/C42H45ClN6O5S2/c1-46(2)23-22-35(30-55-37-9-4-3-5-10-37)44-40-21-20-38(28-41(40)49(51)52)56(53,54)45-42(50)32-14-18-36(19-15-32)48-26-24-47(25-27-48)29-33-8-6-7-11-39(33)31-12-16-34(43)17-13-31/h3-21,28,35,44H,22-27,29-30H2,1-2H3,(H,45,50)/t35-/m1/s1	HPLNQCPCUACXLM-PGUFJCEWSA-N	CN(C)CCC(CSC1=CC=CC=C1)NC2=C(C=C(C=C2)S(=O)(=O)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)CC5=CC=CC=C5C6=CC=C(C=C6)Cl)[N+](=O)[O-]	C42H45ClN6O5S2	CAS 852808-04-9	.	.	.	.	D0L8WH	.	.	.
DR6637	Indole-3-carbinol	CID: 3712	3-Indolemethanol; INDOLE-3-METHANOL; (1H-Indol-3-yl)methanol; 1H-indol-3-ylmethanol; 3-Hydroxymethylindole; 1H-Indole-3-methanol; 3-Indolylcarbinol; Indinol; 3-(Hydroxymethyl)indole; 3-Indole methanol; Indole 3 carbinol; (1H-Indol-3-yl)-methanol; I3C; MFCD00005632; UNII-C11E72455F; CHEBI:24814; C11E72455F; NSC-525801; NCGC00090701-06; indol-3-ylmethan-1-ol; I0496; Indole-3-carbinol, 97%; SMR000385784; CCRIS 3261; EINECS 211-836-2; 1H-Indol-3-Yl-Methanol; NSC 525801; BRN 0121323; AI3-60090; 3-Indolecarbinol; 3-Indolylmethanol; Prevention 4 (indole-3-carbinol); indole-3-carbinole; zlchem 356; PubChem7265; 3-hydroxymethyl indole; Spectrum2_001710; Spectrum3_001973; ACMC-209oc7; 1~{H}-indol-3-ylmethanol; DSSTox_CID_11458; DSSTox_RID_78876; DSSTox_GSID_31458; BSPBio_003573; MLS001333161; MLS001333162; SCHEMBL195520; SPECTRUM1505320; SPBio_001700; CHEMBL155625; 1H-Indole-3-methanol (9CI); 3-Phenoxybenzylaminehydrochloride; DTXSID7031458; GTPL10047; KBio3_002949; ZLC0198; HMS1789O22; HMS2235E10; HMS3369B02; HMS3651I18; HMS3749E07; ZINC158743; ACN-S002804; ACT03591; BCP00087; HY-N0170; INDOLE-3-CARBINOL  (I3C); Tox21_400055; 9344AF; ANW-35813; CCG-38786; HSCI1_000097; NSC525801; s2313; SBB004095; AKOS001075120; AC-7583; CS-7780; DB12881; GS-0916; LS20980; MCULE-6344603304; SB14958; SDCCGMLS-0065970.P001; SDCCGMLS-0065970.P002; VI30396; Indole-3-methanol (Indole-3-carbinol); SMP2_000172; NCGC00090701-01; NCGC00090701-02; NCGC00090701-03; NCGC00090701-04; NCGC00090701-05; NCGC00090701-07; AK-53373; CAS-700-06-1; SY015976; AB0008317; DB-011567; A9256; FT-0615875; ST50308202; SW219849-1; 00I061; I-2100; M-3233; A836732; SR-01000838318; Q1770257; SR-01000838318-3; BRD-K01815685-001-02-3; BRD-K01815685-001-07-2; Z85923165; FXK	Small molecule	1S/C9H9NO/c11-6-7-5-10-9-4-2-1-3-8(7)9/h1-5,10-11H,6H2	IVYPNXXAYMYVSP-UHFFFAOYSA-N	C1=CC=C2C(=C1)C(=CN2)CO	C9H9NO	CAS 700-06-1	.	.	.	.	.	.	.	.
DR6642	Thymic stromal lymphopoietin	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR6644	6-benzylthioinosine	CID: 6477178	6-Benzylthioinosine; CHEMBL60662; (2R,3R,4S,5R)-2-(6-benzylsulfanylpurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; SCHEMBL7617372; BDBM50240561; ZINC13560348; Purine, 6-benzylthio-9-beta-D-ribofuranosyl-; (2R,3R,4S,5R)-2-(6-Benzylsulfanyl-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol; (2R,3R,4S,5R)-2-(6-benzylsulfanylpurin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; (2R,3R,4S,5R)-2-(6-(benzylthio)-9H-purin-9-yl)-5-(hydroxymethyl)-tetrahydrofuran-3,4-diol; (2R,3R,4S,5R)-2-(6-(benzylthio)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol	Small molecule	1S/C17H18N4O4S/c22-6-11-13(23)14(24)17(25-11)21-9-20-12-15(21)18-8-19-16(12)26-7-10-4-2-1-3-5-10/h1-5,8-9,11,13-14,17,22-24H,6-7H2/t11-,13-,14-,17-/m1/s1	OMJRXFOHHLLDFR-LSCFUAHRSA-N	C1=CC=C(C=C1)CSC2=NC=NC3=C2N=CN3C4C(C(C(O4)CO)O)O	C17H18N4O4S	.	.	.	.	.	.	.	.	.
DR6676	Rifaximin alpha	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR6681	Epirubicin	CID: 41867	Epirubicin; Epiadriamycin; Epidoxorubicin; 4'-Epiadriamycin; Ellence; 56420-45-2; Epirubicine; Epirubicinum; Pidorubicina; Pidorubicine; Pidorubicinum; Epirubicina; 4'-epidoxorubicin; 4-Epidoxorubicin; Epirubicin hydrochloride; Pidorubicin; Epirubicin free base; UNII-3Z8479ZZ5X; Ridorubicin; NSC 256942; CHEBI:47898; Epi-DX; Epirubicine [French]; Epirubicinum [Latin]; 3Z8479ZZ5X; Epirubicina [Spanish]; IMI 28; Epirubicine [INN-French]; Epirubicinum [INN-Latin]; Epirubicina [INN-Spanish]; Pidorubicine [INN-French]; Pidorubicinum [INN-Latin]; 56420-45-2 (FREE BASE); Pidorubicina [INN-Spanish]; Epirubicin [INN:BAN]; NSC-256942; WP 697; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside; (8S,10S)-10-(((2R,4S,5R,6S)-4-Amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione; Epirubicin (INN); Farmorubicin (TN); CCRIS 2261; HSDB 6962; NSC256942; BRN 1445813; DM6; Acid, 8; CHEMBL417; SCHEMBL8582; (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; DTXSID0022987; EPIRUBICIN(Hydrochloride form); BDBM43839; Doxorubicin-13CD3 (discontinued); ZINC3938704; DB00445; VA10821; NCGC00263918-04; NCGC00263918-08; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside; (7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; 10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione; 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-; HY-13624; SBI-0206890.P001; A12409; C11230; D07901; 15206-EP2269994A1; 15206-EP2270008A1; 15206-EP2270018A1; 15206-EP2272827A1; 15206-EP2275420A1; 15206-EP2280012A2; 15206-EP2281815A1; 15206-EP2289892A1; 15206-EP2292615A1; 15206-EP2292617A1; 15206-EP2295055A2; 15206-EP2295416A2; 15206-EP2295426A1; 15206-EP2295427A1; 15206-EP2298748A2; 15206-EP2298764A1; 15206-EP2298765A1; 15206-EP2298768A1; 15206-EP2298778A1; 15206-EP2298780A1; 15206-EP2301928A1; 15206-EP2301933A1; 15206-EP2305640A2; 15206-EP2305642A2; 15206-EP2305671A1; 15206-EP2305689A1; 15206-EP2308855A1; 15206-EP2308861A1; 15206-EP2311453A1; 15206-EP2311808A1; 15206-EP2311825A1; 15206-EP2311827A1; 15206-EP2311829A1; 15206-EP2311840A1; 15206-EP2311842A2; 15206-EP2316832A1; 15206-EP2316833A1; AB00698552-11; AB00698552-13; AB00698552-14; AB00698552_15; AB00698552_16; A831042; Q425122; BRD-K04548931-003-16-5; (7S,9S)-7-[(2R,4S,5R,6S)-4-azanyl-6-methyl-5-oxidanyl-oxan-2-yl]oxy-4-methoxy-6,9,11-tris(oxidanyl)-9-(2-oxidanylethanoyl)-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-7-[[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyl-2-oxanyl]oxy]-6,9,11-trihydroxy-9-(2-hydroxy-1-oxoethyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S,10S)-10-{[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione; 4'-Epidoxorubicin; ; ; 4'-Epiadriamycin; ; ; (8S,10S)-10-(((2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione; 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-.alpha.-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)-; 5,12-Naphthacenedione,10-[(3-amino-2,3,6-trideoxy-a-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-	Small molecule	1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22-,27-/m0/s1	AOJJSUZBOXZQNB-VTZDEGQISA-N	CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O	C27H29NO11	CAS 56420-45-2	CHEBI:47898	.	.	.	D0C9XJ	.	.	.
DR6690	Streptomycin	CID: 19649	streptomycin; 57-92-1; Streptomycin A; Strepcen; Gerox; Streptomycine; Streptomycin sulphate; Chemform; Streptomycin sulfate; CHEBI:17076; UNII-Y45QSO73OB; Estreptomicina; NSC-14083; Streptomycin A sulfate; Y45QSO73OB; 2,4-Diguanidino-3,5,6-trihydroxycyclohexyl 5-deoxy-2-O-(2-deoxy-2-methylamino-alpha-L-glucopyranosyl)-3-C-formyl-beta-L-lyxopentanofuranoside; 2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine; Agrimycin; Agrept; Neodiestreptopab; Streptomicina; Streptomycinum; Streptomyzin; Hokko-mycin; [2-deoxy-2-(dimethylamino)-alpha-L-glucopyranosyl]-(1->2)-[5-deoxy-3-C-formyl-alpha-L-lyxofuranosyl]-(1->4)-{N',N'''-[(1,3,5/2,4,6)-2,4,5,6-tetrahydroxycyclohexane-1,3-diyl]diguanidine}; 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine; N,N'''-[(1R,2R,3S,4R,5R,6S)-4-({5-deoxy-2-O-[2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl]-3-C-formyl-alpha-L-lyxofuranosyl}oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine; SRY; Streptomycin Sesquisulfate Hydrate; Caswell No. 804; Streptomyzin [German]; Streptomicina [Italian]; NCGC00159339-02; Streptomycin [INN:BAN]; Streptomycin, Sulfate Salt; streomycin; Geroxeg; Estreptomicina [INN-Spanish]; CCRIS 5730; HSDB 1768; Streptomycin,(S); 1-[(1S,2R,3R,4S,5R,6R)-2-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)tetrahydropyran-2-yl]oxy-4-formyl-4-hydroxy-5-methyl-tetrahydrofuran-2-yl]oxy-5-guanidino-3,4,6-trihydroxy-cyclohexyl]guanidine; Streptomycin (TN); EINECS 200-355-3; Streptomycin (INN); EPA Pesticide Chemical Code 006306; Liposomal Streptomycin; NSC14083; BRN 0074498; Epitope ID:224553; SCHEMBL3276; 4-18-00-07540 (Beilstein Handbook Reference); D-Streptamine, O-2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl-(1-2)-O-5-deoxy-3-C-formyl-alpha-L-lyxofuranosyl-(1-4)-N,N'-bis(aminoiminomethyl)-; CHEMBL372795; DTXSID4023597; GTPL10923; Streptomycin Sesquisulphate Hydrate; ZINC8214681; BDBM50103513; MFCD00072108; AKOS015969759; AM84920; DB01082; AS-35042; tetrahydro-2H-pyran-2-yloxy)-4-formyl-4; 280-EP2269990A1; 280-EP2270001A1; 280-EP2270006A1; 280-EP2270008A1; 280-EP2270014A1; 280-EP2272832A1; 280-EP2275420A1; 280-EP2275422A1; 280-EP2277861A1; 280-EP2277876A1; 280-EP2277880A1; 280-EP2277898A2; 280-EP2281563A1; 280-EP2281824A1; 280-EP2284154A1; 280-EP2284169A1; 280-EP2284171A1; 280-EP2284172A1; 280-EP2286812A1; 280-EP2287161A1; 280-EP2287162A1; 280-EP2289876A1; 280-EP2289882A1; 280-EP2289886A1; 280-EP2289892A1; 280-EP2289893A1; 280-EP2292088A1; 280-EP2292592A1; 280-EP2292608A1; 280-EP2292610A1; 280-EP2292612A2; 280-EP2292614A1; 280-EP2292617A1; 280-EP2295055A2; 280-EP2295402A2; 280-EP2295411A1; 280-EP2295416A2; 280-EP2295417A1; 280-EP2295434A2; 280-EP2298748A2; 280-EP2301536A1; 280-EP2301538A1; 280-EP2301544A1; 280-EP2301940A1; 280-EP2305033A1; 280-EP2305652A2; 280-EP2305658A1; 280-EP2305662A1; 280-EP2305684A1; 280-EP2305688A1; 280-EP2308562A2; 280-EP2308844A2; 280-EP2308845A2; 280-EP2308846A2; 280-EP2308855A1; 280-EP2308857A1; 280-EP2308872A1; 280-EP2308960A1; 280-EP2311453A1; 280-EP2311455A1; 280-EP2311494A1; 280-EP2311806A2; 280-EP2311836A1; 280-EP2314583A1; 280-EP2316452A1; 280-EP2316459A1; 280-EP2316829A1; 280-EP2316832A1; 280-EP2316833A1; 280-EP2316937A1; 280-EP2371811A2; C00413; D08531; 3-((2S,3S,4S,5R,6S)-4,5-dihydroxy-6; AB00443813_02; 057S921; 2,5,6-trihydroxycyclohexane-1,3-diyl)diguanidine; Q192717; BRD-K07166362-330-02-8; 1,-((1R,2R,3S,4R,5R,6S)-4-((2R,3R,4R,5S)-; 2,4-Diguanidino-3,5,6-trihydroxycyclohexyl 5-deoxy-2-O-(2-deoxy-2-methylamino-alpha-glucopyranosyl)-3-formylpentofuranoside; D-Streptamine, O-2-deoxy-2-(methylamino)-.alpha.-L-glucopyranosyl-(1->2)-O-5-deoxy-3-C-formyl-.alpha.-L-lyxofuranosyl-(1->4)-N,N'-bis(aminoiminomethyl)-; D-Streptamine, O-2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl-(1.fwdarw.2)-O-5-deoxy-3-C-formyl-alpha-L-lyxofuranosyl-(1.fwdarw.4)-N,N'-bis(aminoiminomethyl)-; N,N'''-[(1R,2R,3S,4R,5R,6S)-4-{5-deoxy-2-O-[2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl]-3-C-formyl-alpha-L-lyxofuranosyloxy}-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine; O-2-Deoxy-2-(methylamino)-.alpha.-L-glucopyranosyl-(1->2)-O-5-deoxy-3-C-formyl-.alpha.-L-lyxofuranosyl-(1->4)-N,N'-bis(aminoiminomethyl)-D-streptamine and Liposome	Small molecule	1S/C21H39N7O12/c1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35/h4-18,26,29,31-36H,3H2,1-2H3,(H4,22,23,27)(H4,24,25,28)/t5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+/m0/s1	UCSJYZPVAKXKNQ-HZYVHMACSA-N	CC1C(C(C(O1)OC2C(C(C(C(C2O)O)N=C(N)N)O)N=C(N)N)OC3C(C(C(C(O3)CO)O)O)NC)(C=O)O	C21H39N7O12	CAS 57-92-1	CHEBI:17076	.	.	.	D0N0EQ	.	.	.
DR6719	Lincomycin	CID: 3000540	lincomycin; 154-21-2; Cillimycin; Lincomycinum; Lincomicina; Lincomycin A; Lincomycin hydrochloride; UNII-BOD072YW0F; CHEMBL1447; Lincolnensin; Lincomycine; Jiemycin; Lincocin; Lincomycin (USAN/INN); BOD072YW0F; U 10,149A; CHEBI:6472; Frademicina; (2S,4R)-N-((1R,2R)-2-hydroxy-1-((2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)propyl)-1-methyl-4-propylpyrrolidine-2-carboxamide; U-10149; Methyl 6,8-dideoxy-6-trans-(1-methyl-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-D-erythro-alpha-D-galacto-octopyranoside; U-10,149; LCM; (2S,4R)-N-[(1R,2R)-2-hydroxy-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylsulfanyl)oxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide; (2S,4R)-N-[(1R,2R)-2-hydroxy-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyl-tetrahydropyran-2-yl]propyl]-1-methyl-4-propyl-pyrrolidine-2-carboxamide; methyl 6,8-dideoxy-6-{[(4R)-1-methyl-4-propyl-L-prolyl]amino}-1-thio-D-erythro-alpha-D-galacto-octopyranoside; Lincomycin, (2S-cis)-Isomer; Lincomycine [French]; C18H34N2O6S; NSC-70731; AC1MHD7X; Lincomycine [INN-French]; Lincomycinum [INN-Latin]; Lincomicina [INN-Spanish]; Bactramycin; Lincorex; Lincomycin [USAN:INN:BAN]; HSDB 3109; L-Mycin; Lincomycin,(S); 3QB; EINECS 205-824-6; NSC70731; BRN 0707677; SCHEMBL4010; D-erythro-alpha-D-galacto-Octopyranoside, methyl 6,8-dideoxy-6-(((1-methyl-4-propyl-2-pyrrolidinyl)carbonyl)amino)-1-thio-, (2S-trans)-; DTXSID3023215; GTPL10941; HMS2089A13; ZINC3982483; BDBM50335522; AKOS015951392; CCG-208231; DB01627; MCULE-4676929559; NE39438; SMP1_000178; (2S,4R)-N-[(1R,2R)-2-hydroxy-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide; D-erythro-D-galacto-Octopyranoside, methyl 6,8-dideoxy-6-(1-methyl-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-, trans-alpha-; Methyl 6,8-dideoxy-6-(1-methyl-4-propyl-2-pyrrolidinecarboxamido)-1-thio-D-erythro-D-galacto-octopyranoside (alpha-form); 54L212; C06812; D00223; AB01275426-01; Lincomycin, Antibiotic for Culture Media Use Only; Q423428; W-109518; BRD-K49384696-003-01-9; Z1665194511; (2S,4R)-N-((1R,2R)-2-hydroxy-1-((2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylthio)-tetrahydro-2H-pyran-2-yl)propyl)-1-methyl-4-propylpyrrolidine-2-carboxamide; (2S,4R)-N-((1S)-2-hydroxy-1-((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylthio)-tetrahydro-2H-pyran-2-yl)propyl)-1-methyl-4-propylpyrrolidine-2-carboxamide; 1-Methyl-4-propyl-pyrrolidine-2-carboxylic acid [2-hydroxy-1-(3,4,5-trihydroxy-6-methylsulfanyl-tetrahydro-pyran-2-yl)-propyl]-amide; D-Erythro-.alpha.-D-gluco-octopyranoside, methyl 6,8-dideoxy-6-[[[(2S,4R)-1-methyl-4-propyl-2-pyrrolidinyl]carbonyl]amino]-1-thio-; D-erythro-alpha-D-galacto-Octopyranoside, methyl 6,8-dideoxy-6-((((2S,4R)-1-methyl-4-propyl-2-pyrrolidinyl)carbonyl)amino)-1-thio-; Methyl (5r)-5-[(1r,2r)-2-Hydroxy-1-{[(4r)-1-Methyl-4-Propyl-L-Prolyl]amino}propyl]-1-Thio-Beta-L-Arabinopyranoside; methyl 6,8-dideoxy-6-({[(2S,4R)-1-methyl-4-propylpyrrolidin-2-yl]carbonyl}amino)-1-thio-D-erythro-alpha-D-galacto-octopyranoside	Small molecule	1S/C18H34N2O6S/c1-5-6-10-7-11(20(3)8-10)17(25)19-12(9(2)21)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,21-24H,5-8H2,1-4H3,(H,19,25)/t9-,10-,11+,12-,13+,14-,15-,16-,18-/m1/s1	OJMMVQQUTAEWLP-KIDUDLJLSA-N	CCCC1CC(N(C1)C)C(=O)NC(C2C(C(C(C(O2)SC)O)O)O)C(C)O	C18H34N2O6S	CAS 154-21-2	CHEBI:6472	.	.	.	D0Q0EX	.	.	.
DR6727	Balsalazide	CID: 54585	BALSALAZIDE; 80573-04-2; Balsalazido; Balsalazida; Balsalazidum; Balsalazidum [Latin]; Balsalazida [Spanish]; Balsalazido [Spanish]; Balsalazide Disodium; Colazide; (E)-5-((4-((2-Carboxyethyl)carbamoyl)phenyl)diazenyl)-2-hydroxybenzoic acid; UNII-P80AL8J7ZP; (E)-5-((4-(((2-Carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acid; P80AL8J7ZP; CHEMBL1208641; CHEBI:267413; (E)-5-({p-[(2-carboxyethyl)carbamoyl]phenyl}azo)-2-salicylic acid; 5-[4-(2-carboxy-ethylcarbamoyl)-phenylazo]-2-hydroxy-benzoic acid; C17H15N3O6; 5-[(E)-{4-[(2-carboxyethyl)carbamoyl]phenyl}diazenyl]-2-hydroxybenzoic acid; Giazo; 3-(2-{4-[(2-carboxyethyl)carbamoyl]phenyl}hydrazinylidene)-6-oxocyclohexa-1,4-diene-1-carboxylic acid; NCGC00164634-01; Balsalazide [INN:BAN]; DSSTox_CID_20653; DSSTox_RID_79523; DSSTox_GSID_40653; 3-[[4-[(2-carboxyethylamino)-oxomethyl]phenyl]hydrazinylidene]-6-oxo-1-cyclohexa-1,4-dienecarboxylic acid; 5-[[4-(2-carboxyethylcarbamoyl)phenyl]diazenyl]-2-hydroxybenzoic acid; (E)-5-[[[-4-(2-Carboxyethyl)aminocarbonyl]phenyl]azo]-2-hydroxybenzoic acid; Balsalazide (INN); CAS-80573-04-2; Balsalazide-[d3]; (3Z)-3-[[4-(2-carboxyethylcarbamoyl)phenyl]hydrazinylidene]-6-oxocyclohexa-1,4-diene-1-carboxylic acid; MLS001424257; BIDD:GT0772; SCHEMBL118300; SCHEMBL138311; SCHEMBL142548; CHEMBL1201346; DTXSID7040653; SCHEMBL15841310; CHEBI:94605; GTPL11569; HMS2052K19; HMS2233C19; HMS3369E09; HMS3394K19; HY-B0667; ZINC3952881; Tox21_112252; ANW-61237; MFCD00868204; s4842; ZINC13863965; AKOS015892568; Tox21_112252_1; ZINC100050064; ZINC100056740; ZINC242522365; AC-8500; CCG-101140; DB01014; KS-5215; NC00390; NE31766; VA10368; Benzoic acid, 5-((4-(((2-carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxy-, (E)-; NCGC00164634-02; (3E)-3-[[4-(2-carboxyethylcarbamoyl)phenyl]hydrazinylidene]-6-oxocyclohexa-1,4-diene-1-carboxylic acid; AS-17568; SMR000469221; AB0020029; FT-0602905; V0740; D07488; AB01209737-01; 573B042; A839951; Q347337; Q-200671; Q27166431; 5-[4-(2-Carboxyethylcarbamoyl)phenylazo]salicylic acid; Bacitracin zinc, Antibiotic for Culture Media Use Only; (E)-5-((4-(2-carboxyethylcarbamoyl)phenyl)diazenyl)-2-hydroxybenzoic acid; 5-((4-((2-carboxyethyl)carbamoyl)phenyl)diazenyl)-2-hydroxybenzoic acid; 5-(2-{4-[(2-carboxyethyl)carbamoyl]phenyl}diazen-1-yl)-2-hydroxybenzoic acid; (3E)-3-(2-{4-[(2-carboxyethyl)carbamoyl]phenyl}hydrazinylidene)-6-oxocyclohexa-1,4-diene-1-carboxylic acid; 3-[[4-(3-hydroxy-3-oxopropylcarbamoyl)phenyl]hydrazinylidene]-6-oxidanylidene-cyclohexa-1,4-diene-1-carboxylic acid; 399030-81-0	Small molecule	1S/C17H15N3O6/c21-14-6-5-12(9-13(14)17(25)26)20-19-11-3-1-10(2-4-11)16(24)18-8-7-15(22)23/h1-6,9,21H,7-8H2,(H,18,24)(H,22,23)(H,25,26)	IPOKCKJONYRRHP-UHFFFAOYSA-N	C1=CC(=CC=C1C(=O)NCCC(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O	C17H15N3O6	CAS 80573-04-2	CHEBI:267413	.	.	.	D0A6KR	.	.	.
DR6730	10058F4	CID: 1271002	10058-F4; 403811-55-2; (5E)-5-(4-ethylbenzylidene)-2-mercapto-1,3-thiazol-4(5H)-one; 5-[(4-Ethylphenyl)methylene]-2-thioxo-4-thiazolidinone; 5-(4-ethylbenzylidene)-2-thioxothiazolidin-4-one; 10058F4; (E)-5-(4-Ethylbenzylidene)-2-mercaptothiazol-4(5H)-one; c-Myc Inhibitor; 10058-F4 compound; 5-(4-ethylbenzylidene)-2-sulfanylidene-1,3-thiazolidin-4-one; CHEMBL1568415; SCHEMBL10042186; (Z,E)-5-(4-Ethylbenzylidine)-2-thioxothiazolidin-4-one; EX-A660; CHEBI:149696; HMS3260I13; ALBB-009118; Tox21_500046; MFCD00758517; MFCD04969046; NSC764582; s7153; ZINC12406714; (5E)-5-[(4-ethylphenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one; AKOS000307369; AKOS003017633; CCG-221350; CS-3965; LP00046; NSC-764582; SB19479; SDCCGSBI-0633678.P001; NCGC00185994-01; NCGC00185994-10; NCGC00260731-01; AC-32727; AS-55984; HY-12702; c-Myc Inhibitor - CAS 403811-55-2; BB 0259511; SW219661-1; 10058-F4, >=98% (HPLC), solid; A13725; Y-1489; AB00084200-01; SR-01000208026; SR-01000208026-1; 5-(4-ethylbenzylidene)-2-mercapto-1,3-thiazol-4(5H)-one; 5-[(4-ethylphenyl)methylidene]-2-sulfanyl-4,5-dihydro-1,3-thiazol-4-one	Small molecule	1S/C12H11NOS2/c1-2-8-3-5-9(6-4-8)7-10-11(14)13-12(15)16-10/h3-7H,2H2,1H3,(H,13,14,15)/b10-7+	SVXDHPADAXBMFB-JXMROGBWSA-N	CCC1=CC=C(C=C1)C=C2C(=O)NC(=S)S2	C12H11NOS2	CAS 403811-55-2	CHEBI:149696	.	.	.	.	.	.	.
DR6736	Thalidomide	CID: 5426	Algosediv; Asmadion; Asmaval; Bonbrain; Bonbrrin; Calmore; Calmorex; Contergan; Corronarobetin; Distaval; Distaxal; Distoval; Ectiluran; Enterosediv; Gastrinide; Glupan; Glutanon; Grippex; Hippuzon; Imidene; Isomin; Kedavon; Kevadon; Neaufatin; Neosedyn; Neosydyn; Nerosedyn; Neufatin; Neurodyn; Neurosedin; Neurosedym; Neurosedyn; Nevrodyn; Nibrol; Noctosediv; Noxodyn; Pangul; Pantosediv; Polygripan; Profarmil; Psycholiquid; Psychotablets; Quetimid; Quietoplex; Sandormin; Sedalis; Sedimide; Sedin; Sedisperil; Sedoval; Shinnibrol; Sleepan; Slipro; Softenil; Softenon; Synovir; Talargan; Talidomida; Talidomide; Talimol; Talismol; Talizer; Telagan; Telargan; Telargean; Tensival; Thaled; Thalidomidum; Thalin; Thalinette; Thalomid; Thalomide; Theophilcholine; Valgis; Valgraine; Yodomin; Celgene Brand of Thalidomide; Talidomide [DCIT]; Thalidomide Celgene; Thalidomide Pharmion; Asidon 3; ENMD 0995; IN1061; Thalidomine USP26; Alpha-Phthalimidoglutarimide; E-217; Imida-lab; Imidan (peyta); N-Phthalimidoglutamic acid imide; N-Phthaloylglutamimide; N-Phthalylglutamic acid imide; Poly-Giron; Predni-Sediv; Pro-Bam M; Pro-ban M; Sedalis sedi-lab; Shin-naito S; THALIDOMIDE (AIDS INITIATIVE); Talidomida [INN-Spanish]; Thaled (TN); Thalidomide (soluble form); Thalidomidum [INN-Latin]; Thalomid (TM); Thalomid (TN); Thalomid, Thalidomide; Alpha-N-Phthalylglutaramide; Thalidomide [USAN:INN:BAN]; Alpha-(N-Phthalimido)glutarimide; N-Phthalyl-glutaminsaeure-imid; N-Phthalyl-glutaminsaeure-imid [German]; Thalidomide (+ and-); Thalidomide (JAN/USP/INN); N-(2,6-Dioxo-3-piperidyl)phthalimide; (+)-Thalidomide; (+-)-Thalidomide; (+/-)-THALIDOMIDE; (inverted question mark)-Thalidomide; 2,6-Dioxo-3-phthalimidopiperidine; 3-Phthalimidoglutarimide	Small molecule	1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)	UEJJHQNACJXSKW-UHFFFAOYSA-N	C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O	C13H10N2O4	CAS 50-35-1	.	.	.	.	D0U7GK	.	.	.
DR6756	Olaparib	CID: 23725625	Olaparib; 763113-22-0; AZD2281; Lynparza; KU-0059436; AZD 2281; AZD-2281; 1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine; Olaparib (AZD2281, Ku-0059436); 4-(3-(4-(Cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; UNII-WOH1JD9AR8; KU-59436; AZD2281(olaparib); MFCD13185161; WOH1JD9AR8; Olaparib (AZD-2281); 4-[[3-[4-(Cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one; C24H23FN4O3; CHEBI:83766; AZ2281; 4-(3-{[4-(Cyclopropylcarbonyl)piperazin-1-Yl]carbonyl}-4-Fluorobenzyl)phthalazin-1(2h)-One; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one; 937799-91-2; KU59436; 4-[3-[4-(Cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorobenzyl]phthalazin-1(2H)-one; 4-[(3-{[4-(Cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorophenyl)methyl]phthalazin-1(2H)-one; OLAPARIB cpd; Olaparib [USAN:INN]; Acylpiperazine analogue, 47; Olaparibum; AZD221; Lynparza (TN); 09L; 4-((3-{(4-(cyclopropylcarbonyl)piperazin-1-yl)carbonyl}-4-fluorophenyl)methyl)phthalazin-1(2H)-one; PubChem19148; KU 59436; Olaparib (AZD2281); Olaparib - AZD2281; cc-16; AZD-2281 (Olaparib); Olaparib (JAN/USAN/INN); MLS006010185; SCHEMBL426568; CHEMBL521686; GTPL7519; BDBM27566; AOB1085; DTXSID60917988; EX-A002; BCPP000360; HMS3295I09; HMS3426C03; HMS3654G13; HMS3746K07; HMS3870H03; AMY10295; BCP01872; ABP000423; ANW-43329; NSC747856; NSC753686; s1060; ZINC40430143; AKOS005145764; AC-7939; ACN-032229; AZ-2281; BCP9000363; CCG-264799; CS-0075; DB09074; EX-7210; KEYLYNK-010 COMPONENT OLAPARIB; NSC 747856; NSC-747856; NSC-753686; QC-2660; SB14617; SS-4573; AZD2281,Olaparib, KU-0059436; NCGC00238451-01; NCGC00238451-02; NCGC00238451-09; NCGC00238451-11; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; AK-40514; HY-10162; Olaparib (AZD2281, KU0059436); SMR004701291; SY040527; OLAPARIB COMPONENT OF KEYLYNK-010; AB0009952; Olaparib(AZD2281,KuDOSKU-0059436); A9666; BB 0260909; FT-0651458; KU 0059436; SW218142-2; EC-000.2324; D09730; S-3781; S-7836; Z-3275; AZD2281(olaparib)/AZD-2281/KU0059436; J-503540; Q7083106; BRD-K02113016-001-08-9; BRD-K02113016-001-09-7; AZD 2281; ; ; KU 0059436; ; ; KU 59436; 1-(cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazine; 4-(3-(1-(cyclopropanecarbonyl)piperazine-4-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; (2H)-Phthalazinone, 4-((3-((4-(cyclopropylcarbonyl)-1-piperazinyl)carbonyl)-4-fluorophenyl)methyl)-; [4-(Cyclopropanecarbonyl)piperazin-1-yl]{2-fluoro-5-[(4-hydroxyphthalazin-1-yl)methyl]phenyl}methanone; 1(2H)-Phthalazinone, 4-[[3-[[4-(cyclopropylcarbonyl)-1-piperazinyl]carbonyl]-4-fluorophenyl]methyl]-; 1021843-02-6; 4-({3-[(4-cyclopropanecarbonylpiperazin-1-yl)carbonyl]-4-fluorophenyl}methyl)-1,2-dihydrophthalazin-1-one; 4-{[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorophenyl]methyl}-1,2-dihydrophthalazin-1-one	Small molecule	1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)	FDLYAMZZIXQODN-UHFFFAOYSA-N	C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F	C24H23FN4O3	CAS 763113-22-0	CHEBI:83766	.	.	.	D0J9HW	.	.	.
DR6763	Dexamethasone	CID: 5743	Decadron; Dexamethazone; Maxidex; Prednisolone F; Decaspray; Desametasone; Hexadecadrol; Hexadrol; Dexasone; Oradexon; Dexacort; Deltafluorene; Superprednol; Visumetazone; Mediamethasone; Desamethasone; Dergramin; Mymethasone; Dinormon; Dexapolcort; Dexalona; Desameton; Desadrene; Cortisumman; Aphtasolon; Turbinaire; Dextelan; Dexameth; Decaderm; Millicorten; Gammacorten; Fortecortin; Dexadeltone; Dekacort; Dectancyl; Decasone; Dexason; Mexidex; Dexone; Calonat; Corsone; Auxiron; Fluormethylprednisolone; Azium; Dexa-Cortisyl	Small molecule	1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1	UREBDLICKHMUKA-CXSFZGCWSA-N	CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C	C22H29FO5	CAS 50-02-2	.	.	.	.	D0IT2G	.	.	.
DR6764	Riluzole	CID: 5070	riluzole; 1744-22-5; Rilutek; 2-Amino-6-(trifluoromethoxy)benzothiazole; 6-(trifluoromethoxy)benzo[d]thiazol-2-amine; 6-(trifluoromethoxy)-1,3-benzothiazol-2-amine; RP-54274; 2-amino-6-trifluoromethoxybenzothiazole; 2-Benzothiazolamine, 6-(trifluoromethoxy)-; 2-amino-6-(trifluoromethoxy)benzo[d]thiazole; PK-26124; RP 54274; C8H5F3N2OS; 2-Benzothiazolamine,6-(trifluoromethoxy)-; UNII-7LJ087RS6F; Riluzole (Rilutek); Amino-2 trifluoromethoxy-6 benzothiazole; MLS000069369; 6-Trifluoromethoxy-benzothiazol-2-ylamine; 2-Amino-6-(trifluoromethoxy)-benzothiazole; MFCD00210213; CHEMBL744; SMR000058231; 7LJ087RS6F; CHEBI:8863; Riluzol; 2-amino-6-(trifluoromethoxy)-1,3-benzothiazole; BENZOTHIAZOLE, 2-AMINO-6-TRIFLUOROMETHOXY-; Riluzole, 98%; 6-(trifluoromethoxy)benzothiazol-2-amine; NCGC00015882-09; Riluzolum; Riluzol [INN-Spanish]; Riluzolum [INN-Latin]; DSSTox_CID_25192; DSSTox_RID_80739; DSSTox_GSID_45192; Rilutek (TN); CAS-1744-22-5; 6-(trifluoromethoxy)benzothiazole-2-ylamine; Amino-2 trifluoromethoxy-6 benzothiazole [French]; 2-amino-6-(trifluoromethoxyl)benzothiazole; Riluzole, solid; Riluzole [USAN:USP:INN:BAN]; BF-37; ALBB-006046; Riluzole(Rilutek)/; Prestwick-03A08; 6-(trifluoromethoxy)-2-benzothiazolamine; PubChem14501; Tocris-0768; 6-trifluoromethoxybenzothiazole-2-yl-amine; Opera_ID_548; Lopac-R-116; Riluzole-13C-15N2; Prestwick0_000167; Prestwick1_000167; Prestwick2_000167; Prestwick3_000167; Spectrum2_000550; Biomol-NT_000245; cid_5070; Riluzole (JAN/USP/INN); Lopac0_001064; SCHEMBL78905; BSPBio_000033; BIDD:GT0055; SPBio_000599; SPBio_001954; ACMC-209e89; BPBio1_000037; BPBio1_000837; GTPL2326; ZINC6481; DTXSID3045192; BDBM30705; Bio1_000416; Bio1_000905; Bio1_001394; HMS1773G08; HMS2089O19; HMS2094G07; HMS2233E14; HMS3263E10; HMS3371A09; HMS3657E13; Pharmakon1600-01505348; AMY14166; BCP02142; BHV-0223; HY-B0211; Riluzole - CAS 1744-22-5; Tiglutik (thickened oral suspension); Tox21_110252; Tox21_501064; ABP000632; AC-730; ANW-22711; BBL013272; CCG-39528; NSC753433; NSC759823; s1614; SBB012436; STK503686; AKOS000265071; Tox21_110252_1; DB00740; KS-5231; LP01064; MCULE-9362288181; NSC 753433; NSC 759823; NSC-753433; NSC-759823; SDCCGSBI-0051034.P003; 2-amino-6-trifluoromethoxy-benzothiazole; 6-trifluoromethoxy-2-amino-benzothiazole; NCGC00015882-01; NCGC00015882-02; NCGC00015882-03; NCGC00015882-04; NCGC00015882-05; NCGC00015882-06; NCGC00015882-07; NCGC00015882-08; NCGC00015882-10; NCGC00015882-11; NCGC00015882-12; NCGC00015882-13; NCGC00015882-15; NCGC00015882-28; NCGC00023141-02; NCGC00023141-04; NCGC00023141-05; NCGC00023141-06; NCGC00261749-01; 6-(trifluoromethoxy)-2-aminobenzothiazole; 6-trifluoromethoxybenzo[d]thiazol-2-amine; AK-59567; ST038494; ST068834; SBI-0051034.P002; 2-Amino-6-(Trifluoromethoxy) Benzothiazole; 6-(Trifluoromethoxy)-2-amino-benzothiazole; AB0012884; DB-030335; EU-0101064; FT-0611194; SW196805-4; EN300-23782; 6-trifluoromethoxy-1,3-benzothiazol-2-ylamine; A-5766; C07937; D00775; J10184; J10441; VU0239571-11; 744R225; Q415744; SR-01000002997-3; BRD-K21283037-001-02-5; BRD-K21283037-003-03-9; BRD-K21283037-003-06-2; F3282-0020; Z166605314; Rilutek; ; ; Rilutor; ; ; 6-(Trifluoromethoxy)-2-benzothiazolamine; Riluzole, United States Pharmacopeia (USP) Reference Standard	Small molecule	1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13)	FTALBRSUTCGOEG-UHFFFAOYSA-N	C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N	C8H5F3N2OS	CAS 1744-22-5	CHEBI:8863	.	.	.	D0H0KB	.	.	.
DR6823	Osimertinib	CID: 71496458	Tagrisso	Small molecule	1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)	DUYJMQONPNNFPI-UHFFFAOYSA-N	CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC	C28H33N7O2	CAS 1421373-65-0	.	.	.	.	D0O8GK	.	.	Osimertinib
DR6829	Linezolid	CID: 441401	linezolid; 165800-03-3; Zyvox; (S)-N-((3-(3-fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide; Zyvoxid; PNU-100766; U-100766; Zyvoxam; PNU 100766; U 100766; C16H20FN3O4; UNII-ISQ9I6J12J; N-(((S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide; N-[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide; CHEMBL126; ISQ9I6J12J; N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide; CHEBI:63607; Linezolid, 98%; MFCD00937825; U-100,766; Acetamide, N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-; (S)-N-[[3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide; N-{[(5s)-3-(3-Fluoro-4-Morpholin-4-Ylphenyl)-2-Oxo-1,3-Oxazolidin-5-Yl]methyl}acetamide; ZLD; Zivoxid; Zyvoxa; Acetamide, N-(((5S)-3-(3-fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl)-; N-({(5S)-3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide; N-[[(5S)-3-(3-fluoro-4-morpholino-phenyl)-2-oxo-oxazolidin-5-yl]methyl]acetamide; SMR000466335; Zyvox (TN); HSDB 7478; SR-01000759376; Linezolid & VRC3375; Linezoid; Linezolid (JAN/USAN/INN); Linezolid [USAN:INN:BAN]; (S)-N-[[3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide; NCGC00164628-01; Linezolid (Zyvox); N-{[(5S)-3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide; PNU100766; 111GE017; CPD000466335; NDA 21-130 Zyvox (linezolid tablets); SCHEMBL5027; DSSTox_CID_26489; DSSTox_RID_81660; DSSTox_GSID_46489; cc-154; MLS000759444; MLS001424075; BIDD:GT0404; Benzotriazol-2-yl-acetonitrile; cid_441401; Linezolid (PNU-100766); QCR-88; DTXSID5046489; Linezolid, >=98% (HPLC); NDA 21-131 Zyvox for injection (linezolid injection); GTPL10827; SYN3021; (R)-N-((3-(3-fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide; HMS2051F08; HMS2089K06; HMS3260C14; HMS3713K10; NDA 21-132 Zyvox oral suspension (linzolid oral suspension); BCP05586; ZINC2008866; Tox21_112246; Tox21_500096; BDBM50116067; s1408; AKOS016340522; AM84567; BCP9000855; CCG-101009; CS-0756; DB00601; KS-1178; NC00259; Acetamide, N-((3-(3-fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl)-, (S)-; Linezolid 100 microg/mL in Acetonitrile; NCGC00260781-01; NCGC00263531-03; NCGC00263531-05; NCGC00263531-10; HY-10394; AB0012049; CAS-165800-03-3; SW197639-3; C08146; D00947; J90009; M-8338; AB00639994-06; AB00639994-08; AB00639994-09; AB00639994_10; AB00639994_11; 800L033; A810662; Q411377; Q-201308; SR-01000759376-4; SR-01000759376-5; Linezolid, United States Pharmacopeia (USP) Reference Standard; (S)-N-((3-fluoro-4-morpholinophenyl)-2-oxaoxazolidin-5-yl)methyl)acetamide; Linezolid, Pharmaceutical Secondary Standard; Certified Reference Material; (Linezolid)N-[3-(3-Fluoro-4-morpholin-4-yl-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide; (S)-N-((3-(3-fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide; (S)-N-[ [3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-oxazolidin-5-yl]methyl]-acetamide; (S)-N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide; N-[(R)-3-(3-Fluoro-4-morpholin-4-yl-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide; N-[(S)-3-(3-Fluoro-4-morpholin-4-yl-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide; N-[3-(3-Fluoro-4-morpholin-4-yl-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide; N-[3-(3-Fluoro-4-morpholin-4-yl-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide(linezolid); (S)-3-(3-Fluoro-4-morpholin-4-yl-phenyl)-5-[(1-hydroxy-ethylamino)-methyl]-oxazolidin-2-one; N-((S)-2-oxo-3-(S)-2,3,3a,4-tetrahydro-1H-benzo[b]pyrrolo[1,2-d][1,4]oxazin-7-yl-oxazolidin-5-ylmethyl)-acetamide; N-[[(5S)-3-(3-fluoranyl-4-morpholin-4-yl-phenyl)-2-oxidanylidene-1,3-oxazolidin-5-yl]methyl]ethanamide	Small molecule	1S/C16H20FN3O4/c1-11(21)18-9-13-10-20(16(22)24-13)12-2-3-15(14(17)8-12)19-4-6-23-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)/t13-/m0/s1	TYZROVQLWOKYKF-ZDUSSCGKSA-N	CC(=O)NCC1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F	C16H20FN3O4	CAS 165800-03-3	CHEBI:63607	.	.	.	D07UYO	.	.	.
DR6843	Bazedoxifene	CID: 154257	Bazedoxifene; 198481-32-2; Conbriza; TSE-424; UNII-Q16TT9C5BK; Bazedoxifene free base; Q16TT9C5BK; 1-(4-(2-(azepan-1-yl)ethoxy)benzyl)-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol; CHEMBL46740; 1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol; 198481-32-2 (free base); WAY 140424; Bazedoxifeno; C30H34N2O3; 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol; 1H-Indol-5-ol, 1-[[4-[2-(hexahydro-1H-azepin-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methyl-; Bazedoxifene [INN]; Bazedoxifeno [INN-Spanish]; 1-{4-[2-(azepan-1-yl)ethoxy]benzyl}-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol; 1H-Indol-5-ol, 1-((4-(2-(hexahydro-1H-azepin-1-yl)ethoxy)phenyl)methyl)-2-(4-hydroxyphenyl)-3-methyl-; SCHEMBL41935; GTPL7355; DTXSID70173593; CHEBI:135947; HY-A0031; ZINC1895505; 3473AH; BDBM50099585; AKOS030255808; CS-0932; DB06401; SB19326; 1-[[4-[2-(AZEPAN-1-YL)ETHOXY]PHENYL]METHYL]-2-(4-HYDROXYPHENYL)-3-METHYL-INDOL-5-OL; 1-((4-(2-Hexahydro-1H-azepin-1-yl)ethoxy)phenyl)methyl)-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol; US8815934, No. 98; A15019; W-5320; AB01566901_01; J-012822; Q4875166	Small molecule	1S/C30H34N2O3/c1-22-28-20-26(34)12-15-29(28)32(30(22)24-8-10-25(33)11-9-24)21-23-6-13-27(14-7-23)35-19-18-31-16-4-2-3-5-17-31/h6-15,20,33-34H,2-5,16-19,21H2,1H3	UCJGJABZCDBEDK-UHFFFAOYSA-N	CC1=C(N(C2=C1C=C(C=C2)O)CC3=CC=C(C=C3)OCCN4CCCCCC4)C5=CC=C(C=C5)O	C30H34N2O3	CAS 198481-32-2	CHEBI:135947	.	.	.	D0JY8T	.	.	.
DR6872	Nilotinib	CID: 644241	Nilotinib; 641571-10-0; Tasigna; AMN107; AMN 107; AMN-107; Nilotinib(AMN-107); Nilotinib (AMN-107); Nilotinib free base; 4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide; UNII-F41401512X; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; CHEMBL255863; C28H22F3N7O; CHEBI:52172; Nilotinib-d6; 641571-10-0 (free base); MFCD09833716; NSC747599; 4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamide; 4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)benzamide; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzamide; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; F41401512X; 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-{(4-(pyridin-3-yl)pyrimidin-2-yl)amino}benzamide; 4-Methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-; Nilotinib & its intermediates; nilotinibum; 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide; 4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)-phenyl)-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamide; Nilotinib,AMN107,Tasigna;4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; SMR002544680; Nilotinib [USAN:INN:BAN]; Nilotinib/; HSDB 7842; PubChem18272; 3gp0; Nilotinib (USAN/INN); EC 700-544-5; SCHEMBL7901; cc-353; MLS003915611; MLS006010160; GTPL5697; DTXSID5042663; QCR-112; SYN1057; BCPP000149; HMS3244A13; HMS3244A14; HMS3244B13; HMS3295A23; HMS3654M07; HMS3748E11; AOB87115; BCP01367; ZINC6716957; ABP000478; AC-647; ANW-41982; BDBM50237710; NSC800804; s1033; AKOS005063561; BCP9000989; CCG-264784; CS-0102; DB04868; NSC 747599; NSC-747599; NSC-800804; SB17315; NCGC00183285-01; NCGC00183285-03; NCGC00183285-04; NCGC00183285-09; NCGC00183285-15; 4-Methyl-3-(4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide; AK-59889; AS-16214; HY-10159; N-(3-(3-(1H-Imidazolyl)propoxy)phenyl)-4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)benzamide; AB0007991; AM20090651; FT-0654026; SW218083-2; V0705; EC-000.2344; D08953; N-8207; S-6060; 49312-EP2270008A1; 49312-EP2292617A1; 49312-EP2305667A2; 49312-EP2311840A1; 78680-EP2305667A2; AB01273978-01; AB01273978-02; AB01273978_03; 139316-EP2270008A1; 139316-EP2292617A1; 571N100; Q412327; SR-01000931150; Q-101348; SR-01000931150-2; BRD-K81528515-001-04-7; 1353151-22-0; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide; 4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide; 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino] benzamide; Benzamide, 4-methyl-N-((3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(3-pyridinyl)-2-pyrimidinyl)amino)-; Benzamide, 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(3-pyridinyl)-2-pyrimidinyl)amino)-; Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]- (9CI)	Small molecule	1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)	HHZIURLSWUIHRB-UHFFFAOYSA-N	CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5	C28H22F3N7O	CAS 641571-10-0	CHEBI:52172	.	.	.	D00STL	.	.	.
DR6878	lamivudine	CID: 60825	lamivudine; 134678-17-4; Epivir; Zeffix; Heptovir; Epivir-HBV; Heptodin; 3TC; BCH-189; (-)-2'-Deoxy-3'-thiacytidine; 2',3'-Dideoxy-3'-thiacytidine; 4-amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one; 3'-Thia-2',3'-dideoxycytidine; GR-109714X; (-)-BCH-189; beta-L-2',3'-Dideoxy-3'-thiacytidine; beta-L-3'-Thia-2',3'-dideoxycytidine; (-)NGPB-21; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; GR 109714X; 136891-12-8; UNII-2T8Q726O95; BCH 189, (-)-; Hepitec; MFCD00869739; (-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one; CHEBI:63577; (-)-1-[(2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; 4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone; 4-AMINO-1-[(2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL]-1,2-DIHYDROPYRIMIDIN-2-ONE; 2T8Q726O95; Heptivir; Lamivir; Zefix; 4-Amino-1-(cis-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one; GR109714X; 4-AMINO-1-[(2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL]-2(1H)-PYRIMIDINONE; BCH 189; Lamivudine [USAN:BAN:INN]; (-)-(2'R,5'S)-1-[2'-Hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine; 2(1H)-Pyrimidinone, 4-amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-; Epivir(TM); HHA & Lamivudine; Lamivudine & GNA; SMR000466319; Epivir (TN); (-)-BCH 189; DTHC; CHEMBL141; HSDB 7155; DRG-0126; 3TC and NV-01; (-)-SddC; Lamivudeine; Lamivudine (JAN/USP/INN); 3TC & GNA; 3TC & SST; HHA & 3TC; (+/-)-SddC; CCRIS 9274; NSC620753; 2(1H)-Pyrimidinone, 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-; BCH-790; Lamivudine [USAN:USP:INN:BAN]; NCGC00159341-04; Lamivudine, 98%; GG-714; Lamivudine (EPIVIR); CPD000466319; (+/-)-3TC; (+/-)-BCH-189; 2(1H)-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, (2R-cis)-; MLS000759424; MLS001424097; MLS006011910; BIDD:GT0033; SCHEMBL109675; AMY384; PYR356; ZINC12346; HMS2051D21; HMS3259F08; HMS3713C16; HY-B0250; ANW-43098; BBL033871; BDBM50366817; s1706; SBB066293; STK801940; lamivudine & TNF-alpha & IFN-gamma; AKOS005622556; AKOS015854841; Lamivudine, >=98% (HPLC), powder; AB07588; AC-1416; CCG-100984; DB00709; KS-1073; MCULE-2096184994; NC00234; NC00705; NSC 760061; NCGC00159341-05; NCGC00159341-18; L0217; SW197614-3; C07065; D00353; J10244; M-9795; 24222-EP2269989A1; 24222-EP2272516A2; 24222-EP2272825A2; 24222-EP2292227A2; 24222-EP2298761A1; 24222-EP2298783A1; 24222-EP2305243A1; 24222-EP2305640A2; 24222-EP2305680A2; 24222-EP2314590A1; AB00639995-06; AB00639995-08; AB00639995_09; Lamivudeine 100 microg/mL in Acetonitrile:Water; 200973-EP2272825A2; 678L174; Q422631; SR-01000759420; J-700183; Q-201275; SR-01000759420-5; Lamivudine, British Pharmacopoeia (BP) Reference Standard; Lamivudine, European Pharmacopoeia (EP) Reference Standard; (2R,5S)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; .beta.-L-(-)-2',3'-dideoxy-3'-thiacytidine & Sho-Saiko-To; Lamivudine, United States Pharmacopeia (USP) Reference Standard; (+/-) (Cis)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (-)-L-2',3'-DIDEOXY-3'-THIACYTIDINE; LAMIVUDINE; EPIVIR; Lamivudine, 1.0 mg/mL in methanol, certified reference material; Lamivudine, Pharmaceutical Secondary Standard; Certified Reference Material; (+/-)-(cis)-4-Amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one; 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (+/-) (Cis); 3-[(5S,2R)-2-(hydroxymethyl)(1,3-oxathiolan-5-yl)]-6-amino-3-hydropyrimidin-2- one; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-[1,3]-oxathiolan-5-yl]-(1H)-pyrimidin-2-one; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-Oxathiolan-5-yl]-(1H)-pyrimidin-2-one; cis(+/-)-4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone; Lamivudine for system suitability 1, European Pharmacopoeia (EP) Reference Standard; Lamivudine for system suitability 2, European Pharmacopoeia (EP) Reference Standard; 1117764-41-6; 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Galanthus Nivalis Agglutinin (GNA); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Hippeastrum hybrid agglutinin( HHA)	Small molecule	1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1	JTEGQNOMFQHVDC-NKWVEPMBSA-N	C1C(OC(S1)CO)N2C=CC(=NC2=O)N	C8H11N3O3S	CAS 134678-17-4	CHEBI:63577	.	.	.	D07TQV	.	.	.
DR6887	Cefepime	CID: 5479537	cefepime; Maxipime; Cefepima; Cefepimum [Latin]; Cefepima [Spanish]; Cefepimum; 88040-23-7; Axepim; BMY-28142; E-Cefepime; CFPM; UNII-807PW4VQE3; 807PW4VQE3; CHEBI:478164; BMY 28142; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-[(1-methylpyrrolidinium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; Cefepime (USAN/INN); Cefepime [USAN:INN:BAN]; J01DE01; Cefepime(Maxipime)/; 1-(((6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methylpyrrolidinium hydroxide, inner salt, 7(sup 2)-(Z)-(O-methyloxime); Cefepime, Antibiotic for Culture Media Use Only; CHEMBL186; SCHEMBL65720; VNRX-5022; DTXSID70873208; BCPP000292; HMS2089M18; ABP000468; BDBM50350470; AKOS015850865; AKOS016014147; BCP9000504; DB01413; 7beta-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(1-methylpyrrolidinium-1-yl)methyl]-3,4-didehydrocepham-4-carboxylate; C08111; D02376; AB01275446-01; A842445; Q27294816; (6R,7R)-7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-methoxyimino-1-oxoethyl]amino]-3-[(1-methyl-1-pyrrolidin-1-iumyl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-[[(2Z)-2-(2-azanyl-1,3-thiazol-4-yl)-2-methoxyimino-ethanoyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxidanylidene-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 1-{[(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-2-carboxylato-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}-1-methylpyrrolidin-1-ium	Small molecule	1S/C19H24N6O5S2/c1-25(5-3-4-6-25)7-10-8-31-17-13(16(27)24(17)14(10)18(28)29)22-15(26)12(23-30-2)11-9-32-19(20)21-11/h9,13,17H,3-8H2,1-2H3,(H3-,20,21,22,26,28,29)/b23-12-/t13-,17-/m1/s1	HVFLCNVBZFFHBT-ZKDACBOMSA-N	C[N+]1(CCCC1)CC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)[O-]	C19H24N6O5S2	CAS 88040-23-7	CHEBI:478164	.	.	.	D0A1CB	.	.	.
DR6890	L-buthionine sulfoximine	CID: 119565	l-buthionine sulfoximine; L-Buthionine-sulfoximine; 83730-53-4; (2S)-2-Amino-4-(butylsulfonimidoyl)butanoic acid; Butanoic acid, 2-amino-4-(S-butylsulfonimidoyl)-, (2S)-; L-Buthionine-(S,R)-sulfoximine; BUTHIONINE SULFOXIME; (2S)-2-Amino-4-(S-butylsulfonimidoyl)butanoic Acid; MFCD00067000; NSC 326231; BRN 2367136; L-Buthionine-(S,R)-sulfoximine, 99%; l-buthionine(s,r)-sulfoximine; L-BSO; Buthionine sulfoximine, L-; L-Buthionine (SR)-sulfoximine; Buthionine-S,R-sulfoximine, L-; L-Buthionine-(S,R)-sulphoximine; NSC-381100; NCIMech_000342; BUTHIONINE-SULFOXIMINE; Lopac0_000221; SCHEMBL62034; CHEMBL261642; D,L-Buthionine-S,R-sulfoximine; CHEBI:94288; DTXSID70894150; HMS3260N03; BSO; Tox21_500221; BDBM50487312; NSC801426; s9728; 1-beta-DL-Buthionine(S,R)sulfoximine; AKOS027320570; CS-W020947; HY-106376A; LP00221; MCULE-5971306528; NSC-326231; NSC-801426; SDCCGSBI-0050209.P002; BSO (L-Buthionine-(S,R)-sulfoximine); NCGC00093690-01; NCGC00093690-02; NCGC00093690-03; NCGC00093690-11; NCGC00260906-01; AS-69850; L-Buthionine-sulfoximine, >=97% (TLC); EU-0100221; B 2515; SR-01000075712; SR-01000075712-1; BRD-A47706533-001-01-8; Q27166100; UNII-EEY8DZS103 component KJQFBVYMGADDTQ-JKYUHCHBSA-N; UNII-LW4108Q0BV component KJQFBVYMGADDTQ-JKYUHCHBSA-N; (R*,S*)-(+-)-2-Amino-4-(S-butylsulfonimidoyl)butanoic acid; (2S)-2-AMINO-4-[BUTYL(IMINO)OXO-??-SULFANYL]BUTANOIC ACID; Butanoic acid, 2-amino-4-((R)-S-butylsulfonimidoyl)-, (2S)-rel-; Butanoic acid, 2-amino-4-(S-butylsulfonimidoyl)-, (R*,S*)-(+-)-; 97590-40-4	Small molecule	1S/C8H18N2O3S/c1-2-3-5-14(10,13)6-4-7(9)8(11)12/h7,10H,2-6,9H2,1H3,(H,11,12)/t7-,14?/m0/s1	KJQFBVYMGADDTQ-CVSPRKDYSA-N	CCCCS(=N)(=O)CCC(C(=O)O)N	C8H18N2O3S	CAS 83730-53-4	CHEBI:94288	.	.	.	.	.	.	.
DR6904	Canstatin	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR6918	Tacrine	CID: 1935	Tacrine; 1,2,3,4-tetrahydroacridin-9-amine; 321-64-2; Tetrahydroaminacrine; 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE; Tetrahydroaminoacridine; Cognex; Tetrahydroaminocrin; Tetrahydroaminocrine; 9-amino-1,2,3,4-tetrahydroacridine; 9-Acridinamine, 1,2,3,4-tetrahydro-; CS 12602; UNII-4VX7YNB537; 1,2,3,4-Tetrahydro-9-aminoacridine; Acridine, 1,2,3,4-tetrahydro-9-amino-; CHEMBL95; 5-Amino-6,7,8,9-tetrahydroacridine; 4VX7YNB537; CHEBI:45980; 5,6,7,8-tetrahydroacridin-9-amine; tacrine.HCl; NCGC00015054-06; Tacrina; Tacrinum; Tacrine [INN:BAN]; Tacrinum [INN-Latin]; Tacrina [INN-Spanish]; DSSTox_CID_17272; DSSTox_RID_79318; DSSTox_GSID_37272; 5,6,7,8-tetrahydroacridine-9-ylamine; Tacrinal (TN); CAS-321-64-2; Tacrine (INN); EINECS 206-291-2; 5-Amino-6,7,8,9-tetrahydroacridine (European); BRN 0147610; 1,2,3,4-Tetrahydro-acridin-9-ylamine; Tracine; 1acj; 2aow; 2aox; BBL001044; 1,2,3,4-Tetrahydro-9-acridineamine; Romotal (Salt/Mix); 9-Acridinamine,1,2,3,4-tetrahydro-; Spectrum_000416; Tocris-0965; 1mx1; Prestwick0_000329; Prestwick1_000329; Prestwick2_000329; Prestwick3_000329; Spectrum2_001812; Spectrum3_001709; Spectrum4_000819; Spectrum5_001402; Lopac-A-3773; cid_1935; SCHEMBL2828; 9-THA; NCIOpen2_003667; Lopac0_000036; Oprea1_008681; Acridine, 9-aminotetrahydro-; BSPBio_000337; BSPBio_003298; KBioGR_001337; KBioSS_000896; BIDD:GT0090; DivK1c_000936; SPBio_001823; SPBio_002258; BDBM8961; BPBio1_000371; GTPL6687; DTXSID1037272; KBio1_000936; KBio2_000896; KBio2_003464; KBio2_006032; KBio3_002518; NINDS_000936; HMS2089F19; HMS3743C11; BCP03564; Tox21_110073; Tox21_302277; ANW-46208; MFCD00046923; PDSP1_000330; PDSP2_000328; SBB003560; STK101308; ZINC19014866; AKOS000277493; Tox21_110073_1; BCP9000019; CCG-204132; DB00382; MCULE-3628803328; NE25597; SDCCGSBI-0050025.P004; VZ20338; 1,2,3,4-tetra -hydro-9-acridinamine; IDI1_000936; NCGC00015054-01; NCGC00015054-02; NCGC00015054-03; NCGC00015054-04; NCGC00015054-05; NCGC00015054-07; NCGC00015054-08; NCGC00015054-09; NCGC00015054-10; NCGC00015054-12; NCGC00024908-01; NCGC00024908-03; NCGC00024908-04; NCGC00024908-05; NCGC00255540-01; 1,2,3,4-tetrahydro-acridin-9-yl-amine; ST083243; Acridine, 9-amino-1,2,3,4-tetrahydro-; SBI-0050025.P003; AB0126098; DB-000650; 9-amino-1,2,3,4-tetrahydroacridine (THA); AB00053524; C-110; EU-0010966; FT-0631953; R9947; 9-Acridinamine, 1,2,3,4-tetrahydro- (9CI); A18628; C01453; D08555; AB00053524-17; AB00053524_18; AB00053524_19; AE-641/00604043; Q421076; 1,2,3,4-tetrahydroacridin-9-amine dihydrochloride; BRD-K81473089-003-03-0; BRD-K81473089-003-04-8; BRD-K81473089-003-15-4; SR-01000075593-13; Z56790573	Small molecule	1S/C13H14N2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1,3,5,7H,2,4,6,8H2,(H2,14,15)	YLJREFDVOIBQDA-UHFFFAOYSA-N	C1CCC2=NC3=CC=CC=C3C(=C2C1)N	C13H14N2	CAS 321-64-2	CHEBI:45980	.	.	.	D0E6YQ	.	.	.
DR6961	T0901317	CID: 447912	293754-55-9; T 0901317; TO-901317; TO901317; UNII-A07663A39I; T-0901317; CHEMBL62136; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-N-(2,2,2-trifluoroethyl)benzenesulfonamide; A07663A39I; N-(2,2,2-TRIFLUOROETHYL)-N-{4-[2,2,2-TRIFLUORO-1-HYDROXY-1-(TRIFLUOROMETHYL)ETHYL]PHENYL}BENZENESULFONAMIDE; N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]benzenesulfonamide; T-1317	Small molecule	1S/C17H12F9NO3S/c18-14(19,20)10-27(31(29,30)13-4-2-1-3-5-13)12-8-6-11(7-9-12)15(28,16(21,22)23)17(24,25)26/h1-9,28H,10H2	SGIWFELWJPNFDH-UHFFFAOYSA-N	C1=CC=C(C=C1)S(=O)(=O)N(CC(F)(F)F)C2=CC=C(C=C2)C(C(F)(F)F)(C(F)(F)F)O	C17H12F9NO3S	CAS 293754-55-9	.	.	.	.	D0B5FC	.	.	T0901317
DR6969	Platinum	CID: 23939	Precision tolerogens (autoimmune disease), NaniRx	Small molecule	1S/Pt	BASFCYQUMIYNBI-UHFFFAOYSA-N	[Pt]	Pt	CAS 7440-06-4	.	.	.	.	D0E5FF	.	.	Platinum
DR7080	Brinzolamide	CID: 68844	Brinzolamide; 138890-62-7; Azopt; AL-4862; AL 4862; Birnzolamide; MFCD08067749; UNII-9451Z89515; (4R)-4-(ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide; (4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide; CHEBI:3176; (R)-4-(ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide; (+)-4-ETHYLAMINO-3,4-DIHYDRO-2-(METHOXY)PROPYL-2H-THIENO[3,2-E]-1,2-THIAZINE-6-SULFONAMIDE-1,1-DIOXIDE; (R)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno(3,2-e)-1,2-thiazine-6-sulfonamide 1,1-dioxide; (R)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide; 2H-Thieno[3,2-e]-1,2-thiazine-6-sulfonamide, 4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-, 1,1-dioxide, (4R)-; DSSTox_CID_25531; DSSTox_RID_80934; DSSTox_GSID_45531; 138890-50-3; BZ1; 9451Z89515; C12H21N3O5S3; (4R)-4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide; Brinzolamide (BRZ); Azopt (TN); Brinzolamide (JAN/USP/INN); 3znc; NCGC00016979-01; Brinzolamide [USAN:USP:INN:BAN]; CAS-138890-62-7; Prestwick0_000365; Prestwick1_000365; Prestwick2_000365; Prestwick3_000365; SCHEMBL24636; BSPBio_000489; 2H-Thieno(3,2-e)-1,2-thiazine-6-sulfonamide, 4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-, 1,1-dioxide, (R)-; cc-163; MLS002153787; BIDD:GT0039; SPBio_002410; AMY372; BPBio1_000539; CHEMBL220491; GTPL6797; DTXSID6045531; BDBM10885; Brinzolamide, >=98% (HPLC); HMS1569I11; HMS2096I11; HMS2234K06; HMS3713I11; HMS3885I11; BCP22330; EBD27046; HY-B0588; ZINC3953037; Tox21_110722; ABP001062; s3178; AKOS005145708; Tox21_110722_1; AC-5277; CCG-220365; CCG-222516; DB01194; NSC 760050; NCGC00179542-03; NCGC00179542-10; AS-35084; SMR001233169; AB0012787; AB00513824; B4258; SW197152-3; AL4862;AL 4862;AL-4862; C07760; D00652; AB00513824_06; Q411517; SR-01000838832; Q-200751; SR-01000838832-2; BRD-K74913225-001-03-3; Brinzolamide, United States Pharmacopeia (USP) Reference Standard; (4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-2H,3H,4H-1$l^{6},7,2-thieno[3,2-e][1$l^{6},2]thiazine-6-sulfonamide; (4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-2H,3H,4H-1$l^{6},7,2-thieno[3,2-e][1,2]thiazine-6-sulfonamide; (4r)-4-(ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2h-thieno[3,2-e][1,2]thiazine-6-sulfonamide-1,1-dioxide; (4R)-4-ethylamino-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[4,5-e]thiazine-6-sulfonamide; (5R)-5-ethylamino-3-(3-methoxypropyl)-2,2-dioxo-2,9-dithia-3-azabicyclo[4.3.0]nona-1(6)7-diene-8-sulfonamide; (5R)-5-Ethylamino-3-(3-methoxypropyl)-2,2-dioxo-2?6,9-dithia-3-azabicyclo[4.3.0]nona-7,10-diene-8-sulfonamide; (R)- 4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-Thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide; (R)-3,4-Dihydro-4-ethylamino-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide; 2H-Thieno(3,2-e)-1,2-thiazine-6-sulfonamide, 4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-,1,1-dioxide, (R)-	Small molecule	1S/C12H21N3O5S3/c1-3-14-10-8-15(5-4-6-20-2)23(18,19)12-9(10)7-11(21-12)22(13,16)17/h7,10,14H,3-6,8H2,1-2H3,(H2,13,16,17)/t10-/m0/s1	HCRKCZRJWPKOAR-JTQLQIEISA-N	CCNC1CN(S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)CCCOC	C12H21N3O5S3	CAS 138890-62-7	CHEBI:3176	.	.	.	D01MUR	.	.	.
DR7091	Doxycycline	CID: 54671203	doxycycline; Vibramycin; 564-25-0; Doxytetracycline; Doxiciclina; Doxycyclinum; Doxycycline (anhydrous); Monodox; Oracea; Vibra-tabs; Doxycycline hyclate; 6alpha-Deoxy-5-oxytetracycline; 5-Hydroxy-alpha-6-deoxytetracycline; 6-alpha-Deoxy-5-oxytetracycline; Doxycyclin; alpha-6-Deoxy-5-hydroxytetracycline; BMY-28689; Doxycycline anhydrous; Liviatin; DOXY; Doxy-Caps; Vibravenos; UNII-334895S862; Deoxymykoin; Dossiciclina; Azudoxat; Doxitard; Doxivetin; Doxycen; Doxychel; Investin; Ronaxan; CHEBI:50845; Spanor; Doxy-Puren; alpha-Doxycycline; Doxy-Tabs; alpha-6-Deoxyoxytetracycline; MMV000011; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)-; Supracyclin; Doxysol; Jenacyclin; 6-Deoxyoxytetracycline; Dossiciclina [DCIT]; Doxiciclina [Italian]; (4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; GS-3065; Doxycyclinum [INN-Latin]; Doxycycline (internal use); Doxiciclina [INN-Spanish]; 334895S862; BU-3839T; 4-Epidoxycycline; Zenavod; DOXCYCLINE ANHYDROUS; Oxytetracycline, 6-deoxy-; Doxycycline (TN); Doxychel (TN); (4S,4aR,5S,5aR,6R,12aR)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide; 2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)-; Vivox (*Hyclate); Doxycycline (INN); DMSC (*Fosfatex); NSC633557; HSDB 3071; Monodox (*monohydrate); BMY28689; BU 3839T; EINECS 209-271-1; BMY 28689; Vibramycin (*monohydrate); GS-3065 (*monohydrate); Doxirobe; Doxycycline [USAN:INN:BAN]; SR-01000075844; Anhydrous doxycycline; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S-(4alpha,4aalpha,5alpha,5aalpha,6alpha,12aalpha))-; AB08 (*Fosfatex); Spectrum_000807; 24390-14-5; Spectrum2_000143; Spectrum3_000408; Spectrum4_000527; Spectrum5_000947; UPCMLD-DP021; CHEMBL1433; Lopac0_000405; SCHEMBL40930; SCHEMBL66828; BSPBio_001936; KBioGR_001133; KBioSS_001287; BIDD:GT0146; DivK1c_000345; SPBio_000246; CHEMBL436921; GTPL6464; SCHEMBL1176275; 4-Epioxytetracycline, 6-deoxy-; DTXSID0037653; SCHEMBL17826665; SCHEMBL19270298; SCHEMBL21753474; UPCMLD-DP021:001; BCBcMAP01_000024; KBio1_000345; KBio2_001287; KBio2_003855; KBio2_006423; KBio3_001156; DTXSID80992212; NINDS_000345; HMS2090E06; DOXYTETRACYCLINE; DOXYCYCLINE; HY-N0565; LMPK07000001; s5159; ZINC16052277; AKOS015900372; ZINC100056779; ZINC100302137; ZINC100611210; ZINC109562088; CCG-204498; DB00254; MCULE-4368118692; SDCCGSBI-0050391.P005; IDI1_000345; SMP1_000107; NCGC00161602-01; NCGC00161602-03; NCGC00161602-04; NCGC00161602-05; NCGC00161602-14; NCGC00188979-01; (4s,4ar,5s,5ar,6r,12as)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS); 2-Naphthacenecarboxamide, 4-alpha-S-(dimethylamino)-1,4,4a-alpha-5,5a-alpha,6,11,12a-octahydro-3,5-alpha,10,12,12a-alpha-pentahydroxy-6-alpha-methyl-1,11-dioxo-; AS-13499; I455; SBI-0050391.P004; CS-0009105; 1368-EP2269978A2; 1368-EP2269985A2; 1368-EP2269991A2; 1368-EP2284150A2; 1368-EP2284151A2; 1368-EP2284152A2; 1368-EP2284153A2; 1368-EP2284155A2; 1368-EP2284156A2; 1368-EP2284164A2; 1368-EP2287140A2; 1368-EP2287148A2; 1368-EP2287150A2; 1368-EP2289871A1; 1368-EP2295402A2; 1368-EP2295419A2; 1368-EP2298732A1; 1368-EP2301534A1; 1368-EP2301912A2; 1368-EP2301913A1; 1368-EP2301914A1; 1368-EP2301916A2; 1368-EP2305637A2; 1368-EP2305640A2; 1368-EP2308863A1; 1368-EP2311451A1; 1368-EP2311796A1; 1368-EP2311797A1; 1368-EP2311798A1; 1368-EP2311799A1; 1368-EP2316450A1; C06973; D07876; AB00053465-03; AB00053465_04; AB00053465_05; 564D250; Doxycycline, Antibiotic for Culture Media Use Only; Q422442; SR-01000075844-7; W-105517; (4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide; 4-(Dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-3,4,4a,5,5a,6,12,12a-octahydrotetracene-2-carboximidic acid; 7164-70-7	Small molecule	1S/C22H24N2O8/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29/h4-7,10,14-15,17,25-27,30,32H,1-3H3,(H2,23,31)/t7-,10+,14+,15-,17-,22-/m0/s1	SGKRLCUYIXIAHR-AKNGSSGZSA-N	CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O	C22H24N2O8	CAS 564-25-0	CHEBI:50845	.	.	.	D0S0LZ	.	.	.
DR7128	Dutasteride	CID: 6918296	Dutasteride; Avodart; 164656-23-9; GG-745; GI 198745; GI-198745; UNII-O0J6XJN02I; C27H30F6N2O2; O0J6XJN02I; (5alpha,17beta)-N-(2,5-Bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide; alpha,alpha,alpha,alpha',alpha',alpha'-Hexafluoro-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxy-2',5'-xylidide; CHEMBL1200969; Avolve; CHEBI:521033; Dutasteride, 99%; (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide; (4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(2,5-Bis(trifluoromethyl)phenyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide; (1S,2R,7R,10S,11S,14S,15S)-N-[2,5-bis(trifluoromethyl)phenyl]-2,15-dimethyl-5-oxo-6-azatetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-3-ene-14-carboxamide; 1H-Indeno[5,4-f]quinoline-7-carboxamide, N-[2,5-bis(trifluoromethyl)phenyl]-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)-; GG 745; Duagen; Avodart (TN); GI198745; Avidart; Dutasteride [USAN:INN:BAN]; NCGC00164571-01; 1H-Indeno(5,4-f)quinoline-7-carboxamide, N-(2,5-bis(trifluoromethyl)phenyl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)-; GI-198745X; SCHEMBL5903; DSSTox_CID_26452; DSSTox_RID_81626; DSSTox_GSID_46452; Dutasteride (JAN/USP/INN); GTPL7457; DTXSID8046452; Dutasteride, >=98% (HPLC); AOB5568; BCPP000248; BCP02344; EX-A1952; ZINC3932831; Tox21_112199; BDBM50340481; MFCD00937869; NSC740477; s1202; AKOS015920136; AKOS015924431; BCP9000630; CCG-269904; CS-1542; DB01126; GS-3565; MCULE-1602474627; NSC 740477; NSC 759880; NSC-740477; N-[2,5-bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide; HY-13613; CAS-164656-23-9; B-2151; D03820; J10036; AB01274774-01; AB01274774_02; 656D239; Q424760; Q-201052; BRD-K30373883-001-02-8; Z1563146168; Dutasteride, European Pharmacopoeia (EP) Reference Standard; Dutasteride, United States Pharmacopeia (USP) Reference Standard; Dutasteride for system suitability, European Pharmacopoeia (EP) Reference Standard; (5.alpha.,5 bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide;dutasteride;Avodart;; (5alpha,17beta)-N-{2,5-bis(trifluoromethyl)-phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide	Small molecule	1S/C27H30F6N2O2/c1-24-11-9-17-15(4-8-21-25(17,2)12-10-22(36)35-21)16(24)6-7-19(24)23(37)34-20-13-14(26(28,29)30)3-5-18(20)27(31,32)33/h3,5,10,12-13,15-17,19,21H,4,6-9,11H2,1-2H3,(H,34,37)(H,35,36)/t15-,16-,17-,19+,21+,24-,25+/m0/s1	JWJOTENAMICLJG-QWBYCMEYSA-N	CC12CCC3C(C1CCC2C(=O)NC4=C(C=CC(=C4)C(F)(F)F)C(F)(F)F)CCC5C3(C=CC(=O)N5)C	C27H30F6N2O2	CAS 164656-23-9	CHEBI:521033	.	.	.	D0A9YA	.	.	.
DR7137	25-methoxyl-dammarane-3beta, 12beta, 20-triol	.	.	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.
DR7139	AMD3100	CID: 65015	Plerixafor; 110078-46-1; Mozobil; AMD3100; 1,4-Bis((1,4,8,11-tetraazacyclotetradecan-1-yl)methyl)benzene; Amd 3100; bicyclam JM-2987; plerixafor (amd3100); Plerixafor hydrochloride; AMD-3100; SDZ SID 791; JM3100; JM 3100; 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane; JM-3100; UNII-S915P5499N; JKL 169; CHEMBL18442; 1,1'-[1,4-Phenylenebis(methylene)]bis-1,4,8,11-tetraazacyclotetradecane; S915P5499N; SID791; 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane]; Mozobil (TN); plerixaforum; Plerixafor [USAN:INN:BAN]; 1,1'-[1,4-phenylenebis(methylene)]bis(1,4,8,11-tetraazacyclotetradecane); Plerixafor 8HCl; GNA & AMD-3100; HHA & AMD-3100; JM 2987; Plerixafor(AMD3100); 1,4,8,11-Tetraazacyclotetradecane, 1,1'-[1,4-phenylenebis(methylene)]bis-, hydrochloride (1:8); Plerixafor-d4 (deuterated); SCHEMBL19038; GTPL844; cc-304; Plerixafor (JAN/USAN/INN); AOB5591; DTXSID70869520; AMD-3100 (CXCR4); CHEBI:125354; BCPP000104; BCP02337; C28H54N8; EX-A1762; ANW-73610; BDBM50035696; MFCD05662218; NSC754363; NSC761388; s8030; ZINC22443609; 1,1'-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane}; AKOS005266706; CCG-269710; CS-0451; DB06809; NSC-754363; NSC-761388; NCGC00165722-01; NCGC00165722-02; NCGC00165722-03; 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Galanthus nivalis agglutinin (GNA); AC-26837; AK-41732; AS-42504; HY-10046; AB0009909; FT-0660392; FT-0673966; A25446; D08971; S-7677; AB01566900_01; 078P461; A809618; L000104; Q905835; SR-01000941593; J-503718; SR-01000941593-1; 11''''-xylyl bis-1,4,8,11-tetraazacyclotetradecane; BRD-K33240821-367-01-8; Z2196779619; 1,1''''-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane}; 1,1'-(benzene-1,4-diyldimethanediyl)bis(1,4,8,11-tetraazacyclotetradecane); 1,1'[1,4-phenylene-bis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane; 1,4,8,11-Tetraazacyclotetradecane, 1,1'-(1,4-phenylenebis(methylene))bis-; 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Hippeastrum hybrid agglutinin( HHA); 1,4,8,11-tetraazacyclotetradecanyl[4-(1,4,8,11-tetraazacyclotetradecanylmethyl)phenyl]methane; 1,4,8,11-tetraazacyclotetradecanyl[4-(1,4,8,11-tetraazacyclotetradecanylmethyl)phenyl]methane(8HBr.2H2O); 1-({4-[(1,4,8,11-tetraazacyclotetradecan-1-yl)methyl]phenyl}methyl)-1,4,8,11-tetraazacyclotetradecane; 1-{[4-(1,4,8,11-tetraazacyclotetradecan-1-ylmethyl)phenyl]methyl}-1,4,8,11-tetraazacyclotetradecane; 11-{4-[4,8, 11-1,4,8,11tetraaza-cyclotetradec-1-ylmethyl]-benzyl}-1,4,8,11tetraaza-cyclotetradecane-1,4,8-tricarboxylic acid tri-tert-butyl ester	Small molecule	1S/C28H54N8/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36/h5-8,29-34H,1-4,9-26H2	YIQPUIGJQJDJOS-UHFFFAOYSA-N	C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3	C28H54N8	CAS 110078-46-1	CHEBI:125354	.	.	.	D0L5RW	.	.	.
DR7217	Trichostatin A	CID: 444732	trichostatin A; 58880-19-6; Trichostatin A (TSA); TSA; Trichostatin; Tricostatin A; UNII-3X2S926L3Z; CHEBI:46024; (2E,4E,6R)-7-[4-(Dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxohepta-2,4-dienamide; GNF-PF-1011; RTKIYFITIVXBLE-QEQCGCAPSA-N; 3X2S926L3Z; 7-(4-(Dimethylamino)phenyl)-N-hydroxy-4,6-dimethyl-7-oxo-2,4-heptadienamide; 2,4-Heptadienamide, 7-(4-(dimethylamino)phenyl)-N-hydroxy-4,6-dimethyl-7-oxo-; 7-[4-(DIMETHYLAMINO)PHENYL]-N-HYDROXY-4,6-DIMETHYL-7-OXO-2,4-HEPTADIENAMIDE	Small molecule	1S/C17H22N2O3/c1-12(5-10-16(20)18-22)11-13(2)17(21)14-6-8-15(9-7-14)19(3)4/h5-11,13,22H,1-4H3,(H,18,20)/b10-5+,12-11+/t13-/m1/s1	RTKIYFITIVXBLE-QEQCGCAPSA-N	CC(C=C(C)C=CC(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C	C17H22N2O3	CAS 58880-19-6	CHEBI:46024	.	.	.	D0NF6F	.	.	Trichostatin+A
DR7247	Lopinavi	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR7258	Leflunomide	CID: 3899	leflunomide; 75706-12-6; Arava; lefunamide; Leflunomida; Leflunomidum; 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide; HWA 486; Leflunomidum [INN-Latin]; HWA-486; 5-methyl-N-(4-(trifluoromethyl)phenyl)isoxazole-4-carboxamide; SU101; Arava (TN); 5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide; 5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide; 4-Isoxazolecarboxamide, 5-methyl-N-[4-(trifluoromethyl)phenyl]-; alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide; UNII-G162GK9U4W; SU-101; 5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide; CHEMBL960; RS-34821; MLS000069648; CHEBI:6402; G162GK9U4W; 5-Methylisoxazole-4-(4-trifluoromethylcarboxanilide); MFCD00867593; NCGC00015610-02; SMR000058209; 5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide; 4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl)-; CAS-75706-12-6; DSSTox_CID_3201; DSSTox_RID_76923; DSSTox_GSID_23201; Leflunomida [INN-Spanish]; SU 101 (pharmaceutical); Repso; Lefunomide [Inn-Spanish]; HSDB 7289; SR-01000000191; Arabloc; N-(4'-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide; L04AA13; Prestwick_87; Leflunomide [USAN:USP:INN:BAN]; SU 101; SULOL; 1189987-23-2; Spectrum_000322; Opera_ID_1709; Prestwick0_000772; Prestwick1_000772; Prestwick2_000772; Prestwick3_000772; Spectrum5_000850; Lopac-L-5025; L 5025; SCHEMBL5057; BIDD:PXR0189; Lopac0_000649; BSPBio_000844; KBioSS_000802; Leflunomide, Immunosuppressant; MLS001076267; DivK1c_000916; Leflunomide (JAN/USP/INN); SPECTRUM1503927; 5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide; SPBio_002783; BPBio1_000930; GTPL6825; ISO054; ZINC4840; DTXSID9023201; HMS502N18; KBio1_000916; KBio2_000802; KBio2_003370; KBio2_005938; AOB5964; NINDS_000916; 4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl; 5-methyl-n-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamid; HMS1570K06; HMS1922M06; HMS2090O12; HMS2097K06; HMS2235C07; HMS3262A19; HMS3268D12; HMS3371F21; HMS3414P03; HMS3654F07; HMS3673M17; HMS3678N21; HMS3714K06; HMS3865I13; Pharmakon1600-01503927; ALBB-019233; BCP22241; EBD46417; HY-B0083; Tox21_110182; Tox21_301873; Tox21_500649; ABP001076; BDBM50054601; DL-433; NSC677411; NSC759864; s1247; STL426823; AKOS000265193; Tox21_110182_1; AC-6796; BCP9000846; CCG-204736; CS-1781; DB01097; KS-1076; LP00649; MCULE-9490869974; NSC 677411; NSC 759864; NSC-677411; NSC-759864; SB17287; SDCCGSBI-0050629.P003; IDI1_000916; NCGC00015610-01; NCGC00015610-03; NCGC00015610-04; NCGC00015610-05; NCGC00015610-06; NCGC00015610-07; NCGC00015610-08; NCGC00015610-09; NCGC00015610-10; NCGC00015610-11; NCGC00015610-12; NCGC00015610-13; NCGC00015610-14; NCGC00015610-17; NCGC00015610-18; NCGC00015610-30; NCGC00022625-03; NCGC00022625-04; NCGC00022625-05; NCGC00022625-06; NCGC00022625-07; NCGC00022625-08; NCGC00255370-01; NCGC00261334-01; AK161855; H527; ST079287; Leflunomide 100 microg/mL in Acetonitrile; AB0007396; A9622; AB00052389; EU-0100649; FT-0621959; L0250; R3926; SW196399-3; C07905; D00749; MLS-0003109.0001; AB00052389-17; AB00052389-18; AB00052389_19; AB00052389_21; 706L126; Q248550; Q-201289; SR-01000000191-2; SR-01000000191-4; SR-01000000191-7; BRD-K78692225-001-03-9; BRD-K78692225-001-11-2; 5-methyl-4-(4-trifluoromethyl-phenyl)aminocarbonylisoxazole; 5-methyl-4-(4-trifluoromethylphenyl)aminocarbonylisoxazole; Leflunomide, European Pharmacopoeia (EP) Reference Standard; N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide; 5-methyl-N-(4-(trifluoromethyl)phenyl)isoxazole-4-carboxamide;; 5-Methyl-N-[4-(trifluoromethyl)-phenyl]isoxazole-4-carboxamide; 5-methylisoxazole-4-carboxylic acid (4-trifluoromethyl)-anilide; N-(4-trifluoromethylphenyl)-5-methylisoxa-zole-4-carboxamide; (5-methylisoxazol-4-yl)-N-[4-(trifluoromethyl)phenyl]carboxamide; Isoxazole-4-carboxamide, 5-methyl-N-[4-(trifluoromethyl)phenyl]-; Leflunomide, United States Pharmacopeia (USP) Reference Standard; HWA486; RS-34821; SU101;HWA 486; RS 34821; SU 101; Leflunomide, Pharmaceutical Secondary Standard; Certified Reference Material; Leflunomide for peak identification, European Pharmacopoeia (EP) Reference Standard	Small molecule	1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)	VHOGYURTWQBHIL-UHFFFAOYSA-N	CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F	C12H9F3N2O2	CAS 75706-12-6	CHEBI:6402	.	.	.	D08ROP	.	.	.
DR7260	VE-465	CID: 10343860	CHEMBL484609; VE-465; 639089-73-9; N-[4-[[4-(4-Methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]-propanamide; N-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]propanamide; SCHEMBL1080455; SCHEMBL12430853; BDBM50277639; 135408-EP2292614A1; N-(4-(4-(5-methyl-1H-pyrazol-3-ylamino)-6-(4-methylpiperazin-1-yl)pyrimidin-2-ylthio)phenyl)propionamide; N-{4-[4-(4-methyl-piperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino)-pyrimidin-2-ylsulfanyl]-phenyl}-propionamide	Small molecule	1S/C22H28N8OS/c1-4-21(31)23-16-5-7-17(8-6-16)32-22-25-18(24-19-13-15(2)27-28-19)14-20(26-22)30-11-9-29(3)10-12-30/h5-8,13-14H,4,9-12H2,1-3H3,(H,23,31)(H2,24,25,26,27,28)	LCQYMDMUCJFFKN-UHFFFAOYSA-N	CCC(=O)NC1=CC=C(C=C1)SC2=NC(=CC(=N2)N3CCN(CC3)C)NC4=NNC(=C4)C	C22H28N8OS	.	.	.	.	.	.	.	.	.
DR7295	Dexrazoxane	CID: 71384	Dexrazoxane; 24584-09-6; Zinecard; (S)-4,4'-(Propane-1,2-diyl)bis(piperazine-2,6-dione); Cardioxane; ICRF-187; Dextrorazoxane; Dexrazoxanum; Dexrazoxano; Dexrazoxanum [INN-Latin]; Dexrazoxano [INN-Spanish]; ADR 529; ICRF 187; ADR-529; (+)-(S)-4,4'-Propylenedi-2,6-piperazinedione; Dexrazone; (+)-1,2-Bis(3,5-dioxo-1-piperazinyl)propane; Desrazoxane; 2,6-Piperazinedione, 4,4'-[(1S)-1-methyl-1,2-ethanediyl]bis-; UNII-048L81261F; NSC169780; CHEBI:50223; NSC-169780; NSC 169780; MFCD00866449; Razoxanum [INN-Latin]; Razoxana [INN-Spanish]; 048L81261F; 4-[(2S)-1-(3,5-dioxopiperazin-1-yl)propan-2-yl]piperazine-2,6-dione; (S)-1,2-Bis(3,5-dioxo-1-piperazinyl)propane; DSSTox_CID_20647; DSSTox_RID_79520; DSSTox_GSID_40647; (S)-4,4'-(Propane-1,2-diyl)-bis(piperazine-2,6-dione); (+)-dexrazoxane; 4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione; CAS-24584-09-6; 2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, (+)-; 2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, (S)-; HSDB 7319; 2,6-Piperazinedione, 4,4'-propylenedi-, (+)-; SR-01000883995; Dexrazoxane HCl (ICRF-187, ADR-529); BRN 5759131; Soluble ICRF (L-isosomer); Dexrazoxane [USAN:INN:BAN]; CCRIS 9394; NCGC00164737-01; CHEMBL1738; SCHEMBL18400; MLS006010158; BIDD:GT0068; Dexrazoxane (JAN/USAN/INN); (S)-(+)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane; 4,4'-(2S)-propane-1,2-diyldipiperazine-2,6-dione; GTPL7330; DTXSID3040647; Dexrazoxane, >=95% (HPLC); AMY39004; EBD45155; HY-B0581; Tox21_112256; 2, 4,4'-propylenedi-, (+)-; ANW-44923; s5651; ZINC87515509; AKOS015896392; Tox21_112256_1; (+)-1,5-dioxopiperazin-1-yl)propane; CCG-267131; DB00380; DS-1394; MP-0159; NCGC00263544-01; NCGC00263544-02; Dexrazoxane, analytical reference material; NCI60_001367; SMR002529680; AB0011515; (S)-(+)-1,5-dioxopiperazin-1-yl)propane; D4227; D03730; J90038; AB01273932-01; AB01273932-02; AB01273932_03; 2,4,4'-[(1S)-1-methyl-1,2-ethanediyl]bis-; 584D096; A817380; Q524995; 2,4,4'-(1-methyl-1,2-ethanediyl)bis-, (S)-; J-015579; J-520219; SR-01000883995-1; SR-01000883995-2; SR-01000883995-5; (S)-4,4'-(propane-1,2-diyl)dipiperazine-2,6-dione; BRD-K07265709-003-01-5; (S)-4,4-(Propane-1,2-diyl)bis(piperazine-2,6-dione); 4,4'-[(2S)-1,2-Propanediyl]di(2,6-piperazinedione); UNII-5AR83PR647 component BMKDZUISNHGIBY-ZETCQYMHSA-N; 4-[(2S)-2-(3,5-dioxo-1-piperazinyl)propyl]piperazine-2,6-dione; 2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, (+)- (9CI); 4-[(2S)-2-[3,5-bis(oxidanylidene)piperazin-1-yl]propyl]piperazine-2,6-dione; 6-hydroxy-4-[(2S)-2-(5-hydroxy-3-oxo-1,2,3,6-tetrahydropyrazin-1-yl)propyl]-2,3,4,5-tetrahydropyrazin-2-one	Small molecule	1S/C11H16N4O4/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19)/t7-/m0/s1	BMKDZUISNHGIBY-ZETCQYMHSA-N	CC(CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2	C11H16N4O4	CAS 24584-09-6	CHEBI:50223	.	.	.	D07XVN	.	.	.
DR7302	Latamoxef	CID: 47499	Latamoxef; moxalactam; Lamoxactam; Latamoxefum; 64952-97-2; Oxa-cephem; Festamoxin; LMOX; Moxam; Listeria mox supplement; CHEBI:599928; Disodium Moxalactam; 64952-97-2 (FREE ACID); Latamoxefum [INN-Latin]; (6R,7R)-7-[[2-carboxy-2-(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Latamoxef [INN:BAN]; Latamoxef (INN); EINECS 265-287-9; Spectrum_000971; Prestwick0_000819; Prestwick1_000819; Prestwick2_000819; Spectrum2_001067; Spectrum3_000510; Spectrum4_000064; Spectrum5_001371; MOXALACTAMSUPPLEMENT; Epitope ID:180870; BSPBio_002039; KBioGR_000587; KBioSS_001451; (6R-(6alpha,7alpha,7(S*)))-7-((Carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 5-Oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-; 7beta-(2-Carboxy-2-(4-hydroxyphenyl)acetamido)-7alpha-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-1-oxa-1-dethia-3-cephem-4-carboxylic acid; CHEMBL74632; DivK1c_000909; SCHEMBL194012; SPBio_001054; SPBio_002638; DTXSID9023338; KBio1_000909; KBio2_001451; KBio2_004019; KBio2_006587; KBio3_001539; NINDS_000909; BCP12584; 7002AB; BDBM50370589; DB04570; Moxalactam Supplement, for microbiology; IDI1_000909; SMP1_000200; (6R,7R)-7-{[carboxy(4-hydroxyphenyl)acetyl]amino}-7-(methyloxy)-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[carboxy(4-hydroxyphenyl)acetyl]amino}-7-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-((Carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid (6R-(6alpha,7alpha,7(S*)))-; 79120-38-0; SBI-0051450.P003; C07231; D08109; 649L972; Q3827439; (6R,7R)-7-(2-carboxy-2-(4-hydroxyphenyl)acetamido)-7-methoxy-3-((1-methyl-1H-tetrazol-5-ylthio)methyl)-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[3-hydroxy-2-(4-hydroxyphenyl)-3-oxo-propanoyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[2-carboxy-2-(4-hydroxyphenyl)acetamido]-7-methoxy-3-{[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[2-Carboxy-2-(p-hydroxyphenyl)acetylamino]-7-methoxy-3-(1-methyl-1H-tetrazol-5-ylthiomethyl)-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 5-Oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-, (6R-(6alpha,7alpha,7(S*)))-; 5-Oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[carboxy(4-hydroxyphenyl)acetyl]amino]-7methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-; 5-Oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,7-[[(2R)-carboxy(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-,(6R,7R)-	Small molecule	1S/C20H20N6O9S/c1-25-19(22-23-24-25)36-8-10-7-35-18-20(34-2,17(33)26(18)13(10)16(31)32)21-14(28)12(15(29)30)9-3-5-11(27)6-4-9/h3-6,12,18,27H,7-8H2,1-2H3,(H,21,28)(H,29,30)(H,31,32)/t12?,18-,20+/m1/s1	JWCSIUVGFCSJCK-CAVRMKNVSA-N	CN1C(=NN=N1)SCC2=C(N3C(C(C3=O)(NC(=O)C(C4=CC=C(C=C4)O)C(=O)O)OC)OC2)C(=O)O	C20H20N6O9S	CAS 64952-97-2	CHEBI:599928	.	.	.	D0O5LU	.	.	.
DR7304	ABT-263	CID: 24978538	Navitoclax; ABT 263; S1001_Selleck; ABT263, Navitoclax; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide	Small molecule	1S/C47H55ClF3N5O6S3/c1-46(2)20-18-42(34-8-12-37(48)13-9-34)36(31-46)32-55-22-24-56(25-23-55)39-14-10-35(11-15-39)45(57)53-65(60,61)41-16-17-43(44(30-41)64(58,59)47(49,50)51)52-38(19-21-54-26-28-62-29-27-54)33-63-40-6-4-3-5-7-40/h3-17,30,38,52H,18-29,31-33H2,1-2H3,(H,53,57)/t38-/m1/s1	JLYAXFNOILIKPP-KXQOOQHDSA-N	CC1(CCC(=C(C1)CN2CCN(CC2)C3=CC=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(C=C4)NC(CCN5CCOCC5)CSC6=CC=CC=C6)S(=O)(=O)C(F)(F)F)C7=CC=C(C=C7)Cl)C	C47H55ClF3N5O6S3	CAS 923564-51-6	.	.	.	.	D06ETI	.	.	ABT-263
DR7308	Pyrimethamine	CID: 4993	pyrimethamine; 58-14-0; Daraprim; 5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine; Chloridine; Diaminopyritamin; Ethylpyrimidine; Pirimetamin; Chloridin; Chloridyn; Pirimecidan; Pirimetamina; Pyrimethamin; Malocide; Primethamine; Darachlor; Erbaprelina; Khloridin; Tindurin; Malocid; 5-(4-CHLOROPHENYL)-6-ETHYL-2,4-PYRIMIDINEDIAMINE; Darapram; Daraprime; Malacid; Maloprim; 2,4-Pyrimidinediamine, 5-(4-chlorophenyl)-6-ethyl-; Pyremethamine; Pyrimethaminum; 2,4-Diamino-5-(p-chlorophenyl)-6-ethylpyrimidine; RP 4753; 2,4-Diamino-5-chlorophenyl-6-ethylpyrimidine; BW 50-63; 2,4-Diamino-5-(4-chlorophenyl)-6-ethylpyrimidine; 5-(4'-Chlorophenyl)-2,4-diamino-6-ethylpyrimidine; TCMDC-125860; NCI-C01683; WR 2978; 5-(4-Chlorophenyl)-6-ethyl-2,4-diaminopyrimidine; UNII-Z3614QOX8W; GNF-Pf-5586; 4753 R.P.; TCMDC-123831; NSC-3061; CHEMBL36; 5-(4-CHLORO-PHENYL)-6-ETHYL-PYRIMIDINE-2,4-DIAMINE; 2,4-Pyrimidinediamine, 5-(p-chlorophenyl)-6-ethyl-; MLS000028606; MLS002701881; CHEBI:8673; Z3614QOX8W; Daraclor; NSC3061; 5-(4-chlorophenyl)-6-ethyl-pyrimidine-2,4-diamine; Pyrimidine, 2,4-diamino-5-(p-chlorophenyl)-6-ethyl-; Pyrimethamine, 98%; CAS-58-14-0; NCGC00016256-08; SMR000058714; Tinduring; Pirimetamina [Spanish]; DSSTox_CID_1217; DSSTox_RID_76016; DSSTox_GSID_21217; CP6; Pirimetamina [INN-Spanish]; Pyrimethaminum [INN-Latin]; BRD9204; BRD-9204; Daraprim (TN); CCRIS 546; Pyrimethamine (Pyr); SR-01000003150; NSC 3061; EINECS 200-364-2; BRN 0219864; CRL-8131 & Pyrimethamine; CRL-8142 & Pyrimethamine; Lactoferrin B & Pyrimethamine; Lactoferrin H & Pyrimethamine; AI3-25005; Pyrimethamine (JAN/USP/INN); AZT + Pyrimethamine combination; HSDB 8042; EXR-101; Pyrimethamine [USP:INN:BAN:JAN]; Prestwick_504; MFCD00057350; PubChem9611; BW 5063; Daraclor (Salt/Mix); Spectrum_000906; 4km0; CPD000058714; Opera_ID_1437; Prestwick0_000037; Prestwick1_000037; Prestwick2_000037; Prestwick3_000037; Spectrum2_000886; Spectrum3_001701; Spectrum4_000494; Spectrum5_001447; cid_4993; NCIOpen2_008313; BIDD:PXR0173; SCHEMBL25129; BSPBio_000133; BSPBio_003282; KBioGR_001007; KBioSS_001386; MLS001148621; MLS002454446; BIDD:GT0149; DivK1c_000652; SPECTRUM1500520; SPBio_000672; SPBio_002054; BPBio1_000147; GTPL4800; DTXSID9021217; BDBM18512; HMS502A14; KBio1_000652; KBio2_001386; KBio2_003954; KBio2_006522; KBio3_002502; ZINC57464; NINDS_000652; Pirimecidan;Pirimetamin;RP 4753; HMS1568G15; HMS1920N12; HMS2092E13; HMS2095G15; HMS2235A17; HMS3259C04; HMS3371L07; HMS3655D09; HMS3675P11; HMS3712G15; HMS3743O05; HMS3871I03; Pharmakon1600-01500520; 2, 5-(p-chlorophenyl)-6-ethyl-; 2, 5-(4-chlorophenyl)-6-ethyl-; Tox21_110332; Tox21_201834; Tox21_300129; ANW-44788; CCG-39626; NSC757306; AKOS015892534; Tox21_110332_1; AB02313; AC-7879; CS-1717; DB00205; KS-5223; LS40239; NC00528; NSC-757306; RP-4753; WR-2978; IDI1_000652; NCGC00016256-01; NCGC00016256-02; NCGC00016256-03; NCGC00016256-04; NCGC00016256-05; NCGC00016256-06; NCGC00016256-07; NCGC00016256-09; NCGC00016256-10; NCGC00016256-11; NCGC00016256-12; NCGC00016256-13; NCGC00016256-14; NCGC00016256-16; NCGC00016256-17; NCGC00023188-03; NCGC00023188-04; NCGC00023188-05; NCGC00023188-06; NCGC00023188-07; NCGC00254199-01; NCGC00259383-01; WLN: T6N CNJ BZ DZ ER DG& F2; AK-35735; HY-18062; NCI60_002604; SBI-0051500.P003; AB0011152; DB-053158; AB00052084; FT-0631253; P2037; S2006; SW196698-3; C07391; D00488; M-1612; MLS-0002822.0001; AB00052084-21; AB00052084_22; AB00052084_25; 057P350; 2,4-diamino-5(4-chlorophenyl)-6-ethylpyrimidine; A831755; L000713; Pyrimethamine, VETRANAL(TM), analytical standard; Pyrimidine,4-diamino-5-(p-chlorophenyl)-6-ethyl-; Q421072; 2,4,-Diamino-5-(4-chlorophenyl)-6-ethylpyrimidine; 2,4-diamino-5-(4-chloro-phenyl)-6-ethylpyrimidine; 2,4-diamino-6-ethyl-5-(4-chlorophenyl)pyrimidine; Q-201648; SR-01000003150-2; SR-01000003150-4; BRD-K88429204-001-05-4; BRD-K88429204-001-18-7; BRD-K88429204-001-21-1; BRD-K88429204-001-36-9; Z2065727768; 2,4-Diamino-5-(4-chlorophenyl)-6-ethylpyrimidine, 97%; Pyrimethamine, European Pharmacopoeia (EP) Reference Standard; Pyrimethamine, United States Pharmacopeia (USP) Reference Standard	Small molecule	1S/C12H13ClN4/c1-2-9-10(11(14)17-12(15)16-9)7-3-5-8(13)6-4-7/h3-6H,2H2,1H3,(H4,14,15,16,17)	WKSAUQYGYAYLPV-UHFFFAOYSA-N	CCC1=C(C(=NC(=N1)N)N)C2=CC=C(C=C2)Cl	C12H13ClN4	CAS 58-14-0	CHEBI:8673	.	.	.	D0C0SK	.	.	.
DR7335	Pralatrexate	CID: 148121	Pralatrexate; 146464-95-1; Folotyn; 10-Propargyl-10-deazaaminopterin; Pralatrexate(Folotyn); HSDB 7786; PDX; CHEBI:71223; N-(4-(1-((2,4-Diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-L-glutamic acid; 146464-95-1 (racemic); (2S)-2-(4-(1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl)benzamido)pentanedioic acid; (2S)-2-((4-((1RS)-1-((2,4-Diaminopteridin-6-yl)methyl)but-3-ynyl)benzoyl)amino)pentanedioic acid; NCGC00242596-01; (2S)-2-({4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}amino)pentanedioic acid; (2S)-2-[[4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl]amino]pentanedioic acid; N-{4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}-L-glutamic acid; L-Glutamic acid, N-[4-[1-[(2,4-diamino-6-pteridinyl)methyl]-3-butyn-1-yl]benzoyl]-; N -(4-{1-[(2,4-diaminopteridin-6-yl)methyl]but-3-yn-1-yl}benzoyl)-L-glutamic acid; Folotyn (TN); Pralatrexate [USAN:INN]; pralatrexato; pralatrexatum; Pralatrexate(Folotyn)/; DSSTox_CID_28504; DSSTox_RID_82776; N-[4-[1-[(2,4-Diamino-6-pteridinyl)methyl]-3-butyn-1-yl]benzoyl]-L-glutamic Acid; DSSTox_GSID_48578; SCHEMBL21633; GTPL6840; Pralatrexate (JAN/USAN/INN); CHEMBL1201746; DTXSID3048578; SCHEMBL15075302; BCPP000101; EX-A2142; Tox21_112906; 2667AH; ABP000543; BDBM50457437; MFCD00920897; NSC754230; s1497; AKOS015966891; AM84423; CCG-269517; CS-0504; DB06813; NSC 754230; NSC-754230; QC-3214; SB17353; 10-Propargyl-10-deazaaminopterin, 95%; NCGC00386226-01; AC-28388; BS-15438; HY-10446; AB0095450; CAS-146464-95-1; SW220187-1; D05589; AB00443251-02; AB00443251_04; 464P951; Q637059; SR-01000941578; J-008227; SR-01000941578-1; L-Glutamic acid, N-(4-(1-((2,4-diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-	Small molecule	1S/C23H23N7O5/c1-2-3-14(10-15-11-26-20-18(27-15)19(24)29-23(25)30-20)12-4-6-13(7-5-12)21(33)28-16(22(34)35)8-9-17(31)32/h1,4-7,11,14,16H,3,8-10H2,(H,28,33)(H,31,32)(H,34,35)(H4,24,25,26,29,30)/t14?,16-/m0/s1	OGSBUKJUDHAQEA-WMCAAGNKSA-N	C#CCC(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O	C23H23N7O5	CAS 146464-95-1	CHEBI:71223	.	.	.	D02LWU	.	.	.
DR7340	Brentuximab vedotin	.	.	Antibody	.	.	.	.	.	.	.	.	.	D03TIS	.	.	.
DR7358	Vinorelbine	CID: 5311497	vinorelbine; 71486-22-1; Navelbine; Vinorelbinum; Exelbine; Vinorelbina; Nor-5'-anhydrovinblastine; UNII-Q6C979R91Y; Vinorelbinum [Latin]; Vinorelbina [Spanish]; Navelbine base; CHEBI:480999; KW-2307; Q6C979R91Y; Navelbine (TN); Eunades; Vinorelbine [INN:BAN]; KW 2307 base; methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(12S,14R)-16-ethyl-12-methoxycarbonyl-1,10-diazatetracyclo[12.3.1.03,11.04,9]octadeca-3(11),4,6,8,15-pentaen-12-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate; methyl (2b,3b,4b,5a,12b,19a)-4-(acetyloxy)-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate; Vinorelbine (INN); Vinorelbine(Navelbine); SR-05000001504; HSDB 7665; ANX-530; SDP-012; C45H54N4O8; Vinorelbine(Navelbine)/; 5'-Noranhydrovinblastine; NVB; SCHEMBL4765; cc-469; C'-Norvincaleukoblastine, 3',4'-didehydro-4'-deoxy-; CHEMBL553025; GTPL7105; DTXSID8040640; HMS2090E13; ABP000672; ZINC85536958; AKOS024457606; AT-7140; CCG-208616; DB00361; NSC 760087; NCGC00165966-03; K210; methyl (2beta,3beta,4beta,5alpha,12beta,19alpha)-4-acetoxy-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate; FT-0657343; D08680; AB01275493-01; AB01566877_01; 486V221; SR-05000001504-1; SR-05000001504-2; Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-((2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino(4,3-b)indol-8-yl)-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2beta,3beta,4beta,5alpha,12beta,19alpha)-; Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-((2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino(4,3-b)indol-8-yl)-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2beta,3beta,4beta,5alpha,12R,19alpha)-	Small molecule	1S/C45H54N4O8/c1-8-27-19-28-22-44(40(51)55-6,36-30(25-48(23-27)24-28)29-13-10-11-14-33(29)46-36)32-20-31-34(21-35(32)54-5)47(4)38-43(31)16-18-49-17-12-15-42(9-2,37(43)49)39(57-26(3)50)45(38,53)41(52)56-7/h10-15,19-21,28,37-39,46,53H,8-9,16-18,22-25H2,1-7H3/t28-,37-,38+,39+,42+,43+,44-,45-/m0/s1	GBABOYUKABKIAF-IELIFDKJSA-N	CCC1=CC2CC(C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC	C45H54N4O8	CAS 71486-22-1	CHEBI:480999	.	.	.	D01HTL	.	.	.
DR7371	Diethylpropion	CID: 7029	Amfepramone; DIETHYLPROPION; Diethylpropione; Anorex; Tepanil; 90-84-6; Frekentine; Danylen; Dobesin; Magrene; Tylinal; alpha-Benzoyltriethylamine; Amfepramonum; Prefamone; Regenon; alpha-Diethylaminopropiophenone; Anfepramona; 1-Propanone, 2-(diethylamino)-1-phenyl-; Diethylcathinone; Amfepramonum [INN-Latin]; Anfepramona [INN-Spanish]; 2-(Diethylamino)propiophenone; Amfepramone [INN]; 1-Phenyl-2-diethylamino-1-propanone; 2-(Diethylamino)-1-phenyl-1-propanone; 2-(diethylamino)-1-phenylpropan-1-one; Moderatan; Tenuate; Amfepramon; Amfepramone hydrochloride; DEA No. 1610; Propiophenone, 2-(diethylamino)-; Amfepramone (INN); Amphepramon; Amphepramone; Nopropiophenone; Adiposon; Neobes; Tenuate Dospan; Amphepramonum hydrochloride; Diethylpropione hydrochloride; Cegramine; Obesitex; Silutin; Derfon; Regenon hydrochloride; CHEBI:4530; Anfamon; Keramik; Keramin; Modulor; Parabolin; UNII-I535TOV6LY; UNII-P1A5AE6Q2R; C06954; D07444; Tenuate hydrochloride; (+)-Amfepramone; (-)-Amfepramone; UR 1423; (+-)-diethylpropion; Diethylpropion (BAN); Fenyl-(1-diethylaminoethyl)keton [Czech]; Amfepramone, (+)-; Amfepramone, (-)-; Fenyl-(1-diethylaminoethyl)keton; HSDB 3059; I535TOV6LY; P1A5AE6Q2R; Diethylpropion, (+}-; Diethylpropion, (-)-; NCGC00167475-01; EINECS 202-019-1; BRN 2804400; 1-Phenyl-2-diethylaminopropanone-1 hydrochloride; Propiophenone, 2-(diethylamino)-, hydrochloride; Propiophenone, 2-diethylamino-; (+)-2-Diethylaminopropiophenone; (-)-2-Diethylaminopropiophenone; (+/-)-diethylpropion; SCHEMBL27330; 1-Propanone, 2-(diethylamino)-1-phenyl-, (+)-; 1-Propanone, 2-(diethylamino)-1-phenyl-, (-)-; 4-14-00-00144 (Beilstein Handbook Reference); GTPL7161; CHEMBL1194666; DTXSID6022929; MFCD00056154; AKOS025401369; DIETHYLPROPION, DONYLEN,DOBESIN; DB00937; J4.327C; MCULE-3905795013; 2-Diethylaminopropiophenone hydrochloride; 39648-49-2; 39648-50-5; AC-13099; 2-(Diethylamino)-1-phenyl-1-propanone #; 1-Phenyl-2-diethylamino-1-propanone hydrochloride; Q2356505; BRD-A37288617-003-01-4	Small molecule	1S/C13H19NO/c1-4-14(5-2)11(3)13(15)12-9-7-6-8-10-12/h6-11H,4-5H2,1-3H3	XXEPPPIWZFICOJ-UHFFFAOYSA-N	CCN(CC)C(C)C(=O)C1=CC=CC=C1	C13H19NO	CAS 90-84-6	CHEBI:4530	.	.	.	D0B7OD	.	.	.
DR7409	Rituximab	.	.	Antibody	.	.	.	.	.	.	.	.	.	D09EXD	.	.	.
DR7446	Hydroquinone	CID: 785	hydroquinone; 1,4-benzenediol; Benzene-1,4-diol; 123-31-9; Quinol; 1,4-Dihydroxybenzene; p-Benzenediol; p-Hydroquinone; p-Hydroxyphenol; p-Dihydroxybenzene; 4-Hydroxyphenol; Benzoquinol; Eldoquin; hydroquinol; Eldopaque; Phiaquin; p-Dioxybenzene; Benzohydroquinone; Dihydroquinone; Hydroquinole; Idrochinone; Tecquinol; Dihydroxybenzene; Solaquin forte; Arctuvin; Hidroquinone; Tequinol; Derma-Blanch; Tenox HQ; Hydrochinon; Hydrochinone; Artra; Eldopaque Forte; Eldoquin Forte; Diak 5; Benzene, p-dihydroxy-; 1,4-Dihydroxy-benzol; Usaf ek-356; 1,4-Diidrobenzene; p-Dioxobenzene; 1,4-Dihydroxybenzen; para-Dioxybenzene; para-Hydroquinone; Pyrogentistic acid; 1,4-Dihydroxy-benzeen; NCI-C55834; HE 5; para-Dihydroxybenzene; Black and White Bleaching Cream; Melanex; Idrochinone [Italian]; Hydrochinon [Czech, Polish]; 1,4-Dihydroxybenzen [Czech]; 1,4-Diidrobenzene [Italian]; Benzosemiquinone; 1,4-Dihydroxy-benzeen [Dutch]; 1,4-Dihydroxy-benzol [German]; UNII-XV74C1N1AE; NSC 9247; MFCD00002339; UN2662; Hydroquinone [USP]; CHEBI:17594; AI3-00072; 4-DIHYDROXYBENZENE; HQ; CHEMBL537; XV74C1N1AE; DTXSID7020716; NSC-9247; Hydroquinone [UN2662]  [Poison]; Hydroquinone (USP); Hydroquinone, 99%; NCGC00015523-02; beta-quinol; Hydroquinone, 99.5%; DSSTox_CID_716; DSSTox_RID_75754; DSSTox_GSID_20716; Eldopacque; Hydroquinone (Benzene-1,4-diol); Epiquin; Sunvanish; p Benzendiol; p-Dihydroquinone; alpha-hydroquinone; para-Hydroxyphenol; CAS-123-31-9; SMR000059154; CCRIS 714; 1,4-Hydroxybenzene; HSDB 577; SR-01000075920; EINECS 204-617-8; hydroquinon; Hydroquinoue; hydroq uinone; hydroquinone gr; a-Hydroquinone; Black & White Bleaching Cream; p-Hydroxybenzene; b-Quinol; 4-Benzenediol; Hydroquinone, HQ; .beta.-Quinol; 1,4 benzenediol; Hydroquinone,(S); p-dihydroxy benzene; HQE; Hydroquinone polymer; PLQ; Artra (Salt/Mix); 1, 4-Benzenediol; HYDROP; .alpha.-Hydroquinone; phenol derivative, 4; PubChem9139; 4-hydroxyphenyl alcohol; Spectrum_001757; 4e3h; ACMC-209aok; SpecPlus_000769; 1,4-Dihydrobenzoquinone; ELDOQUIN (TN); hydroquinone for synthesis; Spectrum2_001672; Spectrum3_000656; Spectrum4_000633; Spectrum5_001430; Lopac-H-9003; 1,2 BENZOLDIOL; WLN: QR DQ; bmse000293; Epitope ID:116206; EC 204-617-8; Lopac0_000577; SCHEMBL15516; BSPBio_002291; KBioGR_001246; KBioSS_002237; 1,4-Dihydroxybenzene, XIII; Hydroquinone-1,4-Benzenediol; MLS000069815; MLS001074911; BIDD:ER0340; DivK1c_006865; Hydroquinone, LR, >=99%; SPECTRUM1504237; Hydrochinon(CZECH, POLISH); SPBio_001883; BDBM26190; Hydroquinone, puriss., 99.0%; KBio1_001809; KBio2_002237; KBio2_004805; KBio2_007373; KBio3_001511; NSC9247; Benzene-1,4-diol (Hydroquinone); HMS1922H15; HMS2093E08; HMS3261D16; LABOTEST-BB LTBB001931; Pharmakon1600-01504237; HY-B0951; ZINC5133378; Tox21_110169; Tox21_202345; Tox21_300015; Tox21_500577; ANW-18114; BBL011606; CCG-39082; NSC758707; s4580; SBB060421; STK397446; AKOS000119003; Tox21_110169_1; AM10548; AS00174; DB09526; LP00577; MCULE-3953269041; NE10177; NSC-758707; SDCCGSBI-0050559.P003; UN 2662; Hydroquinone, ReagentPlus(R), >=99%; Hydroquinone, USP, 99.0-100.5%; NCGC00015523-01; NCGC00015523-03; NCGC00015523-04; NCGC00015523-05; NCGC00015523-06; NCGC00015523-07; NCGC00015523-08; NCGC00015523-09; NCGC00015523-10; NCGC00015523-11; NCGC00015523-12; NCGC00015523-13; NCGC00015523-19; NCGC00090880-01; NCGC00090880-02; NCGC00090880-03; NCGC00090880-04; NCGC00090880-05; NCGC00254037-01; NCGC00259894-01; NCGC00261262-01; BP-21160; DA-33570; Hydroquinone, ReagentPlus(R), >=99.5%; SBI-0050559.P002; Hydroquinone, SAJ first grade, >=99.0%; EU-0100577; FT-0606877; Hydroquinone, SAJ special grade, >=99.0%; ST50214344; Hydroquinone, meets USP testing specifications; C00530; D00073; H 9003; 19538-EP2272837A1; 19538-EP2284165A1; 19538-EP2302015A1; 19538-EP2305825A1; 19538-EP2309584A1; 19538-EP2311804A2; 19538-EP2314576A1; 19538-EP2314579A1; 19538-EP2314584A1; 19538-EP2315303A1; 19538-EP2371803A1; 19538-EP2377843A1; 97871-EP2305685A1; AB00053361_08; 122680-EP2295053A1; Q419164; J-004910; J-521469; SR-01000075920-1; SR-01000075920-4; Q27102742; Z57127551; 094CADDB-59BF-4EDF-B278-59791B203EA2; F1908-0167; Hydroquinone, certified reference material, TraceCERT(R); Hydroquinone, United States Pharmacopeia (USP) Reference Standard; Hydroquinone, Pharmaceutical Secondary Standard; Certified Reference Material	Small molecule	1S/C6H6O2/c7-5-1-2-6(8)4-3-5/h1-4,7-8H	QIGBRXMKCJKVMJ-UHFFFAOYSA-N	C1=CC(=CC=C1O)O	C6H6O2	CAS 123-31-9	CHEBI:17594	.	.	.	D03UOT	.	.	.
DR7470	Combretastatin A-4 phosphate	CID: 5351387	Fosbretabulin; Combretastatin A-4 phosphate; (Z)-2-Methoxy-5-(3,4,5-trimethoxystyryl)phenyl dihydrogen phosphate; 222030-63-9; Fosbretabulin disodium; UNII-I5590ES2QZ; Fosbretabulin free acid; combretastatin A4 phosphate; CA4DP; I5590ES2QZ; CA 4DP; 222030-63-9 (free acid); Phenol, 2-methoxy-5-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, dihydrogen phosphate; Fosbretabulin [INN]; Phosbretabulin; [2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] dihydrogen phosphate; SCHEMBL66079; GTPL8857; CHEMBL1206232; ZINC1543513; 2-Methoxy-5-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)phenyl phosphate; DB12577; Z-3247; Q5150956	Small molecule	1S/C18H21O8P/c1-22-14-8-7-12(9-15(14)26-27(19,20)21)5-6-13-10-16(23-2)18(25-4)17(11-13)24-3/h5-11H,1-4H3,(H2,19,20,21)/b6-5-	WDOGQTQEKVLZIJ-WAYWQWQTSA-N	COC1=C(C=C(C=C1)C=CC2=CC(=C(C(=C2)OC)OC)OC)OP(=O)(O)O	C18H21O8P	CAS 222030-63-9	.	.	.	.	D07JVO	.	.	.
DR7498	Sulfamethoxazole	CID: 5329	sulfamethoxazole; 723-46-6; Sulphamethoxazole; Gantanol; Sulfisomezole; Sulfamethoxazol; 4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamide; Metoxal; Sulfamethylisoxazole; Simsinomin; Radonil; Sinomin; Sulphamethoxazol; Sulpha-methoxizole; Bactrim; Sulfamethalazole; Azo-gantanol; 4-amino-N-(5-methylisoxazol-3-yl)benzenesulfonamide; Sulphamethylisoxazole; Urobak; Ro 4-2130; 3-Sulfanilamido-5-methylisoxazole; Gantanol-DS; Sulphisomezole; 4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide; 5-Methyl-3-sulfanilamidoisoxazole; MS 53; 3-Sulphanilamido-5-methylisoxazole; Benzenesulfonamide, 4-amino-N-(5-methyl-3-isoxazolyl)-; 5-Methyl-3-sulphanil-amidoisoxazole; 3-(p-Aminophenylsulfonamido)-5-methylisoxazole; 5-Methyl-3-sulfanylamidoisoxazole; N'-(5-Methyl-3-isoxazolyl)sulfanilamide; N1-(5-Methyl-3-isoxazolyl)sulfanilamide; N'-(5-Methylisoxazol-3-yl)sulphanilamide; 3-(para-Aminophenylsulphonamido)-5-methylisoxazole; Sulfamethoxazole-d4; Sulmeprim; Trimeth/Sulfa; A047; SMX; Sulfamethoxazole sodium; UNII-JE42381TNV; N(sup 1)-(5-Methyl-3-isoxazolyl)sulphanilamide; CHEBI:9332; N'-(5-Methyl-3-isoxazole)sulfanilamide; Sulfamethoxizole; Ro 6-2580/11; 4-Amino-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide; Sulfanilamide, N'-(5-methyl-3-isoxazolyl)-; Sulfanilamide, N1-(5-methyl-3-isoxazolyl)-; 4-AMINO-N-(5-METHYL-3-ISOXAZOYL)BENZENESULFONAMIDE; Sulfametoxazol; Bactrimel; Gamazole; MFCD00010546; CHEMBL443; N1-(5-Methylisoxazol-3-yl)sulfanilamide; MLS000069732; JE42381TNV; 4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzene-1-sulfonamide; Solfametossazolo; N(sup1)-(5-Methyl-3-isoxazolyl)sulfanilamide; 5-Methyl-3-sulfonylamidoisoxazole; STX-608; Sulfamethoxazolum; NSC147832; 4-Amino-N-(5-methyl-3-isoxazolyl)-benzenesulfonamide; NSC-147832; NCGC00016533-05; NCGC00186654-01; CAS-723-46-6; SMR000058223; DSSTox_CID_6064; Solfametossazolo [DCIT]; 3-(p-Aminobenzenesulfonamido)-5-methylisoxazole; DSSTox_RID_78001; DSSTox_GSID_26064; [(4-aminophenyl)sulfonyl](5-methylisoxazol-3-yl)amine; Sulfametoxazol [INN-Spanish]; Sulfamethoxazolum [INN-Latin]; CCRIS 567; HSDB 3186; SR-01000000217; EINECS 211-963-3; NSC 147832; BRN 0226453; N(sup 1)-(5-Methyl-3-isoxazolyl)sulfanilamide; Sulfanilamide, N(1)-(5-methyl-3-isoxazolyl)-; 08D; Prestwick_453; ALBB-002089; Septran (Salt/Mix); Septrin (Salt/Mix); Sulfamethoxazole,(S); Eusaprim (Salt/Mix); Ro-4-2130; Spectrum_000994; Sulfamethoxazole(USAN); Sulfamethoxazole-13C6; Opera_ID_882; Maybridge1_007190; Prestwick0_000177; Prestwick1_000177; Prestwick2_000177; Prestwick3_000177; Spectrum2_000788; Spectrum3_000584; Spectrum4_000345; Spectrum5_000982; Sulfamethoxazole [USAN:USP:INN:BAN:JAN]; Epitope ID:114999; Co-trimoxazole (Salt/Mix); SCHEMBL3656; Oprea1_114486; Oprea1_285680; BSPBio_000073; BSPBio_002028; KBioGR_000749; KBioSS_001474; MLS001055354; MLS001074165; MLS006011871; BIDD:GT0731; DivK1c_000649; SPECTRUM1500550; SPBio_000896; SPBio_001994; ARONIS018156; BPBio1_000081; DTXSID8026064; component of Bactrim (Salt/Mix); GTPL10933; HMS502A11; HMS561O18; JLKIGFTWXXRPMT-UHFFFAOYSA-; KBio1_000649; KBio2_001474; KBio2_004042; KBio2_006610; KBio3_001528; ZINC89763; EBD3403; N1-(5-methylisoxazol-3-yl)-4-aminobenzene-1-sulfonamide; WLN: T5NOJ C1 EMSWR DZ; NINDS_000649; HMS1568D15; HMS1921A21; HMS2092K03; HMS2095D15; HMS2233L13; HMS3259E06; HMS3372M22; HMS3655O22; HMS3712D15; Pharmakon1600-01500550; BCP02881; HY-B0322; Sulfamethoxazole (JP17/USP/INN); Sulfamethoxazole, analytical standard; Tox21_110480; Tox21_200353; ANW-43073; BBL004554; BDBM50029770; CCG-40166; HTS001394; KM1475; NSC757328; Ro-42130; s1915; SBB057675; SBB071655; STK007988; AKOS000200952; component of Azo Gantanol (Salt/Mix); Tox21_110480_1; BS-3542; DB01015; MCULE-1450176600; NC00537; NSC-757328; RP-2145; IDI1_000649; NCGC00016533-01; NCGC00016533-02; NCGC00016533-03; NCGC00016533-04; NCGC00016533-06; NCGC00016533-07; NCGC00016533-08; NCGC00016533-09; NCGC00016533-10; NCGC00016533-11; NCGC00016533-12; NCGC00016533-14; NCGC00021995-03; NCGC00021995-04; NCGC00021995-05; NCGC00257907-01; AC-11118; AK-36221; H463; ST024740; SY018888; BCP0726000283; N'-(5-Methyl-3-isoxazolyl)-Sulfanilamide; N1-(5-methyl-3-isoxazolyl)-Sulfanilamide; N1-(5-Methyl-3-isoxazolyl)sulphanilamide; SBI-0051524.P003; DB-055629; AB00052099; BB 0242379; FT-0602616; N^1-(5-Methyl-3-isoxazolyl)-Sulfanilamide; ST51006798; SW196670-3; C07315; D00447; J10090; Sulfamethoxazole 100 microg/mL in Acetonitrile; AB00052099-14; AB00052099-16; AB00052099_17; AB00052099_18; Ndimethyl1-(5-methyl-3-isoxazolyl)-Sulfanilamide; Q415843; Q-201762; SR-01000000217-2; SR-01000000217-3; Sulfamethoxazole, VETRANAL(TM), analytical standard; Sulfanilamide, N1-(5-methyl-3-isoxazolyl)- (8CI); 4-Amino-N-(5-methylisoxazol-3-yl)benzenesulphonamide; BRD-K28494619-001-05-0; BRD-K28494619-001-15-9; BRD-K28494619-001-26-6; Z57198677; 4-Amino-N-(5-methyl-isoxazol-3-yl)-benzene sulfonamide; Sulfamethoxazole, British Pharmacopoeia (BP) Reference Standard; Sulfamethoxazole, certified reference material, TraceCERT(R); 4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide; SMX; SMZ; Sulfamethoxazole, European Pharmacopoeia (EP) Reference Standard; Sulfamethoxazole, United States Pharmacopeia (USP) Reference Standard; Sulfamethoxazole, Pharmaceutical Secondary Standard; Certified Reference Material; 129378-89-8	Small molecule	1S/C10H11N3O3S/c1-7-6-10(12-16-7)13-17(14,15)9-4-2-8(11)3-5-9/h2-6H,11H2,1H3,(H,12,13)	JLKIGFTWXXRPMT-UHFFFAOYSA-N	CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N	C10H11N3O3S	CAS 723-46-6	CHEBI:9332	.	.	.	D0R9OH	.	.	.
DR7504	GW9662	CID: 644213	GW9662; 22978-25-2; 2-Chloro-5-nitro-N-phenylbenzamide; GW 9662; 2-Chloro-5-nitrobenzanilide; GW-9662; benzamide, 2-chloro-5-nitro-N-phenyl-; UNII-UM18UZV2YD; MFCD01215270; UM18UZV2YD; MLS001056751; CHEBI:79993; 2-Chloro-5-nitro-N-phenyl-benzamide; 2-Chloro-5-nitro- N -phenylbenzamide; 2-Chloro-5-nitro-N-4-phenylbenzamide; SMR000326735; (2-chloro-5-nitrophenyl)-N-benzamide; SR-01000075999; Benzamide,2-chloro-5-nitro-N-phenyl-; Tocris-1508; Spectrum5_001989; Lopac-M-6191; DSSTox_CID_20723; DSSTox_RID_79570; DSSTox_GSID_40723; Lopac0_000798; BSPBio_001021; KBioGR_000361; KBioSS_000361; SCHEMBL420231; CHEMBL375270; cid_644213; GTPL3442; DTXSID8040723; BCBcMAP01_000086; BDBM55936; KBio2_000361; KBio2_002929; KBio2_005497; KBio3_000701; KBio3_000702; ZINC39173; EX-A595; Bio2_000341; Bio2_000821; HMS1362C03; HMS1792C03; HMS1990C03; HMS2235C11; HMS3262O18; HMS3267P20; HMS3372P17; HMS3403C03; HMS3412F15; HMS3649C18; HMS3651L10; HMS3676F15; AOB31774; BCP06354; 2-Chloro-5-nitrobenzanilide, 97%; METHYL15-METHYLHEPTADECANOATE; Tox21_301993; Tox21_500798; s2915; SBB006523; STL260137; AKOS000155195; CCG-204882; CS-1102; DB07863; LP00798; MCULE-8174475490; SDCCGSBI-0050775.P002; 2-chloranyl-5-nitro-N-phenyl-benzamide; IDI1_002096; Benzanilide, 2-chloro-5-nitro- (8CI); NCGC00015688-01; NCGC00015688-02; NCGC00015688-03; NCGC00015688-04; NCGC00015688-05; NCGC00015688-06; NCGC00015688-07; NCGC00015688-08; NCGC00015688-09; NCGC00015688-21; NCGC00025193-01; NCGC00025193-02; NCGC00025193-03; NCGC00025193-04; NCGC00025193-05; NCGC00025193-06; NCGC00025193-07; NCGC00255683-01; NCGC00261483-01; AC-31443; AK173264; AS-14069; GW9662, >98% (HPLC); HY-16578; ST055753; SY040458; AB0109180; CAS-22978-25-2; EU-0100798; FT-0664839; SW203813-2; Z6199; EC-000.2405; A11984; Benzamide, 2-chloro-5-nitro-N-phenyl- (9CI); C15627; J90030; M 6191; S-7731; J-014928; SR-01000075999-1; SR-01000075999-3; SR-01000075999-6; SR-01000075999-9; BRD-K93258693-001-02-5; BRD-K93258693-001-05-8; Q27077962; Z27782632	Small molecule	1S/C13H9ClN2O3/c14-12-7-6-10(16(18)19)8-11(12)13(17)15-9-4-2-1-3-5-9/h1-8H,(H,15,17)	DNTSIBUQMRRYIU-UHFFFAOYSA-N	C1=CC=C(C=C1)NC(=O)C2=C(C=CC(=C2)[N+](=O)[O-])Cl	C13H9ClN2O3	CAS 22978-25-2	CHEBI:79993	.	.	.	D00ACX	.	.	.
DR7530	Fluvastatin	CID: 446155	fluvastatin; 93957-54-1; (3R,5S)-fluvastatin; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (+)-(3R,5S)-fluvastatin; (E,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; CHEBI:38565; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,E)-7-(3-(4-Fluorophenyl)-1-isopropyl-1H-indol-2-yl)-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; CHEMBL1078; Fluvastatin & Primycin; (-)-fluvastatin; (E,3R,5S)-7-[3-(4-fluorophenyl)-1-isopropyl-indol-2-yl]-3,5-dihydroxy-hept-6-enoic acid; PubChem10727; DSSTox_CID_636; Prestwick2_000859; SCHEMBL2846; DSSTox_RID_75707; DSSTox_GSID_20636; (3R,5S,6E)-rel-7-[3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid; SCHEMBL556754; GTPL2951; DTXSID2020636; BDBM86704; CHEBI:93160; HMS2089P06; HMS3259J15; Pharmakon1600-01504911; ACT03305; ZINC1886617; Tox21_302765; DL-108; HY-14664B; NSC758896; CCG-213323; NC00659; NSC-758896; NCGC00256490-01; CAS-93957-54-1; CAS_93957-54-1; CS-0019897; EN300-51915; W-5176; 957F541; Q417942; SR-05000001489-1; BRD-K66296774-001-02-0; UNII-4L066368AS component FJLGEFLZQAZZCD-MCBHFWOFSA-N; (E)-(3R,5S)-7-[3-(4-Fluoro-phenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxy-hept-6-enoic acid; 6-Heptenoic acid, 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-, (3R,5S,6E)-; Fluvastatin sodium                                                      L1483	Small molecule	1S/C24H26FNO4/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30)/b12-11+/t18-,19-/m1/s1	FJLGEFLZQAZZCD-MCBHFWOFSA-N	CC(C)N1C2=CC=CC=C2C(=C1C=CC(CC(CC(=O)O)O)O)C3=CC=C(C=C3)F	C24H26FNO4	CAS 93957-54-1	CHEBI:38565	.	.	.	D08GHB	.	.	.
DR7548	Bleomycin	CID: 5360373	bleomycin; Bleocin; Bleomicin; bleomycin a2; Bleomycine [INN-French]; Bleomycinum [INN-Latin]; Bleomicina [INN-Spanish]; Bleomycins; 11056-06-7; Bleomycin sulfate; Bleomicina; Bleomycine; Bleomycinum; Bleomycin [INN]; CCRIS 2754; HSDB 3208; NDC 0015-3010; Bleomycin [INN:BAN]; BLM; NSC 125066; SCHEMBL21090952; LMPK14000006; DB00290	Small molecule	1S/C55H83N17O21S3/c1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-65-26)91-54-43(39(80)37(78)29(15-73)90-54)92-53-40(81)42(93-55(60)88)38(79)30(16-74)89-53)51(87)66-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-67-28(18-94-32)52-68-27(17-95-52)48(84)62-9-7-11-96(5)6/h14,17-19,21-25,29-30,34-43,53-54,64,73-75,77-81H,7-13,15-16,56H2,1-6H3,(H13-,57,58,59,60,61,62,63,65,66,69,70,71,72,76,82,83,84,85,86,87,88)/p+1/t21-,22+,23+,24-,25-,29?,30?,34-,35-,36-,37?,38?,39?,40?,41-,42?,43?,53?,54?/m0/s1	OYVAGSVQBOHSSS-WXFSZRTFSA-O	CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O	C55H84N17O21S3+	CAS 11056-06-7	.	.	.	.	D06UVD	.	.	.
DR7558	ONO-8711	CID: 9824507	6-[(2R,3S)-3-(4-Chloro-2-methylphenylsulfonamidomethyl)bicyclo[2.2.2]oct-2-yl]-5(Z)-hexenoic acid	Small molecule	1S/C22H30ClNO4S/c1-15-13-18(23)11-12-21(15)29(27,28)24-14-20-17-9-7-16(8-10-17)19(20)5-3-2-4-6-22(25)26/h3,5,11-13,16-17,19-20,24H,2,4,6-10,14H2,1H3,(H,25,26)/b5-3-/t16?,17?,19-,20-/m0/s1	VVEXPDRCGCQELD-CFDZEDGGSA-N	CC1=C(C=CC(=C1)Cl)S(=O)(=O)NCC2C3CCC(C2C=CCCCC(=O)O)CC3	C22H30ClNO4S	CAS 216158-34-8	.	.	.	.	D0X2OV	.	.	.
DR7572	PHA665752	CID: 10461815	PHA-665752; 477575-56-7; PHA 665752; TCMDC-125885; UNII-0VXU5T5R3J; (2R)-1-[[5-[(Z)-[5-[[(2,6-DICHLOROPHENYL)METHYL]SULFONYL]-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE]METHYL]-2,4-DIMETHYL-1H-PYRROL-3-YL]CARBONYL]-2-(1-PYRROLIDINYLMETHYL)PYRROLIDINE; 0VXU5T5R3J; CHEMBL450786; CHEBI:90197; (R,Z)-5-(2,6-dichlorobenzylsulfonyl)-3-((3,5-dimethyl-4-(2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl)-1H-pyrrol-2-yl)methylene)indolin-2-one; PHA-665752 hydrate	Small molecule	1S/C32H34Cl2N4O4S/c1-19-29(35-20(2)30(19)32(40)38-14-6-7-21(38)17-37-12-3-4-13-37)16-24-23-15-22(10-11-28(23)36-31(24)39)43(41,42)18-25-26(33)8-5-9-27(25)34/h5,8-11,15-16,21,35H,3-4,6-7,12-14,17-18H2,1-2H3,(H,36,39)/b24-16-/t21-/m1/s1	OYONTEXKYJZFHA-SSHUPFPWSA-N	CC1=C(NC(=C1C(=O)N2CCCC2CN3CCCC3)C)C=C4C5=C(C=CC(=C5)S(=O)(=O)CC6=C(C=CC=C6Cl)Cl)NC4=O	C32H34Cl2N4O4S	CAS 477575-56-7	.	.	.	.	D00TBD	.	.	PHA665752
DR7601	IL-24	.	.	Protein	.	.	.	.	.	.	.	.	.	.	.	.	.
DR7612	Everolimus	CID: 6442177	001, RAD; 40-O-(2-hydroxyethyl)-rapamycin; 40-O-(2-Hydroxyethyl)rapamycin; Afinitor; Certican; Everolimus; RAD; RAD 001; RAD, SDZ; RAD001; SDZ RAD; SDZ-RAD; Zortress; 42-O-(2-Hydroxyethyl)rapamycin; 159351-69-6; Votubia; Afinitor Disperz; CHEBI:68478; RAD-001; UNII-9HW64Q8G6G; 9HW64Q8G6G; NCGC00167512-01; Rapamycin, 42-O-(2-hydroxyethyl)-; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,35R)-1,18-dihydroxy-12-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0(4,9)]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone; everolimusum; NSC733504; Everolimus solution; Everolimus (INN); SDZRAD; XIENCE V; PubChem20048; Everolimus - RAD001; SCHEMBL4378; DSSTox_CID_20599; DSSTox_RID_79508; NVP-RAD001; DSSTox_GSID_40599; Everolimus [USAN:INN:BAN]; NVP-RAD-001; Everolimus, analytical standard; GTPL5889; RAD-001C; CHEMBL1908360; DTXSID0040599; HSDB 8255; RAD 666; RAD-666; Everolimus; RAD001; SDZ-RAD; C53H83NO14; 42-O-(2-Hydroxyethyl)-rapamycin; EX-A2057; Tox21_112510; BDBM50088378; AKOS015850977; ZINC169677008; CS-0064; DB01590; (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone; (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; AS-16971; AT-22180; HY-10218; CAS-159351-69-6; V2036; Everolimus solution, 1.0 mg/ml in acetonitrile; 351E696; Q421052; Q-101413; BRD-K13514097-001-01-2; BRD-K13514097-001-05-3; dihydroxy-[(1R)-2-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxy-cyclohexyl]-1-methyl-ethyl]-dimethoxy-hexamethyl-[?]pentone; Everolimus solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material	Small molecule	1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1	HKVAMNSJSFKALM-GKUWKFKPSA-N	CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC	C53H83NO14	CAS 159351-69-6	CHEBI:68478	.	.	.	D0K3QS	.	.	.
DR7618	Mitotane	CID: 4211	mitotane; 53-19-0; Mitotan; Lysodren; Chloditan; o,p'-DDD; Chlodithane; Khlodithan; Chlodithan; 1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; 2,4'-Ddd; Mitotano; 1-Chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene; NCI-C04933; o,p'-TDE; 2,4'-Dichlorodiphenyldichloroethane; 1-Chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethyl)benzene; o,p'-Dichlorodiphenyldichloroethane; Benzene, 1-chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]-; 2,4'-Dichlorophenyldichlorethane; CB 313; NSC 38721; 1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane; 2-(2-Chlorophenyl)-2-(4-chlorophenyl)-1,1-dichloroethane; 2-(o-Chlorophenyl)-2-(p-chlorophenyl)-1,1-dichloroethane; 1,1-Dichloro-2,2-bis(2,4'-dichlorophenyl)ethane; NSC38721; 1,1-Dichloro-2-(p-chlorophenyl)-2-(o-chlorophenyl)ethane; 2,2-Bis(2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane; CB-313; NSC-38721; 2,4'-DDD;o,p'-DDD; Ethane, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)-; Ethane, 2-(o-chlorophenyl)-2-(p-chlorophenyl)-1,1-dichloro-; Benzene, 1-chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethyl)-; MFCD00000850; Mitotanum [INN-Latin]; o,p-Tde; NCGC00015226-07; 1-chloro-4-[2,2-dichloro-1-(2-chlorophenyl)ethyl]benzene; Mitotanum; DSSTox_CID_372; Mitotano [INN-Spanish]; DSSTox_RID_75548; DSSTox_GSID_20372; 2,4'-(2,2-dichloroethane-1,1-diyl)bis(chlorobenzene); Opeprim; 2,4 -Dichlorodiphenyldichloroethane; Mitotane (Lsodren); CB313; DDD, o,p'-; CAS-53-19-0; Lysodren (TN); SMR000326696; CCRIS 4397; HSDB 3240; SR-01000075751; EINECS 200-166-6; (o,p)-DDD; Mitotane (JAN/USP/INN); BRN 2056007; AI3-07575; Prestwick_75; Ethane,1-dichloro-; Mitotane (Lysodren); Mitotane [USAN:USP:INN:BAN:JAN]; (2,4'-Dichlorodiphenyl)dichloroethane; PubChem14974; Spectrum_001959; DDD-o,p'; (+-)-1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane; Spectrum2_000916; Spectrum3_000869; Spectrum4_000709; Spectrum5_002060; C 3010; (o,p')-DDD; SCHEMBL4040; CHEMBL1670; Lopac0_000251; WLN: GYGYR BG&R DG; BSPBio_002517; KBioGR_001237; KBioSS_002513; SPECTRUM330082; MLS001335899; MLS001335900; MLS002152914; MLS002153233; DivK1c_000703; SPBio_000792; CHEBI:6954; GTPL6957; Mitotane, >=98% (HPLC); DTXSID9020372; 2,4'-DDD, analytical standard; HMS502D05; KBio1_000703; KBio2_002505; KBio2_005073; KBio2_007641; KBio3_002017; NINDS_000703; HMS1923K19; HMS2091E07; HMS2232C16; HMS3260D04; HMS3369H10; HMS3655G06; HMS3715H07; HMS3869F13; Pharmakon1600-00330082; BCP11663; 2,4 inverted exclamation marka-DDD; Tox21_110103; Tox21_302804; Tox21_500251; CCG-40014; NSC755849; s1732; 1,2-bis(2,4'-dichlorophenyl)ethane; AKOS006028802; Benzene, 1-chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethyl)-, (+-)-; Tox21_110103_1; CS-1500; DB00648; LP00251; MCULE-2068358149; NSC-755849; SDCCGSBI-0050239.P006; IDI1_000703; NCGC00015226-02; NCGC00015226-03; NCGC00015226-04; NCGC00015226-05; NCGC00015226-06; NCGC00015226-08; NCGC00015226-09; NCGC00015226-10; NCGC00015226-11; NCGC00015226-12; NCGC00091374-01; NCGC00091374-02; NCGC00091374-03; NCGC00091374-04; NCGC00091374-05; NCGC00091374-06; NCGC00256452-01; NCGC00260936-01; 2,4'-DDD 10 microg/mL in Cyclohexane; AK546750; AS-11690; HY-13690; NCI60_003688; 2,4'-DDD 100 microg/mL in Cyclohexane; SBI-0050239.P004; AB0010565; EU-0100251; FT-0605518; ST51016017; SW199619-3; EN300-37268; 2,4 inverted exclamation marka-DDD;o,p'-DDD; 2,4'-DDD, PESTANAL(R), analytical standard; D00420; W-5031; AB00052337-09; AB00052337_10; 000M850; Q417465; SR-01000075751-1; SR-01000075751-3; SR-01000075751-6; Z425389592; 1-(o-Chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane; 1-[2,2-dichloro-1-(4-chlorophenyl)ethyl]-2-chlorobenzene; Ethane,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)-; 1-Chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene #; Mitotane, United States Pharmacopeia (USP) Reference Standard; Ethane, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)- (8CI); 1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane, analytical standard; o,p'-DDD; ; ; 1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; ; ; Mitotane; 1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane for diagnostic uses (cancer investigation), >=98% (HPLC); 1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane, for diagnostic uses (cancer investigation), >=98% (HPLC)	Small molecule	1S/C14H10Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8,13-14H	JWBOIMRXGHLCPP-UHFFFAOYSA-N	C1=CC=C(C(=C1)C(C2=CC=C(C=C2)Cl)C(Cl)Cl)Cl	C14H10Cl4	CAS 53-19-0	CHEBI:6954	.	.	.	D0Z5OE	.	.	.
DR7626	Docetaxel	CID: 148124	Taxotere; 114977-28-5; Docetaxel anhydrous; Docetaxol; RP-56976; EmDOC; RP 56976; NSC 628503; N-debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol; UNII-699121PHCA; TXL; Taxotere (TN); MFCD00800737; N-debenzoyl-N-Boc-10-deacetyl taxol; Docetaxolum; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol; CHEBI:4672; 699121PHCA; Docetaxel, 98%; NSC628503; NSC-628503; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel; DSSTox_CID_20464; DSSTox_RID_79497; DSSTox_GSID_40464; (2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; Docetaxel, Trihydrate; Taxoel; Taxotere(R); Docetaxel Winthrop; Docetaxel [INN]; (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1,9,12-trihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-acetoxy-9-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxet-12-yl benzoate; CAS-114977-28-5; Docetaxolum [INN-Latin]; Docecad; Docefrez; docetaxel 114977-28-5; HSDB 6965; XRP-6976L; ANX-514; SDP-014; SID 530; Docetaxel (TN); NCGC00181306-01; NCGC00181306-02; 5?,20-Epoxy-1,7?,10?-trihydroxy-9-oxotax-11-ene-2?,4,13?-triyl 4-acetate 2-benzoate 13-[(2R,3S)-3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-3-phenylpropanoate]; Taxotere (Aventis); CID148124; Docetaxel - Taxotere; bind-014; Docetaxel (JAN/INN); CHEMBL92; SCHEMBL4419; docetaxel anhydrous derivatives; GTPL6809; DTXSID0040464; BDBM36351; SYP-0704A; ZDZOTLJHXYCWBA-VCVYQWHSSA-; AMY4356; 114977-28-5, Docetaxel; HMS2089K08; EX-A1206; HY-B0011; Tox21_112781; Tox21_113088; AC-383; CD0182; ZINC85537053; AKOS015960718; AKOS024457953; Tox21_112781_1; CS-1144; DB01248; KS-1452; MCULE-1930158681; ISOCYANATOETHYLMETHACRYLATEPOLYMER; Docetaxel, purum, >=97.0% (HPLC); NCGC00181306-04; NCGC00242509-01; 4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate; Benzenepropanoic acid, beta-(((1,1-dimethylethoxy)carbonyl)amino)-alpha-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester; AB0072965; D4102; C11231; D07866; W-1428; AB01273941-01; AB01273941-02; Q420436; SR-01000003023; W-60384; Q-100074; SR-01000003023-5; BRD-K30577245-001-04-3; BRD-K30577245-341-01-9; Z1551429742; Anhydrous Docetaxel, European Pharmacopoeia (EP) Reference Standard; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate; (2beta,5beta,7alpha,8alpha,10alpha,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1,9,12-trihydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate; [2aR-[2a?,4?,4a?,6?,9?(?R*,?S*),11?,12?,12a?,12b?]]-?-[[(1,1-Dimethylethoxy)carbonyl]amino]-?-hydroxy-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester benzenepropanoic acid; [acetoxy-[(2R,3S)-3-(tert-butoxycarbonylamino)-2-hydroxy-3-phenyl-propanoyl]oxy-trihydroxy-tetramethyl-oxo-[?]yl] benzoate; 114915-20-7; Benzenepropanoic acid, beta-(((1,1-dimethylethoxy)carbonyl)amino)-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (alphaR,betaS)-; Benzenepropanoic acid,1-dimethylethoxy)carbonyl]amino]-.alpha.-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (.alpha.R,.beta.S)	Small molecule	1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1	ZDZOTLJHXYCWBA-VCVYQWHSSA-N	CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O	C43H53NO14	CAS 114977-28-5	.	.	.	.	D0O5WP	.	.	Docetaxel
DR7648	Sodium ferulate	CID: 23669636	Sodium ferulate; 24276-84-4; Sodium ferulic; Sodium 3-(4-hydroxy-3-methoxyphenyl)acrylate; Ferulic acid (sodium); ferulic acid sodium salt; UNII-OIS7F1IRQK; OIS7F1IRQK; Sodium 3-methoxy-4-hydroxycinnamate; Monosodium 4-hydroxy-3-methoxycinnamate; Monosodium 3-(4-hydroxy-3-methoxyphenyl)-2-propenoate; 3-(4-Hydroxy-3-methoxyphenyl)-2-propenoic acid monosodium salt; sodium (E)-3-(4-hydroxy-3-methoxyphenyl)acrylate; sodium;(E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate; ferulic acid sodium; MFCD00075727; Ferulicacidsodiumsalt; C10H9O4.Na; Cinnamic acid, 4-hydroxy-3-methoxy-, monosodium salt; CHEMBL4594451; FEMA NO. 3812; HY-N0060A; DTXSID80894080; CHEBI:114954; BCP05695; s4740; AKOS015890674; AC-7966; ACN-035276; CCG-266691; CS-5275; AS-12205; K-6527; Q3092716; W-200547; sodium (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate; sodium (2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate; 151109-65-8	Small molecule	1S/C10H10O4.Na/c1-14-9-6-7(2-4-8(9)11)3-5-10(12)13;/h2-6,11H,1H3,(H,12,13);/q;+1/p-1/b5-3+;	NCTHNHPAQAVBEB-WGCWOXMQSA-M	COC1=C(C=CC(=C1)C=CC(=O)[O-])O.[Na+]	C10H9NaO4	CAS 24276-84-4	CHEBI:114954	.	.	.	.	.	.	.
DR7688	Erythromycin	CID: 12560	erythromycin; 114-07-8; Erythromycin A; E-Mycin; Erythrocin; Abomacetin; Erythromycinum; Erymax; Emgel; Eritromicina; Erythromycine; Erythro-Statin; Ilotycin; Erythromycin base; E-Glades; Ery-Tab; E-Base; Eryacne; Torlamicina; Erycette; Robimycin; Bristamycin; Erypar; erythro; Erythroguent; Eritrocina; Erythrogran; Stiemycin; Ermycin; Erycen; Erygel; Aknin; ERYC; Pfizer-E; Theramycin Z; Ak-Mycin; Erythromast 36; Erythromycin Lactate; T-Stat; Benzamycin; MFCD00084654; Emycin; Erytab; Inderm; Retcin; UNII-63937KV33D; CHEMBL532; erythromycin-A; Dumotrycin; Mephamycin; CHEBI:42355; Sansac; Wemid; (-)-ERYTHROMYCIN; Eryc Sprinkles; Erythra-Derm; A/T/S; Akne-Mycin; 63937KV33D; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-14-ethyl-7,12,13-trihydroxy-4-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione; R-P Mycin; Endoeritrin; Eritomicina; Erythroderm; Erytrociclin; Paediathrocin; Pharyngocin; Proterytrin; Acneryne; Acnesol; Aknemycin; Derimer; Deripil; Erisone; Eryacnen; Erydermer; Eryhexal; Erysafe; Iloticina; Latotryd; Lederpax; Mercina; Oftamolets; Pantoderm; Pantodrin; Primacine; Romycin; Stiemicyn; Tiloryth; Tiprocin; E-Solve 2; Emuvin; Erecin; Erymed; Erytop; NCI-C55674; AustriaS; Eros; Ery-maxin; Erythro-Teva; Sans-acne; DSSTox_CID_2991; Erimycin-T; Ery-Diolan; Inderm Gel; Del-Mycin; Aknederm Ery Gel; Udima Ery Gel; (-)-Erythromycin, 98%; Eryc 125; UNII-8HPH7ND0LN; DSSTox_RID_76820; DSSTox_GSID_22991; Emu-Ve; 8HPH7ND0LN; Skid Gel E; (3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)-4-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)oxacyclotetradecane-2,10-dione; Akne Cordes Losung; ERY; Ilosone (estolate); Ilotycin T.S.; E-Mycin (base); Ery-Tab (base); (-)-Erythromycin, Eur.Ph.; Emu-V; Ery-B; E-Base (base); ERYC (base); C-Solve-2; N-Methylerythromycin A; PCE Dispertab (base); Eryc-125; Eryc-250; Eritromicina [INN-Spanish]; Erythromycine [INN-French]; Erythromycinum [INN-Latin]; Oftalmolosa Cusi Eritromicina; Staticin (TN); Akne-mycin (TN); Erygel (TN); Eryc (TN); T-stat (TN); Pce (TN); SR-05000001618; Sentry AQ mardel maracyn; 7704-67-8; 9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione; erthromycin; Erythromycines; NSC55929; CCRIS 9078; NSC-55929; HSDB 3074; NCGC00094670-01; Erythromycin [USP:INN:BAN:JAN]; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione; CAS-114-07-8; Prestwick_205; EINECS 204-040-1; Erythromycin C-13; NSC 55929; Spectrum_000115; Spectrum_000659; AI3-50138; EM-A; Prestwick3_000151; Spectrum2_000759; Spectrum2_001263; Spectrum4_000538; Spectrum5_001596; E0751; Erythromycin A, B + C; EC 204-040-1; SCHEMBL2601; BSPBio_000282; BSPBio_002480; Erythromycin standard solution; KBioGR_001175; KBioSS_000555; KBioSS_001139; MLS001066618; BIDD:GT0017; DivK1c_000294; DivK1c_000397; DivK1c_000702; SPECTRUM1500280; SPBio_000778; SPBio_001226; BPBio1_000312; GTPL1456; DTXSID4022991; Erythromycin (JP17/USP/INN); HMS500O16; KBio1_000294; KBio1_000397; KBio1_000702; KBio2_000555; KBio2_001139; KBio2_003123; KBio2_003707; KBio2_005691; KBio2_006275; J01FA01; Erythromycin (mixture of A,B,C); NINDS_000294; NINDS_000397; NINDS_000702; HMS1920M04; HMS2091D05; HMS2095O04; HMS3712O04; Pharmakon1600-01500280; [3R-(3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)]-4-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione; ACT03320; HY-B0220; RKL10096; Tox21_111311; Tox21_111869; Tox21_300515; BDBM50344942; CCG-38992; LMPK04000006; NSC756759; ZINC85534336; Erythromycin, labeled with carbon-13; AKOS015895249; DB00199; MCULE-4566208867; NSC-756759; IDI1_000294; IDI1_000397; IDI1_000702; SMP1_000119; NCGC00179619-01; NCGC00179619-02; NCGC00179619-03; NCGC00254234-01; 82343-12-2; AC-12744; AC-12901; SMR000544946; Erythromycin, potency: >=850 mug per mg; Erythromycin, tested according to Ph.Eur.; SBI-0051368.P003; Erythromycin, N-demethyl-N-(methyl-11C)-; Erythromycin, meets USP testing specifications; C01912; D00140; E-3250; Erythromycin, plant cell culture tested, ~98%; 44496-EP2272846A1; 44496-EP2275422A1; 44496-EP2292608A1; 44496-EP2305644A1; 44496-EP2308866A1; 44496-EP2311814A1; 44496-EP2311828A1; 44496-EP2380568A1; AB00051981_09; AB00051981_10; Erythromycin standard solution, 1 mg/mL in H2O; Erythromycin, Biotechnology Performance Certified; 114E078; Erythromycin estolate impurity, free erythromycin-; Q213511; SR-01000799155; Erythromycin, Antibiotic for Culture Media Use Only; Erythromycin, BioReagent, suitable for cell culture; SR-01000799155-2; SR-05000001618-1; SR-05000001618-2; BRD-K63550407-001-13-5; BRD-K63550407-028-03-9; Erythromycin (mixture of A,B,C) 100 microg/mL in Acetonitrile; Erythromycin A, British Pharmacopoeia (BP) Reference Standard; Erythromycin A, European Pharmacopoeia (EP) Reference Standard; Erythromycin, United States Pharmacopeia (USP) Reference Standard; Erythromycin, for microbiological assay, European Pharmacopoeia (EP) Reference Standard; Erythromycin, Pharmaceutical Secondary Standard; Certified Reference Material; (3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)-4-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-4-(2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyloxy)-14-ethyl-7,12,13-trihydroxy-6-[3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyloxy]-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione (non-preferred name); 215031-94-0	Small molecule	1S/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1	ULGZDMOVFRHVEP-RWJQBGPGSA-N	CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O	C37H67NO13	CAS 114-07-8	CHEBI:42355	.	.	.	D02YIZ	.	.	.
DR7699	Deferoxamine	CID: 2973	deferoxamine; Desferrioxamine B; DESFERRIOXAMINE; 70-51-9; Deferoxamine B; Deferrioxamine B; Deferrioxamine; Deferoxamin; Deferoxaminum; Desferin; DFOM; Desferan; Desferex; Desferral; Desferrin; N-Benzoylferrioxamine B; Desferal; DF B; DFOA; Deferoxamide B; Deferoxamina; NSC-527604; Ferrioxamine B, N-benzoyl-; UNII-J06Y7MXW4D; N1-(5-Aminopentyl)-N1-hydroxy-N4-(5-(N-hydroxy-4-((5-(N-hydroxyacetamido)pentyl)amino)-4-oxobutanamido)pentyl)succinamide; Ba-33112; J06Y7MXW4D; CHEBI:4356; NSC527604; 3,9,14,20,25-Pentaazatriacontane-2,10,13,21,24-pentone, 30-amino-3,14,25-trihydroxy-; 30-Amino-3,14,25-trihydroxy-3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pentaone; Butanediamide, N'-(5-((4-((5-(acetylhydroxyamino)pentyl)amino)-1,4-dioxobutyl)hydroxyamino)pentyl)-N-(5-aminopentyl)-N-hydroxy-; N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentyl]-N'-(5-aminopentyl)-N'-hydroxybutanediamide; Desferal mesylate; Butanediamide, N'-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxy-; N-(5-(3-((5-Aminopentyl)hydroxycarbamoyl)propionamido)pentyl)-3-((5-(N-hydroxyacetamido)pentyl)carbamoyl)propionohydroxamic acid; Propionohydroxamic acid, N-(5-(3-((5-aminopentyl)hydroxycarbamoyl)propionamido)pentyl)-3-((5-(N-hydroxyacetamido)pentyl)carbamoyl)-; Deferoxamine B; Deferriferrioxamine B; Deferrioxamine; Desferriferrioxamin B; MLS002702118; Deferoxamine [USAN:INN]; Deferoxaminum [INN-Latin]; Deferoxamina [INN-Spanish]; N-(5-aminopentyl)-N-hydroxy-N'-[5-(N-hydroxy-3-{[5-(N-hydroxyacetamido)pentyl]carbamoyl}propanamido)pentyl]butanediamide; Ba 29837; NSC268993; NSC644468; HSDB 3311; SMR000058548; EINECS 200-738-5; Ba 33112; BRN 2514118; Cordaneurin; Desferrioxamin; Perineurin; Desferioxamine B; desferrioxamine-B; C25H48N6O8; N'-{5-[acetyl(hydroxy)amino]pentyl}-N-[5-({4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N-hydroxybutanediamide; N-[5-(3-[(5-Aminopentyl)hydroxycarbamoyl]propionamido)pentyl]-3-([5-(N-hydroxyacetamido)pentyl]carbamoyl)propionohydroxamic acid; Propionohydroxamic acid, N-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(N-hydroxyacetamido)pentyl]carbamoyl]-; deferoxamine-mesylate; Deferoxamine (USAN); Desferal (Salt/Mix); Spectrum_000892; N-benzoyl-Ferrioxamine B; Prestwick0_000725; Prestwick1_000725; Prestwick2_000725; Prestwick3_000725; Spectrum2_001155; Spectrum3_000376; Spectrum4_000311; Spectrum5_000827; CHEMBL556; EC 200-738-5; SCHEMBL34571; BSPBio_000650; BSPBio_002131; KBioGR_000922; KBioGR_002429; KBioSS_001372; KBioSS_002435; 1-Amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetyl hydroxylamino)-6,11,17,22-tetraazaheptaeicosane; cid_62881; N'-(5-((4-((5-(Acetylhydroxamino)pentyl)amino)-1,4-dioxobutyl) hydroxyamino)pentyl)-N-(5-aminopentyl)-N-hydroxybutanediamide; DivK1c_000082; Ba 29837 (Salt/Mix); SPBio_001109; SPBio_002589; BPBio1_000716; CGH-749B; ICL-749B; DTXSID7022887; BDBM47715; KBio1_000082; KBio2_001372; KBio2_002429; KBio2_003940; KBio2_004997; KBio2_006508; KBio2_007565; KBio3_001351; KBio3_002908; cMAP_000047; NINDS_000082; HMS3604E17; BCP16524; ZINC3830635; 0917AC; ANW-62156; LMFA08020169; WLN: Z5NQV/2VM5NQV/ 21; DEFEROXAMINE, Deferoxamine Mesylate; AKOS016004824; DB00746; MCULE-3095507442; IDI1_000082; SMP2_000121; NCGC00178802-01; NCGC00178802-02; NCGC00178802-03; NCI60_002181; SMR001550278; SBI-0051332.P003; AB00053447; C06940; D03670; 15182-EP2316832A1; 15182-EP2316833A1; AB00053447_14; 070D519; Q419618; Q-200933; BRD-K09821361-066-05-0; BRD-K09821361-066-06-8; BRD-K09821361-066-08-4; BRD-K09821361-066-13-4; BRD-K09821361-066-15-9; BRD-K09821361-066-16-7; 3,14,20,25-Pentaazatriacontane-2,10,13,21,24-pentone, 30-amino-3,14,25-trihydroxy-; 30-Amino-3,25-trihydroxy-3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pentaone; Butanediamide,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxy-; N''''-(5-azanylpentyl)-N-[5-[[4-[5-[ethanoyl(oxidanyl)amino]pentylamino]-4-oxidanylidene-butanoyl]-oxidanyl-amino]pentyl]-N''''-oxidanyl-butanediamide;methanesulfonic acid; N'-[5-(acetyl-hydroxy-amino)pentyl]-N-[5-[3-(5-aminopentyl-hydroxy-carbamoyl)propanoylamino]pentyl]-N-hydroxy-butane diamide; N'-{5-[acetyl(hydroxy)amino]pentyl}-N-(5-{4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanamido}pentyl)-N-hydroxybutanediamide; N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-1,4-dioxobutyl]-hydroxyamino]pentyl]-N''''-(5-aminopentyl)-N''''-hydroxybutanediamide;methanesulfonic acid; N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-keto-butanoyl]-hydroxy-amino]pentyl]-N''-(5-aminopentyl)-N''-hydroxy-succinamide;mesylic acid; N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentyl]-N''''-(5-aminopentyl)-N''''-hydroxybutanediamide;methanesulfonic acid; N~1~-(5-(Acetyl(hydroxy)amino)pentyl)-N~4~-(5-((4-((5-aminopentyl)(hydroxy)amino)-4-oxobutanoyl)amino)pentyl)-N~4~-hydroxysuccinamide; Propionohydroxamic acid, N-[5-(3-[(5-aminopentyl)hydroxycarbamoyl]propionamido)phentyl]-3-([5-(N-hydroxyacetamido)pentyl]carbamoyl)-; Propionohydroxamic acid, N-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[(5-N-hydroxyacetamido)pentyl]carbamoyl]-	Small molecule	1S/C25H48N6O8/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34)	UBQYURCVBFRUQT-UHFFFAOYSA-N	CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O	C25H48N6O8	CAS 70-51-9	CHEBI:4356	.	.	.	D06GKR	.	.	.
DR7720	HLM006474	CID: 2895500	HLM006474; 353519-63-8; 7-[(4-ethoxy-3-methylphenyl)(2-pyridinylamino)methyl]-2-methyl-8-quinolinol; 7-[(4-ethoxy-3-methylphenyl)-(pyridin-2-ylamino)methyl]-2-methylquinolin-8-ol; 7-[(4-ethoxy-3-methylphenyl)(pyridin-2-ylamino)methyl]-2-methylquinolin-8-ol; Oprea1_498948; SCHEMBL9963974; CHEMBL4571419; BCP34559; EX-A3531; 3384AH; CCG-21518; s8963; STK509159; AKOS000357958; AKOS022004575; CS-3180; HLM 006474; MCULE-1162226397; NCGC00387261-01; HY-16667; EU-0079871; HLM006474, >=98% (HPLC); HLM-006474; HLM 006474; SR-01000502837; SR-01000502837-1	Small molecule	1S/C25H25N3O2/c1-4-30-21-13-11-19(15-16(21)2)23(28-22-7-5-6-14-26-22)20-12-10-18-9-8-17(3)27-24(18)25(20)29/h5-15,23,29H,4H2,1-3H3,(H,26,28)	CYNZBLNMIJNBSF-UHFFFAOYSA-N	CCOC1=C(C=C(C=C1)C(C2=C(C3=C(C=CC(=N3)C)C=C2)O)NC4=CC=CC=N4)C	C25H25N3O2	.	.	.	.	.	.	.	.	.
DR7727	Ertapenem	CID: 150610	Ertapenem; 153832-46-3; Invanz; UNII-G32F6EID2H; (4R,5S,6S)-3-[(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; Invanz (TN); G32F6EID2H; C22H25N3O7S; CHEBI:404903; (1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid; (4R,5S,6S)-3-((3S,5S)-5-((3-carboxyphenyl)carbamoyl)pyrrolidin-3-ylthio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (4R,5S,6S)-3-({(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl}sulfanyl)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; Ertapenem (INN); Ertapenem [INN:BAN]; HSDB 8020; (4R,5S,6S)-3-{[(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; CHEMBL1359; SCHEMBL34454; GTPL10906; AOB6700; DTXSID50165456; ZINC3918453; AKOS015895077; AC-6814; DB00303; NCGC00387409-02; 1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-(((3S,5S)-5-(((3-carboxyphenyl)amino)carbonyl)-3-pyrrolidinyl)thio)-6-((1R)-1-hydroxyethyl-4-methyl-7-oxo-, (4R,5S,6S)-; 1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-(((3-carboxyphenyl)amino)carbonyl)-3-pyrrolidinyl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4R-(3(3S*,5S*),4alpha,5beta,6beta(R*)))-; D07908; 832E463; Q553220	Small molecule	1S/C22H25N3O7S/c1-9-16-15(10(2)26)20(28)25(16)17(22(31)32)18(9)33-13-7-14(23-8-13)19(27)24-12-5-3-4-11(6-12)21(29)30/h3-6,9-10,13-16,23,26H,7-8H2,1-2H3,(H,24,27)(H,29,30)(H,31,32)/t9-,10-,13+,14+,15-,16-/m1/s1	JUZNIMUFDBIJCM-ANEDZVCMSA-N	CC1C2C(C(=O)N2C(=C1SC3CC(NC3)C(=O)NC4=CC=CC(=C4)C(=O)O)C(=O)O)C(C)O	C22H25N3O7S	CAS 153832-46-3	CHEBI:404903	.	.	.	D0Q1MS	.	.	.
DR7735	Insulin	CID: 16131098	12584-58-6; DTXSID60154957; 8A-L-threonine-10A-L-isoleucine-Insulin	Small molecule	1S/C256H381N65O76S6/c1-29-131(23)205(313-193(337)104-258)251(391)317-204(130(21)22)247(387)288-159(75-82-200(347)348)217(357)282-156(71-78-189(262)333)221(361)308-183-116-401-402-117-184-242(382)305-178(111-323)239(379)294-162(88-123(7)8)224(364)295-168(95-140-53-61-146(327)62-54-140)227(367)283-154(69-76-187(260)331)218(358)290-161(87-122(5)6)222(362)285-158(74-81-199(345)346)220(360)302-174(101-190(263)334)234(374)298-170(97-142-57-65-148(329)66-58-142)230(370)309-182(241(381)304-176(255(396)397)103-192(265)336)115-400-399-114-181(213(353)272-107-194(338)278-153(72-79-197(341)342)216(356)281-151(51-42-84-270-256(266)267)211(351)271-108-195(339)279-166(93-138-46-36-32-37-47-138)226(366)297-167(94-139-48-38-33-39-49-139)229(369)299-171(98-143-59-67-149(330)68-60-143)237(377)320-208(136(28)326)253(393)321-85-43-52-186(321)245(385)286-152(50-40-41-83-257)214(354)277-134(26)254(394)395)311-249(389)203(129(19)20)316-235(375)164(90-125(11)12)292-228(368)169(96-141-55-63-147(328)64-56-141)296-223(363)160(86-121(3)4)289-209(349)133(25)276-215(355)157(73-80-198(343)344)287-246(386)202(128(17)18)315-236(376)165(91-126(13)14)293-232(372)173(100-145-106-269-120-275-145)301-238(378)177(110-322)280-196(340)109-273-212(352)180(113-398-403-118-185(310-243(183)383)244(384)319-207(135(27)325)252(392)306-179(112-324)240(380)318-206(132(24)30-2)250(390)312-184)307-225(365)163(89-124(9)10)291-231(371)172(99-144-105-268-119-274-144)300-219(359)155(70-77-188(261)332)284-233(373)175(102-191(264)335)303-248(388)201(127(15)16)314-210(350)150(259)92-137-44-34-31-35-45-137/h31-39,44-49,53-68,105-106,119-136,150-186,201-208,322-330H,29-30,40-43,50-52,69-104,107-118,257-259H2,1-28H3,(H2,260,331)(H2,261,332)(H2,262,333)(H2,263,334)(H2,264,335)(H2,265,336)(H,268,274)(H,269,275)(H,271,351)(H,272,353)(H,273,352)(H,276,355)(H,277,354)(H,278,338)(H,279,339)(H,280,340)(H,281,356)(H,282,357)(H,283,367)(H,284,373)(H,285,362)(H,286,385)(H,287,386)(H,288,387)(H,289,349)(H,290,358)(H,291,371)(H,292,368)(H,293,372)(H,294,379)(H,295,364)(H,296,363)(H,297,366)(H,298,374)(H,299,369)(H,300,359)(H,301,378)(H,302,360)(H,303,388)(H,304,381)(H,305,382)(H,306,392)(H,307,365)(H,308,361)(H,309,370)(H,310,383)(H,311,389)(H,312,390)(H,313,337)(H,314,350)(H,315,376)(H,316,375)(H,317,391)(H,318,380)(H,319,384)(H,320,377)(H,341,342)(H,343,344)(H,345,346)(H,347,348)(H,394,395)(H,396,397)(H4,266,267,270)/t131-,132-,133-,134-,135+,136+,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,201-,202-,203-,204-,205-,206-,207-,208-/m0/s1	NOESYZHRGYRDHS-ZYCCASTOSA-N	CCC(C)C1C(=O)NC2CSSCC(C(=O)NC(CSSCC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)NC(CC(=O)N)C(=O)O)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CC5=CC=CC=C5)C(=O)NC(CC6=CC=CC=C6)C(=O)NC(CC7=CC=C(C=C7)O)C(=O)NC(C(C)O)C(=O)N8CCCC8C(=O)NC(CCCCN)C(=O)NC(C)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CN=CN2)CO)NC(=O)C(CC(C)C)NC(=O)C(CC2=CN=CN2)NC(=O)C(CCC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC2=CC=CC=C2)N)C(=O)NC(C(=O)NC(C(=O)N1)CO)C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)C)NC(=O)C(C(C)CC)NC(=O)CN	C256H381N65O76S6	CAS 12584-58-6	.	.	.	.	D05ELO	.	.	.
DR7740	BIBR1532	CID: 9927531	BIBR 1532; 321674-73-1; BIBR1532; (E)-2-(3-(naphthalen-2-yl)but-2-enamido)benzoic acid; BIBR-1532; CHEMBL27323; 2-{[(2e)-3-(Naphthalen-2-Yl)but-2-Enoyl]amino}benzoic Acid; 2-[[(E)-3-naphthalen-2-ylbut-2-enoyl]amino]benzoic Acid; 2-(3-Naphthalen-2-yl-but-2-enoylamino)-benzoic acid; MLS006011127; SCHEMBL16964998; CHEBI:94985; DTXSID70432975; EX-A381; BIBR-1532/BIBR1532; IBR 1532; ABP000274; BDBM50126186; MFCD11112195; s1186; ZINC13488964; AKOS024457366; CCG-264852; CS-0902; SB19493; NCGC00242492-01; NCGC00242492-09; AC-26865; AS-56088; HY-17353; SMR004702907; SW219803-1; X7524; EC-000.2388; W-5477; 2-(3-(Naphthalen-2-yl)but-2-enamido)benzoic acid; BRD-K04623885-001-01-8; Q27455481; 2-[(e)-3-naphthalen-2-yl-but-2-enoylamino]-benzoic acid; 2-[[(2E)-3-(2-Naphthalenyl)-1-oxo-2-butenyl]amino]benzoic acid; 2-[[(2E)-3-(2-Naphthalenyl)-1-oxo-2-butenyl1-yl]amino]benzoic acid; 2-[[(2E)-3-(2-Naphthalenyl)-1-oxo-2-butenyl1-yl]amino]benzoicacid; 2197129-84-1; 55C	Small molecule	1S/C21H17NO3/c1-14(16-11-10-15-6-2-3-7-17(15)13-16)12-20(23)22-19-9-5-4-8-18(19)21(24)25/h2-13H,1H3,(H,22,23)(H,24,25)/b14-12+	PGFQXGLPJUCTOI-WYMLVPIESA-N	CC(=CC(=O)NC1=CC=CC=C1C(=O)O)C2=CC3=CC=CC=C3C=C2	C21H17NO3	CAS 321674-73-1	CHEBI:94985	.	.	.	.	.	.	.
DR7799	Sulfinosine	CID: 130209	2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purine-6-sulfinamide; 2-Amino-9-beta-ribofuranosylpurine-6-sulfinamide; SCHEMBL6907463; 9H-Purine-6-sulfinamide, 2-amino-9-beta-D-ribofuranosyl-; DTXSID70924860; 2-amino-9-beta-d-ribofuranosylpurine-6-sulfinamide; 2-Amino-9-beta-D-ribofuranosyl-9H-purine-6-sulfinamide; 2-Imino-9-pentofuranosyl-3,9-dihydro-2H-purine-6-sulfinamide	Small molecule	1S/C10H14N6O5S/c11-10-14-7-4(8(15-10)22(12)20)13-2-16(7)9-6(19)5(18)3(1-17)21-9/h2-3,5-6,9,17-19H,1,12H2,(H2,11,14,15)/t3-,5-,6-,9-,22?/m1/s1	NIXVOFULDIFBLB-QVRNUERCSA-N	C1=NC2=C(N1C3C(C(C(O3)CO)O)O)N=C(N=C2S(=O)N)N	C10H14N6O5S	CAS 124508-99-2	.	.	.	.	.	.	.	.
DR7812	Dactolisib	CID: 11977753	BEZ-235; S14-0511; NVP-BEZ-235; NVP-BEZ235, BEZ235; 2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile	Small molecule	1S/C30H23N5O/c1-30(2,18-31)22-9-11-23(12-10-22)35-28-24-15-19(21-14-20-6-4-5-7-25(20)32-16-21)8-13-26(24)33-17-27(28)34(3)29(35)36/h4-17H,1-3H3	JOGKUKXHTYWRGZ-UHFFFAOYSA-N	CC(C)(C#N)C1=CC=C(C=C1)N2C3=C4C=C(C=CC4=NC=C3N(C2=O)C)C5=CC6=CC=CC=C6N=C5	C30H23N5O	CAS 915019-65-7	.	.	.	.	D0VG0D	.	.	Dactolisib
DR7850	Piperacillin	CID: 43672	piperacillin; 61477-96-1; Pipracil; Piperacillin anhydrous; Piperacilline; PIPC; Piperacillina; PIPERACILLIN SODIUM; Piperacillin hydrate; Piperacillin (INN); Piperacillin [INN]; CHEBI:8232; (2S,5R,6R)-6-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; UNII-9I628532GX; CHEMBL702; (2S,5R,6R)-6-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 66258-76-2; Cl-227193; 9I628532GX; C23H27N5O7S; (2S,5R,6R)-6-((R)-2-(4-ethyl-2,3-dioxopiperazine-1-carboxamido)-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6beta-{(2R)-2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido}-2,2-dimethylpenam-3alpha-carboxylic acid; Peperacillin; Piperacilina; Piperacillinum; Pipracil, Piper; Peracin (TN); CCRIS 7362; EINECS 262-811-8; Piperacilina [INN-Spanish]; Piperacilline [INN-French]; Piperacillinum [INN-Latin]; 1-carboxamido)-2-phenylacetamido)-3,3-dimethyl-; Pipracil,(S); PIPERACILLIN NA; Prestwick0_000755; Prestwick1_000755; Prestwick2_000755; Prestwick3_000755; Epitope ID:116652; 6-(D-(-)-alpha-(4-Ethyl-2,3-dioxo-1-piperazinecarboxamido)phenylacetamido)penicillanic acid; SCHEMBL33894; BSPBio_000770; (2S-(2alpha,5alpha,6beta(S*)))-6-(((((4-Ethyl-2,3-dioxopiperazin-1-yl)carbonyl)amino)phenylacetyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; BIDD:GT0167; SPBio_002709; BPBio1_000848; DTXSID2023482; GTPL10921; HMS2090H19; ZINC3913937; Tazocin (piperacillin + tazobactam); BDBM50240426; KM0517; MFCD00865043; AKOS016007827; DB00319; (2S,5R,6R)-6-[[(2R)-2-[(4-ethyl-2,3-dioxo-piperazine-1-carbonyl)amino]-2-phenyl-acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-6-(((((4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl)amino)phenylacetyl)amino)-7-oxo-, (2S-(2-alpha,5-alpha,6-beta(S*)))-; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((((4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl)amino)phenylacetyl)amino)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta(S*)))-; AS-13671; C14034; D08380; J10085; AB01275515-01; 127490-EP2272832A1; 127490-EP2292612A2; 127490-EP2295402A2; 477P961; Q423787; Piperacillin, Antibiotic for Culture Media Use Only; W-105153; BRD-K86873305-236-03-0; (2S,5R,6R)-6-((R)-2-(4-ethyl-2,3-dioxopiperazine-; (2S,5R,6R)-6-[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(2R)-[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, (2S,5R,6R)-; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(2R)-2-[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-, (2S,5R,6R)-; WPP	Small molecule	1S/C23H27N5O7S/c1-4-26-10-11-27(19(32)18(26)31)22(35)25-13(12-8-6-5-7-9-12)16(29)24-14-17(30)28-15(21(33)34)23(2,3)36-20(14)28/h5-9,13-15,20H,4,10-11H2,1-3H3,(H,24,29)(H,25,35)(H,33,34)/t13-,14-,15+,20-/m1/s1	IVBHGBMCVLDMKU-GXNBUGAJSA-N	CCN1CCN(C(=O)C1=O)C(=O)NC(C2=CC=CC=C2)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)O	C23H27N5O7S	CAS 61477-96-1	CHEBI:8232	.	.	.	D04ZAH	.	.	.
DR7865	Birinapant	CID: 49836020	Birinapant; 1260251-31-7; Birinapant (TL32711); TL32711; TL-32711; UNII-6O4Z07B57R; TL 32711; 6O4Z07B57R; (2S)-N-[(2S)-1-[(2R,4S)-2-[[6-fluoro-2-[6-fluoro-3-[[(2R,4S)-4-hydroxy-1-[(2S)-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]pyrrolidin-2-yl]methyl]-1H-indol-2-yl]-1H-indol-3-yl]methyl]-4-hydroxypyrrolidin-1-yl]-1-oxobutan-2-yl]-2-(methylamino)propanamide; (2s,2's)-N,N'-[(6,6'-Difluoro-1h,1'h-2,2'-Biindole-3,3'-Diyl)bis{methanediyl[(2r,4s)-4-Hydroxypyrrolidine-2,1-Diyl][(2s)-1-Oxobutane-1,2-Diyl]}]bis[2-(Methylamino)propanamide]; Propanamide, N,N'-[(6,6'-difluoro[2,2'-bi-1H-indole]-3,3'-diyl)bis[methylene[(2R,4S)-4-hydroxy-2,1-pyrrolidinediyl][(1S)-1-ethyl-2-oxo-2,1-ethanediyl]]]bis[2-(methylamino)-, (2S,2'S)-; Birinapant [USAN:INN]; Birinapant di-HCl; Birinapant (USAN/INN); MLS006011237; GTPL7432; TL32711 2HCl; CHEMBL3039522; SCHEMBL10049847; DTXSID30155057; EX-A258; TL-32711 2HCl; C42H56F2N8O6; AOB87396; 2269AH; ABP001107; BDBM50071920; MFCD25976869; NSC767128; NSC816007; s7015; ZINC96941868; AKOS030526366; CCG-270498; CS-1719; DB11782; NSC-767128; NSC-816007; SB16522; AC-32868; AS-17035; HY-16591; SMR004702997; SW220103-1; A12738; D10417; Z-3165; Q27075298; (2S)-N-[(2S)-1-[(2R,4S)-2-[[6-fluoro-2-[6-fluoro-3-[[(2R,4S)-4-hydroxy-1-[(2S)-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]pyrrolidin-2-yl]methyl]-1H-indol-2-yl]-1H-indol-3-yl]methyl]-4-hydroxypyrrolidin-1-yl]-1-oxobutan-2-yl]-2-(methylamino)propanam; (2S,2'S)-N,N'-((2S,2'S)-((3S,3'S,5R,5'R)-5,5'-((6,6'-difluoro-1H,1'H-[2,2'-biindole]-3,3'-diyl)bis(methylene))bis(3-hydroxypyrrolidine-5,1-diyl))bis(1-oxobutane-2,1-diyl))bis(2-(methylamino)propanamide); (2S,2'S)-N,N'-((2S,2'S)-1,1'-((3S,3'S,5R,5'R)-5,5'-(6,6'-difluoro-1H,1'H-2,2'-biindole-3,3'-diyl)bis(methylene)bis(3-hydroxypyrrolidine-5,1-diyl))bis(1-oxobutane-2,1-diyl))bis(2-(methylamino)propanamide); (2S,2'S)-N,N'-[(6,6'-difluoro-1H,1'H-2,2'-biindole-3,3'-diyl)bis{methanediyl[(2R,4S)-4-hydroxypyrrolidine-2,1-diyl][(2S)-1-oxobutane-1,2-diyl]}]bis[2-(methylamino)propanamide] (non-preferred name); GT6	Small molecule	1S/C42H56F2N8O6/c1-7-33(49-39(55)21(3)45-5)41(57)51-19-27(53)15-25(51)17-31-29-11-9-23(43)13-35(29)47-37(31)38-32(30-12-10-24(44)14-36(30)48-38)18-26-16-28(54)20-52(26)42(58)34(8-2)50-40(56)22(4)46-6/h9-14,21-22,25-28,33-34,45-48,53-54H,7-8,15-20H2,1-6H3,(H,49,55)(H,50,56)/t21-,22-,25-,26-,27-,28-,33-,34-/m0/s1	PKWRMUKBEYJEIX-DXXQBUJASA-N	CCC(C(=O)N1CC(CC1CC2=C(NC3=C2C=CC(=C3)F)C4=C(C5=C(N4)C=C(C=C5)F)CC6CC(CN6C(=O)C(CC)NC(=O)C(C)NC)O)O)NC(=O)C(C)NC	C42H56F2N8O6	CAS 1260251-31-7	.	.	.	.	D0E8NP	.	.	.
DR7874	Diosgenin	CID: 99474	DIOSGENIN; 512-04-9; Nitogenin; UNII-K49P2K8WLX; Spirost-5-en-3-ol, (3b,25R)-; (20R,25R)-Spirost-5-en-3beta-ol; K49P2K8WLX; CHEBI:4629; (25R)-spirost-5-en-3beta-diol; MFCD00016887; NSC 33396; Spirost-5-en-3-beta-ol, (25R)-; (3beta,25R)-spirost-5-en-3-ol; (25R)-Spirost-5-en-3beta-ol; SP 37; C27H42O3; (2'R,4S,5'R,6aR,6bS,8aS,8bR,9S,11aS,12aS,12bS)-5',6a,8a,9-Tetramethyl-1,3,3',4,4',5,5',6,6a,6b,6',7,8,8a,8b,9,11a,12,12a,12b-icosahydrospiro[naphtho[2',1':4,5]indeno[2,1-b]furan-10,2'-pyran]-4-ol; (25R)-14beta,17beta-spirost-5-en-3beta-ol; 3beta-Hydroxy-5-spirostene; nitrogen in; CCRIS 6803; 22alpha-Spirost-5-en-3beta-ol; Dioscorea sapogenin; Diosgenin,(S); (7S,8S,10S,13S,15S,18S,22S,3R,12R,14R,19R)-3,13,15,19-tetramethyl-11-oxaspiro[ 2H-3,4,5,6-tetrahydropyran-6,6'-pentacyclo[10.8.0.0<2,9>.0<4,8>.0<13,18>]icosa ne]-24-en-22-ol; YUV; EINECS 208-134-3; DISOGENIN; BRN 0094582; Diosgenin, >=93%; 3A-Hydroxy-5-spirostene; SCHEMBL83359; 5-19-03-00030 (Beilstein Handbook Reference); (25R)-5-Spirosten-3A-ol; CHEMBL412437; (25R)-5-Spirosten-3beta-ol; DTXSID00895074; (25R)-Spirost-5-en-3.beta-ol; HY-N0177; ZINC6857614; LMST01080037; SBB058140; AKOS015961083; ACN-034765; CS-5303; MCULE-6739922044; NCGC00386027-01; Spirost-5-en-3-ol, (3-beta,25R)-; AS-13640; ST097775; AB0090307; N1715; S2291; Spirost-5-en-3beta-ol, (25R)- (8CI); C08898; J10028; M03858; Spirost-5-en-3-ol, (3beta,25R)- (9CI); 512D049; Q-100574; Q1107734; BRD-K28690501-001-02-1; Diosgenin, European Pharmacopoeia (EP) Reference Standard; UNII-5E5W122QCR component WQLVFSAGQJTQCK-VKROHFNGSA-N; (2R,5'R)-5'-tetramethylspiro[[?]-2,2'-tetrahydropyran]ol; NCGC00386027-01_C27H42O3_Spirost-5-en-3-ol, (3beta,25R)-; (1S,2S,4S,5'R,6R,7S,8R,9S,12S,13R,16S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-16-ol	Small molecule	1S/C27H42O3/c1-16-7-12-27(29-15-16)17(2)24-23(30-27)14-22-20-6-5-18-13-19(28)8-10-25(18,3)21(20)9-11-26(22,24)4/h5,16-17,19-24,28H,6-15H2,1-4H3/t16-,17+,19+,20-,21+,22+,23+,24+,25+,26+,27-/m1/s1	WQLVFSAGQJTQCK-VKROHFNGSA-N	CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CC=C6C5(CCC(C6)O)C)C)C)OC1	C27H42O3	CAS 512-04-9	CHEBI:4629	.	.	.	.	.	.	.
DR7876	Cytarabine	CID: 6253	Alexan; AraC; Arabinocytidine; Arabinofuranosylcytosine; Arabinosylcytosine; Arabitin; Aracytidine; Aracytin; Aracytine; Arafcyt; Citarabina; Cytarabin; Cytarabina; Cytarabinoside; Cytarabinum; Cytarbel; Cytonal; Cytosar; Cytosinearabinoside; DepoCyte; Depocyt; Erpalfa; Iretin; Spongocytidine; Tarabine; Udicil; Arabinosyl Cytosine; Cytarabine liposome injection; Cytosine arabinofuranoside; Cytosine arabinose; Cytosine arabinoside; AR3; BTB15125; CHX 3311; U 19920A; Ara-C; Ara-Cytidine; Beta-Ara C; Beta-Arabinosylcytosine; Beta-cytosine arabinoside; Citarabina [INN-Spanish]; Cytarabinum [INN-Latin]; Cytosar-U; Cytosine arabinoside (VAN); Depocyt (TN); Depocyt (liposomal); Intrathecal (injected into the spinal fluid) DepoCyt; U-19920; Beta-D-Arabinosylcytosine; Cytosar-U (TN); Cytosine beta-D-arabinofuranoside; Cytosine beta-D-arabinofuranoside hydrochloride; Cytosine beta-D-arabinoside; Cytosine-beta-arabinoside; Intrathecal cytarabine (also known as ara-C); U-19,920; CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9); Cytarabine (JP15/USP/INN); Cytarabine [USAN:INN:BAN:JAN]; Cytosine 1-beta-D-arabinofuranoside; Cytosine, beta-D-arabinoside; Cytosine-beta-D-arabinofuranoside; Cytosine-1-beta-D-arabinofuranoside; Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine; (beta-D-Arabinofuranosyl)cytosine; 1-.beta.-D-arabinofuranosyl-cytosine; 1-Arabinofuranosylcytosine; 1-beta-D-Arabinofaranosylcytosine; 1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone; 1-beta-D-Arabinofuranosylcytosine; 1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside; 1-beta-D-Arabinosylcytosine; 1beta-Arabinofuranasylcytosine; 1beta-D-Arabinofuranosylcytosine; 1beta-D-Arabinosylcytosine; 2(1H)-Pyrimidinone, 4-amino-1-D-arabinofuranosyl-[CAS]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine; 4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone; 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; 4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one	Small molecule	1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1	UHDGCWIWMRVCDJ-CCXZUQQUSA-N	C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O	C9H13N3O5	CAS 147-94-4	CHEBI:28680	.	.	.	D07XSN	.	.	Cytarabine
DR7903	SLC-0111	CID: 310360	178606-66-1; U-104; 4-(3-(4-fluorophenyl)ureido)benzenesulfonamide; 1-(4-fluorophenyl)-3-(4-sulfamoylphenyl)urea; SLC-0111; mst-104; 4-{[(4-Fluorophenyl)carbamoyl]amino}benzenesulfonamide; NSC213841; CHEMBL1615281; Carbonic Anhydrase IX/XII Inhibitor II(U-104); 4-{[(4'-Fluorophenyl)Carbamoyl]Amino}Benzenesulfonamide; 4-[[[(4-Fluorophenyl)amino]carbonyl]amino]-benzenesulfonamide; 4-[3-(4-Fluorophenyl)ureido]benzenesulfonamide; WWZ; NSC 213841; 3n4b; SCHEMBL672955; GTPL10149; AOB5732; EX-A904; SLC0111; HMS3651H21; HMS3872E13; BCP14895; ZINC1752601; BDBM50334354; MFCD00159265; s2866; 4-fluorophenylureido-benzenesulfonamide; AKOS001123930; CCG-267573; compound 7 [PMID: 21361354]; CS-4495; MCULE-4710078413; NSC-213841; SB19580; NCGC00379154-03; AC-32932; AK341046; AS-66547; HY-13513; FT-0699833; SW220124-1; U 104; U-104, >=98% (HPLC); U-104;NSC213841;MST104; X5935; A14959; J-690246; (3?,5?)-3,14,17-Trihydroxycard-20(22)-enolide; 3-(4-FLUOROPHENYL)-1-(4-SULFAMOYLPHENYL)UREA; Q27467365; 4-(((4-Fluoroanilino)carbonyl)amino)benzenesulfonamide; 4-{[(4''-Fluorophenyl)carbamoyl]amino}benzenesulfonamide; 4-[[[(4-Fluorophenyl)amino]carbonyl]amino]-benzesulfonamide	Small molecule	1S/C13H12FN3O3S/c14-9-1-3-10(4-2-9)16-13(18)17-11-5-7-12(8-6-11)21(15,19)20/h1-8H,(H2,15,19,20)(H2,16,17,18)	YJQZNWPYLCNRLP-UHFFFAOYSA-N	C1=CC(=CC=C1NC(=O)NC2=CC=C(C=C2)S(=O)(=O)N)F	C13H12FN3O3S	.	.	.	.	.	.	.	.	.
DR7956	Oseltamivir	CID: 65028	oseltamivir; 196618-13-0; Tamvir; Tamiflu-Free; GS-4104; (-)-oseltamivir; GS 4104; GS4104; HSDB 7433; UNII-20O93L6F9H; Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate; GOP-A-Flu; ethyl (3R,4R,5S)-4-acetamido-5-amino-3-pentan-3-yloxycyclohexene-1-carboxylate; Ro-640796; Ro-64-0796; CHEBI:7798; 1-Cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3R-(3alpha,4beta,5alpha))-; 20O93L6F9H; (3R,4R,5S)-Ethyl 4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-enecarboxylate; Ro 640796; ebilfumin; Oseltamivir [INN:BAN]; oseltamivirum; Agucort; ethyl (3R,4R,5S)-5-amino-4-acetamido-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate; Agucort (TN); Oseltamivir (INN); Tamiflu (*Phosphate salt 1:1*); SR-05000001499; oseltamivir-phosphate; CHEMBL1229; SCHEMBL32035; BIDD:GT0426; BDBM5025; GS-4071 ETHYL ESTER; DTXSID9044291; GTPL11427; HMS2090C11; EX-A3415; ZINC3929508; CO0039; AKOS015843442; AKOS015960501; CS-0552; DB00198; DT-0013; MCULE-1441617774; (3R,5S)-ETHYL 4-ACETAMIDO-5-AMINO-3-(PENTAN-3-YLOXY)CYCLOHEX-1-ENECARBOXYLATE; ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)cyclohexene-1-carboxylate; ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate; ethyl (3R,4R,5S)-4-acetamido-5-amino-3-pentan-3-yloxy-cyclohexene-1-carboxylate; Ethyl (5S,3R,4R)-4-(acetylamino)-5-amino-3-(ethylpropoxy)cyclohex-1-enecarboxylate; NCGC00095191-12; NCGC00178698-01; NCGC00178698-02; NCGC00178698-04; 1-Cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3R,4R,5S)-; HY-13317; RO640796; Oseltamivir 100 microg/mL in Acetonitrile; RO64-0796; C08092; D08306; W-5250; AB00173476-02; AB00173476_04; 618O130; AR-270/43507961; Q211509; SR-05000001499-1; BRD-K76011241-045-01-5; (3R,5S)-ethyl4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-enecarboxylate; Ethyl (3R, 4R, 5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate; ethyl 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate; (3r,4r,5s)-4-acetylamino-5-amino-3(1-ethylpropoxy) -1-cyclohexene-1-carboxylic acid ethyl ester; (3R,4R,5S)-4-acetylamino-5-amino-3-(1-ethyl-propoxy)-cyclohex-1-enecarboxylic acid ethyl ester; (3R,4R,5S)-4-acetylamino-5-amino-3-(1-ethyl-propoxy)cyclohex-1-enecarboxylic acid ethyl ester	Small molecule	1S/C16H28N2O4/c1-5-12(6-2)22-14-9-11(16(20)21-7-3)8-13(17)15(14)18-10(4)19/h9,12-15H,5-8,17H2,1-4H3,(H,18,19)/t13-,14+,15+/m0/s1	VSZGPKBBMSAYNT-RRFJBIMHSA-N	CCC(CC)OC1C=C(CC(C1NC(=O)C)N)C(=O)OCC	C16H28N2O4	CAS 196618-13-0	CHEBI:7798	.	.	.	D0O5NK	.	.	.
DR7967	Entinostat	CID: 4261	Entinostat; 209783-80-2; ms-275; SNDX-275; MS 275; MS-27-275; SNDX 275; Entinostat (MS-275); MS 27-275; pyridin-3-ylmethyl 4-((2-aminophenyl)carbamoyl)benzylcarbamate; MS275; pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; UNII-1ZNY4FKK9H; Entinostat (MS-275,SNDX-275); 1ZNY4FKK9H; BAY 86-5274; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; CHEMBL27759; pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; NSC706995; BAY86-5274; NSC-706995; N-[[4-[(2-aminoanilino)-oxomethyl]phenyl]methyl]carbamic acid 3-pyridinylmethyl ester; pyridin-3-ylmethyl 4-((2-aminophenyl)carbamoyl)benzylcarbamate.; pyridin-3-ylmethyl N-({4-[(2-aminophenyl)carbamoyl]phenyl}methyl)carbamate; Carbamic acid, N-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Histone Deacetylase Inhibitor I; entinostatum; N-(2-aminophenyl)-4-[N-(pyridin-3-ylmethoxycarbonyl)aminomethyl]benzamide; Entinostat, free base; PubChem24433; Entinostat [USAN:INN]; MS-275 (Entinostat); MS-275 - Entinostat; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate; benzamide-type inhibitor, 3; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; cc-216; MLS006010183; Entinostat (JAN/USAN/INN); SCHEMBL148309; GTPL7007; DTXSID0041068; BDBM19410; AOB2570; EX-A038; SYN3039; CHEBI:132082; BCPP000155; HMS3426G07; HMS3648K12; HMS3654O11; HMS3744O17; ACT06782; AMY31163; BCP01824; MS-275,Entinostat,SNDX-275/; ZINC1488870; ABP000145; MFCD08272435; NSC756642; s1053; 3-pyridylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; AKOS024262667; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; AC-8968; BCP9000967; Carbamic acid, 3-pyridinylmethyl ester; CCG-208680; CS-0511; DB11841; Entinostat (MS-275, SNDX-275); NSC 706995; NSC-756642; SB16665; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; NCGC00165833-01; NCGC00165833-02; NCGC00165833-03; NCGC00165833-04; NCGC00165833-13; AK158952; AS-17906; Carbamic acid, N-((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3- pyridinylmethyl ester; HY-12163; MS27-275; NCI60_038022; SMR004458705; MS-275, A HDAC1 and HDAC3 inhibitor; AB0021206; MS-275-27; ZK 244894; FT-0667871; SW219667-1; V2451; EC-000.2117; D09338; W-5370; 48247-EP2298768A1; 48247-EP2305643A1; 48247-EP2308868A1; 48247-EP2311494A1; 48247-EP2311840A1; 783M802; A815057; MS-275,Entinostat, SNDX-275, MS-27-275; SR-01000946382; Q1281020; SR-01000946382-1; W-201831; BRD-K77908580-001-02-1; BRD-K77908580-001-04-7; (pyridin-3-yl)methyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; [4-(2-Amino-phenylcarbamoyl)-benzyl]-carbamic acid pyridin-3-ylmethyl ester; N-[[4-[[(2-Aminophenyl)amino]carbonyl]phenyl]methyl]-3-pyridinylmethyl ester, carbamic acid; N-[[4-[[(2-Aminophenyl)amino]carbonyl]phenyl]methyl]carbamic acid 3-pyridinylmethyl ester; 442532-99-2	Small molecule	1S/C21H20N4O3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15(8-10-17)13-24-21(27)28-14-16-4-3-11-23-12-16/h1-12H,13-14,22H2,(H,24,27)(H,25,26)	INVTYAOGFAGBOE-UHFFFAOYSA-N	C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3	C21H20N4O3	CAS 209783-80-2	CHEBI:132082	.	.	.	D0M8FD	.	.	.
DR8004	Sorbitan trioleate	CID: 9920343	Sorbitan, tri-(9Z)-9-octadecenoate; UNII-QE6F49RPJ1; QE6F49RPJ1; Glycomul TO; Liposorb TO; Protachem STO; Sorbitani trioleas; Sorbitan, trioleate; Crill 5; Trioleate de sorbitan; Emasol 430; Rheodol SP 030; Trioleato de sorbitano; Emsorb 2503; Ionet S 85; Nissan nonion OP 85; Anhydrosorbitol trioleate; Nissan nonion OP 85R; Anhydro-D-glucitol trioleate; Sorbitan, tri-9-octadecenoate; OP 85R; CHEMBL3989778; Sorbitani trioleas [INN-Latin]; TE 33; EINECS 247-569-3; Trioleate de sorbitan [INN-French]; Trioleato de sorbitano [INN-Spanish]; Sorbitan trioleate [USAN:INN:BAN:NF]; Sorbitan, tris(9-octadecenoate), (Z)-; AI3-03902; EC 247-569-3; Sorbitan, esters, tri-9-octadecenoate, (Z,Z,Z)-; Sorbitan, tri-9-octadecenoate, (Z,Z,Z)- (9CI); Q27287216; UNII-MDL271E3GR component PRXRUNOAOLTIEF-ADSICKODSA-N; Sorbitan trioleate. (Compound usually contains also associated fatty acids.); [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-[(Z)-octadec-9-enoyl]oxyoxolan-2-yl]-2-[(Z)-octadec-9-enoyl]oxyethyl] (Z)-octadec-9-enoate	Small molecule	1S/C60H108O8/c1-4-7-10-13-16-19-22-25-28-31-34-37-40-43-46-49-56(62)65-53-55(67-57(63)50-47-44-41-38-35-32-29-26-23-20-17-14-11-8-5-2)60-59(54(61)52-66-60)68-58(64)51-48-45-42-39-36-33-30-27-24-21-18-15-12-9-6-3/h25-30,54-55,59-61H,4-24,31-53H2,1-3H3/b28-25-,29-26-,30-27-/t54-,55+,59+,60+/m0/s1	PRXRUNOAOLTIEF-ADSICKODSA-N	CCCCCCCCC=CCCCCCCCC(=O)OCC(C1C(C(CO1)O)OC(=O)CCCCCCCC=CCCCCCCCC)OC(=O)CCCCCCCC=CCCCCCCCC	C60H108O8	CAS 26266-58-0	.	.	.	.	.	.	.	.
DR8026	Ponatinib	CID: 24826799	Iclusig (TN)	Small molecule	1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39)	PHXJVRSECIGDHY-UHFFFAOYSA-N	CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5	C29H27F3N6O	CAS 943319-70-8	.	.	.	.	D0H0EQ	.	.	Ponatinib
DR8028	Erlotinib	CID: 176870	Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-Quinazolinamine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline; 4-[(3-ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline	Small molecule	1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)	AAKJLRGGTJKAMG-UHFFFAOYSA-N	COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC	C22H23N3O4	CAS 183321-74-6	.	.	.	.	D07POC	.	.	Erlotinib
DR8032	Rosiglitazone	CID: 77999	Avandia; 5-(4-(2-(Methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione; Brl-49653; Rosiglizole; Brl 49653; rosiglitazone (Avandia); BRL49653; Avandaryl; TDZ 01; Avandamet; C18H19N3O3S; CHEBI:50122; MFCD00871760; Rosigilitazone; 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-((4-(2-Methyl-2-(pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione-2-butenedioate; 2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-; 2,4-thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-; NCGC00095124-01; BRL 49653C; 5-[4-[2-[Methyl(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione; 5-(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}benzyl)-1,3-thiazolidine-2,4-dione; DSSTox_CID_17131; DSSTox_RID_79303; DSSTox_GSID_37131; Rosiglitazone [INN:BAN]; 5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione; CAS-122320-73-4; SR-01000763023; rosiglitazona; rosiglitazonum; Rezult; Rosi; HSDB 7555; Rosiglitazone base; 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; 5-[4-[2-[N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione; Gaudil (TN); Rosiglitazone (INN); 1132641-22-5; Spectrum_001703; 1217260-35-9; Spectrum2_001241; Spectrum3_000997; Spectrum4_001125; Spectrum5_001464; SCHEMBL5169; Dioxopromethazinehydrochloride; BSPBio_002693; KBioGR_001609; KBioSS_002183; SPECTRUM1504263; SPBio_001142; GTPL1056; TDZ-01; DTXSID7037131; SCHEMBL14383595; KBio2_002183; KBio2_004751; KBio2_007319; KBio3_001913; Rosiglitazone, >=98% (HPLC); HMS1922J11; HMS2094O13; HMS3649G08; HMS3656K16; HMS3744M11; HMS3871L03; HMS3884N08; Pharmakon1600-01504263; ACT04332; BCP03047; Tox21_111434; ANW-44906; BBL029079; BDBM50030474; CCG-39102; NSC758698; STL350047; AKOS015894872; Tox21_111434_1; AC-3459; BCP9000017; CS-1088; DB00412; MCULE-8293284864; MP-0331; NSC-758698; SB17326; VA11695; 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]-phenyl]methyl]-2,4-thiazolidine-dione; NCGC00095124-02; NCGC00095124-03; NCGC00095124-04; NCGC00095124-05; NCGC00095124-06; NCGC00095124-08; AK-72839; HY-17386; SY031184; BCP0726000232; AB0011992; FT-0602578; R0106; S2556; SW197573-6; 20R734; 6P-065; D08491; J10213; S00306; AB00698473-15; AB00698473-17; AB00698473-18; AB00698473-19; AB00698473_20; AB00698473_21; AB00698473_22; AB00698473_23; Q424771; Q-201681; SR-01000763023-5; SR-01000763023-6; BRD-A97437073-001-02-3; BRD-A97437073-001-03-1; BRD-A97437073-001-04-9; SR-01000763023-12; (RS)-5-{4-[2-(Methyl-2-pyridylamino)ethoxy]benzyl}-2,4-thiazolidinedion; 5-(4-(2-(Methyl(pyridin-2-yl)amino)ethoxy)-benzyl)thiazolidine-2,4-dione; 5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4dione; IDMB (1uM BRL49653, 1uM Dexamethasone, 0.5uM IBMX, 10ug/mL Insulin); (+/-)-5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI); 5-[[4-[2-(methyl-(2-pyridyl)amino)ethoxy]phenyl]methyl] thiazolidine-2,4-dione; 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[2-(Methyl-2-pyridinylamino)e thoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[2-(methyl-pyridin-2-ylamino)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2,4-dione; 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]phenyl methyl]thiazolidine-2,4-dione	Small molecule	1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)	YASAKCUCGLMORW-UHFFFAOYSA-N	CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3	C18H19N3O3S	CAS 122320-73-4	.	.	.	.	.	.	.	.
DR8051	Quinidine	CID: 441074	quinidine; 56-54-2; (+)-Quinidine; Conchinin; Chinidin; Pitayine; Quinidex; beta-Quinine; (8R,9S)-Quinidine; (9S)-6'-Methoxycinchonan-9-ol; Cin-Quin; Conquinine; Kinidin; Conchinine; chinidinum; quinidina; Quiniduran; Chinidine; Cinchonan-9-ol, 6'-methoxy-, (9S)-; UNII-ITX08688JL; Quinaglute; Auriquin; Quinidine sulfate; CHEBI:28593; (S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl](6-methoxyquinolin-4-yl)methanol; alpha-(6-Methoxy-4-quinolyl)-5-vinyl-2-quinuclidinemethanol; MFCD00135581; Quinicardine; CHEMBL1294; Cardioquin; Duraquin; Quinact; Quinalan; Quinatime; (1S)-(6-Methoxyquinolin-4-yl)((2R,4S,5R)-5-vinylquinuclidin-2-yl)methanol; Quinidine hydrochloride monohydrate; ITX08688JL; 6-Methoxy-alpha-(5-vinyl-2-quinuclidinyl)-4-quinolinemethanol; beta-Quinidine; (3'.alpha., 9S)-6'-Methoxycinchonan-9-ol; Quinidine, 98%, anhydrous; TCMDC-131239; NCI-C56246; (8R,9S)-6'-Methoxycinchonan-9-ol; (R)-(6-methoxyquinolin-4-yl)((3S,4R,7S)-3-vinylquinuclidin-7-yl)methanol; (S)-(6-methoxy-4-quinolyl)-[(2R,4S,5R)-5-vinylquinuclidin-2-yl]methanol; (S)-[(4S,5R,7R)-5-ethenyl-1-azabicyclo[2.2.2]octan-7-yl]-(6-methoxyquinolin-4-yl)methanol; Chinidin [German]; SMR000857275; Quinidine [BAN:NF]; (S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; Quinindine; CCRIS 672; HSDB 225; (S)-(6-methoxyquinolin-4-yl)((2R,5R)-5-vinylquinuclidin-2-yl)methanol; (S)-(6-methoxyquinolin-4-yl)((1S,2R,4S,5R)-5-vinylquinuclidin-2-yl)methanol; (S)-(6-Methoxy-quinolin-4-yl)-((2R,5R)-5-vinyl-1-aza-bicyclo[2.2.2]oct-2-yl)-methanol; QDN; EINECS 200-279-0; Quinidine, anhydrous; PubChem7994; Prestwick3_000280; bmse000511; Epitope ID:141803; SCHEMBL15943; BSPBio_000160; MLS001335913; MLS001335914; MLS002548869; BPBio1_000176; GTPL2342; DTXSID4023549; SCHEMBL17537608; HMS2234L10; HMS3259O09; ACT09863; HY-B1751; ZINC3831405; (9S)-6-Methoxy-alpha-(5-vinyl-2-quinuclidinyl)-4-quinolinemethanol; alpha-(6-Methoxy-4-quinolyl)-5-vinyl-2-quinuclidinemethanol (9S)-; BDBM50121975; RW2069; AKOS015920101; CCG-256507; CS-7812; DB00908; MCULE-7178915526; NC00478; SDCCGMLS-0066600.P001; NCGC00091231-01; NCGC00091231-02; NCGC00091231-03; AS-30538; AB00514657; 6470-EP1441224A2; 6470-EP2272835A1; 6470-EP2272844A1; 6470-EP2272972A1; 6470-EP2272973A1; 6470-EP2275411A2; 6470-EP2277872A1; 6470-EP2305655A2; 6470-EP2314576A1; 6470-EP2314585A1; M-7594; AB01562940_01; Q412496; W-109256; BRD-K59632282-052-01-5; BRD-K59632282-052-02-3; BRD-K70799801-311-02-7; Quinidine, crystallized, >=98.0% (dried material, NT); 101143-86-6	Small molecule	1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19+,20-/m0/s1	LOUPRKONTZGTKE-LHHVKLHASA-N	COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O	C20H24N2O2	CAS 56-54-2	CHEBI:28593	.	.	.	.	.	.	.
DR8070	S-1	.	Fluoropyrimidine anticancer agent	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR8071	Liraglutide	CID: 16134956	Liraglutide; victoza; Liraglutidum; Liraglutida; NN2211; 204656-20-2; NN-2211; NN 2211; CHEMBL4084119; Saxenda; Liraglutidum [INN-Latin]; Liraglutida [INN-Spanish]; HSDB 8205; Liraglutide [USAN:INN:BAN:JAN]; GTPL1133; CHEBI:71193; EX-A2418; BDBM50240819; AKOS037435224; N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)GLP-1-(7-37)-peptide; N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glucagon-like-peptide-1-(7-37)-peptide; AS-56276; A16115; Arg34Lys26-(N-epsilon-(gamma-Glu(N-alpha-hexadecanoyl)))-GLP-1(7-37); N(sup 26)-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)GLP-1-(7-37)-peptide	Small molecule	1S/C172H265N43O51/c1-18-20-21-22-23-24-25-26-27-28-29-30-37-53-129(224)195-116(170(265)266)59-64-128(223)180-68-41-40-50-111(153(248)199-115(62-67-135(232)233)154(249)204-120(73-100-44-33-31-34-45-100)159(254)214-140(93(11)19-2)167(262)192-97(15)146(241)201-122(76-103-79-183-108-49-39-38-48-106(103)108)157(252)203-118(72-90(5)6)158(253)212-138(91(7)8)165(260)200-110(52-43-70-182-172(177)178)149(244)184-81-130(225)193-109(51-42-69-181-171(175)176)148(243)187-84-137(236)237)196-144(239)95(13)189-143(238)94(12)191-152(247)114(58-63-127(174)222)194-131(226)82-185-151(246)113(61-66-134(230)231)198-155(250)117(71-89(3)4)202-156(251)119(75-102-54-56-105(221)57-55-102)205-162(257)124(85-216)208-164(259)126(87-218)209-166(261)139(92(9)10)213-161(256)123(78-136(234)235)206-163(258)125(86-217)210-169(264)142(99(17)220)215-160(255)121(74-101-46-35-32-36-47-101)207-168(263)141(98(16)219)211-132(227)83-186-150(245)112(60-65-133(228)229)197-145(240)96(14)190-147(242)107(173)77-104-80-179-88-188-104/h31-36,38-39,44-49,54-57,79-80,88-99,107,109-126,138-142,183,216-221H,18-30,37,40-43,50-53,58-78,81-87,173H2,1-17H3,(H2,174,222)(H,179,188)(H,180,223)(H,184,244)(H,185,246)(H,186,245)(H,187,243)(H,189,238)(H,190,242)(H,191,247)(H,192,262)(H,193,225)(H,194,226)(H,195,224)(H,196,239)(H,197,240)(H,198,250)(H,199,248)(H,200,260)(H,201,241)(H,202,251)(H,203,252)(H,204,249)(H,205,257)(H,206,258)(H,207,263)(H,208,259)(H,209,261)(H,210,264)(H,211,227)(H,212,253)(H,213,256)(H,214,254)(H,215,255)(H,228,229)(H,230,231)(H,232,233)(H,234,235)(H,236,237)(H,265,266)(H4,175,176,181)(H4,177,178,182)/t93-,94-,95-,96-,97-,98+,99+,107-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,138-,139-,140-,141-,142-/m0/s1	YSDQQAXHVYUZIW-QCIJIYAXSA-N	CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N)C(=O)O	C172H265N43O51	CAS 204656-20-2	CHEBI:71193	.	.	.	D03GOI	.	.	.
DR8104	Cis-diamminedichloroplatinum	CID: 441203	cis-Platin; cis-DDP; Cisplatine; Cisplatino; Cisplatinum; Lederplatin; Briplatin; Cismaplat; Neoplatin; Platamine; Platinex; Randa; trans-platin; cis-Dichlorodiammineplatinum(II); Peyrone's salt; cis-Diamminedichloroplatinum; Peyrone's chloride; trans-Platinum(II) ammonium chloride; cis-[PtCl2(NH3)2]; trans-Dichlorodiammine platinum; trans-Platinumdiammine dichloride; CHEBI:27899; CHEBI:35852; TRANS-DIAMMINEDICHLOROPLATINUM; trans-Platinum(II) diamminedichloride; trans-DDP, 8; Cisplatin, 1; Epitope ID:194799; Epitope ID:194800; BDBM92386; cis-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloroplatinum; trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloridoplatinum; AKOS025117566; DB00515; EU-0100918	Small molecule	1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+4/p-2	BSJGASKRWFKGMV-UHFFFAOYSA-L	N.N.Cl[Pt+2]Cl	Cl2H6N2Pt+2	CAS 15663-27-1	CHEBI:27899	.	.	.	.	.	.	.
DR8131	Peramivir	CID: 154234	Peramivir; 330600-85-6; Rapiacta; BCX-1812; 229614-55-5; RWJ-270201; UNII-9ZS94HQO3B; RAPIVAB; CHEBI:85202; Peramivir hydrate; BCX1812; BCX 1812; RWJ270201; 229614-56-6; RWJ 270201; 9ZS94HQO3B; (1S,2S,3R,4R)-3-((S)-1-Acetamido-2-ethylbutyl)-4-guanidino-2-hydroxycyclopentanecarboxylic acid; 330600-85-6 (free); (1S,2S,3S,4R)-3-[(1S)-1-acetamido-2-ethylbutyl]-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid; 3-(1-ACETYLAMINO-2-ETHYL-BUTYL)-4-GUANIDINO-2-HYDROXY-CYCLOPENTANECARBOXYLIC ACID; 3-(1'-acetylamino-2'-ethyl)butyl-4-((aminoimino)methyl)amino-2-hydroxycyclopentane-1-carboxylic acid; BCZ; Cyclopentanecarboxylic acid, 3-[(1S)-1-(acetylamino)-2-ethylbutyl]-4-[(aminoiminomethyl)amino]-2-hydroxy-, (1S,2S,3R,4R)-; (+/-)-Peramivir; Peramivir [USAN:INN]; PeramiFlu; Peramivir anhydrous; (1S,2R,3R,4R)-3-(1-acetamido-2-ethyl-butyl)-4-(diaminomethylideneamino)-2-hydroxy-cyclopentane-1-carboxylic acid; Cyclopentanecarboxylic acid, 3-((1S)-1-(acetylamino)-2-ethylbutyl)-4-((aminoiminomethyl)amino)-2-hydroxy-, (1S,2S,3R,4R)-; Peramivir, (+/-)-; cc-227; SCHEMBL744373; BDBM5024; CHEMBL139367; SCHEMBL12795462; DTXSID10904727; BCPP000117; ZINC3981610; ABP000969; BDBM50181441; CP0131; HY-17015A; MFCD09837902; AKOS016007760; CS-0638; DB06614; DT-0029; NCGC00346433-07; (1s,2s,3r,4r)-3-((1s)-1-acetylamino-2-ethylbutyl))-4-((aminoiminomethyl)amino)-2-hydroxycyclopentane; (1S,2S,3R,4R)-4-carbamimidamido-3-[(1S)-1-acetamido-2-ethylbutyl]-2-hydroxycyclopentane-1-carboxylic acid; 3(R)-[1(S)-Acetamido-2-ethylbutyl]-4(R)-guanidino-2(S)-hydroxycyclopentane-1(S)-carboxylic acid; AC-22715; Cyclopentanecarboxylic acid, 3-((1R)-1-(acetylamino)-2-ethylbutyl)-4-((aminoiminomethyl)amino)-2-hydroxy-, (1R,2R,3S,4S)-rel-; A11124; AB01566838_01; 600P856; Q412734; S-021812; (-)-(1S,2S,3R,4R)-3-[(1S)-1-(Acetylamino)-2-ethylbutyl]-4-{[amino(imino)methyl]amino}-2-hydroxycyclopentanecarboxylic Acid; (1S,2S,3R,4R)-3-[(1S)-1-(acetylamino)-2-ethylbutyl]-4-carbamimidamido-2-hydroxycyclopentanecarboxylic acid; (1S,2S,3R,4R)-3-[(1S)-1-acetamido-2-ethyl-butyl]-4-guanidino-2-hydroxy-cyclopentanecarboxylic acid; (1S,2S,3R,4R)-3-[(1S)-1-acetamido-2-ethylbutyl]-4-carbamimidamido-2-hydroxycyclopentane-1-carboxylic acid; (1S,2S,3S,4R)-4-[(DIAMINOMETHYLIDENE)AMINO]-3-[(1S)-1-ACETAMIDO-2-ETHYLBUTYL]-2-HYDROXYCYCLOPENTANE-1-CARBOXYLIC ACID	Small molecule	1S/C15H28N4O4/c1-4-8(5-2)12(18-7(3)20)11-10(19-15(16)17)6-9(13(11)21)14(22)23/h8-13,21H,4-6H2,1-3H3,(H,18,20)(H,22,23)(H4,16,17,19)/t9-,10+,11+,12-,13+/m0/s1	XRQDFNLINLXZLB-CKIKVBCHSA-N	CCC(CC)C(C1C(CC(C1O)C(=O)O)N=C(N)N)NC(=O)C	C15H28N4O4	CAS 330600-85-6	CHEBI:85202	.	.	.	D0P2IW	.	.	.
DR8137	Cotylenin A	CID: 5458687	COTYLENIN A; UNII-O6G9S48JRX; O6G9S48JRX; 12708-37-1; NSC319518; NSC 319518; Dicyclopenta(a,d)cyclooctene-1,5-diol, 1,2,3,3a,4,5,6,8,9,9a-decahydro-1-(methoxymethyl)-4-methyl-7-(1-methylethyl)-6-(((2S,3S,4aS,5R,7S,8R,8aR)-tetrahydro-8-hydroxy-5-(methoxymethyl)-3-methyl-3-((2S)-oxiranyl)-7H-2,4a-epoxy-5H-pyrano(3,4-b)-1,4-dioxin-7-yl)oxy)-, (1R,3aS,4R,5R,6R,9aR)-	Small molecule	1S/C33H50O11/c1-16(2)18-8-10-30(4)12-20-19(9-11-32(20,36)15-38-7)17(3)24(34)26(23(18)30)41-28-25(35)27-33(22(40-28)13-37-6)43-29(42-27)31(5,44-33)21-14-39-21/h12,16-17,19,21-22,24-29,34-36H,8-11,13-15H2,1-7H3/b20-12+/t17-,19+,21?,22?,24-,25?,26-,27?,28-,29?,30-,31+,32+,33+/m1/s1	SMQRKTIIIYTOTN-BQPZYPMMSA-N	CC1C2CCC(C2=CC3(CCC(=C3C(C1O)OC4C(C5C6(C(O4)COC)OC(O5)C(O6)(C)C7CO7)O)C(C)C)C)(COC)O	C33H50O11	CAS 12708-37-1	.	.	.	.	.	.	.	.
DR8144	CD55-TRAIL	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR8145	N-acetyl-S-(N-2-phenethylthiocarbamoyl)-L-cysteine	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR8164	Eicosapentaenoic acid	CID: 446284	Icosapent; Timnodonic acid; 10417-94-4; Icosapentaenoic acid; cis-5,8,11,14,17-Eicosapentaenoic acid; EPA; 5,8,11,14,17-EICOSAPENTAENOIC ACID; Icosapento; Icosapentum; (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid; 5Z,8Z,11Z,14Z,17Z-Eicosapentaenoic acid; (all-Z)-5,8,11,14,17-Eicosapentaenoic acid; (5Z,8Z,11Z,14Z,17Z)-5,8,11,14,17-eicosapentaenoic acid; UNII-AAN7QOV9EA; Icosapent [INN]; (5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid; 5,8,11,14,17-Icosapentaenoic acid; CCRIS 3279; AAN7QOV9EA; (5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid; CHEMBL460026; (5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate; CHEBI:28364; all-cis-icosa-5,8,11,14,17-pentaenoic acid; Icosapent (INN); cis-Delta(5,8,11,14,17)-eicosapentaenoic acid; 5,8,11,14,17-Eicosapentaenoic acid, (all-Z)-; Icosapentaenoate; (all-Z)-delta5,8,11,14,17-Eicosapentaenoic acid; C20:5n-3,6,9,12,15; MFCD00065716; eicosapentaenoate; cis-5,8,11,14,17-EPA; NCGC00161344-03; EICOSAPENTAENOIC ACID (20:5 n-3); all-cis-5,8,11,14,17-icosapentaenoic acid; all-cis-5,8,11,14,17-eicosapentaenoic acid; Miraxion; Eicosapentanoic acid; Eye Q; Eye-Q; 5,8,11,14,17-Eicosapentaenoic acid, (5Z,8Z,11Z,14Z,17Z)-; EPA [drug]; Icosapentum [INN-Latin]; C20:5 omega-3; Icosapento [INN-Spanish]; (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate; Timnodonate; 3gwx; FA 20:5; all-cis-icosapentaenoate; all-cis-icosapentaenoic acid; DSSTox_CID_21023; DSSTox_RID_79612; DSSTox_GSID_41023; SCHEMBL20469; BSPBio_001328; EPA 45G; Eicosa-5Z,8Z,11Z,14Z,17Z-pentaenoic Acid (20:5, n-3); BML3-B01; GTPL3362; DTXSID9041023; HMS1361C10; HMS1791C10; HMS1989C10; HMS3402C10; HMS3649D19; HY-B0660; ZINC4474603; 5,8,11,14,17-Icosapentaenoate; Tox21_111991; 1755AH; 5,8,11,14,17-Eicosapentaenoate; BDBM50242349; LMFA01030759; s6476; AKOS027470327; CCG-207957; CCG-208136; DB00159; cis-5,8,11,14,17-eicosapentaenoate; IDI1_033798; NCGC00161344-01; NCGC00161344-02; NCGC00161344-04; NCGC00161344-07; 5Z,8Z,11Z,14Z,17Z-Eicosapentaenoate; AC-31072; AS-53730; CAS-10417-94-4; E0441; 5,8,11,14,17-Eicosapentaenoic acid (6CI); all cis-5,8,11,14,17-Eicosapentaenoic Acid; all cis-5,8,11,14,17-Icosapentaenoic Acid; C06428; D08061; (all-cis)-5,8,11,14,17-Eicosapentaenoic acid; L001256; Q409990; SR-01000946647; J-001125; SR-01000946647-1; z,z,z,z,z-eicosa-5,8,11,14,17-pentaenoic acid; (Z,Z,Z,Z,Z)-5,8,11,14,17-eicosapentaenoic acid; BRD-K47192521-001-02-1; cis-5,8,11,14,17-Eicosapentaenoic acid, >=99%; 7F8BF016-B146-4F72-A52E-B9298BA3A9AB; C20H30O2 (cis-5,8,11,14,17-eicosapentaenoic acid); Eicosapentaenoic acid, 5,8,11,14,17-(Z,Z,Z,Z,Z)-; 5,8,11,14,17-Eicosapentaenoic acid, (all-Z)- (8CI); cis-5,8,11,14,17-Eicosapentaenoic acid, >=85%, liquid; UNII-317SQ4W8IJ component JAZBEHYOTPTENJ-JLNKQSITSA-N; UNII-71M78END5S component JAZBEHYOTPTENJ-JLNKQSITSA-N; UNII-9B22238JYI component JAZBEHYOTPTENJ-JLNKQSITSA-N; UNII-F85N2YHE4E component JAZBEHYOTPTENJ-JLNKQSITSA-N; cis-5,8,11,14,17-Eicosapentaenoic acid, analytical standard; (5Z,8Z,11 Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid; (5Z,8Z,11Z,14Z,17Z)-eicosa-5,8,11,14,17-pentaenoic acid; cis, cis, cis, cis, cis-eicosa-5,8,11,14,17-pentaenoic acid; 5,8,11,14,17-Eicosapentaenoic acid, (5Z,8Z,11Z,14Z,17Z)- (9CI); cis-5,8,11,14,17-Eicosapentaenoic acid, 500 mug/mL in ethanol, certified reference material	Small molecule	1S/C20H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h3-4,6-7,9-10,12-13,15-16H,2,5,8,11,14,17-19H2,1H3,(H,21,22)/b4-3-,7-6-,10-9-,13-12-,16-15-	JAZBEHYOTPTENJ-JLNKQSITSA-N	CCC=CCC=CCC=CCC=CCC=CCCCC(=O)O	C20H30O2	CAS 10417-94-4	CHEBI:28364	.	.	.	D0G2MW	.	.	.
DR8195	Selenite	CID: 1090	selenite; Selenite ion; 14124-67-5; UNII-KXO0259XJ1; selenite(2-); KXO0259XJ1; Selenit; trioxoselenate(IV); trioxoselenate(2-); trioxidoselenate(2-); Selenium (IV) trioxide; Monohydrated selenuim dioxide; DTXSID9074517; SeO3(2-); CHEBI:18212; [SeO3](2-); C05684; Q27102911	Small molecule	1S/H2O3Se/c1-4(2)3/h(H2,1,2,3)/p-2	MCAHWIHFGHIESP-UHFFFAOYSA-L	[O-][Se](=O)[O-]	O3Se-2	CAS 14124-67-5	CHEBI:18212	.	.	.	.	.	.	.
DR8223	AG1478	CID: 2051	AG-1478; 153436-53-4; Tyrphostin AG 1478; N-(3-chlorophenyl)-6,7-dimethoxyquinazolin-4-amine; 175178-82-2; 4-(3-Chloroanilino)-6,7-dimethoxyquinazoline; AG1478; AG 1478; Tyrphostin AG-1478; 4-Quinazolinamine, N-(3-chlorophenyl)-6,7-dimethoxy-; AG-1478 (Tyrphostin AG-1478); tyrphostin AG1478; SUH0SEZ9HY; UNII-SUH0SEZ9HY; AG-1478 hydrochloride; CHEMBL7917; CHEBI:75404; N-(3-Chlorophenyl)-6,7-dimethoxy-4-quinazolinamine; NSC-693255; Tyrphostin AG-1478;NSC 693255; BRD6408; BRD-6408; SR-01000076156; NSC693255; PubChem22408; Tocris-1276; tyrphostin-AG-1478; AG-1478 free base; BiomolKI_000018; Maybridge1_004001; Lopac-T-4182; BiomolKI2_000028; DSSTox_CID_30044; CBiol_002058; DSSTox_GSID_51447; Lopac0_001127; Oprea1_653581; SCHEMBL93838; BSPBio_001390; KBioGR_000110; KBioSS_000110; cc-598; MLS006012026; PD153035 Analog 31; BDBM3532; GTPL4862; N-(3-chlorophenyl)-6,7-dimethoxy-quinazolin-4-amine; DTXSID0051447; BCBcMAP01_000035; HMS552N19; KBio2_000110; KBio2_002678; KBio2_005246; KBio3_000219; KBio3_000220; AOB2928; Bio1_000344; Bio1_000833; Bio1_001322; Bio2_000110; Bio2_000590; HMS1361F12; HMS1791F12; HMS1989F12; HMS3229O03; HMS3263B15; HMS3656B19; HMS3672E11; ZINC116937; BCP07988; BCP15152; EX-A1236; Tyrphostin AG 1478, >=98%; Tox21_303781; Tox21_501127; BBL101047; CCG-52663; MFCD00270914; s2728; STL554841; AKOS002350880; AG-1478 - Tyrphostin AG-1478; AG-1478/AG1478; CS-1606; LP01127; MCULE-8403703571; SB19361; SDCCGSBI-0051095.P003; VZ27727; IDI1_033860; NCGC00016017-01; NCGC00016017-02; NCGC00016017-03; NCGC00016017-04; NCGC00016017-05; NCGC00016017-06; NCGC00016017-07; NCGC00016017-08; NCGC00016017-09; NCGC00016017-20; NCGC00025093-01; NCGC00025093-02; NCGC00025093-03; NCGC00025093-04; NCGC00025093-05; NCGC00261812-01; NCGC00357072-01; AC-32828; AK-63142; GK 03499; HY-13524; NCI60_033425; SMR001456495; DB-026463; CAS-175178-82-2; EU-0101127; FT-0643504; FT-0643682; SW219714-1; EC-000.2540; 6,7-dimethoxy-4-(3'-chloroanilino)quinazoline; A24890; S-7703; T 4182; 11N-812; InSolution AG 1478 - CAS 175178-82-2; CU-00000000399-1; J-011074; J-519544; SR-01000076156-1; SR-01000076156-4; SR-01000076156-7; (3-Chlorophenyl)(6,7-dimethoxyquinazolin-4-yl)amine; AG 1478 - CAS 175178-82-2; BRD-K68336408-001-02-6; BRD-K68336408-003-02-2; Q27074338; COC1=C(OC)C=C2C(NC3=CC(Cl)=CC=C3)=NC=NC2=C1; 0TO	Small molecule	1S/C16H14ClN3O2/c1-21-14-7-12-13(8-15(14)22-2)18-9-19-16(12)20-11-5-3-4-10(17)6-11/h3-9H,1-2H3,(H,18,19,20)	GFNNBHLJANVSQV-UHFFFAOYSA-N	COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=CC=C3)Cl)OC	C16H14ClN3O2	CAS 153436-53-4	CHEBI:75404	.	.	.	D0ZH1U	.	.	.
DR8240	Ceftazidime	CID: 5481173	ceftazidime; Tazidime; 72558-82-8; Fortaz; Pentacef; Tazicef; Ceptaz; ceftazidima; ceftazidimum; Ceftazidime anhydrous; GR 20263; CHEBI:3508; LY 139381; Ceftazidime (INN); Fortaz (TN); GR-20263; LY-139381; CAZ; (6R,7R)-7-((Z)-2-(2-Aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)imino)acetamido)-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate (contains ca. 10% Na2CO3); C22H22N6O7S2; Ceftazidime (TN); Ceptaz (TN); SCHEMBL36849; BIDD:GT0734; CHEMBL44354; DTXSID5022770; J01DD07; HMS2090M13; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; HY-B0593; BDBM50420259; AKOS015951273; CCG-269983; DB00438; NCGC00179584-05; CEFTAZIDIME (ARGININE FORMULATION); AB00513848; C06889; D07654; AB00513848-02; Cefprozil, Antibiotic for Culture Media Use Only; Q-200811; (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetyl}amino)-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 1-{[(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetamido]-2-carboxylato-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}pyridin-1-ium; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-3-(pyridinium-1-ylmethyl)-3,4-didehydrocepham-4-carboxylate	Small molecule	1S/C22H22N6O7S2/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34)/b26-13-/t14-,18-/m1/s1	ORFOPKXBNMVMKC-DWVKKRMSSA-N	CC(C)(C(=O)O)ON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[N+]4=CC=CC=C4)C(=O)[O-]	C22H22N6O7S2	CAS 72558-82-8	CHEBI:3508	.	.	.	D0PH5Z	.	.	.
DR8244	Imatinib	CID: 5291	Imatinib-d8; Imatinib D8; [d8]-Imatinib; 1092942-82-9; DTXSID70649425; J-002260	Small molecule	1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)	KTUFNOKKBVMGRW-UHFFFAOYSA-N	CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5	C29H31N7O	CAS 152459-95-5	.	.	.	.	D0R6RU	.	.	Imatinib
DR8289	Acyclovir	CID: 135398513	acyclovir; Aciclovir; Acycloguanosine; 59277-89-3; Zovirax; Vipral; Virorax; Wellcome-248U; 9-[(2-Hydroxyethoxy)methyl]guanine; Aciclovirum; Zovir; 2-Amino-9-((2-hydroxyethoxy)methyl)-1H-purin-6(9H)-one; Sitavig; 9-(2-Hydroxyethoxy)methylguanine; 9-HYROXYETHOXYMETHYLGUANINE; W-248-U; Acyclovir-side chain-2-3H; 9-((2-Hydroxyethoxy)methyl)guanine; UNII-X4HES1O11F; 2-Amino-9-[(2-hydroxyethoxy)methyl]-1,9-dihydro-6H-purin-6-one; Acyclovir-d4; NSC 645011; CHEBI:2453; 2-amino-9-(2-hydroxyethoxymethyl)-3H-purin-6-one; Acyclovir (Aciclovir); 2-Amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)-6H-purin-6-one; 6H-Purin-6-one, 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-; Zovirax (TN); MFCD00057880; 9-[(2-Hydroxyethoxy)-methyl]guanine; 2-Amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6H-purin-6-one; X4HES1O11F; MLS000069633; 141294-79-3; Activir; 9-(2-Hydroxyethoxymethyl)guanine; 6H-Purin-6-one, 2-amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)-; 2-amino-9-(2-hydroxyethoxymethyl)-1H-purin-6-one; NSC645011; NSC-645011; AC2; 2-amino-9-((2-hydroxyethoxy)methyl)-3H-purin-6(9H)-one; Acycloguanosine, 98%; NCGC00015061-02; Aciclovirum [Latin]; Aciclovier; Hascovir; SMR000058225; Genvir; Maynar; Zyclir; 2-amino-9-[(2-hydroxyethoxy)methyl]-6,9-dihydro-3H-purin-6-one; CAS-59277-89-3; 6H-Purin-6-one, 1,9-dihydro-2-amino-9-((2-hydroxyethoxy)methyl)-; DSSTox_CID_2556; DSSTox_RID_76626; Aciclovirum [INN-Latin]; DSSTox_GSID_22556; 2-amino-9-[(2-hydroxyethoxy)methyl]hydropurin-6-one; Acicloftal; Cargosil; Viropump; AcycloFoam; 2-amino-9-[(2-hydroxyethoxy)methyl]-3,9-dihydro-6H-purin-6-one; Acic; BW-248U; 2-amino-9-{[(2-hydroxyethyl)oxy]methyl}-1,9-dihydro-6H-purin-6-one; Acyclo-V; Acyclovir Lauriad; DRG-0008; Acyclovir (USP); BW 248U; CCRIS 1953; 1185179-33-2; HSDB 6511; SR-01000075540; Acyclovir [USAN:USP]; EINECS 261-685-1; ACV & Pluronic F-68; Acyclovir & Pluronic F-68; Cyclovir; Poviral; Sitavir; 2-amino-9-((2-hydroxyethoxy)methyl)-3,9-dihydro-6H-purin-6-one; Prestwick_6; ACYCLOVIR-SIDECHAIN-2-3H; 1pwy; Aciclovir [INN]; BW-248-U; Sitavig (TN); PubChem9572; Spectrum_001739; Opera_ID_1674; Prestwick0_000086; Prestwick1_000086; Prestwick2_000086; Prestwick3_000086; Spectrum2_001563; Spectrum3_001874; Spectrum4_000225; Spectrum5_001093; Lopac-A-4669; Aciclovir (JP17/INN); CHEMBL184; A 4669; Acycloguanosine (Acyclovir); SCHEMBL3175; Lopac0_000037; BSPBio_000012; BSPBio_003348; KBioGR_000889; KBioSS_002219; ARONIS27002; BIDD:GT0646; DivK1c_000185; SPECTRUM1503603; SPBio_001466; SPBio_001951; BPBio1_000014; GTPL4829; SCHEMBL9828560; 9(2-hydroxyethoxymethyl)guanine; DTXSID1022556; HMS500J07; KBio1_000185; KBio2_002219; KBio2_004787; KBio2_007355; KBio3_002850; NINDS_000185; HMS1568A14; HMS1922E08; HMS2090G09; HMS2095A14; HMS2234K21; HMS3259N10; HMS3260G15; HMS3269M15; HMS3372K02; HMS3413D21; HMS3655C14; HMS3677D21; HMS3712A14; Pharmakon1600-01503603; BCP11036; EBD48195; ZINC1530555; 9-(2-hydroxyethoxy methyl) guanine; Tox21_110075; Tox21_500037; 59277-89-3 (free); 69657-51-8 (Na salt); ANW-43941; BBL009642; BDBM50021776; BDBM50103518; CCG-39909; NSC758477; NSC780378; s1807; SBB063281; STK796771; STL257059; STL301862; AKOS000656213; AKOS015995680; AKOS022135433; Tox21_110075_1; AC-8068; CS-1353; DB00787; KS-1027; LP00037; MCULE-2703274259; NC00717; NSC-758477; NSC-780378; SDCCGSBI-0050026.P003; IDI1_000185; SMP1_000007; NCGC00015061-01; NCGC00015061-03; NCGC00015061-04; NCGC00015061-05; NCGC00015061-06; NCGC00015061-07; NCGC00015061-08; NCGC00015061-09; NCGC00015061-10; NCGC00015061-12; NCGC00015061-13; NCGC00015061-28; NCGC00022426-03; NCGC00093555-01; NCGC00093555-02; NCGC00093555-03; NCGC00093555-04; NCGC00167756-01; NCGC00167756-02; NCGC00260722-01; NCGC00381719-03; AK-24687; HY-17422; ST024744; SY051130; Acycloguanosine, >=99% (HPLC), powder; AB0012294; AB0068584; Aciclovir 1.0 mg/ml in Dimethyl Sulfoxide; AM20100442; EU-0100037; FT-0621607; FT-0657847; SW196324-3; 6383-EP2270005A1; 6383-EP2305243A1; 6383-EP2305640A2; 6383-EP2305808A1; 6383-EP2314582A1; 6383-EP2314585A1; C06810; D00222; J10243; M-1904; 32284-EP2281815A1; 32284-EP2301933A1; 32284-EP2311827A1; 277A893; A832236; Q147101; Q-200591; SR-01000075540-1; SR-01000075540-3; SR-01000075540-5; 2-amino-9-[(2-hydroxyethoxy)methyl]-9H-purin-6-ol; 2-azanyl-9-(2-hydroxyethyloxymethyl)-3H-purin-6-one; BRD-K32318651-001-17-9; Aciclovir, British Pharmacopoeia (BP) Reference Standard; F2173-0946; Aciclovir, European Pharmacopoeia (EP) Reference Standard; 2-Amino-9-(2-hydroxy-ethoxymethyl)-5,9-dihydro-purin-6-one; Acyclovir, United States Pharmacopeia (USP) Reference Standard; 2-Amino-9-(2-hydroxy-ethoxymethyl)-5,9-dihydro-purin-6-one (ACV); 2-Amino-9-[(2-hydroxyethoxy)methyl]-1,9-dihydro-6H-purin-6-one #; 2-amino-9-[(1,1,2,2-tetradeuterio-2-hydroxyethoxy)methyl]-1H-purin-6-one; ACV; Acycloguanosine; Acyclovir; NSC 645011; NSC-645011; NSC645011; Acyclovir, Pharmaceutical Secondary Standard; Certified Reference Material; Aciclovir for peak identification 1, European Pharmacopoeia (EP) Reference Standard; Aciclovir for peak identification 2, European Pharmacopoeia (EP) Reference Standard; Aciclovir for system suitability, European Pharmacopoeia (EP) Reference Standard	Small molecule	1S/C8H11N5O3/c9-8-11-6-5(7(15)12-8)10-3-13(6)4-16-2-1-14/h3,14H,1-2,4H2,(H3,9,11,12,15)	MKUXAQIIEYXACX-UHFFFAOYSA-N	C1=NC2=C(N1COCCO)N=C(NC2=O)N	C8H11N5O3	CAS 59277-89-3	CHEBI:2453	.	.	.	D0B5MP	.	.	.
DR8297	Capecitabine	CID: 60953	Capecitabin; Capecitabina; Capecitabinum; Capecitibine; Capiibine; Caxeta; Xabine; Xeloda; Capecitabine [USAN]; R340; R-340; RG-340; Ro 09-1978; Xeloda (TN); Ro 09-1978/000; Ro-09-1978; Xeloda, Captabin, Capecitabine; Capecitabine (JAN/USAN/INN); Ro-09-1978/000; N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine; Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate; Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate; Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester; Pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate; (1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester; 5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine; 5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine; Capecitabine (Fluoropyrimidine)	Small molecule	1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1	GAGWJHPBXLXJQN-UORFTKCHSA-N	CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O	C15H22FN3O6	CAS 154361-50-9	CHEBI:31348	.	.	.	D00HCQ	.	.	.
DR8320	Mitoxantrone	CID: 4212	DHAD; DHAQ; Dihydroxyanthraquinone; MIX; Misostol; Mitoxanthrone; Mitoxantron; Mitoxantrona; Mitoxantronum; Mitozantrone; DHAQ HCl; Mitoxantrone [INN]; Mitozantrone hydrochloride; Mitoxantrone 2HCl; Liposome Encapsulated Mitoxantrone (LEM); Misostol (TN); Mitoxantrona [INN-Spanish]; Mitoxantrone (INN); Mitoxantrone (free base); Mitoxantronum [INN-Latin]; Novantrone (TN); AN-584/42007670; Novantrone(R) (mitoxantrone for injection concentrate); DHAQ (*Diacetate salt*); MITOXANTRONE, Mitoxantrone Hydrochloride, Mitoxantrone dihydrochloride, MITOXANTHRONE HYDROCHLORIDE; MITOXANTRONE, 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)ANTHRA-9,10-QUINONE; 1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone; 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONE; 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione; 1,4-Dihydroxy-5,8-bis(5-hydroxy-3-azapentylamino)anthrachinon; 1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione; 1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthra-9,10-quinone; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione; 5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone; 9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-(9CI)	Small molecule	1S/C22H28N4O6/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32/h1-4,23-30H,5-12H2	KKZJGLLVHKMTCM-UHFFFAOYSA-N	C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO	C22H28N4O6	CAS 65271-80-9	CHEBI:50729	.	.	.	D0R3JB	.	.	Mitoxantrone
DR8341	Sulindac	CID: 1548887	Aclin; Aflodac; Arthrobid; Arthrocine; Chibret; Clinoril; Copal; Copals; Kenalin; Klinoril; Mobilin; Sulindaco; Sulindacum; Sulindal; Alphapharm Brand of Sulindac; Apo Sulin; Apotex Brand of Sulindac; Cahill May Roberts Brand of Sulindac; Chemia Brand of Sulindac; Copal resin; Copal rosin varnish; Gum copal; KendrickBrand of Sulindac; Merck Brand of Sulindac; Novo Sundac; Novopharm Brand of Sulindac; Nu Pharm Brand of Sulindac; Nu Sulindac; Resin copal; Sulindac sulfoxide; MK 231; MK231; S 8139; Apo-Sulin; Clinoril (TN); MK-231; Merck Sharp & Dohme Brand of Sulindac; Novo-Sundac; Nu-Pharm Brand of Sulindac; Nu-Sulindac; Sulindaco [INN-Spanish]; Sulindacum [INN-Latin]; Sulindac (JAN/USP/INN); Sulindac [USAN:BAN:INN:JAN]; Z-5-Fluoro-2-methyl-1-[p-(methlsulfinyl)benzylidene]indene-3-acetic acid; Cis-5-Fluoro-2-methyl-1-((p-methylsulfinyl)benzylidene)indene-3-acetic acid; {5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1h-inden-3-yl}acetic acid; Cis-5-Fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; [(1E)-5-fluoro-2-methyl-1-{[4-(methylsulfinyl)phenyl]methylidene}-1H-inden-3-yl]acetic acid; {(1E)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid; {(1Z)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid; (E)-(1)-5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-((p-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-[[4-(methyl-sulfinyl)phenyl]methylene]-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic acid; 2-[(3E)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 2-[6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid	Small molecule	1S/C20H17FO3S/c1-12-17(9-13-3-6-15(7-4-13)25(2)24)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9-	MLKXDPUZXIRXEP-MFOYZWKCSA-N	CC1=C(C2=C(C1=CC3=CC=C(C=C3)S(=O)C)C=CC(=C2)F)CC(=O)O	C20H17FO3S	CAS 38194-50-2	CHEBI:9352	.	.	.	D0Z5IU	.	.	.
DR8350	Cyclosporin	CID: 5284373	cyclosporin A; cyclosporine; Ciclosporin; 59865-13-3; Cyclosporine A; Sandimmune; Sandimmun; Neoral; Cyclosporin; Ciclosporine; Gengraf; Ramihyphin A; Sandimmun Neoral; Sang-35; Ciclosporina; Ciclosporinum; Consupren; Equoral; Neoplanta; UNII-83HN0GTJ6D; Antibiotic S 7481F1; SangCyA; MFCD00274558; 83HN0GTJ6D; MLS001333756; CHEBI:4031; CSA; S-Neoral; Cipol N; Sigmasporin Microoral; Cyclosporin A solution; DSSTox_CID_365; Ciclosporin (Ciclosporin A); DSSTox_RID_75541; DSSTox_GSID_20365; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone; SDZ-OXL 400; Ciclosporin A; OL 27-400; Abrammune; Imusporin; Optimmune; Seciera; Vekacia; Papilock Mini; Arpimune ME; Zinograf ME; Sandimmune Neoral; Ciclosporina Germed; (R-(R*,R*-(E)))-Cyclic(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-3-hydroxy-N,4-dimethyl-L-2-amino-6-octenoyl-L-alpha-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl); CYA; SMR000058578; Cicloral (antibiotic); Debio088; Sang 35; Cyclosporine [USAN:USP]; Ciclosporine [INN-French]; Ciclosporinum [INN-Latin]; Ciclosporina [INN-Spanish]; Cyclospori; Sigmasporin; Cyclokat; Mitogard; Papilock; Pulminiq; Zyclorin; CicloMulsion; Ciclosporin;; CCRIS 1590; Ciclosporin DT; Consupren S; NSC290193; Modusik-A; HSDB 6881; NeuroSTAT; 1cyn; 2wfj; 4jjm; NSC-290193; Cipol-N; NCGC00016890-01; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhex-4-en-1-yl]-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,2; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhex-4-en-1-yl]-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methyl-hex-4-enyl]-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19; (R-[R*,R*-(E)])-Cyclic(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-3-hydroxy-N,4-dimethyl-L-2-amino-6-octenoyl-L-alpha-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl); Cyclo(((E)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl)-L-2-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl); Cyclo[[(E)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl]-L-2-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl]; DRG-0275; Prestwick_731; Ciclosporin [INN]; CAS-59865-13-3; NSC 290193; CsA & IFN.alpha.; 1c5f; 2z6w; S 7481F1; Cyclosporine manufacturer; Prestwick2_000435; Prestwick3_000435; CHEMBL160; Sang-2000; SCHEMBL3491; SCHEMBL4442; Nova-22007; Ikervis (opthalmic solution); BSPBio_000450; Cyclosporin A & IFN.alpha.; MLS000028376; MLS002153454; MLS002207033; Verkazia (opthalmic solution); SDZ-OXL-400; BPBio1_000496; GTPL1024; ANTIBIOTIC S-7481F1; DTXSID0020365; CHEBI:92233; AOB2581; ATH-002; OLO-400; CB-01-09 MMX; HMS1569G12; HMS2089A09; HMS2096G12; HMS2230M14; HMS3713G12; 1,11-cyclo[L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-(E)-(2S,3R,4R)-2-amino-3-hydroxy-N,4-dimethyloct-6-enoyl-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucine]; 30-Ethyl-33-(1-hydroxy-2-methyl-hex-4-enyl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31undecaaza-cyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone; 30-ethyl-33-[(4E)-1-hydroxy-2-methylhex-4-en-1-yl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-bis(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone; 30-ethyl-33-[(4E)-1-hydroxy-2-methylhex-4-en-1-yl]-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone; Cyclo(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-((3R,4R,6E)-6,7-didehydro-3-hydroxy-N,4-dimethyl-L-2-aminooctanoyl)-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methylleucyl); Cyclosporin A, Ready Made Solution; EX-A4110; HY-B0579; Tox21_110667; Tox21_301849; BDBM50022815; DE-076; ST-603; Cyclosporin A, >=98.5% (TLC); AKOS015969287; Tox21_110667_1; CCG-208184; DB00091; EBD2126862; KS-1257; SDCCGSBI-0050230.P004; NCGC00093704-12; NCGC00164258-01; NCGC00164258-02; NCGC00164258-03; NCGC00255232-01; AT-12519; C042; Cyclo(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-((3R,4R,6E)-6,7-didehydro-3-hydroxy-N,4-dimethyl-L-2-aminooctanoyl-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methylleucyl); OL-27400; SBI-0050230.P003; AB0090560; OL-27-400; 5946-EP0930075A1; 5946-EP2289877A1; 5946-EP2292601A1; 5946-EP2292602A1; 5946-EP2292603A1; 5946-EP2292604A2; 5946-EP2292618A1; 5946-EP2293650A1; 5946-EP2298737A1; 5946-EP2298739A1; 5946-EP2298740A1; 5946-EP2298741A1; 5946-EP2298771A2; 5946-EP2301920A1; 5946-EP2301940A1; 5946-EP2308843A1; 5946-EP2308861A1; J10181; J90049; 865C133; Cyclosporin A, VETRANAL(TM), analytical standard; Q367700; SR-01000780563; Q-200913; SR-01000780563-3; BRD-K03222093-001-01-8; BRD-K13533483-001-03-0; Ciclosporin, European Pharmacopoeia (EP) Reference Standard; Cyclosporin A, from Tolypocladium inflatum, >=95% (HPLC), solid; Cyclosporine, United States Pharmacopeia (USP) Reference Standard; Ciclosporin for system suitability, European Pharmacopoeia (EP) Reference Standard; Cyclosporin A, from Tolypocladium inflatum, BioReagent, for molecular biology, >=95%; Cyclosporine, Pharmaceutical Secondary Standard; Certified Reference Material; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-((1R,2R,E)-1-hydroxy-2-methylhex-4-en-1-yl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhex-4-en-1-yl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-bis(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecone; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17; 104250-72-8; 30-Ethyl-33-((E)-1-hydroxy-2-methyl-hex-4-enyl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,28-octamethyl-1,4,7,10,13,16,19,22,25,28,31undecaaza-cyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone	Small molecule	1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42-,43+,44+,45+,46+,47+,49+,50+,51+,52-/m1/s1	PMATZTZNYRCHOR-CGLBZJNRSA-N	CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C	C62H111N11O12	CAS 59865-13-3	CHEBI:4031	.	.	.	D0O3YF	.	.	.
DR8384	Fluocinolone acetonide	CID: 6215	FLUOCINOLONE ACETONIDE; 67-73-2; Synalar; Flucinar; Synandone; Fluonid; Jellin; Synamol; Synemol; Coriphate; Fluovitif; Flupollon; Percutina; Synandrone; Dermalar; Localyn; Omniderm; Radiocin; Sinalar; Synotic; Tefunote; Synsac; Fluotrex; Retisert; Synalar-HP; Fluocet; Localyn Syntex; Derma-smoothe/fs; Cortiplastol; Prodermin; Fluocinolonacetonidum; Flucort; Fluocinolone 16,17-acetonide; Iluvien; Capex; 6alpha-Fluorotriamcinolone acetonide; Fluocinolone acetonide [DCIT]; Fluocinoloni acetonidum; RS-1401 AT; Fluocinoloni acetonidum [INN-Latin]; Acetonide de fluocinolone; C24H30F2O6; component of Neo-Synalar; Fluocinolone (Acetonide); UNII-0CD5FD6S2M; Dermatin (steroid); 6alpha,9alpha-Difluoro-16alpha-hydroxyprednisolone 16,17-acetonide; MFCD00010525; NSC-92339; 0CD5FD6S2M; MLS000028545; CHEBI:31623; Fluocinolone acetonide (Flucort-N); Fs Shampoo; NSC92339; flucinolone; SMR000058329; DSSTox_CID_20674; DSSTox_RID_79533; DSSTox_GSID_40674; Acetonida de fluocinolona; RS 1401AT; Flucort-N; 6.alpha.-Fluorotriamcinolone acetonide; CAS-67-73-2; Retisert (TN); (1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one; (6alpha,11beta,16alpha)-6,9-Difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione; Fluocet (TN); Synalar (TN); Acetonide de fluocinolone [INN-French]; Acetonida de fluocinolona [INN-Spanish]; CCRIS 3250; HSDB 3083; 6.Alpha.,9-Difluoro; EINECS 200-668-5; NSC 92339; Dermatin; Fluzon [Steroid]; NCGC00021301-04; 6-alpha,9-alpha-Difluoro-16-alpha-hydroxyprednisolone 16,17-acetonide; Fluocinoloneacetonide; fluocinolone-acetonide; 6alpha,9-Difluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone; Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-((1-methylethylidene)bis(oxy))-, (6alpha,11beta,16alpha)-; Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; Fluocinolone acetonide intravitreal implant; acetonido de fluocinolona; 6.alpha.,17-acetonide; Opera_ID_1295; F0657; Fluocinolone acetonide [USAN:USP:INN:JAN]; CHEMBL989; SCHEMBL4795; 6alpha,9alpha-Difluoro-11beta,16alpha,17alpha,21-tetrahydroxy-1,4-pregnadiene-3,20-dione 16,17-Acetonide; MLS001076276; ARONIS24561; GTPL7077; DTXSID0040674; EBD4852; HMS2090I14; HMS2230D13; HMS3259G12; HMS3715J11; HY-B0415; ZINC3977981; Tox21_110869; Tox21_302364; AC-429; s2470; AKOS015963144; Tox21_110869_1; ACN-043362; CCG-221165; DB00591; NC00562; Fluocinolone acetonide (JP17/USP/INN); NCGC00021301-06; NCGC00255654-01; (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-6b-glycoloyl-5-hydroxy-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; 4b,12-Difluoro-6b-glycoloyl-5-hydroxy-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; AS-13690; NCI60_042042; Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone (8CI); Fluocinolone acetonide, analytical standard; D01825; J10113; AB00383017-10; AB00383017_11; 010F525; Q924467; SR-01000000109; SR-01000000109-2; W-104704; BRD-K94353609-001-21-6; difluoro-hydroxy-(2-hydroxyacetyl)-tetramethyl-[?]one; 6.alpha., 9.alpha.-Difluoro-16.alpha.-hydroxyprednisolone 16,17-acetonide; Fluocinolone acetonide, European Pharmacopoeia (EP) Reference Standard; Fluocinolone acetonide, United States Pharmacopeia (USP) Reference Standard; Fluocinolone acetonide for system suitability, European Pharmacopoeia (EP) Reference Standard; Fluocinolone Acetonide, Pharmaceutical Secondary Standard; Certified Reference Material; WLN: T F5 E5 B666 GO IO RV AHTTTT&J A BF CQ E FVIQ H H OF -A&BHO -B&ACEF; (1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icosa-14,17-dien-16-one; (2S,6aS,6bR,7S,8aS,8bS,11aR,12aS,12bS)-2,6b-difluoro-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a,10,10-tetramethyl-6a,6b,7,8,8a,8b,11a,12,12a,12b-decahydro-1H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4(2H)-one; 6.alpha.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone; 6alpha,9alpha-difluoro-11beta,21-dihydroxy-16alpha-17alpha-isopropylidenedioxypregna-1,4-diene-3,20-dione;; Fluocinolone acetonide for peak identification, European Pharmacopoeia (EP) Reference Standard; Pregna-1,20-dione, 6,9-difluoro-11,12-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (6.alpha.,11.beta.,16.alpha.)-; Pregna-1,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)-, (6.alpha.,11.beta.,16.alpha.)-; Pregna-1,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (6.alpha.,11.beta.,16.alpha.)-; Pregna-1,20-dione, 6.alpha.,9-difluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone	Small molecule	1S/C24H30F2O6/c1-20(2)31-19-9-13-14-8-16(25)15-7-12(28)5-6-21(15,3)23(14,26)17(29)10-22(13,4)24(19,32-20)18(30)11-27/h5-7,13-14,16-17,19,27,29H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,21-,22-,23-,24+/m0/s1	FEBLZLNTKCEFIT-VSXGLTOVSA-N	CC1(OC2CC3C4CC(C5=CC(=O)C=CC5(C4(C(CC3(C2(O1)C(=O)CO)C)O)F)C)F)C	C24H30F2O6	CAS 67-73-2	CHEBI:31623	.	.	.	D02QJH	.	.	.
DR8398	Flunarizine	CID: 941361	flunarizine; 52468-60-7; Sibelium; 1-(Bis(4-fluorophenyl)methyl)-4-cinnamylpiperazine; Flunarizinum [INN-Latin]; Flunarizina [INN-Spanish]; UNII-R7PLA2DM0J; Flunarizinum; (E)-1-(Bis(4-fluorophenyl)methyl)-4-(3-phenyl-2-propenyl)piperazine; R7PLA2DM0J; 40218-96-0; CHEMBL30008; (E)-1-[Bis-(p-fluorophenyl)methyl]-4-cinnamylpiperazine; Flunarizina; 1-[bis(4-fluorophenyl)methyl]-4-[(2E)-3-phenylprop-2-en-1-yl]piperazine; Piperazine, 1-(bis(4-fluorophenyl)methyl)-4-(3-phenyl-2-propenyl)-, (E)-; Piperazine, 1-[bis(4-fluorophenyl)methyl]-4-(3-phenyl-2-propenyl)-, (E)-; Flunarizine [INN:BAN]; DSSTox_CID_25616; DSSTox_RID_81005; DSSTox_GSID_45616; Narzine; 4-((2E)-3-phenylprop-2-enyl)-1-[bis(4-fluorophenyl)methyl]piperazine; Sibelium (TN); Flunarizine (INN); CAS-52468-60-7; EINECS 257-937-5; Flunarazine; Flunarizine2HCl; NCGC00018102-06; EINECS 254-842-0; Prestwick2_000312; Prestwick3_000312; Spectrum5_001570; Lopac0_000527; SCHEMBL43440; SCHEMBL43441; BSPBio_000304; BSPBio_001341; BSPBio_003096; BPBio1_000336; DTXSID6045616; BCBcMAP01_000120; CHEBI:92209; cid_6365505; 1-[bis(4-fluorophenyl)methyl]-4-[(E)-cinnamyl]piperazine; CHEBI:135652; HMS1361D03; HMS1791D03; HMS1989D03; HMS2089H21; Tox21_110825; BDBM50017702; Piperazine, 1-(bis(4-fluorophenyl)methyl)-4-(3-phenyl-2-propenyl)-; STL477617; ZINC19360739; 1-[Bis(4-fluorophenyl)methyl]-4-[(2E)-3-phenyl-2-propenyl]piperazine; AKOS015960783; Tox21_110825_1; AC-1283; CCG-204617; DB04841; SDCCGSBI-0050510.P004; IDI1_000043; IDI1_033811; NCGC00018102-04; NCGC00018102-05; NCGC00018102-07; NCGC00018102-08; NCGC00018102-09; NCGC00018102-10; NCGC00018102-12; NCGC00018102-24; NCGC00024308-04; NCGC00024308-05; NCGC00024308-06; NCGC00024308-07; ST024768; SBI-0050510.P003; D07971; AB00053586-15; AB00053586_16; AB00053586_17; 118378-EP2270011A1; 118378-EP2275420A1; 118378-EP2280008A2; 118378-EP2298764A1; 118378-EP2298765A1; Q416237; 1-[bis-(4-Fluorophenyl)methyl]-4-cinnamylpiperazine; BRD-K12184470-300-01-8; BRD-K29582677-001-02-7; BRD-K29582677-300-05-6; BRD-K29582677-300-06-4; 1-[Bis-(4-fluoro-phenyl)-methyl]-4-(3-phenyl-allyl)-piperazine; 1-[Bis-(4-fluoro-phenyl)-methyl]-4-((E)-3-phenyl-allyl)-piperazine; Piperazine, 1-[bis(4-fluorophenyl)methyl]-4-[(2E)-3-phenyl-2-propenyl]-; 1-[Bis-(4-fluoro-phenyl)-methyl]-4-(3-phenyl-allyl)-piperazine(Flunarizine)	Small molecule	1S/C26H26F2N2/c27-24-12-8-22(9-13-24)26(23-10-14-25(28)15-11-23)30-19-17-29(18-20-30)16-4-7-21-5-2-1-3-6-21/h1-15,26H,16-20H2/b7-4+	SMANXXCATUTDDT-QPJJXVBHSA-N	C1CN(CCN1CC=CC2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F	C26H26F2N2	CAS 52468-60-7	CHEBI:92209	.	.	.	D05CEU	.	.	.
DR8439	Naproxen	CID: 156391	NAPROXEN; 22204-53-1; (S)-Naproxen; (+)-Naproxen; Naprosyn; Equiproxen; Naproxene; Aleve; (S)-(+)-Naproxen; (S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid; Laraflex; (S)-2-(6-methoxynaphthalen-2-yl)propanoic acid; d-Naproxen; Naproxenum; Calosen; Naprosyne; Naproxeno; Nycopren; Bonyl; Naixan; Reuxen; Axer; (+)-(S)-Naproxen; Ec-Naprosyn; naproxen(+); Acusprain; Anexopen; Arthrisil; Artrixen; Artroxen; Bipronyl; Clinosyn; Danaprox; Flexipen; Leniartil; Novonaprox; Anaprox; Apronax; Artagen; Atiflan; Congex; Daprox; Genoxen; Lefaine; Nafasol; Nalyxan; Napflam; Napmel; Naposin; Napren; Naprius; Veradol; Fuxen; Naxen; Naxyn; Xenar; Dysmenalgit N; Apo-Naproxen; (2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid; Floginax; (S)-2-(6-Methoxy-2-naphthyl)propionic acid; (+)-2-(6-Methoxy-2-naphthyl)propionic acid; (+)-2-(Methoxy-2-naphthyl)-propionic acid; RS-3540; Naprelan; (S)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid; Dysmenalgit; Diocodal; (S)-2-(6-Methoxy-2-naphthyl)propanoic acid; Prexan; Apo-Napro-NA; d-2-(6-Methoxy-2-naphthyl)propionic acid; (+)-2-(Methoxy-2-naphthyl)-propionsaeure; UNII-57Y76R9ATQ; (+)-(S)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid; (S)-(+)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid; Proxen; CG 3117; CHEBI:7476; (2S)-2-(6-methoxy-2-naphthyl)propanoic acid; MFCD00010500; CHEMBL154; (+)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid; Laser; 57Y76R9ATQ; d-2-(6'-Methoxy-2'-naphthyl)-propionsaeure; Naprium; Naprux; Propionic acid, 2-(6-methoxy-2-naphthyl)-, (+)-; Duk; Headlon; Napratec; Naprontag; Narocin; Naxopren; Prafena; Priaxen; Pronaxen; Rheumaflex; Saritilron; Sinartrin; Soproxen; Sutolin; Tohexen; Traumox; Flexen; Napxen; Noflam; Patxen; Rahsen; Sinton; Sutony; Velsay; Vinsen; Narma; Roxen; Anax; CAS-22204-53-1; Flanax Forte; Napren E; Naprosyn LLE; Proxen LE; Naxen F; Proxen LLE; U-Ritis; Naprosyn LLE Forte; (S)-2-(6-Methoxy-naphthalen-2-yl)-propionic acid; Naproxi 250; Naproxi 500; (alphas)-6-methoxy-alpha-methyl-2-naphthaleneacetic acid; (S)-6-Methoxy-.alpha.-methyl-2-naphthaleneacetic acid; Naxyn 250; Naxyn 500; Equiproxen (Veterinary); Naproxene [INN-French]; Naproxenum [INN-Latin]; Naproxeno [INN-Spanish]; 26159-31-9; Xenar-CR; CCRIS 5265; HSDB 3369; EINECS 244-838-7; RS 3540; (S)-(+)-6-Methoxy-alp.-methyl-2-naphthalene acetic acid; 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, (S)-; Naprolag; Naprosine; Naprosy; Panoxen; Proxine; Mnpa; SR-01000075977; 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, (.alpha.S)-; DL Naproxen; Naprosyn (TN); Naproxen,(S); NPS; Prestwick_349; (+)-2-(Methoxy-2-naphthyl)-propionsaeure [German]; Naproxen [USAN:USP:INN:BAN:JAN]; d-2-(6'-Methoxy-2'-naphthyl)-propionsaeure [German]; PubChem8102; 2-Naphthaleneacetic acid, 6-methoxy-alpha-methyl-, (+)-; 2-Naphthaleneacetic acid, 6-methoxy-alpha-methyl-, (S)-; Spectrum_000977; 4or0; 4po0; (S)-(+)-Naproxene; Prestwick0_000791; Prestwick1_000791; Prestwick2_000791; Spectrum2_001043; Spectrum3_000514; Spectrum4_000069; Spectrum5_001327; (+)NAPROXEN; Naproxen2-(6-Methoxy-naphthalen-2-yl)-propionic acid; Epitope ID:139974; UPCMLD-DP001; 2-(6-Methoxy-naphthalen-2-yl)-propionic acid(Naproxen); EC 244-838-7; SCHEMBL3046; DSSTox_CID_20686; DSSTox_RID_79542; DSSTox_GSID_40686; Lopac0_000792; BSPBio_002067; KBioGR_000597; KBioSS_001457; ARONIS24306; BIDD:GT0062; DivK1c_000242; SPECTRUM1500425; Naproxen (JP17/USP/INN); SPBio_000966; SPBio_002861; GTPL5230; DTXSID4040686; UPCMLD-DP001:001; CMWTZPSULFXXJA-VIFPVBQESA-; HMS500M04; KBio1_000242; KBio2_001457; KBio2_004025; KBio2_006593; KBio3_001567; Naproxen 1.0 mg/ml in Methanol; PN400 COMPONENT NAPROXEN; NINDS_000242; HMS1920P13; HMS2089N21; HMS2091H12; HMS3649M13; HMS3886C15; Pharmakon1600-01500425; ZINC105216; ACT02593; Tox21_301953; ANW-24773; BDBM50339185; CCG-40130; NSC750183; NSC757239; AKOS005267223; AC-1363; DB00788; MCULE-2589082817; ME-0100; NSC 750183; NSC 757239; NSC-750183; NSC-757239; SDCCGSBI-0050769.P005; IDI1_000242; Naproxen 100 microg/mL in Acetonitrile; Naproxen solution 1.0 mg/ml in methanol; NCGC00016759-01; NCGC00016759-02; NCGC00016759-03; NCGC00021127-01; NCGC00161591-01; NCGC00255562-01; HY-15030; Naproxen, meets USP testing specifications; SBI-0050769.P004; AM20060551; M1021; S5177; W4580; Naproxen, VETRANAL(TM), analytical standard; (2S)-2-(6-Methoxynaphth-2-yl)propanoic acid; (S)-2-(6-methoxy-2-naphthyl)-propionic acid; 04N531; C01517; D00118; J10145; M-5280; (2S)-2-(6-methoxy(2-naphthyl))propanoic acid; AB00052049-04; AB00052049_05; (+)(S)2-(6-methoxy-2-naphthyl)-propionic acid; 2-(6-Methoxy-2-naphthyl)propanoic acid , (+)-; SR-01000003110; Q-201447; Q1215575; SR-01000003110-5; SR-01000075977-3; SR-01000075977-4; (+)-6-Methoxy-.alpha.-methyl-2-napthaleneacetic acid; BRD-K59197931-001-02-9; BRD-K59197931-001-03-7; BRD-K59197931-236-09-6; SR-01000075977-10; (+)-6-Methoxy-.alpha.-methyl-2-naphthaleneacetic acid; (S)-(+)-2-(6-methoxy-naphthalen-2-yl)-propionic acid; (S)-6-Methoxy-.alpha.-methyl-2-naphthalene acetic acid; Naproxen, British Pharmacopoeia (BP) Reference Standard; Naproxen, European Pharmacopoeia (EP) Reference Standard; (S)-(+)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid, 98%; 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, (+)-; Naproxen, United States Pharmacopeia (USP) Reference Standard; 2-Naphthaleneacetic acid, 6-methoxy-alpha-methyl-, (+)- (8CI); Naproxen, Pharmaceutical Secondary Standard; Certified Reference Material; Naproxen solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; 131991-52-1; d-Naproxen; (2S)-2-(6-Methoxynaphthalen-2-yl)propanoic acid; (S)-6-Methoxy-?-methyl-2-naphthaleneacetic Acid; d-2-(6-Methoxy-2-naphthyl)propionic Acid	Small molecule	1S/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1	CMWTZPSULFXXJA-VIFPVBQESA-N	CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O	C14H14O3	CAS 22204-53-1	CHEBI:7476	.	.	.	D0DJ1B	.	.	.
DR8472	2-methoxyestradiol	CID: 66414	ESM; Panzem; PulmoLAR; Panzem NCD; M 6383; (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol; (17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol; (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER; 1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether; 2,3,17beta-Trihydroxy-1,3,5(10)-estratriene 2-methyl ether; 2-Hydroxyestradiol 2-methyl ether; 2-Hydroxyestradol 2-methyl ether; 2-ME2, 2-Methoxyestradiol; 2-Methoxyestra-1,3,5(10)-triene-3,17beta-diol; 2-Methoxyestradiol-17beta; 3,17beta-Dihydroxy-2-methoxy-1,3,5(10)-estratriene	Small molecule	1S/C19H26O3/c1-19-8-7-12-13(15(19)5-6-18(19)21)4-3-11-9-16(20)17(22-2)10-14(11)12/h9-10,12-13,15,18,20-21H,3-8H2,1-2H3/t12-,13+,15-,18-,19-/m0/s1	CQOQDQWUFQDJMK-SSTWWWIQSA-N	CC12CCC3C(C1CCC2O)CCC4=CC(=C(C=C34)OC)O	C19H26O3	CAS 362-07-2	CHEBI:28955	.	.	.	D06NYA	.	.	.
DR8475	Pemetrexed	CID: 135410875	Pemetrexed; 137281-23-3; Pemetrexed disodium; Alimta; LY231514; UNII-04Q9AIZ7NO; Pemetrexed acid; CHEBI:63616; 04Q9AIZ7NO; LY-231514; (S)-2-(4-(2-(2-Amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedioic acid; N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid; C20H21N5O6; 137281-23-3 (free acid); LY 231514; NSC-698037; LY-2315; N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid; Alimta (TN); (S)-2-(4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedioic acid; 2-{4-[2-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)-ETHYL]-BENZOYLAMINO}-PENTANEDIOIC ACID; N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid; (4-(2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzoyl)-L-glutamic acid; (S)-2-(4-(2-(2-Amino-4-oxo-4,7-dihydro-1H-pyrrolo-[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedioic acid; LYA; N-[4-[2(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid; Pemetrexed [INN:BAN]; HSDB 7316; 1juj; Pemetrexed (TN); N-(4-[2-(2-amino-4,7-Dihydro-4-Oxo-1H-Pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl)-L-Glutamic Acid; Pemetrexed (INN); Alimta (TN) (Lilly); SCHEMBL7968; US9422297, Pemetrexed; N-(4-(2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid; CHEMBL225072; DTXSID2048329; Premetrexed [Common mis-spelling]; ZINC1540998; BDBM50027656; CP0119; NSC698037; s5971; AKOS015896253; AKOS016842348; AC-1701; CS-1297; DB00642; NCGC00166414-11; NCGC00167517-01; NCGC00242485-01; AS-30680; HY-10820; L-Glutamic acid, N-(4-(2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-; DB-024764; P2288; A12668; D07472; S-4927; 41413-EP2270012A1; 41413-EP2270013A1; 41413-EP2305681A1; 41413-EP2311838A1; 41421-EP2270012A1; 41421-EP2270013A1; 41421-EP2305681A1; 41421-EP2311838A1; 89077-EP2270012A1; 89077-EP2270013A1; 89077-EP2305681A1; AB01273937-01; 281P233; Q415220; J-502393; L-Glutamic acid,3-d]pyrimidin-5-yl]ethyl]benzoyl]-; 1006872-74-7; N-({4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]phenyl}carbonyl)-L-glutamic acid; N-[4-[2(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo [2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid; N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7h-pyrrolo[2,3-d]pyrimi-din-5-yl)ethyl]benzoyl]l-glutamic acid; N-[4-[2-[2-Amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl]ethyl]benzoyl]glutamic acid	Small molecule	1S/C20H21N5O6/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29)/t13-/m0/s1	WBXPDJSOTKVWSJ-ZDUSSCGKSA-N	C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O	C20H21N5O6	CAS 137281-23-3	CHEBI:63616	.	.	.	D0Y4GO	.	.	.
DR8551	Decitabine	CID: 451668	AzadC; Dacogen; Dezocitidine; NCGC_5ADOC; Dacogen (TN); E-7373; Decitabine (USAN/INN); Dacogen, 5-aza-2'-deoxycytidine,NSC 127716, Dacogen, DAC, Decitabine; 2'-Deoxy-5-azacytidine; 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one; 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one; 4-Amino-1-(2-deoxy-beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; 5-AZAdC; 5-Aza-2&prime; 5-Azadeoxycytidine; 5-Deoxy-2&prime; 5-aza-2-deoxycytidine; 5-aza-CdR; 5-aza-dC; 5A2dc	Small molecule	1S/C8H12N4O4/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h3-6,13-14H,1-2H2,(H2,9,11,15)/t4-,5+,6+/m0/s1	XAUDJQYHKZQPEU-KVQBGUIXSA-N	C1C(C(OC1N2C=NC(=NC2=O)N)CO)O	C8H12N4O4	CAS 2353-33-5	CHEBI:50131	.	.	.	D0X5XU	.	.	.
DR8562	Pirarubicin	CID: 636397	pirarubicin; 72496-41-4; Theprubicin; MFCD00869742; Therarubicin (TN); (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-6-methyl-5-[(2S)-oxan-2-yl]oxyoxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S,10S)-10-(((2R,4S,5S,6S)-4-amino-6-methyl-5-(((S)-tetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione; THP-doxorubicin; C32H37NO12; NCGC00167982-01; Pirarubicin (JP17/INN); CHEMBL1398373; SCHEMBL15472856; CHEBI:32011; AOB5649; EX-A494; AMY10325; ZINC3913909; AKOS015895621; NCGC00167982-02; NCGC00167982-04; K234; D01885; 15207-EP2272827A1; 15207-EP2275420A1; 15207-EP2295055A2; 15207-EP2295416A2; 15207-EP2295426A1; 15207-EP2295427A1; 15207-EP2298748A2; 15207-EP2298764A1; 15207-EP2298765A1; 15207-EP2298768A1; 15207-EP2298778A1; 15207-EP2305642A2; 15207-EP2311453A1; 15207-EP2311808A1; 15207-EP2311829A1; 15207-EP2316832A1; 15207-EP2316833A1; 496P414; Pirarubicin, Antibiotic for Culture Media Use Only; Q-201589; (8S)-10-((2R,4S,5S,6S)-4-amino-6-methyl-5-((S)-tetrahydro-2H-pyran-2-yloxy)tetrahydro-2H-pyran-2-yloxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione	Small molecule	1S/C32H37NO12/c1-14-31(45-21-8-3-4-9-42-21)17(33)10-22(43-14)44-19-12-32(40,20(35)13-34)11-16-24(19)30(39)26-25(28(16)37)27(36)15-6-5-7-18(41-2)23(15)29(26)38/h5-7,14,17,19,21-22,31,34,37,39-40H,3-4,8-13,33H2,1-2H3/t14-,17-,19-,21-,22-,31+,32-/m0/s1	KMSKQZKKOZQFFG-HSUXVGOQSA-N	CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)OC6CCCCO6	C32H37NO12	CAS 72496-41-4	CHEBI:32011	.	.	.	D0T8EH	.	.	.
DR8583	Glasdegib	CID: 25166913	Glasdegib; 1095173-27-5; PF-04449913; PF 04449913; Glasdegib (PF-04449913); Daurismo; 1-((2R,4R)-2-(1H-benzo[d]iMidazol-2-yl)-1-Methylpiperidin-4-yl)-3-(4-cyanophenyl)urea; UNII-K673DMO5H9; 1-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-3-(4-cyanophenyl)urea; K673DMO5H9; CHEMBL2043437; C21H22N6O; PF-913; 1095173-27-5 (free base); PF-4449913; Glasdegib [USAN:INN]; glasdegibum; Glasdegib (USAN/INN); PF-04449913;Glasdegib; GTPL8201; SCHEMBL2068480; Glasdegib(PF-04449913); EX-A858; CHEBI:145428; AMY38164; 2640AH; BDBM50385635; MFCD25976839; NSC775772; ZINC68251434; CCG-268350; DB11978; NSC-775772; SB16679; NCGC00378600-02; BS-14357; HY-16391; QC-11459; S7160; D10636; Z-3230; J-690029; Q27077810; N-[(2R,4R)-2-(1H-Benzimidazol-2-yl)-1-methyl-4-piperidinyl]-N'-(4-cyanophenyl)urea; N-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-N'-(4-cyanophenyl)urea; 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea(PF-04449913); 4-[(2R)-2-[(1R)-2,2,2-Trifluoro-1-hydroxyethyl]-1-pyrrolidinyl]-2-(trifluoromethyl)-benzonitrile	Small molecule	1S/C21H22N6O/c1-27-11-10-16(24-21(28)23-15-8-6-14(13-22)7-9-15)12-19(27)20-25-17-4-2-3-5-18(17)26-20/h2-9,16,19H,10-12H2,1H3,(H,25,26)(H2,23,24,28)/t16-,19-/m1/s1	SFNSLLSYNZWZQG-VQIMIIECSA-N	CN1CCC(CC1C2=NC3=CC=CC=C3N2)NC(=O)NC4=CC=C(C=C4)C#N	C21H22N6O	CAS 1095173-27-5	CHEBI:145428	.	.	.	D0S5LO	.	.	.
DR8611	Bortezomib	CID: 387447	[(1S)-3-methyl-1-[[(2R)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid; PS 341 (pharmaceutical); MG 341; NSC 681239; NCGC00168751-01; (1S,2R)-Bortezomib; Bortezomib [USAN:INN]; SCHEMBL3676; AC1L3R1E; CHEMBL1530; Bortezomib Impurity (S,S-Isomer); Bortezomib Impurity (R,R-Isomer); Bortezomib Impurity (R,S-Isomer); N-((1S)-1-Benzyl-2-(((1R)-1-(dihydroxyboranyl)-3-methylbutyl)amino)-2-oxoethyl)pyrazinecarboxamide; 1132709-16-0	Small molecule	1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1	GXJABQQUPOEUTA-RDJZCZTQSA-N	B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O	C19H25BN4O4	CAS 179324-69-7	CHEBI:52717	.	.	.	D03AJX	.	.	Bortezomib
DR8626	GM-CSF	.	.	Protein	.	.	.	.	.	.	.	.	.	.	.	.	.
DR8652	SG611-VSTM1	.	.	Gene therapy	.	.	.	.	.	.	.	.	.	.	.	.	.
DR8662	PFK15	CID: 25142799	PFK-015; 4382-63-2; PFK15; 1-(Pyridin-4-yl)-3-(quinolin-2-yl)prop-2-en-1-one; CHEMBL3105836; (E)-1-pyridin-4-yl-3-quinolin-2-ylprop-2-en-1-one; 1-(4-Pyridinyl)-3-(2-quinolinyl)-2-propen-1-one; PFK 15; PFK015; SCHEMBL2702934; SCHEMBL16534534; AOB4632; SYN5216; BCP10875; EX-A4218; 2649AH; BDBM50445946; s7289; AKOS025287166; ZINC103235314; ACN-050165; CCG-267056; NCGC00386328-09; AC-28651; AS-16574; HY-12204; SW219876-1; A14287; (E)-1-(Pyridin-4-yl)-3-(quinolin-2-yl)prop-2-en-1-one; 2314451-67-5	Small molecule	1S/C17H12N2O/c20-17(14-9-11-18-12-10-14)8-7-15-6-5-13-3-1-2-4-16(13)19-15/h1-12H/b8-7+	UJJUKZPBUMCSJZ-BQYQJAHWSA-N	C1=CC=C2C(=C1)C=CC(=N2)C=CC(=O)C3=CC=NC=C3	C17H12N2O	.	.	.	.	.	D0A8AL	.	.	.
DR8666	Reorafenib	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR8680	TNF-related apoptosis inducing ligand 	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	TRAIL
DR8712	C1632	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR8725	Levothyroxine	CID: 5819	L-thyroxine; levothyroxine; 51-48-9; thyroxine; thyroxin; Tetraiodothyronine; Thyrax; 3,3',5,5'-Tetraiodo-L-thyronine; synthroid; Thyratabs; Thyreoideum; Thyroxinal; Thyroxine iodine; Levothyroxin; (-)-Thyroxine; L-Thyroxin; 3,5,3',5'-Tetraiodo-L-thyronine; L-T4; Thyroxine (l); Levothyroxine sodium; DL-Thyroxin; O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-L-tyrosine; t4; Thyroxine (VAN); 3,5,3',5'-Tetraiodothyronine; Laevothyroxinum; T4 (Hormone); L-3,5,3',5'-Tetraiodothyronine; Levothyroxinum (acid); Laevothyroxinum (acid); Thryroxine, l-; Tetramet; Thyroxine I 125; Forthyron (TN); NSC 36397; Levothyroxinum; 3,3',5,5''-Tetraiodo-L-thyronine; CCRIS 6739; Henning; HSDB 3108; 3,5,3'5'-Tetraiodo-L-thyronine; UNII-Q51BO43MG4; Prestwick_548; L-Tyrosine, O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-; 4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodo-L-phenylalanine; CHEBI:18332; O-(4-Hydroxy-3,5-diidophenyl)-3,5-diiodo-L-tyrosine; (S)-2-amino-3-(4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl)propanoic acid; 3-(4-(4-Hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl)alanine; beta-((3,5-Diiodo-4-hydroxyphenoxy)-3,5-diiodophenyl)alanine; 3-[4-(4-Hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]-L-alanine; CHEMBL1624; O-(4-Hydroxy-3,5-diiodophenyl)-3,5-diiodotyrosine; (2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid; C15H11I4NO4; Q51BO43MG4; 51-48-9 (free); THX; MFCD00002595; NCGC00164336-01; L-Thyroxine, 97+%; DSSTox_CID_3214; DSSTox_RID_76927; DSSTox_GSID_23214; Eutirox; Tyrosine, O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-; LT4; SMR000059176; T44; Levothyroxine (BAN); EINECS 200-101-1; Levothyroxine [INN:BAN]; Synthroid (*Sodium salt*); BRN 2228515; SR-01000759430; NSC-36397; 2ceo; L-Tyrosine,; CAS-51-48-9; Spectrum_001076; 1hk1; 1hk2; 1hk3; 1hk4; 1hk5; 1y0x; CPD000059176; L-Thyroxine, free acid; SpecPlus_000871; Prestwick0_000403; Prestwick1_000403; Prestwick2_000403; Prestwick3_000403; Spectrum2_000573; Spectrum3_000611; Spectrum4_000128; Spectrum5_001500; Thyroxine, L- (8CI); bmse000923; Epitope ID:123889; T-3850; (2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodo-phenoxy)-3,5-diiodo-phenyl]propanoic acid; L-Thyroxine (T4) solution; BIDD:PXR0161; Levothroid (*Sodium salt*); SCHEMBL23098; BSPBio_000326; BSPBio_002142; KBioGR_000516; KBioSS_001556; MLS000028647; MLS002548901; DivK1c_006967; SPECTRUM1500774; SPBio_000386; SPBio_002265; BPBio1_000360; GTPL2635; DTXSID8023214; KBio1_001911; KBio2_001556; KBio2_004124; KBio2_006692; KBio3_001642; HMS1569A08; HMS1921I06; HMS2090P18; HMS2092K12; HMS2096A08; HMS2233J18; HMS3259M11; HMS3713A08; L-Thyroxine, >=98% (HPLC); Pharmakon1600-01500774; ZINC3830993; Tox21_112101; Tox21_302156; BDBM50301375; CCG-38738; NSC757434; s2599; AKOS015905129; Tox21_112101_1; AC-7504; AM83594; CS-1819; DB00451; NC00485; NSC-757434; SDCCGMLS-0066571.P001; 2-amino-3-[4-(4-hydroxy-3,5-diiodo-phenoxy)-3,5-diiodo-phenyl]-propanoic acid; 3,3'',5,5''-tetraiodo-L-thyronine; 3,5,3'',5''-tetraiodo-L-thyronine; NCGC00094852-03; NCGC00164336-02; NCGC00164336-03; NCGC00164336-04; NCGC00164336-05; NCGC00164336-06; NCGC00255368-01; AC-10465; HY-18341; SBI-0051608.P002; AB0010528; DB-006261; SW196731-3; C01829; D08125; J10324; O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-; AB00052176-08; AB00052176_09; AB00052176_10; 002T595; Q773449; SR-05000001567; SR-01000759430-2; SR-05000001567-1; BRD-K30685142-001-05-5; BRD-K30685142-001-08-9; Thyroxine (T4), IRMM(R) certified Reference Material; L-Thyroxine, powder, BioReagent, suitable for cell culture; UNII-QR0BV3BRIA component XUIIKFGFIJCVMT-LBPRGKRZSA-N; Levothyroxine, United States Pharmacopeia (USP) Reference Standard; Levothyroxine, Pharmaceutical Secondary Standard; Certified Reference Material; L-Thyroxine (T4) solution, 100 mug/mL in methanol with 0.1N NH3, ampule of 1 mL, certified reference material	Small molecule	1S/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,12,21H,3,20H2,(H,22,23)/t12-/m0/s1	XUIIKFGFIJCVMT-LBPRGKRZSA-N	C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)CC(C(=O)O)N	C15H11I4NO4	CAS 51-48-9	CHEBI:18332	.	.	.	D06RGG	.	.	.
DR8750	Trametinib	CID: 11707110	Trametinib; 871700-17-3; GSK1120212; Mekinist; GSK-1120212; JTP 74057; JTP-74057; GSK 1120212; Trametinib (GSK1120212); N-[3-[3-Cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl]acetamide; GSK212; UNII-33E86K87QN; TMT212; CHEBI:75998; TMT-212; 33E86K87QN; N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide; N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide; Trametinib [USAN:INN]; trametinibum; JTP74057; N-(3-(3-Cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7- tetrahydropyrido(4,3-d)pyrimidin-1(2H)-yl)phenyl)acetamide; N-(3-{3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7- tetrahydropyrido(4,3-d)pyrimidin-1(2H)-yl}phenyl)acetamide; QOM; Trametinib (USAN); Trametinib (GSK1120212JTP 74057); cc-37; SCHEMBL170938; C26H23FIN5O4; GTPL6495; QCR-39; GSK1120212 (Trametinib); CHEMBL2103875; EX-A022; BCPP000218; DTXSID901007381; HMS3295I05; HMS3656J11; AOB87707; BCP02307; ABP000312; BDBM50531540; MFCD17215075; NSC758246; NSC800956; RW4149; s2673; ZINC43100709; AKOS015850628; AM90271; CCG-264976; CS-0060; DB08911; EX-5957; NSC-758246; NSC-800956; SB16553; NCGC00263180-01; NCGC00263180-07; NCGC00263180-14; AC-25891; AK174783; AS-19382; HY-10999; N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-2,4,7-trioxo-pyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide; AB0008115; FT-0688438; SW218089-2; X7454; A11029; A25168; D10175; GSK1120212 - JTP-74057; S-7800; GSK-1120212/GSK1120212/; GSK1120212,JTP-74057, GSK212; SR-01000941589; A1-01871; J-523325; Q7833138; SR-01000941589-1; BRD-K12343256-001-01-4; Acetamide, N-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-3,4,6,7-tetrahydro-6,8- dimethyl-2,4,7-trioxopyrido(4,3-d)pyrimidin-1(2H)-yl)phenyl)-; Acetamide, N-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl]-; N-(3-(3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)phenyl)acetamide; N-[3-[3-Cyclopropyl-5-[(2-Fluoro-4-Iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2h)-yl]phe nyl]acetamide; N-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxopyrido[3,4-e]pyrimidin-1-yl]phenyl]acetamide; N-{3-[3-Cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl}ethanimidic acid; N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide	Small molecule	1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)	LIRYPHYGHXZJBZ-UHFFFAOYSA-N	CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5	C26H23FIN5O4	CAS 871700-17-3	CHEBI:75998	.	.	.	D04XVN	.	.	.
DR8760	Itraconazole	CID: 55283	itraconazole; Oriconazole; 84625-61-6; Sporanox; Itrizole (TN); Sporanox (TN); ITCZ; Itraconazole (Sporanox); Itraconazol [Spanish]; Itraconazolum [Latin]; CHEMBL22587; C35H38Cl2N8O4; cis-Itraconazole; CHEBI:6076; 2-butan-2-yl-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; ITZ; DSSTox_CID_3180; DSSTox_RID_76908; DSSTox_GSID_23180; 1-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-4,5-dihydro-1H-1,2,4-triazol-5-one; 2-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2,4-dihydro-3H-1,2,4-triazol-3-one; 4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-sec-butyl-1,2,4-triazol-3-one; CAS-84625-61-6; R-51211; Intraconazole; Sporanox(TM); NCGC00018268-03; 4-(4-{4-[4-({[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl}oxy)phenyl]piperazin-1-yl}phenyl)-2-(1-methylpropyl)-2,4-dihydro-3H-1,2,4-triazol-3-one; R51211; Itraconazole & Nyotran; Itraconazole (JP17/USP); SCHEMBL23934; 84604-65-9; MLS006011958; AMY922; DTXSID3023180; GTPL11426; Pharmakon1600-01505756; Tox21_110854; 2485AH; AC-542; BDBM50127138; CI0042; MFCD00941396; NSC759239; s2476; AKOS015842738; AKOS015961385; Tox21_110854_1; CCG-270391; DB01167; KS-1268; MCULE-2446846552; NE57775; NSC-759239; NCGC00274068-01; NCGC00274068-02; NCGC00274068-07; 4-(4-(4-(4-(((2R,4S)-2-((1H-1,2,4-triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-(sec-butyl)-2,4-dihydro-3H-1,2,4-triazol-3-one; 873066-43-4; HY-17514; SMR001827898; Itraconazole & Nyotran(Liposomal Nystatin); SBI-0206914.P001; AB0012897; SW219756-1; Itraconazole 2.0 mg/ml in Dimethyl Sulfoxide; D00350; 24236-EP2281816A1; 24236-EP2314590A1; AB01274818-01; AB01274818_02; AB01274818_03; Q411229; BRD-A23067620-001-01-7; 3H-1,2,4-Triazol-3-one, 4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-pipera-zinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl); 4-[4-[4-[4-[[(2R,4S)-2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazole-1-ylmethyl)-1,3-dioxolane-4-yl]methoxy]phenyl]piperazino]phenyl]-2-(1-methylpropyl)-4H-1,2,4-triazole-3(2H)-one	Small molecule	1S/C35H38Cl2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3/t25?,31-,35-/m0/s1	VHVPQPYKVGDNFY-ZPGVKDDISA-N	CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5COC(O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl	C35H38Cl2N8O4	CAS 84625-61-6	CHEBI:6076	.	.	.	D0V4IB	.	.	.
DR8776	Melphalan	CID: 460612	melphalan; 148-82-3; Alkeran; Melfalan; L-PAM; Phenylalanine mustard; L-Sarcolysine; L-Sarcolysin; L-Phenylalanine mustard; p-L-Sarcolysin; Levofalan; Melphalanum; Levopholan; Melfalano; Levofolan; L-Sarkolysin; 4-[Bis(2-chloroethyl)amino]-L-phenylalanine; Phenylalanine nitrogen mustard; p-Di-(2-chloroethyl)amino-L-phenylalanine; p-Bis(beta-chloroethyl)aminophenylalanine; 3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine; Melphalanum [INN-Latin]; p-N-Bis(2-chloroethyl)amino-L-phenylalanine; Melfalano [INN-Spanish]; 4-(Bis(2-chloroet	Small molecule	1S/C13H18Cl2N2O2/c14-5-7-17(8-6-15)11-3-1-10(2-4-11)9-12(16)13(18)19/h1-4,12H,5-9,16H2,(H,18,19)/t12-/m0/s1	SGDBTWWWUNNDEQ-LBPRGKRZSA-N	C1=CC(=CC=C1CC(C(=O)O)N)N(CCCl)CCCl	C13H18Cl2N2O2	CAS 148-82-3	.	.	.	.	D06XES	.	.	.
DR8792	Cell differential agent-II	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR8796	Azoles	CID: 699591	5-(4-fluorophenyl)-3-(3-nitrophenyl)-1,2,4-oxadiazole; 421581-70-6; Azoles; ACMC-209jo2; Cambridge id 6767136; ZINC78448; DTXSID90351417; ANW-29760; MFCD03142768; STK140413; AKOS001657153; MCULE-6698398368; V5884; B-3616; SR-01000496544; SR-01000496544-1	Small molecule	1S/C14H8FN3O3/c15-11-6-4-9(5-7-11)14-16-13(17-21-14)10-2-1-3-12(8-10)18(19)20/h1-8H	PHSKMUVSVYQIRN-UHFFFAOYSA-N	C1=CC(=CC(=C1)[N+](=O)[O-])C2=NOC(=N2)C3=CC=C(C=C3)F	C14H8FN3O3	CAS 421581-70-6	.	.	.	.	D0S1HI	.	.	.
DR8799	Radiation	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR8801	Ibandronate	CID: 60852	Ibandronic Acid; Ibandronate; 114084-78-5; Bondronat; Boniva; Bonviva; (1-Hydroxy-3-(methyl(pentyl)amino)propane-1,1-diyl)diphosphonic acid; UNII-UMD7G2653W; Bondenza; CHEMBL997; [1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphonic acid; UMD7G2653W; Phosphonic acid, [1-hydroxy-3-(methylpentylamino)propylidene]bis-; {1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl}phosphonic acid; Phosphonic acid, (1-hydroxy-3-(methylpentylamino)propylidene)bis-; Acid ibandronico; BFQ; Ibandronic acid [INN:BAN]; Bisphosphonate 2; [1-hydroxy-3-[methyl(pentyl)amino]-1-phosphono-propyl]phosphonic acid; Ibandronic acid (INN); SR-05000001496; (1-Hydroxy-3-(methylpentylamino)propylidene)diphosphonic acid; 1-hydroxy-3-(methylpentylamino)propylidene bisphosphonic acid; [1-HYDROXY-3-(METHYL-PENTYL-AMINO)-1-PHOSPHONO-PROPYL]-PHOSPHONIC ACID; SCHEMBL9183; C9H23NO7P2; GTPL3059; JMC515594 Compound 53; DTXSID5048340; BDBM12577; HY-B0515A; HMS2090A13; ACT05527; BCP13798; ZINC1533877; AC-521; MFCD00868772; AKOS015855723; DB00710; NSC 722623; AS-12948; FT-0602640; FT-0670253; D08056; M-1207; AB01275485-01; 084I785; Q166825; J-003052; SR-05000001496-1; SR-05000001496-2; BRD-K08681769-323-01-1; 1-hydroxy-3-(methyl(pentyl)amino)propane-1,1-diyldiphosphonic acid; {1-hydroxy-3-[methyl(pentyl)amino]propane-1,1-diyl}bis(phosphonic acid); Phosphonic acid, P,P'-[1-hydroxy-3-(methylpentylamino)propylidene]bis-	Small molecule	1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)	MPBVHIBUJCELCL-UHFFFAOYSA-N	CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O	C9H23NO7P2	CAS 114084-78-5	.	.	.	.	D08SJZ	.	.	.
DR8802	Idoxuridine	CID: 5905	idoxuridine; 5-Iodo-2'-deoxyuridine; 54-42-2; 5-Iododeoxyuridine; Idoxuridin; Iododeoxyridine; Iodoxuridine; (+)-5-Iodo-2'-deoxyuridine; 2'-Deoxy-5-iodouridine; IDUR; IUDR; Joddeoxiuridin; Herplex; Allergan 211; Virudox; 5IUDR; Idoxuridinum; Idoxuridina; Dendrid; Allergan 201; IDU; 5-Iodouracil deoxyriboside; Idossuridina [DCIT]; IdUrd; 5-IUDR; Idoxene; Stoxil; Iduridin; Kerecid; 1-(2-Deoxy-beta-D-ribofuranosyl)-5-iodouracil; 5IdU; 1beta-D-2'-Deoxyribofuranosyl-5-iodouracil; 1-beta-D-2'-Deoxyribofuranosyl-5-iodouracil; SK&F-14287; MFCD00134656; NSC-39661; URIDINE, 2'-DEOXY-5-IODO-; Allergan-211; UNII-LGP81V5245; CHEBI:147675; 1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-iodopyrimidine-2,4(1H,3H)-dione; (+)-5-Iodo-2-deoxyuridine; Antizona; Heratil; LGP81V5245; SK&F 14287; ID2; Iduoculos; DSSTox_CID_25238; DSSTox_RID_80769; DSSTox_GSID_45238; Idoxuridinum [INN-Latin]; ent-Idoxuridine; Idoxuridina [INN-Spanish]; (+)-5-Iodo-2 -deoxyuridine; Idossuridina; C9H11IN2O5; 5-Iododesoxyuridine; 5-Iodo-deoxyuridine; (+)-5-Iodo-2'-deoxyuridine, 99%; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; uridine, 2'-deoxy-5-(iodo-131I)-; CCRIS 2827; SR-05000001510; EINECS 200-207-8; BRN 0030397; AI3-50861; HSDB 7479; CAS-54-42-2; NCGC00016243-01; Dendrid (TN); Uracil, 5-iodo-1-(2-deoxy-beta-D-ribofuranosyl)-; Idoxuridine [USAN:USP:INN:BAN:JAN]; 5-iodo-2'deoxyuridine; Idoxuridine (5-IdU); PubChem14202; HERPLEX (TN); Prestwick3_000018; CHEMBL788; Epitope ID:138107; 5-I-2'-dUrd; SCHEMBL3683; 2???-Deoxy-5-iodouridine; BSPBio_000055; 4-24-00-01235 (Beilstein Handbook Reference); MLS002154175; 5-IODO-2-DEOXYURIDINE; BPBio1_000061; Idoxuridine (JP17/USP/INN); DTXSID2045238; SCHEMBL15850897; AOB5602; HMS2090M10; HMS2095C17; HMS2230E10; HMS3712C17; BCP29428; HY-B0307; ZINC3834173; 5-IUdR; IDU; IdUrd; Idoxuridine; Tox21_110324; ANW-32073; BDBM50370388; s1883; AKOS015920431; Tox21_110324_1; (+)-5-Iodo-2'-deoxyuridine, 98%; AC-8219; CCG-220018; DB00249; MCULE-5585466189; SMP2_000072; NCGC00179673-01; NCGC00179673-03; AS-13469; I381; SMR001233472; Idoxuridine 100 microg/mL in Acetonitrile; AB0013659; DB-009133; 5-Iodo-2'-deoxyuridine, >=99% (HPLC); I0258; SW198484-2; 1-(2-Deoxy-??-D-ribofuranosyl)-5-iodouracil; 1-(2-Deoxy-ss -D-ribofuranosyl)-5-iodouracil; C-1149; D00342; 16509-EP2281563A1; 16509-EP2316459A1; 20495-EP2272827A1; 20495-EP2298768A1; 20495-EP2314585A1; 5-Iodo-2 inverted exclamation marka-deoxyuridine; 134I656; Q409765; J-009907; J-700180; SR-05000001510-1; SR-05000001510-3; SR-05000001510-4; BRD-K76634210-001-14-7; Idoxuridine, European Pharmacopoeia (EP) Reference Standard; Idoxuridine, United States Pharmacopeia (USP) Reference Standard; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodo-1,2,3,4-tetrahydropyrimidine-2,4-dione; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-iodo-pyrimidine-2,4-dione; 889872-67-7	Small molecule	1S/C9H11IN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1	XQFRJNBWHJMXHO-RRKCRQDMSA-N	C1C(C(OC1N2C=C(C(=O)NC2=O)I)CO)O	C9H11IN2O5	CAS 54-42-2	CHEBI:147675	.	.	.	D09PZO	.	.	.
DR8812	Lcotinib	CID: 22024915	Icotinib; 610798-31-7; Conmana; BPI-2009; N-(3-ethynylphenyl)-7,8,10,11,13,14-hexahydro-[1,4,7,10]tetraoxacyclododecino[2,3-g]quinazolin-4-amine; UNII-9G6U5L461Q; CHEMBL2087361; 9G6U5L461Q; N-(3-ethynylphenyl)-2,5,8,11-tetraoxa-15,17-diazatricyclo[10.8.0.014,19]icosa-1(12),13,15,17,19-pentaen-18-amine; Lcotinib; BPI2009; Icotinib(Lcotinib); icotinib,BPI-2009H; GTPL7641; SCHEMBL5843603; DTXSID20209952; EX-A306; HMS3651F12; 4-((3-ethynylphenyl)amino)-6,7-benzo-12-crown-4-quinazoline; BCP21716; 2468AH; BDBM50391089; HY-15164A; MFCD22124501; NSC800770; s2922; ZINC43207566; AKOS030231301; CCG-264757; DB11737; NSC-800770; SB16602; NCGC00386224-06; AC-32044; AK547890; AS-55948; DA-33567; N-(3-ethynylphenyl)-7H,8H,10H,11H,13H,14H-1,4,7,10-tetraoxacyclododeca[2,3-g]quinazolin-4-amine; FT-0701617; SW219698-1; D11251; Z-3130; Q16868421; (1,4,7,10)Tetraoxacyclododecino(2,3-g)quinazolin-4-amine, N-(3-ethynylphenyl)-7,8,10,11,13,14-hexahydro-; (3-Ethynyl-phenyl)(7,8,10,11,13,14-hexahydro-6,9,12,15-tetraoxa-1,3-diazacyclododeca[b]naphthalen-4-yl)-amine; N-(3-ethynylphenyl)-2,5,8,11-tetraoxa-15,17-diazatricyclo[10.8.0.0^{14,19]icosa-1(12),13,15,17,19-pentaen-18-amine	Small molecule	1S/C22H21N3O4/c1-2-16-4-3-5-17(12-16)25-22-18-13-20-21(14-19(18)23-15-24-22)29-11-9-27-7-6-26-8-10-28-20/h1,3-5,12-15H,6-11H2,(H,23,24,25)	QQLKULDARVNMAL-UHFFFAOYSA-N	C#CC1=CC(=CC=C1)NC2=NC=NC3=CC4=C(C=C32)OCCOCCOCCO4	C22H21N3O4	CAS 610798-31-7	.	.	.	.	.	.	.	.
DR8841	Mitomycin C	CID: 5746	Mutamycin; Ametycine; Mitocin-C; Ametycin; Mitomycin-C; Mytozytrex; Mitomycinum; Mytomycin; Mitozytrex; Mitomycinum C; Mitocin C; Mitomycins; Mitamycin; MMC; Mitosol; Mitomycyna C; 7-Amino-9alpha-methoxymitosane; NSC-26980; Mitomycyna C [Polish]; Mito-C; Mit-C; Mitomycin (TN); Mitomycinum [INN-Latin]; Mitomycine [INN-French]; Mitomicina [INN-Spanish]; NCI-C04706; RCRA waste number U010; NSC26980; NSC 26980; Mitomycine; CCRIS 414; UNII-50SG953SK6; HSDB 3239; C15H18N4O5; EINECS 200-008-6; Mitomycin C,; Ametycin; Mitomicina; Muamycin; Mitomycin C from Streptomyces caespitosus; Mitomycin C (JP15); Mitomycin C, Streptomyces caespitosus; Muamycin (TN); Mitomycin (USP/INN); Mitomycin [USAN:INN:BAN]; Mitomycin C, Streptomyces caespitosus, Carrier-Free	Small molecule	1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7+,13+,15-/m1/s1	NWIBSHFKIJFRCO-WUDYKRTCSA-N	CC1=C(C(=O)C2=C(C1=O)N3CC4C(C3(C2COC(=O)N)OC)N4)N	C15H18N4O5	CAS 50-07-7	CHEBI:27504	.	.	.	D0Y0GH	.	.	.
DR8879	Praziquantel	CID: 4891	praziquantel; 55268-74-1; Biltricide; Droncit; Pyquiton; Cesol; Embay 8440; Azinox; 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one; 2-(cyclohexanecarbonyl)-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one; MLS000038419; Praziquantel (Biltricide); MFCD00058531; SMR000037139; 2-(cyclohexanecarbonyl)-2,3,6,7-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4(11bH)-one; Cutter Tape Tabs; 2-(cyclohexanecarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1-a)isoquinolin-4-one; 2-cyclohexanecarbonyl-1H,2H,3H,4H,6H,7H,11bH-piperazino[2,1-a]isoquinolin-4-one; 4H-Pyrazino(2,1-a)isoquinolin-4-one, 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-; 4H-Pyrazino[2,1-a]isoquinolin-4-one, 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-; Praziquantelum; Distocide; Prazinon; DSSTox_CID_1182; DSSTox_RID_75995; DSSTox_GSID_21182; Praziquantelum [INN-Latin]; Cutter; Biltricide (TN); CCRIS 4114; SR-01000003100; EINECS 259-559-6; BRN 0761557; Bay-8440; Praziquantel (JAN/USP/INN); EMBAY-8440; Praziquantel,(S); NCGC00016877-01; Prestwick_402; CAS-55268-74-1; (+-)-Praziquantel; ACMC-20emeg; Praziquantel [USAN:USP:INN:BAN:JAN]; Spectrum_001119; Opera_ID_378; Prestwick0_000260; Prestwick1_000260; Prestwick2_000260; Prestwick3_000260; Spectrum2_001288; Spectrum3_000550; Spectrum4_000482; Spectrum5_001064; CHEMBL976; P 4668; cid_4891; Lopac0_000909; Oprea1_163497; SCHEMBL44153; BSPBio_000080; BSPBio_002199; KBioGR_000963; KBioSS_001599; 135526-78-2; 5-24-03-00361 (Beilstein Handbook Reference); MLS000028528; MLS001201812; MLS001304085; MLS002548849; MLS006011880; DivK1c_000130; SPECTRUM1500494; SPBio_001295; SPBio_002299; Praziquantel-(cyclohexyl-d11); BPBio1_000088; DTXSID9021182; SCHEMBL16019896; BDBM74574; CHEBI:91583; HMS500G12; KBio1_000130; KBio2_001599; KBio2_004167; KBio2_006735; KBio3_001699; NINDS_000130; HMS1568D22; HMS1920J06; HMS2090J19; HMS2092A09; HMS2095D22; HMS3259K07; HMS3262F20; HMS3655O19; HMS3712D22; Pharmakon1600-01500494; AMY16524; BCP17829; BCP28525; BCP30228; HY-B0244; Tox21_110660; Tox21_201950; Tox21_302927; Tox21_500909; CCG-39773; CP0098; NSC757285; Praziquantel, anthelminic, neurogenic; s1691; STK030186; AKOS000541869; AKOS016398525; Tox21_110660_1; AC-8426; DB01058; LP00909; MCULE-1638759858; NC00468; NE56665; NSC 757285; NSC-757285; SDCCGSBI-0050884.P005; 2-(Cyclohexylcarbonyl)-1,2,3,6,7-11b-hexahydro-4H-pyrazinoe(2,1a)isoquinolin-4-one; IDI1_000130; NCGC00015818-04; NCGC00015818-05; NCGC00015818-06; NCGC00015818-07; NCGC00015818-08; NCGC00015818-11; NCGC00015818-12; NCGC00015818-14; NCGC00015818-15; NCGC00015818-26; NCGC00089733-02; NCGC00089733-03; NCGC00089733-04; NCGC00089733-05; NCGC00256422-01; NCGC00259499-01; NCGC00261594-01; AK161796; AS-12459; SY052322; SBI-0050884.P004; AB0011974; DB-052707; (S)-Praziquantel; Praziquantel, (S)-Isomer; AB00052075; EU-0100909; FT-0630676; P2125; ST50904686; SW196645-3; 1H-pyrazino[2,1-a]isoquinolin-4(11bH)-one; 2-(cyclohexanecarbonyl)-2,3,6,7-tetrahydro-; C07367; D00471; J10194; AB00052075-13; AB00052075-15; AB00052075_16; AB00052075_17; Praziquantel, VETRANAL(TM), analytical standard; 268P741; Q424145; Praziquantel, Antibiotic for Culture Media Use Only; Q-201612; SR-01000003100-3; SR-01000003100-5; SR-01000003100-7; BRD-A21858158-001-05-2; BRD-A21858158-001-16-9; F0037-0136; Z1563145961; Praziquantel, European Pharmacopoeia (EP) Reference Standard; Praziquantel, United States Pharmacopeia (USP) Reference Standard; 10-(cyclohexylcarbonyl)-5,6,7,11a-tetrahydropiperazino[2,1-a]isoquinolin-8-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro- 4H-pyrazino[2,1-a]-isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino-[2,1- a]isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7-11b-hexahydro-4H-pyrazino[2,1-aisoquinolin-4-one; 2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one; 2-Cyclohexylcarbonyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1-a)isoquinolin-4-one; Praziquantel for system suitability, European Pharmacopoeia (EP) Reference Standard; Praziquantel, Pharmaceutical Secondary Standard; Certified Reference Material	Small molecule	1S/C19H24N2O2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17H,1-3,7-8,10-13H2	FSVJFNAIGNNGKK-UHFFFAOYSA-N	C1CCC(CC1)C(=O)N2CC3C4=CC=CC=C4CCN3C(=O)C2	C19H24N2O2	CAS 55268-74-1	CHEBI:91583	.	.	.	D0L9ZR	.	.	.
DR8953	Captopril	CID: 44093	captopril; 62571-86-2; Capoten; L-Captopril; Lopirin; Captopryl; Cesplon; Captolane; Tensoprel; Acepress; Captoril; Dilabar; Garranil; Hypertil; Tenosbon; Alopresin; Acepril; Lopril; Captoprilum; Acediur; Aceplus; (2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid; Tensobon; Apopril; Captoprilum [INN-Latin]; SQ 14225; SQ-14225; D-2-Methyl-3-mercaptopropanoyl-L-proline; D-3-Mercapto-2-methylpropanoyl-L-proline; SQ 14,225; 1-((2S)-3-Mercapto-2-methylpropionyl)-L-proline; SA 333; D-3-Mercapto-2-methylpropionylproline; 1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline; (2S)-1-(3-Mercapto-2-methylpropionyl)-L-proline; UNII-9G64RSX1XD; Hipertil; CHEBI:3380; L-Proline, 1-[(2S)-3-mercapto-2-methyl-1-oxopropyl]-; L-Proline, 1-(3-mercapto-2-methyl-1-oxopropyl)-, (S)-; 9G64RSX1XD; CHEMBL1560; 1-[(2S)-3-Mercapto-2-methyl-1-oxopropyl]-L-proline; MLS000069484; Asisten; Isopresol; (-)-Captopril; C9H15NO3S; [2S]-1-[3-Mercapto-2-methylpropionyl]-L-proline; 1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline; Captopril, 98%; MFCD00168073; (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline; NCGC00023654-04; SMR000059061; Lopirin [Switzerland]; (S)-1-((S)-3-mercapto-2-methylpropanoyl)pyrrolidine-2-carboxylic acid; 1-Pyrrolidinecarboxylic acid, 1-(D-3-mercapto-2-methyl-1-propionyl)-, L-(S,S)-; DSSTox_CID_17197; DSSTox_RID_79306; DSSTox_GSID_37197; L-Proline, 1-((2S)-3-mercapto-2-methyl-1-oxopropyl)-; Novocaptopril; Captril; Farcopril; Hypopress; Tensiomin; Zapto; Captopril (Capoten); Capozide (Salt/Mix); 3-Mercapto-2-methylpropionyl-proline; X8Z; Apopril (TN); Capoten (TN); HSDB 6527; 1-[(2s)-3-mercapto-2-methylpropionyl]-l-proline; SR-01000075603; EINECS 263-607-1; component of Captea (Salt/Mix); component of Acezide (Salt/Mix); component of Ecazide (Salt/Mix); 1-(D-3-Mercapto-2-methyl-1-oxopropyl)-L-proline (S,S); (2S)-1-((2S)-2-methyl-3-sulfanylpropanoyl)pyrrolidine-2-carboxylic acid; C09AA01; Captopril,(S); Prestwick_103; Captopril [USAN:USP:INN:BAN:JAN]; SQ14534; SCHEMBL4; Spectrum_000688; Opera_ID_1041; Prestwick3_000019; Spectrum2_001211; Spectrum3_001388; Spectrum4_000811; Spectrum5_001587; Lopac-C-4042; 1-((2S)-2-Methyl-3-sulfanylpropanoyl)-L-proline #; Epitope ID:114065; UPCMLD-DP003; C 4042; Lopac0_000302; N-[(S)-3-Mercapto-2-methylpropionyl]-L-proline; BSPBio_000057; BSPBio_002976; KBioGR_001321; KBioSS_001168; MLS001076488; DivK1c_000208; SPECTRUM1500682; SPBio_001022; Captopril (JP17/USP/INN); (S)-1-(3-Mercapto-2-methyl-1-oxo-propyl)-L-proline; BPBio1_000063; GTPL5158; DTXSID1037197; UPCMLD-DP003:001; BDBM21642; HMS500K10; KBio1_000208; KBio2_001168; KBio2_003736; KBio2_006304; KBio3_002196; ZINC57001; 1j37; NINDS_000208; HMS1921C12; HMS2089P19; HMS2092I12; HMS2095C19; HMS2233I04; HMS3259G10; HMS3260N06; HMS3712C19; Pharmakon1600-01500682; HY-B0368; Tox21_110890; Tox21_500302; BBL033600; CCG-39104; EI-213; KM0635; NSC757419; s2051; SA-333; SBB017523; STK802012; AKOS005622581; Captopril, >=98% (HPLC), powder; Tox21_110890_1; AB04252; BCP9000485; CS-2425; DB01197; KS-5025; LP00302; MCULE-1716939647; NC00554; NSC 757419; NSC-757419; SDCCGSBI-0050290.P006; IDI1_000208; SMP1_000056; NCGC00015235-01; NCGC00015235-02; NCGC00023654-03; NCGC00023654-05; NCGC00023654-06; NCGC00023654-07; NCGC00023654-08; NCGC00023654-09; NCGC00023654-10; NCGC00023654-11; NCGC00023654-13; NCGC00023654-25; NCGC00260987-01; AC-12047; AC-32120; ST079562; SBI-0050290.P004; AB0007072; Captopril, meets USP testing specifications; SQ -14225; EU-0100302; ((S)-3-mercapto-2-methylpropanoyl)-L-proline; BIM-0050290.0001; C06867; D00251; J10167; 54254-EP2269989A1; 54254-EP2270011A1; 54254-EP2272841A1; 54254-EP2277879A1; 54254-EP2287165A2; 54254-EP2287166A2; 54254-EP2292620A2; 54254-EP2295406A1; 54254-EP2298742A1; 54254-EP2298772A1; 54254-EP2298776A1; 54254-EP2298779A1; 54254-EP2301923A1; 54254-EP2301931A1; 54254-EP2301936A1; 54254-EP2305219A1; 54254-EP2305648A1; 54254-EP2308562A2; 54254-EP2308839A1; AB00052156-16; AB00052156_17; AB00052156_18; 571C862; Q421119; SR-01000000039; 1-[(2S)-3-Mercapto-2-methylpropionyl]- L-proline; SR-01000000039-2; SR-01000075603-1; SR-01000075603-3; 1-[(S)-3-mercapto-2-methyl-1-oxopropyl]-L-proline; BRD-K54529596-001-04-0; BRD-K54529596-001-15-6; Captopril, British Pharmacopoeia (BP) Reference Standard; Z2786051697; Captopril, European Pharmacopoeia (EP) Reference Standard; Captopril, United States Pharmacopeia (USP) Reference Standard; Captopril, Pharmaceutical Secondary Standard; Certified Reference Material; L-?Proline, 1-?[(2S)?-?3-?mercapto-?2-?methyl-?1-?oxopropyl]?-; Captopril for system suitability, European Pharmacopoeia (EP) Reference Standard	Small molecule	1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1	FAKRSMQSSFJEIM-RQJHMYQMSA-N	CC(CS)C(=O)N1CCCC1C(=O)O	C9H15NO3S	CAS 62571-86-2	CHEBI:3380	.	.	.	D0I0EG	.	.	.
DR8995	Dapagliflozin	CID: 9887712	Dapagliflozin; 461432-26-8; BMS-512148; Forxiga; Farxiga; BMS 512148; (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; UNII-1ULL0QJ8UC; (1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol; 1ULL0QJ8UC; CHEMBL429910; CHEBI:85078; Dapagliflozin [USAN:INN]; BMS512148; (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; Forxiga (TN); CHEMBL3125458; (1S)-1,5-anhydro-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-D-glucitol; D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-, (1S)-; (2S,3R,4R,5S,6R)-2-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-6-(hydroxymethyl)oxane-3,4,5-triol; 960404-48-2; Dagagflozin; (1S)-1,5-anhydro-1-C-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-D-glucitol; D-Glucitol, 1,5-anhydro-1-C-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-, (1S)-; (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol; BMS5121458; C-aryl glucoside, 6; PubChem22435; Tube101; Dapagliflozin (USAN/INN); 2-(3-(4-Ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol; cc-205; SCHEMBL157820; GLU006; GTPL4594; BDBM20880; DTXSID20905104; EX-A005; BCPP000265; AMY18541; AOB87300; ZINC3819138; BDBM50448923; CD0219; MFCD13182359; s1548; AKOS005145763; BCP9000583; BL-0052; CCG-229917; CS-0781; DB06292; EX-7214; PB11055; NCGC00250402-09; AC-24699; HY-10450; A25150; C22193; D08897; Q-3845; 432D268; Q409898; J-500392; BRD-K58160573-001-01-3; BRD-K58160573-001-05-4; 1-[3-(beta-D-Glucopyranosyl)-6-chlorobenzyl]-4-ethoxybenzene; (2S, 3R, 4R, 5S, 6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;BMS-512148; (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol	Small molecule	1S/C21H25ClO6/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21/h3-8,10,17-21,23-26H,2,9,11H2,1H3/t17-,18-,19+,20-,21+/m1/s1	JVHXJTBJCFBINQ-ADAARDCZSA-N	CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl	C21H25ClO6	CAS 461432-26-8	CHEBI:85078	.	.	.	D01TNW	.	.	.
DR9021	5-fluorouracil	CID: 3385	fluorouracil; 5-FU; Fluoroplex; Adrucil; Efudex; Carac; Fluracil; Fluoroblastin; 5-fluoropyrimidine-2,4(1H,3H)-dione; Kecimeton; Timazin; Carzonal; Efudix; Arumel; Fluril; Queroplex; Fluracilum; Ulup; 5-Fluoracil; Phthoruracil; Fluro Uracil; 5-Fluoro-2,4(1H,3H)-pyrimidinedione; Ftoruracil; Fluorouracilum; Efurix; Fluri; 51-21-8; 5 Fluorouracil; Effluderm (free base); 5-fluoro-1H-pyrimidine-2,4-dione; Fluorouracilo; Fluroblastin; Phtoruracil; 2,4-Dihydroxy-5-fluoropyrimidine; 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-; Adrucil; Effluderm; Fluorouracile; Fluoruracil; Fluracedyl; Flurodex; Neofluor; Onkofluor; Ribofluor; Tetratogen; URF; Allergan Brand of Fluorouracil; Biosyn Brand of Fluorouracil; CSP Brand of Fluorouracil; Cinco FU; Dakota Brand of Fluorouracil; Dermatech Brand of Fluorouracil; Dermik Brandof Fluorouracil; Ferrer Brand of Fluorouracil; Fluoro Uracile ICN; Fluorouracil GRY; Fluorouracil Mononitrate; Fluorouracil Monopotassium Salt; Fluorouracil Monosodium Salt; Fluorouracil Potassium Salt; Fluorouracil Teva Brand; Fluorouracile Dakota; Fluorouracile [DCIT]; Fluorouracilo Ferrer Far; Gry Brand of Fluorouracil; Haemato Brand of Fluorouracil; Haemato fu; Hexal Brand of Fluorouracil; ICN Brand of Fluorouracil; Inhibits thymilidate synthetase; Medac Brand of Fluorouracil; Neocorp Brand of Fluorouracil; Onkoworks Brand of Fluorouracil; Ribosepharm Brand of Fluorouracil; Riemser Brand of Fluorouracil; Roche Brand of Fluorouracil; Teva Brand of Fluorouracil; F 6627; F0151; IN1335; U 8953; Adrucil (TN); Carac (TN); Dakota, Fluorouracile; Efudex (TN); Fluoro-Uracile ICN; Fluoro-uracile; Fluoro-uracilo; Fluoroplex (TN); Fluorouracil-GRY; Fluorouracilo [INN-Spanish]; Fluorouracilum [INN-Latin]; Haemato-fu; Ro 2-9757; U-8953; Ro-2-9757; Fluorouracil (JP15/USP/INN); Fluorouracil [USAN:INN:BAN:JAN]; 1-fluoro-1h-pyrimidine-2,4-dione; 2,4-Dioxo-5-fluoropryimidine; 2,4-Dioxo-5-fluoropyrimidine; 5 FU Lederle; 5 FU medac; 5 Fluorouracil biosyn; 5 HU Hexal; 5-FU (TN); 5-FU Lederle; 5-FU medac; 5-Faracil; 5-Fluor-2,4(1H,3H)-pyrimidindion; 5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]; 5-Fluor-2,4-dihydroxypyrimidin; 5-Fluor-2,4-dihydroxypyrimidin [Czech]; 5-Fluor-2,4-pyrimidindiol; 5-Fluor-2,4-pyrimidindiol [Czech]; 5-Fluoracil [German]; 5-Fluoracyl; 5-Fluoro-2,4-pyrimidinedione; 5-Fluoropyrimidin-2,4-diol; 5-Fluoropyrimidine-2,4-dione; 5-Fluorouracil-biosyn; 5-Fluoruracil; 5-Fluoruracil [German]; 5-Ftouracyl; 5-HU Hexal; 5-fluoro uracil; 5FU	Small molecule	1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)	GHASVSINZRGABV-UHFFFAOYSA-N	C1=C(C(=O)NC(=O)N1)F	C4H3FN2O2	CAS 51-21-8	CHEBI:46345	.	.	.	D05LEO	.	.	5-Fluorouracil
DR9044	Hydroxychloroquine	CID: 3652	hydroxychloroquine; 118-42-3; Plaquenil; Oxichloroquine; Hidroxicloroquina; Hydroxychloroquinum; oxichlorochine; WIN 1258; Quensyl; 2-((4-((7-Chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol; 7-Chloro-4-(4-(ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline; Polirreumin; Oxychlorochin; CHEBI:5801; 2-(N-(4-(7-Chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol; 7-Chloro-4-(4-(N-ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino)quinoline; Oxichlorochinum; HYDROXY CHLOROQUINE; HCQ; 2-[{4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino]ethanol; 7-Chloro-4-(5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl)aminoquinoline; 2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol; 2-((4-((7-Chloroquinolin-4-yl)amino)pentyl)(ethyl)amino)ethanol; NSC4375; Ethanol, 2-((4-((7-chloro-4-quinolinyl)amino)pentyl)ethylamino)-; MFCD00242707; Idrossiclorochina [DCIT]; Ethanol, 2-[[4-[(7-chloro-4-quinolinyl)amino]pentyl]ethylamino]-; Idrossiclorochina; 2-({4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino)ethan-1-ol; Hidroxicloroquina [INN-Spanish]; Hydroxychloroquinum [INN-Latin]; Hydroxychloroquine [INN:BAN]; 2-[[4-[(7-chloroquinolin-4-yl)amino]pentyl](ethyl)amino]ethanol; 2-{N-[4-(7-Chloro-4-quinolylamino)pentyl]-N-ethylamino}ethanol; Ethanol, 2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)-; 2-({4-[(7-chloro(4-quinolyl))amino]pentyl}ethylamino)ethan-1-ol; 7-chloro-4-[4-(N-ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino]quinoline; 7-chloro-4-[5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl]aminoquinoline; Polirreumin (TN); NCGC00159483-02; Hydroxychloroquine (INN); EINECS 204-249-8; BRN 0253894; Dolquine; Ethanol, 2-[[4-[(7-chloro-4-quinolyl)amino]pentyl]ethylamino]-; R-Hydroxychloroquine; Ercoquin (Salt/Mix); Ethanol, 2-[[4-[(7-chloro-4-quinolinyl)amino]pentyl]ethylamino]-, sulfate (1:1); (+-)-hydroxychloroquine; Spectrum2_001238; Spectrum5_001697; (+/-)-hydroxychloroquine; SCHEMBL8170; CHEMBL1535; 5-22-10-00280 (Beilstein Handbook Reference); (.+/-.)-Hydroxychloroquine; DivK1c_000942; SPBio_001116; GTPL7198; DTXSID8023135; HMS502P04; KBio1_000942; Win 1258-2; NINDS_000942; 2-[4-[(7-chloro-4-quinolyl)amino]pentyl-ethyl-amino]ethanol; ALBB-022466; BCP30197; BDBM50467780; SBB012559; STL429829; AKOS015997886; CCG-208059; DB01611; DT-0016; HY-W031727; MCULE-6282304706; VZ36170; IDI1_000942; NCGC00159483-03; NCGC00159483-06; M566; ST072188; SY270913; SBI-0052759.P002; CS-0075751; FT-0627143; FT-0669455; FT-0669456; C07043; D08050; AB00053257_02; 118H423; Q421094; BRD-A99117172-065-01-6; BRD-A99117172-065-02-4; F2173-0553; 2-((4-(7-chloroquinolin-4-ylamino)pentyl)(ethyl)amino)ethanol; 2-[(4-[(7-Chloro-4-quinolinyl)amino]pentyl)(ethyl)amino]ethanol #; 2-[[4-[(7-Chloro-4-quinolyl)amino]pentyl](ethyl)amino]ethanol; 7-chloro-4-[4-[ethyl(2-hydroxyethyl)amino]1-methylbutylamino]-quinoline; 7-chloro-4-[4-[ethyl(2-hydroxyethyl)amino]1-methylbutylamino]quinoline; 7-Chloro-4-(4-(N-ethyl-N-.beta.-hydroxyethylamino)-1-methylbutylamino)quinoline; Oxichloroquine;Oxychlorochin;2-[[4-[(7-Chloroquinolin-4-yl)amino]pentyl](ethyl)amino]ethanol	Small molecule	1S/C18H26ClN3O/c1-3-22(11-12-23)10-4-5-14(2)21-17-8-9-20-18-13-15(19)6-7-16(17)18/h6-9,13-14,23H,3-5,10-12H2,1-2H3,(H,20,21)	XXSMGPRMXLTPCZ-UHFFFAOYSA-N	CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO	C18H26ClN3O	CAS 118-42-3	CHEBI:5801	.	.	.	D0OJ4L	.	.	.
DR9093	Sodium butyrate	CID: 5222465	Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)	Small molecule	1S/C4H8O2.Na/c1-2-3-4(5)6;/h2-3H2,1H3,(H,5,6);/q;+1/p-1	MFBOGIVSZKQAPD-UHFFFAOYSA-M	CCCC(=O)[O-].[Na+]	C4H7NaO2	CAS 156-54-7	.	.	.	.	D0I7IB	.	.	.
DR9147	DC/Dribble vaccine	.	.	Vaccine	.	.	.	.	.	.	.	.	.	.	.	.	.
DR9185	Pyrrolo-1,5-benzoxazepine	CID: 69345756	SCHEMBL5185374; 2H-pyrrolo[2,3-i][1,5]benzoxazepine	Small molecule	1S/C11H8N2O/c1-5-12-10-3-2-9-8(4-6-13-9)11(10)14-7-1/h1-6H,7H2	UNHWZPWLXOALOM-UHFFFAOYSA-N	C1C=CN=C2C=CC3=NC=CC3=C2O1	C11H8N2O	.	.	.	.	.	.	.	.	.
DR9224	BI-D1870	CID: 25023738	BI-D1870; 501437-28-1; 2-((3,5-difluoro-4-hydroxyphenyl)amino)-8-isopentyl-5,7-dimethyl-7,8-dihydropteridin-6(5H)-one; 2-(3,5-difluoro-4-hydroxyanilino)-5,7-dimethyl-8-(3-methylbutyl)-7H-pteridin-6-one; C19H23F2N5O2; 2-((3,5-difluoro-4-hydroxyphenyl)amino)-8-isopentyl-5,7-dimethyl-7,8-dihydropteridin-6(5H)-one.; 2-(3,5-difluoro-4-hydroxyphenylamino)-8-isopentyl-5,7-dimethyl-7,8-dihydropteridin-6(5H)-one; 2-[(3,5-DIFLUORO-4-HYDROXYPHENYL)AMINO]-7,8-DIHYDRO-5,7-DIMETHYL-8-(3-METHYLBUTYL)-6(5H)-PTERIDINONE; cc-687; CHEMBL573107; GTPL8038; SCHEMBL13881333; BDBM25017; BID1870; DTXSID40648506; SYN1020; BCPP000343; HMS3244C11; HMS3244C12; HMS3244D11; HMS3651D17; HMS3674C15; BCP01977; EX-A2471; ABP000282; BI-D-1870; MFCD11223662; NSC747342; s2843; AKOS015918879; BCP9000401; CCG-268540; CS-1243; NSC-747342; SB19282; AC-32826; AK-37190; AS-16192; HY-10510; AB0007926; DB-071116; FT-0720677; SW219252-1; X5923; W-5481; 437D281; J-505744; Q27075243; 2-(3,5-Difluoro-4-hydroxy-phenylamino)-5,7-dimethyl-8-(3-methyl-butyl)-7,8-dihydro-5H-pteridin-6-one; 2-(3,5-Difluoro-4-hydroxyanilino)-5,7-dimethyl-8-(3-methylbutyl)-7,8-dihydropteridin-6(5H)-one; 2-(3,5-difluoro-4-hydroxyphenylamino)-8-isopentyl-5,7-dimethyl-7,8-dihydropyrido[2,3-d]pyrimidin-6(5H)-one; 2-[(3,5-difluoro-4-hydroxyphenyl)amino]-5,7-dimethyl-8-(3-methylbutyl)-5,6,7,8-tetrahydropteridin-6-one; 2-[(3,5-Difluoro-4-hydroxyphenyl)amino]-5,7-dimethyl-8-(3-methylbutyl)-7,8-dihydropteridin-6(5H)-one; 2-[(3,5-difluoro-4-hydroxyphenyl)amino]-7,8-dihydro-5,7-dimethyl-8-(3-methylbutyl)-6(5h)-pteridone	Small molecule	1S/C19H23F2N5O2/c1-10(2)5-6-26-11(3)18(28)25(4)15-9-22-19(24-17(15)26)23-12-7-13(20)16(27)14(21)8-12/h7-11,27H,5-6H2,1-4H3,(H,22,23,24)	DTEKTGDVSARYDS-UHFFFAOYSA-N	CC1C(=O)N(C2=CN=C(N=C2N1CCC(C)C)NC3=CC(=C(C(=C3)F)O)F)C	C19H23F2N5O2	CAS 501437-28-1	.	.	.	.	D02VBF	.	.	.
DR9235	PD173074	CID: 1401	219580-11-7; PD173074; PD 173074; PD-173074; 1-(tert-Butyl)-3-(2-((4-(diethylamino)butyl)amino)-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl)urea; 1-tert-butyl-3-[2-{[4-(diethylamino)butyl]amino}-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]urea; UNII-A4TLL8634Y; A4TLL8634Y; CHEMBL189584; PD-0173074; CHEBI:63448; C28H41N7O3; MFCD08705327; 1-tert-butyl-3-(2-(4-(diethylamino)butylamino)-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl)urea; 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea; 3-tert-butyl-1-(2-{[4-(diethylamino)butyl]amino}-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl)urea; 2fgi; N-[2-[[4-(Diethylamino)butyl]amino] -6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-y l]-N'-(1,1-dimethylethyl)urea; SMR000568412; FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074; PubChem22593; cc-523; MLS001074892; MLS006011101; SCHEMBL177946; Pyrido[2,3-d]pyrimidine 12; BDBM6190; GTPL5037; AOB2517; DTXSID30176363; EX-A197; SYN1176; BCPP000121; HMS2233G17; HMS3265E09; HMS3265E10; HMS3265F09; HMS3265F10; HMS3371E08; HMS3648A10; HMS3654L09; BCP02368; ZINC3870533; ABP000888; ANW-73236; NSC766908; s1264; AKOS016008595; BCP9001065; CCG-264881; CS-0182; NSC-766908; QC-7737; SB19382; NCGC00165863-01; NCGC00165863-02; NCGC00165863-17; 1-t-Butyl-3-(6-(3,5-dimethoxyphenyl)-2-(4-diethylaminobutylamino)-pyrido[2,3-d]pyrimidin-7-yl)urea; AC-24850; AK105355; AS-16310; HY-10321; AB0033759; FT-0673540; P2474; SW218104-2; X7486; PD 173074, >=96% (HPLC), powder; A25450; W-5382; PD173074/PD-173074/; SR-01000837541; J-014372; J-523314; SR-01000837541-2; Q27088276; FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074 - CAS 219580-11-7; 1-(tert-Butyl)-3-[7-[[4-(diethylamino)butyl]amino]-3-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-2-yl]urea; 1-tert-Butyl-3-(6-(3,5-dimethoxyphenyl)-2-(4-diethylaminobutylamino)pyrido(2,3-d)pyrimidin-7-yl)urea; N-(tert-Butyl)-N -[2-[[4-(diethylamino)butyl]amino]-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]urea; N-[2-[[4-(Dethylamno)butyl]amno]-6-(3,5-dmethoxyphenyl)pyrdo[2,3-d ]pyrmdn-7-yl]-n'-(1,1-dmethylethyl)urea; N-[2-[[4-(Diethylamino)butyl]amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)urea; N-[2-[[4-(Diethylamino)butyl]amino]-6-(3,5- dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1- dimethylethyl)urea; N-[2-[[4-(diethylamino)butyl]amino]-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-urea; N-[2-[[4-(Diethylamino)butyl]amino]-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)urea; PD 173074;n-[2-[[4-(diethylamino)butyl]amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-n'-(1,1-dimethylethyl)urea	Small molecule	1S/C28H41N7O3/c1-8-35(9-2)13-11-10-12-29-26-30-18-20-16-23(19-14-21(37-6)17-22(15-19)38-7)25(31-24(20)32-26)33-27(36)34-28(3,4)5/h14-18H,8-13H2,1-7H3,(H3,29,30,31,32,33,34,36)	DXCUKNQANPLTEJ-UHFFFAOYSA-N	CCN(CC)CCCCNC1=NC2=NC(=C(C=C2C=N1)C3=CC(=CC(=C3)OC)OC)NC(=O)NC(C)(C)C	C28H41N7O3	CAS 219580-11-7	CHEBI:63448	.	.	.	D0VF6E	.	.	.
DR9241	Gentamicin	CID: 3467	gentamicin; Gentavet; Gentamicins; GENTAMYCIN; Gentamicin sulphate sterile; Gentacycol; 1403-66-3; Cidomycin; Gentamicinum; Gentamycinum; Refobacin; Garasol; Refobacin TM; Gentamicina; Gentamicine; Gentocin; Gentamycin-creme; Gentamycins; Gentamicine [INN-French]; Gentamicinum [INN-Latin]; Gentamycin-creme [German]; Gentamicina [INN-Spanish]; Oksitselanim; Centicin; Lyramycin; Septigen; Gentamicin (TN); Gentamicin (BAN); Gentamicin [INN]; HSDB 3087; Gentamicin [INN:BAN]; EINECS 215-765-8; 4,6-diamino-3-{[3-deoxy-4-c-methyl-3-(methylamino)pentopyranosyl]oxy}-2-hydroxycyclohexyl 2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)heptopyranoside; SCHEMBL537630; CHEMBL329592; GTPL2427; SCHEMBL19996168; STL454325; AKOS015961211; DB00798; J4.074F; 2-[4,6-diamino-3-[3-amino-6-(1-methylaminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-methylaminooxane-3,5-diol; AC-13386; FT-0626646; FT-0668965; D08013; 123871-EP2292088A1; 123871-EP2295422A2; 123871-EP2295439A1; Q422482	Small molecule	1S/C21H43N5O7/c1-9(25-3)13-6-5-10(22)19(31-13)32-16-11(23)7-12(24)17(14(16)27)33-20-15(28)18(26-4)21(2,29)8-30-20/h9-20,25-29H,5-8,22-24H2,1-4H3	CEAZRRDELHUEMR-UHFFFAOYSA-N	CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC	C21H43N5O7	CAS 1403-66-3	.	.	.	.	D0L9UU	.	.	.
DR9249	1,3-bis(2-chloroethyl)-1-nitrosourea	CID: 2578	Carmustine; carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; BCNU; Injectable carmustine, Direct Therapeutics	Small molecule	1S/C5H9Cl2N3O2/c6-1-3-8-5(11)10(9-12)4-2-7/h1-4H2,(H,8,11)	DLGOEMSEDOSKAD-UHFFFAOYSA-N	C(CCl)NC(=O)N(CCCl)N=O	C5H9Cl2N3O2	CAS 154-93-8	.	.	.	.	D01OXI	.	.	.
DR9260	Ethionamide	CID: 2761171	ethionamide; 536-33-4; 2-ethylpyridine-4-carbothioamide; Ethioniamide; Ethyonomide; Amidazine; Ethinamide; Etionamid; Etioniamid; Thioamide; Trecator; Ethylisothiamide; 2-Ethylthioisonicotinamide; Trecator-SC; 4-Pyridinecarbothioamide, 2-ethyl-; Amidazin; Ethimide; Etiocidan; Etionizin; Etionizina; Etionizine; Fatoliamid; Iridocin; Iridozin; Isotiamida; Itiocide; Nicotion; Rigenicid; Sertinon; Thianide; Thioniden; Trekator; Trescatyl; Trescazide; Tubenamide; Tubermin; Tuberoid; Tuberoson; Aetina; Aetiva; Ethina; Etimid; Etionid; Isothin; Nizotin; Teberus; Thianid; Tianid; Atina; Bayer 5312; Ethionamid prothionamid; Iridocin Bayer; Nisotin; Thiomid; 2-ETHYL-4-PYRIDINECARBOTHIOAMIDE; Etionamide [DCIT]; Ethionamidum; Etionamida; Etionamide; Tiomid; 2-Ethylisothionicotinamide; 2-Ethylisonicotinothioamide; Ethionamidum [INN-Latin]; Etionamida [INN-Spanish]; 2-Ethyl-4-thiocarbamoylpyridine; 2-Ethyl-thioisonicotinamide; 1314 TH; 2-Ethylisonicotinic acid thioamide; TH 1314; 2-ethyl-4-thiopyridylamide; NCI-C01694; UNII-OAY8ORS3CQ; 1314-Th; F.I. 58-30; 1314TH; 2-Ethyl-4-thioamidylpyridine; Isonicotinamide, 2-ethylthio-; OAY8ORS3CQ; Aethionamidum; Tio-Mid; MLS000069764; CHEBI:4885; .alpha.-Ethylisothionicotinamide; .alpha.-Ethylthioisonicotinamide; .alpha.-Ethylisonicotinoylthioamide; Trecator SC; NSC255115; NSC-255115; 1314 TN; .alpha.-Ethylisonicotinic acid thioamide; Ethina (VAN); NCGC00016497-05; CAS-536-33-4; SMR000058716; DSSTox_CID_577; DSSTox_RID_75669; DSSTox_GSID_20577; alpha-Ethylisothionicotinamide; alpha-Ethylthioisonicotinamide; alpha-Ethylisonicotinoylthioamide; 2-Ethylisonicotinic thioamide; alpha-Ethylisonicotinic acid thioamide; CCRIS 287; amino(2-ethyl(4-pyridyl))methane-1-thione; HSDB 7473; Bayer5312; SR-01000759219; EINECS 208-628-9; NSC 255115; BRN 0116474; Thiodine; Trecator (TN); Prestwick_842; Isonicotinimidic acid, 2-ethylthio-; MFCD00057361; Ethionamide [USAN:USP:INN:BAN:JAN]; PubChem15920; Spectrum_001082; CPD001370750; Opera_ID_632; Prestwick0_000526; Prestwick1_000526; Prestwick2_000526; Prestwick3_000526; Spectrum2_000994; Spectrum3_000428; Spectrum4_000547; Spectrum5_000979; 2-Ethylisonicotinothiamide; 2-Ethylisonicotinthioamide; E0695; CHEMBL1441; SCHEMBL27007; BSPBio_000511; BSPBio_002016; KBioGR_001213; KBioSS_001562; 5-22-02-00360 (Beilstein Handbook Reference); MLS001074114; MLS002454402; DivK1c_000145; SPECTRUM1500292; WLN: T6NJ B2 DYZUS; SPBio_001087; SPBio_002432; BPBio1_000563; Ethionamide (JP17/USP/INN); DTXSID0020577; AEOCXXJPGCBFJA-UHFFFAOYSA-; HMS500H07; KBio1_000145; KBio2_001562; KBio2_004130; KBio2_006698; KBio3_001236; .alpha.-Ethyl-thioisonicotinamide; Isonicotinamide, 2-ethyl, thio-; NINDS_000145; HMS1569J13; HMS1920M22; HMS2091F03; HMS2096J13; HMS2231F10; HMS2233J11; HMS3259K17; HMS3370I18; HMS3371D12; HMS3655M10; HMS3713J13; Pharmakon1600-01500292; BCP29626; HY-B0276; ZINC3872520; Tox21_110458; Tox21_202409; Tox21_302769; ANW-42028; CCG-40212; NSC757028; s1777; SBB055548; AKOS006220662; Tox21_110458_1; DB00609; FS-1770; MCULE-1322319906; NC00508; NSC-757028; IDI1_000145; NCGC00016497-01; NCGC00016497-02; NCGC00016497-03; NCGC00016497-04; NCGC00016497-06; NCGC00016497-08; NCGC00016497-09; NCGC00091074-01; NCGC00091074-02; NCGC00091074-03; NCGC00091074-04; NCGC00256600-01; NCGC00259958-01; AC-13715; AK163496; M381; SMR001370750; SBI-0051377.P003; AB0015183; DB-049945; AB00051990; ST50949989; SW196973-3; C07665; D00591; 33010-EP2286812A1; 33010-EP2287165A2; 33010-EP2287166A2; 33010-EP2292620A2; 33010-EP2297130A1; 33010-EP2301536A1; 33010-EP2301538A1; 33010-EP2305675A1; 33010-EP2305695A2; 33010-EP2305696A2; 33010-EP2305697A2; 33010-EP2305698A2; 33010-EP2305808A1; 33010-EP2308833A2; 33010-EP2308852A1; 33010-EP2308874A1; 33010-EP2311455A1; 33010-EP2311815A1; 73833-EP2308926A1; 73833-EP2309564A1; AB00051990-09; AB00051990_10; AB00051990_11; A829694; Q414767; SR-01000759219-2; SR-01000759219-5; W-105719; BRD-K33710385-001-05-4; BRD-K51207550-001-09-9; Ethionamide, European Pharmacopoeia (EP) Reference Standard; Ethionamide, United States Pharmacopeia (USP) Reference Standard; Ethionamide for system suitability, European Pharmacopoeia (EP) Reference Standard; Trecator;2-Ethylthioisonicotinamide;Ethinamide; Ethioniamide; Trecator SC; Trecator-SC	Small molecule	1S/C8H10N2S/c1-2-7-5-6(8(9)11)3-4-10-7/h3-5H,2H2,1H3,(H2,9,11)	AEOCXXJPGCBFJA-UHFFFAOYSA-N	CCC1=NC=CC(=C1)C(=S)N	C8H10N2S	CAS 536-33-4	CHEBI:4885	.	.	.	D0P0HB	.	.	.
DR9274	6-OH-11-O-Hydroxyphenanthrene	.	.	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.
DR9285	Diltiazem	CID: 39186	diltiazem; 42399-41-7; d-cis-Diltiazem; Cardizem; Dilt-cd; Diltiazemum; Anoheal; Diltzac; Tiamate; (+)-diltiazem; Cardil; Dilren; Tiazac; (+)-cis-diltiazem; Diltiazen; UNII-EE92BBP03H; Diltiazem free base; CRD-401; (2S,3S)-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate; CHEMBL23; Dilcontin; Dilticard; Endrydil; Acalix; Dilzen; Dilta-Hexal; EE92BBP03H; Incoril AP; CHEBI:101278; 42399-41-7 (free base); (2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate; [(2S,3S)-5-(2-dimethylaminoethyl)-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate; Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester; NCGC00024309-05; DSSTox_CID_2940; Diltiazem [INN:BAN]; Dilacor-XR; DSSTox_RID_76797; Diltiazemum [INN-Latin]; DSSTox_GSID_22940; (+)-cis-5-[2-(dimethylamino)ethyl]-2,3-dihydro-3-hydroxy-2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one acetate ester; (2S-cis)-3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one; Diltiazem (INN); [(2~{S},3~{S})-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxidanylidene-2,3-dihydro-1,5-benzothiazepin-3-yl] ethanoate; Surazem (TN); CAS-42399-41-7; HSDB 6528; Cardizem (Hydrochloride); MK-793 (Malate); RG-83606; EINECS 255-796-4; BRN 3573079; tetrahydrobenzo; RG 83606 (Hydrochloride); Diltiazem HCI; D-(cis)-diltiazem; Tocris-0685; 103532-26-9; Prestwick0_000134; Prestwick1_000134; Prestwick2_000134; Prestwick3_000134; Lopac0_000327; SCHEMBL17776; BSPBio_000208; BSPBio_001311; LITHIUMDICYCLOHEXYLAMIDE; BIDD:GT0548; SPBio_002147; BPBio1_000230; GTPL2298; DTXSID9022940; Bio1_000371; Bio1_000860; Bio1_001349; HMS1791B13; HMS1989B13; HMS2089H09; ZINC621893; [b][1,4]thiazepin-3-yl acetate; Acetic acid 5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester; methoxyphenyl)-4-oxo-2,3,4,5-; Tox21_110898; AC-936; BDBM50004704; CD0163; AKOS015897257; Tox21_110898_1; CCG-204422; DB00343; MCULE-9931403933; SDCCGSBI-0050315.P002; VA10739; NCGC00024309-02; NCGC00024309-04; NCGC00024309-06; NCGC00024309-07; NCGC00024309-08; NCGC00024309-09; NCGC00024309-10; NCGC00024309-11; NCGC00024309-17; NCGC00024309-21; NCGC00024309-27; (2S,3S)-5-[2-(dimethylamino)ethyl]-2-[4-(methyloxy)phenyl]-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate; [(2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate; 1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S,3S)-; C06958; D07845; (2S,3S)-5-(2-(dimethylamino)ethyl)-2-(4-; Q422229; W-106274; BRD-K24023109-001-02-5; BRD-K24023109-003-03-9; BRD-K24023109-003-11-2; BRD-K24023109-003-20-3; 8-Chloro-1-methyl-6-phenyl-4H-2,3,5,10b-tetraaza-benzo[e]azulene; 5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester(Diltiazem)Acetic acid; Acetic acid (S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester; Acetic acid 5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester (Diltiazem); Acetic acid 5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester(cis-(+)-Diltiazem); Acetic acid 5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester; hydrochloride; C9F; cis-Acetic acid 5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester; diltiazem;Acetic acid 5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester	Small molecule	1S/C22H26N2O4S/c1-15(25)28-20-21(16-9-11-17(27-4)12-10-16)29-19-8-6-5-7-18(19)24(22(20)26)14-13-23(2)3/h5-12,20-21H,13-14H2,1-4H3/t20-,21+/m1/s1	HSUGRBWQSSZJOP-RTWAWAEBSA-N	CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC	C22H26N2O4S	CAS 56209-45-1	CHEBI:101278	.	.	.	D0OB1J	.	.	.
DR9295	Tegafur	CID: 5386	tegafur; Ftorafur; 17902-23-7; Futraful; Fluorofur; Sinoflurol; Citofur; Florafur; Fental; Neberk; Coparogin; Franroze; Furafluor; Furflucil; Furofutran; Nitobanil; Exonal; Fulfeel; Lifril; Sunfral; Lamar; Riol; Tefsiel C; FT-207; 5-fluoro-1-(tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione; Phthorafur; 1-(2-Tetrahydrofuryl)-5-fluorouracil; 5-Fluoro-1-(tetrahydro-2-furyl)uracil; 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-; MJF-12264; NSC-148958; N1-(2-tetrahydrofuryl)-5-fluorouracil; 1-(Tetrahydrofuran-2-yl)-5-fluorouracil; 5-Fluoro-1-(tetrahydrofuran-2-yl)uracil; URACIL, 5-FLUORO-1-(TETRAHYDRO-2-FURYL)-; 5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione; Uracil, 1-(tetrahydrofuran-2-yl)-5-fluoro-; FT 207; MFCD00012351; 5-Fluoro-1-(tetrahydro-3-furyl)uracil; 1-(Tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione; MLS000069497; 5-FLUORO-1-(TETRAHYDRO-2-FURFURYL)URACIL; CHEBI:32188; 1-(2-TETRAHYDROFORMYL)-5-FLUOROURACIL; C8H9FN2O3; 5-fluoro-1-tetrahydrofuran-2-yl-pyrimidine-2,4-dione; NCGC00159418-02; NCGC00159418-05; SMR000059106; Racemic Ftorafur; DSSTox_CID_1305; DSSTox_RID_76070; DSSTox_GSID_21305; Phthorafur [Czech]; Fluorafur; Tegafurum; Tegafurum [INN-Latin]; CAS-37076-68-9; CCRIS 2762; FT-207 (NSC 148958); FT207; EINECS 241-846-2; BRN 0525766; Franrose; N1-(2'-Tetrahydrofuryl)-5-fluorouracil; Sunfural; Fulaid; 1-(Tetrahydro-2-furanyl)-5-fluorouracil; N(sub 1)-(2-Tetrahydrofuryl)-5-fluorouracil; Tegafur [USAN:INN:BAN:JAN]; N(sub 1)-(2'-Furanidyl)-5-fluouracil [Czech]; Atillon (TN); Tegafur ,(S); N(sub 1)-(2'-Furanidyl)-5-fluouracil; TS-1 (Salt/Mix); Opera_ID_1726; UPCMLD-DP063; SCHEMBL4552; 5-fluoro-1-(oxolan-2-yl)pyrimidine-2,4-dione; 5-24-06-00285 (Beilstein Handbook Reference); MLS000759414; MLS001076521; MLS001424119; CHEMBL20883; Tegafur (JP17/USAN/INN); F-5-FU; UPCMLD-DP063:001; GTPL10513; DTXSID001009966; HMS1665I05; HMS2051B15; HMS2090K04; HMS2232E05; HMS3371H21; HMS3393B15; HMS3654P13; HMS3715D14; N1-(2'-Furanidyl)-5-fluouracil; 2,4(1H,3H)Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-; 5-Fluoro-1-(tetrahydro-2-furanyl)-2,4(1H,3H)-pyrimidinedione; BCP22714; 5-fluoro-1-(tetrahydrofuran-2-yl); N1-(2'-Furanidyl)-5-fluorouracil; Tox21_111649; Tox21_301812; BBL027795; CCG-50110; STK528044; Tegafur, >=98% (HPLC), powder; 5-Fluoro-1-(2-tetrahydrofuryl)uracil; AKOS000121279; Tox21_111649_1; AC-2112; CCG-100959; CS-1128; DB09256; MCULE-1366455644; NC00209; 1-(tetrahydro-2-furyl)-5-fluorouracil; 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-, didehydroderiv.; 5-fluoro-1-(2-tetrahydrofuranyl)uracil; N1 -(2-tetrahydrofuryl)-5-fluorouracil; NCGC00159418-04; NCGC00255222-01; 79107-97-4; 82294-77-7; AK468738; AS-13528; HY-17400; I580; FT-0653732; FT-0654170; FT-0674829; FT-0693965; C12673; D01244; J10344; W-5041; AB00572620-15; 902T237; Q413370; SR-01000639511; Q-201784; SR-01000639511-1; SR-01000639511-4; 5-fluoro-1-tetrahydro-furan-2-yl-1H-pyrimidine-2,4-dione; 5-Fluoro-1-tetrahydro-2-furanyl-2,4(1H,3H)-pyrimidinedione; 2, 4(1H,3H)-Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-, (R)-	Small molecule	1S/C8H9FN2O3/c9-5-4-11(6-2-1-3-14-6)8(13)10-7(5)12/h4,6H,1-3H2,(H,10,12,13)	WFWLQNSHRPWKFK-UHFFFAOYSA-N	C1CC(OC1)N2C=C(C(=O)NC2=O)F	C8H9FN2O3	CAS 17902-23-7	CHEBI:32188	.	.	.	D0F3SY	.	.	.
DR9316	Lansoprazole	CID: 3883	lansoprazole; 103577-45-3; Prevacid; Bamalite; Monolitum; Ogastro; Lansoprazol; Agopton; Limpidex; Lanzor; Opiren; Prevacid SoluTab; Lanzopral; Takepron; Zoton; Lanproton; Lansopep; Lasoprol; Mesactol; Aprazol; Blason; Ketian; Lancid; Lanston; Lanz; AG-1749; Lansoprazolum; Prevacid Iv; AG 1749; Lansox; Lanzo; A-65006; Prevacid 24HR; 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole; CHEBI:6375; Prezal; Pro Ulco; Compraz; Ilsatec; Prosogan; Suprecid; Dakar; Promp; Zoprol; TAK-390MR; 2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)benzimidazole; MLS000069705; Lanzol-30; Ogast; MFCD00866873; 2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole; C16H14F3N3O2S; NCGC00015615-02; SMR000058469; Lansoprazol [INN-Spanish]; Lansoprazolum [INN-Latin]; CAS-103577-45-3; DSSTox_CID_3200; MLS-0003247.0001; Prevacid NapraPAC; 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-; 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; 2-({[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole; 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole; 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methylsulfinyl]-1H-benzimidazole; DSSTox_RID_76922; DSSTox_GSID_23200; Prevacid I.V.; TAK 390MR; Lansophed; Lanzol; Lanzul; PrevOnco; 1H-Benzimidazole, 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-; 2-((3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methylsulfinyl)-1H-benzo[d]imidazole; 2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole; 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methylsulfinyl]-1H-benzimidazole; 2-[[3-methyl-4-[2,2,2-tris(fluoranyl)ethoxy]pyridin-2-yl]methylsulfinyl]-1H-benzimidazole; Prevacid (TN); 2-({3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl} sulphinylbenzimidazole;2-({3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl} sulphinylbenzimidazole; (r)-(+)-lansoprazole; 1261394-42-6; HSDB 7204; SR-01000000169; A 65006; BRN 4333393; Lanfast; Lapraz; 2-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl}-1H-benzimidazole; ABT-006; Lansoprazole,(S); Lansoprazole [USAN:USP:INN:BAN]; CG-4801; PubChem16834; Spectrum_001580; CPD000058469; Prevacid Delayed Release; Opera_ID_1676; Prestwick0_001072; Prestwick1_001072; Prestwick2_001072; Prestwick3_001072; Spectrum2_000444; Spectrum3_000295; Spectrum4_000856; Spectrum5_001521; Dexlansoprazole-[13C6]; Lopac-L-8533; CHEMBL480; L 8533; cid_3883; Lopac0_000709; SCHEMBL22365; BSPBio_001084; BSPBio_001830; KBioGR_001491; KBioSS_002060; MLS000759405; MLS001074170; MLS001424235; BIDD:GT0006; DivK1c_000920; SPECTRUM1503926; SPBio_000488; SPBio_002992; BPBio1_001194; GTPL7208; DTXSID4023200; BDBM47032; HMS502N22; KBio1_000920; KBio2_002060; KBio2_004628; KBio2_007196; KBio3_001330; Lansoprazole (JP17/USP/INN); 2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole; 2-[(S)-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole; Levolansoprazole;(-)-Lansoprazole; NINDS_000920; HMS1571G06; HMS1922M04; HMS2052F05; HMS2093M07; HMS2098G06; HMS2234B10; HMS3262M19; HMS3264E12; HMS3269D15; HMS3371E21; HMS3394F05; HMS3413J05; HMS3654J17; HMS3677J05; HMS3715G06; Pharmakon1600-01503926; Pharmakon1600-01504282; ACT03358; BCP22331; BCP34129; EBD14854; Tox21_110184; Tox21_301023; Tox21_500709; BBL029072; BDBM50070208; CCG-39952; CL0035; NSC758638; NSC758710; s1354; STK621169; AKOS005554811; Tox21_110184_1; AC-1233; CS-1847; DB00448; KS-1075; Lansoprazole, >=98% (TLC), powder; LP00709; MCULE-8446262134; NC00411; NSC 758638; NSC-758638; NSC-758710; SB19127; SDCCGSBI-0050687.P004; 2-[({3-methyl-4-[(2,2,2-trifluoroethyl)oxy]pyridin-2-yl}methyl)sulfinyl]-1H-benzimidazole; 2-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methanesulfinyl}-1H-1,3-benzodiazole; IDI1_000920; NCGC00015615-01; NCGC00015615-03; NCGC00015615-04; NCGC00015615-05; NCGC00015615-06; NCGC00015615-07; NCGC00015615-08; NCGC00015615-09; NCGC00015615-10; NCGC00015615-11; NCGC00015615-12; NCGC00015615-14; NCGC00015615-15; NCGC00023826-03; NCGC00023826-04; NCGC00023826-05; NCGC00023826-06; NCGC00023826-07; NCGC00254925-01; NCGC00261394-01; NCGC00381720-13; AK308448; HY-13662; SBI-0050687.P003; AB0005100; AB00052388; EU-0100709; FT-0610894; FT-0670721; FT-0670722; L0233; ST51015040; SW197226-4; D00355; AB00052388-17; AB00052388_18; AB00052388_19; 577L453; A800764; Q254296; J-007154; SR-01000000169-2; SR-01000000169-6; SR-01000000169-9; BRD-A49172652-001-05-7; BRD-A49172652-001-13-1; F2173-0222; Lansoprazole, British Pharmacopoeia (BP) Reference Standard; Lansoprazole, European Pharmacopoeia (EP) Reference Standard; Lansoprazole, United States Pharmacopeia (USP) Reference Standard; (+)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole; 2-({[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl}sulfinyl)benzimidazol e; 2-({[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methane}sulfinyl)-1H-1,3-benzodiazole; 2-[[ [3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole; 2-[[[3-methyl-4-(2,2,2-trifluoro-ethoxy)-2-pyridinyl]methyl]-sulfinyl]1H-benzimidazole; 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]benzimidazole; 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]-methyl]sulfinyl]benzimidazole; 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole; 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyrid-2-yl]methylsulfinyl]benzimidazole; 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzoimidazole; 2-[3-Methyl-4-(2,2,2-trifluoro-ethoxy)-pyridin-2-ylmethanesulfinyl]-1H-benzimidazole; 2-[3-methyl-4-(2,2,2-trifluoro-ethoxy)-pyridin-2-ylmethanesulfinyl]-benzimidazole; 2-[3-methyl-4-(2,2,2-trifluoro-ethoxy)pyridin-2-ylmethanesulfinyl]-benzimidazole; 2-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl-methanesulfinyl]-1H-benzimidazole; 2-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-ylmethanesulfinyl]-1H-benzimidazole; Lansoprazole for peak identification, European Pharmacopoeia (EP) Reference Standard; 1H-Benzimidazole, 2-[(S)-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-	Small molecule	1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)	MJIHNNLFOKEZEW-UHFFFAOYSA-N	CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F	C16H14F3N3O2S	CAS 103577-45-3	CHEBI:6375	.	.	.	.	.	.	.
DR9353	BMS-228987	CID: 88045546	SCHEMBL6816325; BMS-228987	Small molecule	1S/C27H30O2/c1-26(2,3)16-14-21-15-17-27(4,5)24-13-10-20(18-23(21)24)7-6-19-8-11-22(12-9-19)25(28)29/h6-16,18H,17H2,1-5H3,(H,28,29)/b7-6+,16-14+	JCIUGJPHCGNCKU-DBSWOVOKSA-N	CC1(CC=C(C2=C1C=CC(=C2)C=CC3=CC=C(C=C3)C(=O)O)C=CC(C)(C)C)C	C27H30O2	.	.	.	.	.	.	.	.	.
DR9368	Folfox	CID: 135659064	Folfox protocol; Folfox regimen; FOLFOX-4 protocol; FOLFOX-6 protocol; FOLFOX-7 protocol; Folfox; FOLFOX-4; FOLFOX-6; FOLFOX-7; C410216000; Fluorouracil regimen with leucovorin calcium and oxaliplatin	Small molecule	1S/C20H23N7O7.C8H14.C4H3FN2O2.C2H2O4.Pt/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30;1-7-5-3-4-6-8(7)2;5-2-1-6-4(9)7-3(2)8;3-1(4)2(5)6;/h1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32);7-8H,1-6H2;1H,(H2,6,7,8,9);(H,3,4)(H,5,6);/q;-2;;;+2/t12?,13-;7-,8-;;;/m01.../s1	YXTKHLHCVFUPPT-YYFJYKOTSA-N	[CH2-]C1CCCCC1[CH2-].C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O.C1=C(C(=O)NC(=O)N1)F.C(=O)(C(=O)O)O.[Pt+2]	C34H42FN9O13Pt	.	.	.	.	.	.	.	.	.
DR9409	Cytidine-5'-diphosp-bocholine	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR9419	Nystatin	CID: 6433272	nystatin; Stamycin; Nilstat; Mycostatin; Biofanal; Diastatin; Moronal; Nystex; Nystatin A1; 1400-61-9; Nistatin; Nyotran; Nystavescent; Myconystatin; Mykostatyna; Nystatinum; Terrastatin; Herniocid; Mykinac; Nystatyna; Nyamyc; Nystan; Nystop; Candio-hermal; Candex Lotion; Zydin E; Mycostatin 20; Nystatin (Fungicidin); Barstatin 100; Mycostatin Pastilles; Nystatyna [Polish]; Moronal (antibiotic); Caswell No. 607B; Nystatin LF (liposome); Nystatine [INN-French]; Nystatinum [INN-Latin]; Nistatina [INN-Spanish]; Nystatin A; HSDB 3138; Nystatin A1, A2, A3 complex; (4E,6E,8E,10E,14E,16E,18S,19R,20R,21S,35S)-3-[(2S,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-19,25,27,29,32,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,14,16-hexaene-38-carboxylic acid; EINECS 215-749-0; EPA Pesticide Chemical Code 202800; NSC 150817; AI3-26526; AV & NYS; Nystatin + Aloe Vera Extract; SCHEMBL284974; Nystatin [USP:INN:BAN:JAN]; CHEBI:473992; (Liposomal Nystatin)Nyotrantrade mark; AKOS016339654; DB00646; KS-1373; (1S,15S,16R,17R,18S,19E,21E,25E,27E,29E,31E)-33-[(3-amino-3,6-dideoxy-a-D-mannopyranosyl)oxy]-1,3,4,7,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid; (1S,15S,16R,17R,18S,19E,21E,25E,27E,29E,31E)-33-[(3-amino-3,6-dideoxy-alpha-D-mannopyranosyl)oxy]-1,3,4,7,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid	Small molecule	1S/C47H75NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-36(53)35(52)20-19-31(49)21-32(50)22-33(51)23-39(55)62-29(3)28(2)42(27)56/h5-6,8,10-18,27-38,40-44,46,49-54,56-58,61H,7,9,19-26,48H2,1-4H3,(H,59,60)/b6-5+,10-8+,13-11+,14-12+,17-15+,18-16+/t27-,28-,29-,30+,31?,32?,33?,34?,35?,36?,37?,38?,40?,41-,42+,43+,44-,46+,47+/m0/s1	VQOXZBDYSJBXMA-RKEBNKJGSA-N	CC1C=CC=CCCC=CC=CC=CC=CC(CC2C(C(CC(O2)(CC(C(CCC(CC(CC(CC(=O)OC(C(C1O)C)C)O)O)O)O)O)O)O)C(=O)O)OC3C(C(C(C(O3)C)O)N)O	C47H75NO17	CAS 1400-61-9	CHEBI:473992	.	.	.	D08XAC	.	.	.
DR9432	Probenecid	CID: 4911	probenecid; 57-66-9; 4-(Dipropylsulfamoyl)benzoic acid; Probenecid acid; Benemid; Probecid; Benecid; Probenemid; Benuryl; Probalan; Probexin; Prolongine; Tubophan; Uricosid; Apurina; Proben; Synergid R; p-(Dipropylsulfamoyl)benzoic acid; 4-[(dipropylamino)sulfonyl]benzoic acid; Probenecida; Probenecide; Probenecidum; 4-((Dipropylamino)sulfonyl)benzoic acid; 4-(Di-n-propylsulfamoyl)benzoesaeure; 4-(N,N-Dipropylsulfamoyl)benzoesaeure; Benzoic acid, 4-[(dipropylamino)sulfonyl]-; NCI-C56097; Benzoic acid, p-(dipropylsulfamoyl)-; 4-(N,N-Dipropylsulfamoyl)benzoic Acid; p-(Dipropylsulfamyl)benzoic acid; MFCD00038402; NSC 18786; CHEBI:8426; Probenecid (Benemid); UNII-PO572Z7917; Benzoic acid, 4-((dipropylamino)sulfonyl)-; CHEMBL897; MLS000028496; 4-Dipropylsulfamoyl-benzoic acid; Benemide; Probenid; Robenecid; Polycillin-BRB; NSC-18786; PO572Z7917; CAS-57-66-9; probenicid; NCGC00016251-08; SMR000058280; DSSTox_CID_1188; DSSTox_RID_75998; DSSTox_GSID_21188; Probenecide [INN-French]; Probenecidum [INN-Latin]; Probenecida [INN-Spanish]; Benemid (TN); CCRIS 3643; HSDB 3387; SR-01000003108; EINECS 200-344-3; BRN 2815775; AI3-50078; Probenecid [USP:INN:BAN:JAN]; Prestwick_809; Spectrum_000834; ColBenemid (Salt/Mix); Opera_ID_677; Prestwick0_000542; Prestwick1_000542; Prestwick2_000542; Prestwick3_000542; Spectrum2_001294; Spectrum3_000554; Spectrum4_000486; Spectrum5_001419; Benemid; Benecid; Benuryl; Epitope ID:180853; SCHEMBL3663; Polycillin-PRB (Salt/Mix); BIDD:PXR0092; Oprea1_416955; WLN: QVR DSWN3&3; BSPBio_000583; BSPBio_002227; KBioGR_000971; KBioSS_001314; MLS001076472; BIDD:GT0626; DivK1c_000056; SPECTRUM1500502; SPBio_001327; SPBio_002504; BPBio1_000643; GTPL4357; Probenecid (JP17/USP/INN); ZINC1982; DTXSID9021188; HMS500C18; KBio1_000056; KBio2_001314; KBio2_003882; KBio2_006450; KBio3_001727; AMY8947; AOB5799; NINDS_000056; HMS1569N05; HMS1920J22; HMS2092C03; HMS2096N05; HMS2233N05; HMS3259G04; HMS3369L18; HMS3652O17; HMS3713N05; HMS3743E07; HMS3885I18; p-(Dipropylsulfamoyl) benzoic acid; Pharmakon1600-01500502; ALBB-025846; BCP21785; HY-B0545; NSC18786; STR06053; Tox21_110328; Tox21_202110; Tox21_302928; BDBM50206509; CCG-39232; KM0133; NSC757292; s4022; SBB028597; STL229614; 4-Dipropylsulfamoyl-benzoic acid anion; AKOS000165123; Tox21_110328_1; 4-(Di-n-propylsulfamoyl)benzoic acid; ; AC-2023; DB01032; HC 5006; MCULE-8664946016; NC00530; NSC-757292; SB17360; IDI1_000056; 4-(Di-n-propylaminosulfonyl)benzoic acid; NCGC00016251-01; NCGC00016251-02; NCGC00016251-03; NCGC00016251-04; NCGC00016251-05; NCGC00016251-06; NCGC00016251-07; NCGC00016251-09; NCGC00016251-10; NCGC00016251-13; NCGC00023829-03; NCGC00023829-04; NCGC00023829-05; NCGC00023829-06; NCGC00023829-07; NCGC00256441-01; NCGC00259659-01; ST099094; 4-(N,N-dipropylaminosulphonyl)benzoic acid; SBI-0051492.P003; 4-Dipropylsulfamoyl-benzoic acid(probenecid); AB00052080; P1975; SW196943-3; EN300-69677; C07372; D00475; J10155; AB00052080_15; AB00052080_16; 038P402; Q900898; Q-201621; SR-01000003108-2; SR-01000003108-3; BRD-K95237249-001-05-9; BRD-K95237249-001-15-8; Z53037954; Probenecid, European Pharmacopoeia (EP) Reference Standard; Probenecid, United States Pharmacopeia (USP) Reference Standard	Small molecule	1S/C13H19NO4S/c1-3-9-14(10-4-2)19(17,18)12-7-5-11(6-8-12)13(15)16/h5-8H,3-4,9-10H2,1-2H3,(H,15,16)	DBABZHXKTCFAPX-UHFFFAOYSA-N	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O	C13H19NO4S	CAS 57-66-9	CHEBI:8426	.	.	.	D0L7FM	.	.	.
DR9458	Physiotherapy	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR9473	Amantadine	CID: 2130	amantadine; 1-Adamantanamine; 768-94-5; adamantan-1-amine; 1-Adamantylamine; 1-Aminoadamantane; Adamantanamine; Adamantylamine; Aminoadamantane; Symmetrel; Amantidine; Symadine; Pk-merz; Adamantamine; 1-Adamantamine; Amantadina; Amantadinum; adamantan-1-ylamine; Gocovri; TCMDC-125869; 1-adamantaneamine; UNII-BF4C9Z1J53; 1-Aminotricyclo(3.3.1.1(sup 3,7))decane; NSC 341865; Tricyclo(3.3.1.13,7)decan-1-amine; tricyclo[3.3.1.1~3,7~]decan-1-amine; Tricyclo[3.3.1.1(3,7)]decan-1-amine; MFCD00074732; CHEMBL660; adamantanylamine; (3s,5s,7s)-Tricyclo[3.3.1.1~3,7~]decan-1-Amine; BF4C9Z1J53; CHEBI:2618; NSC341865; NSC-341865; 768-94-5 (FREE BASE); NCGC00015036-03; Tricyclo[3.3.1.13,7]decan-1-amine; Tricyclo[3.3.1.13,7]decane-1-amine; Amantadine Base; 1-Adamantanamine, 96%; DSSTox_CID_2117; Amantadine [INN:BAN]; DSSTox_RID_76493; Amantadinum [INN-Latin]; DSSTox_GSID_22117; Amantadina [INN-Spanish]; Amant; Amantadine (INN); CAS-768-94-5; NSC83653; 40933-03-7; HSDB 3202; Tricyclo(3.3.1.1(3,7))-decan-1-amine; Tricyclo(3.3.1.1(sup 3.7))decan-1-amine; EINECS 212-201-2; 1-Adamantanamine (8CI); ADAMANTANE,1-AMINO; adamantaneamine; BRN 2204333; adamantyl amine; AmantadineHCl; 1-admantaneamine; 1-Amantadine; Tricyclo(3.3.1.1(sup 3,7))decan-1-amine; 1-adamantanylamine; 1-adamantyl amine; Adamant-1-ylamine; 1-amino-adamantane; adamantane-1-amine; PubChem8733; Mantadine (Salt/Mix); Symmetrel (Salt/Mix); PubChem13903; Spectrum_000030; Tricyclo[3.3.1.1^3,7]decan-1-amine; Prestwick0_000407; Prestwick1_000407; Prestwick2_000407; Prestwick3_000407; Spectrum2_000081; Spectrum3_000291; Spectrum4_000134; Spectrum5_000772; tricyclo[3.3.1.1(3,7)]decan-1-ylamine; tricyclo[3.3.1.1(3,7)]decane-1-amine; 1-Adamantylamine, 97%; Lopac-A-1260; Tricyclo[3.3.1.1(sup3,7)]decan-1-amine; EC 212-201-2; SCHEMBL4098; NCIOpen2_001059; Lopac0_000004; Oprea1_248648; BSPBio_000334; BSPBio_001570; BSPBio_001822; KBioGR_000548; KBioSS_000390; BIDD:GT0757; DivK1c_000815; Exp-105-1 (Salt/Mix); SPBio_000002; SPBio_002273; BPBio1_000368; GTPL4128; SCHEMBL2619248; DTXSID8022117; SCHEMBL15672299; SCHEMBL20409394; SCHEMBL21309814; SCHEMBL21310017; KBio1_000815; KBio2_000390; KBio2_002958; KBio2_005526; KBio3_001322; NINDS_000815; (3R,5S,7s)-Adamantan-1-amine; 1-Adamantamine(1-Aminoadamantane); HMS1791O12; HMS1989O12; HMS3604O07; HMS3887I19; ZINC968256; ACT02873; ALBB-013871; BCP09869; STR04703; Tox21_110068; ANW-43040; BBL004977; BDBM50033369; HTS001826; s5499; SBB071506; STK298781; AKOS000113994; AKOS000119324; AKOS007930692; AKOS015935124; Tox21_110068_1; CCG-204100; CS-W008656; DB00915; MCULE-9686682307; SDCCGSBI-0049993.P005; IDI1_000815; NCGC00015036-01; NCGC00015036-02; NCGC00015036-04; NCGC00015036-05; NCGC00015036-06; NCGC00015036-07; NCGC00015036-08; NCGC00015036-09; NCGC00015036-11; NCGC00015036-13; NCGC00015036-24; NCGC00162039-01; NCGC00162039-02; NCGC00162039-03; NCGC00162039-04; NCGC00179597-01; AC-25879; ADS-5102, EXP 105-1; AK-77141; AS-14215; BP-13040; K333; ST097860; SBI-0049993.P004; AB0014168; WLN: L66 B6 A B- C 1B ITJ BZ; AB00514655; FT-0607338; C06818; D07441; M-4039; AB00053414-14; AB00053414-16; AB00053414_17; AB00053414_18; AB01275427-01; 768A945; A838887; AE-641/01634060; L000868; Q409761; J-650234; W-104338; BRD-K70330367-003-01-2; BRD-K70330367-003-03-8; Q27453436; F0001-1962	Small molecule	1S/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H2	DKNWSYNQZKUICI-UHFFFAOYSA-N	C1C2CC3CC1CC(C2)(C3)N	C10H17N	CAS 768-94-5	CHEBI:2618	.	.	.	D02KRS	.	.	.
DR9477	IPI-549	CID: 91933883	XUMALORDVCFWKV-IBGZPJMESA-N; IPI549; 1693758-51-8; CHEMBL3984425; GTPL9563; SCHEMBL16629991; IPI 549; MolPort-044-756-207; EX-A1057; s8330; BDBM50192880; ZINC584906867; AKOS030627132; CS-6106; compound 26 [PMID: 27660692]; AC-29898; HY-100716; Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-; 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; (S)-2-amino-N-(1-(8-((	Small molecule	1S/C30H24N8O2/c1-19(34-29(39)26-27(31)35-37-15-7-14-32-28(26)37)24-16-22-9-6-8-21(13-12-20-17-33-36(2)18-20)25(22)30(40)38(24)23-10-4-3-5-11-23/h3-11,14-19H,1-2H3,(H2,31,35)(H,34,39)/t19-/m0/s1	XUMALORDVCFWKV-IBGZPJMESA-N	CC(C1=CC2=C(C(=CC=C2)C#CC3=CN(N=C3)C)C(=O)N1C4=CC=CC=C4)NC(=O)C5=C6N=CC=CN6N=C5N	C30H24N8O2	CAS 1693758-51-8	 CHEMBL3984425	.	.	.	D0I3LO	.	.	.
DR9491	Atamestane	CID: 57050	ATAMESTANE; 96301-34-7; 1-Methylandrosta-1,4-diene-3,17-dione; UNII-62GA3K28B6; SH-489; 62GA3K28B6; Atamestane [INN]; Atamestanum [Latin]; Atamestano [Spanish]; Atamestano; Atamestanum; (8R,9S,10S,13S,14S)-1,10,13-trimethyl-7,8,9,10,11,12,13,14,15,16-decahydro-3H-cyclopenta[a]phenanthrene-3,17(6H)-dione; CCRIS 6528; Androsta-1,4-diene-3,17-dione, 1-methyl-; Biomed-777; 1-methyl-1,4-androstadiene-3,17-dione; SCHEMBL59128; CHEMBL2105987; ZINC4214890; DB12194; 1-Methyl-androsta-1,4-diene-3,17-dione; 1-Methyl-androsta-1,4 -diene-3,17-dione; Q4812727	Small molecule	1S/C20H26O2/c1-12-10-14(21)11-13-4-5-15-16-6-7-18(22)19(16,2)9-8-17(15)20(12,13)3/h10-11,15-17H,4-9H2,1-3H3/t15-,16-,17-,19-,20-/m0/s1	PEPMWUSGRKINHX-TXTPUJOMSA-N	CC1=CC(=O)C=C2C1(C3CCC4(C(C3CC2)CCC4=O)C)C	C20H26O2	CAS 96301-34-7	.	.	.	.	.	.	.	.
DR9529	Aspirin	CID: 2244	aspirin; ACETYLSALICYLIC ACID; 50-78-2; 2-Acetoxybenzoic acid; 2-(Acetyloxy)benzoic acid; O-Acetylsalicylic acid; o-Acetoxybenzoic acid; Acylpyrin; Easprin; Ecotrin; Acenterine; Acetophen; Polopiryna; Acetosal; Acetylsalicylate; Colfarit; Salicylic acid acetate; o-Carboxyphenyl acetate; Enterosarein; Aceticyl; Acetonyl; Acetosalin; Acetylin; Aspergum; Aspirdrops; Benaspir; Micristin; Pharmacin; Premaspin; Salcetogen; Temperal; Ecolen; Empirin; Endydol; Rhodine; Saletin; Rheumintabletten; Solprin acid; Acetisal; Acetylsal; Aspirine; Bialpirina; Bialpirinia; Claradin; Clariprin; Entericin; Enterophen; Enterosarine; Globentyl; Measurin; Neuronika; Salacetin; Solpyron; Acesal; Acisal; Asagran; Asteric; Cemirit; Decaten; Duramax; Extren; Globoid; Helicon; Idragin; Levius; Pirseal; Rhonal; Solfrin; Adiro; Aspec; Aspro; Novid; Yasta; Acetosalic acid; Acidum acetylsalicylicum; Triple-sal; Spira-Dine; ZORprin; Benzoic acid, 2-(acetyloxy)-; Bi-prin; Acetilum acidulatum; Acimetten; Delgesic; Entrophen; Persistin; 2-acetyloxybenzoic acid; 2-Carboxyphenyl acetate; Acetilsalicilico; Dolean pH 8; A.S.A. empirin; XAXA; Acido acetilsalicilico; Contrheuma retard; Acide acetylsalicylique; Endosprin; Kapsazal; Bayer; ASA; Acetylsalicylsaure; aspirin (acetylsalicylic acid); Solprin; Triaminicin; Asatard; Tasprin; Nu-seals aspirin; Salicylic acid, acetate; Acido O-acetil-benzoico; Kyselina acetylsalicylova; 2-Acetoxybenzenecarboxylic acid; St. Joseph Aspirin for Adults; A.S.A.; St. Joseph; Kyselina 2-acetoxybenzoova; acetyl salicylic acid; SP 189; Acetard; AC 5230; Acetylsalicylsaeure; Azetylsalizylsaeure; S-211; UNII-R16CO5Y76E; ECM; CHEBI:15365; 2-(acetyloxy)benzoate; MFCD00002430; o-(Acetyloxy)benzoic acid; Acetylsalicylic acid, 99%; acide 2-(acetyloxy)benzoique; R16CO5Y76E; Aspirin form II; component of Midol; NSC27223; component of Synirin; NSC-27223; 8-hour Bayer; component of Zactirin; NSC-406186; component of Coricidin; component of Persistin; component of Robaxisal; o-Acetoxybenzoate; NCGC00015067-04; o-acetyl-salicylic acid; Acetysal; Istopirin; Magnecyl; Medisyl; Polopirin; Ronal; Bayer Buffered; DSSTox_CID_108; Aspro Clear; component of Ascodeen-30; Bayer Plus; WLN: QVR BOV1; Rheumin tabletten; AcetylsalicylicAcid; DSSTox_RID_75372; DSSTox_GSID_20108; Aspirina 03; 11126-35-5; Acetylsalycilic acid; component of Darvon with A.S.A; Bayer Aspirin 8 Hour; Asaphen; Aspalon; Durlaza; Asprin; Bayer Children's Aspirin; AspirinTest2; Nu-seals; component of St. Joseph Cold Tablets; Aspir-Mox; Durlaza ER; Acetylsalicylsaure [German]; CAS-50-78-2; Acetoxybenzoic acid; Acetysalicylic acid; AIN; SMR000059138; Ascoden-30; Benzoicacid, 2-(acetyloxy)-; Acetylsalicyclic acid; CCRIS 3243; HSDB 652; Acide acetylsalicylique [French]; Acido acetilsalicilico [Italian]; Kyselina acetylsalicylova [Czech]; Acido O-acetil-benzoico [Italian]; SR-01000075668; Kyselina 2-acetoxybenzoova [Czech]; Bayer Extra Strength Aspirin for Migraine Pain; EINECS 200-064-1; NSC 27223; Aspirin [USP:BAN:JAN]; Bayer Enteric 325 mg Regular Strength; BRN 0779271; Bay E4465; Aspropharm; Bayer Enteric 81 mg Adult Low Strength; Cardioaspirin; Cardioaspirina; Acetyonyl; Asacard; Ascolong; Bayer Enteric 500 mg Arthritis Strength; Colsprin; Miniasal; Salospir; Acesan; Toldex; AI3-02956; 1oxr; 2-Acetoxybenzoate; 99512-66-0; Aspirin,(S); Aspalon (JAN); Durlaza (TN); Easprin (TN); acetyl-salicylic acid; Aspirin USP-26; acetyl salicyclic acid; o-(Acetyloxy)benzoate; 1173022-25-7; Percodan (Salt/Mix); Ascriptin (Salt/Mix); Micrainin (Salt/Mix); 2-acetoxy benzoic acid; PubChem20190; Spectrum_001245; 2-Acetylsalicyclic acid; ACMC-209kpz; Salicylic acid, acetyl-; CHEMBL25; Spectrum2_001899; Spectrum3_001295; Spectrum4_000099; Spectrum5_000740; Aspirin (JP17/USP); Lopac-A-5376; Salycylacetylsalicylic acid; benzoic acid, 2-acetoxy-; Epitope ID:114151; Percodan Demi (Salt/Mix); Soma Compound (Salt/Mix); ZINC53; EC 200-064-1; Aspirin USP (3080); cid_2244; Pravigard PAC (Salt/Mix); SCHEMBL1353; 2-(Acetyloxy)-benzoic acid; Aspirin USP (2080B); Bay-e-4465; Acetylsalicylic acid-[13C]; Lopac0_000038; KBioGR_000398; KBioGR_002271; KBioSS_001725; KBioSS_002272; 4-10-00-00138 (Beilstein Handbook Reference); MLS001055329; MLS001066332; MLS001336045; MLS001336046; BIDD:GT0118; DivK1c_000555; SPECTRUM1500130; SPBio_001838; Acetylsalicylic acid, >=99%; GTPL4139; (non-d)Acetylsalicylic Acid-d3; O-Acetylsalicylic acid; Aspirin; DTXSID5020108; Acetylsalicylic acid-carboxy-14c; BDBM22360; HMS501L17; KBio1_000555; KBio2_001725; KBio2_002271; KBio2_004293; KBio2_004839; KBio2_006861; KBio2_007407; KBio3_002149; KBio3_002751; Empirin with Codeine (Salt/Mix); Acetylsalicylic acid, >=99.0%; cMAP_000006; component of Zactirin (Salt/Mix); NINDS_000555; HMS1920E13; HMS2090G03; HMS2091K13; HMS2233L18; HMS3260G17; HMS3372N15; HMS3656N14; HMS3715P19; HMS3866L03; HMS3885G03; Pharmakon1600-01500130; BCP21790; STR01551; ACETYLSALICYLIC ACID; ASPIRIN; Tox21_110076; Tox21_202117; Tox21_300146; Tox21_500038; ANW-31125; BBL005469; CCG-39490; NSC406186; NSC755899; s3017; SBB015069; STL137674; 2-Acetoxybenzoic-3,4,5,6-d4 Acid; AKOS000118884; component of Ascodeen-30 (Salt/Mix); Tox21_110076_1; BAY1019036; CS-2001; DB00945; LP00038; MCULE-3199019536; NSC-755899; PL-2200; SDCCGSBI-0050027.P005; BAY-1019036; IDI1_000555; Acetylsalicylic acid, analytical standard; NCGC00015067-01; NCGC00015067-02; NCGC00015067-03; NCGC00015067-05; NCGC00015067-06; NCGC00015067-07; NCGC00015067-08; NCGC00015067-09; NCGC00015067-10; NCGC00015067-11; NCGC00015067-12; NCGC00015067-13; NCGC00015067-14; NCGC00015067-26; NCGC00090977-01; NCGC00090977-02; NCGC00090977-03; NCGC00090977-04; NCGC00090977-05; NCGC00090977-06; NCGC00090977-07; NCGC00254034-01; NCGC00259666-01; NCGC00260723-01; Aspirin, meets USP testing specifications; H740; HY-14654; NCI60_002222; ST075414; SBI-0050027.P004; DS-017139; UNM-0000306102; component of Darvon with A.S.A (Salt/Mix); EU-0100038; FT-0655181; FT-0661360; SW199665-2; 1777-EP2269989A1; 1777-EP2269990A1; 1777-EP2272825A2; 1777-EP2275420A1; 1777-EP2277865A1; 1777-EP2280008A2; 1777-EP2281563A1; 1777-EP2281815A1; 1777-EP2281818A1; 1777-EP2292227A2; 1777-EP2295055A2; 1777-EP2298764A1; 1777-EP2298765A1; 1777-EP2298768A1; 1777-EP2298776A1; 1777-EP2305219A1; 1777-EP2305260A1; 1777-EP2305640A2; 1777-EP2305652A2; 1777-EP2308510A1; 1777-EP2311453A1; 1777-EP2314590A1; 1777-EP2314593A1; 1777-EP2316459A1; 1777-EP2371811A2; 6474-EP1441224A2; 6474-EP2272832A1; 6474-EP2275420A1; 6474-EP2277861A1; 6474-EP2277875A2; 6474-EP2298757A2; 6474-EP2298764A1; 6474-EP2298765A1; 6474-EP2314585A1; A 5376; Acetylsalicylic Acid 1.0 mg/ml in Acetonitrile; C01405; D00109; Q18216; 24189-EP2295409A1; 24189-EP2314590A1; AB00051918-08; AB00051918_09; AB00051918_10; 170197-EP2275413A1; 170197-EP2287156A1; 186947-EP2270113A1; 186947-EP2272935A1; Arthritis Pain Formula Maximum Strength (Salt/Mix); SR-01000075668-1; SR-01000075668-4; SR-01000075668-6; Acetylsalicylic acid, Vetec(TM) reagent grade, >=99%; Aspirin, British Pharmacopoeia (BP) Reference Standard; F2191-0068; Z234893989; Aspirin, United States Pharmacopeia (USP) Reference Standard; D41527A7-A9EB-472D-A7FC-312821130549; Acetylsalicylic acid, European Pharmacopoeia (EP) Reference Standard; Acetylsalicylic acid, BioReagent, plant cell culture tested, >=99.0%; Acetylsalicylic acid for peak identification, European Pharmacopoeia (EP) Reference Standard; Aspirin (Acetyl Salicylic Acid), Pharmaceutical Secondary Standard; Certified Reference Material	Small molecule	1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)	BSYNRYMUTXBXSQ-UHFFFAOYSA-N	CC(=O)OC1=CC=CC=C1C(=O)O	C9H8O4	CAS 50-78-2	CHEBI:15365	.	.	.	D0GY5Z	.	.	.
DR9535	Coralyne	CID: 23306	Coralyne chloride; Coralyne; 38989-38-7; (-)-Coralyne chloride hydrate; 6872-73-7; NSC96349; 2,3,10,11-tetramethoxy-8-methylisoquinolino[2,1-b]isoquinolin-7-ium chloride; 2,3,10,11-tetramethoxy-8-methylisoquinolino[2,1-b]isoquinolin-7-ium;chloride; EINECS 254-239-2; NSC 96349; NSC 154891; Dibenzo[a, 2,3,10,11-tetramethoxy-8-methyl-, chloride; 2,3,10,11-tetramethoxy-8-methylisoquinolino[2,1-b]isoquinoline, chloride; 8-Methyl-2,3,10,11-tetramethoxydibenzo(a,g)quinolizinium chloride; 5,6,7,8,13,13a-Hexadehydro-8-methyl-2,3,10,11-tetramethoxyberbinium chloride; DIBENZO(a,g)QUINOLIZINIUM, 8-METHYL-2,3,10,11-TETRAMETHOXY-, CHLORIDE; SPECTRUM1500861; CHEMBL363506; SCHEMBL3320097; DTXSID50959832; HMS1921K20; 2,3,10,11-Tetramethoxy-8-methyldibenzo(a,g)quinolizinium chloride; 5,6,7,8,13,13a-Hexahydro-8-methyl-2,3,10,11-tetramethoxyberbinium; CCG-38524; NSC-96349; NSC154891; SBB056946; AKOS024348916; MCULE-4271694490; NSC-154891; BERBINIUM, 5,6,7,8,13,13a-HEXADEHYDRO-2,3,10,11-TETRAMETHOXY-8-METHYL-, CHLORIDE; NCGC00094866-01; NCGC00094866-02; ST50826325; SR-05000002641; SR-05000002641-1; 2,3,10,11-Tetramethoxy-8-methylisoquinolino[3,2-a]isoquinolin-7-ium chloride; Dibenzo(a,g)quinolizinium, 2,3,10,11-tetramethoxy-8-methyl-, chloride (9CI)	Small molecule	1S/C22H22NO4.ClH/c1-13-16-11-21(26-4)20(25-3)10-15(16)8-18-17-12-22(27-5)19(24-2)9-14(17)6-7-23(13)18;/h6-12H,1-5H3;1H/q+1;/p-1	PDYBUYVOPAJLKP-UHFFFAOYSA-M	CC1=C2C=C(C(=CC2=CC3=[N+]1C=CC4=CC(=C(C=C43)OC)OC)OC)OC.[Cl-]	C22H22ClNO4	CAS 38989-38-7	.	.	.	.	.	.	.	.
DR9565	Fluoxetine	CID: 3386	fluoxetine; 54910-89-3; Prozac; Pulvules; Portal; Eufor; Animex-On; Fluoxetina; Fluoxetina [Spanish]; Fluoxetinum; Fluoxetinum [INN-Latin]; Fluoxetina [INN-Spanish]; N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine; Fontex; Reconcile; Fluctine; Fluoxac; Fludac; Fluxil; Fluoxetin; (+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine; (+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine; N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; CHEMBL41; dl-3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine; Symbyax; CHEBI:86990; Selfemra; NSC-283480; (+/-)-Fluoxetine; HSDB 6633; NCGC00015428-08; (+/-) -Fluoxetine; Fluval; Methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine; n-methyl-3-phenyl-3-(4-(trifluoromethyl)phenoxy)propan-1-amine; Fluoxetine-d5 solution; Methyl-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propyl]-amine; DSSTox_CID_3067; DSSTox_RID_76861; DSSTox_GSID_23067; Fluoxetine [USAN:INN:BAN]; N-methyl-3-phenyl-3-{[4-(trifluoromethyl)phenyl]oxy}propan-1-amine; N-methyl-3-[4-(trifluoromethyl)phenoxy]-3-(3-tritiophenyl)propan-1-amine; Fluoxetine (TN); CAS-54910-89-3; Fluoxetine (USAN/INN); methyl{3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl}amine; Benzenepropanamine, N-methyl-gamma-(4-(trifluoromethyl)phenoxy)-, (+-)-; 1173147-79-9; Spectrum_001679; SpecPlus_000723; Prestwick0_000511; Prestwick1_000511; Prestwick2_000511; Prestwick3_000511; Spectrum2_001658; Spectrum3_001648; Spectrum4_000613; Spectrum5_001518; Benzenepropamine, N-methyl-gamma-(4-(trifluoromethyl)phenoxy)-, (+-)-; Biomol-NT_000152; Epitope ID:224550; (+) or (-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine; SCHEMBL8353; (+) or (-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine; Lopac0_000558; BSPBio_000461; BSPBio_003375; GTPL203; KBioGR_001166; KBioSS_002159; cid_62857; DivK1c_006819; SPBio_001815; SPBio_002382; BEN445; BPBio1_000354; BPBio1_000509; CHEBI:5118; DTXSID7023067; BDBM30130; KBio1_001763; KBio2_002159; KBio2_004727; KBio2_007295; KBio3_002595; 3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine; HMS2090H14; (+/-)-N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; ALBB-025606; AMY32526; BCP28440; HY-B0102; N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine; Tox21_110144; (+/-)-N-Methyl-3-p-(p-trifluoromethylphenoxy)-3-phenylpropylamine; (+/-)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine]; (+/-)-N-Methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine; BBL012251; MFCD00072041; NS-140; NSC283480; SBB017267; STK734483; AKOS003663021; Tox21_110144_1; AC-8478; CCG-204648; DB00472; NSC 283480; NSC 758685; SDCCGSBI-0050541.P004; (+/-)-N-Methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine; NCGC00015428-06; NCGC00015428-07; NCGC00015428-10; NCGC00015428-11; NCGC00015428-12; NCGC00015428-13; NCGC00015428-15; NCGC00015428-27; NCGC00024879-03; NCGC00024879-04; AS-44989; ST076807; SBI-0050541.P003; AB0107059; DB-015148; AB00053774; FT-0626489; D00326; AB00053774-13; AB00053774-14; AB00053774_15; AB00053774_16; L000931; Q422244; BRD-A31159102-001-01-9; BRD-A31159102-003-05-6; BRD-A31159102-003-16-3; LY-110140;LY 110140;LY110140; N-methyl 3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; N-Methyl-3-phenyl-3-(p-trifluoromethylphenoxy)propylamine; Benzenepropanamine, N-methyl-; A-[4-(trifluoromethyl)phenoxy]-; benzenepropanamine, N-methyl-gamma-[4-(trifluoromethyl)phenoxy]-; N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine #; Benzenepropanamine, N-methyl-gamma-[4-(trifluoromethyl)phenoxy]-, (+/-)-; methyl{3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl}amine hydrochloride; N-methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine; (.+/-.)-N-Methyl-3-phenyl-3-[(.alpha.,.alpha.,.alpha.-trifluoro-p-tolyl)oxy]propylamine; (.+/-.)-N-Methyl-3-phenyl-3-[(.alpha.,la,.alpha.-trifluoro-p-tolyl)oxy]propylamine; Benzenepropanamine, N-methyl-.gamma.-[4-(trifluoromethyl)phenoxy]-, (.+/-.)-; 57226-07-0	Small molecule	1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3	RTHCYVBBDHJXIQ-UHFFFAOYSA-N	CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F	C17H18F3NO	CAS 54910-89-3	CHEBI:86990	.	.	.	D0TR5X	.	.	.
DR9574	Metronidazole	CID: 4173	metronidazole; 443-48-1; Flagyl; Metronidazol; 2-Methyl-5-nitroimidazole-1-ethanol; Anagiardil; Trichazol; MetroGel; Bayer 5360; Gineflavir; Meronidal; Metronidaz; Novonidazol; Trichopol; Trivazol; Danizol; Mexibol; Vagilen; Clont; 2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethanol; Flagemona; Giatricol; Metronidazolo; Sanatrichom; Takimetol; Trichocide; Trichomol; Trikacide; Acromona; Atrivyl; Deflamon; Efloran; Entizol; Flagesol; Monagyl; Monasin; Orvagil; Trichex; Tricocet; Trikamon; Trikojol; Trikozol; Trimeks; Vagimid; Vertisal; Wagitran; Arilin; Bexon; Elyzol; Eumin; Flagil; Klion; Klont; Nalox; Tricom; neo-Tric; Tricowas B; Deflamon-wirkstoff; Protostat; Satric; MetroCream; MetroLotion; MetroGel-Vaginal; CONT; NIDA; Methronidazole; Metromidol; Trichopal; Flegyl; Fossyol; 1H-Imidazole-1-ethanol, 2-methyl-5-nitro-; Flagyl Er; Metronidazolum; Metro I.V.; Metrolyl; Metric 21; Trichomonacid 'pharmachim'; 1-(2-Hydroxyethyl)-2-methyl-5-nitroimidazole; 2-(2-methyl-5-nitroimidazol-1-yl)ethanol; RP 8823; NSC-50364; Metronidazole in Plastic Container; 2-Methyl-1-(2-hydroxyethyl)-5-nitroimidazole; 2-Methyl-3-(2-hydroxyethyl)-4-nitroimidazole; SC 10295; MFCD00009750; 1-(beta-Ethylol)-2-methyl-5-nitro-3-azapyrrole; 1-(2-Hydroxy-1-ethyl)-2-methyl-5-nitroimidazole; 1-(beta-Hydroxyethyl)-2-methyl-5-nitroimidazole; 1-Hydroxyethyl-2-methyl-5-nitroimidazole; Imidazole-1-ethanol, 2-methyl-5-nitro-; 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethan-1-ol; FLAGYL I.V. RTU IN PLASTIC CONTAINER; 1-(beta-Oxyethyl)-2-methyl-5-nitroimidazole; NSC 50364; UNII-140QMO216E; 2-(2-methyl-5-nitro-1-imidazolyl)ethanol; 2-(2-methyl-5-nitro-imidazol-1-yl)ethanol; BAY-5360; NSC69587; Noritate; MLS000028590; CHEBI:6909; 140QMO216E; Metro Gel; NSC50364; NSC-69587; Metronidazole, 99%; NCGC00016446-06; CAS-443-48-1; Metrolag; Metrotop; Rathimed; SMR000058175; Vandazole; Zadstat; 2-(2-methyl-5-nitroimidazolyl)ethan-1-ol; Tricho cordes; DSSTox_CID_892; Metronidazolo [DCIT]; Tricho-gynaedron; DSSTox_RID_75848; DSSTox_GSID_20892; Mexibol 'silanes'; 99616-64-5; Metro I.V. In Plastic Container; 1-(.beta.-Ethylol)-2-methyl-5-nitro-3-azapyrrole; 1-(.beta.-Hydroxyethyl)-2-methyl-5-nitroimidazole; Metronidazol [INN-Spanish]; Metronidazolum [INN-Latin]; Metronidazole-13C2,15N2; Flagyl I.V. RTU; Flagyl 375; Trichobrol; Florazole; Mepagyl; Nidagyl; Rosased; Zidoval; Caswell No. 579AA; WLN: T5N CNJ A2Q B1 ENW; Noritate (TN); CCRIS 410; Metro cream & gel; Flagyl (TN); HSDB 3129; WLN: T6NTJ DQ ANU1- ET5N CNJ A1 BNW; SR-01000000244; EINECS 207-136-1; NSC 69587; EPA Pesticide Chemical Code 120401; BRN 0611683; Polibiotic; Trikhopol; Donnan; Flazol; CB-01-14 MMX; Metro IV; Vandazole (TN); Metronidazole,(S); Prestwick_334; Nuvessa (TN); IDR-90105; Cimetrol 500LPCI; Metronidazole solution; RP-8823; Metronidazole, BioXtra; Metronidazole (Flagyl); PubChem15970; Spectrum_001035; Metronidazole [USAN:USP:INN:BAN:JAN]; ACMC-209jxc; HELIDAC (Salt/Mix); Maybridge1_001999; Opera_ID_1585; Prestwick0_000081; Prestwick1_000081; Prestwick2_000081; Prestwick3_000081; Spectrum2_000883; Spectrum3_000506; Spectrum4_000060; Spectrum5_001289; M0924; CHEMBL137; NCIOpen2_000337; SCHEMBL23042; BSPBio_000002; BSPBio_002031; KBioGR_000559; KBioSS_001515; 5-23-05-00063 (Beilstein Handbook Reference); MLS000758286; MLS001424018; ARONIS24285; BIDD:GT0107; DivK1c_000007; SPECTRUM1500412; SPBio_000666; SPBio_001941; BAYER-5360; BPBio1_000004; DTXSID2020892; Flagyl I.V. RTU (Salt/Mix); BCBcMAP01_000184; GTPL10914; HMS500A09; HMS547C19; KBio1_000007; KBio2_001515; KBio2_004083; KBio2_006651; KBio3_001531; Metronidazole (JP17/USP/INN); Metronidazole, analytical standard; NINDS_000007; HMS1568A04; HMS1920N19; HMS2051G07; HMS2090B19; HMS2091F14; HMS2095A04; HMS2231E11; HMS3373O05; HMS3393G07; HMS3655E22; HMS3712A04; Pharmakon1600-01500412; ZINC113442; BCP13757; HY-B0318; Tox21_110441; Tox21_202413; Tox21_302794; ANW-30094; BBL005452; BDBM50375309; CCG-40016; FP-250; NSC757118; s1907; SBB001486; SBB041018; STK177359; Metronidazole 2.0 mg/ml in Methanol; AKOS000269646; AKOS005169650; Tox21_110441_1; DB00916; KS-5140; MCULE-6891596695; NC00020; NSC-757118; 1-(2-Hydroxyethyl)-2-methyl-5-nitroimidazole N-(5-carboxy-5-aminopentane)carbamate; IDI1_000007; SMP1_000189; NCGC00016446-01; NCGC00016446-02; NCGC00016446-03; NCGC00016446-04; NCGC00016446-05; NCGC00016446-07; NCGC00016446-08; NCGC00016446-09; NCGC00016446-11; NCGC00016446-12; NCGC00016446-17; NCGC00022059-03; NCGC00022059-04; NCGC00022059-05; NCGC00256513-01; NCGC00259962-01; AC-23968; AK-77146; ST024769; SY002821; SBI-0051447.P003; AB0008438; DB-051212; Metronidazole, SAJ first grade, >=99.0%; AB00052046; BB 0218386; FT-0603394; SW196613-4; C07203; D00409; M-2794; 74568-EP2275420A1; 74568-EP2292612A2; 74568-EP2305640A2; 74568-EP2305662A1; 74568-EP2308857A1; AB00052046-17; AB00052046_18; AB00052046_19; A826552; Metronidazole, VETRANAL(TM), analytical standard; Q169569; 2-(2-methyl-5-nitro-1H-imidazol-1-yl)-1-ethanol; 2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethanol #; Metronidazole, Antibiotic for Culture Media Use Only; Q-201403; SR-01000000244-4; SR-01000000244-5; BRD-K52020312-001-05-2; BRD-K52020312-001-15-1; Z87001124; F1773-0073; Metronidazole, certified reference material, TraceCERT(R); Metronidazole, British Pharmacopoeia (BP) Reference Standard; Metronidazole, European Pharmacopoeia (EP) Reference Standard; Metronidazole, United States Pharmacopeia (USP) Reference Standard; Metronidazole solution, 2.0 mg/mL in methanol, ampule of 1 mL, certified reference material; Metronidazole, Pharmaceutical Secondary Standard; Certified Reference Material	Small molecule	1S/C6H9N3O3/c1-5-7-4-6(9(11)12)8(5)2-3-10/h4,10H,2-3H2,1H3	VAOCPAMSLUNLGC-UHFFFAOYSA-N	CC1=NC=C(N1CCO)[N+](=O)[O-]	C6H9N3O3	CAS 443-48-1	CHEBI:6909	.	.	.	D0A2ZX	.	.	.
DR9621	Methylphenidate	CID: 4158	methylphenidate; Methylphenidan; Phenidylate; Concerta; Calocain; Plimasine; Meridil; 113-45-1; Methyl phenidylacetate; Methyl phenidate; Metilfenidato [Italian]; Methylphenidatum; Metilfenidato [INN-Spanish]; Methylphenidatum [INN-Latin]; Methylin; 4311/B Ciba; Methyl phenidyl acetate; methyl phenyl(piperidin-2-yl)acetate; Ritalin; Methyl alpha-phenyl-alpha-(2-piperidyl)acetate; alpha-Phenyl-2-piperidineacetic acid methyl ester; 2-Piperidineacetic acid, alpha-phenyl-, methyl ester; Methylphenidate HCl; NCI-C56280; Methyl alpha-phenyl-alpha-2-piperidinylacetate; CHEMBL796; 2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester; Methyl 2-phenyl-2-(piperidin-2-yl)acetate; Methylfenidan; CHEBI:84276; Metilfenidato; Methylphenidylacetate hydrochloride; .alpha.-Phenyl-2-piperidineacetic acid methyl ester; d-methylphenidate HCl; Daytrana (TN); HSDB 3126; Methyl (2-phenyl-2-(2-piperidyl)acetate); EINECS 204-028-6; C 4311; Methylphenidate (USAN/INN); Rubifen; alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester; Adhd patch; DEA No. 1724; Methylphenidate [USAN:INN:BAN]; Cotempla XR-ODT; Ritalin (Salt/Mix); Methylin (Salt/Mix); Ritaline (Salt/Mix); Centedein (Salt/Mix); Centedrin (Salt/Mix); Centedrine (Salt/Mix); SCHEMBL37178; GTPL7236; DTXSID5023299; Jornay PM (a.k.a. HLD200); 40572-71-2; BCP18286; HY-B1091; BDBM50062912; methyl alpha-piperid-2-ylphenylacetate; Methyl phenyl(2-piperidinyl)acetate #; CS-4657; DB00422; NCGC00248587-01; NCGC00248587-03; Methyl .alpha.-phenyl-2-piperidineacetate; SBI-0206868.P001; Methyl .alpha.-phenyl-2-piperidine-acetate; C07196; D04999; phenyl-piperidin-2-yl-acetic acid methyl ester; AB01563134_01; L001307; Q422112; Methyl .alpha.-phenyl-.alpha.-(2-piperidyl)acetate; Methyl .alpha.-phenyl-.alpha.-2-piperidinylacetate; (S,2S)--Phenyl-2-piperidineacetic acid methyl ester; BRD-A19585813-003-01-7	Small molecule	1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3	DUGOZIWVEXMGBE-UHFFFAOYSA-N	COC(=O)C(C1CCCCN1)C2=CC=CC=C2	C14H19NO2	CAS 113-45-1	CHEBI:84276	.	.	.	D02PPN	.	.	.
DR9623	Tafenoquine	CID: 115358	Tafenoquine; 106635-80-7; Etaquine; WR 238605; Tafenoquine free base; SB-252263-AAB; 106635-80-7 (free base); WR238605; 4-N-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl]pentane-1,4-diamine; Krintafel; N4-(2,6-dimethoxy-4-methyl-5-(3-(trifluoromethyl)phenoxy)quinolin-8-yl)pentane-1,4-diamine; 1,4-Pentanediamine, N4-(2,6-dimethoxy-4-methyl-5-(3-(trifluoromethyl)phenoxy)-8-quinolinyl)-; SB-252263; Arakoda; Tafenoquine [USAN:INN:BAN]; 1,4-Pentanediamine, N4-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]-8-quinolinyl]-; N(4)-(2,6-Dimethoxy-4-methyl-5-((3-trifluoromethyl)phenoxy)-8-quinolinyl)-1,4-pentanediamine; Tafenoquine (USAN); (R)-N3-(2,6-Dimethoxy-4-methyl-5-(3-trifluoromethyl)phenoxy)quinolin-8-yl)pentane-1,4-diamine; SCHEMBL347388; CHEMBL298470; GTPL9722; CHEBI:141487; EX-A3146; DB06608; SB16555; (RS)-N(sup 3)-(2,6-Dimethoxy-4-methyl-5-(3-trifluoro-methylphenoxy)quinolin-8-yl)pentane-1,4-diamine; HY-111529; CS-0042381; FT-0775258; D10490; Q2387553; N4-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]-8-quinolyl]pentane-1,4-diamine; (+/-)-8-[(4-amino-1-methylbutyl)amino]-2,6-dimethoxy-4-methyl-5-(3-trifluoromethylphenoxy) quinoline; (4-Amino-1-methylbutyl){2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy](8-quinolyl)}amine; N(4)-{2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl}pentane-1,4-diamine	Small molecule	1S/C24H28F3N3O3/c1-14-11-20(32-4)30-22-18(29-15(2)7-6-10-28)13-19(31-3)23(21(14)22)33-17-9-5-8-16(12-17)24(25,26)27/h5,8-9,11-13,15,29H,6-7,10,28H2,1-4H3	LBHLFPGPEGDCJG-UHFFFAOYSA-N	CC1=CC(=NC2=C1C(=C(C=C2NC(C)CCCN)OC)OC3=CC=CC(=C3)C(F)(F)F)OC	C24H28F3N3O3	CAS 106635-80-7	CHEBI:141487	.	.	.	D07TWN	.	.	.
DR9639	Daclatasvir	CID: 25154714	Daclatasvir; 1009119-64-5; BMS-790052; Daklinza; Daclatasvir (BMS-790052); EBP 883; Daclatasvir dihydrochloride; BMS 790052; 1214735-16-6; CHEBI:82977; BMS790052; UNII-LI2427F9CI; C40H50N8O6; Dimethyl ((2S,2'S)-((2S,2'S)-2,2'-(5,5'-([1,1'-biphenyl]-4,4'-diyl)bis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl))dica; 1009119-65-6; LI2427F9CI; Carbamic acid, N,N'-[[1,1'-biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, C,C'-dimethyl ester; methyl N-[(1S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methyl-butanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidine-1-carbonyl]-2-methyl-propyl]carbamate; methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate; Daclatasvir (USAN); cc-39; Daclatasvir BMS 790052; dimethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-(biphenyl-4,4'-diyl)bis(1H-imidazole-4,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate; MLS006011140; EBP883; SCHEMBL2756027; CHEMBL2023898; SCHEMBL17897804; GTPL11266; EBP-883; EX-A410; AMY36655; AOB87747; dimethyl ((2S,2'S)-((2S,2'S)-2,2'-(5,5'-([1,1'-biphenyl]-4,4'-diyl)bis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl))dicarbamate; 3503AH; ABP000738; BDBM50387084; MFCD17129086; s1482; ZINC68204830; ACN-050889; CA10002; CCG-270425; CS-0588; DB09102; SB20303; NCGC00346533-09; AC-28958; AS-75298; BMS 790052; EBP 883; HY-10466; SMR004702917; SW219754-1; X7549; D10065; Q-4025; J-520204; Q5207712; methyl [(2s)-1-{(2s)-2-[4-(4'-{2-[(2s)-1-{(2s)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-pyrrolidinyl]-1h-imidazol-4-yl}-4-biphenylyl)-1h-imidazol-2-yl]-1-pyrrolidinyl}-3-methyl-1-oxo-2-butanyl]carbamate; methyl [(2S)-1-{(2S)-2-[4-(4'-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1H-imidazol-4-yl}biphenyl-4-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl}-3-methyl-1-oxobutan-2-yl]carbamate; Methyl [(2S)-1-{(2S)-2-[5-(4'-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1H-imidazol-5-yl}biphenyl-4-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl}-3-methyl-1-oxobutan-2-yl]carbamate; methyl N-[(2S)-1-[(2S)-2-[5-(4'-{2-[(2S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl}-[1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate; methyl-N-[(2s)-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2s)-2-(methoxycarbonylamino)-3-methylbutanoyl] pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1himidazol-2-yl]pyrrolidin-1-yl]3-methyl-1-oxobutan-2-yl]carbamate	Small molecule	1S/C40H50N8O6/c1-23(2)33(45-39(51)53-5)37(49)47-19-7-9-31(47)35-41-21-29(43-35)27-15-11-25(12-16-27)26-13-17-28(18-14-26)30-22-42-36(44-30)32-10-8-20-48(32)38(50)34(24(3)4)46-40(52)54-6/h11-18,21-24,31-34H,7-10,19-20H2,1-6H3,(H,41,43)(H,42,44)(H,45,51)(H,46,52)/t31-,32-,33-,34-/m0/s1	FKRSSPOQAMALKA-CUPIEXAXSA-N	CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)C6CCCN6C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC	C40H50N8O6	CAS 1009119-64-5	CHEBI:82977	.	.	.	D09SGV	.	.	.
DR9647	Temsirolimus	CID: 6918289	Temsirolimus; CCI-779; Torisel; 162635-04-3; UNII-624KN6GM2T; 624KN6GM2T; CHEMBL1201182; 42-[3-Hydroxy-2-methylpropanoate; MFCD00934421; NCGC00167518-01; Cci 779; Rapamycin 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]; Temsirolimus (CCI-779, NSC 683864); CHEBI:79699; Temserolimus; NSC-683864; Temsirolimus - Torisel; Rapamycin 42-(2,2-bis(hydroxymethyl)propionate); Temsirolimus(CCI-779); DSSTox_CID_20945; DSSTox_RID_79605; DSSTox_GSID_40945; SCHEMBL18792; 42-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin; WAY-CCI 779; GTPL5892; DTXSID2040945; HSDB 7931; Temsirolimus, >=98% (HPLC); C56H87NO16; AOB87306; Temsirolimus [USAN:INN:BAN:JAN]; Tox21_112515; BDBM50343413; s1044; AKOS025142069; AM84554; CCG-264790; CS-0129; NCGC00167518-02; NCGC00167518-05; NCGC00167518-09; HY-50910; CAS-162635-04-3; T3574; AB01274736-01; AB01274736_02; 635T043; SR-01000898799; J-009958; Q7699074; SR-01000898799-3; BRD-K08177763-001-02-6; 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]-rapamycin; Rapamycin, 42-(3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate)	Small molecule	1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1	CBPNZQVSJQDFBE-FUXHJELOSA-N	CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC	C56H87NO16	CAS 162635-04-3	CHEBI:79699	.	.	.	D0ES1Q	.	.	.
DR9657	Angiotensin-(1-7)	CID: 123805	Angiotensin (1-7); angiotensin 1-7; 51833-78-4; TXA127; Angiotensin i (1-7); Angiotensin II (1-7) heptapeptide; angiotensin-(1-7); angiotensin II (1-7); ASP-ARG-VAL-TYR-ILE-HIS-PRO; 8-Des-phe-angiotensin II; UNII-IJ3FUK8MOF; IJ3FUK8MOF; Angiotensin, Canine, Rat; CHEBI:55438; TXA-127; Ile(5)-angiotensin II (1-7); MFCD00153513; Ang-(1-7); 39386-80-6; L-alpha-aspartyl-L-arginyl-L-valyl-L-tyrosyl-L-isoleucyl-L-histidyl-L-proline; L-aspartyl-L-arginyl-L-valyl-L-tyrosyl-L-isoleucyl-L-histidyl-L-proline; Angiotensin I/II (1-7); Human angiotensin-(1-7); 1-7-Human angiotensin II; Angiotensin II, des-phe(8)-; TXA 127; C41H62N12O11; AngiotensinI(1-7); Angiotensin II, des-phenylalanine(8)-; Angiotensin, canine, ra; ang 1-7; GTPL582; Ang(1-7); Angiotensin II, 5-L-isoleucine-8-de-L-phenylalanine-; GTPL5578; [Ile5]Angiotensin I (1-7); CHEMBL3545347; SCHEMBL15926158; BDBM85556; [125I]ang-(1-7); TXA127; Ang-(1-7); 3446AH; ZINC96077632; AKOS024456667; CS-3413; DB11720; Angiotensin (1-7) acetate salt hydrate; Angiotensin II, 8-de-L-phenylalanine-; NCGC00167219-01; HY-12403; C15850; [125I]angiotensin-(1-7) (human, mouse, rat); 833A784; Angiotensin I/II  fragment 1-7  trifluoroacetate salt; Q27074464; H-Asp-Arg-Val-Tyr-Ile-His-Pro-OH trifluoroacetate salt; (2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-hydroxy-4-oxobutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(3H-imidazol-4-yl)propanoyl]pyrrolidine-2-carboxylic acid; (S)-1-((6S,9S,12S,15S,18S)-18-((1H-imidazol-4-yl)methyl)-1-amino-6-((S)-2-amino-3-carboxypropanamido)-15-sec-butyl-12-(4-hydroxybenzyl)-1-imino-9-isopropyl-7,10,13,16-tetraoxo-2,8,11,14,17-pentaazanonadecane)pyrrolidine-2-carboxylic acid	Small molecule	1S/C41H62N12O11/c1-5-22(4)33(38(61)50-29(17-24-19-45-20-47-24)39(62)53-15-7-9-30(53)40(63)64)52-36(59)28(16-23-10-12-25(54)13-11-23)49-37(60)32(21(2)3)51-35(58)27(8-6-14-46-41(43)44)48-34(57)26(42)18-31(55)56/h10-13,19-22,26-30,32-33,54H,5-9,14-18,42H2,1-4H3,(H,45,47)(H,48,57)(H,49,60)(H,50,61)(H,51,58)(H,52,59)(H,55,56)(H,63,64)(H4,43,44,46)/t22-,26-,27-,28-,29-,30-,32-,33-/m0/s1	PVHLMTREZMEJCG-GDTLVBQBSA-N	CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)N2CCCC2C(=O)O)NC(=O)C(CC3=CC=C(C=C3)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC(=O)O)N	C41H62N12O11	CAS 39386-80-6	CHEBI:55438	.	.	.	D0MH8O	.	.	.
DR9688	S3I-201	CID: 252682	501919-59-1; Nsc 74859; S3I-201; S31-201; 2-hydroxy-4-(2-(tosyloxy)acetamido)benzoic acid; NSC-74859; NSC74859; UNII-JG1E8503OI; MLS002701911; JG1E8503OI; NSC 74859 (S3I-201); 2-Hydroxy-4-[[2-[[(4-methylphenyl)sulfonyl]oxy]acetyl]amino]benzoic acid; Benzoic acid, 2-hydroxy-4-((2-(((4-methylphenyl)sulfonyl)oxy)acetyl)amino)-; SMR001565495; Benzoic acid, 2-hydroxy-4-[[2-[[(4-methylphenyl)sulfonyl]oxy]acetyl]amino]-; Salicylic acid, 4-p-toluenesulfonate; S3I201; STAT3-inhibitor-VI; S3I 201; NCIOpen2_008987; cc-515; MLS006011065; CHEMBL477936; cid_252682; SCHEMBL4456216; BDBM20283; CHEBI:91224; AOB4162; DTXSID00198234; EX-A342; GLG-302; BCPP000083; HMS3654C12; BCP01761; ZINC1621282; 2-hydroxy-4-[[2-(4-methylphenyl)sulfonyloxyacetyl]amino]benzoic acid; ABP000942; s1155; AKOS016366328; AM81245; CCG-268227; CS-0512; QC-8386; SB17268; NCGC00262641-02; NSC 74859,S3I-201; AC-32045; AK175837; AS-55944; HY-15146; AB0007928; FT-0704713; S31-201,NSC74859/; S3I-201 (NSC-74859); S3I-201 - NSC 74859; SW219398-1; X7562; S3I-201, >=97% (HPLC); A25494; S-7755; J-509627; Q27163139; 2-hydroxy-4-((((4-methylphenyl)sulfonyloxy)acetyl)amino)-benzoic acid; 2-hydroxy-4-(2-{[(4-methylbenzene)sulfonyl]oxy}acetamido)benzoic acid; 2-Hydroxy-4-[[[[(4-methylphenyl)sulfonyl]oxy]acetyl]amino]-benzoic acid; 2-hydroxy-4-{2-[(4-methylbenzene-1-sulfonyl)oxy]acetamido}benzoic acid; S3I-201; ; ; 2-Hydroxy-4-[[2-(4-methylphenyl)sulfonyloxyacetyl]amino]benzoic acid	Small molecule	1S/C16H15NO7S/c1-10-2-5-12(6-3-10)25(22,23)24-9-15(19)17-11-4-7-13(16(20)21)14(18)8-11/h2-8,18H,9H2,1H3,(H,17,19)(H,20,21)	HWNUSGNZBAISFM-UHFFFAOYSA-N	CC1=CC=C(C=C1)S(=O)(=O)OCC(=O)NC2=CC(=C(C=C2)C(=O)O)O	C16H15NO7S	CAS 501919-59-1	CHEBI:91224	.	.	.	D0TU0X	.	.	.
DR9742	Gefitinib	CID: 123631	Iressa; ZD1839; Irressat; gefitinib (zd1839); N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; ZD 1839; ZD-1839; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine; N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; UNII-S65743JHBS; CCRIS 9011; CHEMBL939; 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4; 184475-35-2	Small molecule	1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)	XGALLCVXEZPNRQ-UHFFFAOYSA-N	COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4	C22H24ClFN4O3	CAS 184475-35-2	.	.	.	.	D09XZB	.	.	Gefitinib
DR9750	BRD4770	CID: 72193870	BRD4770; 1374601-40-7; Methyl 2-benzamido-1-(3-phenylpropyl)-1H-benzo[d]imidazole-5-carboxylate; BRD 4770; BRD-4770; methyl 2-benzamido-1-(3-phenylpropyl)benzimidazole-5-carboxylate; C25H23N3O3; GTPL7016; AOB3886; CHEMBL3970748; SCHEMBL16569005; EX-A692; CHEBI:131143; BDBM225263; BCP10433; 2282AH; MFCD23143627; NSC777671; s7591; ZINC95099914; AKOS026750266; BRD 4770;BRD-4770; CCG-268804; CS-3446; NSC-777671; SB19344; NCGC00351780-01; NCGC00351780-04; AS-16771; DA-35008; HY-16705; BRD4770, >=98% (HPLC); FT-0733814; A14401; J-690148; BRD-K72264770-001-01-6; Q27075478; methyl 2-benzamido-1-(3-phenylpropyl)-1H-1,3-benzodiazole-5-carboxylate; Methyl-2-(benzoylamino)-1-(3-phenylpropyl)-1H-benzimidazole-5-carboxylate; 2-(Benzoylamino)-1-(3-phenylpropyl)-1H-benzimidazole-5-carboxylic acid methyl ester	Small molecule	1S/C25H23N3O3/c1-31-24(30)20-14-15-22-21(17-20)26-25(27-23(29)19-12-6-3-7-13-19)28(22)16-8-11-18-9-4-2-5-10-18/h2-7,9-10,12-15,17H,8,11,16H2,1H3,(H,26,27,29)	UCGWYCMPZXDHNR-UHFFFAOYSA-N	COC(=O)C1=CC2=C(C=C1)N(C(=N2)NC(=O)C3=CC=CC=C3)CCCC4=CC=CC=C4	C25H23N3O3	.	CHEBI:131143	.	.	.	D0LA0P	.	.	.
DR9753	Ceftriaxone	CID: 5479530	ceftriaxone; Biotrakson; Rocephin; 73384-59-5; Ceftriazone; Rocefin; Ceftriaxonum [INN-Latin]; Ceftriaxona [INN-Spanish]; Ceftriaxona; Ceftriaxonum; Rocephine; CEFTRIAXONE SODIUM; Rocephalin; CHEBI:29007; UNII-75J73V1629; CHEMBL161; CTRX; 75J73V1629; Ceftriaxone and Dextrose in Duplex Container; 74578-69-1; Ro 139904; Rophex; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-5,6-dioxo-1H-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; DRG-0071; Ceftriaxone (TN); Ceftriaxone (INN); C18H18N8O7S3; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; EINECS 277-405-6; Ceftriaxone [USAN:INN:JAN]; SCHEMBL23354; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-3-(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio)methyl)-, (6R-(6alpha,7beta(Z)))-; 78384-59-5; DTXSID0022773; (6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; HY-B0712; ZINC8584434; BDBM50049707; BDBM50103601; AKOS015960618; AC-1592; DB01212; (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-{[(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-1,2,4-triazin-3-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-aminothiazol-4-yl)-2-methoxyimino-acetyl]amino]-3-[(2-methyl-5,6-dioxo-1H-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid; AS-56320; K250; C06683; D07659; Cefatriaxone, Antibiotic for Culture Media Use Only; W-104454; (6R,7R)-7-[2-(2-Amino-4-thiazolyl)glyoxylamido]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-as-triazin-3-yl)thio]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7^2-(Z)-(O-; (6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-3-(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-[1,2,4]triazin-3-ylsulfanylmethyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-3-(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-[1,2,4]triazin-3-ylsulfanylmethyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R,)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-((2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-ylthio)methyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R,Z)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-((2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-ylthio)methyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R,Z)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-((6-hydroxy-2-methyl-5-oxo-2,5-dihydro-1,2,4-triazin-3-ylthio)methyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-3-(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio)methyl)-, (6R,7R)-; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio]methyl]-, (6R,7R)-; 7-[2-(2-Amino-thiazol-4-yl)-2-methoxyimino-acetylamino]-3-(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-[1,2,4]triazin-3-ylsulfanylmethyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid (Ceftriaxone); 7-[2-(2-Amino-thiazol-4-yl)-2-methoxyimino-acetylamino]-3-(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-[1,2,4]triazin-3-ylsulfanylmethyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid(Ceftriaxone)	Small molecule	1S/C18H18N8O7S3/c1-25-18(22-12(28)13(29)23-25)36-4-6-3-34-15-9(14(30)26(15)10(6)16(31)32)21-11(27)8(24-33-2)7-5-35-17(19)20-7/h5,9,15H,3-4H2,1-2H3,(H2,19,20)(H,21,27)(H,23,29)(H,31,32)/b24-8-/t9-,15-/m1/s1	VAAUVRVFOQPIGI-SPQHTLEESA-N	CN1C(=NC(=O)C(=O)N1)SCC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)O	C18H18N8O7S3	CAS 73384-59-5	CHEBI:29007	.	.	.	D07ACT	.	.	.
DR9830	HSV-TK/GCV	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
DR9842	Chloramphenicol 	.	.	.	.	.	.	.	.	.	.	.	.	D0X6IU	.	.	.
DR9844	Anti-CD4 (GK1.5) antibody	.	.	Antibody	.	.	.	.	.	.	.	.	.	.	.	.	.
DR9857	Bivalirudin	CID: 16129704	Bivalirudin; 128270-60-0; Angiomax; BG-8967; Bivalirudin Trifluoroacetate; BG8967; Hirulog; UNII-TN9BEX005G; CHEBI:59173; TN9BEX005G; D-Phenylalanyl-L-prolyl-L-arginyl-L-prolylglycylglycylglycylglycyl-L-asparaginylglycyl-L-alpha-aspartyl-L-phenylalanyl-L-alpha-glutamyl-L-alpha-glutamyl-L-isoleucyl-L-prolyl-L-alpha-glutamyl-L-alpha-glutamyl-L-tyrosyl-L-leucine; L-Leucine, D-phenylalanyl-L-prolyl-L-arginyl-L-prolylglycylglycylglycylglycyl-L-asparaginylglycyl-L-alpha-aspartyl-L-phenylalanyl-L-alpha-glutamyl-L-alpha-glutamyl-L-isoleucyl-L-prolyl-L-alpha-glutamyl-L-alpha-glutamyl-L-tyrosyl-; Angiox; bivalirudina; bivalirudine; bivalirudinum; BG 8967; Bivalirudin [USAN:INN:BAN]; C98H138N24O33; HS-2004; SCHEMBL25739; GTPL6470; Bivalirudin trifluoroacetate salt; CHEMBL2103749; DTXSID00155847; Bivalirudin;0.9% Sodium Chloride; 1191386-55-6; EBD32115; BDBM50248103; MFCD08692016; AKOS015994644; DB00006; 70B600; 270B600; J-005587; Q4919218; (R,R)-2,6-Bis(4,5-dihydro-4-phenyl-2-oxazolyl)pyridine; (R,R)-2,6-Bis(4-phenyl-2-oxazolinyl)pyridine; (+)-2,6-Bis[(4R)-4-phenyl-2-oxazolin-2-yl]pyridine	Small molecule	1S/C98H138N24O33/c1-5-52(4)82(96(153)122-39-15-23-70(122)92(149)114-60(30-34-79(134)135)85(142)111-59(29-33-78(132)133)86(143)116-64(43-55-24-26-56(123)27-25-55)89(146)118-67(97(154)155)40-51(2)3)119-87(144)61(31-35-80(136)137)112-84(141)58(28-32-77(130)131)113-88(145)63(42-54-18-10-7-11-19-54)117-90(147)66(45-81(138)139)110-76(129)50-107-83(140)65(44-71(100)124)109-75(128)49-106-73(126)47-104-72(125)46-105-74(127)48-108-91(148)68-21-13-38-121(68)95(152)62(20-12-36-103-98(101)102)115-93(150)69-22-14-37-120(69)94(151)57(99)41-53-16-8-6-9-17-53/h6-11,16-19,24-27,51-52,57-70,82,123H,5,12-15,20-23,28-50,99H2,1-4H3,(H2,100,124)(H,104,125)(H,105,127)(H,106,126)(H,107,140)(H,108,148)(H,109,128)(H,110,129)(H,111,142)(H,112,141)(H,113,145)(H,114,149)(H,115,150)(H,116,143)(H,117,147)(H,118,146)(H,119,144)(H,130,131)(H,132,133)(H,134,135)(H,136,137)(H,138,139)(H,154,155)(H4,101,102,103)/t52-,57+,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,82-/m0/s1	OIRCOABEOLEUMC-GEJPAHFPSA-N	CCC(C)C(C(=O)N1CCCC1C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)NC(CC(C)C)C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)CNC(=O)C(CC(=O)N)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)C4CCCN4C(=O)C(CCCNC(=N)N)NC(=O)C5CCCN5C(=O)C(CC6=CC=CC=C6)N	C98H138N24O33	CAS 128270-60-0	CHEBI:59173	.	.	.	D09HVL	.	.	.
DR9868	HA14-1	CID: 3549	Ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate; HA 14-1; Ethyl [2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)]-4H-chromene-3-carboxylate; MFCD00218213; HA-14-1; Ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-1-benzopyran-3-carboxylate; 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-1-benzopyran-3-carboxylic acid ethyl ester; 927635-64-1; SR-01000511000; C17H17BrN2O5; Maybridge1_000786; 2-oxo-2-(2-(tritylamino)thiazol-5-yl)acetic acid; BSPBio_001583; KBioGR_000303; KBioSS_000303; cc-453; SCHEMBL1427458; CHEBI:94328; HMS543L16; KBio2_000303; KBio2_002871; KBio2_005439; KBio3_000605; KBio3_000606; AOB6777; DTXSID20274403; EX-A148; Bio2_000303; Bio2_000783; HMS1361P05; HMS1791P05; HMS1989P05; HMS3268C09; HMS3414M05; HMS3678M05; BCP01804; ABP000246; BTB 02933; HA 141; HA14-1/HA141; HSCI1_000186; NSC720569; AKOS007930839; BCP9000758; CCG-233971; NSC-720569; QC-8196; 2-Amino-6-bromo-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester; IDI1_034053; SMP2_000039; NCGC00025207-02; NCGC00025207-03; NCGC00025207-04; NCGC00025207-05; NCGC00025207-06; NCGC00025207-12; NCGC00025207-15; NCGC00025207-16; AC-32822; AK687960; NCI60_041312; PS-10256; AB0008001; DB-011974; FT-0761318; Y9750; HA 14-1, >=95% (CHN/NMR), powder; S-7766; J-520710; SR-01000511000-1; SR-01000511000-2; BRD-A13807286-001-03-9; Q27166151; 2-Amino-6-bromo-?-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester; (;  inverted exclamation markR,4R)-rel-2-amino-6-bromo-; A-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid, ethyl ester; (alphaR,4R)-rel-2-amino-6-bromo-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-aceticacid,ethylester	Small molecule	1S/C17H17BrN2O5/c1-3-23-16(21)11(8-19)13-10-7-9(18)5-6-12(10)25-15(20)14(13)17(22)24-4-2/h5-7,11,13H,3-4,20H2,1-2H3	SXJDCULZDFWMJC-UHFFFAOYSA-N	CCOC(=O)C1=C(OC2=C(C1C(C#N)C(=O)OCC)C=C(C=C2)Br)N	C17H17BrN2O5	CAS 65673-63-4	.	.	.	.	.	.	.	.
DR9900	Sildenafil	CID: 135398744	VIAGRA; Sildenafil [INN:BAN]; UK-92480; UNII-3M7OB98Y7H; UK-92,480-10; C22H30N6O4S; HSDB 7305; CHEMBL192; UK 92480-10; CHEBI:9139; 3M7OB98Y7H; BNRNXUUZRGQAQC-UHFFFAOYSA-N	Small molecule	1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29)	BNRNXUUZRGQAQC-UHFFFAOYSA-N	CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C	C22H30N6O4S	CAS 139755-83-2	.	.	.	.	D05ULR	.	.	.
DR9913	Edrophonium	CID: 3202	edrophonium; Edrophonum; Tensilon; EDROPHONIUM ION; 312-48-1; Enlon; Reversol; Benzenaminium, N-ethyl-3-hydroxy-N,N-dimethyl-; Edrophone Chloride; UNII-70FP3JLY7N; N-ethyl-3-hydroxy-N,N-dimethylanilinium; (3-hydroxyphenyl)dimethylethylammonium; 70FP3JLY7N; 3-hydroxy-N,N-dimethyl-N-ethylanilinium; Ethyl-(3-hydroxy-phenyl)-dimethyl-ammonium; N-ethyl-3-hydroxy-N,N-dimethylbenzenaminium; CHEBI:251408; Ammonium, ethyl(m-hydroxyphenyl)dimethyl-(8CI); ENLON-PLUS; NCGC00015409-02; CAS-116-38-1; ethyl-(3-hydroxyphenyl)-dimethylazanium; Edrophonium cation; Spectrum_000442; Edrophonium Chloride, 3; Prestwick0_000083; Prestwick1_000083; Prestwick2_000083; Prestwick3_000083; Spectrum2_001110; Spectrum4_000736; Spectrum5_001531; Lopac-E-3256; cid_8307; CHEMBL1104; Lopac0_000511; SCHEMBL34790; BSPBio_000006; BSPBio_002386; KBioGR_001032; KBioSS_000922; DivK1c_000809; SPBio_001220; SPBio_001945; BPBio1_000008; GTPL9073; ZINC1341; DTXSID4046943; KBio1_000809; KBio2_000922; KBio2_003490; KBio2_006058; NINDS_000809; BDBM120262; CCG-204602; DB01010; MCULE-5963849469; IDI1_000809; NCGC00015409-01; NCGC00015409-03; NCGC00015409-04; NCGC00015409-05; NCGC00015409-06; NCGC00015409-07; NCGC00015409-08; NCGC00015409-15; NCGC00023975-03; AB00053796; C06976; AB00053796_15; Q3177745	Small molecule	1S/C10H15NO/c1-4-11(2,3)9-6-5-7-10(12)8-9/h5-8H,4H2,1-3H3/p+1	VWLHWLSRQJQWRG-UHFFFAOYSA-O	CC[N+](C)(C)C1=CC(=CC=C1)O	C10H16NO+	CAS 312-48-1	CHEBI:251408	.	.	.	D0S5LH	.	.	.
DR9921	Tumor necrosis factor alpha	.	.	Protein	.	.	.	.	.	.	.	.	.	.	.	.	.
DR9940	Ciprofloxacin	CID: 2764	ciprofloxacin; 85721-33-1; Ciprobay; Ciprofloxacine; Cipro; Ciproxan; Ciprofloxacina; Cipro IV; 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid; Ciprofloxacino; Ciprofloxacinum; Ciproflox; Ciproxina; BAY q 3939; 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; Cetraxal; Ciloxan; Cipro XR; CPFX; 1-Cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydro-3-quinolinecarboxylic acid; Bay-09867; C17H18FN3O3; UNII-5E8K9I0O4U; Ciproxin; Ciflox; BAYQ3939; 1-CYCLOPROPYL-6-FLUORO-4-OXO-7-PIPERAZIN-1-YL-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID; 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-; Ciprofloxacin (Cipro); CHEMBL8; 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid; Bay o 9867; 5E8K9I0O4U; Ciprocinol; Cipromycin; Ciproquinol; Bacquinor; Bernoflox; Cifloxin; Ciprinol; Ciprodar; Septicide; CHEBI:100241; Ciprofloxacin-d8; Velmonit; Ciprofloxacin monohydrochloride; MFCD00185755; Ciprofloxacin, 98%; Ciprecu; Ciprogis; Ciprolin; Ciprolon; Ciprowin; Ciproxine; Citopcin; Corsacin; Fimoflox; Ipiflox; Italnik; Otiprio; Probiox; Proflaxin; Quinolid; Quintor; Roxytal; Spitacin; Superocin; Zumaflox; Baflox; Ciplus; Ciriax; Rancif; Cilab; Cixan; Cycin; Loxan; Unex; Sophixin Ofteno; Ciprobay Uro; Alcon Cilox; Bi-Cipro; Cipro (TN); 3-Quinolinecarboxylic acid, 1,4-dihydro-1-cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)-; Proksi 250; Proksi 500; Cyprobay; AuriPro; Eni; 1-cyclopropyl-6-fluoro-4-oxo-7-piperazinylhydroquinoline-3-carboxylic acid; 1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid; 1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid; BAY-o 9867; Ciprofloxacine [INN-French]; Ciprofloxacinum [INN-Latin]; 1-Cyclopropyl-6-fluoro-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid; SMR000471901; Ciprofloxacino [INN-Spanish]; BAY-O-9867; CCRIS 5241; NSC620634; HSDB 6987; SR-05000001863; NCGC00016959-01; CAS-93107-08-5; CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER; BRN 3568352; rubrum; Ciprine; Linhaliq; Bay 09867; CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER; Ciprofloxacin,(S); Ciprofloxacin [USAN:USP:INN:BAN]; Spectrum_000162; 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-, hydrochloride; Prestwick0_000113; Prestwick1_000113; Prestwick2_000113; Prestwick3_000113; Spectrum2_001567; Spectrum3_001872; Spectrum4_000874; Spectrum5_001089; Cipro (*Hydrochloride*); CBMicro_048498; Ciloxan (*Hydrochloride*); SCHEMBL2900; Oprea1_008239; Oprea1_313572; BSPBio_000126; BSPBio_003344; KBioGR_001567; KBioSS_000642; ANHYDROUS CIPROFLOXACIN; MLS001336035; MLS006011837; BIDD:GT0205; DivK1c_000095; SPECTRUM1503614; SPBio_001474; SPBio_002065; ARONIS020379; BPBio1_000140; DTXSID8022824; BAY-O9867; BDBM21690; GTPL10902; HMS500E17; KBio1_000095; KBio2_000642; KBio2_003210; KBio2_005778; KBio3_002846; Linhaliq [Liposomal Formulation]; ZINC20220; BAY O 9867 FREE BASE; BAY-O-9867 FREE BASE; Ciprofloxacin (JP17/USP/INN); NINDS_000095; Bay o 9867 (*Hydrochloride*); BAY-Q-3939; HMS1922E18; HMS2090O07; HMS2093I03; Pharmakon1600-01503614; ALBB-015909; BCP28586; HY-B0356; RKL10073; BBL005612; CCG-39345; CIPROFLOXACIN EXTENDED RELEASE; Ciprofloxacin, >=98.0% (HPLC); NSC758467; NSC759028; s2027; SBB012554; STK021082; 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-quinoline-3-carboxylic acid; AKOS000269653; AC-7613; DB00537; KS-5006; MCULE-8631780654; NSC 758467; NSC-758467; NSC-759028; IDI1_000095; SMP1_000125; NCGC00016959-02; NCGC00016959-03; NCGC00016959-04; NCGC00016959-05; NCGC00016959-07; NCGC00095058-01; NCGC00095058-02; NCGC00178128-01; AK163192; ST024751; SBI-0048462.P003; AB0011928; FT-0601635; A-8526; C05349; Ciprofloxacin 100 microg/mL in Methanol:Water; D00186; J10137; 721C331; Ciprofloxacin, VETRANAL(TM), analytical standard; Q256602; Ciprofloxacin, Antibiotic for Culture Media Use Only; SR-05000001863-1; SR-05000001863-3; BRD-K04804440-311-02-3; Z56933707; Ciprofloxacin, European Pharmacopoeia (EP) Reference Standard; Ciprofloxacin, United States Pharmacopeia (USP) Reference Standard; 1-Cyclopropyl-6-fluoro-1,4-dihydro 4-oxo-7-[1-piperazinyl)-quinoline-3-carboxylic Acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7- (1-piperazinyl)-3-quinoline-carboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3- quinolinecarboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline-carboxylic acid; 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-quinoline -3-carboxylic acid; 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-quinoline-3-carboxylic acid; 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)quinoline-3-carboxylic acid; 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1piperazinyl)-3quinolinecarboxylic acid; 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(piperazin-1-yl)-quinoline-3-carboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(1-piperazinyl)-4-oxo-3-quinoline carboxylic acid; 1-cyclopropyl-6-fluoro-7-(piperazin-1-yl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid; Ciprofloxacin, Pharmaceutical Secondary Standard; Certified Reference Material; 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylic acid hydrochloride	Small molecule	1S/C17H18FN3O3/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h7-10,19H,1-6H2,(H,23,24)	MYSWGUAQZAJSOK-UHFFFAOYSA-N	C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O	C17H18FN3O3	CAS 85721-33-1	CHEBI:100241	.	.	.	D0O1WX	.	.	.
DR9949	Tiazofurin	CID: 457954	TIAZOFURIN; Tiazofurine; 60084-10-8; Riboxamide; 2-b-D-Ribofuranosyl-4-thiazolecarboxamide; Tiazofurinum; Tiazofurina; Tiazofurin [USAN]; TCAR; NSC-286193; 2-beta-D-Ribofuranosyl-4-thiazolecarboxamide; UNII-ULJ82834RE; CI-909; Tiazofurine (INN); Tiazofurin (USAN); ULJ82834RE; CHEBI:90239; Tiazofurine [INN]; Tiazofurinum [Latin]; Tiazofurina [Spanish]; 2-(beta-D-ribofuranosyl)-4-thiazolecarboxamide; (1R)-1,4-anhydro-1-(4-carbamoyl-1,3-thiazol-2-yl)-D-ribitol; (1r)-1-[4-(Aminocarbonyl)-1,3-Thiazol-2-Yl]-1,4-Anhydro-D-Ribitol; 2-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)thiazole-4-carboxamide; BRN 1084555; Cpd-5825; 2-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]thiazole-4-carboxamide; 2-beta-D-Ribofuranosylthiazole-4-carboxamide; 4-Thiazolecarboxamide, 2-beta-D-ribofuranosyl-; SCHEMBL4287; DIBUTYLAMINEHYDROCHLORIDE; CHEMBL108358; DTXSID00208827; ZINC4217560; 8957AB; BDBM50368057; MFCD00866494; DB13243; BS-17271; C22196; D06130; 124722-EP2295426A1; 124722-EP2295427A1; Q7800305	Small molecule	1S/C9H12N2O5S/c10-8(15)3-2-17-9(11-3)7-6(14)5(13)4(1-12)16-7/h2,4-7,12-14H,1H2,(H2,10,15)/t4-,5-,6-,7-/m1/s1	FVRDYQYEVDDKCR-DBRKOABJSA-N	C1=C(N=C(S1)C2C(C(C(O2)CO)O)O)C(=O)N	C9H12N2O5S	CAS 60084-10-8	CHEBI:90239	.	.	.	D0S7DV	.	.	.
DR9957	Ampicillin 	CID: 6249	69-53-4; Ampicillin; Aminobenzylpenicillin; Ampicillin acid; Amcill; Polycillin; Principen; Omnipen; Ampicilline; Penbritin; Pentrexyl; Synpenin; Tokiocillin; Totacillin; Novo-ampicillin; D-Ampicillin; Ampicillin Anhydrous; D-(-)-Ampicillin; Adobacillin; Amblosin; Ampichel; Ampicilina; Ampicillinum; Ampifarm; Ampipenin; Ampiscel; Amplacilina; Amplipenyl; Amplisom; Amplital; Bonapicillin; Britacil; Campicillin; Copharcilin; Delcillin; Divercillin; Doktacillin; Duphacillin; Grampenil; Guicitrina; Lifeampil; Norobrittin; Orbicilina; Penbristol; Penbrock; Penicline; Pentrexl; Princillin; Racenacillin; Rosampline; Roscillin; Semicillin; Servicillin; Sumipanto; Texcillin; Totalciclina; Trifacilina; Ultrabion; Ultrabron; Viccillin; Acillin; Amfipen; Ampicil; Ampikel; Ampimed; Ampisyn; Ampivax; Ampivet; Amplin; Binotal; Morepen; Nuvapen; Penimic; Pensyn; Pentrex; Ponecil; Tolomol; Totapen; Vampen; Cimex; Supen; anhydrous ampicillin; Ampicillin anhydrate; Pfizerpen A; Amipenix S; Ampi-bol; SK-Ampicillin; Amfipen V; Pen Ampil; QIDamp; Ampi-Tab; D-Cillin; Olin Kid; Ro-Ampen; Ampi-Co; Austrapen; Pen A; Ampicillina [DCIT]; Bayer 5427; D-(-)-alpha-Aminobenzylpenicillin; ABPC; Ampicilina [INN-Spanish]; Ampicilline [INN-French]; Ampicillinum [INN-Latin]; Ampicin; D-(-)-alpha-Aminopenicillin; Deripen; Wypicil; Alpen; Ampicillin A; Polycillin-N; Totacillin-N; Penbritin-S; AY-6108; Omnipen-N; BRL 1341; Penbritin syrup; Semicillin R; D-(-)-6-(alpha-Aminophenylacetamido)penicillanic acid; P-50; KS-R1; Penbritin paediatric; NSC-528986; AB-PC; BRL-1341; 6-(D(-)-alpha-Aminophenylacetamido)penicillanic acid; Guicitrine; Ampen; NSC 528986; AB-PC Sol; Ampicillin, anhydrous; UNII-7C782967RD; C16H19N3O4S; CHEBI:28971; MFCD00005175; Alpha-Aminobenzylpenicillin; 6-(D-(2-Amino-2-phenylacetamido))-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; MLS000028405; (2S,5R,6R)-6-{[(2R)-2-amino-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Ampicillina; HI 63; Ukapen; Pfizerpen-A; WY-5103; AMPI; 7C782967RD; (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; P 50; SQ 17382; Penicillin, (aminophenylmethyl)-; SMR000058352; Ampicillin Base; DSSTox_CID_2602; AY 6108; DSSTox_RID_76654; DSSTox_GSID_22602; (2S,5R,6R)-6-((R)-2-Amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; (2S,5R,6R)-6-[(R)-2-Amino-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Polyflex (Veterinary); ampicillanyl; Ampicillin [USAN:BAN:INN:JAN]; CAS-69-53-4; (2S,5R,6R)-6-{[(2R)-2-AMINO-2-PHENYLETHANOYL]AMINO}-3,3-DIMETHYL-7-OXO-4-THIA-1-AZABICYCLO[3.2.0]HEPTANE-2-CARBOXYLIC ACID; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,6-[[(2R)-aminophenylacetyl]amino]-3,3-dimethyl-7-oxo-, trihydrate,(2S,5R,6R)-; Omnipen (TN); Totacillin (sodium); BA 7305; HSDB 3009; AMPICILLIN/AMPICILLIN TRIHYDRATE; Ampicillin (USP/INN); EINECS 200-709-7; vidopen; Vidocillin; Marcillin; Pentritin; NSC528986; D-(-)-.alpha.-Aminobenzylpenicillin; Ampicillin,(S); NCGC00018160-02; (2s,5r,6r)-6-((r)-2-amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[[(2R)-2-amino-2-phenyl-acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta(S*)))-; Ampicillin [USAN:USP:INN:BAN:JAN]; Ampicillin (anhydrous); Spectrum_000050; 1h8s; AY  6108; D-a-Aminobenzylpenicillin; Opera_ID_1630; Prestwick0_000114; Prestwick1_000114; Prestwick2_000114; Prestwick3_000114; Spectrum2_000769; Spectrum3_000301; Spectrum4_000149; Spectrum5_000814; CHEMBL174; Epitope ID:115008; Epitope ID:116057; EC 200-709-7; SCHEMBL3526; BSPBio_000128; BSPBio_001862; KBioGR_000598; KBioSS_000430; Anhydrous ampicillin (JP17); MLS001074168; BIDD:GT0184; DivK1c_000466; SPBio_000818; SPBio_002067; Ampicillin, analytical standard; BPBio1_000142; DTXSID4022602; CHEBI:53713; GTPL10896; KBio1_000466; KBio2_000430; KBio2_002998; KBio2_005566; KBio3_001362; NINDS_000466; HMS2090I11; HMS2233H23; Ampicillin acid; Principen; Amcill; HY-B0522; ZINC3830218; Tox21_113049; Tox21_301416; BDBM50350465; SBB063111; AKOS015888156; Tox21_113049_1; AC-8805; DB00415; VA10275; WY 5103; 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carboxylic acid; IDI1_000466; SMP1_000211; NCGC00023282-05; NCGC00023282-06; NCGC00023282-21; NCGC00178944-03; NCGC00248937-01; NCGC00255127-01; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2-amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-, D-(-)-; ST077148; SBI-0051283.P003; 6-(a-Aminophenylacetamido)penicillanic acid; C06574; D00204; AMPICILLIN ANHYDROUS,  PHARMACEUTICAL GRADE; Q244150; 6-D(-)-alpha-Aminophenylacetamido-penicillanic acid; BRD-K68432770-001-08-0; Ampicillin, anhydrous, 96.0-100.5% (anhydrous basis); Ampicillin, United States Pharmacopeia (USP) Reference Standard; Anhydrous ampicillin, British Pharmacopoeia (BP) Reference Standard; Ampicillin, anhydrous, European Pharmacopoeia (EP) Reference Standard; (2S,5R,6R)-6-[(2R)-2-amino-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2R)-2-AMINO-2-PHENYLETHANOYL]AMINO}-3,3-DIMETHYL-7-OXO-4-THIA-1-AZABICYCLO[3.2.0]HEPTANE-2-CARBOXYLIC; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((2R)-aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, (2S,5R,6R)-; 6-((2R)-2-amino-2-phenylacetylamino)(2S,5R,6R)-3,3-dimethyl-7-oxo-4-thia-1-aza bicyclo[3.2.0]heptane-2-carboxylic acid; 6-((2R)-2-amino-2-phenylacetylamino)(2S,5R,6R)-3,3-dimethyl-7-oxo-4-thia-1-aza bicyclo[3.2.0]heptane-2-carboxylic acid, oxamethane, oxamethane, oxamethane; 6-[(Aminophenylacetyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 9CI; AMPICILLIN; D(-)-ALPHA-AMINOBENZYLPENICILLIN; 6-[D(-)-ALPHA-AMINOPHENYLLACETAMIDO]PENICILLANIC ACID	Small molecule	1S/C16H19N3O4S/c1-16(2)11(15(22)23)19-13(21)10(14(19)24-16)18-12(20)9(17)8-6-4-3-5-7-8/h3-7,9-11,14H,17H2,1-2H3,(H,18,20)(H,22,23)/t9-,10-,11+,14-/m1/s1	AVKUERGKIZMTKX-NJBDSQKTSA-N	CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=CC=C3)N)C(=O)O)C	C16H19N3O4S	CAS 69-53-4	CHEBI:28971	.	.	.	D0YA9Z	.	.	.
NP7887	Interferon alpha-2a	.	.	Antibody	.	.	.	.	.	.	.	.	.	.	.	.	.